---
document_datetime: 2025-01-22 14:12:05
document_pages: 298
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/masitinib-ab-science-epar-refusal-public-assessment-report_en.pdf
document_name: masitinib-ab-science-epar-refusal-public-assessment-report_en.pdf
version: success
processing_time: 491.2527877
conversion_datetime: 2025-12-15 22:52:43.693339
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

17 October 2024 EMA/CHMP/514389/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Masitinib AB Science

International non-proprietary name: masitinib

Procedure No. EMEA/H/C/005897/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                             | ..............................................7                                                           |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................     | 7                                                                                                         |
| 1.2. Legal basis, dossier content.................................................................................     | 7                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................           | 7                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                 | ................................................... 7                                                     |
| 1.4.1. Similarity                                                                                                      | ....................................................................................................... 7 |
| 1.5. Applicant's request(s) for consideration                                                                          | ................................................................. 7                                       |
| 1.5.1. Conditional marketing authorisation                                                                             | ................................................................... 7                                     |
| 1.5.2. New active Substance status.............................................................................        | 8                                                                                                         |
| 1.6. Protocol assistance.............................................................................................  | 8                                                                                                         |
| 1.7. Steps taken for the assessment of the product                                                                     | ....................................................... 8                                                 |
| 1.8. Steps taken for the re-examination procedure........................................................              | 9                                                                                                         |
| 2. Scientific discussion                                                                                               | ..............................................................................11                          |
| 2.1. Problem statement...........................................................................................      | 11                                                                                                        |
| 2.1.1. Disease or condition.......................................................................................     | 11                                                                                                        |
| 2.1.2. Epidemiology                                                                                                    | ................................................................................................ 11       |
| 2.1.3. Aetiology and pathogenesis.............................................................................         | 11                                                                                                        |
| 2.1.4. Clinical presentation, diagnosis and prognosis....................................................              | 12                                                                                                        |
| 2.1.5. Management.................................................................................................     | 14                                                                                                        |
| 2.2. About the product ............................................................................................    | 14                                                                                                        |
| 2.3. Type of application and aspects on development...................................................                 | 14                                                                                                        |
| 2.4. Quality aspects                                                                                                   | ................................................................................................ 15       |
| 2.4.1. Introduction                                                                                                    | ................................................................................................. 15      |
| 2.4.2. Active Substance...........................................................................................     | 16                                                                                                        |
| 2.4.3. Finished Medicinal Product ..............................................................................       | 18                                                                                                        |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                      | 21                                                                                                        |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                              | ..................... 21                                                                                  |
| 2.4.6. Recommendations for future quality development ..............................................                   | 22                                                                                                        |
| 2.5. Non-clinical aspects..........................................................................................    | 22                                                                                                        |
| 2.5.1. Introduction .................................................................................................  | 22                                                                                                        |
| 2.5.2. Pharmacology...............................................................................................     | 22                                                                                                        |
| 2.5.3. Pharmacokinetics                                                                                                | .......................................................................................... 24             |
| 2.5.4. Toxicology....................................................................................................  | 28                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................               | 36                                                                                                        |
| 2.5.6. Discussion on non-clinical aspects....................................................................          | 37                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................            | 43                                                                                                        |
| 2.6. Clinical aspects ................................................................................................ | 43                                                                                                        |
| 2.6.1. Introduction                                                                                                    | ................................................................................................. 43      |
| 2.6.2. Clinical pharmacology ....................................................................................      | 45                                                                                                        |
| 2.6.3. Discussion on clinical pharmacology .................................................................           | 59                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology                                                                            | ............................................................... 63                                        |
| 2.6.5. Clinical efficacy ............................................................................................. | 64                                                                                                        |
| 2.6.6. Discussion on clinical efficacy                                                                                 | .........................................................................105                              |

<div style=\"page-break-after: always\"></div>

| 2.6.7. Conclusions on the clinical efficacy..................................................................117        |                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 2.6.8. Clinical safety                                                                                                  | ..............................................................................................118     |
| 2.6.9. Discussion on clinical safety                                                                                    | ...........................................................................154                        |
| 2.6.10. Conclusions on the clinical safety                                                                              | ..................................................................157                                 |
| 2.7. Risk Management Plan.....................................................................................158       |                                                                                                       |
| 2.7.1. Safety concerns                                                                                                  | ...........................................................................................158        |
| 2.7.2. Pharmacovigilance                                                                                                | plan.................................................................................158              |
| 2.7.3. Risk minimisation measures...........................................................................159         |                                                                                                       |
| 2.7.4. Conclusion...................................................................................................161 |                                                                                                       |
| 2.8. Pharmacovigilance...........................................................................................162    |                                                                                                       |
| 2.8.1. Pharmacovigilance system.............................................................................162         |                                                                                                       |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                           | ...................................162                                                                |
| 2.9. Product information.........................................................................................162    |                                                                                                       |
| 2.9.1. User consultation..........................................................................................162   |                                                                                                       |
| 3. Benefit-Risk Balance............................................................................162                  |                                                                                                       |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................162           |
| 3.1.1. Disease or condition......................................................................................162    |                                                                                                       |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................162                                               |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................163             |
| 3.2. Favourable effects...........................................................................................163   |                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................164                                                         |
| 3.4. Unfavourable effects........................................................................................165    |                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................166                                                            |
| 3.6. Effects Table                                                                                                      | ..................................................................................................166 |
| 3.7. Benefit-risk assessment and discussion                                                                             | ..............................................................168                                     |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................168                                                        |
| 3.7.2. Balance of benefits and risks..........................................................................169       |                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance                                                            | .........................................169                                                          |
| 3.8. Conclusions....................................................................................................173 |                                                                                                       |
| 4. Recommendations...............................................................................173                    |                                                                                                       |
| 5. Re-examination of the CHMP opinion of 27 June 2024                                                                   | ........................174                                                                           |
| 5.1. Detailed grounds for re-examination submitted by the Applicant                                                     | ............................174                                                                       |
| 5.1.1. Ground #1                                                                                                        | ..................................................................................................174 |
| 5.1.2. Ground #2.1................................................................................................180   |                                                                                                       |
| 5.1.3. Ground #2.2................................................................................................211   |                                                                                                       |
| 5.1.4. Ground #3                                                                                                        | ..................................................................................................272 |
| 5.2. Report from the SAG                                                                                                | .......................................................................................284            |
| 5.3. Oral Explanation                                                                                                   | .............................................................................................285      |
| 5.4. Overall conclusion on grounds for re-examination                                                                   | ................................................285                                                   |
| 6. Benefit-risk balance following re-examination                                                                        | ....................................286                                                               |
| 6.1. Therapeutic Context                                                                                                | ........................................................................................286           |
| 6.1.1. Disease or condition......................................................................................286    |                                                                                                       |
| 6.1.2. Available therapies and unmet medical need                                                                       | ....................................................286                                               |
| 6.1.3. Main clinical studies                                                                                            | ......................................................................................287             |

<div style=\"page-break-after: always\"></div>

6.2. Favourable effects  ...........................................................................................  287

6.3. Uncertainties and limitations about favourable effects ..........................................  287

6.4. Unfavourable effects  ........................................................................................  289

6.5. Uncertainties and limitations about unfavourable effects .......................................  290

6.6. Effects Table ..................................................................................................  291

6.7. Benefit-risk assessment and discussion ..............................................................  291

6.7.1. Importance of favourable and unfavourable effects ...........................................  291

6.7.2. Balance of benefits and risks  ..........................................................................  293

6.7.3. Additional considerations on the benefit-risk balance .........................................  293

6.8. Conclusions  ....................................................................................................  297

7. Recommendations following re-examination  ....................................... 297

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverse event

(s)(f)ALS

(spontaneous) (familial) amyotrophic lateral sclerosis

ALSAQ-40

Amyotrophic Lateral Sclerosis Specific Assessment Questionnaire

ALSFRS - R

Amyotrophic Lateral Sclerosis Functional Rating Scale Revised

ALT

Alanine aminotransferase

ANCOVA

Analysis of covariance

ANOVA

Analysis of variance

AST

Aspartate aminotransferase

AUC0-24h

Area under the concentration-time curve from time zero to 24 hours

AUC0-t

Area under the concentration-time curve from time zero to time t

AUC0- ∞

Area under the concentration-time curve from time zero to infinity

BID

Twice daily

CSF-1R

Colony-stimulating factor 1 receptor

BCRP

Breast cancer resistance protein

BMI

Body mass index

BMDL10

BMDCL associated with a benchmark response of 10%

CAFS

Combined assessment of function and survival

CMA

Conditional marketing authorisation

Cmax

Maximum concentration observed

CI

Confidence interval

CIR

Copy increments from reference

CL(/F)

(Apparent) clearance

CNS

Central nervous system

DDI

Drug to drug interaction

DRESS

Drug rash with eosinophilia and systemic symptoms

ECG

Electrocardiogram

EMG

Electromyography

ERA

Environmental risk assessment

FVC

Forced vital capacity

HED

Human equivalent dose

HPLC

High performance liquid chromatography

HR

Hazard ratio

IC50

Half maximal inhibitory concentration

IDMC

Independent Data Monitoring Committee

J2R, JTR

Jump to reference

(m)ITT

(modified) Intent-to-treat

MI

Multiple imputation

IWRS

Interactive Web Response System

LMN

Low motor neuron

(m)LOCF

(modified) Last observation carried forward

MAR

Missing at random

MOE

Margin of exposure

MTA

Major therapeutic advantage

NOAEL

No-observed-adverse-effect-level

NPP

Named patient programme

OAT(1)(3)

Organic anion transporter (1)(3)

OATP1B1

Organic anion transporting polypeptide 1B1

OCT2

Organic cation transporter 2

<div style=\"page-break-after: always\"></div>

| OS    | Overall survival                          |
|-------|-------------------------------------------|
| PBPK  | Physiologically based pharmacokinetic     |
| PBT   | Persistence, bioaccumulation and toxicity |
| PDGFR | Platelet derived growth factor receptor   |
| PFS   | Progression free survival                 |
| PK    | Pharmacokinetic                           |
| PNS   | Peripheral nervous systems                |
| popPK | Population PK                             |
| PP    | Per protocol                              |
| QD    | Once daily                                |
| SA    | Scientific advice                         |
| SEM   | Standard error of the mean                |
| SD    | Standard deviation                        |
| SmPC  | Summary of product information            |
| SOC   | System organ class                        |
| SOD1  | Superoxide Dismutase type 1               |
| TKI   | Tyrosine kinase inhibitors                |
| t max | Time of maximum concentration observed    |
| t 1/2 | Apparent half-life                        |
| UMN   | Upper motor neuron                        |
| Vd/F  | apparent volume of distribution           |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant AB Science submitted on 29 July 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Masitinib AB Science, through the centralised procedure falling within  Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 March 2021.

Masitinib AB Science was designated as an orphan medicinal product EU/3/16/1722 on 29 August 2016 in the following condition: treatment of amyotrophic lateral sclerosis (ALS).

The applicant applied for the following indication: Masitinib AB Science in combination with riluzole is indicated for the treatment of adult patients with amyotrophic lateral sclerosis (ALS)

During the procedure, the applicant amended the indication to: Masitinib AB Science in combination with riluzole is indicated for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) prior to any loss of function.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and  clinical  data  based  on  the  applicant's  own  tests  and  studies  and/or  bibliographic  literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0001/2020 on the granting of a (product-specific) waiver.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## 1.5. Applicant's request(s) for consideration

## 1.5.1. Conditional marketing authorisation

The applicant requested consideration of its application for a Conditional Marketing Authorisation (CMA) in accordance with Article 14-a of the above-mentioned Regulation.

<div style=\"page-break-after: always\"></div>

## 1.5.2. New active Substance status

The applicant requested the active substance Masitinib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.6. Protocol assistance

The applicant received the following protocol assistance on the development relevant for the indication subject to the present application:

| Date              | Reference                            | SAWP co-ordinators                     |
|-------------------|--------------------------------------|----------------------------------------|
| 20 September 2018 | EMEA/H/SA/573/16/2018/PA/SME/II      | Dr. Susan Morgan Dr. Mario Miguel Rosa |
| 13 December 2018  | EMEA/H/SA/573/16/FU/1/2018/PA/SME/II | Dr. Susan Morgan Dr. Mario Miguel Rosa |

The protocol assistance pertained to the following clinical aspects:

- Study run-in period and definition of the study population, overall, 3-arm study design, proposed dosing scheme for masitinib, the proposed PK protocols and PK model, choice of primary endpoint, proposed estimand, statistical analysis, randomisation approach and study size.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Larisa Gorobets Co-Rapporteur:  Elita Poplavska

| The application was received by the EMA on                                                                                                                      | 29 July 2022     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                        | 18 August 2022   |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                    | 15 November 2022 |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                 | 22 November 2022 |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                    | 18 November 2022 |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                         | 15 December 2022 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                             | 25 March 2023    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on | 02 May 2023      |

<div style=\"page-break-after: always\"></div>

| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                             | 12 May 2023      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                              | 25 May 2023      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                      | 21 December 2023 |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                             | 10 January 2024  |
| The CHMP agreed on a 2nd list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                          | 25 January 2024  |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                      | 30 April 2024    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                             | 15 May 2024      |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                              | 28 May 2024      |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a marketing authorisation to Masitinib AB Science on | 27 June 2024     |
| The CHMP adopted a report on similarity of Masitinib AB Science with Qalsody on (see Appendix on similarity)                                                                                         | 27 June 2024     |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                                         | 27 June 2024     |

## 1.8. Steps taken for the re-examination procedure

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Daniela Philadelphy

Co-Rapporteur:  Margareta Bego

| The applicant submitted written notice to the EMA, to request a re- examination of Masitinib AB Science CHMP opinion of 27 June 2024 on   | 16 July 2024      |
|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP appointed Daniela Philadelphy as Rapporteur and Margareta Bego as Co-Rapporteur on                                               | 26 August 2024    |
| The applicant submitted the detailed grounds for the re-examination on                                                                    | 02 September 2024 |
| The re-examination procedure started on                                                                                                   | 03 September 2024 |
| The CHMP Rapporteur's re-examination assessment report was circulated to all CHMP and PRAC members on                                     | 01 October 2024   |
| SAG group experts were convened to address questions raised by the                                                                        | 10 October 2024   |

<div style=\"page-break-after: always\"></div>

| CHMP on The CHMP considered the views of the SAG experts as presented in the minutes of this meeting                                                                                                                                                                                                                                |                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the detailed grounds for re-examination to all CHMP and PRAC members on                                                                                                                                                                    | 11 October 2024 |
| The detailed grounds for re-examination were presented by the applicant during an oral explanation before the CHMP on                                                                                                                                                                                                               | 16 October 2024 |
| The CHMP, in the light of the scientific data available and the scientific discussion within the Committee, re-examined its initial opinion and in its final opinion concluded that the application did not satisfy the criteria for authorisation and did not recommend the granting of the conditional marketing authorisation on | 17 October 2024 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

ALS is a neurodegenerative disorder affecting upper (UMN) and lower motor neurons (LMN) causing progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2-5 years after disease onset.

1. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020 Oct;27(10):1918-1929.

2. Brotman RG, Moreno-Escobar MC, Joseph J, et al. Amyotrophic Lateral Sclerosis. [Updated 2022 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.

## 2.1.2. Epidemiology

Of the two forms of ALS, 90-95% of cases are sporadic (sALS), with the remainder being familial (fALS). ALS has an estimated incidence of 1.75-3 per 100 000 persons per year and a prevalence of 10-12 per 100 000 in Europe, but significant geographical differences exist. The incidence amounts to 4-8 per 100 000 persons per year in the age group with the highest risk of developing ALS (45-75 years). The estimated number of 2020 ALS cases across the 22 countries is 121,028 prevalent. Mean age at onset of symptoms is variable: 58-63 years for sALS and 40-60 years for fALS. An estimation of the cumulative lifetime  risk  for  developing  ALS  is  1:350  in  men  and  1:400  in  women.  Men  have  a  higher  risk  of developing limb onset sALS compared to women; the global sex ratio is 1.2-1.5. Globally, a higher incidence is associated with White ethnicity. The only established risk factors for ALS are age and family history.

## 2.1.3. Aetiology and pathogenesis

ALS is thought to be caused by a combination of genetic factors, environmental factors and aging -related dysfunction. At the genetic level, more than 20 genes have been linked with the disease to date, and it is  anticipated  that  more  genetic  factors  will  be  discovered.  The  genetic  architecture  of  ALS  appears complex, where monogenetic mutations with high effect size currently explain about 15% of patients, but where common and rare genetic variants with low and moderate effect size seem to contribute to the risk of developing ALS as well. The overall heritability of ALS is high; in patients with sALS the heritability is estimated to be 30%-60%. The risk of developing ALS doubles in first degree relatives of ALS patients.

Although many potential mechanisms have been proposed, a precise, single aetiology of sporadic ALS is yet unproven. These mechanisms include altered RNA processing leading to prion-like self-aggregation, superoxide dismutase type 1 (SOD1) mutations leading to free radical toxicity, cascading inflammatory responses,  and  excessive  concentrations  of  glutamate,  among  others.  The  rarer  entity  of  fALS  has numerous genetic mechanisms, most frequently repeat expansion of the C9ORF72 gene and various mutations of the SOD1 gene. Mutated SOD1 protein misfolds and forms aggregates, leading to cellular injury and eventually apoptosis. Both genetic aberrations are inherited in a mainly autosomal dominant pattern. Ultimately, rather than a single unifying cause, ALS is an etiologically diverse clinical entity, which is the result of a multitude of separate potential preceding aberrations.

<div style=\"page-break-after: always\"></div>

In 1993, the first ALS -related gene was discovered: SOD1, responsible for 20% of fALS and 1%-2% of sALS. Mutations in this gene do not cause ALS by loss of SOD1 function but rather by rendering the protein prone to aggregation, which disturbs multiple important cellular functions.

In 2008 and 2009, mutations in TARDBP and FUS, the genes encoding the RNA -binding proteins TDP -43 and FUS, were discovered. These mutations are responsible for 3%-5% of fALS and for &lt;1% of sALS. In 2011, C9orf72 was discovered, responsible for 30%-50% of fALS and for 7%-10% of sALS. Patients with hexanucleotide repeat expansions in C9orf72 are more likely to get bulbar onset ALS and to have cognitive and behavioural impairment as well.

Mutations  in  TBK1  are  most  probably  the  fifth  most  common  cause  of  autosomal  dominant  ALS, responsible for about 1% of patients, but up to 10% of patients with amyotrophic lateral sclerosis with frontotemporal dementia.

Although most SOD1 mutations have a high penetrance, the other genes mentioned are known to have a reduced penetrance, which complicates genetic counselling. Rarely, patients carry mutations in more than one of these genes, suggesting that ALS can be oligogenic in origin.

Using next -generation sequencing, several rare variants in additional genes have been identified. Whilst mutations in many of these genes are rarely identified as the cause of ALS, they appear to cluster in some emerging disease pathways.

Apart from genetic factors, age and male sex increase the risk for ALS. Several studies have suggested environmental risk factors for ALS, such as smoking, body mass index, physical exercise, occupational and  environmental  exposures  to  metals,  pesticides, β -methylamino -l -alanine,  head  injury  and  viral infections. However, the causal relationship of these factors with ALS remains to be established.

## 2.1.4. Clinical presentation, diagnosis and prognosis

The hallmark of ALS is progressive muscle weakness, accompanied by muscle atrophy, fasciculations, muscle cramps and slowness of movements with muscle stiffness. The onset of muscle weakness in ALS is usually focal and typically spreads to adjacent body regions. This pattern is compatible with spreading of disease pathology within the motor system, with neuroanatomic propagation within the spinal cord segments and the motor cortex.

The disease usually presents with unilateral distal muscle weakness and atrophy in upper or lower limb muscles (spinal ALS, roughly in two -thirds of patients) or in bulbar muscles (bulbar ALS, in about one -third of patients). Upper limb onset is most commonly in the dominant hand, with thenar muscles being more affected than hypothenar muscles (which is referred to as the split -hand syndrome), with early involvement of the first interosseous muscle and finger extensors more affected than finger flexors. In the  lower  limb  the  anterior  tibial  muscle  is  typically  affected  earlier  in  the  disease  course  than  the gastrocnemius muscle, the hamstrings before the quadriceps muscles.

Bulbar onset ALS presents most commonly with dysarthria or dysphagia, less commonly with dysphonia, or reduced mouth closure or chewing problems. Axial muscle weakness with head drop and problems with posture are common in later stages of the disease, but rarely can be the presenting symptom. In about one -third  of  patients,  there  can  be  bouts  of  uncontrolled  laughing  or  crying  (referred  to  as  a pseudobulbar affect).

In some patients, the muscle weakness is preceded by a period in which fasciculations, muscle cramps or mild weight loss has been noted.

On neurological examination, a combination of signs of UMN and LMN involvement is found in patients with classic ALS. Signs of LMN involvement include muscle weakness, atrophy, fasciculations and reduced

<div style=\"page-break-after: always\"></div>

muscle tone. Signs of UMN involvement to look for include hyperreflexia (or retained reflexes in atrophic muscles), increased muscle tone (especially in upper limb flexors and lower limb extensors) and slowness of movements (e.g. of tongue movement).

Although the majority of patients can be labelled as having a classic ALS phenotype with spinal or bulbar onset, it is increasingly recognised that ALS is clinically a heterogeneous syndrome with distinct motor and extra -motor manifestations. There is considerable heterogeneity within the motor manifestations of the  disease  itself  and  the  motor  manifestations  can  be  accompanied  by  variable  degrees  of frontotemporal involvement. This results in different phenotypic presentations of the disease which have different  disease  trajectories.  Although  no  widely  accepted  clinical  criteria  for  the  different  ALS phenotypes exist, there is a growing need for a new classification system using universally accepted terms to account for the disease heterogeneity in ALS.

The diagnosis of ALS remains a clinical diagnosis and is based on the presence of both UMN and LMN signs, in patients with progressive muscle weakness in whom no alternative explanation can be found. Most clinicians do not rely on the available revised El Escorial criteria or the Awaji algorithm, as these criteria lack sensitivity, especially in patients with bulbar-onset ALS (Brooks, 2000) and importance to electromyography (EMG) signs, particularly the fasciculation potentials recorded during  EMG examination, rather capturing disease progression and only indirectly diagnostic certainty. Moreover, these criteria have been developed for research purposes to select patients for participation in clinical trials. There is a high need for clinical diagnostic criteria of ALS and related subtypes of motor neuron disease, to reduce the diagnostic delay, which is unfortunately still often up to a year after disease onset. Recently, new simplified diagnostic criteria for ALS have been proposed, requiring only combined UMN and LMN dysfunction in one body region, or LMN dysfunction in at least two regions. Whether this will reduce the diagnostic delay requires further study.

The diagnosis of ALS relies on the medical history, physical examination, electrodiagnostic testing (with needle EMG) and neuroimaging. EMG remains a very useful diagnostic tool to confirm LMN involvement in  clinically  affected  and  non -affected  muscles (with fibrillation  potentials,  sharp  waves, fasciculation potentials in relaxed muscles and chronic neurogenic changes upon contraction).

Biomarkers can play a crucial role in diagnostic, prognostic or predictive research studies. They could potentially become important for stratification of patients and monitoring treatment effects in clinical trials.  Although  not  yet  integrated  into  standard  clinical  practice,  several  biomarkers  such  as cerebrospinal  fluid  neurofilament  levels  (especially  phosphorylated  neurofilament  heavy  subunit)  are useful in supporting the diagnosis, particularly in patients with very recent onset of muscle weakness, without clear signs of UMN  involvement, or with concomitant neuropathy/plexopathy/cervical myelopathy.

Brain and spinal cord magnetic resonance imaging are often performed to exclude structural lesions affecting  the  motor  system.  Furthermore,  18F -fluorodeoxyglucose  (18F -FDG)  positron emission tomography, if readily available, can reveal a typical pattern of hypometabolism in Rolandic brain regions and frontotemporal involvement.

Genetic testing of the five most prevalent genes found to be mutated in ALS is routinely offered to patients  with  a  positive  family  history  (C9orf72,  SOD1,  TDP -43,  FUS,  TBK -1).  Although  there  is  no consensus on genetic testing for patients with sALS, there is a trend to offer it to all patients. However, genetic testing should only be performed if genetic counselling can be provided in the event that a pathogenic gene mutation is identified. Gene panels also including rarer ALS -related genes are emerging, but the diagnostic yield on top of the five most prevalently mutated genes remains low.

Life expectancy in ALS is extremely variable. Many different clinical features, already present at first disease presentation, are known to be associated with a shorter survival. They include a bulbar onset, a

<div style=\"page-break-after: always\"></div>

short diagnostic delay, a fast functional decline [e.g. as measured by the revised ALS Functional Rating Scale (ALSFRS -R) decline], a pronounced loss of weight (or body mass index (BMI)), the presence of frontotemporal  dementia,  an  older  age  at  the  onset  of  symptoms  and  a  low  forced  vital  capacity. Moreover, genetic factors also influence survival. Some monogenetic causes are associated with a shorter survival (Ala5Val mutation in SOD1, C9orf72 repeat expansion, P525L mutation in FUS), but common and rare variants with effects on survival have been described as well. For example, homozygosity for the C allele of rs12608932 in UNC13a is associated with a shorter survival.

## 2.1.5. Management

There are two medicinal products authorised for ALS in the EU. Riluzole is an antiglutamatergic medicinal product  authorised  for  the  treatment  of  ALS.  Riluzole  50  mg  twice  daily  prolongs  the  mean  patient survival by 3-6 months. The most common side effects include nausea, diarrhoea, fatigue, dizziness, and liver problems.

Qalsody (tofersen) has been recently authorised for the treatment of SOD1-ALS.

On top of the above, ALS treatment benefits from a multidisciplinary symptomatic management including pharmacological and non -pharmacological interventions

## 2.2. About the product

Masitinib AB Science (also referred to as AB1010, the mesilate salt of AB1003) is a non-cytotoxic new chemical entity that belongs to the pharmacological class of drug known as tyrosine kinase inhibitors (TKI). Masitinib AB Science is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF-1R), c-Kit, LYN, FYN, and platelet derived growth factor receptor (PDGFR) α and β, in the sub micromolar range [Dubreuil 2009; Davis 2011]. At the cellular level, Masitinib AB Science is a potent inhibitor of CSF1R-dependent cell proliferation, of wild-type c-Kitdependent cell proliferation, of LYN- and FYN-dependent cell proliferation, and of PDGFR dependent cell proliferation.  Two  independent  studies  have  demonstrated  masitinib  mesilate  to  be  one  of  the  most highly selective protein kinase inhibitors developed (circa 2011) [Anastassiadis 2011; Davis 2011].

## 2.3. Type of application and aspects on development

The applicant requested consideration of its application for a CMA in accordance with Article 14-a of the above-mentioned Regulation, based on the following criteria:

- The benefit-risk balance is positive. The applicant's position is that considering the impact of ALS on the life prognosis of patients suffering from the disease, the urgent need for developing more efficacious ALS therapeutic alternatives, and based on the study results from AB10015, as well on long term survival data, the benefit associated with Masitinib AB Science outweigh the known and potential risks of Masitinib AB Science in treating patients with ALS.
- It is likely that the applicant will be able to provide comprehensive data. The applicant committed to continue the ongoing pivotal Phase 3 randomised, placebo-controlled study AB19001 to evaluate the  efficacy  and  safety  of  masitinib  in  ALS  patients.  The  applicant  initially  claimed  that  the completion of the Phase 3 AB19001 study would lead to comprehensive data on the efficacy and safety of masitinib in ALS patients and that the granting of a CMA will not affect the ability to complete this study. In order to minimise the impact on the recruitment and conduction of AB19001 study in case the CMA is granted, the applicant proposed to amend the protocol to replace these patients with patients from other geographies and to activate non-EU sites as a substitution to sites

<div style=\"page-break-after: always\"></div>

in the EU. During the procedure, the applicant stated that the enrolment in study AB19001 has been slow due to the restrictive design features of that study. Consequently, the applicant proposed a new confirmatory study - AB23005 study- and presented the previously proposed confirmatory AB19001 study as an exploratory one. The new confirmatory AB23005 study is expected to enrol 408  patients.  The  applicant  presented  a  feasibility  analysis  and  concluded  that  a  total  of  855 patients could be enrolled over a 12-month period including 583 patients in non-EU countries and US. The applicant claimed that Study AB23005 can be completed within 2.5 years with involvement of site from USA and other non-EU countries or within 3 years with involvement of site only from other non-EU countries. Thus, the applicant position is that confirmatory study AB23005 is feasible outside  of  the  EU  and  further  facilitated  since  Relyvrio  (tradename  of  the  fixed  combination medicinal product including sodium phenylbutyrate and ursodoxicoltaurine, known as Albrioza in EU) is withdrawn from market in USA and Canada. Upon the withdrawal, edaravone and riluzole will be the only medicinal products specifically authorised for all ALS patients except those with SOD1-ALS who can also benefit from treatment with tofersen. The applicant's position is that the willingness to participate in a trial assessing efficacy and safety of a new medicinal product for ALS is expected to be increased among the patients with ALS upon Relyvrio withdrawal.

- Unmet  medical  needs  will  be  addressed,  as  ALS  is  a  severely  debilitating  and  life-threatening disease that leads to a progressive inability to move, respiratory function insufficiency, and poor prospects of long-term survival. Currently, there is no cure for ALS. The applicant position is that no treatment can halt the course of the disease and no authorised medicinal treatments generate clinically significant prolongation of survival. At the time of submission of this application, riluzole was the only medicinal product authorised in the EU for the treatment of ALS. Riluzole, a glutamate antagonist, has been the standard treatment approach for people with ALS for over 25 years, even though  it  is  associated  with  a  very  modest  increase  in  survival  and  with  little  improvement  in quality-of-life or slowing of functional loss. Riluzole is still required to be used along with any new drug candidates by all/most regulatory agencies. During the procedure, Qalsody was authorised for the  treatment  of  SOD1-ALS.  The  applicant  claimed  that  Masitinib  AB  science  has  a  different mechanism of action and that SOD1 represents approximately 2% of people living with ALS. The applicant  claimed  that  Masitinib  AB  Science  makes  a  major  contribution  to  patient  care  with  a benefit on ALSFRS-R, quality of life, progression free survival (PFS), overall survival (OS) (+12 months).
- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. The applicant position is that benefit associated with the immediate availability of Masitinib AB Science based on number of deaths avoided and total gain in life-years as estimated based on AB10015 study (pivotal study for this CMA) outweighs the risk of adverse events (AEs).

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product was proposed as film-coated tablets containing 100 mg and 200 mg of masitinib (as mesilate) as active substance.

Other  ingredients  were:  microcrystalline  cellulose,  povidone,  crospovidone,  magnesium  stearate, polyvinyl alcohol, titanium dioxide, macrogol, talc and sunset yellow lake (E110).

The proposed packaging was HDPE bottle, closed with a sealed film and a child-resistant (polypropylene) PP cap.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Active Substance

An ASMF for masitinib mesilate was submitted. A letter of access to the ASMF in relation to the application for the proposed 100 mg and 200 mg film-coated tablets was provided. The discussion below refers to this  source  alone,  as  it  is  the  only  proposed  for  marketing.  Masitinib  mesilate  is  considered  by  the applicant to be a new active substance.

## 2.4.2.1. General information

The  chemical  name  of  masitinib  mesilate  is  4-[(4-methyl-piperazin-1-yl)methyl]N -(4-methyl-3-{[4(pyridin-3-yl)-1,3-thiazol-2-yl]amino}-phenyl)benzamide,  methane  sulphonic  acid  salt  and  has  the following structure:

Figure 1: Structure of masitinib mesilate

<!-- image -->

The  molecular  structure  of  masitinib  mesilate  has  been  confirmed  by  elemental  analysis,  UV spectroscopy,  IR  spectroscopy, 1 H-NMR, 13 C-NMR,  and  LC-MS  using  a  reference  batch  of  active substance.

Masitinib mesilate is a white to pale yellow powder, slightly hygroscopic, practically insoluble in acetone, slightly soluble in ethanol, sparingly soluble in methanol. It exhibits pH-dependent aqueous solubility. It is freely soluble in 0.1 N HCl and soluble in water.

The molecular structure does not contain asymmetric carbon atoms.

Three polymorphic forms of masitinib mesilate were identified by differential scanning calorimetry and x-ray spectrometry. It has been demonstrated that masitinib mesilate consistently manufactured by the proposed manufacturer is the polymorphic Form DRX1, anhydrous which is the most stable form. The polymorphic forms can be differentiated by melting point/range. Melting point is included in the active substance specification.

## 2.4.2.2. Manufacture, characterisation and process controls

The  active  substance  is  synthesised  in  a  convergent  synthesis  consisting  of  several  chemical  steps, purification, salt formation followed by drying and sieving. Detailed information on the manufacturing of the  active  substance  has  been  provided  in  the  restricted  part  of  the  ASMF  and  it  was  considered satisfactory.

The synthesis is comprised of 6 steps (with step 4 being divided into 3 sub-steps). Steps 1 to 4.1 are synthetic  steps  (bond  breaking/formation),  steps  4.2  to  6  comprise  purification  and  salt  formation. Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

The proposed starting materials comply with the general principles for selection of the starting materials as outlined in ICH Q11 and its Q&amp;A document and were found to be acceptable. The information provided on the route of synthesis of the starting materials allows for an adequate assessment of the impurities arising from their synthesis.

<div style=\"page-break-after: always\"></div>

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of active substances.

Comprehensive details and discussion are provided on impurities. Potential and actual impurities were well discussed with regards to their origin. Specified impurities are controlled in compliance to the ICH Q3A guideline. Several mutagenic impurities were identified and control strategies in accordance with ICH M7 guideline have been proposed for.

The active substance is packed in double LDPE bags which comply with EC 10/2011 and with the Ph. Eur. monograph 3.1.4.

## 2.4.2.3. Specification

The  active  substance  specification  includes  tests  for  appearance  (colour),  identity  masitinib  (IR, UPLC/UV) identity mesilate ion ( 1 H-NMR), melting point (DSC), water content (Ph. Eur.), sulphated ash (Ph. Eur.), heavy metals (Ph. Eur.), related substances (UPLC/UV), residual solvents (GC), microbiological purity (Ph. Eur.), particle size distribution (laser diffraction), assay masitinib (UPLC/UV) and methanesulfonic acid (titration).

In addition, tests for the metal impurities palladium and vanadium (ICP OES), test for the alkyl mesilates (GC) and tests for a number of potential mutagenic impurities (UPLC/MS) are included.

The  analytical  methods  used  have  been  adequately  described  and  the  non-compendial  methods appropriately validated in accordance with the ICH guidelines.

The specifications and their limits are considered to be acceptable and have been appropriately justified. The potential formation of genotoxic impurities has been investigated and appropriate specifications have been set.

Batch  analysis  data  on  3  production  scale  batches  of  the  active  substance  (manufactured  in  2015 according to the process described in the current version of the ASMF) were provided. The batches were all analysed according to the analytical methods presented in the dossier. The results were within the proposed specifications and consistent from batch to batch.

## 2.4.2.4. Stability

Stability data on 3 production scale batches of the active substance stored for up to 12 months under long term conditions at 25ºC / 60% RH and for up to 6 months under accelerated conditions at 40ºC / 75% RH were provided. These batches were tested according to the specifications and with the analytical methods presented in the current version of the ASMF.

A  statistically  significant  trend  is  observed  for  increasing  a  certain  impurity  content  and  for  an unidentified impurity. An OOS result was observed. It is claimed that for one of batches this is due to the fact that batch was placed on stability studies more than 1 year after manufacturing date, besides it was stored at room temperature. However, the same is observed for another batch as well. Only one batch stored at 5ºC complies with all parameters tested for 24 months, whereas 12 months' compliant data is available for another batch. Therefore, based on results of these two batches, a 12-month retest period if stored at 5ºC can be granted.

A  forced  degradation  study  was  conducted  on  masitinib  mesilate  in  the  solid  state  and  in  aqueous solution. In aqueous solution, degradation was observed under all conditions, except alkaline with the

<div style=\"page-break-after: always\"></div>

formation of an impurity (for which formation mechanism is unexplained) and unknown degradation products. The impurity is due to masitinib hydrolysis occurring under the stressed conditions. In the solid state, no significant change was observed.

Two batches of masitinib mesilate were exposed to light for about 24 h (1.2 MioLux/h), according to ICH guideline Q1B. This photostability study revealed no significant changes due to the UV-light exposure; masitinib mesilate appears not to be photosensitive.

Historical stability data was submitted for information only. Primary (batches manufactured from 2015 to 2017) and supportive stability data were presented to support the initially claimed 18 months retest period  and  storage  (at  5ºC)  and  transport  conditions  (no  specific  condition).  The  stability  data  was obtained under the ICH Q1A(R2) conditions: 5ºC for long term conditions, 25ºC±2ºC / 60%±5% RH for accelerated  conditions  and  40ºC±2ºC  /  75%±5%  RH  for  stress  conditions.  Stability  studies  on  six batches of the drug substance manufactured in 2009 and 2010 (before changes to the manufacturing process of the drug substance were implemented) were provided. These batches were tested as per the specifications and using the analytical methods in force at the time of the studies. The results from longterm stability studies (3 batches x 60 months and 3 batches x 48 months) as well as from the accelerated stability studies (6 batches x 6 months) show that the drug substance is stable as all parameters comply with  the  established  specification  limits;  no  trend  and  no  significant  differences  between  room temperature and accelerated conditions were observed.

Overall, the batch data provided justify the retest period of 12 months for the masitinib mesilate active substance.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

The finished product was proposed as 100 mg film-coated tablets that are light orange coloured, capsule shaped, embossed with '100' on one side and 'C' on the other side, and 200 mg film-coated tablets that are light orange coloured, capsule shaped, embossed with '200' on one side and 'C' on the other side. mesilate The strengths are distinguished by size and number marking which is acceptable. The 100 mg &amp; 200 mg strengths are manufactured fully dose proportional.

The excipients are microcrystalline cellulose (Avicel pH101 and pH200), povidone, crospovidone type A and magnesium stearate. The film coat contains polyvinyl alcohol, titanium dioxide, macrogol, talc and sunset yellow lake (E110). Opadry II orange 85F23318 contains hydrolysed polyvinyl alcohol, titanium dioxide, talc, macrogol and sunset yellow lake (E110).

The two strengths of the formulation are manufactured from one common blend.

The proposed container closure system was HDPE bottle, closed with a sealed film and a child-resistant (polypropylene) PP cap.

The applicant has not defined the quality target product profile (QTPP), has not identified potential critical quality attributes (CQAs) of the finished product and has not defined a control strategy, which according to ICH guideline Q8 (R2) on pharmaceutical development (EMA/ CHMP/ICH/167068/2004) requirements. It is acknowledged the applicant's position regarding the quality target product profile (QTPP) which was not requirement in 2004 when product development began. Since manufacturing process of film-coated tablets is considered a standard process and critical/non-critical aspects of process and product quality were  considered  during  product  development  and  implemented  in  the  updated  process  validation protocol, this can be considered acceptable.

<div style=\"page-break-after: always\"></div>

Masitinib mesilate exists in three polymorphic forms. Polymorphic form DRX 1, the most stable form, is used to manufacture the finished product. This form exhibits a pH-dependant solubility profile across the physiological pH range with highest solubility at low pH (34 g/l at pH 1.3). The particle size of the drug substance is reduced by impact milling and is controlled in the active substance specification.

All excipients are well known pharmaceutical ingredients, and their quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The compatibility of the active substance and excipients was investigated. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

In early clinical development masitinib 50 mg capsules were used. Later on, an immediate release tablet was  developed  as  the  commercial  formulation.  Bioequivalence  has  been  demonstrated  between  the phase 1 capsule formulation (2 x 50 mg) and the tablet formulation (1 x 100 mg). The applicant provided detailed  information  on  the  selection  of  dissolution  method  to  bridge  between  the  clinical  tablet formulation and the proposed commercial tablet formulation. Since the tablets used during phase 2 and phase 3 studies have the same composition and are manufactured by a simple manufacturing process, the  bridging  between  clinical  formulations  and  the  proposed  commercial  formulation,  supported  by relevant dissolution data, was considered acceptable.

The proposed dissolution method uses the Ph. Eur. paddle apparatus with 0.01 N HCl as dissolution medium, 900 ml volume, 37.0 ± 0.5ºC temperature. The applicant initially proposed the dissolution method with a paddle speed of 100 rpm. However, this was not considered sufficiently discriminatory resulting in a major objection. The applicant proposed to reduce paddle speed to 75 rpm based on similar dissolution results at 20 minutes time points to increase the discriminatory power of the method this way. However, several deficiencies and the lack of a reasonable explanation for the significant differences of dissolution data between the 100 mg strength and the 200 mg strength, as well as differences of dissolution data between different batches of 200 mg strength were identified. The suitability of the dissolution method to ensure proper control of the medicinal product, especially for 200 mg strength has not been demonstrated. The applicant has been repeatedly asked to explain and justify the differences in dissolution results between the 100 mg batches and the 200 mg batches, given that both strengths are homothetic, qualitative and quantitative composition is proportional and the same manufacturing process is used. It is not obviously demonstrated that tablet mass, hardness and film-coating or the differences observed between the two strengths are the root causes for the differences in dissolution results observed between 100 mg and 200 mg tablets. The dissolution of two 100 mg tablets could have been compared with the dissolution of one 200 mg tablet to obtain data that could potentially reveal the causes of the different and variable dissolution results (according to Guideline on the Investigation of Bioequivalence; CPMP/EWP/QWP/1401/98), however this data has not been provided. Potential reasons for different dissolution results between 200 mg batches (intra-batch and inter-batch) have not been discussed and justified in order to ensure that, e.g., the manufacturing process is adequate to obtain a high-quality product. For finished product batches of 200 mg strength where results of dissolution do not exceed 85% in 15 minutes and high RSD% values have been observed, similarity with 100 mg strength should have been confirmed by statistical methods other than F2 calculation (e.g., bootstrap method etc), which was also not done. Therefore, the major objection regarding the dissolution method has not been resolved.

## 2.4.3.2. Manufacture of the product and process controls

The film-coated tablets are manufactured from a quantitatively identical common granule formulation using  conventional  mixing,  wet  granulation,  fluid  bed  drying,  final  blending  (3  granulation  sub-lots) compression and film-coating. Differentiation of the tablet strengths is applied at the compression stage,

<div style=\"page-break-after: always\"></div>

where both target tablet core weight and compression tooling are different. The manufacturing process is considered a standard manufacturing process.

Based on the submitted batch data, the batch size ranges are considered approvable.

The in-process controls are adequate for this type of manufacturing process and pharmaceutical form.

Process validation for three production scale batches has been carried out on the granulation steps only. The process validation protocol and approach to validation are considered acceptable.

## 2.4.3.3. Product specification

The finished product release specifications include appropriate tests for this kind of dosage form, such as  appearance  (visual  assessment),  identification  (HPLC,  UV),  uniformity  of  dosage  units  by  mass variation  (Ph.  Eur.),  average  weight,  dissolution  (Ph.  Eur.),  moisture  content  (Ph.  Eur.),  degradants (HPLC), microbiological quality (Ph. Eur.), assay (HPLC) and a specific impurity.

The  specifications  have  been  justified  in  accordance  with  relevant  guidelines  and  pharmacopoeial requirements.

A risk-based approach to assess the potential presence of elemental impurities in the drug product is provided and complies with the ICH Q3D Guideline for Elemental Impurities Option 2b.

A risk evaluation of the manufacturing process in terms of risk of formation and contamination of Nnitrosamines  in  active  substance  and  finished  product  is  presented  from  the  finished  product manufacturer. A risk of presence of nitrosamines impurities has been identified due to amine-containing functional groups in the active substance and nitrites/nitrates in the excipients, and according to the results  of  confirmatory  testing,  the  finished  product  must  be  controlled  for  nitrosamines.  The  major objection raised in the previous round is considered resolved.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers  for  marketing  authorisation  holders/applicants  on  the  CHMP  Opinion  for  the  Article  5(3)  of Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal  products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine  impurities  in  human  medicinal  products'  (EMA/369136/2020).  Based  on  the information provided, a limit for an impurity was proposed for the specifications of the finished product and this was considered acceptable. The acceptable intake (AI) has been adopted by the CHMP after consulting the Nitrosamines Safety Operational Expert Group (NSOEG).

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for 16 batches of 100 mg tablets and 33 batches of 200 mg tablets manufactured  at  the  proposed  commercial  manufacturing  site  and  clinical  site,  at  various  scales, confirming the consistency of the manufacturing process.

## 2.4.3.4. Stability of the product

Stability  data  from  five  batches  of  the  100  mg  tablets  and  ten  batches  of  the  200  mg  tablets  (all manufactured at commercial scale) stored under long term conditions at 25ºC / 60% RH for up to 36 months and for up to 6 months under accelerated conditions at 40ºC / 75% RH according to the ICH guidelines  were  provided.  Samples  were  tested  for  appearance,  moisture  content,  hardness,  assay,

<div style=\"page-break-after: always\"></div>

impurity content, dissolution and microbial testing. During the assessment procedure, both release and shelf-life specifications of the finished product have been updated to include an acceptable limit for Nnitroso-masitinib, thereby ensuring control of the impurity throughout shelf-life.

The batches of medicinal product are representative to those proposed for marketing and were packed in the primary packaging proposed for marketing.

The  stability  data  presented  do  not  show  degradation  in  any  of  the  batches  presented  under  any condition.

Force degradation was carried out under various stress conditions as part of the analytical validation. Degradation was observed under acidic, alkaline and oxidative conditions. Satisfactory mass balance data showed that the analytical procedure for impurities is stability indicating.

In addition, a photostability study as per ICH Q1B conducted on one batch of tablets from each strength showed a slight fading of the colour of film-coating, however the proposed HDPE primary packaging offers sufficient protection from light exposure. No change was observed in any of the other parameters tested.

A holding time study was conducted for each dosage strength on one batch of core tablets and one batch of film-coated tablets packaged and stored in bulk in PE bags. The holding time of 1 month before coating step and 6 months as coated tablet was confirmed.

Based on available stability data, the shelf-life of 36 months when stored in the original container to protect from light is acceptable.

## 2.4.3.5. Adventitious agents

No excipients derived from animal or human origin have been used. It is confirmed that the raw materials used for the production of magnesium stearate are of synthetic or plant origin.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

The major objection, raised during the procedure, on the suitability of the proposed dissolution method to ensure proper control of the medicinal products during the lifecycle of the medicinal product, especially for the 200 mg strength, and therefore to ensure batch to batch consistency has not been sufficiently demonstrated and therefore not resolved. Several deficiencies and the lack of an acceptable explanation for the significant differences of dissolution data between the 100 mg strength and the 200 mg strength, as well as differences in dissolution profiles between different batches of the 200 mg strength remain at the time of opinion. The applicant has not convincingly demonstrated that tablet hardness and filmcoating are the main issues for differences in dissolution results between 100 mg and 200 mg tablets as dissolution results do not correlate with these parameters. Moreover, the potential reasons for different dissolution results between 200 mg batches (intra-batch and inter-batches) were not discussed in order to ensure that, e.g., the manufacturing process is adequate to obtain a product with the intended high quality.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is not considered acceptable. Physicochemical and biological aspects relevant to the uniform clinical performance of the product were not demonstrated.

The suitability of the proposed dissolution method, raised as a major objection during the procedure,

<div style=\"page-break-after: always\"></div>

has not been sufficiently demonstrated. It can not be assured that the medicinal products during the lifecycle of the medicinal product will be controlled in a satisfactory manner, especially for the 200 mg strength, and therefore batch to batch consistency cannot be ensured.

## 2.4.6. Recommendations for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Within this application, Masitinib AB Science, in combination with riluzole, is proposed for the treatment of adults with ALS.

The nonclinical development strategy followed for Masitinib AB Science is compliant with ICH guidance as laid out in ICH M3 (R2). The nonclinical package addresses all of the principal nonclinical issues, including pharmacokinetics, general toxicity, reproductive toxicity (segment III study), carcinogenicity, genotoxicity, mutagenicity, and safety pharmacology. Individual studies are compliant with detailed ICH safety guidance documents.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

Masitinib  AB  Science  (mesilate  salt  of  AB1003  also  referred  to  as  AB1010)  is  a  non-cytotoxic  new chemical entity that belongs to the pharmacological class of drug known as TKI [Dubreuil 2009]. Masitinib AB Science is a small molecule drug that selectively inhibits specific tyrosine kinases such as CSF1R, cKit,  LYN,  FYN,  and  PDGFR α and β, in  the  submicromolar  range  [Dubreuil  2009;  Davis  2011].  Two independent studies showed masitinib mesilate to have a very high level of selectivity from a wide range of protein kinase inhibitors [Anastassiadis 2011; Davis 2011]. At the cellular level, masitinib mesilate is a potent inhibitor of CSF1R-dependent cell proliferation (half maximal Inhibitory Concentration (IC50) 90 nM), of wild-type c-Kit-dependent cell proliferation (IC50 100-300 nM), of LYN- and FYN-dependent cell proliferation (IC50 225-240 nM), and of PDGFR-dependent cell proliferation (IC50 0.25-20 nM).

There is a growing body of evidence indicating that immune dysfunction and neuroinflammation may be pathological characteristics of ALS [Vahsen 2021; Clarke 2020; Skaper 2018; Iyer 2018; Crisafulli 2018; Skaper 2014]. Microglia are the immune cells of the central nervous system (CNS) that play a wellknown pathogenic role during ALS progression [Brites 2014]. Mast cells are effector immune cells and key  in  chronic  neuroinflammatory  processes,  constituting  an  important  source  of  inflammatory mediators, sustaining the neuroinflammatory network and modulating the blood-brain barrier permeability. Moreover, evidence suggests that ALS is a neurodegenerative disorder in which crosstalk between mast cells, microglia and astrocytes results in motor neuron damage.

Within this application, Masitinib AB Science is intended for the treatment of adult patients with ALS. The exact molecular pathways causing motor neuron degeneration in ALS remain unknown, but as with other neurodegenerative  diseases,  it  is  likely  to  involve  a  complex  interplay  between  multiple  pathogenic cellular mechanisms.

<div style=\"page-break-after: always\"></div>

Hence, because of its potent and selective activity against CSF1R, masitinib mesilate is able to inhibit the CSF1/CSF1R signalling pathway thereby regulating CSF1R-dependent cells such as microglia, the immune cells of the CNS that play a well-known pathogenic role during ALS progression [Brites 2014]. Likewise, by merit of its activity against c-Kit, LYN and FYN, masitinib mesilate is able to inhibit mast cells, an effector immune cell that is key in chronic inflammatory processes. The development of Masitinib AB Science in ALS is therefore based on its pharmacological action in microglia and mast cells, among others, an approach that has been shown to slow microglial-related disease progression, reduce neuroinflammation, and modulate the degenerative neuronal microenvironment in both central and peripheral (PNS) nervous systems [Kovacs 2021; Harrison 202; Trias 2016, Trias 2020; Trias 2018; Trias 2017].

Mast cells orchestrate inflammatory processes and contribute to the neuroinflammatory cascade by merit of the wide array of pro-inflammatory mediators they release. Indeed, mast cells represent one of the main CNS sources of cytokines and chemokines [Stassen 2002; Kinet 2007]. In both the CNS and PNS, as in other tissues, activated mast cells may undergo explosive degranulation or may steadily release granules  into  their  microenvironment.  Following  activation,  mast  cells  remain  intact  and  viable  to resynthesise their granules. Secretory granules store a wide variety of mediators, which when released into the CNS can alter the function of both neural and vascular elements. The importance of c-Kit, LYN and FYN for mast cell function and activation is well-known. Krystel-Whittemore 2016; Reber 2014

Microglia play a fundamental pathogenic role during ALS disease progression. It is now well established in the literature that proliferation and accumulation of microglial cells (microgliosis), which also promotes the emergence of aberrant glial cells, is a major neuropathological feature of SOD1G93A ALS animal models [Trias 2013; Díaz-Amarilla 2011]. Microglial cells are regulated by the CSF1/CSF1R signalling pathway. Additionally, evidence suggests that ALS is a neurodegenerative disorder in which crosstalk between mast cells, microglia and astrocytes may result in motor neuron damage [Sandhu 2021; Skaper 2014].

Thus, while microglial and mast cells individually play important roles in sustaining the inflammatory network of the PNS and CNS, the existence of mast cell-microglia crosstalk is likely to further contribute to the exacerbation of neurodegenerative disease and to accelerate disease progression. Microglia and mast cells therefore represent potential therapeutic targets in ALS for a pharmacological agent capable of simultaneously modulating their pathogenic roles.

## 2.5.2.2. Secondary pharmacodynamic studies

Secondary PD studies were not performed.

## 2.5.2.3. Safety pharmacology programme

From a safety pharmacology perspective, Masitinib AB Science after single dose administration did not induce significant effects on the central nervous and respiratory system in rats, and no modifications of cardiovascular function or electrophysiological parameters in telemetered dogs were observed. Results from chronic toxicology studies in dogs demonstrated that Masitinib AB Science had no significant effect on the cardiovascular function and the cardiac electrophysiology. Moreover, the clinical experience did not evidence any sign of cardiotoxicity with Masitinib AB Science. However, when the effects of AB1010 were  tested  on  hERG  channel  stably  expressed  in  HEK-293,  there  was  a  significant  concentrationdependent reduction (IC50: 8.3 ± 1.1 μ mol/L) in hERG tail current amplitude in presence of AB1010 from 0.1 to 30 μ mol/L. This effect was only partially reversed after the washout period and was significant compared to the spontaneous run-down observed in the control group.

<div style=\"page-break-after: always\"></div>

## 2.5.2.4. Pharmacodynamic drug interactions

No PD drug to drug interaction (DDI) studies were performed for Masitinib AB Science. All studies are pharmacokinetic (PK) drug interactions.

## 2.5.3. Pharmacokinetics

Preclinical PK and toxicokinetic investigations have been conducted in mice, rats, and dogs in order to characterise the PK behaviour of Masitinib AB Science.

## Absorption

Masitinib  AB  Science  is  well  absorbed  after  oral  administration.  Oral  bioavailability  following  gavage administration of radiolabelled AB1010 (labelled on the phenylpiperazine moiety) to rats or dogs at 10 mg/kg was:

- -69.5% and 74.8% as plasma radioactivity in male and female rats, respectively
- -64.3% and 66.2% as whole blood radioactivity in male and female rats, respectively
- -84.6% and 81.4% as plasma radioactivity in male and female dogs, respectively
- -79.8% 78.0% as whole blood radioactivity in male and female dogs, respectively

In mice, the time of maximum concentration observed (tmax) was reached 1 or 2 hours after oral (gavage) administration. Systemic exposure [as measured by the maximum concentration observed (Cmax) and area under the concentration-time curve from time zero to 24 hours (AUC0-24h)] increased with doselevel in an approximately dose proportional manner. There was no gender effect on systemic exposure to AB1010, but plasma levels of AB3280 tended to be approximately 2-fold higher in females than males. Systemic exposure to AB3280 represented between 6 and 23% (approximately) of the AB1010 exposure in terms of AUC.

In rats, following single oral administration of AB1010 the maximum concentration was reached at 4 hours  (tmax)  with  an  apparent  half-life  t1/2  of  3  hours.  A  supra-linear  increase  in  systemic  test  item exposure expressed as area under the concentration-time curve from time zero to time t (AUC0-t) or area under the concentration-time curve from time zero to infinity (AUC0-∞ ) was noted in males and females and this was more marked between 10 and 30 mg/kg/day. A gender effect was also noted after single and repeated administration, as test item exposure was about 2-fold higher in females than in males. After repeated daily administration, comparison of AUC0-∞ values obtained on days 1 and 28 showed increased systemic AB1010 exposure at all dose-levels in both sexes. Exposure to the plasma metabolite AB3280 was higher in males than in females.

In dogs, in a 4-week study by daily oral administration at 3, 10 and 30 mg/kg/day AB1010 was rapidly absorbed with a tmax at 1 or 2 hours after administration. A supra-linear increase in systemic exposure was noted between 3 and 30 mg/kg/day in males and females after single and repeated administration. Systemic exposure to AB1010 and AB3280 was similar in males and females. Systemic exposure to AB1010 and AB3280 was broadly similar after single administration or repeated administration for 4 weeks.

Overall, masitinib mesilate appeared to be well absorbed after oral administration in the different animal models (mice, rats, cats and dogs). Bioavailability (in terms of measured radioactivity) varies from 65% in rats to around 80% in dogs. Absorption was reasonably rapid with tmax values between 0.5 and 4 hours in all species and (apparent half-life t1/2) values in the range 1-4 hours in the rat and 2 -5 hours in the dog.

In mice there was no effect of sex on systemic exposure to Masitinib AB Science, but plasma levels of AB3280  were  approximately  2-fold  higher  in  females  than  males.  In  rats  a  sex  effect  on  systemic

<div style=\"page-break-after: always\"></div>

exposure  to  masitinib  was  noted  after  single  and  repeated  administration,  with  consistently  an approximate 2-fold higher exposure in female rats than males. In dogs there was no evidence of any sex effect on systemic exposure to Masitinib AB Science.

Absorption was broadly dose-proportional with a tendency to increase in a supralinear fashion; this was more marked at lower dose-levels. There was evidence of increased systemic exposure after repeated daily administration in the rat but not in the dog.

## Distribution

Binding of AB1010 to the cellular fraction of whole blood was studied by partitioning and protein binding of AB1010 was studied by equilibrium dialysis. Binding to blood cells was high when suspended in buffer (&gt;90% for human, rat, mouse, and dog blood cells) and reduced in the presence of plasma (63% for human, 45% for rat, 78% for mouse, and 56% for dog blood cells). Plasma protein binding of AB1010 was also high for human (93%), rat (92%), mouse (86%), dog (93%) and rabbit (98%) at therapeutic plasma concentrations.

AB3280 metabolite plasma protein binding was determined by a blood partitioning method. Binding was high in all species: more than 90% in human plasma and more than 85% in dog, mouse and rat plasma. It is interesting to notice that human plasma has a total binding capacity for AB3280 twice as high (NKp =14.0) as in animal plasma (NKp =5.77, 6.56 and 7.23 respectively for dog, mouse and rat) implying a lower free fraction in human plasma.

Tissue distribution of  14 C-AB1010 was studied in the rat. Following oral gavage at 10 mg/kg, quantifiable levels of radioactivity were found in most tissues at 24 hours, the highest levels being found in the adrenals, kidneys, spleen and intestines (in the range 3000 to 16 000 ngeq/g tissue at 24 hours). The high values for volume of distribution (6.7 L/kg at 5 mg/kg, i.v. ; 11.7 L/kg at 10 mg/kg, oral) indicate extensive distribution of AB1010 to the tissues. Radioactivity was rapidly eliminated and only trace levels remained at 7 days post administration. There was no data suggesting that AB1010 crosses the bloodbrain barrier under normal circumstances.

## Metabolism

Several in vitro and in vivo studies allowed identification of four main metabolic pathways for AB1010: N-demethylation, hydrolysis of amide bond, N-oxidation, Hydroxylation.

Below table summarises the results of these in vitro and in vivo studies, according to the species used for toxicity testing and in humans.

Table 1: Overview of metabolic pathways in species used for toxicity testing and in humans

| Metabolic pathways                  |          | Mouse   | Rat   | Dog   | Human   |
|-------------------------------------|----------|---------|-------|-------|---------|
| N-demethylation (AB3280)            | in vitro | +       | +     | -     | +       |
| N-demethylation (AB3280)            | in vivo  | +       | +     | +     | +       |
| Hydrolysis (AB1187.3+AB2436)        | in vitro | +       | +     | -     | -       |
| Hydrolysis (AB1187.3+AB2436)        | in vivo  | +       | +     | +     | +       |
| N-oxidation (AB1010 N- oxide)       | in vitro | +       | +     | +     | +       |
| N-oxidation (AB1010 N- oxide)       | in vivo  | ND      | +     | +     | ND      |
| Hydroxylation (mono- hydroxyAB1010) | in vitro | ND      | ND    | ND    | ND      |
| Hydroxylation (mono- hydroxyAB1010) | in vivo  | ND      | +     | +     | ND      |

ND: not determined. '+' = present in one of the studies. '-' = not present in any studies

<div style=\"page-break-after: always\"></div>

## N-demethylation

When the  N-methyl  piperazine  group  is  removed,  the  N-demethyl  derivative  (AB3280)  of  masitinib mesilate (AB1010) is formed.

The  N-demethylation  pathway  leading  to  the  formation  of  AB3280  is,  by  far,  the  major  route  of metabolism  of  AB1010.  This  reaction  was  observed in  vitro in  all  species  except  dogs. In  vivo Ndemethylation  has  been  identified  as  the  main  pathway  of  metabolism  since  AB3280  was  the  main metabolite found in plasma as well as in feces. In urine, however, AB3280 was present only in small quantities, a logical consequence of its poorly soluble in aqueous media, with it therefore being expected to be mainly excreted in feces.

## Hydrolysis

When the amide group of AB1010 is hydrolysed by drug metabolizing enzymes, in particular in mice and rats, two hydrolysis products are formed:

- -A carboxylic acid moiety (internal code: AB1187.3) containing the phenylpiperazine moiety that then undergoes conjugation with glucuronic acid.
- -An aniline part (internal code: AB2436) containing the thiazole heterocycle, which is subject to oxidation to a further metabolite (internal code: AB5235).

The hydrolysis of the central amide bond leading to the formation of AB236 and AB1187.3 takes place in all species but there are some conflicting results between in vitro and in vivo data.

In vitro , AB2436 was present as a major metabolite in mouse and rat but not in human (&lt;1%). Cleavage of the amide bond to give AB1187.3 and AB2436 was detected by LC-MS/MS in human; however, it was not determined to be a major route of metabolism in human.

AB1187.3 was found in non-negligible amounts in human plasma. AB1187.3 was identified as the major urinary metabolite in rats and dogs. It was also found in significant quantities in human urine but was not looked for in mouse urine.

AB2436 could be detected in human plasma and AUC values of AB2436 at steady-state represented less than 3% of AUCs of AB1010. It was found in rat plasma albeit in low concentrations i.e. at AUCs 200 times lower than the plasmatic AUCt measured for AB1010; in mouse plasma it was detected at high concentrations i.e. at an AUCt 4 times higher than the plasmatic AUCt measured for AB1010. AB2436 was found in urine of mice, rats and humans. An oxidised form of AB2436, the pyridone AB5235 has been found but only in mouse urine, which is in agreement with the large quantities of AB2436 found in this biological fluid.

AB2436 was not detected in dogs' urine although AB1187.3 was present. In feces, there was no evidence of the presence of either AB1187.3 or AB2436.

## N-oxidation

The N-oxidation was identified as a minor metabolic pathway whatever the species, including humans. This pathway was evidenced in vitro and confirmed in vivo with the formation of N-oxide metabolites in urine and feces of rats and dogs.

## Hydroxylation

The other minor metabolic pathway was the hydroxylation pathway identified in rats and dogs with the formation of mono-hydroxylated derivatives of the parent compound in urine and feces and conjugates such as sulfates. It was not determined in mice and humans.

Role of cytochromes in the AB1010 metabolism

<div style=\"page-break-after: always\"></div>

An in  vitro metabolism  study  with  pooled  human  liver  microsomes  was  performed  to  identify  which human cytochrome P450 isotype(s) contribute to the metabolism of AB1010. The results indicated that that CYP3A4 catalyses the metabolism of AB1010 (and the formation of metabolites named MET 1-4) in human liver, with a possible minor contribution by CYP2C8 in the formation of AB3280.

An in vitro study with human liver microsomes confirmed the involvement of CYP2C8 in the formation of AB3280 (AB3280 formation ratio = 7.0% at 5 µM). However, when CYP2C8 specific inhibitor montelukast was incubated with microsomes, the inhibition of AB3280 formation was partial and was only about 52%. These results seem to indicate the involvement of another enzyme in AB3280 formation. The additional data submitted by the applicant supports the conclusion that CYP3A4 and CYP2C8 are the main enzymes involved in AB3280 formation. This information was included in the SmPC.

## Excretion/Elimination

The principal route of elimination of masitinib mesilate appeared to be biliary excretion. After oral or intravenous administration of radiolabelled masitinib mesilate (AB1010) to rats or dogs, approximately 90% of radioactivity was excreted in the feces, mainly as parent compound. Less than 10% of the administered dose was found in urine with a moderately rapid elimination within 48 hours. Excretion was almost complete within 7 days, regardless of administration route, dose, and species. There was no evidence of hepatobiliary cycling, and no evidence of sex differences in excretion.

AB3280 is the main metabolite in feces (the principal route of elimination). The second major metabolite in dog feces corresponds to a sulfate conjugate of a mono-hydroxylated form of masitinib. The major metabolite in urine is AB1187.3, the carboxylic acid fragment arising from the hydrolysis of the central amide linkage present in masitinib. Apart from the parent compound up to 12 metabolites were detected in urine and 8 metabolites were identified in the feces.

The analysis of urine samples of male Sprague Dawley rats having received masitinib mesilate at oral doses of 30, 125, 250 and 500 mg/kg demonstrated a low concentration of masitinib mesilate in urine, confirming that urinary excretion is not the main route of excretion, whatever the masitinib dose tested. Only one metabolite, AB2436 was found in rat urine in concentrations similar to those of AB1010. No AB6465 was detected, which was expected since this acetylated-aniline is most probably cleaved into the parent aniline (AB2436) before being excreted.

Conversely, in male Swiss mice, analysis of urine samples demonstrated the presence of AB1010 and two metabolites, AB2436 and AB5235, whatever the masitinib dose tested. Except for one sample at the 500 mg/kg dose, AB6465 was not detectable in mouse urine.

## Pharmacokinetic Drug Interactions

## Medicinal products That may decrease masitinib plasma concentrations

Concomitant  administration  of  masitinib  with  inducers  of  CYP3A4  may  decrease  masitinib  plasma concentrations. The extent has not been elucidated in vivo . However, as demonstrated in the clinical trial AB14004, masitinib plasma exposure was poorly altered by a strong inhibitor of both CYP3A4 and P-gp (itraconazole).  It  may  thus  be  estimated  that  masitinib  will  be  weakly  sensitive  to  CYP3A4  or  P-gp inducers.

## Medicinal products that may increase masitinib plasma concentrations

Concomitant administration of masitinib with CYP3A4 inhibitors or P-gp inhibitors may increase masitinib plasma concentrations. As demonstrated in the clinical trial AB14004, masitinib plasma exposure was poorly  altered  by  a  strong  inhibitor  of  both  CYP3A4  and  P-gp  (itraconazole).  CYP2C8  is  partially responsible for masitinib in vitro biotransformation. Because of the lack of in vivo DDI investigations, the co-administration of masitinib with CYP2C8 inhibitors should be used with caution.

## Effect of masitinib on other medicinal products

<div style=\"page-break-after: always\"></div>

Masitinib is an inhibitor of CYP3A4 in vitro with an IC50 ≥ 14μ M. However, this concentration is unlikely to be reached for masitinib dose up to 6.0mg/kg.

Masitinib is an inhibitor of P-gp at concentrations higher than 10 μ M. This concentration is unlikely to be reached in case of masitinib treatment at 6.0mg/kg/day. However, coadministration by oral route of masitinib with narrow therapeutic index P-gp substrates should be avoided.

There  is  a  risk  of  DDI  with  medicinal  products  which  are  Breast  Cancer  Resistance  Protein  (BCRP) substrates. The extent has not been investigated in vivo .  Co-administration of masitinib with narrow therapeutic index BCRP substrates should be avoided.

No data are available concerning masitinib inhibitory potential on CYP2B6. Caution should be taken when administering masitinib with CYP2B6 substrates.

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

Single dose toxicity studies comprised three GLP-compliant studies in Sprague-Dawley rats, two with administration by oral gavage (0 or 2000 mg/kg) and one with administration by intravenous injection (0  or  100  mg/kg).  Clinical  signs  of  toxicity  were  observed  in  all  studies,  including,  after  oral administration, hypoactivity or sedation, piloerection and dyspnoea and, after intravenous administration, hypoactivity. Mortality (2 out of 10 animals) was observed in one of the studies with oral administration.  The  approximately  lethal  doses  in  rats  were,  therefore,  2000  mg/kg,  following  oral administration, and higher than 100 mg/kg, following intravenous administration. Results of the studies showed that masitinib mesilate has low acute toxicity.

## 2.5.4.2. Repeat dose toxicity

Repeat-dose toxicity studies were conducted in mice, rats and dogs, with daily administration by oral gavage, and a duration of treatment of up to 13, 26 and 39 weeks, respectively. Except for three studies, all the others were claimed to be GLP-compliant.

The main toxicity target organs identified were the bone marrow, liver, kidney, gastrointestinal tract, and reproductive organs. At higher dose-levels these findings were accompanied by bodyweight changes and mortality.

Bone marrow toxicity observed in mice, rats and dogs was characterised by a reduction in red blood cell parameters (reductions in red blood cells, haemoglobin and packed cell volume), a reduction in white blood cells (leucocytes, lymphocytes and neutrophils), bone marrow hypocellularity in rats and dogs as well as clinical signs in the form of pallor and abnormal breathing in the dog. Haematological effects were observed at doses ≥ 10 mg/kg/day in rats and dogs.

Liver weight increase and hepatocellular hypertrophy was noted in mice, rats and dogs. This finding was accompanied  by  a  moderate  (≥  2 -fold)  increase  in  liver  enzymes  (alanine  aminotransferase  (ALT)/ aspartate aminotransferase (AST)) at doses ≥100 and ≥ 150 mg/kg/day in rats and dogs, respectively. Moreover, reversible bile canalicular plugs were noted in dogs treated with 50 mg/kg masitinib for 4 weeks.

Renal toxicity was observed in rats (protein in the urine, increased urine volume and pH, increased kidney  weight,  increases  in  plasma  creatinine  and  urea  as  well  as  degenerative/necrotic  tubular nephropathy) and in dogs (blood, bilirubin, proteins in urine) at the highest dose in the 4-week study.

<div style=\"page-break-after: always\"></div>

In the mouse there was urinary bladder urothelial hyperplasia in male mice which was not fully reversible during a recovery period. Similar results were found in a 13-week follow-up study in male mice to further investigate the neoplastic findings in bladders of mice in the carcinogenicity study.

Gastro-intestinal toxicity was recorded in dogs and was mostly characterised by clinical observations. These clinical observations included vomiting, regurgitation, and soft feces.

Female genital organs showed morphological changes indicative of oestrous cycle disturbance in rats from 10 mg/kg/day. At 100 mg/kg/day, the ovaries had moderate to large number of luteal and/or follicular haemocysts, no or few corpora lutea, and very few or few follicular development. Depending on ovarian stage, this was associated with endometrial cell atrophy or hypertrophy together with vaginal epithelial cell hyperplasia, hyperkeratinisation or mucification. Ovary weight was increased and on the macroscopic level, discoloured and enlarged ovaries were observed. Partial reversibility was noted in the 4-week toxicity in rats, although not confirmed in the 13-week toxicity in rats.

Following  39-weeks  treatment  with  30  mg/kg/day  masitinib,  vacuolation  of  the  epithelium  in  the seminiferous tubules and oligospermia in the epididymides were observed in dogs. Most male Beagle dogs are sexually mature by eight to nine months of age and since the animals applied in the 39-week dog study were 6 to 7 months at study initiation the majority were sexually mature at sacrifice (1 male out of 4 was pubertal).

Additional effects identified included hyperostosis - slight to moderate hyperostosis were observed in the bones of rats administered 100 mg/kg/day for 6 months - and cardiac changes.

The repeated dose toxicity studies revealed myocardial degeneration and fibrosis in the rat 26-week study at doses 30 and 100 mg/kg/day and pericardial oedema in 1/4 female dogs at the 30 mg/kg/day dose in the 39-week study.

Regarding toxicokinetic data and safety margins, following a routine GLP compliance inspection in June 2007 by the French National Authorities, the bioanalytical (and dosage form) analysis activity for studies performed in the period 25 March 2005 to 06 June 2007, are not to be claimed GLP-compliant. The toxicokinetics data for such studies, which include the chronic toxicity studies in rats and dogs, can be considered  to  have  indicative  value  only.  For  this  reason,  the  repeated  dose  toxicity  studies  were complemented by two 4-weeks toxicokinetic studies conducted in rats and dogs using the same dose levels as in the chronic toxicity studies.

Systemic exposures in rats and dogs increased with dose levels; in rats, but not in dogs, there was a gender effect, with relatively higher systemic exposures in females; there was no marked accumulation with treatment duration.  On a few occasions, masitinib was detected in the plasma samples collected from control animals. However, it is considered that these minor deviations have not impacted on the validity of the affected studies.

## 2.5.4.3. Genotoxicity

In vitro and in vivo studies were performed with masitinib mesilate to determine potential genotoxicity.

Masitinib  was  non-genotoxic  in  a  test  battery  comprising  the  following  assays:  Ames  test,  human lymphocytes, L5178Y TK+/- mouse lymphoma cells, in vivo mouse bone morrow micronucleus test and Comet assays of mouse and rat liver and bladder tissues.

<div style=\"page-break-after: always\"></div>

## 2.5.4.4. Carcinogenicity

An  overview  of  the  carcinogenicity  studies  performed  is  presented  in  the  below  table.  The  vehicle consisted of a sterile, isotonic saline solution.

Table 2: Carcinogenicity studies

| Study ID /GLP                                                       | Dose (mg/kg/day)                                                                          | Species/ No. of animals/ Route         | NOAEL (mg/kg/ day)   | Major findings                                                                                 |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------|----------------------|------------------------------------------------------------------------------------------------|
| SR-1-29400-tcs/ In vivo phase: GLP Dosage form analysis: partly GLP | Group 1: Vehicle (isotonic saline) Group 2: 30/20 Group 3: 150/100/40 Group 4: 500/300/80 | CD-1 mice/ 50/sex/group/ p.o. (gavage) | 30/20                | Urinary bladder neoplasms                                                                      |
| SR-2-29402-tcd GLP                                                  | Group 1: vehicle (isotonic saline) Group 2: 10 Group 3: 30 Group 4: 75/60                 | Sprague-Dawley rats /50/sex/group      | 10                   | Uterine adenocarcinomas Pulmonary cystic keratinizing epitheliomas Thyroid follicular adenomas |

## Long-term carcinogenicity study in CD-1 mice (SR-1-29400-tcs)

## Toxicology

- Clinical signs

Treatment with AB1010 caused reflux at dosing in all treated groups, hard abdomen in all test itemtreated males and in all females, increase in size of the abdomen for males from groups 3 and 4 and in all females. Limited cases of loud breathing from groups 3 and 4 and few animals showed dyspnoea in all groups.

- Palpable masses

The frequency, time of onset, location, size, and morphological type of the palpable masses recorded were similar in the controls and treated groups.

- Body weight and food consumption

The mean body weight of males and females given 500/300/80 mg/kg/day was statistically significantly lower than that of controls from week 1, but differences were 10 to 14% lower between weeks 38 and 77 (males) or -1 to -8% lower between weeks 42 and 77 (females). The overall body weight gain of males in this group was -20% lower than that of controls. In both sexes, these effects were not observed after the reduction of the dose to 80 mg/kg/day. There were no remarkable and/or consistent differences from  control  in  the  body  weight  gain  of  males  and  females  in  the  other  test  item-treated  groups. Generally, the mean food consumption of males and females given 500/300/80 mg/kg/day groups was affected from week 9 and until the dose reduction to 80 mg/kg/day from week 77. Food intake in the other test item- treated groups was not affected throughout the study.

- Haematology and blood biochemistry

There were no treatment-related differences of toxicological importance in any of the haematological or blood biochemical parameters investigated at the end of the dosing scheduled or premature period.

## Neoplastic findings

After repeated administration of Masitinib AB Science for 2 years, urinary bladder transitional carcinomas and papillomas were seen in five high-dose males, while transitional papillomas were observed in the

<div style=\"page-break-after: always\"></div>

intermediate dose group. Urinary bladder transitional cell hyperplasia was also seen in group 3 and 4 males and females with a greater incidence than in controls and low-dose mice. As the tumours were seen only in treated animals, with a clear dose-relationship, in association with pre-neoplastic finding in males and females, in incidences far outside from historical control data and with statistically positive trend, they were attributed to treatment with Masitinib AB Science.

## Malignant lymphoma

A  slight  decrease  in  malignant  lymphoma  was  observed  in  males  and  females  treated  at  30/20, 150/100/40 and 500/300/80 mg/kg/day. This was likely related with shorter survival of treated animals. However, an effect of AB1010 could have contributed to this lower incidence.

## - Non-neoplastic findings in the liver and pigments

The following findings were observed in the liver:

- Hepatocellular centrilobular hypertrophy  from  150/100/40  mg/kg/day  in  males  and  at 500/300/80 mg/kg/day in females,
- Marginally increased incidence of hepatocellular necrosis from 150/100/40 mg/kg/day in males and females,
- Hepatocellular enlargement/microvacuolation in occasional animals from 150/100/40 mg/kg/day in males and at 500/300/80 mg/kg/day in females.

Two types of pigments were noted in treated animals:

- Renal dark grey pigment at 500/300/80 mg/kg/day in both sexes,
- Brown pigment in multiple organs from 20/30 mg/kg/day in both sexes (kidneys, heart, brain, liver, adrenals, adipose tissue, skeletal muscle, tongue, spleen, lymph nodes, thyroid glands).

Results suggest:

- There were no treatment-related neoplastic findings in female mice.

- In males, administration of AB1010 at the dose-levels of 500/300/80 mg/kg/day for 2 years initially resulted in treatment-related urinary bladder transitional carcinoma and papilloma. At the intermediate dose-level, only papillomas were observed.

Treatment-related urinary bladder transitional carcinomas and papillomas were observed in male mice treated at the high dose-level of AB1010, while transitional papillomas were observed in the mid-dose group of male mice. Noteworthy, in subsequent in  vivo Comet assays performed in accordance with OECD Test Guideline No. 489, AB1010 induced no significant increase in DNA strand breaks either in the liver or in the bladder of male mice and rats and was thus considered as having no in vivo genotoxic activity in both these organs.

The lack of genotoxicity in the bladder of mice receiving high doses of masitinib mesilate appears in contradiction with the formation of bladder carcinomas during the carcinogenicity study during which mice were administered lower doses. Anyway, even if it is not possible to totally exclude non-genotoxic carcinogenic  mechanisms  of  action  in  mice  (e.g.,  urinary  crystals,  shunting  of  kinase  activity),  the hypothesis that the formation of carcinomas after administration of AB1010 to male mice is due to the high concentration of genotoxic metabolites (anilines) present in their urine cannot be excluded. In that way, a genotoxic mode of action constitutes a worst-case.

From  the  mouse  carcinogenesis  study,  the  calculation  of  the  BMDCL  associated  with  a  benchmark response of 10% (BMDL10) for an extra risk of 10% bladder carcinomas as observed in male mice was of 220 mg/kg bw/d. The level of confidence of this reference value is very high considering the choice of the critical effect and the choice of the key study (the most sensitive species and gender).

<div style=\"page-break-after: always\"></div>

Furthermore, it was deemed useful to convert experimental doses used in mice in Human Equivalent Dose (HED) by using allometric factors and to compare the interspecies differences of urinary exposure to AB1010 and genotoxic anilines, as measures of the achieved local exposure of the carcinogenic target organ rather than to compare \"administered external dose\" values.

In the mouse, the urine concentration of genotoxic anilines at external dose of 125 mg/kg bw, i.e. 10 mg/kg  bw  in  HED,  was  of  58,545  ng/mL.  In  Human,  the  dose  of  6.7-8  mg/kg  bw  led  to  a  urine concentration (0-24h) of 190 ng/mL genotoxic anilines. At equivalent dose, the ratio between the urine concentrations of genotoxic anilines in mouse and Human corresponds to 308 (table below).

Table 3: Dose and exposure in carcinogenicity studies

| Species          | Dose (mg/kg)              | Dose (mg/kg)          | Dose (mg/kg)          | Exposure to AB1010 Plasma AUC0-24h) (ng.b/ mL)   | Exposuretogenotoxicanilines AB2436 + AB5235 + AB6465   | Exposuretogenotoxicanilines AB2436 + AB5235 + AB6465   | Signs of bladder carcinogenicity                 |
|------------------|---------------------------|-----------------------|-----------------------|--------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|
| Species          | External dose             | Averaged dose2        | HED:                  | Exposure to AB1010 Plasma AUC0-24h) (ng.b/ mL)   | Plasma AUC(0-24h) (ng.b/ mL)                           | Urine Concentration(o-24h) (ng/ mL)                    | Signs of bladder carcinogenicity                 |
| Human            | 400                       | -                     | 6.7 to 8*             | 7,024                                            | 53                                                     | 190                                                    | None expected                                    |
| Rat              | 30 125 250 500            | -                     | 4.8 20 40 80          | 2,618 40,934 70,900 121,337                      | 51 1,553 3,425 13,275                                  | 141 656 2,487 4,427                                    | None NA NA NA                                    |
| 30 125 Mouse 250 | 150/100/40 500/300/80 500 | 30 96 125 250 281 500 | 2.4 7,8 10 20 22.5 40 | 1,193 12,864** 6,816 17,342 64,998*** 55,075     | 7,600 NA 33,000 78,601 NA 169,605                      | 12,962 NA 58,545 158,490 NA 253,294                    | None Papillomas NA NA Papillomas & carcinomas NA |
| Mouse/Human      |                           |                       |                       | 1.83 (=12,864/7,024)                             | 622 (=33,000/53)                                       | 308 (=58,545/190)                                      |                                                  |

*400 mg/day corresponds to weight-adjusted doses of 6.7 to 8 mg/kg for patients weighing 60 to 50 kg

1: Human Equivalent Dose: HED (mg/kg/day) = Animal dose (mg/kg/day) X [Animal weight (kg)/Human weight (kg)]3 (Shin et al, 20102 ; Nair and Jacob, 2016)3

2 The averaged doses were calculated only for doses used in the carcinogenicity study (see Paragraph A.1Dose levels used in the carcinogenicity study in mice)

NA: not available

Otherwise,  it  is  currently  considered  that  for  carcinogenic  and  genotoxic  compounds  for  which  a Benchmark Dose (BMDL10) has been defined, the risk can be ruled out beyond a margin of exposure (MOE) of 10,000 for a lifetime exposure. This MOE of 10,000 corresponds to an excess risk of developing cancer of 1 in 1.105. As the urinary concentration of anilines in humans is 308 times lower than that observed in mice at a comparable dose, the adjustment can be made directly to the acceptable MOE of 10,000, i.e. 10,000/308, giving an adjusted MOE of 32.5.

In terms of posology, treatment in Human is performed at a daily dose of 4.5 mg/kg bw/twice a day that reaches  a  very  low  level  of  urinary  concentration  (a  dose  of  6.7  to  8  mg/kg  bw/day  led  to  a  urine concentration of 190 ng/mL).

Therefore, the BMDL10/32.5 would lead to an acceptable level of excess risk with the occurrence of one bladder tumour per 1.105. Therefore, a daily treatment of 6.7 mg/kg bw/day (220/32.5) for lifetime in Human is acceptable in terms of excess risk of bladder tumours with an occurrence of 1 for 1.105.

Long-term carcinogenicity study in Sprague-Dawley rats (SR-2-29402-tcr)

## Neoplastic findings

Trend test statistics, conducted according to Peto et al. (1980), revealed statistically significant increases for neoplasms in several organs at the dose level of 75/60 mg/kg/day.

Incidence of selected uterine neoplastic and pre-neoplastic findings

<div style=\"page-break-after: always\"></div>

The incidence of uterine adenocarcinomas seen at the high dose was higher than that observed in CIT control  data  or  in  the  literature,  therefore  this  neoplasm  was  considered  to  be  related  to  the administration of the test item at 75/60 mg/kg/day. The increased incidence observed in this study may be related to the increased incidence of ovarian follicular cysts as this lesion is reported to be associated with such cysts and is thought to be the result of prolonged oestrogen stimulation (Boorman et al., 1990).

## Incidence of selected thyroid neoplastic and pre-neoplastic findings

The incidence of follicular cell adenomas (benign tumours) at 75/60 mg/kg/day was higher than that noted in female Sprague-Dawley rats in CIT control data or in the literature (Charles River Laboratories, 2004), and therefore the high incidence at 75/60 mg/kg was considered to be related to the test item. The incidence recorded at 30 mg/kg/day was within the range of that recorded in CIT control data or in the literature and was not considered to be treatment related. The single occurrence of a follicular cell carcinoma (malignant tumour) noted for each dose-levels of 10, 30 and 75/60 mg/kg/day in females was within the range of that recorded in the literature in control female Sprague-Dawley rats.

## Incidence of selected neoplastic and pre-neoplastic findings in the lungs

Pulmonary  cystic  keratinizing  epithelioma  was  found  in  4/50  high-dose  females  whereas  it  was  not recorded in the CIT control data or in the compilation of spontaneous neoplasms of control SpragueDawley rats from Charles River Laboratories (2004) and therefore was considered to be induced by masitinib mesilate. The cystic keratinizing epithelioma appears to be a proliferative lesion limited to the rat and is rarely seen in other species (Boorman et al. , 1996). In the current study, it was thought to be secondary to the irritation elicited in the alveoli by the presence of foamy macrophages induced by the test item administration. Bronchoalveolar hyperplasia in the lungs and squamous metaplasia in the lungs, trachea  and  larynx  were  considered  to  be  regenerative  and  secondary  to  the  injury  elicited  by  the presence of foamy alveolar macrophages.

Two cases of astrocytoma and a single case of oligodendroglioma was seen in the male high-dose group comprising 50 animals while a single case of astrocytoma was noted in a female control animal. While a possible relationship to treatment cannot be excluded, in view of the presence of one astrocytoma in a control female and incidences within the range of that noted in male Sprague-Dawley rats in CIT control data or in the literature (Charles River Laboratories, 2004), this was considered unlikely.

In addition, a reduced incidence of pituitary adenomas was observed in high-dose animals.

The main conclusions of this study, as described by pathologists, indicate that:

- There is no significant increase in the total number of primary tumours with masitinib.
- There were no neoplastic findings related to the test item in male rats.
- At  the  high  dose  (75/60  mg/kg/day),  a  statistically  significant  increase  in  malignant  uterine tumours (adenocarcinomas) is observed, probably linked to endocrine imbalance.
- There is an induction of benign pulmonary tumours (cystic keratinizing epithelioma) at the high dose (75/60 mg/kg/day) in female rats. These tumours are considered to be secondary to the irritation elicited in the alveoli by the presence of foamy macrophages induced by masitinib.
- There is a statistically significant increase in benign thyroid tumours (follicular cell adenomas) in female rats at the high dose (75/60 mg/kg/day). Although the single occurrence of a follicular cell  carcinoma  (malignant  tumour)  was  noted  for  each  dose-  levels  of  10,  30  and  75/60 mg/kg/day  in  females,  it  was  not  considered  as  treatment  related  at  doses  of  10  and  30 mg/kg/day and its significance was thought to be equivocal at the high dose-level.
- There is a statistically significant decrease in benign tumours of the pituitary (adenomas of the pars distalis) in female rats at the high dose (75/60 mg/kg/day).

Rat uterus tumours

<div style=\"page-break-after: always\"></div>

In female rats there was an increase in the incidence of malignant uterine adenocarcinomas at the high dose-level of 75/60 mg/kg. These tumours are proposed to result from the elevated levels of oestrogens secreted by the ovarian cysts. A histopathological profile of 'persistent oestrus' was observed in female rats,  characterised  by  uterine  hyperplasia  and  squamous  metaplasia,  vaginal  increased  epithelial thickness  (hypertrophy)  and  cornification.  No  hormonal  imbalance  was  observed  in  female  patients treated with masitinib. In females, the increase of uterine adenocarcinomas could be specific of the species.

## Rat thyroid tumours

A single occurrence of follicular cell carcinoma was reported at each dose level in female rats. These findings were within the historical control ranged recorded by the animal supplier for female SD rats. A statistically significant increase in the incidence of benign thyroid tumours (follicular cell adenomas) was seen  at  the  high-dose  level  (75/60  mg/kg)  in  female  rats.  These  thyroid  effects  in  female  rats  are proposed to be related to the proestrogenic effect described above, and not observed in humans.

## Pulmonary cystic keratinizing epitheliomas

Pulmonary  cystic  keratinizing  epithelioma  was  found  in  4/50  high-dose  females  whereas  it  was  not recorded in the CIT control data or in the compilation of spontaneous neoplasms of control Sprague Dawley rats from Charles River Laboratories (2004) [Charles River Laboratories 2004] and therefore was considered  to  be  induced  by  the  test  item.  The  cystic  keratinizing  epithelioma  appears  to  be  a proliferative lesion limited to the rat and is rarely seen in other species [Boorman 1996]. Pulmonary cystic keratinizing epithelioma was described to occur in the rat lung after chronic exposure to high burdens of particulate material, and more commonly in female rats [Boorman 1996]. In the current study, it was thought to be secondary to the irritation elicited in the alveoli by the presence of foamy macrophages induced by the test item administration. Bronchoalveolar hyperplasia in the lungs and squamous metaplasia in the lungs, trachea and larynx were considered to be regenerative and secondary to the injury elicited by the presence of foamy alveolar macrophages. Foamy macrophages were not considered to be adverse at the dose-level of 10 mg/kg/day in the absence of associated hyperplastic and metaplastic changes.

## No increase in malignant tumours in males

In  the  study  29402  TCR,  in  males,  there  is  no  increase  in  malignant  tumours,  regardless  of  the administered dose. No increase in the frequency of malignant tumours has been observed in male rats, with the exception of a slight increase in the frequency of astrocytomes and oligodendrogliomes at the high dose. No increased frequency for these tumours has been observed for the CIT control data.

## 2.5.4.5. Reproductive and developmental toxicity

Reproductive toxicity studies comprised studies on fertility and early embryonic development, in rats, and embryo-fetal development, in rats and rabbits. All studies used the oral route of administration and were  claimed  to  be  GLP-compliant.  The  lack  of  studies  on  pre-postnatal  development  and  juvenile animals was justified by the applicant on the basis of the target patients' population and risk mitigation measures in the SmPC.

The fertility and early embryo-fetal development studies with treatment of males and females (0, 10, 30 or 100 mg/kg/day) starting before mating and continuing up to gestation day 7 showed effects in the ovaries (haemorrhagic cysts, low number of corpora lutea), reduction in pregnancy rate and implantation sites and the higher pre-implantation loss. No effects were observed in male reproductive organs or sperm parameters. The reproductive no-observed-adverse-effect-level (NOAEL) for males and females were set at 100 and 10 mg/kg/day, respectively. No effects were observed in an additional study in rats

<div style=\"page-break-after: always\"></div>

were masitinib mesilate was administered to females only (15 or 50 mg/kg/day) which were mated with untreated males after a recovery period of two weeks.

The potential  effects  of  masitinib  (0,  10,  30  or  100  mg/kg/day)  on  embryo-fetal  development  were evaluated in rats and rabbits. The study in rats revealed, at the maximum tested dose, lower fetal body weights  and  statistically  significant  increased  incidence  of  unossified  or  incompletely  ossified  bones. Maternal  toxicity  was  observed  in  the  form  of  a  significant  reduction  in  body  weight  gain  at  100 mg/kg/day. Moreover, maternal macroscopic findings were made in all masitinib-treated groups. The study in rabbits showed maternal toxicity (reduced body weight and food consumption) but no adverse effects on embryo-fetal development. None of the studies revealed teratogenic effects of masitinib. The NOAEL for effects on embryo-fetal development in rats and rabbits were determined to be, respectively, 30 mg/kg/day (AUC0.5-24 at gestation day 17 =20191 ng.h/mL) and 100 mg/kg/day (AUC1-24h at gestation day 18=110938 ng.h/mL).

## 2.5.4.6. Local tolerance

Skin sensitization potential was assessed in mice using the local lymph node assay (Study 33510 TSS). Significant lymphoproliferative responses were observed in the absence of local skin irritation at the site of administration (Study 33510 TSS). Masitinib mesilate showed skin sensitization potential and exposure may result in delayed contact hypersensitivity. Masitinib should be considered as a strong sensitiser. Masitinib mesilate was found to be a slight irritant when applied topically (Study 33511 TAL) and to be severely irritating when administered by the ocular route to rabbits (Study 33512 TAL).

## 2.5.4.7. Other toxicity studies

AB3280 being the major plasmatic metabolite of AB1010 found in all species including man, a 2-week toxicity study was conducted, and results are presented hereafter. Under the experimental conditions of the  study  and  considering  the  slight  effects  on  blood  biochemical  parameters,  the  NOAEL  is  250 mg/kg/day. No effects on the organ weights and no macroscopic or microscopic findings were observed at any dose-levels. The test item did not induce any noteworthy increase in the number of revertants, in either experiment, in any of the six strains. Although in vitro studies have been carried out in the presence of S9 which is supposed to metabolise AB1010, two specific genotoxicity studies have been performed on AB3280, its main plasmatic metabolite. AB3280 did not show any mutagenic activity in the  bacterial  reverse  mutation  test  with Salmonella  typhimurium and Escherichia  coli .  Additionally, AB3280 did not induce chromosome aberrations in cultured human lymphocytes.

AB1187.3 did not show any mutagenic activity either with or without a rat liver metabolic activation system in Salmonella typhimurium TA 98 and TA 100.

AB2436 showed mutagenic activity in the bacterial reverse mutation test with metabolic activation in the TA 1537, TA 98, TA 100, and TA 102 Salmonella typhimurium strains.

AB2436 induced chromosome aberrations in cultured human lymphocytes in the presence of S9 mix.

AB5235, showed a mutagenic activity in the presence of S9 mix both in TA 98, TA 100, and TA 102 Salmonella typhimurium strains.

Among the potential reasons for the formation of tumours, the more plausible hypothesis is based on the genotoxicity of masitinib aniline metabolites. The applicant further discussed that:

- From literature, aniline compounds are well-known to be responsible for urinary bladder cancers.

<div style=\"page-break-after: always\"></div>

- The bladder carcinogenic risk has been reported to be dose-dependent [Bolt and Huici- Montagud 2008] as it is the case with masitinib since the low dose administered during the carcinogenicity study did not induce any tumours.
- Three anilines, namely AB2436, AB5235 and AB6465, have been found to be formed after from different in vitro studies  performed  both  on  hepatic  microsomes  and  freshly  prepared hepatocytes and from in vivo studies.
- According to available studies, these three anilines AB2436, AB5235 and AB6465 were found mutagenic only in the presence of metabolic activation via the S9 mix.

Following  these in  vitro results  and  in  order  to  evaluate  the  risk  of  carcinogenicity  in  humans,  the formation of the three mutagenic anilines has been quantified in vivo using fully validated analytical methods in plasma and urine of mice, rats, and humans.

The estimated ratios between mice and humans are: 152 regarding plasma AUCs and 68 regarding urinary concentrations.

Thus, it is hypothesised that the high concentrations of aniline metabolites in male mice urine and plasma could be responsible for the formation of bladder cancer.

## 2.5.5. Ecotoxicity/environmental risk assessment

An environmental risk assessment (ERA) Phase I was conducted to consider the risk to the environment arising from the use of masitinib mesilate 100 mg and 200 mg, film-coated tablet. In combination with riluzole is indicated for the treatment of adult patients with ALS

According  to  the  applicant,  the  ERA  report  was  prepared  in  accordance  with  the Guideline  on  the Environmental Risk Assessment of Medicinal Products for Human Use EMEA/CHMP/SWP/4447/00 corr 2, 2006 and Questions and answers document on the same Guideline EMA/CHMP/SWP/44609/2010 Rev.1. 26 May 2016.

Relevant endpoints, methods and results were discussed, and study results are summarised below.

Table 4: Summary of main study results of ERA

| Substance (INN/Invented Name): Masitinib mesilate                   | Substance (INN/Invented Name): Masitinib mesilate   | Substance (INN/Invented Name): Masitinib mesilate   | Substance (INN/Invented Name): Masitinib mesilate   |
|---------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| CAS-number (if available): 790299-79-5                              | CAS-number (if available): 790299-79-5              | CAS-number (if available): 790299-79-5              | CAS-number (if available): 790299-79-5              |
| PBT screening                                                       |                                                     | Result                                              | Conclusion                                          |
| Bioaccumulation potential- log K ow                                 | OECD 117                                            | 1.44                                                | Potential PBT N                                     |
| PBT-assessment                                                      | PBT-assessment                                      | PBT-assessment                                      | PBT-assessment                                      |
| Parameter                                                           | Result relevant for conclusion                      |                                                     | Conclusion                                          |
| Bioaccumulation                                                     | log K ow                                            | 1.44                                                | not B                                               |
| Bioaccumulation                                                     | BCF                                                 |                                                     | not B                                               |
| PBT-statement:                                                      | The compound is not considered as PBT nor vPvB      | The compound is not considered as PBT nor vPvB      | The compound is not considered as PBT nor vPvB      |
| Phase I                                                             | Phase I                                             | Phase I                                             | Phase I                                             |
| Calculation                                                         | Value                                               | Unit                                                | Conclusion                                          |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | Refined PEC                                         | 0.00824 µ g/L                                       | > 0.01 threshold N                                  |
| Other concerns (e.g. chemical class)                                |                                                     |                                                     | N                                                   |

For screening on persistence bioaccumulation and toxicity (PBT) an experimental Log Kow value was calculated by the High-Performance Liquid Chromatography (HPLC) method according to OECD 117. It was below the limit set in the EMA´s Guideline on the Environmental Risk Assessment of Medicinal

<div style=\"page-break-after: always\"></div>

Product  for  Human  Use  (EMEA/CHMP/SWP/4447/00  corr  2)  and  study  report  was  provided  by  the applicant.

Fpen was refined based on prevalence data in the EU taken from the orphan designation for masitinib (Orphanet,  Amyotrophic  lateral  sclerosis,  accessed  June  2016)  for  the  treatment  of  ALS.  Based  on prevalence data of approximately 0.5 in 10,000 Fpen was refined and used for calculation of PECsurface water resulting in a value of 0.00824 µg/L. The refined PECsurfacewater does not exceed the action limit of 0.01 µg/L and the provided calculation is acceptable. It is in line with Questions and answers document of  the Guideline  on  the  Environmental  Risk  Assessment  of  Medicinal  Products  for  Human  Use EMA/CHMP/SWP/44609/2010 Rev. 1, 2016 .

## 2.5.6. Discussion on non-clinical aspects

The non-clinical pharmacology dossier consists of the combination of documents of non-clinical study reports ('original data') and bibliographical references. The in vivo studies all have been performed in human SOD1 G93A  transgenic rodents, which show a phenotype similar to ALS in humans. The chosen animal study has a good face validity that strengthens the translatability potential of the obtained nonclinical data into clinical setting.

None of the studies had GLP status. It is generally acceptable that proof-of principle in-house studies are performed in a non-GLP setting, nor the GLP status is required by ICH S7A guidelines. Most studies were approved by authorised animal ethics committees, one lacked the ethics statement. Randomisation were performed in most cases; however, some study documentation did not state this information and thus, in case if not applied, it might have led to the data bias. Blinding was not mentioned. Not all the studies could  be  fully  evaluated  regarding  3Rs  standard  compliance  since  in  the  study  reports  the  provided information was scarce (e.g., regarding housing conditions, acclimatisation etc). Proper endpoints for the studies were chosen to minimise the suffering of animals but allowing to gain relevant scientific data on survival, which is in line with the 3Rs principle in animal research ethics.

Human  dose  equivalents  for  the  animal  studies  were  appropriately  chosen.  No  information  on  the deviation from the initial study protocols was present in any of the in vivo study reports present in the primary PD dossier.

From  a  primary  PD  perspective,  Masitinib  AB  Science  distinguishes  itself  from  many  other  ALSdevelopmental drugs by exerting neuroprotection in both the CNS and the PNS via selective kinase inhibition that modulates functionality of different cells implicated in ALS pathogenesis.

Non-clinical  pharmacology  evidenced  the  biological  plausibility  for  using  masitinib  mesilate  in  ALS through its dual targeting of mast cells and microglia and also supports the hypothesis that masitinib may provide a clinical benefit if administered early stage of disease progression (i.e., prior to the point of a permanent loss of function or a severe impairment of functionality). The importance of CSF1R in microglial proliferation, and the importance of c-Kit and Lyn for mast cell activation is well-established. The potent and selective activity of masitinib against CSF1R leads to the inhibition of the CSF1/CSF1R signalling pathway, thereby regulating CSF1R-dependent cells such as microglia and aberrant glial cells. Due to its activity against c-Kit and Lyn, masitinib is also able to modulate the function of mast cells.

It is hypothesised that via this multifaceted therapeutic approach, Masitinib AB Science is capable of slowing or preventing ALS disease progression.

After evaluating in vivo study protocols on primary pharmacodynamics, several technical/methodological issue-related concerns raised. Namely, experimental results were not always set out clearly (the actual effect size from the drug treatment was not always expressed, also the use of standard deviation (SD) instead of standard error of the mean (SEM) would have been of higher informative value), and the

<div style=\"page-break-after: always\"></div>

interpretation of the obtained data was not comprehensively carried out. Besides, in the study protocols, only representative examples of the obtained of histopathological microscopy results were provided, and the full  dataset  was  not  found  to  enable  comprehensive  assessment  of  the  study  results.  Statistical procedures used to design the in vivo experiments and to analyse the obtained data were not always clearly  traceable  and/or  meaningful  and  may  have  resulted  in  overoptimistic  statistical  significance estimations. Moreover, studies were not always properly designed to reach the necessary power for the clear demonstration of the drug effect (ALS-MICE Apr 2014, ALS RATS Jan 2013). Moreover, in the study ALS-MICE Apr 2014, the applicant concludes that ' these results are very encouraging considering that masitinib alone could improve grip strength in symptomatic mice and the combination of masitinib with riluzole could in fact improve riluzole effect on it ' - this conclusion cannot be drawn as seen from the presented study report data since sex-related differences are obviously present - in males, riluzole alone seems to outperform the combination of Masitinib AB Science and riluzole, in contrast to females. These differences  were  not  commented  or  discussed  elsewhere  by  the  applicant.  Besides,  no  proper  data analyses (e.g., two-way analysis of variance (ANOVA) in case of factorial experiment design, which would be  appropriate  in  this  case)  were  applied  to  evaluate  the  significance  of  the  observed  sex-related differences regarding the effect of masitinib alone or in combination with riluzole. The interaction of the sex as a possible confounding factor to the combined Masitinib AB Science and riluzole treatment effect was not properly addressed and assessed.

The applicant was requested to justify the reliability of the non-clinical pharmacological results and the extrapolability to an in vivo ALS model and further discussed the discrepancy in the results on survival between the two ALS model animals (mice vs. rats) and its clinical relevance. First, a reasoning behind the observed discrepancies in survival data between murine and rat ALS models have been discussed emphasizing that the data from the rat ALS model should be seen as the definitive data set, which can be agreed (the sample sizes were appropriate allowing to gain robust data and draw more credible conclusions). Besides, the applicant has additionally submitted 4 full study reports (previously presented as research papers) allowing to further substantiate the mechanism of action of Masitinib AB Science in ALS - i.e., provided biological plausibility for the use of Masitinib AB Science in ALS through its dual targeting of mast cells and microglia. Furthermore, Masitinib Science is proposed for the treatment of adults with ALS in combination with Riluzole. The combination of riluzole and Masitinib AB Science was tested only in ALS mice (study ALS-MICE Apr 2014). Moreover, the study of combined masitinib and riluzole treatment lacked power (not enough animals per group were used to convincingly demonstrate the effect). Combination value of the two drugs on the therapeutic effect was not further discussed or elaborated in non-clinical setting but has been assessed in the clinical setting. Based on the summary of existing data provided by the applicant, this comparison is only relative/indicative (riluzole data coming mainly from ALS mice model exploited in a different setting), although all the available data are in favour of Masitinib AB Science's beneficial effect and use in clinical setting for ALS patients.

Secondary PD studies were not performed. It is nevertheless accepted that masitinib by itself or in combination with riluzole did not impact negatively on the global condition of treated animals, which is indicative that there were no detrimental secondary PD effects at the administered dose.

Concerning safety pharmacology, masitinib did not induce any relevant modification of the respiratory function or central nervous system activity. Masitinib mesilate, at 10 mg/kg and 50 mg/kg also did not induce modifications of cardiovascular function or electrophysiological parameters in telemetered dogs. Moreover, the clinical experience did not evidence any sign of cardiotoxicity with masitinib. However, when the effects of AB1010 were tested on hERG channel stably expressed in HEK-293, there was a significant concentration-dependent reduction (IC50: 8.3 ± 1.1 μ mol/L) in hERG tail current amplitude in presence of AB1010 from 0.1 to 30 μ mol/L. This effect was only partially reversed after the washout period and was significant compared to the spontaneous run-down observed in the control group. The applicant  was  requested  to  provide  further  clarification  on  the  mechanism  involved  in  the  effect  of

<div style=\"page-break-after: always\"></div>

masitinib in the hERG tail current and evaluate possible pharmacological interactions of masitinib with other drugs known to induce QT prolongation. Upon revision of the answers, it can be agreed that at a therapeutic dose in humans, it is unlikely that masitinib inhibit hERG channel. This is reinforced by the fact that in the clinical trial AB14004 masitinib did not induce QT prolongation.

No  PD  drug  interaction  studies  were  performed  for  masitinib.  All  studies  are  PK  drug  interactions. Masitinib is indicated for the treatment of adult patients with ALS in combination with riluzole, which have different targets in vivo . Thus, not performing the DDI in the non-clinical setting is acceptable.

Preclinical PK and toxicokinetic investigations have been conducted in mice, rats, and dogs in order to characterise the PK behaviour of masitinib.

Masitinib mesilate appeared to be well absorbed after oral administration in the different animal models (mice, rats, cats and dogs). Bioavailability (in terms of measured radioactivity) varies from 65% in rats to around 80% in dogs. Absorption was reasonably rapid with tmax values between 0.5 and 4 hours in all species and apparent t1/2 values in the range 1-4 hours in the rat and 2 -5 hours in the dog. In mice there  was  no  effect  of  sex  on  systemic  exposure  to  masitinib,  but  plasma  levels  of  AB3280  were approximately 2-fold higher in females than males. In rats a sex effect on systemic exposure to masitinib was  noted  after  single  and  repeated  administration,  with  consistently  an  approximate  2-fold  higher exposure  in  female  rats  than  males.  In  dogs  there  was  no  evidence  of  any  sex  effect  on  systemic exposure  to  masitinib.  Absorption  was  broadly  dose-proportional  with  a  tendency  to  increase  in  a supralinear  fashion;  this  was  more  marked  at  lower  dose-levels.  There  was  evidence  of  increased systemic exposure after repeated daily administration in the rat but not in the dog.

Binding to blood cells was reduced in the presence of plasma (63% for human, 45% for rat, 78% for mouse, and 56% for dog blood cells). Plasma protein binding of AB1010 was also high for human (93%), rat (92%), mouse (86%), dog (93%) and rabbit (98%) at therapeutic plasma concentrations. AB3280 metabolite plasma protein binding was high in all species: more than 90% in human plasma and more than  85%  in  dog,  mouse,  and  rat  plasma.  Tissue  distribution  of 14 C-AB1010  indicate  extensive distribution of AB1010 to the tissues. Radioactivity was rapidly eliminated and only trace levels remained at 7 days post-administration. There was no data suggesting that AB1010 crosses the blood-brain barrier under normal circumstances.

AB2436 could be detected in human plasma and AUC values of AB2436 at steady-state represented less than 3% of AUCs of AB1010. It was found in rat plasma albeit in low concentrations i.e. at AUCs 200 times lower than the plasmatic AUCt measured for AB1010; in mouse plasma it was detected at high concentrations i.e. at an AUCt 4 times higher than the plasmatic AUCt measured for AB1010. AB2436 was found in urine of mice, rats and humans. An oxidised form of AB2436, the pyridone AB5235 has been found but only in mouse urine, which is in agreement with the large quantities of AB2436 found in this  biological  fluid.  Upon  request,  the  pharmacological  and  toxicological  implications  related  to  the observed metabolic differences between humans and mice have been discussed. The applicant suggests that the hypothesis of the contribution of aniline derivatives of the bladder tumour in mouse is plausible. An estimation of threshold in human was made which shows that bladder tumour is unlikely to occur in human at the estimated therapeutic dose of masitinib mesilate.

An in vitro study with human liver microsomes (Study DC15041/AB1010-2C8) confirmed the involvement of CYP2C8 in the formation of AB3280 (AB3280 formation ratio = 7.0% at 5 µM). However, when CYP2C8 specific inhibitor montelukast was incubated with microsomes, the inhibition of AB3280 formation was partial and was only about 52%. These results seem to indicate the involvement of another enzyme in AB3280 formation. The additional data submitted by the applicant during the procedure supports the conclusion  that  CYP3A4  and  CYP2C8  are  the  main  enzymes  involved  in  AB3280  formation.  This information was included in the SmPC.

<div style=\"page-break-after: always\"></div>

After oral administration to rats and dogs, the majority of administered masitinib is excreted in bile as parent (AB1010) or as desmethylated (AB3280). Overall, AB1010 is cleared via metabolism and via biliary (and to a lesser degree, urinary) excretion.

Concerning  PK  interactions,  co-administration  of  masitinib  mesilate  with  BCRP  substrates,  P-gp substrates  with  narrow  therapeutic  index  and  BCRP  inhibitors  or  inducers  should  be  avoided. Coadministration  of  masitinib  mesilate  with  CYP2B6  substrates,  CYP3A4  substrates  with  narrow therapeutic index, CYP2C8 inhibitors, CYP3A4 inhibitors and strong inducers and P-gp strong inducers should be given with caution.

Potential PK interactions are adequately addressed in the SmPC, considering the available data.

Focusing on interactions with drugs that are potentially going to be co-administered as per the requested indication, (treatment of adults with ALS in combination with riluzole), the applicant was requested to justify the absence of PK PD DDI studies. It was shown in a clinical study, by co-administering Riluzole and Masitinib at therapeutic range - 3.0 mg/kg/day (7 patients) and 4.5 mg/kg/day (11 patients) - the PK parameters of Riluzole were not significantly different when comparing both arms. It is important to note  that  low  patient  number  in  this  study  and  considerably  high  inter-individual  variability  in  the riluzole's main metabolising enzyme CYP1A2 obviously leads to low power of the study to convincingly demonstrate the putative impact of Masitinib's PK. However, the fact that Riluzole and Masitinib AB Science have different main metabolising pathways strengthens the conclusion made by the applicant, that Masitinib AB Science, regardless of the dose, does not significantly modify the AUC of Riluzole in humans.

Results  of  single  dose  toxicity  studies  showed  that  masitinib  mesilate  has  low  acute  toxicity.  The approximately lethal dose in rats is 2000 mg/kg following oral administration and higher than 100 mg/kg following intravenous dosing. Clinical signs of toxicity after oral administration included hypoactivity or sedation, piloerection, and dyspnoea and, after intravenous administration, hypoactivity. Repeat-dose toxicity studies were conducted in mice, rats, and dogs, with daily administration by oral gavage, and a duration of treatment up to 13, 26 and 39 weeks, respectively. Among these, the studies in rats and dogs may be considered as the main repeated dose toxicity studies; the studies in mice were mostly related  to  the  carcinogenicity  studies,  aiming  either  at  selecting  doses  levels  for  such  studies  or  at investigating mechanisms of carcinogenicity.

In repeated dose toxicity studies, the main toxicity target organs identified were the bone marrow, the liver and the kidney in dogs and rats, gastrointestinal tract intolerance in dogs, the female genital tract in rats and the male genital tract in dogs. At higher dose-levels these findings were accompanied by bodyweight  changes  and  mortality.  Additional  effects  identified  included  hyperostosis  and  cardiac changes.

Considering the important role of c-Kit during haematopoiesis, the bone marrow toxicity represents an expected finding. The applicant hypothesised that the renal disorders observed in rats and dogs may be explained by the mechanism of action of masitinib which induces some permeability dysfunctions through inhibition of PDGFR or other kinases involved in podocyte function and renal leakage. The urinary bladder urothelial hyperplasia in male mice, an effect not observed in other species, was attributed to a much higher  production  of  the  aniline  metabolite  AB2436  in  mice  as  compared  with  other  species.  As requested,  the  applicant  discussed  the  findings  of  the  ovarian  dysfunction  observed  in  rats  and  the cardiac effects observed in the chronic toxicity studies - myocardial degeneration and fibrosis in rats and pericardial oedema in 1/4 female dogs at the top dose. According to the applicant, the pericardial oedema observed in one dog was part of a generalised oedema and was attributed to severe anaemia. Masitinib did not directly caused the pericardial oedema. For the ovary findings according to the applicant, these are attributed to inhibition of c-kit by masitinib. c-kit plays a key role in the development of ovarian primordial follicles and is involved in the release of prolactin in rat. The discussion regarding cardiac

<div style=\"page-break-after: always\"></div>

effects in rats suggests that the applicant considers that the findings have not been caused by masitinib. It may not be concluded that the ovarian disfunction and cardiac findings observed in rats are not of relevance to humans.

The  available  data  on  pharmaco/toxicokinetics  suggest  low  to  no  safety  margins  for  bone  marrow toxicity, renal toxicity, reproductive toxicity in male dogs and oestrous cycle disturbances in female rats, and small to moderate safety margins for liver toxicity, ovarian toxicity, hyperostosis, and myocardial toxicity.

Masitinib mesilate is not genotoxic. Negative results were obtained with masitinib in all in vitro assays. Moreover, no genotoxic activity of masitinib was reported in vivo in the mouse micronucleus test or in the comet test performed on the liver and the bladder of mice and rats. No genotoxicity was found for the main plasma masitinib metabolite AB3280, whatever the species. No genotoxicity was found for the metabolite AB1187.3 in the Ames test either with or without a rat liver metabolic activation system. In contrast, the metabolites AB2436, AB5235 and AB6465 showed some evidence of mutagenicity in the Ames test, only in the presence of rat live S9 metabolic activation.

The applicant has submitted long-term carcinogenicity studies conducted with masitinib in CD-1 mice and Sprague-Dawley rats. masitinib-treatment was associated with mortality in the mice. Hence, the overall survival rates ranged from 26-38% in the treated animals versus 40% in the control group. Due to high mortality rates, the study treatment period and the administered doses were reduced. Urinary bladder transitional carcinomas and papillomas were seen in, respectively, 5/52 and 3/52 male CD-1 administered 500/300/80 mg/kg/day masitinib for 80 weeks, while transitional papillomas (2/52) were observed  in  the  intermediate  dose  group  (150/100/40  mg/kg/day).  Urinary  bladder  transitional  cell hyperplasia was also seen in 150/100/40 and 500/300/80 mg/kg/day males and females with a greater incidence than in controls and mice administered with 30/20 mg/kg/day mice. As the tumours were seen only in treated animals, with a clear dose-relationship, in association with pre-neoplastic finding in males and females, in incidences far outside from historical control data and with statistically positive trend, they were attributed to treatment with masitinib. A NOAEL for the urinary bladder transitional carcinomas was established at 30/20 mg/kg/day.

The applicant hypothesised that the increase in urinary bladder carcinomas and papillomas and urothelial papillomas were mouse-specific findings based on the production of two aniline metabolites in mouse hepatocytes in  vitro and  not  in  hepatocytes  from  other  species  including  humans.  This  hypothesis appears incorrect since the genotoxic metabolite AB2436 was also formed in rat hepatocytes in vitro and urinary bladder carcinomas and papillomas were not observed in the rat carcinogenicity study.

While Masitinib AB Science treatment was not associated with significant mortality in the long-term rat carcinogenicity study, it induced uterine adenocarcinomas and atypical uterine hyperplasia with a NOAEL of  30  mg/kg/day.  Thyroid  follicular  cell  adenomas  were  observed  in  1/50  and  5/50  female  rats administered 30 and 75/60 mg/kg/day, respectively. These findings were accompanied by follicular cell hyperplasia hence the overall NOAEL is considered 10 mg/kg/day.

For the rat uterine and thyroid tumours, the applicant proposes a proestrogenic effect of masitinib in female rats, which is not observed in humans. Upon request, the applicant has presented additional data that sufficiently supports the view that masitinib leads to hypoprolactinaemia and this is reflected in the tumour findings in the rat carcinogenicity study. It is agreed that due to markedly different mechanism in female reproductive hormonal regulation between humans and rats, these rat tumours are generally considered to have no significance to humans. The lack of clinical relevance is further supported by the absence of estrous cycle disturbances in clinical studies.

<div style=\"page-break-after: always\"></div>

Pulmonary  cystic  keratinising  epithelioma  was  found  in  4/50  high-dose  females  whereas  it  was  not recorded in the CIT control data or in the compilation of spontaneous neoplasms of control SpragueDawley rats from Charles River Laboratories (2004) and therefore was induced by masitinib.

The applicant further addressed whether there is a carcinogenic risk for patients under the presumption that bladder tumours in mice are caused by the aniline metabolites and taking into consideration the ADME data on differences in exposure to aniline metabolites in mice versus humans.

The way the applicant has taken to apply the principles of ICH M7 for this case is agreed. However, there is some uncertainty about parameters taken into the calculation.

The principle for deriving at a dose resulting in a less than 1/10 5  cancer risk is to take the dose resulting in a 50% tumour incidence (TD50) and divide by 50000. As an alternative one may use the benchmark dose lower confidence limit 10% (BMDL10, an estimate of the lowest dose which is 95% certain to cause no more than a 10% cancer incidence in rodent). The applicant has chosen this approach, which is understandable since tumour incidence was clearly below 50%. While the data do not allow a clear calculation of BMDL10, the applicant has presented a value of 220 mg/kg bw/d which may be agreed. However, calculations need to consider both transitional carcinomas and papillomas, and not separately, given that these tumours are likely to be related in terms of mechanism. Nevertheless, even if this approach was not considered in the calculations, the BMDL10 would still fall in the interval between the mid dose and high dose.

The dose was lowered at two occasions during the mouse carcinogenicity due to toxicity and high levels of mortality. The applicant has made a calculation of an average lifetime daily dose. This is considered acceptable as a conservative dose estimate.

To make a risk estimate based on exposure to the aniline metabolites, the applicant refers to data showing about 622 times higher plasma exposure and about 308 times higher urine exposure in mice versus humans when comparing at a human equivalent dose. These factors are based on PK data.

As the urinary concentration of anilines in humans is 308 times lower than that observed in mice at a comparable  dose,  the  adjustment  may  be  made  directly  to  the  acceptable  MOE  of  10,000,  i.e. 10,000/308, giving an adjusted MOE of 32.5. In terms of posology, treatment in Human is performed at a daily dose of 4.5 mg/kg bw/twice a day that reaches a very low level of urinary concentration (a dose of 6.7 to 8 mg/kg bw/day led to a urine concentration of 190 ng/mL).

As calculated by the applicant, the BMDL10/32.5 would lead to an acceptable level of excess risk with the occurrence  of  one  bladder  tumour  per  1.105.  Therefore,  a  daily  treatment  of  6.7  mg/kg  bw/day (220/32.5) for lifetime in Human may be acceptable in the setting of the proposed therapeutic indication in terms of excess risk of bladder tumours with an occurrence of 1 for 1.105.

Overall, given the conservative nature of the AI calculation it is concluded that the presence of aniline metabolites is not considered a carcinogenic threat in patients. However, based on uncertainties related to the performance of the carcinogenicity study and the lack of a full characterisation of metabolic pattern in humans, a carcinogenic risk of masitinib for patients, based on the bladder tumour findings in mice cannot be fully excluded. It is not anticipated that further nonclinical evaluation will clarify this risk. These  findings  should  be  mentioned  in  the  product  information  and  be  taken  care  of  in  the  risk management programme (as proposed by the applicant).

The lack of studies on pre-postnatal development and juvenile animals was justified by the applicant on the basis of the target patients' population and risk mitigation measures in the SmPC, mentioning that masitinib is contraindicated in pregnant women or in women of childbearing potential. The lack of such studies is accepted based on the target patient's population.

<div style=\"page-break-after: always\"></div>

Altogether, results from fertility and early embryonic development studies indicate reversible adverse effects on female fertility. This is consistent with the results from the repeated dose toxicity studies where the ovaries were identified as one of the target organs of toxicity.

Skin sensitization potential was assessed in mice using the local lymph node assay (Study 33510 TSS). Significant lymphoproliferative responses were observed in the absence of local skin irritation at the site of administration (Study 33510 TSS). Masitinib mesilate showed skin sensitisation potential and exposure may result in delayed contact hypersensitivity. Masitinib should be considered as a strong sensitiser. Masitinib mesilate was found to be a slight irritant when applied topically (Study 33511 TAL) and to be severely irritating when administered by the ocular route to rabbits (Study 33512 TAL).

The provided value for log Kow determined by OECD 117 HPLC method is not acceptable for ERA. The n-octanol /water distribution coefficient (logD) is a key parameter in environmental risk assessment as they are used to estimate environmental fate and bioconcentration and thus exposure and toxicity. Since masitinib is an ionisable substance (pKa =7.5) for which the solubility is pH dependent, an ion-corrected log  Dow  should  be  performed,  covering  the  environmentally  relevant  pH  range.  The  applicant  was requested to submit log Dow values at environmental relevant pHs (5,7 and 9) to guarantee that the assay was performed at different ionization stages, and the respective study report. According to the applicant, the Log D of masitinib varies from 0.53 (cationic form at pH 4.70) to 3.75 (neutral form at pH 11).  As Log D values are well below the trigger value, at all environmentally relevant pHs, screening for Persistence, Bioaccumulation and Toxicity (PBT) is not required, in line with the Questions and answers document on 'Guideline on the environmental risk assessment of medicinal products for human use' (EMA/CHMP/SWP/44609/2010 Rev. 1, 2016). Therefore, an ERA phase II assessment is not necessary.

It was concluded that this medicinal product is unlikely to represent a risk for the environment following its prescribed usage in patients.

## 2.5.7. Conclusion on the non-clinical aspects

The CHMP considers that the non-clinical data could be sufficient for a marketing authorisation application.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The applicant claims that the Clinical trials were performed in accordance with GCP.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 5: Clinical pharmacology programme

<!-- image -->

| Iype of study     | Study number       | Location in eCTD   | Objective(s) of the study                                                                                                             | Study Design and Iype of Control                                                                                                                    | Test product, dosage regimen, administration route of                                                            | No. of subjects            | Healthy subjects or diagnosis of patients              | Duration of treatment         | status, type Study of report   |
|-------------------|--------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------------------------------|-------------------------------|--------------------------------|
| BA (food-effect)  | PIHV05031 AB1010-  | 5.3.1.1            | evaluatethefood intake influence on pharmacokinetic profiles                                                                          | Cross over                                                                                                                                          | Masitinib, Tablet, 200mg, oral                                                                                   | 12                         | healthy volunteers                                     | Single dose                   | Complete, Full                 |
| Comparative BE    | PIHV04015 AB1010-  | 5.3.1.2            | compare the relative BAofAB1010 from formulations (capsule two different or tablet)                                                   | Cross over                                                                                                                                          | Masitinib, Capsules, Tablet, 100mg, oral                                                                         | 12                         | healthy volunteers                                     | Single dose                   | Complete,                      |
| PK (HV)           | AB1010- PIHV03001  | 5.3.3.1            | tolerability and PK determine safety/ parameters of AB1010                                                                            | Double blind, placebo- controlled                                                                                                                   | Masitinib, powder for ascending doses solution, (40,100,200, 400 and 800 mg), oral                               | 40                         | healthy volunteers                                     | escalations, Dose single dose | Complete, Full                 |
| PK (HV)           | AB1010- PIHV03003  | 5.3.3.1            | determine safety / tolerability and PK parameters of AB1010                                                                           | Double blind, placebo- controlled                                                                                                                   | Masitinib, Capsule, ascending doses (100,200,400 and 800 mg), oral                                               | 30                         | healthy volunteers                                     | 7 days                        | Complete, Full                 |
| PK (patients)     | AB03002            | 5.3.3.2            | Assess safety ,tolerability and determine theMTD Assess PK parameters of AB1003, assess clinical activity of masitinib                | dose escalating open-label, study                                                                                                                   | Masitinib, doses ranging from 40 to 1,000 mg/day, oral                                                           | 40 (with 19 GIST patients) | patients with advanced and/or metastatic solid tumours | 12 weeks + extension phase    | Complete, Full                 |
| Extrinsic PK (HV) | 18-169             | 5.3.3.4            | Determination of Riluzole concentration and pharmacokinetic parameters in human plasma samples.                                       | Samples coming from the pivotal study AB AB10015                                                                                                    | -masitinib (AB1010) at4.5 mg/kg/day + riluzole -masitinib (AB1010) at3 mg/kg/day+ +riluzole -Placebo + +riluzole | 18                         | Patients with ALS                                      | 48 weeks                      | Complete, full                 |
| Extrinsic PK (HV) | (DDI part) AB14004 | 5.3.3.4            | Evaluate the pharmacokinetics (PK) ofa single dose masitinib and its metabolites after CYP3A4 and P-Gp inhibition using itraconazole. | single-center, controlled, 4- open-label, active- sequence study                                                                                    | Masitinib, tablet, 3 mg/kg/day at day1,oral 3 mg/kg/day Masitinib, tablet, from day 17 to 24, oral               | 15                         | healthy volunteers                                     | 28 days                       | Complete, Full                 |
|                   |                    |                    |                                                                                                                                       |                                                                                                                                                     | moxifloxacin 400 mg at Day 1 Itraconazole 200 mg once daily (QD) from Day 9 toDay 13                             |                            |                                                        |                               |                                |
| Population PK     | AB010015           | 5.3.3.5            | To evaluate pK of patients. masitinib in ALS -To validate POP PK model population                                                     | This study was part ofa double blind, placebo- parallel groups, study for which randomised controlled, the primary objective is efficacy and safety | Each subject dose ofeither3 placebo at the masitinib or received mg/kg or4.5 mg/kg per day.                      | 18                         | amyotrophic lateral Patients with sclerosis            | 48 weeks                      | Complete Full                  |
| Population PK     | AB14004            | 5.3.3.5            | Toevaluate pK of patients. masitinib -To validate POP PK in ALS model population                                                      | This study was part ofa double blind, placebo- parallel groups, randomised controlled, study for which the primary objective is efficacy and safety | 3.0 mg/kg/day 6.0 mg/kg/day (single dose) (repeated doses -5 days).                                              | 15                         | amyotrophic lateral Patients with sclerosis            | 48 weeks                      | Complete Full                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Mass-balance (AH)   | AB17001/QC L118054       | 5.3.3.1   | Toassess themass a singleoraldose of balancerecoveryafter 14C-AB1010 (masitinib)                                 | Open Label, Non- Randomised, Single-Dose, Single-Period Study   | single dose, solution4mg/ml 14C-AB1010oral (free base)   | 4            | healthyvolunteers   | Single oral administration regimen on a single occasion.   | Complete, Full   |
|---------------------|--------------------------|-----------|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------|--------------|---------------------|------------------------------------------------------------|------------------|
| Mass balance        | AB17001/ ABS06           | 5.3.3.1   | Identificationofthe metabolitesofAB1010 (Masitinib)inplasma, urineandfaecesfrom Clinical Study AB17001-QCL118054 | SeeAB17001                                                      | SeeAB17001                                               | SeeAB 17001  | SeeAB17001          | SeeAB17001                                                 | Complete, full   |
| Massbalance         | AB/17001/TN 02018 R10121 | 5.3.3.1   | Investigationof metaboliteprofilesin plasma,urineand homogenizedfaeces samples collected duringstudyAB17001      | SeeAB17001                                                      | SeeAB17001                                               | See AB 17001 | SeeAB17001          | SeeAB17001                                                 | Complete, full   |

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Absorption

The absorption profile of Masitinib AB Science demonstrates a relatively slow absorption with tmax median values between 1.5 to 5.0 hours at the proposed clinical doses.

No data on absolute bioavailability in healthy subjects or the target population has been presented.

Bioequivalence has been adequately demonstrated in vivo for the tablet formulation intended for the market versus the formulation used in phase I. In the study No AB1010-PIHV04015, twelve healthy male volunteers received a single oral dose of AB1010 base (100 mg) on day 1 of each of both treatment periods. The two administrations were separated by at least a one-week interval where no AB1010 was taken  in  order  to  prevent  any  carry  over  effect.  The  aim  of  the  study  was  to  compare  the  relative bioavailability  of  AB1010  from  two  different  formulations  (capsule  or  tablet)  in  12  healthy  male volunteers after a 100 mg AB1010 base single oral administration.

The PK results obtained for AB1010 base are provided in the Figure 2 and Table 6.

Figure 2: Mean and SD plasma concentration versus time profiles of AB1010 base following single oral administration of 100 mg of AB1010 base as one tablet (Treat A) or as two capsules (Treat B)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 6: Geometric mean and CV% PK parameters of AB1010 base following single oral administration of 100 mg of AB1010 base as one tablet (Treat A) or as two capsules (Treat B)

|                                          | N=12                                     | Cmax (ng/mL)     | tmax # (h)   | (b)         | AUCo-t (h*ng/mL)   | AUCo-inf (h*ng/mL)   | t1/2 (h)   | Frel   |
|------------------------------------------|------------------------------------------|------------------|--------------|-------------|--------------------|----------------------|------------|--------|
| Treat A                                  | Geom. Mean                               | 67.00            | 3.50         | 0.00        | 791                | 977                  | 13.7       | 1.00   |
| (Tablet)                                 | CV%                                      | 57               | [1.50;6.00]  | [0.00;1.00] | 49                 | 44                   | 17         | 27     |
| Treat B                                  | Geom. Mean                               | 65.88            | 4.00         | 0.00        | 748                | 977                  | 15.5       |        |
| (Capsule)                                | CV%                                      | 41               | [1.50;6.00]  | [0.00;0.50] | 39                 | 29                   | 27         |        |
| Analysis ofvariance                      | Analysis ofvariance                      | NS               | NS           | NS          | NS                 | NS                   |            |        |
| Point estimate [90% confidence interval] | Point estimate [90% confidence interval] | 1.02 [0.84;1.23] |              |             | 1.06 [0.92;1.22]   | 1.00 [0.87;1.15]     |            |        |

#median and[min-max]

NS: Not Significant (p&gt;0.05)

The effect of food (a high-fat meal) on the PKs of Masitinib AB Science was determined in a single centre, open, randomised, two-way crossover study No AB1010-PIHV05031/ AB05031. According to the study results, following a high fat meal, Masitinib AB Science Cmax and AUC0-∞ increased by 19% and 23%, respectively.

## Distribution

Masitinib AB Science is extensively bound to plasma proteins; the major binding protein appears to be albumin. No information is provided on protein binding ex/in vivo . The blood: plasma ratio is around 1. The distribution kinetics of Masitinib AB Science in healthy subjects is non-linear. The apparent volume of distribution (Vd/F) is high, indicating an extensive tissue distribution.

## In vitro

Study PR6592-1-CC2099: binding to human serum albumin was high, 91.44 %. A lower binding occurred on α1 -acid-glycoprotein and on gamma-globulin, 74.26% and 45.95%, respectively. According to the 14 C-AB1010 concentration used, 100-3000 ng/mL the binding to human, rat, mouse, dog, and rabbit plasma proteins is  high  93.93%,  92.15%,  86.12%,  93.33%  and  97.50%,  respectively  and  constant within the tested concentration range.

Study AB3280-PB: The plasma protein binding was high in all species: more than 90% in human plasma and more than 85% in dog, mouse, and rat plasma. It is interesting to notice that human plasma has a total binding capacity for AB3280 twice as high (NKp =14.0) as in animal plasma (NKp =5.77, 6.56 and 7.23 respectively for dog, mouse, and rat) implying a lower free fraction in human plasma.

## Studies in humans

Study AB17001: plasma concentrations ratios were found close to 1.

Study AB03001: The Vd/F of Masitinib AB Science decreased with increasing doses: from 2144 L at 40 mg dose to 1052 L at 800 mg dose.

## Elimination

Steady  state  apparent  total  clearance  and  renal  clearance  were  0.7-1.4  L/min  and  9-18  ml/min, respectively.  Apparent  clearance  (CL/F)  decreased  with  increasing  dose  indicating  a  saturation  of enzymes responsible for metabolism and/or increased bioavailability  (potentially  due  to  inhibition  of intestinal  P-pg).  Elimination  half-life  after  single-dose  and  repeated  dose  Masitinib  AB  Science  were approximately 13 h and 17 h, respectively. Urinary recovery rates were low with less than 2% recovery for Masitinib AB Science and metabolite AB3280. A mass-balance study has additionally been conducted. A mean of 69% (range 55% to 83%) of radioactivity administered was recovered by the end of the

<div style=\"page-break-after: always\"></div>

sampling period (168 h) and the majority of radioactivity was recovered in faeces, up to 59% of the administered dose. The urinary recovery was low, approximately 10% of the dose. It can be concluded that the main excretion pathway for AB1010 and its related metabolites is the faeces.

The PK of plasma Masitinib AB Science was described by a two-compartment open model with linear elimination. The main covariate effects were related to body weight, which influenced all PK parameters, and to albumin. The model showed that clearance (CL) was not affected by dose, and that AUC thus, behaves  in  a  dose-proportional  manner.  AUC-based  accumulation  ratios  for  Masitinib  AB  Science  in healthy subjects was 1.8-2.3 at therapeutic doses.

The applicant's position is that PK in adult patients with probable or definitive ALS was similar to healthy subjects. However, Masitinib AB Science is administered concomitantly with riluzole and no DDI study was presented.

## Study AB03001 (AB1010-PIHV03001)

This was a double blind, placebo-controlled, single dose study, with parallel groups of ascending doses (40, 100, 200, 400 and 800 mg); there was a minimum of 6 days between dose escalations. A total of 40 subjects were studied in 5 successive groups, each group consisting of 8 subjects (6 received active drug, AB1010 and 2 subjects received placebo).

Figure 3: Mean plasma concentrations versus time profiles of Masitinib AB Science following single oral doses of 40, 100, 200, 400 and 800 mg of AB1010 (linear scale)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 7: Mean and CV% PK parameters of Masitinib AB Science following single oral doses of 40, 100, 200, 400 and 800 mg of Masitinib AB Science

| Treatment (N=6)   | Treatment (N=6)   | Cmax(l) (ng/mL)   | tmax(2) (h)   | t1/2 (h)   | AUCo-t (1) (h*ng/mL)   | AUC0-(1) (h*ng/mL)   | CI/F (L/min)   | Vd/F (L)   |
|-------------------|-------------------|-------------------|---------------|------------|------------------------|----------------------|----------------|------------|
| 40 mg             | Mean              | 14.51             | 2.0           | 11.8*      | 103                    | 269 56               | 2.71* 41       | 2144* 19   |
|                   | CV%               | 59                | [1.0-5.0]     | 76         | 96                     |                      |                |            |
| 100 mg            | Mean              | 82.43             | 5.0           | 12.6       | 981                    | 1201                 | 1.41           | 1547       |
| 100 mg            | CV%               | 23                | [1.5-5.0]     | 22         | 27                     | 19                   | 18             | 30         |
| 200 mg            | Mean              | 238.77            | 1.5           | 13.3       | 2557                   | 2823                 | 1.20           | 1367       |
| 200 mg            | CV%               | 32                | [1.0-5.0]     | 18         | 23                     | 21                   | 21             | 20         |
| 400 mg            | Mean              | 711.10            | 3.5           | 13.9       | 8244                   | 8951                 | 0.77           | 937        |
|                   | CV%               | 35                | [1.5-5.0]     | 13         | 31                     | 30                   | 26             | 34         |
| 800 mg            | Mean CV%          | 1121.54 21        | 3.5 [3.0-5.0] | 13.0 9     | 13471 21               | 14456 22             | 0.94 23        | 1052 20    |

(1): geometric mean and CV calculated from logarithmic values; (2): median and [min-max]; *:N=4

## Study AB14004

This was a single-centre, open-label, active-controlled, 4-sequence study in 15 healthy subjects. Each subject received in sequence the 4 following treatments:

1. Treatment Sequence 1: single dose oral administration of moxifloxacin 400 mg on Day 1.
2. Treatment  Sequence  2:  single  dose  oral  administration  of  Masitinib  AB  Science  3  mg/kg according to the subject's weight at screening on the morning of Day 3
3. Treatment Sequence 3: repeated dose oral administration of itraconazole 200 mg once daily (QD) from Day 9 to Day 13. On the morning of Day 12, a single dose of Masitinib AB Science 3 mg/kg was administered 1h after the administration of itraconazole 200 mg.
4. Treatment  Sequence  4:  repeated  dose  twice  daily  (BID)  oral  administration  of  Masitinib  AB Science  6  mg/kg/day  according  to  according  to  the  subject's  weight  at  screening  from  the evening of Day 17 to the morning of Day 24. The evening dose had to be taken in a range time from 30 min before to 30 min after dinner. The morning dose had to be taken in a range time from 30 min before to 30 min after breakfast. Masitinib AB Science had to be administered in a sitting position. All study drugs were administered with a large glass of water (250 mL or 8 oz). Masitinib  AB  Science  and  moxifloxacin  were  administered  after  breakfast;  itraconazole  was administered in fasting condition.

Table 8: Plasma PK Parameters of Moxifloxacin After Oral Administration of Moxifloxacin at 400 mg to Healthy Volunteers (Treatment Sequence 1)

| Dose (mg)    | Subject   |   Cmax (ng/mL) |   Tmax (h) |   AUCt (ng/mL*h) |   %AUCextra |   AUCinf (ng/mL*h) |   Kel (1/h) |   t1/2 (h) |
|--------------|-----------|----------------|------------|------------------|-------------|--------------------|-------------|------------|
| Moxifloxacin | N         |          15    |      15    |            15    |     15      |              15    |   15        |    15      |
| Moxifloxacin | Mean      |        2429.1  |       3.4  |         29453.4  |     26.496  |           40181.2  |    0.05959  |    12.214  |
| Moxifloxacin | Stdev     |         387.02 |       1.5  |          3938    |      7.3134 |            4402.4  |    0.013535 |     2.8698 |
| Moxifloxacin | %CV       |          15.93 |      44.88 |            13.37 |     27.6    |              10.96 |   22.71     |    23.5    |

<div style=\"page-break-after: always\"></div>

Table 9:  Mean Plasma PK Parameters of AB1010 and AB3280 After Oral Administration of AB1010 at 3 mg/kg to Healthy Volunteers (Treatment Sequence 2)

| Analyte   | Subject   |   Cmax (ng/mL) |   (h) |   AUCt (ng/mL*h) |   %AUCextra |   AUCinf (ng/mL*h) |   Kel (1/h) |   t12 (h) |
|-----------|-----------|----------------|-------|------------------|-------------|--------------------|-------------|-----------|
| AB1010    | N         |         15     | 15    |            15    |     15      |              15    |  15         |   15      |
| AB1010    | Mean      |        198.11  |  4.5  |          3065.7  |      6.4773 |            3244.9  |   0.044918  |   16.268  |
| AB1010    | Stdev     |         89.777 |  2.1  |          1375.7  |      3.1273 |            1378.2  |   0.0098632 |    4.172  |
| AB1010    | %CV       |         45.32  | 45.37 |            44.87 |     48.28   |              42.47 |  21.96      |   25.65   |
| AB3280    | N         |         15     | 15    |            15    |     14      |              14    |  14         |   14      |
| AB3280    | Mean      |         47.795 |  4.8  |           566.19 |     32.73   |             862.48 |   0.060063  |   14.5    |
| AB3280    | Stdev     |         23.82  |  1.4  |           385.33 |     13.239  |             461.64 |   0.027568  |    8.3031 |
| AB3280    | %CV       |         49.84  | 29.67 |            68.06 |     40.45   |              53.52 |  45.9       |   57.26   |

Table 10: Mean Plasma PK Parameters of AB1010 and AB3280 After Oral Administration of AB1010 at 3 mg/kg and Itraconazole at 200 mg Daily to Healthy Volunteers (Treatment Sequence 3)

| Analyte     |   Subject | Cmax (ng/mL)   |   Tmax (h) | AUCt (ng/mL*h)   |   %AUCextra |   AUCinf (ng/mL*h) | Kel (1/h)   | t12 (h)   |
|-------------|-----------|----------------|------------|------------------|-------------|--------------------|-------------|-----------|
| N           |    14     | 14             |      14    | 14               |      14     |         14         | 14          |           |
| Mean AB1010 |   250.93  | 5.0            |    4341.8  | 7.0771           |    4653.1   |          0.034303  |             | 21.239    |
| Stdev       |    90.284 | 1.4            |    1372.2  | 3.2004           |    1413.2   |          0.0078441 |             | 4.9931    |
| %CV         |    35.98  | 27.17          |      31.6  | 45.22            |      30.37  |         22.87      |             | 23.51     |
| N           |    14     | 14             |      14    |                  |      13     |         13         | 13          | 13        |
| Mean AB3280 |    53.269 | 4.9            |     763.3  |                  |      37.098 |       1301         | 0.035345    | 28.637    |
| Stdev       |    27.181 |                |       1    | 449.39           |      13.232 |        557.73      | 0.026028    | 16.715    |
| %CV         |    51.03  |                |      20.23 | 58.87            |      35.67  |         42.87      | 73.64       | 58.37     |

Table 11: Mean Plasma PK Parameters of AB1010 and AB2436 Plasma Concentration Measured After Oral Administration of AB1010 at 3 mg/kg Twice Daily to Healthy Volunteers (Treatment Sequence 4)

| Analyte   | Subject   |   Cmax,ss (ng/mL) |   Tmax,ss (h) |   AUCt,ss (ng/mL*h) |   AUC0-12,sS (ng/mL*h) |   AUC0-24,SS (ng/mL*h) |   %AUCextra | AUCinf,ss (ng/mL*h)   | Kel (1/h)   | t12 (h)   |
|-----------|-----------|-------------------|---------------|---------------------|------------------------|------------------------|-------------|-----------------------|-------------|-----------|
| AB1010    | N         |           12      |         12    |              12     |                 12     |                 12     |     12      | 12                    | 12          | 12        |
| AB1010    | Mean      |          471.63   |          5.6  |           10802.7   |               4499.1   |               7024.3   |      3.8326 | 11211.0               | 0.033494    | 21.543    |
| AB1010    | Stdev     |          160.3    |          1.6  |            3633.8   |               1557.6   |               2397.6   |      1.9425 | 3688.9                | 0.0070266   | 4.5408    |
| AB1010    | %CV       |           33.99   |         29.04 |              33.64  |                 34.62  |                 34.13  |     50.68   | 32.90                 | 20.98       | 21.08     |
| AB2436    | N         |           12      |         12    |              12     |                 12     |                 12     |      5      | 12                    | 12          | 12        |
| AB2436    | Mean      |            3.5311 |         10.1  |              52.955 |                 28.406 |                 49.242 |     54.935  | NC                    | NC          | NC        |
| AB2436    | Stdev     |            1.3471 |          5.6  |              40.378 |                 14.093 |                 30.407 |      9.389  | NC                    | NC          | NC        |
| AB2436    | %CV       |           38.15   |         55.85 |              76.25  |                 49.61  |                 61.75  |     17.09   | NC                    | NC          | NC        |

NC:Notcalcutated

In  Treatment  Sequence  4,  AB1010,  AB2436,  AB5235  and  AB6465  concentrations  in  plasma  were measured and PK parameters were calculated for AB1010 and AB2436 (all concentrations for AB5235 and AB6465 were below the limit of quantification). Mean Cmax at steady state was 471.63 ng/mL for AB1010 and 3.5311 ng/mL for AB2436. Ratios of AUCs between AB2436 and AB1010 were calculated. AUCs of AB2436 at steady state were lower than 3% of AUCs of AB1010. All PK urine samples were below the limit of quantification for AB5235 and AB6465. At steady state, the mean amount of AB1010 excreted in urine was 6.697 mg and of AB2436 was 0.340 mg (about 5% of AB1010 amount). The mean excreted  fraction  was  1.44%  of  administered  dose  for  AB1010  and  0.128%  of  administered  dose (equivalent AB1010) for AB2436.

Study AB17001 (ABS/06)

<div style=\"page-break-after: always\"></div>

This was an open label, non-randomised, single-dose, single-period study designed to assess the mass balance  recovery,  metabolite  profile  and  metabolite  identification  of  14C-AB1010  in  healthy  male subjects (n=4). Each volunteer entered into this study received a single dose of the Investigational Medicinal  Product,  14C-AB1010  oral  solution  4  mg/ml  (free  base)  provided  as  50mL  oral  solution containing NMT 37 kBq (1000nCi) 14C in the fasted state. Blood, plasma, urine and faeces samples were collected for all 4 volunteers until 168h (Day8).

Following a single 200 mg (50 ml of 4mg/ml) oral dose of [14C] AB1010 a mean of 69% (range 55% to 83%) of  radioactivity  administered  was  recovered  by  the  end  of  the  sampling  period  (168  h).  The majority of radioactivity was recovered in faeces, up to 59% of the administered dose. Urinary recovery was low (approximately 10% of the dose). The percentage of the mean cumulated radioactivity in faeces compared to the mean cumulated radioactivity in excreta (urine + faeces) is about 85%. For all subjects, this ratio is higher than 80%. So, the main excretion pathway for AB1010 and its related metabolites is the faeces.

Blood: plasma concentrations ratios were found close to 1.

AB1010 was rapidly absorbed with tmax values between 0.5 and 2 h then declined with a mean geometric half-life of 29 h, longer than the 13 to 17 h previously reported. The PK parameters determined following dosing at 200 mg were also considered similar to those observed in previous studies. AB1010 contributed to 12 % of the total circulating radioactivity in plasma when comparing AUC0-last values of AB1010 and total radioactivity. Plasma concentrations of the major and active N-desmethylated metabolite AB3280 peaked approximately 1.5h after dosing. The geometric mean Cmax of AB3280 was approximately 28% of  that  for  AB1010,  with  a  similar  terminal  elimination  phase  (geometric  mean  t1/2  of  29h).  Total exposure  (AUC0-∞) to  AB3280  was  approximately  3.4-fold  lower  than  the  parent  AB1010.  The  aniline metabolite AB2436 was quantifiable in plasma at low concentrations (geometric Cmax 0.985 ng/mL) from 0.5h up to between 12 and 48 h after dosing. Geometric mean Cmax and AUC0-last of AB2436 were both 0.4% of those for parent AB1010. Due to the low levels of AB2436, an accurate characterisation of the terminal elimination was not possible. Plasma concentrations of metabolites AB6465 and AB5235 were below the limit of quantification (0.2 ng/mL) throughout, therefore no PK parameters could be derived. Total  radioactivity  was  detectable  in  plasma  shortly  after  dosing,  consistent  with  the  appearance  of AB1010 and its metabolites. tmax ranged between 2 and 6h, and total radioactivity remained quantifiable until the final sampling time point of 168 h in all subjects. Overall geometric mean exposure (AUC0-last) of parent AB1010, AB3280 and AB2436, accounted for approximately 12%, 3.1% and 0.05% of the total circulating radioactivity measured in plasma, respectively. The geometric mean apparent terminal halflife  for  total  radioactivity  was  94.7  h  which  was  longer  than  that  observed  in  parent  AB1010  or quantifiable metabolites AB3280 and AB2436. Supporting the presence of uncharacterised metabolites with considerably longer terminal eliminations. Safety 2 out of 4 subjects experienced adverse events. One subject had 1 AE (blister). One other subject had 3 AEs namely headache, decreased white blood cell count and neutropenia. All the AEs were analysed and not considered to be related to the study treatment.

## Study AB03003

This  was  a  phase  I,  randomised,  double  blind,  placebo-controlled  study  to  determine  the  safety, tolerability and PK profiles of ascending, multiple oral doses of AB1010 in healthy, young male subjects. Plasma concentrations of Masitinib AB Science observed about 2-fold greater than after single oral dose. CL/F and Vd/F of Masitinib AB Science decreased with increasing doses and the mean half-life was about 17 h. Elimination route of Masitinib AB Science almost extra-renal. Exposure to Masitinib AB Science more  than  dose  proportional  over  the  100-400  mg  dose  range.  Increase  of  AB3280  concentrations concomitant with the increase of Masitinib AB Science concentrations. Concentrations of AB3280 about 4-fold lower than Masitinib AB Science concentrations. The mean half-life of AB3280 ranged from 25 to

<div style=\"page-break-after: always\"></div>

38 h. At steady-state about 1% of the dose recovered in urine as AB3280 over the dosing interval. Increase of Cmax and AUC0-Tau. of AB3280 over the 100-400 mg range at steady-state was proportional. The safety and tolerability good up to 400 mg per day defined as MLT.

## Study AB1010-PIHV03003

This  was  a  phase  I,  randomised,  double  blind,  placebo-controlled  study  to  determine  the  safety, tolerability and PK profiles of ascending, multiple oral doses of AB1010 in healthy, young male subjects.

Thirty-two subjects were studied in 4 successive groups (Groups 1, 2, 3 and 4), each group consisting of 8 subjects. In each group, 6 subjects received active drug (AB1010) and 2 subjects received placebo. Each subject received either AB1010base or placebo once daily for 7 days. Doses were administered in an escalating manner following satisfactory review of safety data and PK data from the lower doses. Four dose levels of AB1010base (100 mg, 200 mg, 400 mg, 800 mg) were planned to be studied.

<div style=\"page-break-after: always\"></div>

Figure 4: AB1010base - Day 1 Mean and SD plasma concentration versus time profiles of AB1010base following the first oral administration of 100, 200, 400 and 800 mg of AB1010base

<!-- image -->

Table 12: Mean and CV% PK parameters of AB1010base following the first administration with 100, 200, 400 and 800 mg of AB1010base

| Treatment   |      |   Cmax (ng/mL) | tmax## (h)    | tlag# (h)     |   AUCo-t (h*ng/mL) |   Ctrough* (ng/mL) |   fe(0-24)* (%) |   CLr* (mL/min) |
|-------------|------|----------------|---------------|---------------|--------------------|--------------------|-----------------|-----------------|
| 100 mg      | Mean |          63.16 | 5.00          | 0.00          |                675 |              11.92 |            0.7  |           17.2  |
| (N=6)       | CV%  |          33    | [3.00 - 6.00] | [0.00 - 0.50] |                 33 |              32    |           23    |           17    |
| 200 mg      | Mean |         175.92 | 2.50          | 0.00          |               1772 |              26.74 |            0.52 |            9.98 |
| (N=6)       | CV%  |          39    | [1.00 - 5.00] | [0.00 - 0.00] |                 23 |              20    |           26    |           36    |
| 400 mg      | Mean |         379.59 | 3.00          | 0.00          |               4317 |              81.49 |            0.98 |           14.99 |
| (N=6)       | CV%  |          26    | [2.00 - 4.00] | [0.00 - 0.50] |                 26 |              26    |           63    |           60    |
| 800 mg      | Mean |        1063.24 | 4.00          | 0.00          |               9724 |             168.08 |            0.89 |           12.66 |
| (N=4)       | CV%  |          38    | [3.00 -5.00]  | [0.00 -0.50]  |                 43 |              29    |           31    |           39    |

#. median and [min-max]; *: Arithmetic mean and CV from natural data

<div style=\"page-break-after: always\"></div>

Figure 5: Mean and SD plasma concentration versus time profiles of AB1010base following the last oral administration of 100, 200 and 400 mg of AB1010base once daily for 7 days

<!-- image -->

Table 13: Mean and CV% PK parameters of AB1010base following the last administration with 100, 200 and 400 mg of AB1010base once daily for 7 days

| Dose   |      | Cmax (ng/mL)   | tmax# (h)        | AUCo-t (h*ng/mL)   | AUCo-t (h*ng/mL)          | t1/2* (b)   | CL/F* (L/min)              | Vd/F* (L)                  | fe:(0-48)* (%)     | CLr* (mL/min)      |
|--------|------|----------------|------------------|--------------------|---------------------------|-------------|----------------------------|----------------------------|--------------------|--------------------|
| 100 mg | Mean | 99.98          | 4.00             | 1706               | 1249                      | 16.3        | 1.43                       | 1935                       | 1.74               | 17.97              |
| (N=6)  | CV%  | 43             | [2.00 ; 5.00]    | 57                 | 40                        | 27          | 41                         | 37                         | 28                 | 20                 |
| 200 mg | Mean | 264.46         | 4.00             | 4638               | 3179                      | 17.5        | 1.06                       | 1578                       | 1.22               | 9.79               |
| (N=6)  | CV%  | 17             | [3.00 ; 5.00]    | 19                 | 13                        | 19          | 13                         | 17                         | 60                 | 53                 |
| 400 mg | Mean | 764.27         | 3.00             | 14759              | 10000                     | 18.0        | 0.67                       | 1043                       | 1.71               | 8.99               |
| (N=6)  | CV%  | 11             | [3.00 ; 5.00]    | 9                  | 8                         | 14          | 7                          | 17                         | 16                 | 28                 |
| Dose   |      |                | Ctrough* (ng/mL) | fe;(0-24)* (%)     | Ratio Cmax* * Day 7/Day 1 |             | Ratio Ctrough* Day 7/Day 1 | Ratio Ctrough* Day 7/Day 1 | Theoretical* ratio | Theoretical* ratio |
| 100 mg | Mean | 27.54          |                  | 1.37               | 1.60                      |             | 2.31                       |                            | 1.57               | 1.57               |
| (N=6)  | CV%  | 45             |                  | 27                 | 17                        |             | 29                         |                            | 15                 | 15                 |
| 200 mg | Mean | 66.99          | 0.96             |                    | 1.54                      |             | 2.54                       |                            | 1.63               | 1.63               |
| (N=6)  | CV%  | 18             |                  | 53                 | 24                        |             | 17                         |                            | 11                 | 11                 |
| 400 mg | Mean | 210.13         | 1.34             |                    | 2.09                      |             | 2.71                       |                            | 1.66               | 1.66               |
| (N=6)  | CV%  | 11             |                  | 22                 | 33                        |             | 25                         |                            | 9                  | 9                  |

#. median and [min-max]; *: Arithmetic mean and CV from natural data

In this study Blood Sampling for the Analysis was conducted not only for the AB1010base but also for Masitinib AB Science metabolite - AB3280.

After multiple oral dosing with AB1010 in healthy volunteers it was shown that the safety and tolerability were good up to the dose of 400 mg per day which was found to be the maximum tolerated dose. The plasma concentrations of AB1010base observed were about 2-fold greater than after single oral dose. CL/F and Vd/F of AB1010base decreased with increasing doses and the mean half-life was about 17h. The elimination route of AB1010base was almost entirely extra-renal. The exposure to AB1010base was

<div style=\"page-break-after: always\"></div>

more than dose proportional over the 100-400 mg dose range and it seems it would be confirmed at 800 mg.  The  increase  of  AB3280  concentrations  was  concomitant  with  the  increase  of  AB1010base concentrations. Concentrations of AB3280 were about 4-folds lower than AB1010base concentrations. The  mean  half-life  of  AB3280  ranged  from  25  to  38  h.  At  steady-state  about  1%  of  the  dose  was recovered in urine as AB3280 over the dosing interval.

## Study AB03002

This was a multicentre, non-randomised, open-label, sequential cohort, dose-escalation phase I study of oral Masitinib AB Science in adults with advanced and/or metastatic cancer. Patients with advanced solid tumours were included in subsequent cohorts of escalating treatment dose as follows: The first dose levels were administered as initially planned in the protocol. Successive cohorts of one patient each received escalating doses of oral Masitinib AB Science daily for up to three months or until unacceptable toxicity or documentation of disease progression or any other reason for patient's withdrawal. Masitinib was administered.

PK parameters after the first administration of masitinib were as follows:

- The Cmax increased with the dose at day 1 from 54.96 ng/mL with 40 mg to 1303.47 ng/mL with 1000mg. In the dose range 250, 500 and 1000 mg, mean Cmax increased in a ratio of 1.39 and 2.44 when dose increased in a ratio of 2 and 4.
- The tmax was found between 1.7 and 4.1 hours.
- Extrapolated AUC0-24 increased with the dose at day 1 from 249 h*ng/mL with 40 mg to 12945 h*ng/mL with 1000mg. In the dose range 250, 500 and 1000 mg, the mean AUC0-24 increased in a ratio of 2.02 and 3.66.
- The CL/F and Vd/F were high, decreasing from 153.23 L/h to 62.27 L/h and from 1330 L to 1059 L respectively when dose increased from 100 mg to 1000 mg.
- The half-life of AB1003 was between 6 and 14 hours.
- The inter-individual variability was high with heterogeneous with coefficient of variation varying between 15% and 96% depending on parameters.

PK parameters after repeated administration of Masitinib AB Science were as follows:

- The Cmax increased with the dose at day 14 from 157.62 ng/ml with 100 mg to 1563.26 ng/mL with 1000mg. In the dose range 250, 500 and 1000 mg, mean Cmax increased in a ratio of 1.56 and 2.24 when dose increased in a ratio of 2 and 4.
- The tmax was found between 1.7 and 4.7 hours.
- Extrapolated AUC0-24 increased with the dose at day 1 from 1483 h*ng/mL with 100 mg to 20871 h*ng/mL with 1000mg. In the dose range 250, 500 and 1000 mg, the mean AUC0-24 increased in a ratio of 1.71 and 3.21.
- The half-life of AB1003 was relatively long (from 10 to 40 hours).
- The CL/F and Vd/F of AB1003 were high, decreasing from 82.05 L/h to 23.91 L/h and from 1870 L to 859 L respectively when dose increased from 100 mg to 1000 mg.
- The inter-individual variability was high with heterogeneous with coefficient of variation varying between 25% and 60% depending on parameters.

CYP3A4 catalyses the metabolism of Masitinib AB Science and the formation of metabolites in human liver, with a minor contribution by CYP2C8 in the formation of AB3280, which is considered to be the

<div style=\"page-break-after: always\"></div>

primary metabolite. The PK profile for the metabolite AB3280 is similar to its parent compound Masitinib AB Science. AB3280 steady state plasma concentration in healthy subjects corresponded to roughly 2030% of the steady state Masitinib AB Science plasma concentration. The transformation of masitinib mesilate  to  AB3280  appears  to  be  rapid,  indicating  that  Masitinib  AB  Science  undergoes  first-pass conversion to AB3280. Several Masitinib AB Science metabolites have been identified. It is unclear in which extent metabolites have been identified in humans. In addition to this, under the mass-balance study, the plasma PK for parent, AB1010, known metabolites i.e. AB3280, AB2436, AB5235 and AB6465 and total  radioactivity  were  also  determined.  Overall  geometric  mean  exposure  (AUC0-last)  of  parent AB1010,  AB3280  and  AB2436,  accounted  for  approximately  12%,  3.1%  and  0.05%  of  the  total circulating radioactivity measured in plasma, respectively. The geometric mean apparent terminal halflife  for  total  radioactivity  was  94.7  h  which  was  longer  than  that  observed  in  parent  AB1010  or quantifiable  metabolites  AB3280  and  AB2436.  These  are  strong  indications  that  there  are  yet  to  be identified major metabolites involved in the masitinib elimination.

## Pharmacokinetics of metabolites

In vitro studies identified AB3280, an N-desmethylated compound, as the main metabolite of Masitinib AB Science after incubation with human hepatocytes. AB3280 is the product of the metabolization of AB1010 by CYP3A4 with minor contribution of CYP2C8.

Plasma concentrations of AB3280 are approximately equivalent to 20-25% of the Masitinib AB Science plasma concentrations.

Aniline-derivatives metabolites were identified (AB2436, AB5235 and AB6465). PK of these metabolites were found in low concentration in human. They were genotoxic in in  vitro studies after undergoing metabolization.

Concentrations  of  Masitinib  AB  Science  and  its  metabolites  (AB2436,  AB5235  and  AB6465)  were evaluated in human plasma and urine (Study AB14004). They were determined at steady state following 7 days of dosing at 3.0 mg/kg/day bid:

- Plasma Cmax at steady state were 471.63 ng/mL for Masitinib AB Science and 3.53 ng/mL for AB2436. Cmax was below the limit of quantification for AB5235 and AB6465.
- Ratios of AUC0-t between AB2436 and AB1010 was &lt;3%, meaning that the AUC of AB2436 at steady-state was lower than 3% of AUC of AB1010.
- Urine Cmax at steady state were between 59.89 ng/mL and 338.16 ng/mL for AB2436 (mean: 187.79 ng/mL) and between 1,064.4 and 6,249.3 ng/mL for AB1010 (mean: 3792.3 ng/mL). Thus, in human urine, AB2436 concentration was lower than 5% of AB1010 concentration.

## Dose proportionality and time dependencies

## Study AB1010-PIHV03003

Table 14: Dose proportionality of AB1010base Cmax and AUC0-t within the dose range 100-400 mg after the first oral administration of AB1010base

| Parameters       |   Proportionality constant, a | Shape parameter, β - [90% CI]   |
|------------------|-------------------------------|---------------------------------|
| Cmax (ng/mL)     |                          0.17 | 1.29 - [1.06; 1.52]             |
| AUCo-r (h*ng/mL) |                          1.43 | 1.34 - [1.15; 1.53]             |

Dose proportionality seems to be nonlinear.

<div style=\"page-break-after: always\"></div>

Table 15: Dose proportionality of AB1010base Cmax and AUC0-t within the dose range 100-400 mg after the last administration with 100, 200 and 400 mg of AB1010base once daily for 7 days

| Parameters       |   Proportionalityconstant,a | Shape parameter, β - [90% C1]   |
|------------------|-----------------------------|---------------------------------|
| Cmax (ng/mL)     |                        0.11 | 1.47 - [1.28; 1.65]             |
| AUCo-t (h*ng/mL) |                        1.2  | 1.50 -[1.33; 1.67]              |

Dose proportionality seems to be nonlinear.

Systemic exposure after (single and) multiple dose administration of the therapeutic dose and evaluation of time dependency was evaluated in study AB1010-PIHV03003. Concentrations were greater on Day 7 than on Day 1. The mean ratio of Cmax observed between Day 7 and Day 1 was 1.60, 1.54 and 2.09 following treatment with Masitinib AB Science 100, 200 and 400 mg respectively. In addition, the mean ratio of Ctrough was 2.31, 2.54 and 2.71 over this dose range. AUC-based accumulation was calculated using AUC values obtained on day 1 and day 7.

Table 16: AUC(0-tau) (h*ng/mL) at day 1 and 14 and resulting accumulation ratios for Masitinib AB Science in healthy volunteers

|                            |   100 mg |   200 mg |   400 mg | 800 mg   |
|----------------------------|----------|----------|----------|----------|
| AUCo-tau (day 1) [h*ng/mL] |    675   |   1772   |   4317   | 9724     |
| AUCo-tau (day 7) [h*ng/mL] |   1249   |   3179   |  10000   | na       |
| Accumulation               |      1.9 |      1.8 |      2.3 | na       |

For the doses of 100, 200, and 400 mg, the AUC-based accumulation ratios were 1.8, 1.8, and 2.3, respectively.

## Special populations

## Study AB010015 population PK

The PK of Masitinib AB Science in healthy volunteers and oncology patients was satisfactorily described by a two-compartment open model with linear elimination. The main covariate effects were related to body weight. A central volume higher than the circulating blood volume and a large volume of deep compartment  suggest  that  masitinib  has  large  tissue  diffusion.  No  significant  gender  effect  on  PK parameters of Masitinib AB Science was observed. However, a tendency was observed for sex effect on central volume of distribution of Masitinib AB Science. The V1 is higher in male than female which is not consistent with lipophilic characteristic of masitinib.

## Pharmacokinetic interaction studies

In Silico: Quantitative prediction of the systemic exposure of AB1010 using prior in vitro and in vivo data: potential for CYP3A4 mediated drug-drug interactions with AB1010 as a perpetrator (Quantitative Prediction Report)

The primary aim of this study was to use physiologically based pharmacokinetic (PBPK) modelling and prior in vitro and clinical PK data for AB1010 to predict the in vivo drug interaction potential of the drug as a perpetrator of CYP3A4 mediated interactions. As the relative contributions of CYP3A4, CYP2C8 and P-gp could not be elucidated using the available data, a non-mechanistic 'fit for purpose' model was developed using the PK data to drive the model. The objective of the modelling was to evaluate the likely impact  of  co-administration  of  AB1010  on  the  exposure  (Cmax  and  AUC)  of  the  CYP3A4  substrates midazolam (high extraction) and alprazolam (relatively low extraction) in healthy subjects.

Following the incorporation of the in vitro CYP3A4 Ki,u of 1.79 μ M, the 'fit for purpose' PBPK model was used  prospectively  to  predict  the  extent  of  drug  interaction  with  the  CYP3A4  substrates  midazolam (sensitive substrate) and alprazolam (moderate sensitive substrate) following co-administration of the

<div style=\"page-break-after: always\"></div>

victim drugs on the 7th day of 10 or 14 days of dosing of AB1010 at 400 mg QD and 6 mg/kg/day BID. Simulations indicated increases of 1.01-and 1.02- fold and 1.00-and 1.01-fold in the Cmax and AUC for midazolam  and  alprazolam,  respectively,  following  co-administration  of  6  mg/kg/day  BID  AB1010. Corresponding Cmax and AUC ratios following co-administration of AB1010 400 mg QD were 1.10 and 1.12 and 1.10 and 1.03, respectively.

## In vivo: AB14004 (DDI part)

AB1010 and its main metabolite AB3280 concentrations in plasma were measured and PK parameters were calculated. As detailed above, all the calculated PK parameter were significantly increased after the inhibition of CYP 3A4 by itraconazole. There was a significant increase in exposure to Masitinib AB Science (the mean Cmax and AUCt of Masitinib AB Science rose by 26% and 41.6%, respectively) in healthy subjects when it was co-administered with itraconazole (a CYP3A4 inhibitor and P-gp inhibitor). The exposure to the main active metabolite of masitinib (AB3280) was significant increased but less than the exposure to Masitinib AB Science  (the mean Cmax and AUCt of Masitinib AB Science rose by 11% and 34.8%, respectively).

## Pharmacokinetics using human biomaterials

The potential for DDI has mainly been investigated in vitro . The applicant has provided several CYPP450 metabolism  and  transporter  studies  that  suggest  that  there  may  be  several  clinically  relevant  DDI interactions. Concomitant administration of masitinib with CYP3A4 or P-gp inducers may decrease its plasma concentrations. Clinical trial AB14004 showed that masitinib exposure was minimally affected by a strong inhibitor of both CYP3A4 and P-gp (itraconazole), suggesting weak sensitivity to these inhibitors. While the Masitinib inhibits CYP3A4 and P-gp in vitro, but likely not at clinical doses, so caution is advised with  narrow  therapeutic  index  substrates.  Co-administration  with  narrow  therapeutic  index  BCRP substrates should be avoided or given with caution due to potential drug-drug interactions. A number of questions were raised during the procedure that require further discussion and additional studies. The potential  for  inhibition  of  the  transporter  bile  salt  export  pump  have  not  been  investigated  as recommended in the DDI guideline CPMP/EWP/560/95/Rev.1 Corr.**. The clinical relevance of the in vitro findings needs to be further clarified and the commitment of in vivo studies must be justified based on the relevance of the data acquired through in vitro studies.  Since the solubility of Masitinib AB Science is  pH  dependent in the physiological pH range, there is a potential for an interaction with medicinal products that moderate pH in the gut.  The caution has been included in the SmPC (section 4.5) to minimise risk: H2 antagonists and PPIs should be taken 2 hours after Masitinib AB Science, and antacids 2  hours  before  or  after  masitinib;  if  not  possible,  avoid  co-administration  with  pH-modifying  drugs. Overall, at the current time, additional in  vitro and, if  necessary, in vivo studies were requested for elucidating the PK of Masitinib AB Science in special populations and its DDI potential:

The applicant proposed to conduct following studies as a post-authorization commitments:

1) In vitro study investigating Masitinib AB Science inhibition activity on BSEP using inside-out vesicles expressing  BSEP  and  taurocholic  acid  as  probe  substrate  (with  Ketoconazole  as  a  positive  control inhibitor).

- 2) In vitro study investigating Masitinib AB Science inhibition activity on CYP2B6.
- 3) In vitro study to assess Masitinib AB Science as an inhibitor of BCRP substrate.

4) A study to evaluate the consequences of DDI interaction between Masitinib AB Science and CYP3A4/5 inducers.

<div style=\"page-break-after: always\"></div>

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Masitinib mesilate is claimed to target independent pathological mechanisms in different cell types of the brain, spinal cord, and peripheral nervous system components, such as sciatic nerve and neuromuscular junctions In particular, masitinib is claimed to be able to inhibit the CSF1/ CSF1R signalling pathway thereby regulating CSF1R-dependent cells such as microglia, the immune cells of the central nervous system that play a well-known pathogenic role during ALS progression. Likewise, by merit of its activity against c-Kit, LYN and FYN, masitinib is claimed to be able to inhibit mast cells, an effector immune cell that is key in chronic inflammatory processes. Of significance, recent data provide a direct link between SOD1 model-derived evidence and human ALS pathology (with data being derived from ALS patient autopsied quadriceps femoris muscles). This implies that cell targets identified in masitinib preclinical studies might also be implicated in ALS human pathology.

In  vitro experiments  have  demonstrated  that  masitinib  inhibited  purified  recombinant  CSF1R  kinase activity  at  nanomolar  concentrations  (IC50  90  nM)  and  prevented  M-CSF  induced  proliferation  and migration in cultured microglia [Trias 2016]. Therefore, it has been concluded that the concentrations needed to inhibit CSF-induced microglia proliferation is around 0.1 μ M.

In a recombinant enzymatic assay, masitinib mesilate exhibited inhibitory activity against c-Kit-mediated phosphorylation (IC50 20 ± 2 nM) and Lyn and Fyn-mediated phosphorylation (IC 50  225 ± 40 nM and IC50 240 ± 130 nM, respectively). In Ba/F3 cells expressing human or mouse wild-type KIT, masitinib inhibited stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC50 of 150 ± 80nM. Hence, it was concluded that the concentration needed to inhibit these kinase targets is around 0.2 μ M.

## Primary and Secondary pharmacology

No PK/PD clinical data is currently available in ALS patients. No primary pharmacology studies were conducted.

Masitinib AB Science at therapeutic doses of 6 mg/kg/day is unlikely to induce clinically relevant increases in QTc interval or provoke any proarrhythmia. The issue of a drug effect on QTc interval is intricately linked to the potential of the drug for interactions with comedications or comorbidities (Study AB14004).

The applicant also reports the Analysis of gastrointestinal toxicities by dose level did not show a clear dose-dependence of gastro-intestinal disorders, except for a trend of increased frequency at dose levels above 12mg/kg/day (Table 17).

Table 17:  Frequency of gastrointestinal disorders by weight-adjusted dose in study AB03002

|           | Weight-adjusted initial dose (mg/kg/day)   | Weight-adjusted initial dose (mg/kg/day)   | Weight-adjusted initial dose (mg/kg/day)   | Weight-adjusted initial dose (mg/kg/day)   |
|-----------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|           | <3  (N=7)                                  | [3; 6] (N=4)                               | ]6; 12] (N=18)                             | >12 (N=11)                                 |
| Nausea    | 2 (28.6%)                                  | 2 (50.0%)                                  | 8 (44.4%)                                  | 10 (90.9%)                                 |
| Vomiting  | 5 (71.4%)                                  | 2 (50.0%)                                  | 7 (38.9%)                                  | 7 (63.6%)                                  |
| Diarrhoea | 5 (71.4%)                                  | 1 (25.0%)                                  | 8 (44.4%)                                  | 7 (63.6%)                                  |

Table 18:  Dose limiting toxicity in study AB03002

|                                       | AlI      | #1 40mg   | #2 100mg   | #3 150mg   | #4 250mg   | #5 500mg   | #6 1,000 mg   | #7 800mgb.i.d.   |
|---------------------------------------|----------|-----------|------------|------------|------------|------------|---------------|------------------|
| N                                     | 26       | 1         | 3          | 3          | 4          | 3          | 6             | 6                |
| Number(%)ofpatients withatleastoneDLT | 2 (7.7%) | 0 (0.0%)  | 0 (0.0%)   | 0 (0.0%)   | 0 (0.0%)   | 0 (0.0%)   | 1 (16.7%)     | 1 (16.7%)        |

<div style=\"page-break-after: always\"></div>

Table 19: Brief summary of adverse events by weight-adjusted initial dose (mg/kg/day)

| Number of patients with                             | AlIl (N=40)   | <3 (N=7)   | [3; 6] (N=4)   | ]6; 12] (N=18)   | >12 (N=11)   |
|-----------------------------------------------------|---------------|------------|----------------|------------------|--------------|
| At least one AE                                     |               |            |                |                  |              |
| All                                                 | 40 (100%)     | 7 (100%)   | 4 (100%)       | 18 (100%)        | 11 (100%)    |
| Suspected                                           | 38 (95.0%)    | 7 (100%)   | 3 (75.0%)      | 17 (94.4%)       | 11 (100%)    |
| At least one SAE (non fatal)                        |               |            |                |                  |              |
| A11                                                 | 15 (37.5%)    | 4 (57.1%)  | 2 (50.0%)      | 4 (22.2%)        | 5 (45.5%)    |
| Suspected                                           | 7 (17.5%)     |            |                | 3 (16.7%)        | 4 (36.4%)    |
| Death                                               |               |            |                |                  |              |
| A11                                                 | 4 (10.0%)     |            | 1 (25.0%)      |                  | 3 (27.3%)    |
| Suspected                                           | 1 (2.5%)      |            |                |                  | 1 (9.1%)     |
| AtleastonesuspectedAEleadingtodiscontinuation       | 8 (20.0%)     |            | 1 (25.0%)      | 2 (11.1%)        | 5 (45.5%)    |
| At least one suspected AE leading to interruption   | 8 (20.0%)     |            |                | 5 (27.8%)        | 3 (27.3%)    |
| At least one suspected AE leading to dose reduction | 7 (17.5%)     |            |                | 3 (16.7%)        | 4 (36.4%)    |
| At least one severe AE (grade ≥3)                   |               |            |                |                  |              |
| A1l                                                 | 29 (72.5%)    | 6 (85.7%)  | 3 (75.0%)      | 11 (61.1%)       | 9 (81.8%)    |
| Suspected                                           | 16 (40.0%)    | 2 (28.6%)  |                | 6 (33.3%)        | 8 (72.7%)    |
| At leastoneAEgrade4/5ornon-hematologicalG3          |               |            |                |                  |              |
| A11                                                 | 29 (72.5%)    | 6 (85.7%)  | 3 (75.0%)      | 11 (61.1%)       | 9 (81.8%)    |
| Suspected                                           | 15 (37.5%)    | 2 (28.6%)  |                | 6 (33.3%)        | 7 (63.6%)    |
| At least one DLT*                                   | 7 (17.5%)     |            |                | 3 (16.7%)        | 4 (36.4%)    |

*Dose LinitingToxicity

## 2.6.3. Discussion on clinical pharmacology

## Pharmacokinetics

The clinical pharmacology programme was based on several clinical studies examining single-dose and multiple-dose PK, and in addition, a population PK (popPK) model was used to estimate population PK parameters as well as to characteriseise explore possible covariates, and PBPK study was conducted to predict the extent of possible DDI. The applicant has investigated PK of Masitinib AB Science in four phase 1 studies (AB03001, AB03003, AB14004 and AB17001), all of which were conducted in healthy volunteers.

The provided popPK analysis utilised pooled PK data collected from 7 studies and included a total of 144 subjects (111 males, 33 females) with 1807 concentration records. The parameter estimates of the final model were determined with a reasonable precision. The model showed that CL was not affected by dose, and that AUC thus behaves in a dose-proportional manner. However, observations in the patient population are sparse.

## ADME

The PK characteristics of Masitinib AB Science after a single dose of Masitinib AB Science from 40 mg to 800 mg in 40 healthy volunteers were determined in the study AB03001 and are as follows: single dose at 200 mg: mean Cmax = 238.8 ng/mL and AUC0-t = 2,557 ng.h/mL; single dose at 400 mg: mean Cmax = 711.1 ng/mL and AUC0-t = 8,244 ng.h/mL; mean tmax obtained after 1.5 to 5 hours; Mean half-life of plasma Masitinib AB Science between 13 to 17 hours; mean half-life of plasma AB3280 (main metabolite) between 15 to 38 hours.

The PK characteristics of Masitinib AB Science after repeated doses of Masitinib AB Science at 200 mg and 400 mg are as follows (based on Study AB1010-PIHV03003 data): Steady state reached at 4 to 5

<div style=\"page-break-after: always\"></div>

days; Plasma level at steady state increased to up 1.5-fold; Repeated doses at 200 mg: mean Cmax = 264.5 ng/mL and AUC0-t = 3,179 ng.h/mL; Repeated doses at 400 mg: mean Cmax = 764.3 ng/mL and AUC0-t = 10,000 ng.h/mL. Following a high fat meal, Masitinib AB Science Cmax and AUC0-∞ increased by 19% and 23%, respectively. As no clinically meaningful food effect seems to be evident in terms of overall  exposure,  the  omission  of  precautions  with  respect  to  concomitant  food  intake  is  considered acceptable. However, the contribution of biliary excretion to drug elimination is unclear. The applicant proposed performing an absolute bioavailability clinical trial to provide further evidence that could enable conclusions regarding the contribution of different elimination routes to Masitinib AB Science clearance and quantify the contribution of biliary excretion.

Steady state plasma concentration for Masitinib AB Science (200 mg and 400 mg) was reached on or prior to day 5 in healthy subjects. The Vd/F is high, indicating an extensive tissue distribution. Masitinib AB  Science  extensively  bound  to  plasma  proteins  (approximately  93%);  the  major  binding  protein appears to be albumin. The blood: plasma ratio is around 1. The distribution PK of Masitinib AB Science in healthy subjects is non-linear.

At clinically significant concentrations of Masitinib AB Science, binding to human plasma proteins was approximately 93% based on in vitro experiments, mostly to albumin and alpha-acid-glycoprotein, with little binding to gamma-globulin (Study PR6592-1-CC2099).

The study AB05031 data shows that simultaneous administration of 200 mg of AB1010 with a high fat breakfast increase the exposure to AB1010base by about 23%. Hence, the extent of formation of the metabolite AB3280 also increase by about 17%. In the clinical pharmacology programme, the studies AB1010-PIHV05031 and AB0503 seem to be the same study. This was clarified by the applicant upon request.

In vitro studies identified AB3280, an N-desmethylated compound, as the main metabolite of Masitinib AB Science after incubation with human hepatocytes. AB3280 is the product of the metabolization of AB1010  by  CYP3A4  with  minor  contribution  of  CYP2C8.  Plasma  concentrations  of  AB3280  are approximately  equivalent  to  20-25%  of  the  Masitinib  AB  Science  plasma  concentrations.  Anilinederivatives metabolites were identified (AB2436, AB5235 and AB6465). PK of these metabolites were found in low concentration in human. Concentrations of masitinib and its metabolites (AB2436, AB5235 and AB6465) were evaluated in human plasma and urine (Study AB14004). They were determined at steady state following 7 days of dosing at 3.0 mg/kg/day bid: Plasma Cmax at steady state were 471.63 ng/mL for Masitinib AB Science and 3.53 ng/mL for AB2436. Cmax was below the limit of quantification for AB5235 and AB6465. Ratios of AUC0τ between AB2436 and AB1010 was &lt;3%, meaning that the AUC of AB2436 at steady-state was lower than 3% of AUC of AB1010. Urine Cmax at steady state were between 59.89 ng/mL and 338.16 ng/mL for AB2436 (mean 187.79 ng/mL) and between 1,064.4 and 6,249.3 ng/mL for AB1010 (mean: 3792.3 ng/mL) Thus, in human urine, AB2436 concentration was lower than 5% of AB1010 concentration.

PK analysis in healthy volunteers showed that the elimination route of masitinib was mainly extra-renal. The  renal  clearance  was  slow  (about  9  to  18  mL/min)  compared  with  total  clearance  (about  1000 mL/min). The elimination of Masitinib AB Science and its major metabolites was further investigated in a mass balance study (Study AB17001). In this study, a single 200 mg oral solution dose of [14C]AB1010 (radiolabelled Masitinib AB Science) was administrated in 4 healthy volunteers and the following results were found: Overall, 69% (range 55% to 83%) of radioactivity administered was recovered by the  end  of  the  sampling  period  (168  h).  Up  to  59%  of  the  radioactivity  was  recovered  in  feces. Approximately  10%  of  the  radioactivity  was  recovered  in  urine  (low  urinary  recovery).  The  main compounds (accounting for more than 10%) found in faeces were AB1010 followed by AB3280 co-elating with a mono-hydroxy, desaturated (or keto) metabolite of AB1010. In plasma, about 60% of radioactivity were related to unextractable compounds which might be a pool of metabolites covalently bound to

<div style=\"page-break-after: always\"></div>

plasma proteins. Total recovery of 69% of radioactivity administered is considered insufficient However, it is considered that the covalent binding of some metabolites to plasma proteins is the basis for this phenomenon. The recovery of radioactivity increases very slowly after 168 hours, as the 7-day stay of volunteers was not sufficient to recover more than 69% of the total radioactivity. This is in accordance with  the  very  long  half-life  of  plasma  proteins  (3  weeks  for  the  most  abundant  of  them,  albumin), indicating that the rate of elimination of radioactivity is very low after 120 hours.

While it can be agreed that the present data support that faeces is the main excretion pathway for Masitinib AB Science and its related metabolites, it is noted that the overall geometric mean exposure (AUC0-last) of parent masitinib (AB1010) and its respective metabolites AB3280 and AB2436 accounted for approximately 12%, 3.1% and 0.05% of the total circulating radioactivity measured in plasma. In single- and repeated-dose PK studies, elimination half-life after single-dose and repeated dose Masitinib AB Science were approximately 13 h and 17 h, respectively, which is not in line with the results obtained in the human mass-balance study, where the plasma half-life time for Masitinib AB Science and its main metabolite AB3280 was found to be at about 29 h.

## PK in special populations

No study was conducted in special populations. The potential impact of some intrinsic factors, including age, bodyweight, human serum albumin and impact of hepatic activity described by ASAT and ALAT populations have been examined by the use of popPK analyses. No studies were performed in patients with impaired renal function. No studies in patients with hepatic impairment were performed, and no information is available on how race may affect the PK of masitinib. A contraindication of Masitinib AB Science use with hepatic impairment was requested to be included in the SmPC. No significant gender effect on PK parameters of Masitinib AB Science was observed. The PK data on elderly were not initially provided, however during the procedure the applicant clarified that there were 6 ALS patients over 70 years of age, of whom one was in the target population (age = 75). In this patient, PK parameters of Masitinib AB Science mesilate were in accordance with his age and body weight.

## Interactions

The AB14004 (DDI part) study showed that there is a risk of DDI between Masitinib AB Science and CYP 3A4 and P-gp inhibitors.

In vitro studies demonstrated CYP3A4 to be the primary CYP enzyme responsible for Masitinib AB Science metabolism, with a minor contribution by CYP2C8. As Masitinib AB Science is administered concomitantly with riluzole, the DDI study of Masitinib AB Science and riluzole has been provided. In study AB10015, riluzole PK parameters (Cmax, tmax and AUC0-t) were analysed in 18 patients. Together with in vitro studies it could be agreed that Masitinib AB Science did not significantly modify the AUC of riluzole.

In vitro data suggested that Masitinib AB Science was mainly metabolised by CYP3A4 but a DDI study with  the  strong  CYP3A4  inhibitor  itraconazole  increased  masitinib  AUC0-∞ with  43%.  Therefore,  the elimination pathways are not clear. Masitinib AB Science is a substrate and an inhibitor of P-gp, a weak inhibitor  of  organic  anion  transporting  polypeptide  1B1  (OATP1B1)  (IC50  not  reached)  and  a  slight inhibitor towards organic anion transporting polypeptide 1B3 OATP1B3 (IC50 of 130 μ M). Masitinib AB Science is a strong inhibitor of human BCRP with a calculated IC50 of 0.7 μ M. Masitinib AB Science is a substrate of BCRP-mediated transport.

Further  studies  were  proposed  by  the  applicant  as  post-authorization  measures  to    investigate  the potential for clinically relevant DDI with Masitinib AB Science: in vitro study investigating Masitinib AB Science inhibition activity on BSEP using inside-out vesicles expressing BSEP and taurocholic acid as probe substrate (with Ketoconazole as a positive control inhibitor), in vitro study investigating Masitinib AB Science inhibition activity on CYP2B6, in vitro study to assess Masitinib AB Science as an inhibitor of

<div style=\"page-break-after: always\"></div>

BCRP substrate, and a study to evaluate the consequences of DDI between Masitinib AB Science and CYP3A4/5 inducers.

## Studies in target population

In study AB010015 a model for the popPK of Masitinib AB Science was validated. The PK of masitinib in healthy volunteers and oncology patients was satisfactorily described by a two-compartment open model with linear elimination. The main covariate effects were related to body weight. However, the decision to use an unequal splitting in the dosing scheme e.g. 100mg in the morning and 200 mg in the evening could  not  be  based  on  PK  data.  This  decision  to  use  this  dosing  scheme,  could  be  justified  by  the tolerability (PD) parameters. The visual predictive check and prediction-corrected visual predictive check showed some outlier areas but are given the current data acceptable. This is probably due to the lack of exact information about sampling times or dosing time of subsequent cycles of treatment or residual sampling. The applicant provided explanations that no such data is available: the sampling times were not recorded in the studies. It was also shown that a change in AUC values (drug exposition) is expected when the body weight changes as the CL is affected by body weight.

No PK studies were performed in adult patients with probable or definitive ALS. The applicant tried to overcome the respective limitation through popPK modelling approach because the applicant´s position is that PK of Masitinib AB Science does not depend on the indication. The Masitinib AB Science plasma concentrations from 18 ALS patients who had PK samples in Study AB10015 were added to the previously established popPK model. The initial popPK modelling has been performed using data from 5 different studies  (AB03001,  AB03003,  AB05031,  AB04015,  and  AB03002).  Variations  in  clearance  between healthy  individuals  and  those  with  ALS  were  observed.  The  applicant  has  not  provided  expected  PK differences between the healthy and ALS populations at least in terms of T1/2 and AUC0-t and/or AUC0-∞.

The existing sample size of ALS patients in the popPK analysis is deemed inadequate. The limited number of ALS patients included in the popPK analysis (18 patients) was acknowledged by the applicant. Given the current evidence, the applicant did not provide any acceptable evidence to support posology in ALS. PK in target population remains not to be clearly established which hampers the establishment of optimal posology. Given the small sample size, only tentative data shows that there might be a relationship between  Cmax,  AUC  and  PD.  However,  it  is  unclear  whether  higher  exposure  is  not  associated  with occurrence of adverse events.

The applicant did not provide PK/PD clinical data in ALS patients. The applicant suggests that Masitinib AB Science downregulates secondary damage mediated by chronically activated glial and immune cells in the CNS and PNS, based on provided non-clinical data for PD. However, the potential effect of Masitinib AB Science on the underlying mechanisms of disease in ALS is not considered fully demonstrated and provided evidence by preclinical data are fragmented, limiting possibility to establish further conclusions on possible therapeutic utility of a treatment in clinical practice.

While currently provided in vitro data and data from literature in general support proposed PD concept, further demonstration of proof-of-concept was expected and was requested because it is considered that studies in rodent models aimed to demonstrate replication of effect would be beneficiary in support of proposed effect of masitinib on the underlying mechanisms of disease. The applicant is apparently unable to  provide  any  clinical  PD  or  PK/PD  data  in  patients  despite  the  current  scientific  progress  provide possibilities to use a relatively wide array of different blood-based biomarkers. It is agreed that the data presented can be considered feasible and might support the claimed mechanism of action of masitinib AB Science in ALS patients, although certain limitations exist, e.g. associated with the animal model limitations, doses administered to experimental animals etc. Thus, it is still considered that primary PD effect  of  masitinib  AB  Science  is  not  adequately  described  and  confirmed  with  any  human  PD  data; however, non-clinical data provided could support the claimed mechanism of action although certain limitations exist.

<div style=\"page-break-after: always\"></div>

In terms of safety, there is no specific discussion on possible secondary PD except the phase I study on possible QT/QTc effects of masitinib and it(s) metabolite(s) Thorough QT/QTc Study with positive control of  moxifloxacin  was  conducted  to  evaluate  possible  secondary  pharmacology.  Exposure-response modelling by the PK/PD analysis was performed separately for masitinib and moxifloxacin by matching individual values of changes in QTcF with the corresponding concentrations measured at the same time points. After a single dose of 3 mg/kg the bootstrap predicted mean effect was a QTc shortening of 3.10 msec (90% CI: -5.01; -0.810) and after a repeated dose of 6 mg/kg the mean predicted effect was -1.8 msec (90% CI: -4.7, 1.4 msec). Overall, it is considered justified that masitinib holds a limited and clinically non-significant potential on QTc interval change. However, besides the potential QT/QTc effects, secondary pharmacology aspects were not addressed by the applicant.

## 2.6.4. Conclusions on clinical pharmacology

The PK in the target population and PK/PD relationship are not clearly  established which may have hampered the establishment of optimal posology for ALS in the clinical studies. The pharmacological mechanism of Masitinib AB Science on the underlying pathophysiology of disease in ALS is not considered fully demonstrated and provided evidence could not be considered supportive for efficacy studies. There is insufficient knowledge of the concentration-response.

The CHMP considers the following measures would have been necessary to further address the issues related to pharmacology:

- In  vitro study  investigating  Masitinib  AB  Science  inhibition  activity  on  BSEP  using  inside-out vesicles expressing BSEP and taurocholic acid as probe substrate (with Ketoconazole as a positive control inhibitor).
- In vitro study investigating Masitinib AB Science inhibition activity on CYP2B6.
- In vitro study to assess Masitinib AB Science as an inhibitor of BCRP substrate.
- A  study  to  evaluate the  consequences  of  DDI  between  Masitinib  AB  Science  and  CYP3A4/5 inducers.
- A study to evaluate Masitinib AB Science PK profile in patients with impaired hepatic function.

It is possible that further studies may be needed to investigate possible DDI interactions with newly characterised metabolites.

The CHMP considers that the above uncertainties would have not prevented a positive recommendation for a CMA.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Clinical efficacy

Table 20:  The main efficacy study performed with Masitinib AB Science

| Study ID   | No. of study centres / locations                                                                                                              | Design                                                                                                                                                                                         | Study Posology                                                  | Study Objective                                                             | Subjs by arm entered/ compl.                                                                    | Duration                                                                       | Gende r M/F Media n Age                                                          | Diagnosis Incl. criteria                                                                                                                                                                                                                                                                                                                   | Primary Endpoint                                |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| AB10015    | 34 sites from 9 countries (Spain, Argentina, Slovakia, Portugal, Mexico, Italy, Greece, Netherlands, and Canada) enrolled at least 1 patient. | A prospective, multicentre, randomised, double-blind, placebo- controlled, parallel groups, phase II/III study to compare the efficacy and safety of masitinib versus placebo in ALS patients. | masitinib at 3 or 4.5 mg/kg/day + riluzole or placebo +riluzole | efficacy and safety of two doses of masitinib as add-on therapy to Riluzole | 394 patients were enrolled (active control, N=133; masitinib 4.5, N=130; masitinib 3.0, N=131). | 08 April 2013 - 05 December 2016; follow-up phase: November 2017- 14 June 2020 | The mean age at screeni ng was 56 y (range 22-75), 62,4% of patient s were male. | Laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology revised El Escorial criteria with disease duration from diagnosis no longer than 36 months at the screening visit; treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening; FVC ≥60% | Change from baseline to week 48 in the ALSFRS-R |

## 2.6.5.1. Dose response study(ies)

During the clinical Phase 3 studies in patients with ALS that were designed for the evaluation of the efficacy  and  safety  of  Masitinib  AB  Science  a  dose  escalation  part  is  an  integral  part  of  this  study. Separate  dose  response  studies  were  not  performed.  Dose  response  PK/PD  is  discussed  in  clinical pharmacology section.

## 2.6.5.2. Main study(ies)

Phase IIb/III AB10015 prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from ALS.

## Methods

## · Study Design

After the visit week 48, patients could enter a protocol extension phase on an optional basis depending only if the benefit/risk was assessed as positive by the investigator after discussion with the patient. During this protocol extension period, the double-blind was maintained. The study periods are presented below according to Supplemental clinical study report, version 3.1.

Long-term assessment for study AB10015 encompassed five distinct periods:

- #1: The double-blind main protocol period, which incorporated the prospectively declared 48-week treatment period of all patients (with date of first enrolment in April 2013 and date of last completed W48 visit in December 2016). This period is part of the planned blinded, prospective part of the study.

-  #2:  The  double-blind  first  extension  period,  which  incorporated  the  prospectively  declared  blinded extension period after week 48 visit for all patients, until week 48 last patient last visit was completed

<div style=\"page-break-after: always\"></div>

in December 2016. This period defines the data cut-off date (December 5, 2016) for the clinical study report.

- #3: The double-blind second extension period, a double-blinded period commencing at the date of data readout in December 2016 until April 2017.

- #4: The open label third extension period, an open-label period from April 2017 until November 2017. During this period all patients remained in their assigned treatment groups and no switching between arms was permitted.

- #5: The open label post study follow-up period from November 2017 until June 2020, during which patients were followed for overall survival. At the start of this period, an optional, open-label, early access,  Named  Patient  Programme  (NPP)  was  initiated.  This  allowed  those  patients  still  receiving Masitinib AB Science to continue treatment, while also allowing patients from the AB10015 placebo arm to begin Masitinib AB Science treatment.

For analysis of long-term overall survival, the vital status (i.e., survival status of alive or dead, including date  of  death)  of  all  patients  originally  randomised  to  study  AB10015  was  collected  from  each participating investigational site. As such, three patient groups were defined: long-term high-dose (4.5 mg/kg/day) Masitinib AB Science, long-term low-dose (3.0 mg/kg/day) Masitinib AB Science, and longterm placebo.

Long-term assessment for study AB10015 encompassed the prospectively declared 48-week treatment period with associated double-blind extension (commencing in April 2013 until data readout), and a post study follow-up period (from November 2017 until June 2020). Following data readout for the main protocol period of study AB10015, treatment assignment was unblinded and an optional, open-label, early access NPP was initiated. This allowed those patients still receiving Masitinib AB Science to continue treatment (23% (30/131) of patients from the Masitinib AB Science 3.0 mg/kg/day treatment arm, and 22% (29/130) of patients from Masitinib AB Science 4.5 mg/kg/day treatment arm), while also allowing patients from the AB10015 placebo arm to enter Masitinib AB Science treatment arm (19% (25/133) of patients  from  the  placebo  arm  switched  to  Masitinib  AB  Science  arm).  During  the  assessment,  the applicant clarified that 5 patients from placebo arm started Masitinib AB Science treatment - 3 patients started the treatment with 6 mg/kg/d dose, 1 - with 4 mg/kg/d, 1 - with 3 mg/kg/d.  Patients still alive at the time of analysis were censored at the date of last contact.

## Methods

## · Study Participants

Patients enrolled in study AB10015 diagnosed with \"probable\" or \"definite\" ALS according to the World Federation of Neurology revised El Escorial criteria. The study population included ALS patients without restriction on the baseline ALSFRS-R score, with up to 3 years of disease history, and excluded patients on gastrostomy. Patients had to be aged between 18 aged between 18 and 75 years old with a weight &gt; 50 kg and a BMI between 18 and 35 kg/m 2 . Patients must present with FVC (Forced Vital Capacity) equal or more than 60 % predicted normal value for gender, height, and age at the screening visit.

Patient with various conditions, including but not limited to significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness, and psychiatric illness were also not eligible. Patient who underwent tracheotomy and /or gastrostomy were also excluded.

## · Treatments

Patients were to be enrolled into one of three groups:

- Group 1: patients on Masitinib AB Science at 4.5 mg/kg/day and riluzole

<div style=\"page-break-after: always\"></div>

- Group 2: patients on Masitinib AB Science at 3 mg/kg/day and riluzole
- Group 3: patients on placebo and riluzole

Subjects enrolled were to receive a total daily dose of 4.5 or 3 mg/kg masitinib AB Science, or a matching placebo, to be taken orally during meals in two daily doses over 48 weeks with a possibility of doubleblind extension period.

Irrespective of the treatment allocated, active or placebo in combination with riluzole, them adaptation of the total dose to the weight followed the same procedure. The following table was used to determine the number of tablets to take at each administration and their dosage. Study treatment daily dose of 3 mg/kg was administered in divided doses as indicated below.

Table 21: Dose of study treatment (mg) according to patient's weight (3 mg/kg/day; 4,5 mg/kg/day

|                        |                        | 3 mg/kg/day     | 3 mg/kg/day   | 3 mg/kg/day    |
|------------------------|------------------------|-----------------|---------------|----------------|
| Patient's weight in kg | Patient's weight in kg | Daily dose (mg) | Morning* (mg) | Evening** (mg) |
|                        | ≤49.9                  | NOTPOSSIBLE     | NOTPOSSIBLE   | NOTPOSSIBLE    |
| > 49.9                 | 83.3                   | 200             | 100           | 100            |
| > 83.3                 |                        | 300             | 100           | 200            |
|                        |                        | 4.5 mg/kg/day   | 4.5 mg/kg/day | 4.5 mg/kg/day  |
| Patient's weight in kg | Patient's weight in kg | Daily dose (mg) | Morning* (mg) | Evening** (mg) |
|                        | ≤55.5                  | 200             | 100           | 100            |
| > 55.5                 | 77.7                   | 300             | 100           | 200            |
| > 77.7                 | 99.9                   | 400             | 200           | 200            |
| > 99.9                 |                        | 500             | 200           | 200+100        |

*Morning: the tablets were to be taken during breakfast. In case of nausea, the administration could be taken place during lunch. **Evening: the tablets were to be taken during dinner.

Riluzole was not considered as investigational medical product in this study and as such was not provided by the Sponsor. The product was prepared, handled, used, and stored according to standard practices and the Summary of Product Information (SmPC).

Prohibited concomitant treatments included live attenuated vaccines, phenytoin prescribed as prophylactic anticonvulsive agent, benzodiazepine, amiodarone, chemotherapies, any hepatotoxic agent (e.g. allopurinol, methyldopa, sulfasalazine), any investigational treatment related or not to ALS, drugs known  to  be  at  high  risk  of  Stevens-Johnson  syndrome:  allopurinol,  lamotrigine,  carbamazepine, phenytoin, phenobarbital, sulfasalazine, sulfamide, oxicam and nevirapine; or to be at high risk of drug rash with eosinophilia and systemic symptom syndrome: minocycline, modafinil, dapsone.

## · Objectives

## Main study period:

- The  primary  objective  of  the  study  was  to  evaluate  the  efficacy  of  Masitinib  AB  Science  in combination with riluzole based on the change in the ALSFRS-R from baseline to week 48.
- The  secondary  objectives  of  the  study  were  to  evaluate  efficacy  of  Masitinib  AB  Science  in combination with riluzole based on other efficacy endpoints (see below endpoints section)

## Open-label follow up period:

- To test whether a signal in OS based on the long-term follow-up dataset from study AB10015 is evident in an enriched patient population - excluding very severe and/or severe patients.

<div style=\"page-break-after: always\"></div>

- To test whether any survival benefit detected in the aforementioned enriched patient population is also evident at the earlier cut-off corresponding to the end of the prospectively blinded protocol study period.
- To test the consistency of any detected survival treatment effect with the clinical endpoints of Δ ALSFRS  at  week  48  and  PFS,  thereby  testing  whether  these  endpoints  are  appropriate surrogates of OS.
- To analyse long-term safety.

## · Outcomes/endpoints

## Primary Efficacy Endpoint

• Change from baseline to week 48 in the ALSFRS-R

The ALSFRS-R is a score from 0-48 assessing disability. The ALSFRS-R includes 12 questions, each task is rated on a five-point scale from 0 = can't do, to 4 = normal ability. Individual item scores are summed to produce a reported score of between 0=worst and 48=best. ALSFRS-R scores correlate significantly with quality of life (Cedarbaum, Stambler et al. 1999).

## Secondary study endpoints

## Efficacy Endpoints

· Time to event analysis, defined as median Progression free survival (PFS), with progression defined death or &gt; 9 points decline in ALSFRS-R from baseline.

- Change from baseline to week 48 in Forced Vital Capacity (FVC).
- Combined Assessment of Function and Survival (CAFS) between baseline and week 48
- OS defined as the time from randomization to the time of the documented death
- Tracheostomy free survival defined as the time from randomization to the date of documented death or first tracheostomy

## Quality of Life Endpoint

·  Absolute  and  relative  change  from  baseline  in  ALSAQ-40  (Amyotrophic  Lateral  Sclerosis  Specific Assessment Questionnaire) at week 4, 8, 12, 24, 36 and week 48

## Safety Endpoints

- Occurrence AEs

· Treatment emergent changes in physical examination, vital signs (blood pressure, pulse rate and body temperature) and electrocardiogram (ECG) and clinical laboratory tests  (biochemistry, haematology, urinalysis)

## · Sample size

The objective of the study was to compare each 'Masitinib AB Science + riluzole' group (i.e. Masitinib AB Science 3 mg/kg/day + riluzole and Masitinib AB Science 4.5 mg/kg/day + riluzole) to 'placebo + riluzole' group. Therefore, the sample size was calculated in a 1:1 randomization ratio for the comparison of each Masitinib AB Science group to the active control group making the same hypothesis for each Masitinib AB Science group.

The original sample size estimation has been modified following three amendments of the study protocol (see conduct of the study) (changing the phase 2 to a phase 2/3) from 45 patients to 381 patients.

<div style=\"page-break-after: always\"></div>

A distinction between Normal and Fast Progressors was introduced through an amended protocol (version 3.0). This distinction was based on ALSFRS-R progression rate from disease-onset to baseline ( Δ FS). The 'Normal Progressors' were those with Δ FS &lt;1.1 points/month before randomization while the 'Fast Progressors' were defined as having ΔFS ≥1.1 po ints/month before randomization.

Sample size calculation was based on absolute change from baseline to Week 48 in ALSFRSR (hypothesis for riluzole are based on data from Fornai and colleagues [Fornai et al., 2008]). ALSFRS-R change from baseline to week 48 was supposed to be higher in the full study population comprising 'normal + fast progressors' (with a SD equal to 9) than in the 'normal progressor' subpopulation (with a SD equal to 7.5), notably because patients have more tracheostomy and death in the full study population comprising 'normal + fast progressors' than in 'normal progressor' subpopulation.

Primary analysis was performed using a re-randomization test basis the estimates from the Analysis of Covariance (ANCOVA) model.

## ▪ 'Normal Progressor' subpopulation

The  parameters  considered  for  sample  size  calculations  in  the  normal  progressor  subpopulation  as follows:

- Alpha set to 5% 2-sided test
- Power set to 80%
-  Difference  in  mean  change  of  ALSFRS-R  between  placebo  control  group  and  Masitinib  AB Science group equal to 3.3
- Standard deviation of the change from baseline to week 48 from all groups equal to 7.5
- Effect size = 0.44
- Allocation ratio: 1:1
- One interim analysis planned at around 50% of information fraction
-  Pocock  alpha  spending  method  approximated  with  Hwang,  Shih  and  DeCani  class  alpha spending function.

## Comparison of the 'Masitinib AB Science 4.5 mg/kg/day + riluzole' group to the 'placebo + riluzole' group

With the hypotheses described above, 186 evaluable patients (93 patients treated in Masitinib AB Science 4.5 mg/kg/day group / 93 patients treated with placebo) were necessary to detect a 3.3 (±7.5) point difference between Masitinib AB Science 4.5 mg/kg/day group and placebo control group with a power of 80% and a type-I error of 5%.

## Comparison of the 'Masitinib AB Science 3 mg/kg/day + riluzole' group to the 'placebo + riluzole' group

Same calculation as for the comparison of the 'Masitinib AB Science 4.5 mg/kg/day + riluzole' group to the 'placebo + riluzole' group.

Taking into account around 5% of non-evaluable patients, 300 patients defined as 'normal progressors' (100 in each Masitinib AB Science group and 100 treated in the placebo control group) were enough to detect a 3.3 (±7.5) point difference between groups (each of the Masitinib AB Science groups versus placebo control group) in order to achieve a power of 80% with a significance level for a two sided test of 5% in 'normal progressor' subpopulation.

## Full study population comprising 'Normal + Fast Progressors'.

The parameters considered for sample size calculations in the full population comprising normal + fast progressor as follows:

- Alpha set to 5% 2-sided test
- Power set to 80%
- Mean change from baseline for active control group equal to -11 (from 38 to 27)

<div style=\"page-break-after: always\"></div>

- Mean change from baseline for Masitinib AB Science groups equal to -7.7 (from 38 to 30.3)
- Difference in mean change of ALSFRS-R between active control group and Masitinib AB Science group equal to 3.3 which is considered to reflect clinically meaningful improvement.
- Standard deviation of the change from baseline to week 48 from all groups equal to 9
- Effect size = 0.36
- Allocation ratio: 1:1

354 patients (118 in each Masitinib AB Science group and 118 in the placebo control group) should be included to detect a 3.3 (±9) point difference between groups (each of the Masitinib AB Science groups versus placebo control group) in order to achieve a power of 80% with a significance level for a twosided test of 5%.

Considering around 5% of non-evaluable patient, 381 patients (127 in each Masitinib AB Science group and 127 in the placebo control group) were included to detect a 3.3(±9) point difference between groups (each of the Masitinib AB Science groups vs active control group) in order to achieve a power of 80% with a significance level for a two-sided test of 5%.

During the assessment, the applicant clarified that secondary endpoints (CAFS and FVC) for the normal progressor subpopulation also reached a power of 80% based on the primary sample size calculation and are therefore, also sufficiently powered for this study. PFS and OS endpoints were not powered for this study.

Table 22: Sample size in each ALS population

|                               | Change of ALSFRS-R from baseline to W48                | Change of ALSFRS-R from baseline to W48   | Change of ALSFRS-R from baseline to W48                            | Change of ALSFRS-R from baseline to W48   | Change of ALSFRS-R from baseline to W48    |
|-------------------------------|--------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------|-------------------------------------------|--------------------------------------------|
| Population                    | Difference between masitinib and active control groups | N per arm                                 | N to detect a difference between masitinibandactive control groups | N total                                   | N total taking account of discontinuations |
| \"Normal Progressors\"          | 3.3 (± 7.5)                                            | 93                                        | 186                                                                | 279                                       | 300                                        |
| \"Normal + Faster Progressors\" | 3.3 (± 9)                                              | 118                                       | 236                                                                | 354                                       | 381                                        |

## Follow-up phase

For analysis of long-term overall survival, the vital status (i.e., survival status of alive or dead, including date  of  death)  of  all  patients  originally  randomised  to  study  AB10015  was  collected  from  each participating investigational site. As such, three patient groups were defined: long-term high-dose (4.5 mg/kg/day) Masitinib AB Science, long-term low-dose (3.0 mg/kg/day) Masitinib AB Science, and longterm placebo. Long-term assessment for study AB10015 encompassed the prospectively declared 48week treatment period with associated double-blind extension (commencing in April 2013 until data readout), and a post study follow-up period (from November 2017 until June 2020).

Following  data  readout  for  the  main  protocol  period  of  study  AB10015,  treatment  assignment  was unblinded and an optional, open-label, early access named patient programme was initiated. This allowed those patients still receiving Masitinib AB Science to continue treatment (23% (30/131) of patients from the Masitinib AB Science 3.0 mg/kg/day treatment arm, and 22% (29/130) of patients from the Masitinib AB Science 4.5 mg/kg/day treatment arm), while also allowing patients from the AB10015 placebo arm to begin Masitinib AB Science treatment (19% (25/133) of patients from the placebo arm switched to receive Masitinib AB Science). Patients still alive at the time of analysis were censored at the date of last contact.

- Randomisation and Blinding (masking)

<div style=\"page-break-after: always\"></div>

A  randomization  list  was  generated  for  packaging  and  labelling  by  cardinal  system  (Vendor  later rebranded as Venn Life Sciences).

Eligible patients were randomised by means of a computerised central randomization system called IWRS (Interactive Web Response System). The automated system assigned the appropriate investigational medicinal product for each patient. Interaction with the automated system was initiated by Sponsor. Sponsor supplied the Investigators with user guides for the automated system in the national language.

Randomization was performed with a minimization algorithm on:

- ALS patient's population ('normal progressors' (progression of ALSFRS-R score before randomization &lt; 1.1 points/month) versus 'faster Progressors' (progression of ALSFRS-R score before randomization ≥ 1.1 points/month))

- Progression of ALSFRS-R score (point/month) from date of first symptom to baseline (ALSFRS-R score at date of first symptom supposed to be 48), balanced between treatment groups in each of ALS patient's subpopulation 'normal progressors' and 'faster progressors'.

- Site of onset (bulbar versus spinal)
- ALSFRS-R score at baseline
- Age at baseline
- Region (Canada and Western Europe versus Eastern Europe versus other countries).

The  study  is  a  double-blind  study.  In  the  study  AB10015,  three  patients  were  unblinded  by  the pharmacovigilance department due to SUSAR before the data lock of the clinical database: toxic hepatitis with jaundice, oral and pharyngeal candidiasis and Drug Rash with Eosinophilia and Systemic Symptom (DRESS) likely.

## · Statistical methods

## A. Analysis datasets and subpopulations

Intent-To-Treat (ITT) dataset: all randomised patients with probable or definite ALS, whether they have received the study treatment or not. Patients were classified according to the treatment arm to which they have been randomised, irrespective of the actual treatment received. The actual number of patients in the final analysis ITT population was 394 patients, including 330 'normal progressor' patients and 64 'fast progressors' patients.

Modified  Intent-To-Treat  (mITT)  dataset: all  ITT  patients  with  at  least  one  post  baseline  efficacy assessment who took at least one dose of study treatment (Masitinib AB Science /placebo). The actual number  of  patients  in  the  final  analysis  mITT  population  was  391  patients,  including  328  'normal progressor' patients and 63 'fast progressors' patients. Efficacy analyses were performed primarily in mITT set.

Per Protocol (PP) dataset: all patients of the mITT population without any major protocol deviation. This was  the  set  of  patients  who  participated  in  the  study  as  intended.  Patients  terminating  the  study prematurely were included in the PP population provided that there was no protocol deviation. Before locking the data base, the precise reasons for excluding patients from the PP population were fully defined and documented by Data Review Committee. This population was used for certain sensitivity analyses. Protocol deviations are defined as: inclusion and non-inclusion criteria were not met , intake of forbidden medication , non-respect of visit dates , missing value for main criterion without premature termination , non-respect of protocol design , any other deviations during the course of the study.

<div style=\"page-break-after: always\"></div>

Safety population: The safety population consists of all patients randomised and who took at least one dose of study medication (Masitinib AB Science or placebo).

A distinction between normal and fast Progressors was introduced through an amended protocol (version 3.0). As indicated above, this distinction was based on ALSFRS-R progression rate from disease onset to baseline ( Δ FS). The 'normal progressors' were those with Δ FS &lt;1.1 points/month before randomization while the 'fast progressors' were defined as having ΔFS ≥1.1 points/month before randomization.

According to the applicant, this approach selected a more homogeneous primary efficacy population (i.e., 'normal progressors'), while concurrently permitting assessment (secondary analysis) of the broader more heterogeneous population (i.e., full study population comprising 'normal and fast progressors'). According to the applicant, this split was recommended by the principal investigator and supported by literature  reference  [Kimura  2006;  Kollewe  2008;  Gordon  2006]  and  approved  by  investigators  and external experts solicited.

Table 23: Number and Percent of Subjects by Treatment Group

| Number of Subjects            | Placebo     | Masitinib 4.5   | Masitinib 3.0   | Total       |
|-------------------------------|-------------|-----------------|-----------------|-------------|
| Overall Population            |             |                 |                 |             |
| ITT population                | 133         | 130             | 131             | 394         |
| mITT population               | 132 (99.2%) | 128 (98.5%)     | 131 (100.0%)    | 391 (99.2%) |
| Normal Progressors            |             |                 |                 |             |
| ITT population (n (% overall) | 114 (85.7%) | 106 (81.5%)     | 110 (84.0%)     | 330 (83.8%) |
| mITT population (n (%ITT)     | 113 (99.1%) | 105 (99.1%)     | 110 (100%)      | 328 (99.4%) |
| Fast Progressors              |             |                 |                 |             |
| ITT population (n (% overall) | 19 (14.3%)  | 24 (18.5%)      | 21 (16.0%)      | 64 (16.2%)  |
| mITT population (n (%ITT)     | 19 (100%)   | 23 (95.8%)      | 21 (100%)       | 63 (98.5%)  |

At the time of the amendment, 12% of the patients enrolled in the study could have reached the week 48 time point.

Table 24: Enrolment Status at the Time of Protocol amendment version 3.0

|                                                       | Placebo   | Masitinib 3.0   | Masitinib 4.5   | Total     |
|-------------------------------------------------------|-----------|-----------------|-----------------|-----------|
|                                                       | N = 133   | N = 131         | N = 130         | 394       |
| Patients enrolled at the time of amendment submission | 49        | 46              | 47              | 142 (36%) |
| Patients reaching week 48 at the time of amendment    | 18        | 15              | 13              | 46 (12%)  |

## Follow up phase

For long-term survival analysis, the definitions of studied subpopulations were:

Step 1 an enriched cohort of patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) and a Δ FS of less than 1.1 points/month (subset of normal progressors subpopulation).

Step 2 an enriched cohort of patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a Δ FS of less than 1.1 points/month (subset of normal progressors subpopulation).

<div style=\"page-break-after: always\"></div>

Step 3 the cohort of patients having moderate, severe, and very severe ALS (i.e., any baseline ALSFRSR score) and a Δ FS of less than 1.1 points/month (subset of normal progressors subpopulation).

## B. Study treatment period and protocol extension phase

## Analysis of the primary endpoint:

## Control of family-wise type I error

While the study was ongoing, the applicant changed the primary efficacy population of the study through an amendment of the protocol (third amendment, dated 08 October 2014) so the efficacy of Masitinib AB Science in combination with riluzole based on the change in the ALSFRS-R from baseline to week 48 was first evaluated in the mITT 'normal progressors' subpopulation and only subsequently, in the mITT full study population comprising the normal and fast progressors. The below sequence for controlling family-wise type I error was re-defined according to the change of the primary study population.

To control overall family-wise type I error rate at the study level, analyses of efficacy will be conducted in a stepwise manner (fixed sequence method) to control the global family-wise error rate.

- -Sequence 1 'Normal progressors' subpopulation - Masitinib AB Science 4.5 mg/kg/day.
- -Sequence 2 'Normal progressors' subpopulation - Masitinib AB Science 3 mg/kg/day.
- -Sequence 3 full study population comprising 'normal + fast progressors' - Masitinib AB Science 4.5 mg/kg/day.
- -Sequence 4 full study population comprising 'normal + fast progressors' - Masitinib AB Science 3 mg/kg/day.

Primary  analysis  was  to  be  performed  in  mITT  'normal  progressors'  subpopulation  on  patients randomised at an initial Masitinib AB Science dose of 4.5mg/kg/day (Group 1) versus placebo patients (Group 3) at a 5% alpha-level. In accordance with the fixed sequence method as above described, the first step is to demonstrate a statistically significant difference between Masitinib AB Science at a dose of 4.5 mg/kg/day + riluzole versus placebo + riluzole on ALSFRS-R after a 48-week treatment period in the normal progressor subpopulation. If this analysis is conclusive, then the next objective is to compare Masitinib AB Science 3.0 mg/kg/day + riluzole versus placebo + riluzole for change from baseline in ALSFRS score at week 48 in the normal progressor subpopulation. If this analysis is conclusive, then based on fixed sequence method, the next objective is to compare Masitinib AB Science 4.5 mg/kg/day + riluzole versus placebo + riluzole for change from baseline in ALSFRS score at week 48 in the full study population comprising normal + fast progressors. If this analysis is conclusive then based on the fixed sequence method, the last objective is to compare Masitinib AB Science 3.0 mg/kg/day + riluzole versus placebo + riluzole for change from baseline in ALSFRS score at week 48 in the full study population comprising normal + fast Progressors.

## Missing data

Missing values of ALSFRS-R at study visit were to be replaced based on the modified last observation carried Forward (mLOCF) method defined as follows:

- Case 1: discontinuation before week 48 for toxicity, lack of efficacy, or unknown reason. In this case, missing data will be imputed with the LOCF method.
- Case 2: discontinuation before week 48 for a documented reason excluding toxicity or lack of efficacy. In this case, non-observed values can be considered as Missing at Random (MAR), and no imputation will be done (observed cases).
- Case 3: death for related disease progression before week 48. If patient was treated when he died, score ALSFRS-R is replaced by 0.

<div style=\"page-break-after: always\"></div>

## Primary analysis

Absolute change from baseline to week 48 in ALSFRS-R will be estimated using a model of ANCOVA adjusted on following factors: treatment (Masitinib AB Science /placebo) and stratification criteria:

- ALS patients' population ('normal progressors' versus 'faster progressors') only for analyses in the full study population comprising 'normal progressors + faster progressors'.
- Progression of ALSFRS-R score (point/month) from date of first symptom to baseline (ALSFRSR score at date of first symptom supposed to be 48).
- ALS patients' subpopulations ('normal progressors' versus 'faster progressors')
- ALSFRS-R score at baseline
- Site of onset (bulbar versus others)
- Age at baseline
- Region (North America and West Europe versus Est Europe versus Other Countries)

Two-sided 95% confidence interval (CI) of the difference of mean change from baseline to week 48 between groups will be provided.

The primary analysis uses a re-randomization test. Re-randomization test, also called randomization test involves the reshuffling of observed data and computing the test statistic (in this case test associated with the treatment effect estimate in analysis of covariance model), with the following conditions:

- -Re-running  of  the  minimization  algorithm  in  order  to  assign  a  treatment  group  for  each randomised patient.
- -Maintenance  of  the  real  order  (=observed)  of  arrival  of  the  patients  (e.g.  patient  00101 randomised in first)
- -Maintenance of the hazard set for minimization algorithm (20% in hazard in study AB10015)
- -Maintenance of the ALSFRS-R score at each visit for the statistical analysis

Step 1: Model of analysis of covariance described above will be performed on observed data, and test statistic will be provided along with p-value.

Step 2: The minimization algorithm will be run to obtain a new 'randomization list' (assignment of each patient to a treatment group) for the population of randomised patients (ITT). For the population of interest (mITT), the ANCOVA model will be computed at each rerandomization.

This step (rerandomization and computation of the test statistic) will be performed 10,000 times, to obtain 10, 000 replicate datasets.

Step 3: The proportion of replicates for which the p-value of treatment factor is at least as small as the p-value of treatment factor from the original data will be calculated. In this proportion the observed pvalue of treatment factor will be also accounted for one replicate in numerator and denominator.

That proportion is the p-value for the randomization test.

The hypothesis of no treatment difference will be rejected at the 5% level of significance if the observed test statistic falls outside the middle 95% of the observed distribution of the resampled statistic. This step determines how often the resampled statistic of interest is as extreme as the observed value of the same statistic.

## Sensitivity Analysis

<div style=\"page-break-after: always\"></div>

1. Absolute change from baseline to week 48 in ALSFRS-R will be estimated using a model of ANCOVA adjusted on following factors: treatment (Masitinib AB Science /placebo) and stratification criteria (no re-randomization test).

2. Multivariate sensitivity analysis: Absolute change from baseline until week 48 in ALSFRS-R will be estimated using a model of ANCOVA adjusted on the following factors: treatment (Masitinib AB Science / placebo), stratification criteria and following criteria: sex, time from date of first symptom to baseline, time from date of diagnosis to baseline, time from date of first symptom to date of diagnosis, progression of ALSFRS-R score (point/month) from date of diagnosis to baseline (ALSFRS-R score at date of diagnosis supposed to be 48), FVC at baseline, BMI, other parameters defined by the blind review committee before lock of data-base. Firstly, univariate analyses will be done at a 20% level. At a second time, only significant  factors  presenting  less  than  20%  of  missing  data  will  be  introduced  into  the  multivariate model. Some interactions will be tested. Treatment factor will be included in the final model whatever its level of significance. Two-sided 95% CI of the difference of baseline change until week 48 between groups will be provided.

3. Primary analysis and sensitivity analysis 1- and 2- will be repeated using observed cases method (i.e.no imputation of missing data).

4. Primary analysis and sensitivity analysis 1- and 2- will be repeated using multiple imputation (MI) for missing data.

5. Absolute change from baseline to week 48 in ALSFRS-R will be estimated using a model of analysis of covariance (ANCOVA using SAS PROC MIXED) adjusted on following factors: treatment (Masitinib AB Science /placebo), visit as well as a treatment by visit interaction and stratification criteria. Treatment by visit interaction will be tested and study treatment effect will be given at each time (using SLICE=TIME option). LSMEANS of absolute variation from baseline at each visit with corresponding95% two-sided CI will be given with this model.

6. Primary analysis and sensitivity analysis 1-, 2-, 3-, 4- and 5- will be repeated on the ITT and PP populations.

Missing values of ALSFRS-R at study visit were replaced based on the mLOCF, referred to as Rule 1 method. Six sensitivity analyses, referred to as Rule 2 to Rule 7, were pre-specified to assess the impact of missing data based on the reasons of premature patient withdrawal from the study.

A description of censoring rules used for the primary efficacy analysis and sensitivity analyses of study AB10015 are described below [Mora 2020].

- Rule 1 was used for the primary analysis. Missing data was imputed via LOCF when patients discontinued before week-48 for documented reasons of toxicity or lack of efficacy. If patient died before week-54 (included) after randomization, ALSFRS-R score was replaced by zero (0). Patients discontinuing prematurely for the following documented reasons were not imputed (lost to  follow-up,  non-compliance,  travel,  procedure,  protocol  deviation,  any  other  reason  not mentioned above). LOCF sensitivity analyses.
- Rule 2 was the same as rule 1 with the exception that imputation via LOCF was also done in case of premature discontinuation due to withdrawal of consent related to study procedure.
- Rule 3 was the same as rule 1 with the exception that imputation via LOCF was also done in case of premature discontinuation due to any travel issue.
- Rule 4 was the same as rule 1 with the exception that imputation via LOCF was also done in case of premature discontinuation due to withdrawal of consent related to study procedure or due to any travel issue.

<div style=\"page-break-after: always\"></div>

- Rule 5 imputed data via LOCF for all patients with the exception of those patients who were noncompliant after the date of non-compliance. For these patients, the week-48 ALSFRS score was imputed  using  the  last  available  score  before  non-compliance,  where  non-compliance  was defined as per site clinical judgement, 'patient who could and should have continued to use study treatment  but  did  not  due  to  different  reasons  as  mentioned  in  statement  signed  by  the investigators'.

## Single imputation based on clusters

In the two imputation methods detailed below (rule 6 and rule 7), missing data for early discontinuation or death were imputed, regardless of the cause of discontinuation.

- Rule  6  used  single  imputation  methodology,  i.e.,  non-LOCF,  copying  increment  from  similar patients, i.e., imputation was done by clustering patients by a given prognostic factor, then using the average increment within groups.
- Rule 7 was the same as rule 6 with the exception that a penalty of 50% was applied to those patients  who  discontinued  early  due  to  lack  of  efficacy,  an  imputation  method  based  on recommendations from The National Research Council Panel on Handling Missing Data in Clinical Trials [Permutt 2016].

In this analysis, no imputation was performed for three patients who had no other patient in their cluster.

Considering further the full analysis dataset methods of rules 6 and 7, these sensitivity analyses estimate ALS disease progression for similarly clustered patients, with clustering being done on the variables of: site of onset at baseline, region, and treatment group. The applicant states that this method decreases possible bias introduced by LOCF methods because it tries to identify the trend within similar patients and then imputes the missing value using this average trend.

Furthermore, to ensure that these pre-specified methods for handling missing data arising from patient withdrawals did not give rise to bias in the estimated treatment effect, the applicant performed additional sensitivity analyses based on alternative methodologies. These analyses were performed in the 'normal progressor' subpopulation receiving Masitinib AB Science 4.5 mg/kg/day.

- Sensitivity analysis based on MI,

- Sensitivity analyses applying the most conservative approaches, namely multiple imputation with jump to reference (J2R).

## Analysis of the secondary endpoints:

According to the Final Statistical Analysis Plan dated 16 March 2017 for secondary endpoints type I error was controlled as part of the testing sequence if primary analysis is significant.

## Combined Assessment of Function and Survival (CAFS)

CAFS on rank data will be analysed with an ANCOVA model with treatment as a fixed effect adjusted on stratification criteria.

Re-randomization test using treatment effect statistic test of ANCOVA model will be performed.

Sensitivity analyses:

1. CAFS will be analysed with an ANCOVA model with treatment as a fixed effect adjusted on stratification criteria (no re-randomization test).

2. CAFS difference between groups will be analysed with a Generalised Gehan-Wilcoxon rank test.

<div style=\"page-break-after: always\"></div>

3. Primary analysis corresponding to CAFS and sensitivity analysis 1- and 2- will be repeated on the ITT and PP populations.

## Change of FVC from baseline to week 48

Absolute change from baseline to week 48 in FVC will be estimated using a ANCOVA model adjusted on following factors: treatment (Masitinib AB Science / placebo) and stratification criteria. Missing values of FVC at study visit will be replaced based on the mLOCF method.

Re-randomization test using treatment effect statistic test of ANCOVA model will be performed.

Sensitivity analyses:

1. Absolute change from baseline to week 48 in FVC will be estimated using a ANCOVA model adjusted  on  following  factors:  treatment  (Masitinib  AB  Science  /  placebo)  and  stratification criteria (no re-randomization test). Missing values of FVC at study visit will be replaced based on the mLOCF.
2. Primary analysis corresponding to FVC and sensitivity analysis 1- will be repeated using observed cases method (i.e. no imputation of missing data).
3. Primary analysis corresponding to FVC and sensitivity analysis 1- and 2- will be repeated on the ITT and PP populations.

## Time to first tracheotomy defined as the time from randomisation to the time of the first tracheotomy.

Time to first tracheotomy analysis will be analysed with a rerandomization test using stratified log-rank test as statistical test.

Sensitivity analyses:

1. Time to first tracheotomy will be analysed using stratified log-rank test (no re-randomization test).
2. Multivariate Cox proportional hazards regression model will be constructed to compare hazard rates  between  treatment  groups  if  the  basic  assumption  that  hazard  ratio  (HR)  is  constant through time is verified.
3. Primary analysis corresponding to time to first tracheotomy and sensitivity analysis 1- and 2will be repeated on the ITT and PP populations.

## Survival defined as the time from randomisation to the date of documented death or first tracheotomy.

Survival analysis will be analysed with a rerandomization test using stratified log-rank test as statistical test.

Sensitivity analyses:

1. Survival analysis will be analysed using stratified log-rank test (no re-randomization test).
2. Multivariate cox proportional hazards regression model will be constructed to compare hazard rates between treatment groups if the basic assumption that HR is constant through time is verified.
3. Primary  analysis  corresponding  to  overall  survival  and  sensitivity  analysis  1-  and  2-  will  be repeated on the ITT and PP populations.

## Futility analysis

<div style=\"page-break-after: always\"></div>

For each dose group (3mg kg/day and 4.5mg/kg/day) and each subpopulation ('normal progressors' and full study population comprising 'normal progressors + faster progressors'), the independent data monitoring committee (IDMC) should review the different efficacy criteria about 48 weeks after the [60th - 75th] patient randomised.

In case of lack of efficacy, the IDMC recommends the discontinuation of the dose group for futility reason. The futility boundary will be based on conditional power.

Study could be considered as non-futile for a dose group (3mg /kg/day or 4.5mg/kg/day) if:

- Conditional power is less than a prespecified threshold for 'Normal progressors' subpopulation.

OR

- Conditional power is less than a prespecified threshold for the full population comprising 'normal progressors + faster progressors'.

Full details were prespecified in the interim statistical analysis plan.

For planned analysis, the significance levels to be used for rejecting the null hypotheses will be directly derived from the above cumulative alpha spending function so that the type I error would be controlled at the level.

The interim analyses to be performed without any unblinding for the sponsor. An independent CRO was mandated by AB Science to perform the analysis. The results were sent directly to the IDMC members. The IDMC had to recommend either stopping or continuing the study. If the size of treatment effect seems lower than expected but still clinically relevant, the IDMC were able to recommend a sample size re-estimation, respecting an upper limit for the increase of 100% of the initial sample size, and will communicate it directly to the CRO in charge of Interactive Randomization System.

## Follow-up phase

The primary endpoint is defined as the OS for participants from study AB10015 and its associated longterm follow-up until  survival  cut-off  date.  The  primary  endpoint  OS  was  analysed  based  on  the  ITT population according to the treatment group patients are randomised and the strata they are assigned at randomization using a stratified log-rank test.

All  investigational  sites  from  study  AB10015  were  contacted  with  a  request  for  an  update  on  each patient's vital (survival) status. Overall survival was defined as the time elapsed between randomization and death from any cause. Overall survival P values were calculated via the multivariate log-rank test using the covariates of age and ALSFRS-R score at randomization, site of onset (spinal versus bulbar), geographical region, and post-onset ALSFRS-R progression rate ( Δ FS). All covariates were prespecified in  the  AB10015  protocol  as  randomization  stratification  factors  [Mora  2020].  HR  and  95%  CI  were calculated via the Cox proportional-hazards model using the abovementioned covariates.

During the assessment, the applicant provided information the 25 patients initially randomised in the placebo arm and subsequently switched to Masitinib AB Science, were included in the long-term OS analysis. For long-term OS analysis, these patients were analysed based on their initial randomization scheme in AB10015 study, i.e., the placebo group.

Primary  analysis  was  performed  on  enriched  patient  populations  from  the  ITT  dataset  following  the sequence described before and according to the full follow-up period cut-off of 14 June 2020.

Sensitivity  analyses  of  the  primary  endpoint  will  repeat  the  above  sequence  with  the  following modifications:

<div style=\"page-break-after: always\"></div>

- Using a cut-off date of 14 June 2020 as above but without restrictions placed on baseline Δ FS (i.e., cohorts including both normal and fast progressors.
- Using a cut-off date of 05 December 2016, corresponding to the planned blinded and prospective part of the study.

## Results

## · Participant flow

The mITT population has been used for the efficacy analysis (132, 131, and 128 patients in the placebo, Masitinib  AB  Science  3.0  mg/kg/day,  and  Masitinib  AB  Science  4.5  mg/kg/day  treatment-arms, respectively).

Table 25:  Subject Disposition - Number and Percent of Subjects by Treatment Group

|                                                   | Placebo (N=133)   | Masitinib 4.5 (N=130)   | Masitinib 3 (N=131)      | Total (N=394)   |
|---------------------------------------------------|-------------------|-------------------------|--------------------------|-----------------|
| Number of Subjects in ITT population N            | 133               | 130                     | 131                      | 394             |
| Number of Subjects in mITT population Yes         | 132 (99.2%)       |                         | 128 (98.5%) 131 (100.0%) | 391 (99.2%)     |
| Number of Subjects in Safety population Yes       | 133 (100.0%)      |                         | 129 (99.2%) 131 (100.0%) | 393 (99.7%)     |
| Number of Subjects in PP population Yes           | 130 (97.7%)       | 127 (97.7%)             | 129 (98.5%)              | 386 (98.0%)     |
| Subjects status in main period W0-W48 W48 reached | 92 (69.2%)        | 83 (63.8%)              | 89 (67.9%)               | 264 (67.0%)     |
| Prematurely discontinued before W48               | 41 (30.8%)        | 47 (36.2%)              | 42 (32.1%)               | 130 (33.0%)     |
| Reason of discontinuation Wo-W48 period           |                   |                         |                          |                 |
| N                                                 | 41                | 47                      | 42                       | 130             |
| AE Related                                        | 1 (2.4%)          | 12 (25.5%)              | 7 (16.7%)                | 20 (15.4%)      |
| Lost to Follow-up                                 | 0 ( 0.0%)         | 1 (2.1%)                | 0 ( 0.0%)                | 1 ( 0.8%)       |
| Non compliance                                    | 0 ( 0.0%)         | 3 (6.4%)                | 2 ( 4.8%)                | 5 ( 3.8%)       |
| Lack of Efficacy                                  | 15 (36.6%)        | 19 (40.4%)              | 19 (45.2%)               | 53 (40.8%)      |
| Travel                                            | 8 (19.5%)         | 4 ( 8.5%)               | 1 (2.4%)                 | 13 (10.0%)      |
| Procedure                                         | 3 ( 7.3%)         | 0 ( 0.0%)               | 0 ( 0.0%)                | 3 ( 2.3%)       |
| Death                                             | 9 (22.0%)         | 6 (12.8%)               | 9 (21.4%)                | 24 (18.5%)      |
| Protocol Deviation                                | 2 ( 4.9%)         | 1 (2.1%)                | 2 ( 4.8%)                | 5 ( 3.8%)       |
| Cancer not related                                | 2 ( 4.9%)         | 1 (2.1%)                | 0 ( 0.0%)                | 3 (2.3%)        |
| Prohibited Concomitant treatment                  | 1 (2.4%)          | 0 ( 0.0%)               | 2 ( 4.8%)                | 3 (2.3%)        |

A total of 267 patients completed the week 48 main protocol period at week 48. Patients could enter the extension phase on an optional basis depending only if the benefit/risk was assessed as positive by the investigator after discussion with the patient.

Table 26:  Number of Patients Dropping out at Initiation of Extension Period

| Study Period             | Placebo (N= 133)   | Masitinib 4.5 mg/kg (N=130)   | Masitinib 3 mg/kg (N= 131)   | Total (N=394)   |
|--------------------------|--------------------|-------------------------------|------------------------------|-----------------|
| Reached visit week 48    | 92 (69.2%)         | 83 (63.8%)                    | 89 (67.9%)                   | 264 (67.0%)     |
| Extension Period         | 80 (60.2%)         | 73 (56.2%)                    | 80 (61.1%)                   | 233 (59.1%)     |
| Dropout at visit week 48 | 12 (9.0%)          | 10 (7.7%)                     | 9 (6.9%)                     | 31 (7.9%)       |

In absolute value, 12 patients in the active control arm dropped out at the visit week 48 versus 19 patients  in  the  combined  Masitinib  AB  Science  arms.  The  randomization  ratio  between  Masitinib  AB

<div style=\"page-break-after: always\"></div>

Science and placebo control being 2:1.

Table 27:  Patients' disposition by treatment-arm and status - normal progressor subpopulation-[W0 W48]

|                                       | Placebo (N=114)   | Masitinib 4.5 (N=106)   | Masitinib 3 (N=110)   |
|---------------------------------------|-------------------|-------------------------|-----------------------|
| Patients status in main period Wo-W48 |                   |                         |                       |
| N                                     | 114               | 106                     | 110                   |
| W48 reached                           | 83 (72.8%)        | 73 (68.9%)              | 76 (69.1%)            |
| Prematurely discontinued before W48   | 31 (27.2%)        | 33 (31.1%)              | 34 (30.9%)            |
| Reason of discontinuation main part   |                   |                         |                       |
| N                                     | 31                | 33                      | 34                    |
| AE Related                            | 1 (3.2%)          | 11 (33.3%)              | 7 (20.6%)             |
| Non compliance                        | 0 (0.0%)          | 2 (6.1%)                | 1 (2.9%)              |
| Lack of Efficacy                      | 9 (29.0%)         | 13 (39.4%)              | 15 (44.1%)            |
| Travel                                | 7 (22.6%)         | 3 (9.1%)                | 1 (2.9%)              |
| Procedure                             | 2 (6.5%)          | 0 (0.0%)                | 0 (0.0%)              |
| Death                                 | 7 (22.6%)         | 2 (6.1%)                | 7 (20.6%)             |
| Protocol Deviation                    | 2 (6.5%)          | 1 (3.0%)                | 2 (5.9%)              |
| Cancer not related                    | 2 (6.5%)          | 1 (3.0%)                | 0 (0.0%)              |
| Prohibited Concomitant treatment      | 1 (3.2%)          | 0 (0.0%)                | 1 (2.9%)              |

Table 28: Patients' disposition by treatment-arm and status - full study population comprising normal + fast progressors -[W0 - W48]

|                                       | Placebo (N=133)   | Masitinib 4.5 (N=130)   | Masitinib 3 (N=131)   |
|---------------------------------------|-------------------|-------------------------|-----------------------|
| Patients status in main period WO-W48 |                   |                         |                       |
| n                                     | 133               | 130                     | 131                   |
| W48 reached                           | 92 (69.2%)        | 83 (63.8%)              | 89 (67.9%)            |
| Prematurely discontinued before W48   | 41 (30.8%)        | 47 (36.2%)              | 42 (32.1%)            |
| Reason of discontinuation main part   |                   |                         |                       |
| N                                     | 41                | 47                      | 42                    |
| AE Related                            | 1 (2.4%)          | 12 (25.5%)              | 7 (16.7%)             |
| Lost to Follow-up                     | 0 (0.0%)          | 1 (2.1%)                | 0 (0.0%)              |
| Non compliance                        | 0 (0.0%)          | 3 (6.4%)                | 2 (4.8%)              |
| Lack of Efficacy                      | 15 (36.6%)        | 19 (40.4%)              | 19 (45.2%)            |
| Travel                                | 8 (19.5%)         | 4 (8.5%)                | 1 (2.4%)              |
| Procedure                             | 3 (7.3%)          | 0 (0.0%)                | 0 (0.0%)              |
| Death                                 | 9 (22.0%)         | 6 (12.8%)               | 9 (21.4%)             |
| Protocol Deviation                    | 2 (4.9%)          | 1 (2.1%)                | 2 (4.8%)              |
| Cancer not related                    | 2 (4.9%)          | 1 (2.1%)                | 0 (0.0%)              |
| Prohibited Concomitant treatment      | 1 (2.4%)          | 0 (0.0%)                | 2 (4.8%)              |

The largest portion of the patients discontinued the study due to lack of efficacy in Masitinib AB Science 4.5  mg/kg/day  (40,4%)  and  Masitinib  AB  Science  3  mg/kg/day  (45,2%)  groups  in  both  study

<div style=\"page-break-after: always\"></div>

subpopulations and more than in placebo (36,6%) group. Discontinuation due to the death is the same in placebo and Masitinib AB Science 3 mg/kg/day groups (22% and 21,4 % respectively) and lower (12,8%) in Masitinib AB Science 4.5 mg/kg/day in the full study population comprising normal + fast progressors.

A breakdown of updated survival status according to study period and patient disposition from study AB10015 is shown below.

Table 29: Survival status according to study periods

| Period (Start-End)   | Main Protocol Period (Apr 2013-Dec 2016)   | Main Protocol Period (Apr 2013-Dec 2016)   | Protocol Ext.Period (Dec 2016-Nov 2017)          | Protocol Ext.Period (Dec 2016-Nov 2017)          | Follow-up (Nov 2017-June 2020)            |
|----------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------------|--------------------------------------------------|-------------------------------------------|
| Blinding status      | Blinded                                    | Blinded                                    | Blinded up to Apr 2017 Open label firom Apr 2017 | Blinded up to Apr 2017 Open label firom Apr 2017 | Open-label                                |
| Survival status      | Alive at start                             | Deaths during                              | Alive at start                                   | Deaths during                                    | Alive at start                            |
| M3.0                 | 131 (100%)                                 | 45/131 (34%)                               | 86/131 (66%)                                     | 19/86 (22%)                                      | 67/131 (51%) Entered NPP: 30 No NPP: 37   |
| M4.5                 | 130 (100%)                                 | 44/130 (34%)                               | 86/130 (66%)                                     | 16/86 (19%)                                      | 70/130 (54%) Entered NPP: 29 No NPP: 41   |
| PBO                  | 133 (100%)                                 | 43/133 (32%)                               | 90/133 (68%)                                     | 12/90 (13%)                                      | 78/133 (59%) Entered NPP: 25 No NPP: 53   |
| Total                | 394 (100%)                                 | 132/394 (34%)                              | 262/394 (66%)                                    | 47/262 (18%)                                     | 215/394 (54%) Entered NPP: 84 No NPP: 129 |

Table 30: Disposition of populations for long-term overall survival analysis of study AB10015

| COHORT                               | PBO (m) (   | M4.5 (m)   | M3.0 (n   | Total     |
|--------------------------------------|-------------|------------|-----------|-----------|
| Overall (mITT) population            | 133         | 130        | 131       | 394       |
| Survival status verified less than 7 | 128         | 122        | 124       | 374       |
| months prior to cut-off              | (96.2%)     | (93.8%)    | (94.7%)   | (94.9%)   |
| Survival status older than 7 months  | 5 (3.8%)    | 8 (6.2%)   | 7 (5.3%)  | 20 (5.1%) |

$ Survival status (also referred to as vital status) verified by investigational site within 7 months prior to cut-off (June 2020) for long-term OS analysis. OS: Overall survival.

## · Recruitment

Between April 2013 and December 2015, a total of 394 patients underwent randomization from 34 sites in 9 countries (specifically: Spain, Argentina, Italy, Slovakia, Netherlands, Canada, Greece, Portugal, and Mexico).

## · Conduct of the study

## Protocol amendments

The protocol version 1.0 dated 03 August 2012 (version 1.0 ESP) was designed as a phase II and planned to enrol 45 patients, comparing two treatment arms (pooled Masitinib AB Science 3.0 or Masitinib AB Science 4.5 mg/kg/day + riluzole versus placebo + riluzole). The study was initiated in April 2013. There were four protocol  amendments while the study remained blinded. The details of these are provide below:

<div style=\"page-break-after: always\"></div>

- Protocol  version  2.0  (first  amendment,  dated  02  July  2013)  with  successful  recruitment,  it  was decided to transform the phase 2 directly into a phase 3, without reviewing the phase 2 data. Protocol Version 2.0 incorporated the following changes for primary analysis: defined hypothesis of difference between the two treatment groups of 3.3. points, use of repeated measure from week 4 to week 48, replacement of missing data with LOFC, the modification of the sample size change from phase 2 to phase 2/3 study with 210 patients.
- Protocol version 3.0 (second amendment, dated 21 March 2014) incorporated the comparison of three  treatment-arms  (Masitinib  AB  Science  3.0  mg/kg/day  versus  Masitinib  AB  Science  4.5 mg/kg/day  versus  placebo),  use  of  repeated  measures  at  week  24,  36  and  48,  replacement  of missing data with observed cases, sequence of testing Masitinib AB Science 4.5 mg/kg/day then Masitinib AB Science 3.0 mg/kg/day, new stratification factors introduced, definition of treatment failure, the planning for a futility test and an interim analysis. The sample size was further modified as a result of the changes in the study design (change from 210 patients to 300 patients).
- Protocol Version 4.0 (third amendment, dated 08 October 2014) introduced a distinction between 'normal progressor' patients and 'fast progressor' patients. 'Normal progressors' were redefined as the primary efficacy population for primary analysis. The applicant considers that this amendment was  indicated  to  be  not  data  driven  and  was  made  to  avoid  the  risk  of  bias  inherent  to  'fast progressor' subpopulation. A switch from repeated measures to absolute change from baseline to week 48 was also introduced in the primary analysis, with LOCF as primary method for missing data handling at week 48. Sequence of analysis was redefined as Masitinib AB Science 4.5mg/kg/day normal  progressors  subpopulation  then  Masitinib  AB  Science  3.0  mg/kg/day  normal  progressors subpopulation  then  Masitinib  AB  Science  4.5mg/kg/day  in  the  full  study  population  comprising normal  +  fast  progressors  then  Masitinib  AB  Science  3mg/kg/day  in  the  full  study  population comprising  normal  +  fast  progressors.  The  sample  size  was  further  increased  taking  into consideration the change from repeated measure to LOCF method (change from 300 patients to 381 patients). Interim analyses were changed from 200 to 190 patients (to represent 50% of the target population).
- Protocol Version 5.0 (fourth amendment, dated 16 March 2015) introduced minor changes, including modification in the LOCF method.

## Inspections

A total  of  four  GCP  inspections  of  study  AB10015  were  conducted,  by  EMA,  Health  Canada,  ANMAT (Argentina), and Infarmed (Portugal).

The following conclusions have been made by local agencies:

## Argentina

Administrative and/or legal penalty against the investigator, Sponsor or CRO, after development of the pertaining disciplinary proceedings. Official Action Indicated point 12.2, Section D, ANMAT Disposition 6677/10 for PI in his role of PI to carry out the following actions: Sign a commitment letter with the Administration for the future clinical trials to be conducted. Official Action Indicated for the Sponsor LAT Research to carry out the following actions: Sign a commitment letter with the Administration for the future clinical trials to be conducted.

## Canada

No observations or corrective actions required.

## Portugal

<div style=\"page-break-after: always\"></div>

The  selection  of  participants  was  made  by  fulfilling  the  inclusion  criteria  (although  with  certain shortcomings  in  the  documentation  process).  There  were  no  indications  of  a  possible  relationship between  the  publication  of  results  of  the  interim  analysis  that  might  have  put  into  question  the concealment of the trial in this centre. Critical non-compliances were not identified.

## EMA coordinated inspections:

As part of a previous marketing authorisation application based on the same pivotal trial, GCP inspections were carried-out at the request of the Committee, at the two main sites which enrolled &gt;40% of the full study population. During the inspection critical and major findings were identified. Critical findings were related to clinical trial monitoring, inadequate clinical conduct of the trial, failing to communicate relevant protocol deviations to the Spanish Medicines Agency and suboptimal management of trial at site by the Sponsor and CRO.

Major findings were related to clinical conduct of the trial, safety reporting, investigational medicinal product, source data verification, qualification and training, production, version control and content of essential documents. It was concluded that it cannot be ensured that the data are trustworthy. The integrity of data was likely impaired, and it was considered highly likely to have an impact on the final results. During the current marketing authorisation procedure, the applicant was requested to justify the use  of  data  from  AB10015  study  to  substantiate  the  current  MAA.  The  applicant  presented  the implemented corrective measures and provided updated version of the CSR for study AB10015. The corrective measures the applicant implemented on the AB10015 study were assessed and, despite some improvements, were found insufficient to ensure the trustworthiness of the data (please see also section 2.6.6 Discussion on clinical efficacy below).

## · Baseline data

## Study treatment period and extension phase

<div style=\"page-break-after: always\"></div>

Table  31:  Demographics  and  disease  characteristics  of  the  study  patients  (full  study  population comprising normal + fast Progressors)

|                                                         | Placebo (N=133)   | Masitinib 4.5 (N=130)   | p-value (M 4.5 vs P))   | Masitinib 3 (N=131)   | p-value (M 3 vs P)   |
|---------------------------------------------------------|-------------------|-------------------------|-------------------------|-----------------------|----------------------|
| Country                                                 |                   |                         | 0.6972 (F)              |                       | 0.9875 (F)           |
| N                                                       | 133               | 130                     |                         | 131                   |                      |
| ARGENTINA                                               | 38 (28.6%)        | 40 (30.8%)              |                         | 41 (31.3%)            |                      |
| CANADA                                                  | 4 (3.0%)          | 1 (0.8%)                |                         | 3 (2.3%)              |                      |
| GREECE                                                  | 2 (1.5%)          | 4 (3.1%)                |                         | 2 (1.5%)              |                      |
| ITALY                                                   | 28 (21.1%)        | 21 (16.2%)              |                         | 26 (19.8%)            |                      |
| MEXICO                                                  | 1 (0.8%)          | 1 (0.8%)                |                         | 1 (0.8%)              |                      |
| NETHERLANDS                                             | 3 (2.3%)          | 4 (3.1%)                |                         | 3 (2.3%)              |                      |
| PORTUGAL                                                | 0 (0.0%)          | 2 ( 1.5%)               |                         | 1 (0.8%)              |                      |
| SLOVAKIA                                                | 6 (4.5%)          | 4 (3.1%)                |                         | 3 (2.3%)              |                      |
| SPAIN                                                   | 51 (38.3%)        | 53 (40.8%)              |                         | 51 (38.9%)            |                      |
| Gender                                                  |                   |                         | 0.5370 (C)              |                       | 0.7794 (C)           |
| N                                                       | 133               | 130                     |                         | 131                   |                      |
| Male                                                    | 80 (60.2%)        | 83 (63.8%)              |                         | 81 (61.8%)            |                      |
| Female                                                  |                   |                         |                         |                       |                      |
|                                                         | 53 (39.8%)        | 47 (36.2%)              |                         | 50 (38.2%)            |                      |
| Progression ALSFRS_R before randomisation (point/month) |                   |                         | 0.7516 (A)              |                       | 0.4667 (A)           |
| n                                                       | 133               | 130                     |                         | 131                   |                      |
| Mean +/- SD                                             | 0.7 +/-0.7        | 0.7 +/-0.6              |                         | 0.7 +/-0.5            |                      |
| Median                                                  | 0.5               | 0.6                     |                         | 0.5                   |                      |
| Range                                                   | 0.1 ; 5.0         | 0.0 ; 3.7               |                         | 0.1 ; 2.2             |                      |
| Normal progressors (Progression                         |                   |                         |                         |                       |                      |
| ALSFRS R before                                         |                   |                         | 0.3599 (C)              |                       | 0.6926 (C)           |
| randomisation<1.1)                                      |                   |                         |                         |                       |                      |
| 1n1                                                     | 133               | 130                     |                         | 131                   |                      |
| Yes                                                     | 114 (85.7%)       | 106 (81.5%)             |                         | 110 (84.0%)           |                      |
| Progression ALSFRS_R before                             |                   |                         |                         |                       |                      |
| randomisation (point/month)                             |                   |                         | 0.7516 (A)              |                       | 0.4667 (A)           |
| n                                                       | 133               | 130                     |                         | 131                   |                      |
| Mean +/- SD                                             | 0.71 +/- 0.69     | 0.73 +/- 0.63           |                         | 0.65 +/- 0.48         |                      |
| Median                                                  | 0.53              | 0.55                    |                         | 0.53                  |                      |
| Range                                                   | 0.05 ; 5.00       | 0.03 ; 3.69             |                         | 0.09 ; 2.24           |                      |
| ALSFRSscore atbaseline                                  |                   |                         | 0.3773 (A)              |                       | 0.3119 (A)           |
| N                                                       | 133               | 130                     |                         | 131                   |                      |
| Mean +/- SD                                             | 38.1 +/-5.5       | 37.5 +/-5.5             |                         | 37.4 +/-5.7           |                      |
| Median                                                  | 39.0              | 38.0                    |                         | 38.0                  |                      |
| Range                                                   | 21.0 ; 47.0       | 23.0 ; 47.0             |                         | 21.0 ; 46.0           |                      |
| Age (years)                                             |                   |                         |                         |                       |                      |
| N                                                       | 133               | 129                     |                         | 131                   |                      |
| Mean +/- SD                                             | 55.2 +/-10.6      | 55.5 +/- 10.6           |                         | 55.7 +/- 10.2         |                      |
| Median                                                  | 56.0              | 55.0                    |                         | 57.0                  |                      |
| Range                                                   | 27.0 ; 75.0       | 24.0 ; 79.0             |                         | 33.0 ; 75.0           |                      |
| Site of onset                                           |                   |                         | 0.9405 (C)              |                       | 0.6634 (C)           |
| N                                                       | 133               | 130                     |                         | 131                   |                      |
| Other_than_bulbar                                       | 109 (82.0%)       | 107 (82.3%)             |                         | 110 (84.0%)           |                      |
| Bulbar                                                  | 24 (18.0%)        | 23 (17.7%)              |                         | 21 (16.0%)            |                      |
| Region                                                  |                   |                         |                         |                       | 0.6664 (C)           |
|                                                         |                   |                         | 0.9206 (C)              | 131                   |                      |
| N North and West                                        | 133               | 130                     |                         |                       |                      |
| America Europe                                          | 86 (64.7%)        | 81 (62.3%)              |                         | 84 (64.1%)            |                      |
| Eastern Europe                                          | 8 (6.0%)          | 8 (6.2%)                |                         | 5 (3.8%)              |                      |
| Other Countries                                         | 39 (29.3%)        | 41 (31.5%)              |                         | 42 (32.1%)            |                      |

<div style=\"page-break-after: always\"></div>

|                   | Placebo (N=133)   | Masitinib 4.5 (N=130)   | Masitinib3 (N=131)   | Total (N=394)   |
|-------------------|-------------------|-------------------------|----------------------|-----------------|
| ALSFRS-R Baseline |                   |                         |                      |                 |
| N                 | 133               | 130                     | 131                  | 394             |
| Mean ± SD         | 38.1 ± 5.5        | 37.7 ±5.5               | 37.4±5.7             | 37.7±5.6        |
| Median            | 39.0              | 38.0                    | 38.0                 | 38.0            |
| Range             | 21.0 ; 47.0       | 23.0 ; 47.0             | 21.0 ; 46.0          | 21.0 ; 47.0     |
| FVC Baseline      |                   |                         |                      |                 |
| N                 | 133               | 130                     | 131                  | 394             |
| Mean ± SD         | 89.2± 18.7        | 87.5± 16.9              | 86.8 ± 18.7          | 87.8 ± 18.1     |
| Median            | 88.0              | 85.0                    | 87.5                 | 87.0            |
| Range             | 37.0 ; 136.0      | 45.0 ; 131.0            | 51.0 ; 149.0         | 37.0 ; 149.0    |

Table  32:  Demographics  and  disease  characteristics  of  the  study  patients  (normal  progressors subpopulation)

|                                                         | Placebo (N=114)   | Masitinib 4.5 (N=106)    | p-value (M 4.5 vs P)   | Masitinib 3 (N=110)   | p-value (M3 vs P)   |
|---------------------------------------------------------|-------------------|--------------------------|------------------------|-----------------------|---------------------|
| Country                                                 |                   |                          | 0.5411 (F)             |                       | 0.9730 (F)          |
| N                                                       | 114               | 106                      |                        | 110                   |                     |
| ARGENTINA                                               | 33 (28.9%)        | 36 (34.0%)               |                        | 36 (32.7%)            |                     |
| CANADA                                                  | 4 (3.5%)          | 1 (0.9%)                 |                        | 3 (2.7%)              |                     |
| GREECE                                                  | 2 ( 1.8%)         | 4 (3.8%)                 |                        | 2 ( 1.8%)             |                     |
| ITALY                                                   | 26 (22.8%)        | 16 (15.1%)               |                        | 22 (20.0%)            |                     |
| MEXICO                                                  | 1 (0.9%)          | 1 (0.9%)                 |                        | 1 (0.9%)              |                     |
| NETHERLANDS                                             | 3 (2.6%)          | 4 (3.8%)                 |                        | 2 ( 1.8%)             |                     |
| PORTUGAL                                                | 0 (0.0%)          | 2 ( 1.9%)                |                        | 1 (0.9%)              |                     |
| SLOVAKIA                                                | 6 (5.3%)          | 4 (3.8%)                 |                        | 3 (2.7%)              |                     |
| SPAIN                                                   | 39 (34.2%)        | 38 (35.8%)               |                        | 40 (36.4%)            |                     |
| Gender                                                  |                   |                          | 0.4838 (C)             |                       | 0.6316 (C)          |
| 11                                                      | 114               | 106                      |                        | 110                   |                     |
| Male                                                    | 69 (60.5%)        | 69 (65.1%)               |                        | 70 (63.6%)            |                     |
| Female                                                  | 45 (39.5%)        | 37 (34.9%)               |                        | 40 (36.4%)            |                     |
| Normal progressors (Progression                         |                   |                          |                        |                       |                     |
| ALSFRS R before                                         |                   |                          | NA                     |                       | NA                  |
| randomisation<1.1)                                      |                   |                          |                        |                       |                     |
| Yes                                                     |                   | 114 (100.0%)106 (100.0%) |                        | 110 (100.0%)          |                     |
| Progression ALSFRS_R before randomisation (point/month) |                   |                          | 0.9986 (A)             |                       | 0.7830 (A)          |
| 11                                                      | 114               | 106                      |                        | 110                   |                     |
| Mean +/- SD                                             | 0.49 +/- 0.24     | 0.49 +/-0.25             |                        | 0.48 +/- 0.25         |                     |
| Median                                                  | 0.48              | 0.50                     |                        | 0.45                  |                     |
| Range                                                   | 0.05 ; 1.07       | 0.03 ; 1.08              |                        | 0.09 ; 1.07           |                     |
| ALSFRSscore atbaseline                                  |                   |                          | 0.1341 (A)             |                       | 0.2557 (A)          |
| 1n                                                      | 114               | 106                      |                        | 110                   |                     |
| Mean +/- SD                                             | 39.3 +/- 4.6      | 38.3 +/- 5.3             |                        | 38.6 +/- 5.1          |                     |
| Median                                                  | 39.0              | 39.0                     |                        | 40.0                  |                     |
| Range                                                   | 27.0 ; 47.0       | 23.0 ; 47.0              |                        | 23.0 ; 46.0           |                     |
| Age (years)                                             |                   |                          |                        |                       |                     |
| 11                                                      | 114               | 105                      |                        | 110                   |                     |
| Mean +/- SD                                             | 55.4 +/-10.5      | 54.8 +/- 10.8            |                        | 54.9 +/- 10.3         |                     |
| Median                                                  | 57.0              | 54.0                     |                        | 54.5                  |                     |
| Range                                                   | 27.0 ; 75.0       | 24.0 ; 79.0              |                        | 33.0 ; 75.0           |                     |
| Site of onset                                           |                   |                          | 0.8196 (C)             |                       | 0.3687 (C)          |
| 1n1                                                     | 114               | 106                      |                        | 110                   |                     |
| Other_than_bulbar                                       | 90 (78.9%)        | 85 (80.2%)               |                        | 92 (83.6%)            |                     |
| Bulbar                                                  | 24 (21.1%)        | 21 (19.8%)               |                        | 18 (16.4%)            |                     |
| Region                                                  |                   |                          | 0.6885 (C)             |                       | 0.6498 (C)          |
| n1                                                      | 114 72 (63.2%)    | 106 61 (57.5%)           |                        | 110                   |                     |
| North America and West Europe                           | 8 (7.0%)          |                          |                        | 68 (61.8%)            |                     |
| Eastern Europe                                          |                   | 8 (7.5%)                 |                        | 5 (4.5%)              |                     |
| Other Countries                                         | 34 (29.8%)        | 37 (34.9%)               |                        | 37 (33.6%)            |                     |

<div style=\"page-break-after: always\"></div>

|                 | Placebo (=114)   | Masitinib4.5 (=106)   | Masitinib 3 (N=110)   | Total (N=330)   |
|-----------------|------------------|-----------------------|-----------------------|-----------------|
| ALSFRSRBaseline |                  |                       |                       |                 |
| 1n              | 114              | 106                   | 110                   | 330             |
| Mean +/- SD     | 39.3 +/-4.6      | 38.3 +/-5.3           | 38.6 +/-5.1           | 38.7 +/-5.0     |
| Median          | 39.0             | 39.0                  | 40.0                  | 39.0            |
| Range           | 27.0 ; 47.0      | 23.0 ; 47.0           | 23.0 ; 46.0           | 23.0 ; 47.0     |
| FVCBaseline     |                  |                       |                       |                 |
| n               | 114              | 106                   | 110                   | 330             |
| Mean +/-SD      | 90.3 +/-19.0     | 89.0 +/-16.5          | 88.1 +/- 18.9         | 89.2 +/- 18.1   |
| Median          | 87.0             | 92.0                  | 88.0                  | 89.0            |
| Range           | 37.0 ; 136.0     | 60.0 ; 131.0          | 51.0 ; 149.0          | 37.0 ; 149.0    |

Table 33: Baseline characteristics for fast and normal progressors subpopulations (ITT population)

|                                                         | Normal Progressors   | Normal Progressors   | Fast Progressors   | Fast Progressors   |
|---------------------------------------------------------|----------------------|----------------------|--------------------|--------------------|
|                                                         | Placebo              | Masitinib 4.5        | Placebo            | Masitinib 4.5      |
|                                                         | (N=113)              | (N=105)              | (N=19)             | (N=23)             |
| Gender                                                  |                      |                      |                    |                    |
| Male                                                    | 69 (61.1%)           | 68 (64.8%)           | 11 (57.9%)         | 13 (56.5%)         |
| Female                                                  | 44 (38.9%)           | 37 (35.2%)           | 8 (42.1%)          | 10 (43.5%)         |
| Progression ALSFRS-R before randomization (point/month) |                      |                      |                    |                    |
| Mean +/- SD                                             | 0.49 +/- 0.24        | 0.49 +/- 0.25        | 1.98 +/- 1.06      | 1.76 +/- 0.75      |
| Median                                                  | 0.48                 | 0.49                 | 1.47               | 1.42               |
| ALSFRS-R score at baseline                              |                      |                      |                    |                    |
| Mean +/- SD                                             | 39.3 +/- 4.6         | 38.2 +/- 5.4         | 31.0 +/-5.3        | 34.4 +/- 4.5       |
| Median                                                  | 39.0                 | 39.0                 | 32.0               | 34.0               |
| Time from first symptom to randomization(months)        |                      |                      |                    |                    |
| Mean +/- SD                                             | 19.5 +/- 8.5         | 21.6 +/- 8.8         | 9.8 +/- 3.7        | 8.4 +/- 3.2        |
| Median                                                  | 19.0                 | 22.0                 | 10.0               | 8.0                |
| Time from diagnosis to randomization (months)           |                      |                      |                    |                    |
| Mean +/- SD                                             | 9.8 +/- 7.3          | 11.1 +/- 8.6         | 5.0 +/- 2.4        | 4.1 +/- 3.0        |
| Median                                                  | 8.0                  | 9.1                  | 4.7                | 3.0                |
| FVC (% predicted)                                       |                      |                      |                    |                    |
| Mean +/- SD                                             | 90.2 +/- 19.0        | 88.9 +/- 16.5        | 82.0 +/- 15.1      | 82.7 +/- 16.1      |
| Median                                                  | 87.0                 | 92.0                 | 88.0               | 79.0               |
| Age (years)                                             |                      |                      |                    |                    |
| Mean +/- SD                                             | 55.5 +/-10.6         | 54.8 +/- 10.8        | 53.8 +/-11.2       | 59.3 +/- 9.1       |
| Median                                                  | 57.0                 | 54.0                 | 49.0               | 61.0               |
| Site of onset                                           |                      |                      |                    |                    |
| Spinal                                                  | 89 (78.8%)           | 84 (80.0%)           | 19 (100.0%)        | 21 (91.3%)         |
| Bulbar                                                  | 24 (21.2%)           | 21 (20.0%)           | 0 (0.0%)           | 2 (8.7%)           |
| Region                                                  |                      |                      |                    |                    |
| North America and West Europe                           | 72 (63.7%)           | 61 (58.1%)           | 19 (82.6%)         | 49 (77.8%)         |
| Eastern Europe                                          | 8 (7.1%)             | 7 (6.7%)             |                    |                    |
| Other Countries                                         | 33 (29.2%)           | 37 (35.2%)           | 4 (17.4%)          | 14 (22.2%)         |

Delta-FS before randomization for normal progressors subpopulation was comparable between treatment arms,  in  terms  of  mean  (0.49  and  0.50  points/month  for  placebo  and  Masitinib  AB  Science  4.5 mg/kg/day,  respectively,  median  (0.48  and  0.49  points/month,  respectively  and  range.  In  the  fast progressors subpopulation, median Δ FS was comparable between the treatment groups (1.47 and 1.42 points/month for placebo and Masitinib AB Science 4.5 mg/kg/day, respectively).

<div style=\"page-break-after: always\"></div>

## Follow-up phase

Table 34 : Baseline characteristics for the moderate ALS enriched cohort (≥2 on each baseline ALSFRS -R item) with ΔFS&lt;1.1 (Primary analysis - step 1)

|                               |                                  | PBO (N=62)   | M4.5 (N=45)   | Delta*   |
|-------------------------------|----------------------------------|--------------|---------------|----------|
| Sex; n (%)                    | Male                             | 39 (62.9%)   | 31 (68.9%)    | +6.0%    |
| △FS<1.1; n (%)                | Yes                              | 62 (100.0%)  | 45 (100.0%)   | 0%       |
| Average △FS (pts/month)       | Mean ± SD                        | 0.41 ±0.23   | 0.39 ± 0.25   | -4.9%    |
|                               | Range                            | 0.05 ; 1.07  | 0.03 ; 1.01   |          |
| Average ALSFRS-R Mean ± SD    |                                  | 42.0±3.2     | 42.2 ±3.1     | +0.5%    |
|                               | Range                            | 34.0 ; 47.0  | 36.0 ; 47.0   |          |
| Age (years)                   | Mean ± SD                        | 55.0± 10.1   | 55.6± 11.5    | +1.1%    |
|                               | Range                            | 28.0 ; 73.0  | 24.0 ; 78.0   |          |
| ALS diagnosis; n (%) Definite | ALS diagnosis; n (%) Definite    | 39 (62.9%)   | 25 (55.6%)    | -7.3%    |
|                               | Probable                         | 19 (30.6%)   | 16 (35.6%)    | +5.0%    |
|                               | Probable, lab                    | 4 (6.5%)     | 4 (8.9%)      | +2.4%    |
| Disease (suou)uone.mp         | Mean ± SD                        | 7.3±5.9      | 8.2± 7.6      | +12.3%   |
| FVC (% predicted)             | Mean ± SD                        | 92.9 ± 17.9  | 93.8 ±17.0    | +1.0%    |
| Site of onset; n (%)          | Spinal                           | 46 (74.2%)   | 35 (77.8%)    | +3.6%    |
|                               | Bulbar                           | 16 (25.8%)   | 10 (22.2%)    | -3.6%    |
| Region; n (%)                 | North America and Western Europe | 35 (56.5%)   | 24 (53.3%)    | -3.2%    |
|                               | Eastern Europe                   | 4 (6.5%)     | 4 (8.9%)      | +2.4%    |
|                               | Other Countries                  | 23 (37.1%)   | 17 (37.8%)    | +0.7%    |

<div style=\"page-break-after: always\"></div>

Table 35: Baseline characteristics for the moderate/severe ALS enriched cohort (≥1 on each baseline ALSFRSR item) with ΔFS&lt;1.1 (Primary analysis - step 2)

|                              |                                  | PBO (N=104)   | M4.5 (N=85)   | Delta*   |
|------------------------------|----------------------------------|---------------|---------------|----------|
| Sex; n (%)                   | Male                             | 64 (61.5%)    | 58 (68.2%)    | +6.7%    |
| △FS<1.1; n (%)               | Yes                              | 104 (100%)    | 85 (100%)     | 0%       |
| Average △FS (pts/month)      | Mean ± SD                        | 0.49 ± 0.25   | 0.45 ± 0.25   | -8.2%    |
|                              | Range                            | 0.05 ; 1.07   | 0.03 ; 1.08   |          |
| Average ALSFRS-R Mean ± SD   |                                  | 39.8 ±4.3     | 39.9± 4.2     | +0.3%    |
|                              | Range                            | 29.0 ; 47.0   | 30.0 ; 47.0   |          |
| Age (years)                  | Mean ± SD                        | 55.4± 10.8    | 54.3 ± 10.7   | -2.0%    |
|                              | Range                            | 27.0 ; 75.0   | 24.0 ; 78.0   |          |
| ALS diagnosis; n (%)Definite | ALS diagnosis; n (%)Definite     | 61 (58.7%)    | 50 (58.8%)    | +0.1%    |
|                              | Probable                         | 35 (33.7%)    | 29 (34.1%)    | +0.4%    |
|                              | Probable, lab                    | 8 (7.7%)      | 6 (7.1%)      | -0.6%    |
| Disease (suo) uone.inp       | Mean ± SD                        | 9.4 ± 7.1     | 9.8± 7.8      | +4.3%    |
| FVC (% predicted)            | Mean ± SD                        | 90.9 ± 18.4   | 91.8 ± 15.9   | +1.0%    |
| Site of onset; n (%)         | Spinal                           | 81 (77.9%)    | 69 (81.2%)    | 3.3%     |
|                              | Bulbar                           | 23 (22.1%)    | 16 (18.8%)    | -3.3%    |
| Region; n (%)                | North America and Western Europe | 66 (63.5%)    | 49 (57.6%)    | -7.9%    |
|                              | Eastern Europe                   | 7 (6.7%)      | 8 (9.4%)      | +2.7%    |
|                              | Other Countries                  | 31 (29.8%)    | 28 (32.9%)    | +3.1%    |

<div style=\"page-break-after: always\"></div>

Table  36:  Baseline  characteristics  for  the  moderate/severe/very  severe  ALS  cohort  (regardless  of baseline ALSFRSR item) with ΔFS&lt;1.1 (Primary analysis - step 3)

|                           |                                  |             | PBO (N=114) M4.5 (N=106)   | Delta*   |
|---------------------------|----------------------------------|-------------|----------------------------|----------|
| Sex; n (%)                | Male                             | 69 (60.5%)  | 69 (65.1%)                 | 4.6%     |
| △FS<1.1; n (%)            | Yes                              |             | 114 (100.0%) 106 (100.0%)  | 0%       |
| Average △FS (pts/month)   | Mean ± SD                        | 0.49 ± 0.24 | 0.49 ± 0.25                | 0%       |
|                           | Range                            | 0.05 ; 1.07 | 0.03 ; 1.08                |          |
| Average ALSFRS-R          | Mean ± SD                        | 39.3 ± 4.6  | 38.3 ± 5.3                 | -2.5%    |
|                           | Range                            | 27.0 ; 47.0 | 23.0 ; 47.0                |          |
| Age (years)               | Mean ± SD                        | 55.4 ±10.5  | 54.8 ± 10.8                | -1.1%    |
|                           | Range                            | 27.0 ; 75.0 | 24.0 ; 79.0                |          |
| ALS diagnosis; n (%)      | Definite                         | 66 (57.9%)  | 64 (60.4%)                 | 2.5%     |
|                           | Probable                         | 38 (33.3%)  | 33 (31.1%)                 | -2.2%    |
|                           | Probable, lab                    | 10 (8.8%)   | 9 (8.5%)                   | -0.3%    |
| Disease duration (months) | Mean ± SD                        | 9.6 ± 7.1   | 11.0± 8.6                  | 14.6%    |
| FVC (% predicted)         | Mean ± SD                        | 90.3 ± 19.0 | 89.0 ± 16.5                | -1.4%    |
| Site of onset; n (%)      | Spinal                           | 90 (78.9%)  | 85 (80.2%)                 | 1.3%     |
|                           | Bulbar                           | 24 (21.1%)  | 21 (19.8%)                 | -1.3%    |
| Region; n (%)             | North America and Western Europe | 72 (63.2%)  | 61 (57.5%)                 | -5.7%    |
|                           | Eastern Europe                   | 8 (7.0%)    | 8 (7.5%)                   | 0.5%     |
|                           | Other Countries                  | 34 (29.8%)  | 37 (34.9%)                 | 5.1%     |

- Outcomes and estimation

## Primary endpoint: Change in ALSFRS-R

The primary analysis was to test a statistically significant difference between the treatment arms of Masitinib AB Science + riluzole and placebo + riluzole on the ALSFRS-R. In accordance with the amended fixed sequence method to control the global family-wise error rate, the first step was to demonstrate a statistically  significant  difference  between  Masitinib  AB  Science  at  a  dose  of  4.5  mg/kg/day  or  3 mg/kg/day + riluzole versus placebo + riluzole on ALSFRS-R after a 48-week treatment period in the normal progressor subpopulation. Table 37 summarises the datasets for the primary and sensitivity analyses on ALSFRS-R absolute change from baseline to week 48.

<div style=\"page-break-after: always\"></div>

Table  37:  Number  of  patients  analysed  for  the  primary  and  sensitivity  analyses  on  ALSFRS-R  -  A. Masitinib  AB  Science  4.5  mg/kg/day;  B.  Masitinib  AB  Science  3  mg/kg/day  -  Normal  Progressor subpopulation (mITT)

| A.                          | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   |
|-----------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|                             | Primary                                                                      | Rule 2                                                                       | Rule 3                                                                       | Rule 4                                                                       | Rule 5                                                                       | Rule 6                                                                       | Rule 7                                                                       |
| Placebo + riluzole          | 102/113                                                                      | 103/113                                                                      | 107/113                                                                      | 108/113                                                                      | 111/113                                                                      | 111/113                                                                      | 111/113                                                                      |
| Masitinib 4.5 mg + riluzole | 99/105                                                                       | 99/105                                                                       | 102/105                                                                      | 102/105                                                                      | 104/105                                                                      | 104/105                                                                      | 104/105                                                                      |

## B.

Table  38:  Absolute  change  from  baseline  to  week  48  in  ALSFRS-R  -  Primary  efficacy  analysis  -  A. Masitinib  AB  Science  4.5  mg/kg/day;  B.  Masitinib  AB  Science  3  mg/kg/day    -  Normal  Progressor subpopulation (mITT, LOCF Rule 1/Primary)

|                           | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   | Number of patients with LOCF or Single imputation data / Number of patient   |
|---------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|                           | Primary                                                                      | Rule 2                                                                       | Rule 3                                                                       | Rule 4                                                                       | Rule 5                                                                       | Rule 6                                                                       | Rule 7                                                                       |
| Placebo + riluzole        | 102/113                                                                      | 103/113                                                                      | 107/113                                                                      | 108/113                                                                      | 111/113                                                                      | 111/113                                                                      | 111/113                                                                      |
| Masitinib 3 mg + riluzole | 106/110                                                                      | 106/110                                                                      | 107/110                                                                      | 107/110                                                                      | 110/110                                                                      | 110/110                                                                      | 110/110                                                                      |

## A.

| Treatment group   |   N |   LS Mean | Difference of means [95% confidence interval]   | p-value   | p-value re- randomisatio n test   |
|-------------------|-----|-----------|-------------------------------------------------|-----------|-----------------------------------|
| Placebo           | 102 |    -12.63 | 3.39                                            |           |                                   |
| Masitinib 4.5 mg  |  99 |     -9.24 | [0.65;6.13]                                     | 0.0157    | 0.0158                            |

B.

| Treatment group   |   N |   LS Mean | Difference of means [95% confidence interval]   | p-value   |
|-------------------|-----|-----------|-------------------------------------------------|-----------|
| Placebo           | 102 |    -11.34 | 2.73                                            |           |
| Masitinib 3 mg    | 106 |     -8.61 | [-0.18;5.65]                                    | 0.0661    |

The applicant claimed there was a statistically significant difference in the  ALSFRS-R score between Masitinib AB Science 4.5 mg.kg/d and placebo (difference of least quare means=3.39; p=0.0158) but not  between  Masitinib  AB  Science  3mg/kg/d  and  placebo  (difference  of  least  scare  means  =  2.73, p=0.0661) in the normal progressor subpopulation.

## Sensitivity analyses

The  applicant  claimed  that  sensitivity  analyses  on  the  primary  endpoint,  based  on  reasons  of discontinuation, were all positive for Masitinib AB Science 4.5 mg/kg/day treatment arm (p-value ranging

<div style=\"page-break-after: always\"></div>

from 0.019 to 0.029), but not for Masitinib AB Science 3 mg/kg/day treatment arm (the treatment difference  estimates  ranging  from  2.16  to  2.61,  with  p-value  ranging  from  0.07  to  0.13)  in  normal progressor subpopulation.

Table 39: Masitinib AB Science 4.5 mg/kg/day - Primary Analysis: Rule 2 to Rule 7

| Rule   | Analysis                                                                                                                                                                       | Diff of LS means [95 % CI] (P-Value)   |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| 2      | Rule 2: Same as mLOCF. In addition, imputation was also done only in case of premature discontinuation due to withdrawal of consent-related to study procedure.                | 3.28 [SE: 1.38] [0.55;6.01] 0.019      |
| 3      | Rule 3: Same as mLOCF. In addition, imputation was also done only in caseofprematurediscontinuationduetotravel.                                                                | 3.06 [SE: 1.35] [0.39;5.73] 0.0248     |
| 4      | Rule 4: Same as mLOCF. In addition, imputation was also done only in case of premature discontinuation dueto travel or due towithdrawal of consent related to study procedure. | 2.96 [SE: 1.34] [0.31;5.62] 0.0289     |
| 5      | Rule 5: LOCF method was applied for all patients but excluded data of those patients who were non-compliant after the date of non-compliance.                                  | 2.86 [SE: 1.30] [0.29;5.43] 0.0291     |
| 6      | Clusterbased imputation                                                                                                                                                        | 3.01 [SE: 1.26] [0.53;5.49] 0.0176     |
|        | Same as Rule 6 but in addition we will apply a penalty of 50% average increment in the group for those who discontinue due to lack of efficacy.                                | 3.03 [SE: 1.27] [0.52;5.54] 0.0182     |

## Secondary endpoint: Progression free survival (PFS)

In the normal progressor subpopulation, median PFS was increased by 4 months in the Masitinib AB Science 4.5 mg/kg/day group as compared with placebo group, and this improvement was claimed to be statistically significant (p-value=0.0159), corresponding to a 25% increase. No statistically significant difference is claimed between Masitinib AB Science 3 mg/kg/day group and placebo group. The analysis in ITT population showed consistent results with mITT population.

Figure 6: Kaplan Meier of PFS - Masitinib AB Science 4.5 mg/kg/day vs active control - Normal Progressor subpopulation (mITT, LOCF Rule 1/Primary)

<!-- image -->

## Secondary endpoint: Quality of life

The  applicant  claimed  that a  statistically significant  difference  was  observed  between  Masitinib  AB Science 4.5 mg/kg/day (P=0.0078) group and placebo group and also between Masitinib AB Science 3

<div style=\"page-break-after: always\"></div>

mg/kg/day  (p=0.0057)  group  and  placebo  group  in  the  ALSAQ  40  for  the  normal  progressor subpopulation  (improvement  42%  -  46%  and  34  respectively).  The  applicant  claimed  that  the improvement was observed across all components except emotion reactions. Results were consistent in ITT population.

Table 40: ALSAQ-40 score - Masitinib AB Science 4.5 mg/kg/day A; Masitinib AB Science 3 mg/kg/dayversus placebo in the normal progressor subpopulation (mITT)

## A.

Placebo + R =Placebo + riluzole (Active control). Masitinib 4.5 + R = Masitinib 4.5 mg/kg/day + Riluzole

<!-- image -->

| Treatment group   | N            | LS Mean      | Differenceofmeans [95%confidenceinterval]   | p-value      |
|-------------------|--------------|--------------|---------------------------------------------|--------------|
| mLOCF Rule 1      | mLOCF Rule 1 | mLOCF Rule 1 | mLOCF Rule 1                                | mLOCF Rule 1 |
| Placebo           | 102          | 27.18        | -7.76 [SE: 2.888] [-13.45;-2.06]            | 0.0078       |
| Masitinib 4.5 + R | 99           | 19.42        |                                             | 0.0078       |
| mLOCF Rule 5      | mLOCF Rule 5 | mLOCF Rule 5 | mLOCF Rule 5                                | mLOCF Rule 5 |
| Placebo           | 111          | 25.51        | -6.72 [SE: 2.721]                           | 0.0143       |
| Masitinib 4.5 + R | 104          | 18.79        | [-12.08;-1.36]                              | 0.0143       |

Source:StatisticalTable14.2.8.1 andTable14.2.8.7

## B.

Placebo + R =Placebo + riluzole (Active control). Masitinib 3.0 + R = Masitinib 3.0 mg/kg/day + Riluzole

| Treatmentgroup    | N           | LS Mean     | Differenceofmeans [95%confidenceinterval]   | p-value     |
|-------------------|-------------|-------------|---------------------------------------------|-------------|
| mLOCFRule 1       | mLOCFRule 1 | mLOCFRule 1 | mLOCFRule 1                                 | mLOCFRule 1 |
| Placebo           | 102         | 23.65       | -8.04 [SE: 2.876]                           | 0.0057      |
| Masitinib 3.0 + R | 106         | 15.60       | [-13.71;-2.37]                              | 0.0057      |

Source:StatisticalTable14.2.8.3andTable14.2.8.9

## Secondary endpoint: Functional Vital Capacity (FVC)

The  applicant  claimed  that  a  statistically  significant  difference  was  observed  between  Masitinib  AB Science 4.5 mg/kg/day group and placebo group in the absolute change from baseline to week 48 in FVC for the normal progressor subpopulation (improvement between 25% and 29%). The difference observed for  FVC  in  Masitinib  AB  Science  3  mg/kg/day  group  versus  placebo  group  was  lower.  Results  were consistent in ITT population.

<div style=\"page-break-after: always\"></div>

Table 41: Absolute change from baseline to week 48 in FVC - Masitinib AB Science 4.5 mg/kg/day versus placebo in the normal progressor subpopulation (mITT)

| Treatment group   | N            | LS Mean      | Differenceofmeans [95%confidenceinterval]   | p-value      |
|-------------------|--------------|--------------|---------------------------------------------|--------------|
| mLOCF Rule 1      | mLOCF Rule 1 | mLOCF Rule 1 | mLOCF Rule 1                                | mLOCF Rule 1 |
| Placebo           | 102          | -33.99       | 7.55 [SE: 3.439] [0.75;14.32]               | 0.0296       |
| Masitinib 4.5+R   | 98           | -26.45       | 7.55 [SE: 3.439] [0.75;14.32]               | 0.0296       |
| mLOCF Rule 5      | mLOCF Rule 5 | mLOCF Rule 5 | mLOCF Rule 5                                | mLOCF Rule 5 |
| Placebo           | 111          | -32.02       | 6.40 [SE: 3.262] [-0.03;12.83]              | 0.0511       |
| Masitinib 4.5 + R | 103          | -25.62       | 6.40 [SE: 3.262] [-0.03;12.83]              | 0.0511       |

Placebo + R = Placebo + riluzole (Active control). Masitinib 4.5 + R = Masitinib 4.5 mg/kg/day + Riluzole

Source:StatisticalTable14.2.13.1 and Table 14.2.13.5

## Secondary endpoint: Combined assessment of function and survival (CAFS)

The applicant claims that there was a trend (p = 0.0776; difference = 14.95 and p = 0.0698; difference = 15.57) observed between Masitinib AB Science 4.5 mg/kg/day and Masitinib AB Science 3 mg/kg/day treatment groups versus placebo group for CAFS score in the normal progressor subpopulation. Results were consistent in ITT population.

Table 42: CAFS score - Masitinib AB Science 4.5 mg/kg/day A.; Masitinib AB Science 3 mg/kg/day B. versus placebo in the normal Progressor subpopulation (mITT)

## A.

| Treatment group   |   N |   Mean Score |   Differenceofmeans |   p-value |
|-------------------|-----|--------------|---------------------|-----------|
| Placebo           | 111 |       100.77 |               14.95 |    0.0776 |
| Masitinib4.5+R    | 104 |       115.72 |               14.95 |    0.0776 |

Placebo + R = Placebo + riluzole (Active control). Masitinib 4.5 + R = Masitinib 4.5 mg/kg/day + Riluzole

Source:Statistical Table14.2.12.1

## B.

| Treatment group   |   N |   Mean Score |   Differenceofmeans |   p-value |
|-------------------|-----|--------------|---------------------|-----------|
| Placebo           | 111 |       103.25 |               15.57 |    0.0698 |
| Masitinib3.0+R    | 110 |       118.82 |               15.57 |    0.0698 |

Placebo + R = Placebo + riluzole (Active control). Masitinib 3.0 + R = Masitinib 3.0 mg/kg/day + Riluzole

Source:StatisticalTable14.2.12.3

## Secondary endpoint: Tracheostomy free survival (TFS)

No  statistically  significant  difference  (p  =  0.7382)  is  claimed  between  Masitinib  AB  Science  4.5 mg/kg/day or Masitinib AB Science 3 mg/kg/day groups and placebo group for time to TFS in the normal progressor subpopulation.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint: Overall survival (OS)

There  was  no  benefit  on  OS  with  Masitinib  AB  Science  4.5  mg/kg/day  or  Masitinib  AB  Science  3 mg/kg/day as compared with placebo group in the normal progressor subpopulation.

## Fast progressors

The applicant claimed that results in fast progressor subpopulation did not show statistically significant differences in primary endpoint as well as FVC and ALSAQ-40 secondary endpoints. Analyses of other secondary endpoints were not provided.

Table  43:  Masitinib  AB  Science  4.5  mg/kg/day  versus  placebo  in  the  fast  progressor  subpopulation (mITT)

|                                                              | Treatment group   | N   | LS Mean   | Difference of means [95% confidence interval]   |   p-value |
|--------------------------------------------------------------|-------------------|-----|-----------|-------------------------------------------------|-----------|
| AALSFRS-R mLOCF1                                             | Active control    | 17  | -14.18    | -3.75 [-12.84;5.35]                             |    0.4069 |
| AALSFRS-R mLOCF1                                             | Masitinib 4.5 +R  | 21  | -17.93    | -3.75 [-12.84;5.35]                             |    0.4069 |
| AALSFRS-R Imputation of all missing data by cluster (Rule 6) | Active control    | 19  | -18.10    | -3.60 [-11.09;3.90]                             |    0.3365 |
| AALSFRS-R Imputation of all missing data by cluster (Rule 6) | Masitinib 4.5 +R  | 21  | -21.69    | -3.60 [-11.09;3.90]                             |    0.3365 |
| AALSFRS-R Multiple imputation                                |                   |     |           | -2.77 [SE:4.223]                                |    0.5186 |
| FVC mLOCF1                                                   | Active control    | 17  | -42.20    | -7.61 [-30.08;14.88]                            |    0.4945 |
| FVC mLOCF1                                                   | Masitinib 4.5 +R  | 20  | -49.81    | -7.61 [-30.08;14.88]                            |    0.4945 |
| ALSAQ-40 mLOCF Rule 1                                        | Active control    | 17  | 29.19     | 1.22 [-16.07;18.52]                             |    0.8862 |
| ALSAQ-40 mLOCF Rule 1                                        | Masitinib 4.5 +R  | 20  | 30.41     | 1.22 [-16.07;18.52]                             |    0.8862 |

## Normal + fast progressors

The applicant claimed that results for the full study population comprising normal + fast progressors are presented only for descriptive purposes because there was no statistically significant difference between Masitinib  AB  Science  3  mg/kg/day  and  placebo  group  for  the  normal  progressor  subpopulation  (as defined for amended fixed sequence method for statistical analysis).

The  observed  difference  in  the  primary  endpoint  between  Masitinib  AB  Science  4.5  mg/kg/day  and placebo group was mean LS 2.09 95% CI (-0.55; 4.73), pnominal = 0.1202. The observed difference in the primary endpoint between Masitinib AB Science 3 mg/kg/day and placebo group was mean LS 1.80 95% CI (-0.91; 4.51), pnominal = 0.1918.

Table 44: Absolute change from baseline to week 48 in ALSFRS-R - Primary efficacy analysis - Masitinib AB Science 4.5 mg/kg/day versus placebo - Normal + Fast Progressor total population (mITT)

| Treatment group   |   N |   LS Mean | Differenceofmeams [95%6confidence interval]   |   p-value |
|-------------------|-----|-----------|-----------------------------------------------|-----------|
| Activecontrol     | 119 |    -12.97 | 2.09 [SE: 1.339]                              |    0.1202 |
| Masitimib 4.5 + R | 120 |    -10.89 | [-0.55;4.73]                                  |    0.1202 |

Active conhrol=placebo+riluzole.Masitinib 4.5+R=Masitinib 4.5mg/kg/day +Riluzole

Source: Statistical Table 14.2.1.2

<div style=\"page-break-after: always\"></div>

Table 45: Number of patients analysed for the primary and sensitivity analyses on ALSFRS-R - Masitinib AB Science 3 mg/kg/day versus placebo Normal + Fast Progressor total population (mITT)

| Treatment group   |   N |   LS Mean | Differemceofmeans [9596confidence interval]   |   p-value |
|-------------------|-----|-----------|-----------------------------------------------|-----------|
| Active control    | 119 |    -12.07 | 1.80 [SE: 1.375]                              |    0.1918 |
| Masitimib 3.0 + R | 126 |     10.27 | [-0.91;4.51]                                  |    0.1918 |

Active control =placebo + riluzole. Masitinib 3.0 + R =Masitinib 3.0 mg/kg/day + Riluzole

Source:Statistieal Table14.2.1.4

## Secondary endpoints

PFS in full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5 mg/kg/day gain versus placebo group was 3 months (17 [ 14; 22] versus 14 [ 11; 17]), pnominal=0.1389.

ALSAQ-40 (mLOCF Rule 1) in full study population comprising normal + fast progressors treated with Masitinib  AB  Science  4.5  mg  the  difference  of  means  versus  the  placebo  group  was  -6.59,  pnominal =0.0148.

FVC in full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5 mg difference of means versus the placebo group was 5.63, pnominal =0.0914.

CAFS in full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5 mg relative benefit versus the placebo group was 11.9%, pnominal =0.1185.

Result for TFS in full study population comprising normal + fast progressors was not presented.

There were not enough deaths to estimate median OS during the double-blind period.

## Follow-up phase

Vital status (i.e., survival status of alive or dead, including date of death, with patients still alive at the time of analysis being censored at the date of last contact) of all patients originally randomised to study AB10015 was collected from each participating investigational site. Information for 95% (374/394) of patients being verified less than 7 months prior to cut-off, while 5% (20/394) of patients had a status that dated back further than 7 months from the June 2020 cut-off.

As such, three patient groups were defined: long-term high-dose (4.5 mg/kg/day) Masitinib AB Science, long-term low-dose (3.0 mg/kg/day) Masitinib AB Science, and long-term placebo. These new long-term OS data are based on an average follow-up of 75.6 months since diagnosis and 66.1 months since randomization and included cross-over from placebo to Masitinib AB Science treatment.

The study AB10015 conducted throughout the 2013-2016 period had broad inclusion criteria in terms of disease severity at baseline. There was a study population enrichment strategy applied based on the severity of ALS at baseline used for the assessment of OS after follow-up phase of the study. The flowing cohorts were used during statistical analysis in both populations - normal progressors subpopulation and full study population comprising normal + fast progressors:

1. Moderate ALS enriched cohort (≥2 on each baseline ALSFRS -R item) with pre-randomization Δ FS&lt;1.1 (i.e. restricted normal progressors subpopulation)
2. Moderate/severe  ALS  enriched  cohort  (≥1  on  each  baseline  ALSFRS -R  item)  with  prerandomization Δ FS&lt;1.1(i.e. restricted normal progressors subpopulation)
3. Moderate/severe/very severe ALS cohort (regardless of (any) baseline ALSFRS-R item) with prerandomization Δ FS&lt;1.1 (i.e. normal progressors subpopulation)
4. Moderate ALS enriched cohort (≥2 on each baseline ALSFRS -R item and any Δ FS) (i.e.. restricted full study population comprising normal and fast progressors)

<div style=\"page-break-after: always\"></div>

5. Moderate/severe ALS enriched cohort (≥1 on each baseline ALSFRS -R item and any Δ FS) (ie. restricted full study population comprising normal and fast progressors)
6. Moderate/severe/very severe ALS cohort (regardless of (any) baseline ALSFRS-R item and any Δ FS (i.e. full study population including normal and fast progressors)

At the 14 June 2020 cut-off date (corresponding to the end of the long-term follow-up period) there has been an average follow-up from diagnosis of 75 months. A summary of long-term median OS results for various patient cohorts of the AB10015 study population is presented in the tables below.

For  the  moderate  ALS  enriched  cohort  of  restricted  normal  progressors  subpopulation  [i.e.  LT-M4.5 including ALS patients with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1 (cohort number 1)]. A median OS for Masitinib AB Science 4.5 mg/kg/day (n=45) of 69 months (95%CI [45-NE]) versus 44 months (95%CI [33-62]) for placebo (n=62). Hazard ratio analysis showed a 44% reduced risk of death (HR= 0.555 (95%CI [0.321-0.961]); pnominal =0.0355).

For the moderate/severe ALS enriched cohort of restricted normal progressors subpopulation [i.e. LTM4.5 including ALS patients with ≥ 1 on each baseline ALSFRS -R item and Δ FS&lt;1.1 (cohort number 2)] a median OS for Masitinib AB Science 4.5 mg/kg/day (n=85) of 53 months (95% CI 36; NE) versus 43 months (95% CI 31;49) for placebo (n=104). Hazard ratio analysis showed a 30% reduced risk of death (HR=0.699 95% CI (0.475-1.029) pnominal=0.0695.

For the moderate/severe/very severe ALS enriched cohort of restricted normal progressors subpopulation  [i.e.  regardless  of  (any)  baseline  ALSFRS-R  item)  with  pre-randomization Δ FS&lt;1.10, (cohort number 3)], the between group difference in median OS was 6 months (median OS of 46 versus 40  months,  respectively),  hazard  ratio  0.773  (95%  CI  [0.545-1.096]))  pnominal  =0.1489.  The  total included population was 106 in the Masitinib AB Science 4.5mg/kg/day and 114 in the Placebo group.

## Table 46:

A Long-term overall survival analysis in enriched patient populations of study AB10015 with ΔFS ≤1.1 points/month (June 2020 cut-off; Masitinib AB Science 4.5 mg/kg/day versus placebo) - Primary analysis

| COHORT                                                            | MAS (m)   | PBO (m)   | Deaths   | Deaths   | MedianOS[95%CI]   | MedianOS[95%CI]   | △OS (months)   | P-value (Log rank)   |
|-------------------------------------------------------------------|-----------|-----------|----------|----------|-------------------|-------------------|----------------|----------------------|
|                                                                   |           |           | MAS      | PBO      | MAS               | PBO               |                |                      |
| ModerateALS >2 eachbaselineALSFRS-R item, △FS<1.1)                | 45        | 62        | 21(47%)  | 38 (61%) | 69 [45;NE]        | 44 [33;62]        | +25            | 0.0477               |
| Moderate/severe ALS (21 each baseline ALSFRS-Ritem,△FS<1.1)       | 85        | 104       | 44 (52%) | 66 (63%) | 53 [36;NE]        | 43 [31;49]        | +10            | 0.0395               |
| Moderate/severe/verysevereALS (Anybaseline ALSFRS-Rscore,△FS<1.1) | 106       | 114       | 60 (57%) | 73 (64%) | 46 [33;69]        | 40 [30;48]        | +6             | 0.1054               |

MAS:Masitinib.PBO:placebo.OS:OverallSurvival.△OS:Betweengroup difference in median OS(MAS minusPBO).△FS:ALSFRS-R progression rate calculated from disease-onset tobaseline.NE:Non-estimable.P-value calculated using theLogRank test.Source:StatisticalTable 14.2.1.1d,Table 14.2.1.1e,Table 14.2.1.1f

B Longterm hazard ratio analysis in enriched  patient  populations  of  study  AB10015  with  ΔFS  ≤1.1 points/month (June 2020 cut-off; Masitinib AB Science 4.5 mg/kg/day versus placebo) - Primary analysis

| COHORT                                                                 |   MAS (=) |   PBO (m) |   Hazard Ratio | 95%CI        | Reduced risk of death   |   P- value |
|------------------------------------------------------------------------|-----------|-----------|----------------|--------------|-------------------------|------------|
| Moderate ALS (≥2 each baseline ALSFRS-R item, △FS<1.1)                 |        45 |        62 |          0.555 | 0.321- 0.961 | 44%                     |     0.0355 |
| Moderate/severe ALS (≥l each baseline ALSFRS-R item, △FS<l.1)          |        85 |       104 |          0.699 | 0.475- 1.029 | 30%                     |     0.0695 |
| Moderate/severe/very severe ALS (any baseline ALSFRS-R score, △FS<1.1) |       106 |       114 |          0.773 | 0.546- 1.096 | 23%                     |     0.1489 |

MAS:Masitinib.PBO:placebo.△FS:ALSFRS-R progression rate calculated from disease-onset tobaseline.Source:Statistical Table 14.2.1.1.2a

<div style=\"page-break-after: always\"></div>

For the moderate ALS enriched cohort of restricted full study population comprising normal and fast progressors [i.e.  ALS  patients  with  ≥2  on  each  baseline  ALSFRS -R  item,  regardless  of Δ FS  (cohort number 4)], a  survival benefit of 15 months (median OS of 59 versus 44 months) and 43% reduced risk of death (pnominal =0.0407, hazard ratio 0.569 (95%CI [0.332-0.976])) was observed for patients receiving 4.5 mg/kg/day Masitinib AB Science (n=50) versus placebo (n=63).

For the moderate/severe ALS enriched cohort of restricted full study population comprising normal and fast progressors [i.e. ALS patients with ≥1 on each baseline ALSFRS -R item, regardless of Δ FS (cohort 5)], the between group difference in median OS was 7 months (median OS of 46 versus 39 months) for patients receiving 4.5 mg/kg/day Masitinib AB Science (n=97) versus placebo (n=115), corresponding to a 23% reduced risk of death (pnominal =0.1435, hazard ratio 0.767 (95% CI [0.538-1.094])). The between mean difference for the moderate/severe/very severe ALS enriched cohort of restricted full study population comprising normal and fast progressors [i.e. regardless of (any) baseline ALSFRS-R item) regardless of Δ FS (cohort 6)] was 1 month (median OS of 36 versus 37 months) for patients receiving Masitinib AB Science 4.5 mg/kg/day (n=130) versus placebo (n=133). This cohort corresponds to the full study population of Study AB10015 comprising normal plus fast progressor) population of study AB10015).

## Table 47:

A Long-term overall survival analysis in enriched patient populations of study AB10015 regardless of baseline ΔFS (June 2020 cut-off; Masitinib AB Science 4.5 mg/kg/day versus placebo) - Sensitivity analysis

| COHORT                                                                | MAS (三)   | PBO (=)   | Deaths   | Deaths   | Median OS [95%C1]   | Median OS [95%C1]   | △OS (months)   | P-value (Log rank)   |
|-----------------------------------------------------------------------|-----------|-----------|----------|----------|---------------------|---------------------|----------------|----------------------|
|                                                                       |           |           | MAS      | PBO      | MAS                 | PBO                 |                |                      |
| ModerateALS(≥2eachbaselineALSFRS-R item, any △FS)                     | 50        | 63        | 25 (50%) | 38 (60%) | 59 [44;NE]          | 44 [33;62]          | +15            | 0.0477               |
| Moderate/severe ALS (21 eachl baseline ALSFRS-R item, any △FS)        | 97        | 115       | 55 (56%) | 74 (64%) | 46[30;69]           | 39 [30;48]          | +7             | 0.1152               |
| Moderate/severe/very severe ALS (regardless of baselineALSFRS-Ror△FS) | 130       | 133       | 81 (63%) | 89 (67%) | 36 [28;48]          | 37[28;44]           | -1             | 0.1507               |

MAS:Masitinib.PBO:placebo.OS:Overall Survival.△OS:Betweengroup difference in median OS(MASminus PBO).△FS:ALSFRS-R progression rate calculated from disease-onset tobaseline.NE:Non-estimable.P-value calculatedusing theLogRank test.Source:Statistical Table 14.2.1.1a,Table 14.2.1.1b,Table 14.2.1.1c

B  Long-term  hazard  ratio  analysis  in  enriched  patient  populations  of  study  AB10015  regardless  of baseline  ΔFS  (June  2020  cut -off;  Masitinib  AB  science  4.5  mg/kg/day  versus  placebo)  -  Sensitivity analysis

| COHORT                                                                 |   MAS (n) |   PBO (n) |   Hazard Ratio | 95%CI        | Reduced risk ofdeath   |   P- value |
|------------------------------------------------------------------------|-----------|-----------|----------------|--------------|------------------------|------------|
| Moderate ALS (≥2 each baseline ALSFRS-R item, any △FS)                 |        50 |        63 |          0.569 | 0.332- 0.976 | 43%                    |     0.0407 |
| Moderate/severe ALS (≥1 each baseline ALSFRS-R item, any △FS)          |        97 |       115 |          0.767 | 0.538- 1.094 | 23%                    |     0.1435 |
| Moderate/severe/very severe ALS (regardless ofbaseline ALSFRS- Ror△FS) |       130 |       133 |          0.808 | 0.592- 1.102 | 19%                    |     0.1778 |

In contrast, results from the Masitinib AB Science 3 mg/kg/day arm of study AB10015 (LT-M3.0) showed that none of the enriched patient subgroups tested produced an improvement in median OS with respect to placebo.

<div style=\"page-break-after: always\"></div>

Figure 7: Kaplan-Meier survival curves from Masitinib AB Science study AB10015 long-term survival analysis. (A) Overall Masitinib AB Science 4.5 mg/kg/day cohort versus placebo (regardless of baseline ΔFS or individual component scores). (B) Enriched* Masitinib AB Science 4.5 mg/kg/day cohort versus placebo (≥2 on each baseline ALSFRS -R individual component score and postonset ΔFS&lt;1.1)

<!-- image -->

* Enriched cohort (≥2 on each baseline ALSFRS-R individual component score and post-onset △FS&lt;1.1), (corresponding to the population enrolled in confirmatory phase 3 AB19001). M4.5: masitinib at 4.5 mg/kg/day treatment-arm. PBO: placebo. OS: Overall Survival. △OS: Between group difference in median OS. △FS: ALSFRS-R progression rate calculated from disease-onset to baseline.

Considering the cohort most closely matched to the target population of study AB19001 (i.e. 'M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1'), Δ ALSFRS-R for Masitinib AB Science 4.5 mg/kg/day was -6.36  versus  -11.03  for  placebo,  corresponding  to  a  significant  42%  slowing  in  rate  of  decline (Pnominal=0.0176),  while  PFS  for  this  cohort  showed  a  trend  improvement  of  13  months  in  favour  of Masitinib AB Science 4.5 mg/kg/day (Pnominal=0.0597).

<div style=\"page-break-after: always\"></div>

Table 48: Summary of ΔALSFRS -R analysis at week-48, exploring impact of patient enrichment on the AB10015 study dataset

|                                                     | 11                                                  | △ALSFRS-R (LSM)                                     | △LSM [95%CI]  △Effect * Pvalue                      |                                                     |                                                     |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| M4.5, regardless of baseline ALSFRS-R scores or △FS | M4.5, regardless of baseline ALSFRS-R scores or △FS | M4.5, regardless of baseline ALSFRS-R scores or △FS | M4.5, regardless of baseline ALSFRS-R scores or △FS | M4.5, regardless of baseline ALSFRS-R scores or △FS | M4.5, regardless of baseline ALSFRS-R scores or △FS |
| PBO                                                 | 119                                                 | -12.97                                              | 2.09 [-0.55; 4.73]                                  | 16%                                                 | 0.1202                                              |
| M4.5                                                | 120                                                 | -10.89                                              | 2.09 [-0.55; 4.73]                                  | 16%                                                 | 0.1202                                              |
| M4.5 (△FS<1.1, any baseline ALSFRS-R scores)        | M4.5 (△FS<1.1, any baseline ALSFRS-R scores)        | M4.5 (△FS<1.1, any baseline ALSFRS-R scores)        | M4.5 (△FS<1.1, any baseline ALSFRS-R scores)        | M4.5 (△FS<1.1, any baseline ALSFRS-R scores)        | M4.5 (△FS<1.1, any baseline ALSFRS-R scores)        |
| PBO                                                 | 102                                                 | -12.63                                              | 3.39 [0.65; 6.13]                                   | 27%                                                 | 0.0157                                              |
| M4.5                                                | 99                                                  | -9.24                                               | 3.39 [0.65; 6.13]                                   | 27%                                                 | 0.0157                                              |
| M4.5 (≥2 each baseline ALSFRS-R item, any △FS)      | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)      | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)      | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)      | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)      | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)      |
| PBO                                                 | 57                                                  | -11.51                                              | 4.81 [0.95; 8.67]                                   | 42%                                                 | 0.0152                                              |
| M4.5                                                | 48                                                  | -6.70                                               | 4.81 [0.95; 8.67]                                   | 42%                                                 | 0.0152                                              |
| M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)      | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)      | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)      | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)      | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)      | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)      |
| PBO                                                 | 56                                                  | -11.03                                              | 4.68 [0.84; 8.52]                                   | 42%                                                 | 0.0176                                              |
| M4.5                                                | 43                                                  | -6.36                                               | 4.68 [0.84; 8.52]                                   | 42%                                                 | 0.0176                                              |

PBO = Placebo. M4.5 = Masitinib 4.5 mg/kg/day. Patients having a score above a given threshold value for each ALSFRS-R item (a higher threshold indicates less severe disease). △FS: ALSFRS-R progression rate calculated from disease-onset to baseline. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. LSM = Least-squares means difference from baseline. △LSM = Between treatment-arm difference of LSM. 95% two-sided confidence intervals [95%CI]. *Treatment effect defined as slowing in the rate of decline for masitinib treatment-arm relative to placebo. Missing data was imputed via last observation carried forward (LOCF) when patients discontinued before week-48 for documented reasons of toxicity or lack of efficacy. If patient died before week-54 (included) after randomization, ALSFRS-R score was replaced by zero (O). Patients discontinuing prematurely for the following documented reasons were not imputed (lost to follow-up, non-compliance, travel, procedure, protocol deviation, any other reason not mentioned above).

<div style=\"page-break-after: always\"></div>

Table 49: Summary of time-to-event (PFS) analysis, exploring impact of patient enrichment strategy on the AB10015 study dataset

|                                                      |                                                      | Median [95%CI] (months)                              | △Median (M-P) P-value                                |                                                      |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| M4.5 (regardless of baseline ALSFRS-R scores or △FS) | M4.5 (regardless of baseline ALSFRS-R scores or △FS) | M4.5 (regardless of baseline ALSFRS-R scores or △FS) | M4.5 (regardless of baseline ALSFRS-R scores or △FS) | M4.5 (regardless of baseline ALSFRS-R scores or △FS) |
| PBO                                                  | 132                                                  | 14 [11; 17]                                          | +3                                                   | 0.1389                                               |
| M4.5                                                 | 128                                                  | 17 [14; 22]                                          | +3                                                   | 0.1389                                               |
| M4.5 (AFS<1.1, any baseline ALSFRS-R scores)         | M4.5 (AFS<1.1, any baseline ALSFRS-R scores)         | M4.5 (AFS<1.1, any baseline ALSFRS-R scores)         | M4.5 (AFS<1.1, any baseline ALSFRS-R scores)         | M4.5 (AFS<1.1, any baseline ALSFRS-R scores)         |
| PBO                                                  | 113                                                  | 16 [11; 19]                                          | +4                                                   | 0.0159                                               |
| M4.5                                                 | 105                                                  | 20 [14; 30]                                          | +4                                                   | 0.0159                                               |
| M4.5 (≥2 each baseline ALSFRS-R item, any △FS)       | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)       | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)       | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)       | M4.5 (≥2 each baseline ALSFRS-R item, any △FS)       |
| PBO                                                  | 63                                                   | 17 [11; 33]                                          | +13                                                  | 0.1499                                               |
| M4.5                                                 | 50                                                   | 30 [15; NE]                                          | +13                                                  | 0.1499                                               |
| M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)       | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)       | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)       | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)       | M4.5 (≥2 each baseline ALSFRS-R item, △FS<1.1)       |
| PBO                                                  | 62                                                   | 17 [11; 33]                                          | +13                                                  | 0.0597                                               |
| M4.5                                                 | 45                                                   | 30 [22; NE]                                          | +13                                                  | 0.0597                                               |

Patients having a score above a given threshold value for each ALSFRS-R item (a higher threshold indicates less severe disease). △FS: ALSFRS-R progression rate calculated from disease-onset to baseline. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. Time-to-event analysis defined as time interval (months) for ALSFRS-R deterioration of 9 points from baseline or death. △Median = Between treatment-arm difference of time-to-event median. 95% two-sided confidence intervals [95%CI]. PBO = Placebo. M4.5 = Masitinib 4.5 mg/kg/day. P-value calculated using the Log Rank test. NE: Non-estimable.

During the assessment, the applicant proposed new target population - ALS patients prior to any loss of function.

This enriched population is based on baseline functional score severity, i.e., baseline ALSFRS-R score&gt;0 on each individual component of the ALSFRS-R (considering that at baseline, for each of the 12 ALSFRSR items, patients can have a score of 4 (normal function), a score of 3 (mild impairment of function), a score of 2 (moderate impairment of function), a score of 1 (severe impairment of function) or a score of 0 (loss of function)). The ALS population prior to any loss of function, accounted for 80% (311/391) of patients from the mITT population.

The applicant claims that selection of this population is methodologically acceptable and mechanistically plausible. It exhibits a higher benefit / risk ratio, being associated with several efficacy endpoints showing a favourable direction or statistical significance for Masitinib AB Science 4.5 mg/kg/day (including the highly relevant endpoint CAFS) and is associated with an improved safety profile (patients with loss of functions tending to have more adverse events). Furthermore, it is seen as generalisable to the majority of diagnosed patients and easily applicable in clinical practice. Results for ALS patients prior to any loss of function are shown below.

<div style=\"page-break-after: always\"></div>

Table 50: Results for ALS patients prior to any loss of function

| △ALSFRS-R mLOCF                                              | Diff. of mean      | 3.27                       |
|--------------------------------------------------------------|--------------------|----------------------------|
| △ALSFRS-R mLOCF                                              | p-value            | 0.0266                     |
| △ALSFRS-R Imputation of all missing data by cluster (Rule 6) | Diff. of mean      | 2.91                       |
| △ALSFRS-R Imputation of all missing data by cluster (Rule 6) | p-value            | 0.0315                     |
| Median PFS                                                   | Gain in Median PFS | +5 months                  |
| Median PFS                                                   | Median [95% CI]    | 20 [14; 30] vs 15 [11; 19] |
| Median PFS                                                   | p-value log rank   | 0.0236                     |
| Median PFS                                                   | p-value Wilcoxon   | 0.0183                     |
| ALSAQ-40 mLOCF Rule 1                                        | Diff. of mean      | -8.17                      |
| ALSAQ-40 mLOCF Rule 1                                        | p-value            | 0.0074                     |
|                                                              | Diff. of mean      | 8.29                       |
|                                                              | p-value            | 0.0182                     |

## · Ancillary analyses

Validation of a population PK model for Masitinib AB Science used in patients with ALS was performed to validate  a  previously  developed  popPK  model  for  Masitinib  AB  Science  using  internal  and  external techniques.

For a given patient, riluzole PK parameters was first determined at week 0 (before Masitinib AB Science /placebo  intake)  and  week  1  visits.  Up  to  10  patients  were  planned  to  be  enrolled  in  this  analysis. Recruitment for the PK study could be done at any step of the study until the desired number of patients for the analysis was reached.

## · Summary of main efficacy results

| Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                    | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                  | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                       | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                                            | Multicentre, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib in combination with riluzole versus placebo in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). | Multicentre, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib in combination with riluzole versus placebo in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). |
| Design                                                                                                                                                                                                                                                            | Duration of main phase: Duration of Run-in phase: Duration of Extension phase (OLE):                                                                                                                                                                                                               | 08 April 2013 - 05 December 2016 NA. November 2017 - 14 June 2020                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                                        | Superiority of Masitinib AB Science 4.5 mg/kg/day plus riluzole on placebo plus riluzole and Masitinib AB Science 3 mg/kg/day plus riluzole on placebo plus riluzole                                                                                                                               | Superiority of Masitinib AB Science 4.5 mg/kg/day plus riluzole on placebo plus riluzole and Masitinib AB Science 3 mg/kg/day plus riluzole on placebo plus riluzole                                                                                                                               |
| Treatments groups                                                                                                                                                                                                                                                 | Group 1: masitinib at 4.5 mg/kg/day + riluzole                                                                                                                                                                                                                                                     | Masitinib or placebo were administered orally in two daily doses.                                                                                                                                                                                                                                  |

Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

Study identifier

AB10015

EudraCT number: 2010-024423-24

ClinicalTrials.gov number NCT02588677

Group 2: masitinib at 3 mg/kg/day + riluzole

Riluzole was prepared, handled, used and stored according to standard practices and the Summary of Product Characteristics (SPC).

Group 3: placebo + riluzole

## Endpoints definitions

and Primary endpoint:

- Absolute change from baseline to week 48 in Amyotrophic Lateral Sclerosis Functional Rating Scale

∆ ALSF RS-R

Absolute change from baseline to week 48 in ALSFRS-R

Secondary endpoint:

- Progression Free Survival

PFS

Progression  Free  Survival,  defined  as  a  9-point  drop  in ALSFRS-R score from baseline or death.

Secondary  endpoint:  Overall survival OS

Overall survival, defined as the time from randomization to the time of the documented death.

Secondary  endpoint:  Quality of Life (measured by ALSAQ- 40) ALSAQ -40

Quality of life  was assessed based on the absolute change from baseline to week 48 in the ALSAQ-40 score.

Secondary endpoint: Absolute change from baseline to week 48 in FVC score FVC

Absolute change of FVC from baseline to week 48

Secondary endpoint: Tracheostomy-free survival TFS

Tracheostomy-free survival defined as the time from randomization  to  the  date  of  documented  death  or  first tracheotomy.

Secondary endpoint: CAFS on rank data

CAFS   CAFS which takes  into  account  changes  in  ALSFRS-R  total scores and time to death up to week 48.

Database lock

05 December 2016

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                  | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                      | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                        |
| Long-Term Overall Survival Follow-up                                                                                                                                                                                                                              | Primary objective                                                                                                                                                                                                                                                 | Long-term OS analysis performed based on mature OS data, using the following sequential analysis in 3 steps.                                                                                                                                                                                                                                                                                                                        |
| Long-Term Overall Survival Follow-up                                                                                                                                                                                                                              | Primary objective                                                                                                                                                                                                                                                 | As a sensitivity analysis, the OS analysis was performed at the December 2016 cut-off date, corresponding to the planned blinded and prospective part of the study. As another sensitivity analysis, the criteria related to progression rate from disease- onset to baseline (ΔFS) were relaxed to include fast progressors (i.e., ΔFS≥1.1) to assess whether a significant benefit is detected in an enriched patient population. |
| Long-Term Overall Survival Follow-up                                                                                                                                                                                                                              | Secondary objectives                                                                                                                                                                                                                                              | - to test the consistency of the treatment effect with the clinical endpoint of ∆ALSFRS at week 48, ALSFRS being a surrogate endpoint of survival. - Time-to-event analysis referred to as PFS.                                                                                                                                                                                                                                     |
| Long-Term Overall Survival Follow-up                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                     |

## Results and Analysis

Analysis description

Analysis population and time point

description

Effect estimates per comparison

Primary Analysis

Modified-Intent to treat (mITT) patients with at least one post baseline efficacy assessment who took at least one dose of study treatment (masitinib/placebo).

Treatment group

Comparison groups

Number of subject

Primary endpoint

Absolute change from baseline to

week 48 in

ALSFRS-R

Secondary endpoints

Normal progressors

M4.5 vs

Placebo

105:113

Diff. of mean

3.39

p-value

0.0157

Normal progressors

M3.0 vs

Placebo

110:113

Diff. of mean

2.73

p-value

0.0661

Full study population normal

+ fast progressors

M4.5 vs Placebo

128:132

Diff. of mean

2.09

p-value 0.1202

Full study population normal + fast

progressors

M3.0 vs Placebo

131:132

Diff. of mean

1.80

p-value 0.1918

<div style=\"page-break-after: always\"></div>

| Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                  | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                   | Median PFS Gain in Median PFS Median [95%CI] +4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 months 16[14;17] vs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | +3 months 17 [14;22]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | +3 months 17 [14;22]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0 months 14 [12;17] Vs 14 [11;17] p-value 0.3073                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                   | Median PFS Gain in Median PFS Median [95%CI] +4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16[11;19] p-value 0.1003                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | vs 14[11;17] p-value 0.1389                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | vs 14[11;17] p-value 0.1389                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                   | ALSAQ-40 mLOCF Rule 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Diff. of mean -7.76 p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Diff. of mean -7.76 p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Diff. of mean -8.04 p-value 0.0057                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Diff. of mean -6.59 p-value 0.0148                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Diff. of mean -6.59 p-value 0.0148                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Diff. of mean -7.15 p-value 0.0077                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                   | FVC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0078 Diff. of mean 7.55 p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.0078 Diff. of mean 7.55 p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Diff. of mean 4.99 p-value 0.1562                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Diff. of mean 5.63 p-value 0.0914                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Diff. of mean 5.63 p-value 0.0914                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Diff. of mean 3.35 p-value 0.3220                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                   | CAFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0296 Relative benefit 14.8% p-value 0.0776                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.0296 Relative benefit 14.8% p-value 0.0776                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Relative benefit 15.1% p-value 0.0698                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Relative benefit 11.9% p-value 0.1185                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Relative benefit 11.9% p-value 0.1185                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Relative benefit 9.7% p-value 0.1943                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                   | Median OS Gain in Median OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NE p-value 0.4858                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NE p-value 0.4858                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NE p-value 0.7637                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -1month p-value 0.5928                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | -1month p-value 0.5928                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NE p-value#0.5924                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Database lock                                                                                                                                                                                                                                                     | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14 June 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis population and time point description                                                                                                                                                                                                                    | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any | Long-term overall survival analysis Primary analysis was performed on the ITT dataset and according to the full follow-up period cut off of 14 June 2020. - Step 1 of the primary analysis was OS analysis on patients having moderate (non-severe) ALS, defined as a baseline score of at least 2 on each individual component of the ALSFRS-R (i.e., prior to any complete loss or severe impairment of functionality) a nd a ΔFS of less than 1.1 points/month. - Step 2 was OS analysis on patients having moderate and severe ALS, defined as a baseline score of at least 1 on each individual component of the ALSFRS-R (i.e., prior to any complete loss of functionality) and a ΔFS of less than 1.1 points/month. - Step 3 was OS analysis on the cohort of patients having moderate, severe, and very severe ALS (i.e., any |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | baseline ALSFRS- R score) and a ΔFS of Treatment group STEP #1 Moderate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | baseline ALSFRS- R score) and a ΔFS of Treatment group STEP #1 Moderate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Normal progressors M4.5 vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | Number of subject 45:62                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Number of subject 45:62                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 85:104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | :114                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | MAS:PBO Median OS [95%CI] MAS/PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | MAS:PBO Median OS [95%CI] MAS/PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 69[45;NE]/ 44[33;62]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 69[45;NE]/ 44[33;62]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 53[36;NE]/ 43[31;49]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 46[33;69]/ 40[30;48]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 46[33;69]/ 40[30;48]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | ΔOS +25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ΔOS +25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | +10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | (months) P-value 0.0477                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (months) P-value 0.0477                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.0395                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | (Log rank) Hazard Ratio [95%CI] 0.555                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (Log rank) Hazard Ratio [95%CI] 0.555                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | [0.321-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.699 [0.475- 1.029]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.773 [0.546-1.096]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | Reduced risk of 44%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Reduced risk of 44%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.0695                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                   | death p-value 0.0355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | death p-value 0.0355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.1489                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.1489                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.1489                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   | Title : A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                  | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                      | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                      | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                      | AB10015 EudraCT number: 2010-024423-24 ClinicalTrials.gov number NCT02588677                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                   | Number of subject MAS:PBO                                                                                                                                                                                                                                         | 50:63                                                                                                                                                                                                                                                             | 97:115                                                                                                                                                                                                                                                            | 130:133                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                   | Median OS [95%CI] MAS/PBO                                                                                                                                                                                                                                         | 59[44;NE]/ 44[33;62]                                                                                                                                                                                                                                              | 46[30;69]/ 39[30;48]                                                                                                                                                                                                                                              | 36[28;48]/ 37[28;44]                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                   | ΔOS (months)                                                                                                                                                                                                                                                      | +15                                                                                                                                                                                                                                                               | +7                                                                                                                                                                                                                                                                | -1                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                   | P-value (Log rank)                                                                                                                                                                                                                                                | 0.0477                                                                                                                                                                                                                                                            | 0.1152                                                                                                                                                                                                                                                            | 0.1507                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                   | Hazard Ratio [95%CI]                                                                                                                                                                                                                                              | 0.569 [0.332- 0.976]                                                                                                                                                                                                                                              | 0.767 [0.538- 1.094]                                                                                                                                                                                                                                              | 0.808 [0.592-1.102]                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                   | Reduced risk of death                                                                                                                                                                                                                                             | 43%                                                                                                                                                                                                                                                               | 23%                                                                                                                                                                                                                                                               | 19%                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                   | p-value                                                                                                                                                                                                                                                           | 0.0407                                                                                                                                                                                                                                                            | 0.1435                                                                                                                                                                                                                                                            | 0.1778                                                                                                                                                                                                                                                            |

## 2.6.5.3. Clinical studies in special populations

During the assessment, results in older patients were requested as ALS incidence is highest at older ages (60-75 years). The applicant provided aged-based analysis in normal progressor mITT subpopulation for primary  endpoint  and  secondary  CAFS  endpoint.  No  data  were  submitted  for  ITT  and  full  study population.

The primary endpoint showed a numerical benefit for Masitinib AB Science over placebo, both in patient ≤60 (Δ ALSFRS-R of 2.49 (95% CI [-0.91-5.90]) and in patients &gt;60 ( Δ ALSFRS-R of 4.65 (95% CI [0.20-9.50]). This numerical benefit in both treatment arms was observed with other analyses using alternative  rules  for  imputation  of  missing  data  (namely  rule  6,  multiple  imputation,  and  multiple imputation with jump to reference).

There was a numerical benefit on CAFS in favour of Masitinib AB Science over placebo, both in patient ≤60 (relative benefit of 9.7%) and in patients &gt;60 (relative benefit of 24.6%).

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

N/A

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## 2.6.5.6. Supportive study(ies)

N/A

<div style=\"page-break-after: always\"></div>

## 2.6.6. Discussion on clinical efficacy

In this Application for a CMA, the development programme of Masitinib AB Science in ALS comprises a completed phase 2/3 study (AB10015), including long-term survival follow-up analysis. The applicant also indicated an ongoing phase 3 study (AB19001); however, no data has been submitted for this study.

The  applicant  initially  applied  for  an  indication  as  for  the  treatment  of  adult  patients  with  ALS  in combination with riluzole.  During  the  procedure,  the  applicant  proposed  a  new  indication  as  for  the treatment of adult patients with ALS in combination with riluzole prior to any loss of function.

## Design and conduct of clinical studies

The  phase  2b/3  international,  multicentre,  phase  2/3,  randomised,  double-blind,  placebo-controlled study AB10015 is proposed as a single pivotal study to assess efficacy and safety of Masitinib AB Science in ALS patients. The primary objective of study AB10015 was to evaluate the efficacy of Masitinib AB Science in combination with riluzole based on the change in the ALSFRS-R from baseline to week 48. Only after an amendment while the study was already ongoing (see below further details), the primary objective of the study was changed to primarily assess the efficacy of Masitinib AB Science in combination with riluzole in the normal progressor subpopulation. Initially, the trial was planned as a phase 2 dosefinding study comparing two treatment arms.

A triggered GCP inspection (GCP/2017/001) was requested by the CHMP on the conduct of the clinical study AB10015 in the context of a previous marketing authorisation application for ALS. The triggered GCP inspection reported critical and major inspection findings affecting different aspects of the study, which  impact  on  the  reliability  of  the  study  data.  Major  findings  were  observed  at  qualification  and training, trial master file, clinical conduct of the trial, safety reporting, investigational medicinal product, source data verification and clinical study report. The GCP inspection concluded that the data obtained at the sites inspected are not trustworthy.

It is noted that at the time of the GCP inspection, the applicant presented a series of corrective and preventive  actions  which  have  been  assessed  by  the  inspectors  and  were  not  found  sufficient  to recommend the use of data. In accordance with the GCP inspection report conclusion, after the evaluation of the responses submitted by the applicant, the Inspection Team considered that due to the departures from GCP observed, it cannot be ensured that the data inspected are trustworthy and are likely to have an impact on the final results. Data integrity is high likely to be impaired as several protocol deviations at eligibility, conduct and in other aspects inspected.

Given the nature of the findings, the systematic deficiencies observed (i.e. massive number of protocol deviations) and the fact that some findings such as the deficiencies during inclusion/exclusion criteria verification  and  subjects'  follow  up  (critical  finding  1  in  the  inspection  report)  cannot  be  corrected retrospectively, the proposed corrective actions presented by the applicant were not considered adequate to address all the concerns raised.

As part of this current application, the applicant claimed that the GCP findings were addressed with implementation of preventive actions across study and functions within AB Science. The applicant also claimed that for study AB10015, corrective actions were implemented wherever feasible. The measures which the applicant claims to have implemented after the inspection, have been assessed as part of the current marketing authorisation procedure and were found insufficient to address the issues raised and re-assure CHMP on the trustworthiness of the data.

During the procedure, the applicant argued that GCP findings related to ALSFRS-R were not systematic and  the  ALSFRS-R  scores  data  are  reliable,  it  is  feasible  to  perform  re-monitoring  and  manage retrospective/impact analysis and refers to the EMA guidelines EMA/868942/2011. In addition, during the procedure the applicant performed an impact analysis of protocol deviations and concluded that GCP

<div style=\"page-break-after: always\"></div>

inspection findings which are likely to influence the evaluation of the primary efficacy endpoint, whether correctable or not, had no significant impact on the study's outcomes. The applicant's conclusions that the primary endpoint is not affected are not agreed by the CHMP. In addition, it should be noted that even the execution of the different analysis excluding just one or two inspected sites are often not meaningful since these do not address the uncertainty regarding the non-inspected sites (EMA/8689942/2011).

The applicant has provided justifications for the GCP aspects during the procedure including expanded written  discussions  after  the  oral  explanation.  The  applicant  provided  numerous  arguments  on  the extensive corrective actions implemented after the inspection conducted in the context of the previous marketing authorisation application and other regulatory authorities, including an impact analysis of identified protocol deviations. The applicant upholds the position that the corrective actions implemented after the GCP inspection and the applicant interpretation of the guidelines on benefit/risk evaluation demonstrates an absence of impact on the results of the AB10015 study. Following the review of the information submitted in support of this application, including the implemented corrective measures, it is considered that the issues identified cannot be resolved by performing re-monitoring and retrospective analyses  at  the  study  sites.  The  numerous  retrospectives  analyses  applied  by  the  applicant  do  not compensate for the deficiencies in the conduct of the study and thus the data are not considered reliable. The applicant has reiterated the relevance of the impact analysis of identified deviations during GCP inspections, however the applicant's claim that the primary endpoint is not affected is not agreed by the CHMP. From this point of view, the primary and secondary endpoint results (i.e. ALSFRS-R) of the single pivotal study are based on dataset of compromised quality and reliability. The statement of the applicant that 'the CHMP's decision to base its findings solely on the inspectors' position from 2017, fails to take into  consideration  the  entire  sum  of  evidence  now  available  and  is  not  therefore  consistent  with guidelines on benefit-risk assessment' is not agreed with.

Therefore, despite the fact, that the applicant has provided impact analysis and arguments, the existing evidence of data quality does not assure CHMP that the AB10015 trial data is trustworthy. The applicant's provided impact analysis and arguments are not sufficient to assure CHMP that the AB10015 trial data is trustworthy. considering the conclusions of GCP inspection and the presented implemented corrective actions. The data from clinical study AB10015 cannot be relied upon. The CHMP is of the opinion that this  conclusion  is  in  line  with  EMA/8689942/2011  document  'Points  to  consider  on  GCP  inspection findings and the benefit-risk balance'.

## Treatment

In  the  pivotal  trial  patients  were  randomly  allocated  to  one  of  the  three  following  groups:  group  1: Masitinib AB Science at 4.5 mg/kg/day + riluzole; group 2: Masitinib AB Science at 3 mg/kg/day + riluzole; group 3: placebo of masitinib + riluzole.

## Study duration

Patients received treatment for 48 weeks. It consisted of a 48-week double-blind treatment period with an  open-label  extension  phase.  The  duration  of  the  double-blind  period  of  48  weeks  is  considered acceptable and in line with EMA/531686/2015, Corr.1. Open label extension phase was used to evaluate OS.

## Population

Participants were recruited from 34 sites in 9 countries (Spain, Argentina, Slovakia, Portugal, Mexico, Italy, Greece, Netherlands, and Canada). The key inclusion criteria were definite diagnosis of familial or sporadic  ALS  diagnosed  according  to  El  Escorial  revised  criteria,  disease  duration  no  more  than  36 months from the onset of symptoms, BMI above 18, stable dose of riluzole and FVC equal or more than 60 % of predicted value. El Escorial criteria have been validated pathologically and are commonly used

<div style=\"page-break-after: always\"></div>

for  diagnosing  ALS.  Key  exclusion  criteria  were  patients  with  tracheotomy  and  /or  gastrostomy  and patients with various cardiac disorders. Defined inclusion criteria, such as FVC equal of more than 60% of predicted value, BMI above 18 and exclusion criteria for participants with tracheotomy or gastrostomy excludes patients with complex disease leads to selective population that is not fully representative of the overall ALS population.

The protocol of AB10015 study underwent multiple amendments. There were four protocol amendments while the study remained blinded. One of the key amendments was transforming phase 2 study into phase 2/3 study. The initially planned AB1015 study was a 3-group phase 2 dose finding study. After the decision to upgrade the study to phase 3 confirmatory trial the endpoints have not been modified, and the sample size calculation was based on a difference of the ALSFRS-R between baseline and week 48. Such upgrade presents limitations in chosen endpoints and study population because the primary endpoint  ALSFRS-R  without  another  co-primary  or  key  secondary  measurement  to  assess  muscle strength or overall benefit on survival would be acceptable only under a phase 2 programme. Upon transformation into the phase 3 study there were the changes in the patients' population definition: from the ITT population to mITT population.

The second key amendment is post hoc division  of  enrolled  participants  in  two  subgroups:  fast  and normal progressors. The division into  two subpopulations was  made based on the mITT population. Normal  progressors  were  defined  as  the  primary  analysis  population  while  the  study  was  already ongoing. During the assessment, the applicant was requested to justify this approach. The applicant claimed  that  such  approach  reduces  heterogeneity  in  trial  population.  The  reasoning  for  reducing heterogeneity is understood but the approach with post hoc dichotomization while the study is ongoing is  not  supported.  The  applicant  appealed  to  the  guideline  EMA/CHMP/539146/2013  (section  5.4. Assessment  scenario  3)  to  justify  the  validity  of  the  division  into  groups.  Indeed,  the  section  5.4. Assessment  scenario  3  presents  the  situation  in  which  the  clinical  data  presented  fail  to  establish statistically persuasive evidence in the primary analysis population but there is interest in identifying a subgroup where a relevant treatment effect and compelling evidence of a favourable risk-benefit profile can be assessed (guideline EMA/CHMP/539146/2013). It should be noted that no further confirmatory conclusions are possible in a clinical trial where the primary null hypothesis cannot be rejected in the total  ITT  population.  To  remind:  ' a  statistically  significant  difference  compared  to  placebo  was  not demonstrated  for  the  primary  endpoint  in  the  full  study  population '.  The  introduction  of  the subpopulations as an attempt to rescue the study is acceptable by the guideline only in certain situations. The guideline states that interpretation of subgroup findings should be done with caution. Credibility of the subgroup findings, in other words, the extent to which subgroup findings can be concluded as being well substantiated and hence, relied on for decision making depends on the degree of well-founded, a priori definition, the biological plausibility for a particular finding and replication. Indeed, the guideline EMA/CHMP/539146/2013 in section 6.1 states the assessors should have ' expected to find discussion in the  trial  protocol  of  the  expected  degree  of  heterogeneity  of  the  patient  population '.  However,  the ' restrictions of a trial population to a sub-population of the target population should be justified, detailing whether restrictions are made due to safety concerns, anticipated lack of efficacy, or other operational considerations '  at  the  planning  stage  of  the  study  (EMA/CHMP/539146/2013).  Indeed,  if  the  study results  indicate  that  the  treatment  effect  may  vary  according  to  the  levels  of  a  particular  factor, subsequent  investigations  might  need  to  be  based  on  a  categorisation  (for  a  continuous  factor)  or collapsing categories (for an ordered categorical variable with a higher number of levels). This is because these categories should relate to criteria that might ultimately be used in product labelling or clinical decision-making ((EMA/CHMP/539146/2013). However, this possibility should be carefully considered at the  planning  stage,  pre-specifying  categories  that  might  ultimately  serve  this  purpose.  Analyses investigating  the  choice  of  cut-off  on  the  robustness  of  conclusions  should  also  be  planned  as  well (EMA/CHMP/539146/2013). The applicant claims that the normal progressors' subpopulation is the preplanned  primary  analysis  population  of  study  AB10015.  However,  the  applicant  recognised  that  the

<div style=\"page-break-after: always\"></div>

dichotomisation of patients into 'fast' and 'normal' progressors was implemented after the study start, which is not agreed. This approach can generate the questionable results, as ' post-baseline covariates may be affected by treatment received and will not usually be appropriate to define subgroups for the investigation  of  a  treatment  effect '  (EMA/CHMP/539146/2013).  Moreover,  if  a  particular  factor  is considered prognostic for outcome or at least some biological plausibility or external evidence such that an inconsistent response might be observed, the CHMP expected to find a discussion of subgroup of investigations conducted and their consideration.

In the opinion of the CHMP, the aforementioned criteria for subgroup analyses (guideline EMA/CHMP/539146/2013) were not met nor for the normal progressor subpopulation selected by the applicant after amendments to the protocol while the study was ongoing.

During  the  assessment,  the  applicant  argued  that  categorisation  of  patients  as  Normal  and  Fast progressors was endorsed by the CHMP scientific advice (SA). This is not agreed, as the SA addressed the use of Δ FS as a potential inclusion criterion for the Phase 3 AB10019 study. The applicant insisted on that this categorisation of the population is supported in terms of clinical relevance, statistical design, and pathophysiology of ALS. Although changes in the ALSFRS-R could be considered a useful measure of disease progression in some studies. However, its use as a single indicator for convincing prediction of the progression of ALS is not acceptable, because Δ FS alone has relatively low predictive value of progression (Thakore et al, 2017) and is not stable throughout the course of disease (Requardt, 2021). For  this  reason,  a  linear  assumption  for  the Δ FS  decline  (average  rate  of  change  from  onset  to randomization) might lead to misclassification of patients. Additionally, despite the fact that delta FS from the first symptom to time of diagnosis or during the whole disease could be reliable predictor of survival,  it  possesses  uncertainties  related  to  the  patient's  knowledge  of  the  exact  time  of  the  first symptoms as well as the investigator knowledge of the exact time of the first symptoms' set up. The justifications  for  the  cut-off  ( Δ FS  1.1)  provided  by  the  applicant  during  the  assessment  were  not convincing and the applicant was repeatedly informed during the application assessment that the delta FS cut-off 1.1 points/months for the categorization of patients into normal and fast progressors is not acceptable as a single indicator of the progression.

During the extended discussion after the OE, the applicant insisted on that the cut-off 1.1 of delta FS is based on the best evidence found in the literature at the moment of study development. According to the applicant, the calculation of the cut off level 1.1 of delta FS is based on the study of Kollewe et al J. (2008). Referring to Kollewe et al (2008) the applicant has explained the calculation of cut-off of delta FS: ' the median delta FS calculated between onset and first examination was 1.0 points/month and the median delta FS calculated over the whole course of disease was 1.185 points/month, a range therefore of approximately 1.0 - 1.2 points/month. The choice of 1.1 points/month is situated at the midpoint of this range '. However, the authors highlighted in the referred publication that if the investigators fail to note exact time there will be no correct calculation for ALSFRS-R score ratio between first symptom and first examination. Additionally, the authors noted that the change of ALSFRS-R score over the whole course of disease is not useful to establish, because only the endpoint defined as death or tracheotomy allows assuming it. They concluded that ALSFRS-R score ratio within a defined period (i.e. 100 days) could solve the problem. They proposed to compute this parameter as ' difference of ALSFRS-R score between two visits divided by days between two visits '. Notably, the conclusion of the authors was that the ratio of ALSFRS-R score within 100 days is a useful parameter for clinical trials and they proposed &lt;0.25; 0.25-0.65 and &gt;0.65 cut-off levels of delta FS. Based on all above, it could be concluded that the applied cut-off level by the applicant seems to be chosen arbitrarily and, therefore, the quantitative choice  of  delta  FS  cut-off  at  1,1  is  not  supported  for  the  distinction  patients  into  Normal  and  Fast progressors. The CHMP stressed again that the distinction into normal and Fast progresses are unlikely to happen in the clinical practice by simply applying a cut-off level 1.1.

<div style=\"page-break-after: always\"></div>

The applicant states that showed benefit in ALSFRS-R and PFS and a trend towards benefit on OS and CAFS is in alignment with EMA guidance (ref.: EMA/531686/215, Corr. 1.1.). According to the applicant, many ALS studies, including pivotal studies of registered products such as tofersen (EMA approval), have used delta FS as a patients' selection criterion without providing justification that defined cut-off is stable over time. Based on this, the applicant believes that there is no precedent to reject a study based on the categorization of its population via delta FS. In response to the applicant's argument about the delta FS use in other trials, it is acknowledged that the calculation of delta FS has been used in clinical studies, however the exact cut-off of delta FS to distinct fast or normal progressors is questionable. Indeed, the numerous clinical studies operate with a variety of slope of ALSFRS-R, which could be defined as early, late, pre-randomised or run-in slope, and they range from 0.25 to 1.7. However, no exact cut-off level can be defined for the categorization of disease progression, as the higher delta FS simply indicates the higher chance or probability of the survival event (death or tracheotomy) compared with lower one. The CHMP considers that the distinction into normal and fast progresses are unlikely to happen in the clinical practice taking into account the variety of ALS phenotypes or predominated type of onset of disease and severity of disease at the baseline. As per reference to Tofersen, the applicant categorised the population using two factors the delta ALSFRS-R and type of SOD1-ALS. Results from the Tofersen clinical data suggested that two factors did not adequately discriminate the probability progression of ALSFRS-R. The data suggested that the baseline level of neurofilaments was a better prognostic factor (Tofersen EPAR). It is believed that, yet no new convincing data or arguments were presented that would alter previous assessment and CHMP conclusions about efficacy demonstration in the full study population, thus issue is not resolved.

During the assessment, the applicant proposed a newly target population including adult patients with ALS prior to any function loss. This subpopulation was also not pre-specified in the protocol, and it was only  identified  after  the  result  of  the  OS  analyses  (data  driven).  In  the  opinion  of  the  CHMP,  the aforementioned criteria for subgroup analyses (guideline EMA/CHMP/539146/2013) were also not met for adults with ALS prior to any loss of function. Further, the definition of newly target population may not reflect a target population existing in the clinical practice.

## Outcomes

The  primary  endpoint  was  change  from  baseline  to  week  48  in  ALSFRS-Revised.  Functional  decline averages about 1 point per month in untreated patients (Castrillo-Viguera 2010). The ALSFRS and the revised version that includes respiratory function (ALSFRS-R) is the most widely used instrument to measure function in ALS clinical studies, therefore it is recommended to be used in the ALS clinical studies.  The  change  in  ALSFRS-R,  i.e.  delta  FS,  was  accepted  as  a  primary  endpoint,  however,  to demonstrate the effect of Masitinib AB Science on ALS progression using the delta FS alone is not enough. It  should  have  been  supported  with  the  muscle  strength  measurements.  According  to  the  guideline EMA/531686/2015,  Corr.1  1,  the  muscle  strength  and  function  are  considered  the  most  important endpoints and should show consistency in effect. Notably, it was recommended by the SA to support this primary endpoint delta FS with muscle strength measurements.

Secondary endpoints were PFS, OS, CAFS, TFS, change from baseline in ALSAQ- 40 and change in FVC. These  endpoints  are  considered  relevant  measures  for  ALS  and  are  in  line  with  EMA/531686/2015, Corr.1.

The SAP included additional composite endpoint ' Survival defined as the time from randomization to the date of documented death or first tracheotomy ' which was not presented elsewhere. The applicant was asked to clarify this definition. The applicant provided an explanation on secondary endpoint TFS defined as the time from randomization to the date of documented death or first tracheostomy. There was no significant difference (p=0.7382) observed between Masitinib AB Science (4.5 mg/kg/day) and placebo for time to TFS in the normal progressor subpopulation. The applicant states that TFS has been impacted

<div style=\"page-break-after: always\"></div>

by three imbalances that could affect the Masitinib AB Science arms, in particular the Masitinib AB Science 4.5 mg/kg/day treatment arm. These three imbalances are i) disease duration at baseline, ii) severity at baseline, and iii) speed of deterioration at baseline.

In  accordance  with  'Guideline  on  clinical  investigation  of  medicinal  products  for  the  treatment  of amyotrophic  lateral sclerosis  (ALS)'  (EMA/531686/2015,  Corr.1)  criteria  for  tracheostomy  and continuous assisted ventilation dependence as a study endpoint event should be carefully pre-specified and standardised since patient management varies considerably between countries and regions. Where these endpoints are used, an additional analysis using only time to death as the endpoint should also be provided to allow evaluation of the consistency of the results.

In  this  study  criteria  for  tracheostomy  were  not  carefully  pre-specified  and  standardised.  Since tracheostomy analysis can be biased due to different confounding factors, the applicant preplanned a PFS analysis, which is combining decline in ALSFRS-R score (9 points) and death. Time to event analysis, defined as median PFS was added to the final statistical analysis plan to comply with EMA guidance (EMA/531686/2015, Corr.1).

Since  lack  of  efficacy  time  to  tracheostomy  (primary  defined  secondary  endpoint)  have  not  shown benefits and secondary endpoint PFS analysis, which is combining decline in ALSFRS-R score (9 points) and death, was added to the final statistical analysis plan, uncertainty about the claimed efficacy of masitinib in connection with other findings remains.

Importantly, there was no endpoint for muscle strength measurement. This is considered an important issue as muscle strength is one of the key indicators of disease progression.

## Randomisation

Randomisation  was  performed  with  a  minimization  algorithm  on  progression  of  ALSFRS-R  score (point/month), site of onset (Bulbar vs Others), ALSFRS-R score at baseline, age at baseline and region. Proposed method is acceptable. According to EMA/CHMP/295050/2013 dynamic allocation (in this case minimisation method) can be used if stratification is needed for several prognostic factors. Concern with this method relates to the fact that conventional methods may not allow for Type I error control in data analysis. This can be mitigated by using re-randomisation method, which has been used by the applicant.

## Blinding

Blinding procedure is acceptable. There were no attempts to assess success of masking.

## Statistical methods

Sample size was calculated in a 1:1 randomisation ratio for the comparison of each Masitinib AB Science group to the placebo group making the same hypothesis for each masitinib group.

The total sample size estimation was expanded from 45 to 381394 following the different amendments of the protocol. It was estimated that for normal progressor subpopulation 300 patients and for the full study population comprising normal + fast progressors 381 patients are required to detect a 3.3(+/-7.5) and (+/-9) point difference between groups (each of the Masitinib AB Science groups vs placebo group) in order to achieve a power of 80% with a significance level for a two-sided test of 5%.

Approach for estimating sample size is supported. The applicant considered that 3.3-point difference in ALSFRS-R score is considered clinically relevant. The applicant has provided justification for the clinical relevance of 3.3-point difference. A 3.3 ALSFRS-R point difference over a 12-month period is equivalent to a difference in slope decline of 0.275 points/month (i.e., 3.3/12). It is well-established in the literature that  ALS  patients  demonstrate  approximately  a  1.0-point  decline  on  ALSFRS-R  score  per  month. Furthermore, a survey of past ALS clinical studies reveals that there is precedence for basing statistical

<div style=\"page-break-after: always\"></div>

hypothesis on a treatment-effect similar to that used in study AB10015. Study AB10015 is therefore consistent with historical study design in terms of treatment-effect hypothesis.

The applicant has presented sample size considerations for some of the secondary endpoints such as CAFS and FVC, but not for PFS and OS. The applicant confirmed that OS and PFS analysis were not powered for this study.

The mITT population was used for the primary analyses. The analysis with ITT population is preferred and was also conducted by the applicant but was not initially presented in the clinical study report. The applicant has presented ITT data for Normal progressors subpopulation; however, despite request from the CHMP no ITT data are presented for overall population. Considering that results were negative in the primary population and differences between ITT and mITT populations were small it is unlikely that ITT analysis would show different results.

Absolute change from baseline to week 48 in ALSFRS-R was estimated using a ANCOVA model adjusted on following factors: treatment (Masitinib AB Science / placebo), and stratification criteria- ALS patients population, progression of ALSFRS-R score (point/month) from date of first symptom to baseline, site of onset (bulbar versus others), ALSFRS-R score at baseline, age at baseline and region. In the study protocol,  the  applicant  planned  multiple  sensitivity  analysis  including  multivariate  ANCOVA  analysis which  accounts  for  non-linear  relationship  between  variables  and  covariates.  Primary  analysis  and sensitivity  analysis  1-  and  2-  will  be  repeated  using  observed  cases  method  (i.e.,  no  imputation  of missing data) and using multiple imputation for missing data. Primary analysis and sensitivity analysis 1-, 2-, 3-, 4- and 5- will be repeated on the ITT and PP populations. For the primary endpoint missing data were imputed via mLOCF when patients discontinued before week-48 for documented reasons of toxicity or lack of efficacy. If patient died before week-54 (included) after randomization, ALSFRS-R score was replaced by zero (0). Patients discontinuing prematurely for the following documented reasons were not imputed (lost to follow-up, non-compliance, travel, procedure, protocol deviation, any other reason not mentioned above). There were number of sensitivity analysis provided using mLOCF method.

The study had approximately 30% of missing data in each Masitinib AB Science arm despite highly selective patient population. In the clinical trial, high rates of treatment discontinuation were showed, the regulatory interest is to handle this intercurrent event with a treatment policy strategy. In particular, mainly after treatment discontinuation, high proportions of missing data were observed in each Masitinib AB Science arm despite highly selective patient population. Therefore, an adequate choice of statistical methods for handling missing data which are appropriately conservative and not biased in favour of the investigational treatment under realistic data generating mechanisms is critical for the trustworthiness of the study results.

The methods for handling missing data applied by the applicant and requested by CHMP includeD:

-a mLOCF approach that assumes that the benefit experienced until the time of missing data is also retained thereafter.

-a  Copy  increments  from  reference  (CIR)  method  was  used  that  assumes  that  the  outcome develops similarly from that point onward to the placebo group.

-a J2R method was used that assumes that the benefit experienced until the point of missing data is not retained and instead the outcome would correspond to the outcome in the reference group.

In the situation of ALS, only the J2R method is considered to not potentially overestimate the missing outcome and hence lead to a biased treatment effect estimate in favour of the investigational treatment. Therefore, only the J2R approach is considered to be appropriately conservative. In order to account for missing data after treatment discontinuation, the applicant used the mLOCF method for the first and secondary endpoints. More conservative approaches were also provided such as the J2R, but only to handle missing data after discontinuations that were attributed to lack of efficacy or toxicity, whereas missing data after discontinuations for other reasons were presumably handled with a mLOCF approach.

<div style=\"page-break-after: always\"></div>

A detailed description of the statistical methods is not available, which further increases the uncertainty about the appropriateness of this analysis approach.

Additionally, as an underlying assumption, the applicant is assuming that it can ascertain which missing case are MAR (protocol deviation / non-compliance, etc.) and which cases are MNAR (efficacy/toxicity). The applicant does not provide convincing arguments that substantiate this categorisation, hence the handling of missing data following discontinuations for different reasons with different methods is not considered adequate.

Further, the applicant has presented a tipping point analysis based on the mLOCF approach, where the assumed retained effect as compared to baseline is reduced by increasingly larger percentages.

In the clarification after the OE  the applicant maintains that CHMP  is  inconsistent with its recommendations on acceptability of tipping point analysis above 75% and CIP with p value below 5%. The methods for handling missing data applied by the applicant and requested by CHMP include mLOCF, CIR  and  J2R  methods.  The  statistical  analyses  applied  by  the  applicant  were  assessed  respectively. Moreover, the applicant is acknowledged for the providing the multiple statistical analyses requested by CHMP. Indeed, the applicant has presented a tipping point analysis based on the mLOCF approach, where the assumed retained effect as compared to baseline is reduced by increasingly larger percentages.

The applicant shows that retaining 24% of the difference to baseline still leads to p-value smaller than 5% in the corresponding analysis and argues that this should be sufficient proof of efficacy since the same threshold had been accepted in a different regulatory procedure. However, this argument does not hold since the suitable statistical method for analysis (including an assumption about a realistic and acceptable loss  in  efficacy  in  the  imputation  model)  depends  on  the  specific  clinical  context.  In  this situation, the analysis assuming the retainment of some effect is still considered not as adequate as the J2R approach, which assumes that patients discontinuing treatment have outcomes similar to the control group.

Overall,  the  applicant's  position  that  the  mLOCF  and  the  cluster  method  are  the  most  appropriate methods to address missing data in the AB10015 trial is not acceptable. Considering the progressive nature of ALS and that, the effect of treatment will not be maintained after discontinuation of medication, the J2R method is considered the most appropriately conservative method in this setting. This analysis does not show a convincing result in favour of Masitinib AB Science.

Multiplicity across primary and secondary endpoints was handled using fixed sequence method. This is considered acceptable approach to preserve the study-wise type I error rate. However, it should be considered that fixed sequence was amended while the study was ongoing to align with the change in the primary efficacy population (from the full study population comprising normal and fast progressors to  normal  progressors  subpopulation).  Further,  secondary  endpoints  were  considered  part  of  the hierarchical testing procedure, however. since second test for the amended primary efficacy analysis did not  result  in  statistically  significant  differences,  multiplicity  is  no  longer  controlled  for  secondary endpoints. It is also noted that testing hierarchy for secondary endpoints is defined differently in SAP and clinical study protocol.

## Efficacy data and additional analyses

## Population characteristics

The  cut-off  date  for  the  primary  analysis  is  05  December  2016,  which  is  the  date  the  last  patient completed the last visit. A total of 394 patients were randomised from 34 sites in 9 countries.

The average follow-up of patients including double-blind extension period - from randomization of the first patient (April 2013) until date of study data readout (November 2017), was 34.1 ± 10.1 months.

<div style=\"page-break-after: always\"></div>

In the normal progressor subpopulation, 330 participants were included in the ITT population, 328 in the mITT population, 323 in PP population set, and 329 in the safety population.

In the full study population comprising Normal + Fast progressors, 394 participants were included in the ITT, 391 in the mITT, 386 in PP and 393 in safety population.

31.1 % discontinued before week 48 in Masitinib AB Science 4.5 mg group, 30.9% in Masitinib AB Science 3mg group and 27.3% in placebo group. Most frequent reasons for discontinuation were AE related and lack of efficacy. 7 people died in placebo, 2 in Masitinib AB Science 4.5 mg and 7 in masitinib 3 mg group.

Baseline  characteristics  of  treatment  arms  were  comparable.  For  main  predictive  indicators  for progression and survival, such as ALSFRS-R at baseline, age, site of onset and lung function treatment arms were similar. Baseline data shows that normal progressor subpopulation had mean of 0.41 (placebo and Masitinib AB Science 4.5.mg) and full study population comprising norma l+ fast progressors had mean  of  0.71  (placebo)  and  0.73  (Masitinib  AB  Science  4.5  mg)  point  per  month  decline  before randomization. This might suggest that the trial included rather selective population. It is also noted that baseline characteristics, including main predictive indicators for normal progressor subpopulation and full  study  population  comprising  normal  +  fast  progressors  are  similar  further  suggesting  that distinguishing two subpopulations might not be clinically relevant. The applicant was asked to present delta-FS before randomization for normal and fast progressors as well as baseline characteristics and results  for  fast  progressor  subpopulation.  For  normal  progressors, Δ FS  was  comparable  between treatment arms, in terms of mean (0.49 and 0.50 points/month for placebo and Masitinib AB Science 4.5 mg/kg/day, respectively, median (0.48 and 0.49 points/month, respectively and range. However, there were some differences in terms of mean (1.98 and 1.76 points/month for placebo and Masitinib AB Science 4.5 mg/kg/day, respectively), and range in the Fast progressor subpopulation, participants appear to have worse ALSFRS-R scores compared to Masitinib AB Science group, however the sample size is small and meaningful conclusions cannot be made.

## Primary analysis

The primary analyses were performed in a sequential manner so that the family-wise error rate was controlled at 5% level of significance. The predefined sequence of analyses was amended while the study was ongoing after the decision to dichotomise the study population into two subpopulations and the redefinition of  the normal progressors subpopulation as the primary efficacy population. The amended sequence of analyses was I [Masitinib AB Science 4.5 mg/kg/day versus Placebo 'normal progressor' subpopulation], II [Masitinib AB Science 3 mg/kg/day versus Placebo 'normal progressor' subpopulation], III [Masitinib AB Science 4.5 mg/kg/day versus Placebo full study population comprising 'normal + fast progressors'], IV [Masitinib AB Science 3 mg/kg/day versus Placebo full study population comprising 'normal + fast progressors'].

Primary analysis for ALSFRS-R endpoint in normal progressor subpopulation:

-with Masitinib AB Science 4.5 mg/kg/day dose difference of means was 3.39 CI (0.65-6.13), pvalue 0.0157. Various sensitivity analysis using LOCF imputation method showed consistent results.

-with  Masitinib  AB  Science  3  mg/kg/day  dose  difference  of  means  was  2.73  (-0.18-5.65), p=0.0661.

Primary  analysis  for  ALSFRS-R  endpoint  in  the  full  study  population  comprising  Normal  +  Fast progressors:

-with  Masitinib  AB  Science  4.5  mg/kg/day  dose  difference  of  means  was  2.09  (-0.55-4.73) p=0.1202

<div style=\"page-break-after: always\"></div>

- -with Masitinib AB Science 3 mg/kg/day dose difference of means was 1.8 (-0.91;4.51) p=0.1918

First, the dichotomization of normal and fast progressors subpopulations and the selection of the normal progressor subpopulation as the primary efficacy population are not agreed as explained in the above section.  The  full  study  population  comprising  normal  and  fast  progressors  is  considered  the  primary population of the pivotal study. Efficacy is not demonstrated in the full population.

Further, the mLOCF is not considered a conservative analysis in ALS, where patients usually progress quickly, even the nominated normal progressors subpopulation.

## Secondary analysis

It needs to be considered that even using the amended hierarchical testing, all secondary endpoints can only be considered as descriptive (i.e. below p-values are pnominal values) because the null hypothesis was not rejected in the second analysis of Masitinib AB Science 3mg/kg/day.

PFS: In full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5mg/kg/day gain versus placebo group was 3 months (17 [ 14; 22] vs 14 [ 11; 17]), (pnominal =0.1389). In normal progressor subpopulation treated with Masitinib AB Science 4.5mg/kg/day gain versus placebo group was 4 months ((20 [14; 30] versus 16 [ 11; 19]), (pnominal =0.0159).

ALSAQ-40 (mLOCF Rule 1): In the full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5mg/kg/day difference of means versus placebo group was -6.59 (pnominal =0.0148).  In  normal  progressor  subpopulation  treated  with  Masitinib  AB  Science  4.5mg/kg/day difference of means versus placebo group was -7.76 (pnominal =0.0078).

FVC: In full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5mg/kg/day dose difference of means versus placebo group was 5.63, (pnominal =0.0914). In normal progressor subpopulation treated with Masitinib AB Science 4.5mg/kg/day difference of means versus placebo group was 7.55 (pnominal =0.0296).

CAFS: In full study population comprising normal + fast progressors treated with Masitinib AB Science 4.5mg/kg/day relative benefit versus placebo group was 11.9%, (pnominal =0.1185). In normal progressor subpopulation treated with Masitinib AB Science 4.5mg/kg/day relative benefit versus placebo group was 14.8%, (pnominal =0.0776).

TFS: Result for the full study population comprising normal + fast progressors was not presented. In normal  progressor  subpopulation  treated  with  Masitinib  AB  Science  4.5mg/kg/day  there  was  no difference observed versus placebo group.

OS: Median OS could not be estimated during the double-blind period.

## Long term overall survival

A post  hoc long-term  OS  analysis  was  performed  in  an  enriched  patient  population.  The  enriched population was defined as 'Moderate' ALS, based on baseline functional score severity (i.e., Baseline ALSFRSR score≥2 on each item and rate of functional and Δ FS&lt;1.1 point per month). Considering post hoc nature of these analysis, they are considered only as descriptive (i.e. below p-values are pnominal values).

Investigational  sites  were  contacted  with  a  request  for  an  update  on  each  patient's  survival  status. Overall survival was defined as the time elapsed between randomization and death from any cause. Hazard ratios were calculated via the Cox proportional-hazards model using the predefined covariates. The population of moderate ALS included in the long-term survival analysis had 107 patients (45 in Masitinib AB Science 4.5 mg/kg/day and 62 in placebo arm).

<div style=\"page-break-after: always\"></div>

Following data readout for the main protocol period of study AB10015 (database lock on 05 December 2016), open-label follow-up period starts in November 2017. This allowed those patients still receiving Masitinib AB Science to continue treatment. 23% (30/131) of patients from the Masitinib AB Science 3.0 mg/kg/day treatment arm, and 22% (29/130) of patients from the Masitinib AB Science 4.5 mg/kg/day treatment arm continued the treatment. It was also allowed for patients from the AB10015 placebo arm to begin Masitinib AB Science treatment (19% (25/133) of patients from the placebo arm switched to receive Masitinib AB Science. Upon request, the applicant has provided the information on the patients which from the AB10015 placebo arm entered the NPP (n=25) and begun Masitinib AB Science treatment (n=5). As the applicant declares these patients have been included in the long-term OS analysis and were analysed based on their initial randomization scheme in AB10015 study, i.e., the placebo group. However,  long-term  OS  of  both  Masitinib  AB  Science  treatment-arms  and  NPP  subpopulations  are compared with Masitinib AB Science -naïve PBO: cohort from AB10015 placebo arm that were alive on 01 November 2017 and did not enter NPP. The Moderate ALS population had mean Δ FS of 0.41 in placebo arm vs 0.39 in Masitinib AB Science arm, mean ALSFRS-R score of 42, mean age of 55.0, mean FVC 92.9 in placebo arm vs 93.8 Masitinib AB Science arm.  Site of onset was bulbar for 25.8% participants in placebo and 22.2% in Masitinib AB Science group. These baseline characteristics show that included patients had relatively better survival chance compared to overall ALS population.

In moderate ALS population, including ALS patients with ≥2 on each baseline ALSFRS -R item the between group difference in median OS was 25 if population was further restricted to pre-randomization Δ FS&lt;1.10 (moderate  ALS  enriched  cohort  of  restricted  normal  progressors  subpopulation)  or  15  months  if regardless  of  baseline Δ FS (restricted  full  study  population  comprising  normal  and  fast  progressors) corresponding  to  a  43-44%  reduced  risk  of  death.  However,  these  results  are  for  selective  cohorts including 45-50 patients treated with Masitinib AB Science 4.5mg/kg/day and 62-63 patients treated with placebo. Results from this cohort cannot be generalised to overall ALS population that is targeted by proposed indication.

When analysis was conducted in population that more closely corresponds to full study population of pivotal study and hence, the overall ALS population OS was not observed. The between mean difference for the moderate/severe/very severe ALS enriched cohort of restricted full study population comprising normal and fast progressors [i.e. regardless of (any) baseline ALSFRS-R item) regardless of Δ FS] was 1 month (median OS of 36 versus 37 months) for patients receiving Masitinib AB Science 4.5 mg/kg/day (n=130) versus placebo (n=133).

The CHMP considers that the compelling evidence of efficacy on all clinically relevant endpoints including PFS and OS was not demonstrated. The long-term assessment of the available data encompassed five distinct periods. Notably, the categorization of patients into normal and fast progressions were conducted with third amendment, while the open label post study follow-up period from November 2017 until June 2020 was added as the fifth the amendment. During the open label period patients were followed for overall survival, however, the PFS and OS results generated in the open label conditions inherit potential biased  information  on  survival  events,  because  of  impact  of  various  factors,  which  occurred  under unrandomised conditions (i.e. used medicines in the post pivotal study period, tracheostomy events, needs for the non-/invasive ventilation etc.). Therefore, the long-term survival data presented by the applicant  is  derived  from  a  highly  selected  patients'  population  defined post  hoc therefore,  can  be considered  only  as  descriptive  not  confirmatory  of  Masitinib  AB  Science  efficacy  in  the  proposed indication.  Further, in order to address the concern of CHMP regarding an indication for ALS treatment that excludes fast progressors, the applicant has presented a modified indication, based on up-dated efficacy and safety analyses, to the 'treatment of ALS patients prior to any loss of function' (wherein loss of function is defined as a score of zero on any item of the ALSFRS-R). However, the strategies to post hoc identify new tar get populations ('M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version

<div style=\"page-break-after: always\"></div>

of section 4.1 of the SmPC) are considered as data driven decisions and are, therefore, not acceptable. In the response, the applicant has reiterated previously assessed data and justifications. The post hoc subgroup  analysis  may  be  performed  at  the  initiative  of  the  applicant  according  to  the  guidelines EMA/CHMP/539146/2013. However, the guideline Scenario 2 criteria ' Replication of subgroup findings from other relevant trials or if not available the biological plausibility and the clinical trial data from the subgroup would have to be exceptionally strong ' is considered not fulfilled, as the effect observed in the subgroup is not replicated across trials by the time of opinion.

Overall, the efficacy is not considered demonstrated for proposed indication in the full study population of patients. As discussed above, the full study population (normal + fast progressors) is regarded as primary population and statistically significant difference was not demonstrated for primary endpoint in this population. Furthermore, no benefit was shown with secondary endpoints, including highly relevant endpoints such as CAFS or TFS and since not all the endpoints are pointing in a favourable direction for Masitinib AB Science or are statistically significant, the study is considered failed. The data from the open label follow-up period do not show meaningful OS gain in ALS population corresponding to proposed indication.

## Additional efficacy data needed in the context of a conditional MA

The applicant applied for conditional marketing authorisation.

As per the requested CMA, the applicant initially presented study AB19001 as proposed specific obligation that would provide comprehensive evidence on efficacy and safety of Masitinib AB Science post approval. Study AB19001 is a multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to evaluate the efficacy and safety of Masitinib AB Science as add-on therapy in ALS patients treated with Riluzole. Patients will be randomised (1:1:1) to receive Masitinib AB Science 6 mg/kg/day, Masitinib AB Science 4.5mg/kg/day or matching placebo. The primary endpoint is the absolute change in ALSFRS-R from baseline to week 48 week. In this study, the secondary endpoints include measures of muscle strength and survival. As per the study population, the applicant still proposes categorization of the full study population into three subpopulations of progressors based on the change in ALSFRS-R score  from  onset  to  screening  and  from  screening  to  baseline.  More  importantly,  the  applicant  also establishes that the primary efficacy population will be the one comprising patients with an ALSFRS-R total score progression between onset of the disease and screening of &gt; 0.3 and &lt;1.1 point/month and an ALSFRSR total score decrease of ≥ 1 point between screening a nd baseline. All aforementioned considerations  on  the  categorization  of  the  study  population  and  the  selection  of  a  restricted subpopulation of the full study population as the primary efficacy population are applicable here. It is considered that these study design features could lead to a study population that is not representative of the target indication.

During the procedure, the applicant stated that the enrolment in study AB19001 has been slow due to the restrictive design features of that study (i.e. long 3 months run-in period, with no control of FVC at baseline / Moderate ALS only / approved treatment in the USA - Edaravone, Relyvrio - not allowed / blinded extension at week 48). Consequently, the applicant proposed to conduct a new confirmatory study post approval - AB23005 study- and presented the AB19001 study as an exploratory study.

Study AB23005 is a multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to evaluate the efficacy and safety of masitinib as add-on therapy in ALS patients treated with standard of care. Patients will be randomised (1:1) to receive Masitinib AB Science 4.5 mg/kg/day or matching  placebo  and  Masitinib  AB  Science  6  mg/kg/day  will  not  be  pursued  further  in  the  study AB23005. The primary endpoint is the absolute change in ALSFRS-R from baseline to week 48. In this study, the secondary endpoints include measurements of muscle strength, progression free survival and overall  survival.  According  to  the  synopsis  of  the  study  provided  during  the  procedure,  the  primary efficacy population will be the ITT (all randomised full study population). The applicant specifies two

<div style=\"page-break-after: always\"></div>

measures of ALSFRS-R progression rate (point/month) will be evaluated at screening to categorise ALS patient as slow, moderate, or fast progressor. As per the inclusion criteria, only patients with a ALSFRSR progression rate between &gt; 0.3 and &lt;1.1 point/month as measured between onset of the disease and screening AND as measured by any available ALSFRS-R assessment during the period ranging from 7 months to 2 months prior to screening and screening, reassessed and documented by certified rater performing ALSFRS-R assessment from screening visit onward will be enrolled (synopsis of AB23005 protocol). Further restriction is included as per the baseline ALSFRS-R scores as a total score of at least 15 points of ALSFRS-R at baseline and screening [at least 3 in item3; at least 2 in item12; at least 1 in each of the other items] is also requested as inclusion criterion. All aforementioned considerations on using delta FS to select study population are also applicable here. While no further categorization is proposed to be done after enrolment (i.e. primary efficacy population is full study population), it is considered that the mentioned inclusion criteria could lead to the inclusion of a restricted ALS population. Moreover, it is considered that a duration of the study AB23005 (48 weeks) might not be long enough to generate sufficient data on survival events, which are necessary to support the primary endpoint and considering that the positive data on survival or survival equivalent are expected.

- Besides to the above considerations on the study design features and the potential impact on the ability of Study AB23005 to provide comprehensive evidence, the CHMP was concerned about the feasibility to properly conduct that study if Masitinib AB Science is authorised in the EU. It needs to be bear in mind that ALS is a fatal condition for which the only therapeutic options in the EU are symptomatic treatment and riluzole for all ALS patients except those with SOD1-ALS. Hence, the CHMP is concerned that the authorisation of Masitinib AB Science will impact the recruitment and the conduction of the AB23005 study in the EU sites as ALS patients will likely start (i.e. impact on recruitment) or shift (i.e. impact on conduction) to the commercial Masitinib AB Science when available. The new confirmatory AB23005 study is expected to enrol 408 patients. The applicant presented a feasibility analysis and concluded that a  total  of  855  patients  could  be  enrolled  over  a  12-month  period  including  583  patients  in  non-EU countries and US. The applicant claimed that Study AB23005 can be completed within 2.5 years with involvement of site from USA and other non-EU countries or within 3 years with involvement of site only from other non-EU countries. These figures assume the study starts in Q2 2024. Thus, the applicant position is that confirmatory study AB23005 is feasible outside of the EU and further facilitated since Relyvrio is withdrawn from market in USA and Canada. However, considering the numerous changes undertaken in the protocol of the pivotal study during its execution as well as the slow enrolment in the study AB19001, which became an exploratory study later on , the applicant capability of properly conduct this study is still unclear, despite the applicant's declared commitment.

In view of the above, high uncertainties remain with regard to the possibility to provide comprehensive clinical data, should a CMA have been granted.

## 2.6.7. Conclusions on the clinical efficacy

The  data  from  the  pivotal  clinical  study  AB10015  cannot  be  relied  upon.  Despite  the  applicant's arguments, and the implementation of corrective measures, the deficiencies identified during previous GCP inspection cannot be resolved by performing re-monitoring and retrospective analyses at the study sites and cannot be corrected retrospectively. Beside the data not being reliable, the results from the pivotal study AB10015 do not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS, because a statistically significant difference compared to placebo was not demonstrated for the primary endpoint in the full study population; the approach to categorise the population into normal and fast progressors is not supported; considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition

<div style=\"page-break-after: always\"></div>

of  intercurrent  events  in  J2R  strategy  are  not  considered  acceptable  and  the  strategies  to post  hoc identify new target populations (M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1 for analyses of survival and ALS patients prior to any loss of function) as proposed in the latest version of 4.1 of the SmPC) are considered as data driven decisions and are, therefore, not acceptable. Therefore, the CHMP considers that the efficacy of Masitinib AB Science in the claimed indication has not been demonstrated.

## 2.6.8. Clinical safety

Safety data are derived from a phase 2/3 placebo-controlled study (AB10015) in patients with ALS. The total number of subjects for safety analysis in this study is 393 patients. Exposure duration for ALS patients were 48 weeks with possible extension; exposure duration for non-oncology studies ranged from 8 to 48 weeks. In ALS studies Masitinib AB Science was used as add-on therapy to riluzole compared to riluzole. ALS patients were exposed to either Masitinib AB Science 3 mg/kg/day or Masitinib AB Science 4.5 mg/kg/day doses. In previous non-ALS studies patients were exposed also to higher dose of Masitinib AB Science 6 mg/kg/day.

It seems that long-term data at from patients enrolled in the extended phase following to week 48 are available for 153 Masitinib AB Science exposed patients with 73 patients exposed to higher intended dose 4.5 mg/kg/day.

Safety data are also obtained from phase 2 and 3 clinical studies for non-oncological indications. Those are  19  completed  or  stopped  studies  in  patients  with  mastocytosis  (AB04010,  AB06013),  asthma (AB04026, AB07015, AB14001), rheumatoid arthritis (AB04012, AB06010, AB06012), Crohn's disease (AB04014, AB11003), active ankylosing spondylitis (AB04013), chronic psoriasis (AB04029), multiple sclerosis (AB04011, AB04018, AB07002), Alzheimer's disease (AB04024, AB09004), supranuclear palsy (AB13004), pulmonary arterial hypertension associated with scleroderma (AB05038).

Safety data are presented further in following groupings:

1 - ALS study population (study AB10015)

2 - Non-oncology Studies (19 studies for non-oncological indications mentioned above)

In the safety assessment the main focus has mainly been put on the safety profile of Masitinib AB Science administered in ALS patients and data from previous studies were presented as supportive.

Additionally,  conclusions  on  safety  in  114  healthy  subjects  were  provided  as  well  from  6  clinical pharmacology studies: AB03001, AB03003, AB04015, AB05031, AB14004, AB17001. Safety results of phase 1/2 study AB10009 were not included into safety analysis as all 5 treated subjects were patients with Alzheimer's disease.

## 2.6.8.1. Patient exposure

In Masitinib AB Science clinical development programme 2,184 patients have received at least one dose of Masitinib AB Science, and 1,137 patients have received at least one dose of placebo. The accrued 'time-on-treatment' is 2663 patient-years of exposure for Masitinib AB Science and 1516 patient-years of exposure for placebo.

All 114 healthy subjects in phase 1 studies received at least one dose of Masitinib AB Science with dosing regimens ranging from 3.0 mg/kg/day to 11.5 mg/kg/day for up to 15 days.

In 2/3 phase study AB10015 ALS patients received doses as described further: 131 patients received Masitinib  AB  Science  at  3.0  mg/kg/day+  riluzole,  129  patients  received  Masitinib  AB  Science  at  4.5 mg/kg/day + riluzole, and 133 patients received active control (placebo+ riluzole). The duration of this

<div style=\"page-break-after: always\"></div>

study (main protocol period) was 48 weeks. After completion of the 48-week treatment period, eligible patients were allowed to continue in the extension period.

Of 19 non-oncology studies (AB10015 study included), a total of 2184 patients received Masitinib AB Science at dose 3.0, 4.5 or 6.0 mg/kg/day (287 patients at a dose of 3.0 mg/kg/day and 590 patients at a dose of 4.5 mg/kg/day and 1307 patients received Masitinib AB Science 6.0 mg/kg/day [Flat + titration]) and a total of 1137 patients received placebo (+active comparator). The duration of these studies ranged from 8 to 48 weeks.

Table 51:  Extent of exposure in non-oncology studies by indication and treatment groups

| Statistics                 |   M3 |   M4.5 |   M6.0T |   M6.0F |   All |   Placebo* | Blinded   |   Total |
|----------------------------|------|--------|---------|---------|-------|------------|-----------|---------|
| Patients on Treatment      |  287 |    590 |     728 |     579 |  2184 |       1137 | 119       |    3440 |
| NeurodegenerativeStudies   |  191 |    513 |     421 |      69 |  1194 |        662 | 9         |    1865 |
| ChronicInflammatoryStudies |   96 |     77 |     307 |     510 |   990 |        475 | 24        |    1489 |
| InfectiousStudies          |    0 |      0 |       0 |       0 |     0 |          0 | 86        |      86 |
| Time on Treatment (yeal's) |  322 |    772 |     906 |     663 |  2663 |       1516 | 19        |    4198 |
| NeurodegenerativeStudies   |  246 |    715 |     521 |      61 |  1543 |        966 | 3         |    2512 |
| ChronicInflammatoryStudies |   76 |     57 |     385 |     602 |  1120 |        550 | 13        |    1684 |
| InfectiousStudies          |    0 |      0 |       0 |       0 |     0 |          0 | 乙         |       2 |

Source: Table 1.1.1 Number of Randomised Patients and Patient-Years of Exposure by Indication Category (Safety Population)' dated 15MAR2022; Patient time exposure figures have been rounded. Abbreviations: M 3= 3.0 mg/kg/day masitinib, M 4.5= 4.5 mg/kg/day masitinib, M 6.0T = 6.0 mg/kg/day masitinib with Dose titration, M 6.0F=6.0 mg/kg/day masitinib Flat Dose, M-All=Masitinib all doses Note: Placebo*= 75 Active control (i.e., Methotrexate) patients added to placebo from study AB06012.

Patient population at each respective Masitinib AB Science dose:

- At a Masitinib AB Science dose of 3.0 mg/kg/day: 131 patients from ALS study and 156 patients from controlled unblinded studies.
- At a Masitinib AB Science dose of 4.5 mg/kg/day: 129 patients from ALS study and 461 patients from controlled unblinded studies.
- At a Masitinib AB Science dose of 3.0 and/or 4.5 mg/kg/day: 260 ALS patients, 617 patients from other non-oncology studies

In total, 3340 patients (including placebo/active control/blinded) were included in this safety analysis.

Table 52: Treatment duration in ALS study - main protocol period

|                           | P+R (N=133)   | M3.0+R (N=131)   | M4.5+R (=129)   |
|---------------------------|---------------|------------------|-----------------|
| Time on Treatment (weeks) |               |                  |                 |
| 11                        | 133           | 131              | 129             |
| Median                    | 48.0          | 47.9             | 47.9            |
| Range                     | 1.0; 56.6     | 3.1; 55.7        | 1.3; 52.9       |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

<div style=\"page-break-after: always\"></div>

Table 53: Treatment Duration in ALS study - extension period

| Time on Treatment (weeks)   | P+R (=80)   | M3.0+R (N=80)   | M4.5+R (N=73)   |
|-----------------------------|-------------|-----------------|-----------------|
| 11                          | 80          | 80              | 73              |
| Median                      | 15.4        | 25.3            | 25.0            |
| Range                       | 0.1;142.6   | 1.7; 139.0      | 0.1; 139.6      |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

Table 54: Dose and duration of exposure to Masitinib AB Science, planned dose - ALS study, main protocol period

| Number of patients exposed (months)   | Number of patients exposed (months)   |   AlI |   >6months |   >12months |
|---------------------------------------|---------------------------------------|-------|------------|-------------|
|                                       | M3.0+R                                |   131 |        100 |          73 |
|                                       | M4.5+R                                |   129 |         99 |          70 |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. *Blinded estimates. Source: Statistical

Table 55: Dose and duration of exposure to masitinib, the last daily dose - ALS study, extension period

| Number of patients exposed for ≥12 months   | P+R (N=133)   |   M3.0+R (N=131) |   M4.5+R (N=129) |
|---------------------------------------------|---------------|------------------|------------------|
| All                                         |               |               73 |               70 |
| >12months                                   |               |               73 |               70 |
| ≥24 months                                  |               |               14 |               17 |
| ≥36months                                   |               |                2 |                3 |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Source:

Table 56: Dose and duration of exposure to masitinib, planned dose - non-oncology studies

|                       |               |   All |   >6M |   >12M |
|-----------------------|---------------|-------|-------|--------|
| Non-Controlledstudies | Masitinib3.0  |     9 |     4 |      2 |
| Controlledstudies     | Masitinib3.0  |   147 |    66 |     37 |
| Controlled studies    | Masitinib 4.5 |   461 |   261 |    207 |

Table 57: Demographics of Patients - ALS study (Safety population)

| Number of patients            | P+R         | M3.0+R      | M4.5+R      |
|-------------------------------|-------------|-------------|-------------|
|                               | (N=133)     | (N=131)     | (N=130)     |
| Sex                           |             |             |             |
| Female                        | 53 (39.8%)  | 50 (38.2%)  | 47 (36.4%)  |
| Male                          | 80 (60.2%)  | 81 (61.8%)  | 82 (63.6%)  |
| Age                           |             |             |             |
| ≤65                           | 110 (82.7%) | 105 (80.2%) | 105 (81.4%) |
| >65                           | 23 (17.3%)  | 26 (19.8%)  | 24 (18.6%)  |
| Region                        |             |             |             |
| Eastern Europe                | 8 (6.0%)    | 5 (3.8%)    | 7 (5.4%)    |
| North America and West Europe | 86 (64.7%)  | 83 (63.4%)  | 79 (61.2%)  |
| Other                         | 39 (29.3%)  | 43 (32.8%)  | 43 (33.3%)  |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

<div style=\"page-break-after: always\"></div>

Table 58: Demographics of Patients - All Non-oncology Studies (Safety population)

| Tim                               | Masitinib   | Masitinib   | Masitinib   |
|-----------------------------------|-------------|-------------|-------------|
|                                   | 3.0 N=156   | 4.5 N=461   | All N=1924  |
| Number of patients                |             |             |             |
| Sex                               |             |             |             |
| Female                            | 120(76.9%)  | 283(61.4%)  | 1237(64.3%) |
| Male                              | 36(23.1%)   | 178(38.6%)  | 687(35.7%)  |
| Age                               |             |             |             |
| 18-65                             | 93(59.6%)   | 298(64.6%)  | 1398(72.7%) |
| >65                               | 63(40.4%)   | 163(35.4%)  | 526(27.3%)  |
| Ethnic or Racial Origin           |             |             |             |
| Caucasian, White or North African | 105(67.3%)  | 422(91.5%)  | 1430(74.3%) |
| AmericanIndian orAlaskaNative     | 1(0.6%)     | 0           | 23(1.2%)    |
| Asian                             | 21(13.5%)   | 21(4.6%)    | 146(7.6%)   |
| Black or AfricanAmerican          | 0           | 1(0.2%)     | 12(0.6%)    |
| Other                             | 1(0.6%)     | 4(0.9%)     | 20(1.0%)    |
| Unknown                           | 28(17.9%)   | 13(2.8%)    | 293(15.2%)  |

## 2.6.8.2. Adverse events

The  treatment  emergent  adverse  events  are  referred  to  as  AEs.  The  AEs  reported  during  the administration of study treatment or up to 28 days after the last dose of study treatment are listed below.

## Adverse events in study AB10015

During 48 weeks of treatment, at least 1 AE was reported by 83.7% of patients: 104 patients (78.2%) in the active control arm, 111 (84.7%) in the 3.0 mg/kg Masitinib AB Science arm, and 114 (88.4%) in the 4.5 mg/kg/day Masitinib AB Science arm.

Table 59: Summary of AEs over time - Study AB10015 (Main protocol period and protocol extension period)

| Number(%o)ofpatientswith at least one                                 | P +R (N=133)   | M3.0 + R (N=131)   | M4.5+R (=129)   | P+R (N=80)   | M3.0+R (N=80)   | M4.5+ R (N=73)   |
|-----------------------------------------------------------------------|----------------|--------------------|-----------------|--------------|-----------------|------------------|
|                                                                       | W0-V48         | W0-V48             | W0-V48          | Extension    | Extension       | Extension        |
| AE                                                                    | 104 (78.2%)    | 111 (84.7%)        | 114 (88.4%)     | 39 (48.8%)   | 45 (56.3%)      | 46 (63.0%)       |
| FatalSAE                                                              | 12 (9.0%)      | 11 (8.4%)          | 10 (7.8%)       | 7 (8.8%)     | 13 (16.3%)      | 14 (19.2%)       |
| Non-fatalSAE                                                          | 24 (18.0%)     | 30 (22.9%)         | 40 (31.0%)      | 8 (10.0%)    | 12 (15.0%)      | 14 (19.2%)       |
| Severe AE                                                             | 26 (19.5%)     | 28 (21.4%)         | 39 (30.2%)      | 11 (13.8%)   | 19 (23.8%)      | 22 (30.1%)       |
| AEleadingtostudytreatment permanentdiscontinuation (excluding deaths) | 11 (8.3%)      | 20 (15.3%)         | 21 (16.3%)      | 2 (2.5%)     | 1 (1.3%)        | 5 (6.8%)         |
| AEleadingtostudytreatment dosereduction                               | 3 (2.3%)       | 3 (2.3%)           | 4 (3.1%)        | 0 (0.0%)     | 0 (0.0%)        | 2 (2.7%)         |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

More frequently reported AEs in one of the Masitinib AB Science arms vs placebo arm were maculopapular rash, nausea, peripheral oedema, iron deficiency anaemia, respiratory failure, and dyspnoea. Majority of them were mild to moderate in intensity and their occurrence and severity appeared to be dose related.

<div style=\"page-break-after: always\"></div>

The most common AEs leading to dose modification or discontinuation in Masitinib AB Science were dysphagia, weight decreased, maculopapular rash, and diarrhoea.

The most frequently reported Serious AEs (SAEs) in patients receiving masitinib mesilate categorised under  the  MedDRA  SOC  was  gastrointestinal  disorders,  then  Respiratory,  Thoracic  and  Mediastinal Disorders, Infections and Infestations, Injury Poisoning and Procedural Complications, and Investigations. Other MedDRA SOCs involved less than 5% of the remaining reported events.

Table 60 : Frequent AEs (PT≥5%) in Study AB10015 - ALL

|                                          | P+R (N=133)                                                                   | P+R (N=133)                                                                   | M3.0 + R (N=131)   | M3.0 + R (N=131)   | M4.5+R (N=129)    | M4.5+R (N=129)   |
|------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------|--------------------|-------------------|------------------|
| Causality                                | 28 (21.1) 15 (11.3) 34 (25.6) 12 (9.0) 13 (9.8) 18 (13.5) 16 (12.0) 16 (12.0) | 28 (21.1) 15 (11.3) 34 (25.6) 12 (9.0) 13 (9.8) 18 (13.5) 16 (12.0) 16 (12.0) | All                | All                |                   |                  |
| Severity                                 | All                                                                           | Severe                                                                        | All                | Severe             | Al1               | Severe           |
| All                                      | 104 (78.2)                                                                    | 26 (19.5)                                                                     | 111 (84.7)         | 28 (21.4)          | 114 (88.4)        | 39 (30.2)        |
| BloodandLymphatic System Disorders       | 2 (1.5)                                                                       | 0 (0.0)                                                                       | 11 (8.4)           | 3 (2.3)            | 19 (14.7)         | 2 (1.6)          |
| Iron Deficiency Anaemia                  | 1 (0.8)                                                                       |                                                                               | 3 (2.3)            | 1 (0.8)            | 9 (7.0)           |                  |
| Gastrointestinal Disorders               | 33 (24.8)                                                                     | 4 (3.0)                                                                       | 48 (36.6)          | 4 (3.1)            | 61 (47.3)         | 7 (5.4)          |
| Dysphagia                                | 14 (10.5)                                                                     | 3 (2.3)                                                                       | 18 (13.7)          | 4 (3.1)            | 17 (13.2)         | 6 (4.7)          |
| Nausea                                   | 6 (4.5)                                                                       |                                                                               | 9 (6.9)            |                    | 16 (12.4)         |                  |
| Diarrhoea                                | 5 (3.8)                                                                       |                                                                               | 11 (8.4)           |                    | 10 (7.8)          |                  |
| Abdominal Pain Upper                     | 3 (2.3)                                                                       |                                                                               | 4 (3.1)            |                    | 9 (7.0)           |                  |
| Dyspepsia                                | 3 (2.3)                                                                       |                                                                               | 3 (2.3)            |                    | 9 (7.0)           |                  |
| General Disorders and AdministrationSite | 9 (6.8)                                                                       | 1 (0.8)                                                                       | 12 (9.2)           | 0 (0.0)            | 20 (15.5)         | 0 (0.0)          |
| Conditions Oedema Peripheral             | 1 (0.8)                                                                       |                                                                               | 7 (5.3)            |                    | 9 (7.0)           |                  |
| Infections and Infestations              |                                                                               | 3 (2.3)                                                                       | 33 (25.2)          | 2 (1.5)            | 45 (34.9)         | 1 (0.8)          |
| Viral Upper Respiratory Tract Infection  | 6 (4.5)                                                                       |                                                                               | 9 (6.9)            |                    | 7 (5.4)           |                  |
| Injury, Poisoning and Procedural         |                                                                               | 0 (0.0)                                                                       | 13 (9.9)           | 2 (1.5)            | 21 (16.3)         | 4 (3.1)          |
| Complications Fall                       | 9 (6.8)                                                                       |                                                                               | 9 (6.9)            | 1 (0.8)            | 13 (10.1)         | 1 (0.8)          |
| Investigations                           |                                                                               | 5 (3.8)                                                                       | 30 (22.9)          | 6 (4.6)            | 38 (29.5)         | 6 (4.7)          |
| Weight Decreased                         |                                                                               | 2 (1.5)                                                                       | 14 (10.7)          | 1 (0.8)            | 12 (9.3)          |                  |
| Nervous System                           |                                                                               | 1 (0.8)                                                                       | 18 (13.7)          | 4 (3.1)            | 24 (18.6)         | 4 (3.1)          |
| Disorders Headache                       | 8 (6.0)                                                                       |                                                                               | 6 (4.6)            |                    | 9 (7.0)           |                  |
| PsychiatricDisorders                     |                                                                               | 0 (0.0)                                                                       | 22 (16.8)          | 1 (0.8)            | 22 (17.1)         | 0 (0.0)          |
| Depression                               | 9 (6.8)                                                                       |                                                                               | 12 (9.2)           |                    | 11 (8.5)          |                  |
| Insomnia                                 | 6 (4.5)                                                                       |                                                                               | 9 (6.9)            |                    | 5 (3.9)           |                  |
| Anxiety                                  | 1 (0.8)                                                                       |                                                                               | 5 (3.8)            | 1 (0.8)            | 7 (5.4)           |                  |
| Respiratory, Thoracic andMediastinal     |                                                                               | 8 (6.0)                                                                       | 19 (14.5)          | 12 (9.2)           | 35 (27.1)         | 13 (10.1)        |
| Disorders Respiratory Failure Dyspnoea   | 6 (4.5) 1 (0.8)                                                               | 5 (3.8)                                                                       | 8 (6.1) 3 (2.3)    | 7 (5.3)            | 13 (10.1) 8 (6.2) | 9 (7.0) 2 (1.6)  |
| SkinandSubcutaneous                      |                                                                               | 0 (0.0)                                                                       | 27 (20.6)          |                    | 39 (30.2)         | 2 (1.6)          |
| TissueDisorder's Rash Maculo-Papular     | 1 (0.8)                                                                       |                                                                               | 6 (4.6)            | 1 (0.8)            | 11 (8.5)          | 1 (0.8)          |
| Rash                                     | 4 (3.0)                                                                       |                                                                               | 2 (1.5)            |                    | 10 (7.8)          |                  |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

<div style=\"page-break-after: always\"></div>

Table 61 : Frequent AEs (PT≥5%) in Study AB10015 - RELATED

|                                               | P+R (N=133)   | P+R (N=133)   | M3.0 + R (N=131)   | M3.0 + R (N=131)   | M 4.5 + R (N=129)   | M 4.5 + R (N=129)   |
|-----------------------------------------------|---------------|---------------|--------------------|--------------------|---------------------|---------------------|
| Causality                                     |               |               | Related            | Related            |                     |                     |
| Severity                                      | All           | Severe        | All                | Severe             | All                 | Severe              |
| AI                                            | 36 (27.1)     | 1 (0.8)       | 58 (44.3)          | 1 (0.8)            | 78 (60.5)           | 7 (5.4)             |
| Blood and Lymphatic System Disorders          | 2 (1.5)       | 0 (0.0)       | 4 (3.1)            | 0 (0.0)            | 13 (10.1)           | 2 (1.6)             |
| Iron Deficiency Anaemia                       | 1 (0.8)       |               | 0 (0.0)            |                    | 6 (4.7)             |                     |
| Gastrointestinal                              | 10 (7.5)      | 0 (0.0)       | 25 (19.1)          | 0 (0.0)            | 33 (25.6)           | 0 (0.0)             |
| Disorders Dysphagia                           | 0 (0.0)       |               | 1 (0.8)            |                    |                     |                     |
| Nausea                                        | 3 (2.3)       |               | 7 (5.3)            |                    | 11 (8.5)            |                     |
| Diarhoea                                      | 3 (2.3)       |               | 8 (6.1)            |                    | 6 (4.7)             |                     |
| Abdominal Pain Upper                          | 1 (0.8)       |               | 3 (2.3)            |                    | 4 (3.1)             |                     |
| Dyspepsia                                     | 2 (1.5)       |               | 1 (0.8)            |                    | 6 (4.7)             |                     |
| General Disordersand Administration Site      | 0 (0.0)       | 0 (0.0)       | 6 (4.6)            | 0 (0.0)            | 9 (7.0)             | 0 (0.0)             |
| Conditions Oedema Peripheral                  |               |               | 4 (3.1)            |                    | 6 (4.7)             |                     |
| Infections and Infestations                   | 0 (0.0)       | 0 (0.0)       | 5 (3.8)            | 0 (0.0)            | 8 (6.2)             | 0 (0.0)             |
| Viral Upper Respiratory Tract Infection       |               |               |                    |                    |                     |                     |
| Injury, Poisoning and                         |               |               |                    |                    |                     |                     |
| Procedural                                    | 1 (0.8)       | 0 (0.0)       | 2 (1.5)            | 0 (0.0)            | 2 (1.6)             | 0 (0.0)             |
| Complications Fall                            |               |               | 1 (0.8)            |                    | 1 (0.8)             |                     |
| Investigations Weight Decreased               | 5 (3.8)       | 1 (0.8)       | 4 (3.1)            | 0 (0.0)            | 8 (6.2)             | 2 (1.6)             |
| Nervous System                                | 1 (0.8)       | 0 (0.0)       | 1 (0.8)            | 0 (0.0)            | 3 (2.3)             | 0 (0.0)             |
| Disorders Headache                            | 1 (0.8)       |               |                    |                    | 2 (1.6)             |                     |
| Psychiatric Disorders                         | 2 (1.5)       | 0 (0.0)       | 3 (2.3)            | 0 (0.0)            | 1 (0.8)             | 0 (0.0)             |
| Depression                                    | 1 (0.8)       |               | 1 (0.8)            |                    | 1 (0.8)             |                     |
| Insomnia                                      | 1 (0.8)       |               | 2 (1.5)            |                    |                     |                     |
| Anxiety Respiratory, Thoracic and Mediastinal | 1 (0.8)       | 0 (0.0)       | 1 (0.8)            | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             |
| Disorders                                     |               |               |                    |                    |                     |                     |
| Respiratory Failure Dyspnoea                  |               |               |                    |                    |                     |                     |
| Skin and Subcutaneous TissueDisorders         | 12 (9.0)      | 0 (0.0)       | 23 (17.6)          | 1 (0.8)            | 33 (25.6)           | 2 (1.6)             |
| RashMaculo-Papular                            | 1 (0.8)       |               | 5 (3.8)            |                    | 11 (8.5)            | 1 (0.8)             |
| Rash                                          | 4 (3.0)       |               | 2 (1.5)            |                    | 6 (4.7)             |                     |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

## Adverse events in all non-oncology patients

Overall, 89% of patients reported at least one AE during neurodegenerative and chronic inflammatory studies. According to Applicant, the most frequently reported AEs were consistent with events related to the diseases under study and with the known safety profile of Masitinib AB Science.

<div style=\"page-break-after: always\"></div>

The  most  common  AEs  included  general  gastrointestinal  symptoms  -  decreased  appetite,  nausea, vomiting, abdominal pain and diarrhoea. They were experienced by up to 70% of patients in clinical studies. Up to 60% of patients experienced uncomplicated cutaneous reactions, such as maculopapular erythema with or without pruritus. Up to 30% of patients reported constitutional symptoms, i.e. mild myalgia, pain, fatigue, and dizziness. Up to 20% of patients experienced fluid retention and superficial oedema.

Most of mentioned AEs were mild to moderate in intensity, usually more frequent at the start of therapy and manageable with symptomatic treatments and dose reductions.

Table 62: Summary of TEAEs by dose - non-oncology excluding AB10015

|                                                   | Masitinib   | Masitinib   | Masitinib    |                 |
|---------------------------------------------------|-------------|-------------|--------------|-----------------|
|                                                   | 3.0 N=156   | 4.5 N=461   | All N=1924   | Placebo* N=1004 |
| No.of Subjectswith atleastone                     |             |             |              |                 |
| AllAEs                                            | 136 (87.2%) | 421 (91.3%) | 1702 (88.5%) | 834 (83.1%)     |
| SAE (non-fatal) (all)                             | 32 (20.5%)  | 98 (21.3%)  | 423 (22.0%)  | 134 (13.3%)     |
| Fatal (all)                                       | 0           | 5 (1.1%)    | 13 (0.7%)    | 11 (1.1%)       |
| Leading to permanent discontinuation (excl Death) | 49 (31.4%)  | 110 (23.9%) | 467 (24.3%)  | 66 (6.6%)       |
| Leadingtodosereduction                            | 1 (0.6%)    | 25 (5.4%)   | 143 (7.4%)   | 20 (2.0%)       |
| Severe(Grade3andabove)                            | 37 (23.7%)  | 145 (31.5%) | 732 (38.0%)  | 288 (28.7%)     |

## A comparative analysis of the safety of Masitinib AB Science in the ALS and in the supporting non-oncology studies, when dose used was 4.5mg/kg/day or 3mg/kg/day

The percentage of patients with AE in the Masitinib AB Science arm was comparable in the ALS study and the controlled-unblinded studies (88.4%/84.7% vs. 91.3%/87.2%). Frequency of severe AEs was comparable in ALS vs. non-oncology (30.2%/21.4% vs. 31.5%/23.7%). More SAEs reported in the 4.5 mg/kg/day arm in ALS compared to the non-oncology studies (31.0% vs 21.3%). Overall, less patients discontinued in the ALS study vs. non-oncology studies (16.3%/15.3% versus 23.9%/31.4%).

<div style=\"page-break-after: always\"></div>

Table  63:  TEAEs  with  a  difference  of  more  than  5%  compared  to  placebo  -  non-oncology  excluding AB10015

<!-- image -->

|                                                    | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib    | Masitinib   |                 |                 |
|----------------------------------------------------|-------------|-------------|-------------|-------------|--------------|-------------|-----------------|-----------------|
|                                                    | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | All N=1924   | All N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No.of Subjectswith at least one                    | n (%)       | events      | n (%)       | events      | n (%)        | events      | (%) uI          | events          |
| AllAEs                                             | 136 (87.2%) | 1013        | 421 (91.3%) | 3667        | 1702 (88.5%) | 15064       | 834 (83.1%)     | 6930            |
| Eye Disorders                                      | 10 (6.4%)   | 12          | 41 (8.9%)   | 56          | 222 (11.5%)  | 314         | 36 (3.6%)       | 60              |
| Eyelid Oedema                                      | 0           | 0           | 19 (4.1%)   | 21          | 122 (6.3%)   | 150         | 9 (0.9%)        | 11              |
| Gastrointestinal Disorders                         | 51 (32.7%)  | 96          | 158 (34.3%) | 302         | 719 (37.4%)  | 1756        | 214 (21.3%)     | 478             |
| Nausea                                             | 8 (5.1%)    | 10          | 37 (8.0%)   | 50          | 277 (14.4%)  | 365         | 54 (5.4%)       | 70              |
| Diarrhoea                                          | 16 (10.3%)  | 19          | 62 (13.4%)  | 81          | 274 (14.2%)  | 400         | 78 (7.8%)       | 103             |
| General Disordersand AdministrationSite Conditions | 26 (16.7%)  | 35          | 93 (20.2%)  | 129         | 438 (22.8%)  | 783         | 148 (14.7%)     | 240             |
| SkinandSubcutaneous TissueDisorders                | 48 (30.8%)  | 71          | 145 (31.5%) | 250         | 615 (32.0%)  | 1185        | 143 (14.2%)     | 243             |
| Rash                                               | 9 (5.8%)    | 10          | 31 (6.7%)   | 36          | 125 (6.5%)   | 153         | 16 (1.6%)       | 19              |
| Pruritus                                           | 6 (3.8%)    | 7           | 22 (4.8%)   | 27          | 114 (5.9%)   | 145         | 34 (3.4%)       | 45              |
| Rash Maculo-Papular                                | 5 (3.2%)    | 7           | 31 (6.7%)   | 37          | 98 (5.1%)    | 119         | 13 (1.3%)       | 16              |

## Adverse events in healthy subjects

30% of healthy subjects (29/96) receiving masitinib mesilate reported regarding 154 AEs. The most common  ones  were  nausea,  vomiting,  diarrhoea,  abdominal  pain,  rash,  dizziness,  and  episodes  of headaches. Two cases of severe AE neutropenia were reported, one of which was then later considered a laboratory error. The majority of AEs were assessed as related to Masitinib AB Science.

<div style=\"page-break-after: always\"></div>

## Analysis of most common AEs

Table 64: Classification of analyses of most common AEs (W0 to W48)

<!-- image -->

| AEsincluded   | MedDRA termsincluded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rash          | Acute generalized exanthematous pustulosis, Chronic spontaneous urticaria, Dermatitis, Drug eruption, Drug reaction with eosinophilia and systemic symptoms, Ear pruritus, Eczema, Eczema asteatotic,Eczema eyelids,Eczema infected,Eczema nummular,Erythema,Erythema nodosum, Erythema of eyelid, Erythrosis, Eyelids pruritus, Generalised erythema, Hand dermatitis, Macule, Mechanical urticaria, Mucocutaneous rash, Nodular rash, Palmar erythema, Papule, Perianal erythema, Plantar erythema, Prurigo, Pruritus, Pruritus generalized, Rash, Rash erythematous, Rash generalized, Rash macular, Rash maculo-papular, Rash papular, Rash pruritic, Rash pustular, Scrotal erythema, Skin irritation, Skin lesion, Skin reaction, Urticaria, Urticaria contact, Vasculitic rash, Vulvovaginal erythema |
| Nausea        | Nausea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Vomiting      | Regurgitation of food, Vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Diarrhoea     | Abnormal faeces, Defaecation urgency, Diarrhoea, Diarrhoea haemorrhagic,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Oedema        | Allergic oedema, Breast oedema, Circumoral oedema, Eye oedema, Eye swelling, Eyelid oedema, Face oedema, Fluid Overload, Fluid Retention, Generalised oedema, Gingival oedema, Gingival swelling, Lip oedema, Lip swelling, Local swelling, Localised oedema, Lymphoedema, Mouth swelling, oedema, oedema Genital, oedema Mouth, oedema Peripheral, Orbital oedema, Papilloedema, Penile oedema, Penile swelling, Periorbital oedema, Peripheral swelling, Scrotal oedema, Scrotal swelling, Swelling, Swelling face, Swollen fongue, Testicular oedema, Testicular swelling, Tongue oedema, Vaginal oedema, Vulval oedema                                                                                                                                                                                   |
| Anaemia       | Anaemia, Anaemia folate deficiency, Anaemia macrocytic, Anaemia of chronic disease, Anaemia vitamin B12 deficiency, Aplasia pure red cell, Aplastic anaemia, Cold type haemolytic anaemia, anaemia, Iron deficiency anaemia, microcytic anaemia, Normochromic normocytic anaemia, Pancytopenia, Haemoglobin decreased, Mean cell haemoglobin concentration decreased, Mean cell haemoglobin decreased, and Red blood cell count decreased                                                                                                                                                                                                                                                                                                                                                                    |

## Rash

Table 65: Summary of Skin Rash - in Study AB10015 (W0-W48, N=393)

|                           | P+R (N=133)   | M 3.0 + R (N=131)   | M4.5 + R (N=129)   | P+R (N=133)   | M3.0 + R (N=131)   | M4.5 + R (N=129)   |
|---------------------------|---------------|---------------------|--------------------|---------------|--------------------|--------------------|
|                           | All           | All                 | All                | Related       | Related            | Related            |
| Rash                      | 12 (9.0%)     | 27 (20.6%)          | 33 (25.6%)         | 11 (8.3%)     | 23 (17.6%)         | 29 (22.5%)         |
| Severe Cases              | 0             | 1 (0.8%)            | 2 (1.6%)           | 0             | 1 (0.8%)           | 2 (1.6%)           |
| Serious cases (non-fatal) | 1 (0.8%)      | 2 (1.5%)            | 2 (1.6%)           | 1 (0.8%)      | 2 (1.5%)           | 2 (1.6%)           |
| Death                     | 0             | 0                   | 0                  | 0             | 0                  | 0                  |
| Discontinuation           | 0             | 3 (2.3%)            | 5 (3.9%)           |               |                    |                    |
| Outcome (worst, including |               |                     |                    |               |                    |                    |
| fatal cases if any)       |               |                     |                    |               |                    |                    |
| n (patients with Rash)    | 12            | 27                  | 33                 |               |                    |                    |
| Resolved without sequelae | 11            | 25                  | 33                 |               |                    |                    |
| Resolved with sequelae    | 0             | 0                   | 0                  |               |                    |                    |
| Time of occurrence (days) |               |                     |                    |               |                    |                    |
| n (AEs)                   | 14            | 35                  | 54                 |               |                    |                    |
| Median                    | 48            | 31                  | 31                 |               |                    |                    |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

Source:. Note: All frequencies are in number of patients, excepted for Time of occurrence that is in number of AEs.

<div style=\"page-break-after: always\"></div>

Rash was a very common AE in ALS patients treated with Masitinib AB Science. It was dose-dependent and mostly mild, short lived and fully recoverable.

Table 66: Most frequent AEs in SOC skin and Subcutaneous Tissue Disorders - excluding AB10015

<!-- image -->

|                                       | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib    | Masitinib   |                 |                 |
|---------------------------------------|-------------|-------------|-------------|-------------|--------------|-------------|-----------------|-----------------|
|                                       | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | All N=1924   | All N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No.of Subjectswith at least one       | n(%)        | events      | n(%)        | events      | (%)u         | events      | n(%)            | events          |
| AllAEs                                | 136 (87.2%) | 1013        | 421 (91.3%) | 3667        | 1702 (88.5%) | 15064       | 834 (83.1%)     | 6930            |
| Skinand Subcutaneous Tissue Disorders | 48 (30.8%)  | 71          | 145 (31.5%) | 250         | 615 (32.0%)  | 1185        | 143 (14.2%)     | 243             |
| Rash                                  | 9 (5.8%)    | 10          | 31 (6.7%)   | 36          | 125 (6.5%)   | 153         | 16 (1.6%)       | 19              |
| Pruritus                              | 6 (3.8%)    | 7           | 22 (4.8%)   | 27          | 114 (5.9%)   | 145         | 34 (3.4%)       | 45              |
| Rash Maculo-Papular                   | 5 (3.2%)    | 7           | 31 (6.7%)   | 37          | 98 (5.1%)    | 119         | 13 (1.3%)       | 16              |
| Erythema                              | 3 (1.9%)    | 3           | 14 (3.0%)   | 18          | 55 (2.9%)    | 63          | 14 (1.4%)       | 20              |
| Dry Skin                              | 1 (0.6%)    | 1           | 11 (2.4%)   | 12          | 43 (2.2%)    | 47          | 7 (0.7%)        | 7               |
| Urticaria                             | 1 (0.6%)    | 2           | 3 (0.7%)    | 3           | 39 (2.0%)    | 51          | 7 (0.7%)        | 10              |
| Eczema                                | 3 (1.9%)    | 4           | 2 (0.4%)    | 2           | 33 (1.7%)    | 49          | 14 (1.4%)       | 14              |
| Rash Macular                          | 4 (2.6%)    | 4           | 6 (1.3%)    | 7           | 33 (1.7%)    | 38          | 5 (0.5%)        | 5               |
| Skin Exfoliation                      | 1 (0.6%)    | 1           | 5 (1.1%)    | 6           | 33 (1.7%)    | 42          | 4 (0.4%)        | 4               |
| Dermatitis Allergic                   | 3 (1.9%)    | 3           | 9 (2.0%)    | 9           | 31 (1.6%)    | 32          | 4 (0.4%)        | 4               |
| Rash Generalised                      | 1 (0.6%)    | 1           | 8 (1.7%)    | 10          | 28 (1.5%)    | 31          | 1 (0.1%)        | 1               |
| PruritusGeneralised                   | 3 (1.9%)    | 3           | 4 (0.9%)    | 4           | 23 (1.2%)    | 25          | 1 (0.1%)        | 1               |
| Swelling Face                         | 3 (1.9%)    | 3           | 3 (0.7%)    | 4           | 21 (1.1%)    | 25          | 2 (0.2%)        | 2               |

Up to 32% of non-oncology patients treated with Masitinib AB Science (excluding ALS) experienced at least one occurrence of cutaneous reactions. They were more prevalent in the beginning of treatment, mostly mild to moderate, dose-related, and self-limited and were manageable through dose reductions and interruptions. Their frequency and severity usually decrease over time.

## GI symptoms

GI symptoms - mild abdominal discomfort, nausea, vomiting and diarrhoea - are known adverse drug reactions to masitinib and other TKI products. GI symptoms were mostly dose-dependent, mild, shortlived, and fully recoverable. Usually, it was observed in the beginning of treatment.

## Nausea

Table 67: Summary of Nausea - in Study AB10015 (W0-W48, N=393)

|                         | P+R (N=133)   | M3.0+R (N=131)   | M4.5+R (N=129)   | P+R (N=133)   | M3.0+R (N=131)   | M4.5+R (N=129)   |
|-------------------------|---------------|------------------|------------------|---------------|------------------|------------------|
|                         | Al            | Al               | Al               | Related       | Related          | Related          |
| Nausea                  | 6 (4.5%)      | 9 (6.9%)         | 16 (12.4%)       | 3 (2.3%)      | 7 (5.3%)         | 11 (8.5%)        |
| SevereCases             | 0             | 0                | 0                | 0             | 0                | 0                |
| Seriouscases(non-fatal) | 0             | 0                | 0                | 0             | 0                | 0                |
| Death                   | 0             | 0                | 0                | 0             | 0                | 0                |

<div style=\"page-break-after: always\"></div>

| Discontinuation                               |    | 1 (0.8%)   | 1 (0.8%)   |
|-----------------------------------------------|----|------------|------------|
| Outcome (worst, including fatal cases if any) |    |            |            |
| n (patients with Nausea)                      | 6  | 8          | 16         |
| Resolved without sequelae                     | 6  | 8          | 16         |
| Resolved with sequelae                        | 0  | 0          | 0          |
| Tine of occurrence (days)                     |    |            |            |
| n (AEs)                                       | 6  | 10         | 17         |
| Median                                        | 44 | 17         | 38         |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable. Note: All frequencies are in number of patients, excepted for Time of occurrence that is in number of AEs.

Table 68: Nausea - non-oncology excluding AB10015

|                                | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | All N=1924  | All N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No.of Subjectswith at leastone | n(%)        | events      | n(%)        | events      | n(%)        | events      | n(%)            | Events          |
| GastrointestinalDisorder's     | 51 (32.7%)  | 96          | 158 (34.3%) | 302         | 719 (37.4%) | 1756        | 214 (21.3%)     | 478             |
| Nausea                         | 8 (5.1%)    | 10          | 37 (8.0%)   | 50          | 277 (14.4%) | 365         | 54 (5.4%)       | 70              |

## Vomiting

Table 69: Summary of vomiting - in Study AB10015 (W0-W48, N=393)

| Number (%)of subject with at least one AE   | P+R (I=133)   | M3.0+R (I=131)   | M 4.5 + R (N=129)   |
|---------------------------------------------|---------------|------------------|---------------------|
| Vomiting- All AEs                           | 0             | 0                | 3 (2.3%)            |
| Severe Cases                                | 0             | 0                | 0                   |
| Serious cases (non-fatal)                   | 0             | 0                | 0                   |
| Death                                       | 0             | 0                | 0                   |
| Discontinuation                             | 0             | 0                | 0                   |
| Time of occurrence (days)                   |               |                  |                     |
| n (AEs)                                     |               |                  | 4                   |
| Median                                      |               |                  | 44                  |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Note: All frequencies are in number of patients, excepted for Time of occurrence that is in number of AEs.

Table 70: Vomiting - non-oncology excluding AB10015

|                                 | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|---------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                 | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | AlI N=1924  | AlI N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No.of Subjects with at leastone | n(%)        | events      | n(%)        | events      | n(%)        | events      | n(%)            | Events          |
| GastrointestinalDisorders       | 51 (32.7%)  | 96          | 158 (34.3%) | 302         | 719 (37.4%) | 1756        | 214 (21.3%)     | 478             |
| Vomiting                        | 9 (5.8%)    | 15          | 27 (5.9%)   | 34          | 144 (7.5%)  | 199         | 32 (3.2%)       | 42              |

7.5% of non-oncology patients treated with Masitinib AB Science (excluding ALS patients) experienced at least one episode of vomiting vs. 3.2% of the patients in placebo groups.

<div style=\"page-break-after: always\"></div>

## Diarrhoea

Table 71: Summary of Diarrhoea - in Study AB10015 (W0-W48, N=393)

| Number (%) of subject with at least one AE   | P+R (I=133)   | M3.0+R (=131)   | M4.5+R (N=129)   |
|----------------------------------------------|---------------|-----------------|------------------|
| Diarrohea-AllAEs                             | 5 (3.8%)      | 11 (8.4%)       | 10 (7.8%)        |
| SevereCases                                  | 0             | 0               | 0                |
| Serious cases (non-fatal)                    | 0             | 1 (0.8%)        | 1 (0.8%)         |
| Death                                        | 0             | 0               | 0                |
| Discontinuation                              | 0             | 0               | 0                |
| Time of occurrence (days)                    |               |                 |                  |
| n (AEs)                                      | 5             | 13              | 13               |
| Median                                       | 51            | 56              | 123              |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Note: All frequencies are in number of patients, except for Time of occurrence that is in number of AEs.

Most of the diarrhoea and related AEs were observed in the initial 6 months of the start of Masitinib AB Science treatment. All the cases were manageable with temporary interruption or dose reductions.

Table 72: Diarrhoea - non-oncology excluding AB10015

|                                | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | AIl N=1924  | AIl N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No.of Subjectswith at leastone | n(%)        | events      | (%)u        | events      | (%)u        | events      | n(%)            | Events          |
| Gastrointestinal               | 51 (32.7%)  | 96          | 158 (34.3%) | 302         | 719 (37.4%) | 1756        | 214 (21.3%)     | 478             |
| Diarrhoea                      | 16 (10.3%)  | 19          | 62 (13.4%)  | 81          | 274 (14.2%) | 400         | 78 (7.8%)       | 103             |

## Oedema

Superficial oedemas are common and well described ADRs of TKIs including Masitinib AB Science. It occurs due to peripheral fluid retention, which is explained by the pharmacological mechanism of action of  Masitinib  AB  Science  (or  other  TKIs)  by  blocking  the  PDGFR  pathway.  In  most  cases,  superficial oedema-related events are dose-dependent, mild, short-lived, and fully recoverable.

Table 73: Summary of Oedema - in Study AB10015 (W0-W48, N=393)

| Number(%o)of subjectwith atleastoneAE   | P+R (N=133)   | M3.0+R (I=131)   | M4.5+R (N=129)   |
|-----------------------------------------|---------------|------------------|------------------|
| Oedema-AllAEs                           | 1 (0.8%)      | 8 (6.1%)         | 16 (12.4%)       |
| Severe Cases                            | 0             | 0                | 0                |
| Serious cases (non-fatal)               | 0             | 0                | 0                |
| Death                                   | 0             | 0                | 0                |
| Discontinuation                         | 0             | 0                | 2 (1.6%)         |
| Time of occurrence (days)               |               |                  |                  |
| n (AEs)                                 | 1             | 10               | 21               |
| Median                                  | 80            | 41               | 28               |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Note: All frequencies are in number of patients, except for Time of occurrence that is in number of AEs.

<div style=\"page-break-after: always\"></div>

The median time of occurrence of oedema in ALS patients exposed to Masitinib AB Science was between 28 to 41 days. No risk of oedema observed with long term usage of study drug.

Table 74: Selected terms 'Oedema' - in non-oncology studies excluding AB10015

<!-- image -->

|                                                     | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib    | Masitinib   |                 |                 |
|-----------------------------------------------------|-------------|-------------|-------------|-------------|--------------|-------------|-----------------|-----------------|
|                                                     | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | All N=1924   | All N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No. of Subjects with at least one                   | n(%)        | events      | n(%)        | events      | n(%)         | events      | n(%)            | Events          |
| AllAEs                                              | 136 (87.2%) | 1013        | 421 (91.3%) | 3667        | 1702 (88.5%) | 15064       | 834 (83.1%)     | 6930            |
| Eye Disorders                                       |             |             |             |             |              |             |                 |                 |
| Eyelid Oedema                                       | 0           | 0           | 19 (4.1%)   | 21          | 122 (6.3%)   | 150         | 9 (0.9%)        | 11              |
| Periorbital Oedema                                  | 2 (1.3%)    | 4           | 1 (0.2%)    | 1           | 14 (0.7%)    | 17          | 3 (0.3%)        | 4               |
| Eye Oedema                                          | 1 (0.6%)    | 1           | 1 (0.2%)    | 1           | 8 (0.4%)     | 8           | 1 (0.1%)        | 1               |
| GastrointestinalDisorder's                          |             |             |             |             |              |             |                 |                 |
| Lip Oedema                                          | 0           | 0           | 2 (0.4%)    | 2           | 9 (0.5%)     | 9           | 0               | 0               |
| Oedema Mouth                                        | 0           | 0           | 1 (0.2%)    | 1           | 3 (0.2%)     | 3           | 0               | 0               |
| Tongue Oedema                                       | 0           | 0           | 1 (0.2%)    | 1           | 3 (0.2%)     | 3           | 0               | 0               |
| Gastrointestinal Oedema                             | 0           | 0           | 0           | 0           | 0            | 0           | 1 (0.1%)        | 1               |
| Gingival Oedema                                     | 0           | 0           | 0           | 0           | 1 (0.1%)     | 1           | 0               | 0               |
| General Disorders and AdninistrationSite Conditions |             |             |             |             |              |             |                 |                 |
| Oedema Peripheral                                   | 8 (5.1%)    | 11          | 23 (5.0%)   | 24          | 114 (5.9%)   | 134         | 20 (2.0%)       | 22              |
| Face Oedema                                         | 2 (1.3%)    | 2           | 6 (1.3%)    | 7           | 57 (3.0%)    | 69          | 6 (0.6%)        | 6               |
| Oedema                                              | 1 (0.6%)    | 1           | 2 (0.4%)    | 2           | 15 (0.8%)    | 20          | 3 (0.3%)        | 3               |
| Localised Oedema                                    | 0           | 0           | 1 (0.2%)    | 1           | 8 (0.4%)     | 8           | 3 (0.3%)        | 3               |
| Generalised Oedema                                  | 0           | 0           | 1 (0.2%)    | 1           | 4 (0.2%)     | 4           | 1 (0.1%)        | 2               |
| ReproductiveSystemand Breast Disorders              |             |             |             |             |              |             |                 |                 |
| Oedema Genital                                      | 0           | 0           | 0           | 0           | 1 (0.1%)     | 1           | 0               | 0               |
| Vulval Oedema                                       | 0           | 0           | 0           | 0           | 0            | 0           | 1 (0.1%)        | 1               |
| SkinandSubcutaneous TissueDisorder's                |             |             |             |             |              |             |                 |                 |
| Circumoral Oedema                                   | 0           | 0           | 1 (0.2%)    | 1           | 1 (0.1%)     | 1           | 0               | 0               |

## Anaemia

Increase in frequency of anaemia in ALS patients exposed to Masitinib AB Science was a dose dependent. Asymptomatic decrease in red blood count is common for Masitinib AB Science. The median time of occurrence of anaemia-related AEs in patients exposed to masitinib was between 27 to 47 days. Anaemia is an uncommon (&lt;1%) AE for riluzole. There was no imbalance of severe anaemia observed with long term Masitinib AB Science usage.

<div style=\"page-break-after: always\"></div>

Table 75: Summary of Anaemia - in Study AB10015 (W0-W48, N=393)

| Number(%o)of subjectwith at least one AE   | P+R (N=133)   | M3.0+R (N=131)   | M4.5+R (N=129)   |
|--------------------------------------------|---------------|------------------|------------------|
| Anaemia-AllAEs                             | 3 (2.3%)      | 9 (6.9%)         | 20 (15.5%)       |
| SevereCases                                | 0             | 2 (1.5%)         | 2 (1.6%)         |
| Serious cases (non-fatal)                  | 0             | 1 (0.8%)         | 1 (0.8%)         |
| Death                                      | 0             | 0                | 0                |
| Discontinuation                            | 0             | 0                | 2 (1.6%)         |
| Time of occurrence (days)                  |               |                  |                  |
| n (AEs)                                    | 6             | 26               | 10               |
| Median                                     | 47            | 27               | 47               |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day Note: All frequencies are in number of patients, except for Time of occurrence that is in number of AEs.

Table 76: Summary of Anaemia - in non-oncology studies excluding AB10015

|                               |                      |           | Masitinib   | Masitinib   | Masitinib       |
|-------------------------------|----------------------|-----------|-------------|-------------|-----------------|
| MedDRA PT                     |                      | 3.0 N=156 | 4.5 N=461   | All N=1924  | Placebo* N=1004 |
| PT NAME                       |                      |           |             |             |                 |
| Aplastic Anaemia              | No. of patients(all) | 0         | 0           | 1 (0.1%)    | 0               |
|                               | Mild                 | 0         | 0           | 1 (0.1%)    | 0               |
| Erythropenia                  | No. of patients(all) | 1 (0.6%)  | 3 (0.7%)    | 6 (0.3%)    | 3 (0.3%)        |
|                               | Mild                 | 1 (0.6%)  | 3 (0.7%)    | 6 (0.3%)    | 3 (0.3%)        |
| Microcytic Anaemia            | No. of patients(all) | 0         | 0           | 1 (0.1%)    | 1 (0.1%)        |
|                               | Mild                 | 0         | 0           | 1 (0.1%)    | 1 (0.1%)        |
| RedBlood Cell Count Decreased | No. of patients(all) | 15 (9.6%) | 44 (9.5%)   | 114 (5.9%)  | 24 (2.4%)       |
|                               | Mild                 | 15 (9.6%) | 44 (9.5%)   | 114 (5.9%)  | 24 (2.4%)       |
|                               | Missing              | 0         | 0           | 1 (0.1%)    | 0               |
| Reticulocyte Count Decreased  | No. of patients(all) | 0         | 0           | 1 (0.1%)    | 0               |
|                               | Mild                 | 0         | 0           | 1 (0.1%)    | 0               |

Anaemia related AEs were more common in patients exposed to Masitinib AB Science vs. placebo (6.3% vs. 2.8%). Some of Anaemia related AEs are further discussed in 4.5 Laboratory findings.

Table 77 : Severe AEs (Risk ≥1% in any PT) - in Study AB10015 (W0-W48, N=393)

| Number(%o)of subjectwithatleast one severe AE   | P+R (N=133)   | M3.0+ R (N=131)   | M4.5+ R (=129)   | P+R (N=133)   | M 3.0 + R (N=131)   | M 4.5 + R (N=129)   |
|-------------------------------------------------|---------------|-------------------|------------------|---------------|---------------------|---------------------|
|                                                 | All           | All               | All              | Related       | Related             | Related             |
| AllAEs                                          | 26 (19.5%)    | 28 (21.4%)        | 39 (30.2%)       | 1 (0.8%)      | 1 (0.8%)            | 7 (5.4%)            |
| CardiacDisorder's                               | 2 (1.5%)      | 5 (3.8%)          | 2 (1.6%)         | 0             | 0                   | 0                   |
| Cardio-RespiratoryArrest                        | 1 (0.8%)      | 4 (3.1%)          | 1 (0.8%)         | 0             | 0                   | 0                   |
| GastrointestinalDisorders                       | 4 (3.0%)      | 4 (3.1%)          | 7 (5.45)         | 0             | 0                   | 0                   |
| Dysphagia                                       | 3 (2.3%)      | 4 (3.1%)          | 6 (4.7%)         | 0             | 0                   | 0                   |
| Investigations                                  | 5 (3.8%)      | 6 (4.6%)          | 6 (4.7%)         | 1 (0.8%)      | 0                   | 2 (1.6%)            |
| Blood Phosphorus Decreased                      | 0             | 0                 | 3 (2.3%)         | 0             | 0                   | 0                   |
| NervousSystemDisorder's                         | 1 (0.8%)      | 4 (3.1%)          | 4 (3.1%)         | 0             | 0                   | 0                   |
| Brain Oedema                                    | 0             | 2 (1.5%)          | 0                | 0             | 0                   | 0                   |
| Respiratory, Thoracic and Mediastinal Disorders | 8 (6.0%)      | 12 (9.2%)         | 13 (10.1%)       | 0             | 0                   | 0                   |
| Respiratory Failure                             | 5 (3.8%)      | 7 (5.3%)          | 9 (7.0%)         | 0             | 0                   | 0                   |
| Dyspnoea                                        | 0             | 0                 | 2 (1.6%)         | 0             | 0                   | 0                   |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

<div style=\"page-break-after: always\"></div>

Table 78: Severe AEs - in non-oncology studies excluding AB10015

<!-- image -->

|                                                                     | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|---------------------------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                                                     | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | AIl tt6I=N  | AIl tt6I=N  | Placebo* N=1004 | Placebo* N=1004 |
| No.of Subjects withat least one                                     | (%)u        | events      | n(%)        | events      | n(%)        | events      | m(%)            | events          |
| AllAEs                                                              | 37 (23.7%)  | 49          | 145 (31.5%) | 231         | 732 (38.0%) | 1791        | 288 (28.7%)     | 568             |
| Blood and Lymphatic System                                          | 5 (3.296)   | 5           | 18 (3.9%)   | 20          | (966′+) +6  | 114         | 23 (2.3%)       | 29              |
| Disorders                                                           |             |             |             |             |             |             |                 |                 |
| Neutropenia                                                         | 5 (3.2%)    | 5           | 10 (2.2%)   | 10          | 59 (3.1%)   | 63          | 10 (1.0%)       | 12              |
| Lymphopenia                                                         | 0           | 0           | 5 (1.1%)    | 5           | 13 (0.7%)   | 15          | 1 (0.1%)        | 1               |
| Cardiae Disorders                                                   | 0           | 0           | 5 (1.1%)    | 5           | 20 (1.0%)   | 22          | 8 (0.8%)        | 8               |
| Gastrointestinal Disorders                                          | 3 (1.9%)    | 3           | 7 (1.5%)    | 10          | 83 (4.3%)   | 174         | 15 (1.5%)       | 25              |
| Diarhoea                                                            | 0           | 0           | 4 (0.9%)    | 4           | 36 (1.9%)   | 45          | 5 (0.5%)        | 6               |
| Nausea                                                              | 0           | 0           | 1 (0.2%)    | 1           | 22 (1.1%)   | 23          | 1 (0.1%)        | 1               |
| General Disorders and                                               | 0           | 0           | 4 (0.9%)    | 5           | 75 (3.9%)   | 123         | 15 (1.5%)       | 19              |
| Asthenia                                                            | 0           | 0           | 1 (0.2%)    | 1           | 32 (1.7%)   | 41          | 4 (0.4%)        | 5               |
| Hepatobiliary Disorders                                             | 0           | 0           | 4 (0.9%)    | 4           | (%6t'D) tt  | 25          | 3 (0.3%)        | 4               |
| InfectionsandInfestations                                           | 2 (1.3%)    | 2           | 8 (1.7%)    | 9           | 73 (3.8%)   | 95          | 25 (2.5%)       | 30              |
| Injury - Poisoning and Procedural Complications                     | 0           | 0           | 0           | 0           | 0           | 0           | 0               | 0               |
| Accidental Overdose                                                 | 0           | 0           | 0           | 0           | 0           | 0           | 0               | 0               |
| Injury, Poisoning and Procedural Complieations                      | 1 (0.6%)    | 3           | 2 (0.4%)    |             | 20 (1.0%)   | 24          | 11 (1.1%)       | 13              |
| Investigations                                                      | 8 (5.1%)    | 9           | 68 (14.8%)  | 96          | 246 (12.8%) |             | 103 (10.3%)     | 131             |
| Blood Phosphorus Decreased                                          | 2 (1.3%)    | 2           | 18 (3.9%)   | 23          | 48 (2.5%)   | 59          | 9 (0.9%)        | 11              |
| Lymphocyte Count Decreased                                          | 1 (0.6%)    | 1           | 11 (2.4%)   | 12          | 39 (2.0%)   | 43          | 9 (0.9%)        | 10              |
| Gamma-Glutamyltransferase Increased                                 | 0           | 0           | 9 (2.0%)    | 11          | 38 (2.0%)   | 43          | 15 (1.5%)       | 18              |
| Neutrophil Count Decreased                                          | 1 (0.6%)    | 1           | 6 (1.3%)    | 6           | 23 (1.2%)   | 23          | 7 (0.7%)        | 7               |
| Blood Potassium Increased                                           | 0           | 0           | 6 (1.3%)    | 6           | 18 (0.9%)   | 20          | 7 (0.7%)        | 8               |
| Metabolism and Nutrition Disorders                                  | 2 (1.3%)    |             | 8 (1.7%)    | 8           | 57 (3.0%)   | 65          | 28 (2.8%)       | 40              |
| Musculoskeletal and Connective Tissue Disorders                     | 1 (0.6%)    | 1           | 1 (0.2%)    | 1           | 44 (2.3%)   | 69          | 8 (0.8%)        | 14              |
| Neoplasms Benign, Maliguant and Unspecified (Incl Cysts and Polyps) | 0           | 0           | 10 (2.2%)   | 10          | 23 (1.2%)   | 26          | 9 (0.9%)        | 11              |
| Nervous System Disorders                                            | 1 (0.6%)    | 1           | 11 (2.4%)   | 11          | 53 (2.8%)   | 74          | 16 (1.6%)       | 19              |
| Psychiatric Disorders                                               | 0           | 0           | 3 (0.7%)    | 3           | (967'1) +t  | 28          | 6 (0.6%)        | 7               |
| Renal and Urinary Disorders                                         | 2 (1.3%)    | 2           | 5 (1.1%)    | 9           | 23 (1.2%)   | 28          | 4 (0.4%)        | 4               |
| Respiratory,Thoracic and Mediastinal Disorders                      | 4 (2.6%)    | 4           | 7 (1.5%)    | 7           | 176 (9.1%)  | 312         | 80 (8.0%)       | 161             |
| Asthma                                                              | 2 (1.3%)    | 2           | 2 (0.4%)    | 2           | 145 (7.5%)  | 271         | 77 (7.7%)       | 156             |
| Skin and Subcutaneous Tissue Disorders                              | 6 (3.8%)    | 7           | 10 (2.2%)   | 15          | 98 (5.1%)   | 154         | 10 (1.0%)       | 12              |
|                                                                     |             | 0           | 1 (0.2%)    | 3           | 19 (1.0%)   | 23          | 3 (0.3%)        | 3               |
| Rash Maculo-Papular                                                 | 0 4 (2.6%)  |             | 3 (0.7%)    | 3           | 16 (0.8%)   | 19          | 0               | 0               |
| VascularDisorders                                                   | 8 (5.19)    | 9           | 11 (2.4%)   | 11          | 47 (2.4%6)  | 63          | 26 (2.6%)       | 30              |
| Hypertension                                                        | 7 (4.5%)    | 8           | 10 (2.2%)   | 10          | 29 (1.5%)   | 33          | 17 (1.7%)       | 20              |

Long-term safety analysis

<div style=\"page-break-after: always\"></div>

130 of the 233 patients (55.8%) reported at least one AE during the extension period: 39 patients (48.8%) in the active control arm, 45 (56.3%) in the Masitinib AB Science 3mg/kg/day arm, and 46 (63.0%) in the Masitinib AB Science 4.5 mg/kg/day arm.

More frequently reported AEs in one of the Masitinib AB Science arms vs. placebo arm were dysphagia, depression, lower respiratory tract infection, and weight decrease. Occurrence and severity of AEs are dose related. According to Applicant, most of AEs were related to underlying progression of the disease, therefore, the increased frequency of these AEs in the Masitinib AB Science arm could be caused, at least partially, by the longer median treatment exposure in these arms.

Table 79 : Frequent AEs (Risk ≥5% in any PT) - study AB10015, extension period

| Number(%) of subject with at leastone AE        | P+R (N=80)   | M3.0 + R (N=80)   | M4.5 + R (N=73)   | P+R (N=80)   | M3.0+R (N=80)   | M 4.5 + R (N=73)   |
|-------------------------------------------------|--------------|-------------------|-------------------|--------------|-----------------|--------------------|
|                                                 | All          | All               | All               | Related      | Related         | Related            |
| AllAEs                                          | 39 (48.8)    | 45 (56.3)         | 46 (63.0)         | 1 (1.3)      | 8 (10.0)        | 8 (11.0)           |
| GastrointestinalDisorders                       | 7 (8.8)      | 11 (13.8)         | 19 (26.0)         | 0            | 0               | 2 (2.7)            |
| Dysphagia                                       | 7 (8.8)      | 8 (10.0)          | 12 (16.4)         | 0            | 0               | 0                  |
| InfectionsandInfestations                       | 16 (20.0)    | 16 (20.0)         | 15 (20.5)         | 1 (1.3)      | 1 (1.3)         | 1 (1.4)            |
| Lower Respiratory Tract Infection               | 1 (1.3)      | 5 (6.3)           | 1 (1.4)           | 0            | 0               | 0                  |
| Pneumonia                                       | 3 (3.8)      | 2 (2.5)           | 5 (6.8)           | 0            | 0               | 0                  |
| Investigations                                  | 11 (13.8)    | 12 (15.0)         | 10 (13.7)         | 0            | 1 (1.3)         | 2 (2.7)            |
| Weight Decreased                                | 3 (3.8)      | 6 (7.5)           | 4 (5.5)           | 0            | 1 (1.3)         | 0                  |
| PsychiatricDisorder's                           | 2 (2.5)      | 10 (12.5)         | 7 (9.6)           | 0            | 1 (1.3)         | 1 (1.4)            |
| Affect Lability                                 | 0            | 4 (5.0)           | 0                 | 0            | 0               | 0                  |
| Depression                                      | 0            | 4 (5.0)           | 4 (5.5)           | 0            | 1 (1.3)         | 1 (1.4)            |
| Respiratory, Thoracic and MediastinalDisorder's | 10 (12.5)    | 13 (16.3)         | 10 (13.7)         | 0            | 0               | 0                  |
| RespiratoryFailure                              | 5 (6.3)      | 7 (8.8)           | 4 (5.5)           | 0            | 0               | 0                  |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

The safety profile of Masitinib AB Science was comparatively better in the extension period vs. main protocol period. There was lower frequency of the overall AEs and TEAEs.

Table 80: Summary of frequent risks (combined PTs) - study AB10015, extension period

| Number(%)of subjectwith atleastone AE   | P+R (N=80)   | M3.0+R (N=80)   | M4.5+R (N=73)   | P +R (N=80)   | M3.0+R (N=80)   | M4.5+R (N=73)   |
|-----------------------------------------|--------------|-----------------|-----------------|---------------|-----------------|-----------------|
|                                         | All          | All             | All             | Related       | Related         | Related         |
| Nausea                                  | 0            | 1 (1.3%)        | 0               | 0             | 0               | 0               |
| Vomiting                                | 0            | 1 (1.4%)        | 0               | 0             | 0               | 0               |
| Diarrohea                               | 0            | 2 (2.5%)        | 2 (2.7%)        | 0             | 0               | 1 (1.4%)        |
| Oedema                                  | 0            | 0               | 0               | 0             | 0               | 0               |
| Anaemia                                 | 2 (2.5%)     | 2 (2.5%)        | 1 (1.4%)        | 0             | 0               | 0               |
| Rash                                    | 0            | 1 (1.3%)        | 4 (5.5%)        | 0             | 1 (1.3%)        | 3 (4.1%)        |
| SevereCases                             | 0            | 0               | 0               | 0             | 0               | 0               |
| Seriouscases(non-fatal)                 | 0            | 0               | 1 (1.4%)        | 0             | 0               | 0               |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

No discontinuations were recorded in the extension period.

The frequency of rash in Masitinib AB Science arms was lower vs. main protocol period and was still dose proportionally increased vs. placebo arm. During the extension period, 5 patients experienced rash, none in placebo arm, 1 patient (1.3%) in the Masitinib AB Science 3 mg/kg/day arm, and 4 patients (5.5%) in the Masitinib AB Science 4.5 mg/kg/day arm.

<div style=\"page-break-after: always\"></div>

## 2.6.8.3. Serious adverse event/deaths/other significant events

## Deaths

## Deaths in Study AB10015

According to Applicant, there was no increase in the frequency of fatal SAEs in patients treated with Masitinib AB Science during the main protocol period.

33 patients had a fatal SAEs. Of them, 12 patients (9.0%) in placebo arm, 11 patients (8.4%) in the Masitinib  AB  Science  3.0  mg/kg/day  arm,  and  10  patients  (7.8%)  in  the  Masitinib  AB  Science  4.5 mg/kg/day arm. The most common causes of death were related to underlying conditions, i.e. respiratory failures, respiratory infections, obstructive disorders. None of the on-treatment deaths were assessed by the investigators as treatment-related. None of the on-treatment deaths was associated with known adverse reactions of Masitinib AB Science or other TKIs. According to the applicant, detailed assessment of each death confirmed that events leading to death were due to natural progression and complications observed in patients with advanced ALS. Although several events of cardiac and respiratory arrests were reported, these are not infrequently seen in patients with severe ALS, often resulting from massive aspiration  followed  by  respiratory  and  cardiac  arrest.  There  were  no  unanticipated  causes  of  death reported in the study.

Table 81: Serious AEs Resulting in Death - in Study AB10015 (W0-W48, N=393)

| SYSTEMORGANCLASS                                 | P+R (N=133)   | M3.0 +R (N=131)   | M4.5 + R (N=129)   | P+R (N=133)   | M3.0+R (=131)   | M4.5 + R (=129)   |
|--------------------------------------------------|---------------|-------------------|--------------------|---------------|-----------------|-------------------|
| PREFERREDTERM                                    | All           | All               | All                | Related       | Related         | Related           |
| All deaths                                       | 12 (9.0)      | 11 (8.4)          | 10 (7.8)           | 0             | 0               | 0                 |
| CardiacDisorder's                                | 2 (1.5)       | 4 (3.1)           | 1 (0.8)            | 0             | 0               | 0                 |
| Cardio-Respiratory Arrest                        | 1 (0.8)       | 3 (2.3)           | 1 (0.8)            | 0             | 0               | 0                 |
| Cardiopulmonary Failure                          | 1 (0.8)       | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| GeneralDisordersandAdministrationSite            | 1 (0.8)       | 0                 | 0                  | 0             | 0               | 0                 |
| Conditions Euthanasia                            | 1 (0.8)       | 0                 | 0                  | 0             | 0               | 0                 |
| Infections andInfestations                       | 2 (1.5)       | 0                 | 0                  | 0             | 0               | 0                 |
| Pneumonia                                        | 2 (1.5)       | 0                 | 0                  | 0             | 0               | 0                 |
| Investigations                                   | 0             | 0                 | 1 (0.8)            | 0             | 0               | 0                 |
| Aspiration Bronchial                             | 0             | 0                 | 1 (0.8)            | 0             | 0               | 0                 |
| Neoplasms Benign, Malignant and                  | 1 (0.8)       | 0                 | 0                  | 0             | 0               | 0                 |
| Unspecified Pleural Mesothelioma                 | 1 (0.8)       | 0                 | 0                  | 0             | 0               | 0                 |
| Nervous System Disorders                         | 1 (0.8)       | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| Brain Oedema                                     | 0             | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| Hypercapnic Coma                                 | 1 (0.8)       | 0                 | 0                  | 0             | 0               | 0                 |
| Respiratory, Thoracic and Mediastinal Disorder's | 6 (4.5)       | 8 (6.1)           | 8 (6.2)            | 0             | 0               | 0                 |
| Respiratory Failure                              | 4 (3.0)       | 4 (3.1)           | 5 (3.9)            | 0             | 0               | 0                 |
| Dyspnoea                                         | 0             | 0                 | 2 (1.6)            | 0             | 0               | 0                 |
| Acute RespiratoryFailure                         | 1 (0.8)       | 0                 | 1 (0.8)            | 0             | 0               | 0                 |
| Chronic Respiratory Failure                      | 0             | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| Obstructive Airways Disorder                     | 0             | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| PulmonaryOedema                                  | 0             | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| Respiratory Arrest                               | 0             | 1 (0.8)           | 0                  | 0             | 0               | 0                 |
| Pneumonia Aspiration                             | 1 (0.8)       | 0                 | 0                  | 0             | 0               | 0                 |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

Deaths in non-oncology studies excluding AB10015

24 patients died in the unblinded studies. Of them, 10 patients died in a study of Alzheimer's disease (AB09004), 6 patients in studies of severe asthma (AB04026, AB07015, AB14001), 5 patients in a study

<div style=\"page-break-after: always\"></div>

of  progressive  multiple  sclerosis  (AB07002),  2  patients  in  studies  of  rheumatoid  arthritis  (AB06010; AB06012) and 1 patient in a study of severe mastocytosis (AB06006).

Table 82: Patients with Fatal SAEs - in non-oncology studies excluding AB10015

|                                                                     | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|---------------------------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                                                     | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | All N=1924  | All N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| MedDRA System Organ Class(SOC)                                      | Event       | n(%)        | Event       | n(%)        | Event       | n(%)        | Event           | n(%)            |
| AllMedDRA SOC                                                       | 0           | 0           | 6           | 5(1.1%)     | 16          | 13(0.7%)    | 13              | 11(1.1%)        |
| Infections and Infestations                                         | 0           | 0           | 1           | 1(0.2%)     | 3           | 3(0.2%)     | 1               | 1(0.1%)         |
| General Disorders and Administration Site Conditions                | 0           | 0           | 1           | 1(0.2%)     | 3           | 3(0.2%)     | 4               | 4(0.4%)         |
| Cardiac Disorders                                                   | 0           | 0           | 1           | 1(0.2%)     | 2           | 2(0.1%)     | 4               | 4(0.4%)         |
| Respiratory - Thoracic and Mediastinal Disorders                    | 0           | 0           | 0           | 0           | 0           | 0           | 0               | 0               |
| Vascular Disorders                                                  | 0           | 0           | 0           | 0           | 2           | 2(0.1%)     | 1               | 1(0.1%)         |
| Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) | 0           | 0           | 1           | 1(0.2%)     | 1           | 1(0.1%)     | 2               | 2(0.2%)         |
| Injury, Poisoning and Procedural Complications                      | 0           | 0           | 0           | 0           | 1           | 1(0.1%)     | 1               | 1(0.1%)         |
| NervousSystemDisorders                                              | 0           | 0           | 1           | 1(0.2%)     | 2           | 2(0.1%)     | 0               | 0               |
| Renal and Urinary Disorders                                         | 0           | 0           | 0           | 0           | 0           | 0           | 0               | 0               |
| Respiratory, Thoracic and Mediastinal Disorders                     | 0           | 0           | 1           | 1(0.2%)     | 2           | 2(0.1%)     | 0               | 0               |
| Gastrointestinal Disorders                                          | 0           | 0           | 0           | 0           | 0           | 0           | 0               | 0               |

Source: Table 1: Patients with Fatal SAEs excluding AB10015. Human Safety Report 20222. Dated on 15MAR22

## Deaths in healthy subjects

No deaths in healthy subjects reported.

## Other (Non-fatal) SAEs

## SAEs in Study AB10015

Increase in the frequency of non-fatal SAEs in Masitinib AB Science arms was dose-dependent during the main protocol period. 94 patients experienced SAEs, of those, 24 patients (18.0%) in placebo arm, 30 patients (22.9%) in the Masitinib AB Science 3 mg/kg/day arm, and 40 patients (31.1%) in the Masitinib AB Science 4.5 mg/kg/day arm.

The most common SAEs in Masitinib AB Science arms vs. placebo were respiratory failure, dysphagia, transaminase increase, fall, and dyspnoea. Of those, Respiratory failure, dysphagia, and dyspnoea are associated with ALS disease progression and none of these SAEs were reported as treatment related.

<div style=\"page-break-after: always\"></div>

Table 83: NonFatal Serious AEs (Risk ≥1% in any PT) - in Study AB10015 (W0-W48, N=393)

| SYSTEMORGANCLASS PREFERREDTERVI                | P+R (N=133)   | (N=131)   | M3.0+RM4.5+R (N=129)   | P+R (N=133)   | (N=131)   | M3.0+RM4.5+R (N=129)   |
|------------------------------------------------|---------------|-----------|------------------------|---------------|-----------|------------------------|
|                                                | All           | All       | All                    | Related       | Related   | Related                |
| All                                            | 24 (18.0)     | 30 (22.9) | 40 (31.0)              | 1 (0.8)       | 5 (3.8)   | 9 (7.0)                |
| GastrointestinalDisorder's                     | 10 (7.5)      | 15 (11.5) | 14 (10.9)              | 0 (0.0)       | 2 (1.5)   | 1 (0.8)                |
| Dysphagia                                      | 9 (6.8)       | 14 (10.7) | 11 (8.5)               | 0             | 0         | 0                      |
| Respiratory, Thoracic and Mediastinal          | 4 (3.0)       | 7 (5.3)   | 13 (10.1)              | 0 (0.0)       | 0 (0.0)   | 0 (0.0)                |
| Disorder's                                     |               |           |                        |               |           |                        |
| Respiratory Failure                            | 2 (1.5)       | 5 (3.8)   | 8 (6.2)                | 0             | 0         | 0                      |
| Dyspnoea                                       | 1 (0.8)       | 2 (1.5)   | 3 (2.3)                | 0             | 0         | 0                      |
| InfectionsandInfestations                      | 7 (5.3)       | 3 (2.3)   | 10 (7.8)               | 0 (0.0)       | 0 (0.0)   | 2 (1.6)                |
| Bronchitis                                     | 1 (0.8)       | 1 (0.8)   | 2 (1.6)                | 0 (0.0)       | 0 (0.0)   | 1 (0.8)                |
| Lower Respiratory Tract Infection              | 2 (1.5)       | 2 (1.5)   | 2 (1.6)                | 0             | 0         | 0                      |
| Injury, Poisoning and Procedural Complications | 1 (0.8)       | 1 (0.8)   | 6 (4.7)                | 0 (0.0)       | 0 (0.0)   | 0 (0.0)                |
| Fall                                           | 0             | 1 (0.8)   | 2 (1.6)                | 0             | 0         | 0                      |
| Investigations                                 | 2 (1.5)       | 4 (3.1)   | 5 (3.9)                | 0 (0.0)       | 0 (0.0)   | 3 (2.3)                |
| TransaminasesIncreased                         | 0             | 0         | 2 (1.6)                | 0             | 0         | 2 (1.6)                |
| Blood and Lymphatic System Disorder's          | 0             | 2 (1.5)   | 1 (0.8)                | 0             | 1 (0.8)   | 1 (0.8)                |
| Neutropenia                                    | 0             | 2 (1.5)   | 0                      | 0             | 1 (0.8)   | 0                      |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

## SAEs in non-oncology studies excluding AB10015

Table 84: Patients with NonFatal SAEs (≥0.5% Total Population) - excluding AB10015

|                                                                   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|-------------------------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                                                   | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | All N=1924  | All N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| MedDRA System Organ Class (SOC)                                   | Event       | n(%)        | Event       | n(%)        | Event       | n(%)        | Event           | n(%)            |
| AllMedDRA SOC                                                     | 36          | 32(20.5%)   | 156         | 98(21.3%)   | 736         | 423(22.0%)  | 213             | 134(13.3%)      |
| SkinandSubcutaneousTissue Disorders                               | 6           | 6(3.8%)     | 19          | 17(3.7%)    | 95          | 77(4.0%)    | 3               | 3(0.3%)         |
| Respiratory, Thoracic and Mediastinal Disorders                   | 4           | 4(2.6%)     | 8           | 8(1.7%)     | 92          | 67(3.5%)    | 37              | 26(2.6%)        |
| InfectionsandInfestations                                         | 2           | 2(1.3%)     | 17          | 15(3.3%)    | 89          | 81(4.2%)    | 33              | 23(2.3%)        |
| Gastrointestinal Disorders                                        | 1           | 1(0.6%)     | 17          | 11(2.4%)    | 62          | 47(2.4%)    | 9               | 7(0.7%)         |
| Nervous System Disorders                                          | 1           | 1(0.6%)     | 19          | 16(3.5%)    | 52          | 44(2.3%)    | 29              | 23(2.3%)        |
| Blood and Lymphatic System Disorders                              | 5           | 5(3.2%)     | 12          | 12(2.6%)    | 51          | 47(2.4%)    | 6               | 5(0.5%)         |
| Musculoskeletal and Connective Tissue Disorders                   | 4           | 4(2.6%)     | 1           | 1(0.2%)     | 36          | 25(1.3%)    | 12              | 10(1.0%)        |
| GeneralDisorders andAdministration Site Conditions                | 1           | 1(0.6%)     | 3           | 3(0.7%)     | 32          | 26(1.4%)    | 9               | 7(0.7%)         |
| RenalandUrinaryDisorders                                          | 0           | 0           | 13          | 6(1.3%)     | 29          | 21(1.1%)    | 6               | 6(0.6%)         |
| Investigations                                                    | 3           | 3(1.9%)     | 6           | 6(1.3%)     | 27          | 25(1.3%)    | 2               | 2(0.2%)         |
| NeoplasmsBenign,Malignant and Unspecified (Incl Cysts and Polyps) | 0           | 0           | 10          | 10(2.2%)    | 27          | 25(1.3%)    | 13              | 11(1.1%)        |
| Injury, Poisoning and Procedural Complications                    | 3           | 1(0.6%)     | 8           | 5(1.1%)     | 25          | 16(0.8%)    | 22              | 16(1.6%)        |
| Surgical and Medical Procedures                                   | 1           | 1(0.6%)     | 3           | 2(0.4%)     | 25          | 15(0.8%)    | 3               | 3(0.3%)         |
| Hepatobiliary Disorders                                           | 0           | 0           | 4           | 4(0.9%)     | 18          | 18(0.9%)    | 6               | 5(0.5%)         |
| Cardiac Disorders                                                 | 1           | 1(0.6%)     | 5           | 5(1.1%)     | 17          | 16(0.8%)    | 5               | 4(0.4%)         |
| MetabolismandNutritionDisorders                                   | 2           | 2(1.3%)     | 0           | 0           | 12          | 12(0.6%)    | 2               | 2(0.2%)         |
| Vascular Disorders                                                | 1           | 1(0.6%)     | 3           | 3(0.7%)     | 11          | 9(0.5%)     | 3               | 3(0.3%)         |

<div style=\"page-break-after: always\"></div>

## SAEs in healthy subjects

There was 1 severe treatment-related SAE of uncomplicated neutropenia in 1 subject after repeated doses of 400 mg Masitinib AB Science (corresponding to ~6.0 mg/kg/day) in Study AB03003. The event fully resolved.

## Long-term safety analysis - Deaths

34 patients had fatal SAEs, i.e. 7 placebo patients (8.8%), 13 patients (16.3%) in the Masitinib AB Science 3 mg/kg/day arm, and 14 patients (19.2%) in the Masitinib AB Science 4.5 mg/kg/day arm.

According to the applicant, imbalance in the death rate between the treatment arms may be attributable to:

- Poorer performance status of patients in the active control arm, who decided not to participate in the extension phase of the study due to lack of positive benefit/risk. There was an excess of 5 patients dropping out of the study at the initiation of the extension period in placebo arm as compared with the combined Masitinib AB Science arms. Should these patients have entered the extension  phase,  they  might  had  contributing  to  additional  fatal  SAEs  recorded  during  the extension phase on the active control arm.
- Longer  duration  under  treatment  for  Masitinib  AB  Science  treated  patients  in  the  extension period.  The  median  treatment  time  was  15.4  weeks  with  placebo,  versus  25.3  weeks  with Masitinib AB Science 3 mg/kg/day and 25.0 weeks with Masitinib AB Science 4.5 mg/kg/day.

Table 85: SAEs Resulting in Death - Study AB10015, extension period

| SYSTEM ORGAN CLASS/ PREFERREDTERM               | P+R (N=80)   | M3.0 + R (N=80)   | M4.5+R (N=73)   | P+R (N=80)   | M3.0 + R (N=80)   | M4.5+R (N=73)   |
|-------------------------------------------------|--------------|-------------------|-----------------|--------------|-------------------|-----------------|
| SYSTEM ORGAN CLASS/ PREFERREDTERM               | AIl          | AIl               | AIl             | Related      | Related           | Related         |
| Allnon-fatal SAEs                               | 7 (8.8)      | 13 (16.3)         | 14 (19.2)       | 0            | 0                 | 0               |
| CardiacDisorder's                               | 0            | 2 (2.5)           | 1 (1.4)         | 0            | 0                 | 0               |
| Cardio-Respiratory Arrest                       | 0            | 2 (2.5)           | 1 (1.4)         | 0            | 0                 | 0               |
| Gastrointestinal Disorder's                     | 0            | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Dysphagia                                       | 0            | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Infections and Infestations                     | 2 (2.5)      | 1 (1.3)           | 5 (6.8)         | 0            | 0                 | 0               |
| Pneumonia                                       | 1 (1.3)      | 1 (1.3)           | 3 (4.1)         | 0            | 0                 | 0               |
| Lower Respiratory TractInfection                | 1 (1.3)      | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Respiratory Tract Infection                     | 0            | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Investigations                                  | 0            | 1 (1.3)           | 0               | 0            | 0                 | 0               |
| Aspiration Bronchial                            | 0            | 1 (1.3)           | 0               | 0            | 0                 | 0               |
| NervousSystemDisorder's                         | 1 (1.3)      | 0 (0.0)           | 2 (2.7)         | 0            | 0                 | 0               |
| Amyotrophic Lateral Sclerosis                   | 1 (1.3)      | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Hypercapnic Coma                                | 0            | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Respiratory, Thoracic and Mediastinal Disorders | 6 (7.5)      | 9 (11.3)          | 7 (9.6)         | 0            | 0                 | 0               |
| RespiratoryFailure                              | 3 (3.8)      | 6 (7.5)           | 3 (4.1)         | 0            | 0                 | 0               |
| Respiratory Arrest                              | 0            | 1 (1.3)           | 3 (4.1)         | 0            | 0                 | 0               |
| Acute RespiratoryFailure                        | 0            | 2 (2.5)           | 1 (1.4)         | 0            | 0                 | 0               |
| Dyspnoea                                        | 2 (2.5)      | 0                 | 1 (1.4)         | 0            | 0                 | 0               |
| Pulmonary Embolism                              | 1 (1.3)      | 0                 | 0               | 0            | 0                 | 0               |
| VascularDisorder's                              | 1 (1.3)      | 0                 | 0               | 0            | 0                 | 0               |
| Deep Vein Thrombosis                            | 1 (1.3)      | 0                 | 0               | 0            | 0                 | 0               |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable. Source: Statistical Table 14.3.1.3.2 (CSR-AB10015).

According to the applicant, during the main protocol period, the death rates were comparable amongst treatment groups, with a trend towards lower rates in the Masitinib AB Science groups vs. placebo.

<div style=\"page-break-after: always\"></div>

During the extension period, the trend was reversed with higher rates observed in the Masitinib AB Science groups vs. placebo.

Table 86: Deaths in Study AB10015 - main protocol period vs. extension period

|                                      | Placebo (N=133)   | Masitinib 4.5 mg/kg (N=129)   | Masitinib 3.0 mg/kg (N=131)   | All (N=393)   |
|--------------------------------------|-------------------|-------------------------------|-------------------------------|---------------|
| TreatmentPeriod                      | n (%)             | n (%)                         | n (%)                         | n (%)         |
| TotalDeathsfronFatalSAEs             | 19 (14.3)         | 24 (18.6)                     | 24 (18.3)                     | 67 (17.0)     |
| Main period (48 Weeks)               | 12 (9.0)          | 10 (7.8)                      | 11 (8.4)                      | 33 (8.4)      |
| Extension period (up to Dec 5, 2016) | 7 (5.3)           | 14 (10.9)                     | 13 (9.9)                      | 34 (8.7)      |

Abbreviations: N = number of patients in population

A trend towards higher mortality in the Masitinib AB Science groups vs. placebo during the extension period  was  further  investigated.  Variables  that  could  potentially  impact  mortality  were  reviewed  for patients  who  extended  treatment  beyond  week  48.  Overall,  no  particular  imbalance  at  baseline  or differences during the study could be identified except for a difference in the median treatment duration after the week 48 protocol period.

Patients in the Masitinib AB Science groups remained on study treatment significantly longer than placebo patients. The median on-treatment duration after week 48 in the extension period was up to 66% longer in the Masitinib AB Science arms vs. placebo.

Table 87: Median Treatment Time in Study AB10015 - main protocol period vs. extension period

| TreatnentPeriod                      |   Placebo (IN=133) |   Masitinib 4.5 mg/kg (=129) |   Masitinib 3.0 mg/kg (=131) |
|--------------------------------------|--------------------|------------------------------|------------------------------|
| Main period (up to visit week 48)    |                 48 |                           48 |                           48 |
| Extension period (up to Dec 5, 2016) |                 15 |                           25 |                           25 |

Abbreviations: N = number of patients in population

According to the applicant, the most frequent causes of deaths were related to underlying ALS conditions such as respiratory failure events, cardio-respiratory events, infection events, and aspirations. None of the fatal SAEs were assessed as related to study treatment by the investigators.

An analysis of the elapsed time after last study treatment intake before death was performed. It revealed that the difference in reported deaths amongst treatment groups stemmed mainly from deaths occurring within less than 1 day after last intake. The causes of deaths occurring within 24 hours of last intake displayed the same similarities both in nature and frequency as all other deaths reported in the study. The majority of deaths resulted from typical ALS complications, such as respiratory failures, aspirations, and  respiratory  infections.  According  to  the  available  case  information,  most  unexpected  cardiorespiratory  arrests  occurred  at  home,  often  in  bed  and  without  health  professional  eyewitnesses. However, despite the challenges of reporting accurate death information, sudden and unexpected cardiorespiratory arrests are not uncommonly reported in patients with advanced ALS conditions [Rosenbohm, 2017].

The applicant emphasised that from a methodological point of view, the protocol and the case report forms were not designed to collect unexpected fatal events with sufficient level of detail required to conduct accurate analyses. For instance, the date and time of last treatment intake for patients who died were often solely based on declaration made by family member to the investigator sometimes weeks

<div style=\"page-break-after: always\"></div>

later. These made the collection of accurate data such as last intake, and cause of death challenging for the investigators.

Table 88: Patients who died from fatal SAEs within 24 hours after last intake

| System Organ Class                                  | Placebo (N=133)   | Masitinib 4.5 mg/kg (N=129)   | Masitinib 3.0 mg/kg (N=131)   |
|-----------------------------------------------------|-------------------|-------------------------------|-------------------------------|
| Preferred Term                                      | (%) uI            | n (%)                         | n (%)                         |
| At Least One Fatal Serious Adverse Event (24 hours) | 5 (3.8%)          | 7 (5.4%)                      | 14 (10.7%)                    |
| Respiratory, Thoracic and Mediastinal Disorders     | 3 (2.3%)          | 3 (2.3%)                      | 8 (6.1%)                      |
| RespiratoryFailure                                  | 2 (1.5%)          | 2 (1.6%)                      | 2 (1.5%)                      |
| Respiratory Arrest                                  |                   | 1 (0.8%)                      | 2 (1.5%)                      |
| Acute Respiratory Failure                           |                   |                               | 1 (0.8%)                      |
| Chronic Respiratory Failure                         |                   |                               | 1 (0.8%)                      |
| Dyspnoea                                            | 1 (0.8%)          |                               |                               |
| Aspiration                                          |                   | 1 (0.8%)                      | 1 (0.8%)                      |
| Pulmonary Oedema                                    |                   |                               | 1 (0.8%)                      |
| CardiacDisorder's                                   | 1 (0.8%)          | 2 (1.6%)                      | 6 (4.6%)                      |
| Cardio-Respiratory Arrest                           |                   | 2 (1.6%)                      | 5 (3.8%)                      |
| Cardiac Arrest                                      | 1 (0.8%)          |                               |                               |
| Cardiopulmonary Failure                             |                   |                               | 1 (0.8%)                      |
| NervousSystemDisorder's                             |                   | 1 (0.8%)                      | 1 (0.8%)                      |
| Amyotrophic Lateral Sclerosis                       |                   | 1 (0.8%)                      |                               |
| Brain Oedema                                        |                   |                               | 1 (0.8%)                      |
| InfectionsandInfestations                           | 1 (0.8%)          |                               | 1 (0.8%)                      |
| Pneumonia                                           | 1 (0.8%)          |                               | 1 (0.8%)                      |

Source: AB10015 Mortality Analysis Doc Tae\\_socpt\\_dth24hr; Abbreviations: N = number of patients in population. n = number of patients with a fatal SAE.

## Other Significant Adverse Events

TKI  products  have  been  associated  with  acute  adverse  reactions,  such  as  peripheral  and  superficial oedema, skin toxicity, gastrointestinal reactions such as nausea and diarrhoea, and laboratory related reactions such as leukopenia, anaemia, and liver toxicity.

The carcinogenicity of Masitinib AB Science was identified in 2 preclinical studies in mice (in male mice urinary bladder cell carcinoma and malignant transitional cell carcinoma) and rats (in female rats at the highest dose - an increase in adenocarcinomas, and in incidence of benign tumours in the lung and in the thyroid).

In study AB10015, 2 patients (1.5%) in placebo and none in Masitinib AB Science arms were reported with  malignancies.  Although  no  risk  of  carcinogenicity  was  observed  with  study  drug  in  ALS  study, considering the limited duration of this study, no concluding statement can be made for this risk with Masitinib AB Science.

In regard to all non-oncology studies, 39 patients (1.3% of total safety population) were diagnosed with new or recurrent malignancies. Of those, there were 25 patients on Masitinib AB Science (1.3%) as compared to 14 patients on placebo (1.4%).

<div style=\"page-break-after: always\"></div>

## 2.6.8.4. Laboratory findings

## Haematology Parameters

## Study AB10015, during W0-W48

## Neutrophils Count

The number of patients with low neutrophil counts was higher in the Masitinib AB Science arms. Severe neutropenia was reported for one patient (0.8%) in the active control arm (G3), two patients (1.6%) in masitinib 3 mg/kg/day arm (G4) and one patient (0.8%) in Masitinib AB Science 4.5 mg/kg/day arm (G3). The risk of severe neutropenia with Masitinib AB Science was observed at 0.8%. (Table 89)

## Haemoglobin

Both high and low abnormal haemoglobin values were noted in the study, and they both were higher in the Masitinib AB Science arms (Table 89). A severe increase (G3) of haemoglobin was reported for two patients (1.6%) in Masitinib AB Science 3 mg/kg/day arm and none in placebo and Masitinib AB Science 4.5 mg/kg/day arms. A severe decrease (G3) of haemoglobin was reported for two patients (1.8%) in Masitinib AB Science 3 mg/kg/day arm and none in placebo and Masitinib AB Science 4.5 mg/kg/day arms.

## Leukocytes

Both high and low abnormal leukocytes counts were observed, and they both were higher in the Masitinib AB Science arms (Table 89). No case of severe increased or decreased leukocyte count with Masitinib AB Science was reported.

## Lymphocytes

Both  low  and  high  abnormal  lymphocytes  counts  were  observed,  and  they  both  were  higher  in  the Masitinib AB Science arms (Table 89). No case of severe increased or decreased lymphocytes count was recorded.

## Platelets

Low platelet counts were noted in masitinib arms, all of them were of Grade 1. More details below.

<div style=\"page-break-after: always\"></div>

Table 89: Frequency of Abnormal Blood Cell Counts (Shift from Normal/High to Low or from Normal/Low to High) - in Study AB10015 (W0-W48, N=393)

| Parameter   | Abnormality   | Worst grade during study   | P+R (N=133)   | M3.0+R (=131)   | M4.5 +R (N=129)   |
|-------------|---------------|----------------------------|---------------|-----------------|-------------------|
|             |               | 1n                         | 130           | 126             | 129               |
| Neutrophils |               | Abnormal                   | 7 (5.4%)      | 15 (11.9%)      | 18 (14.0%)        |
| Neutrophils |               | G1                         | 4 (3.1%)      | 6 (4.8%)        | 13 (10.1%)        |
| Neutrophils | Low           | G2                         | 1 (0.8%)      | 7 (5.6%)        | 3 (2.3%)          |
| Neutrophils |               | G3                         | 1 (0.8%)      |                 | 1 (0.8%)          |
| Neutrophils |               | G4                         |               | 2 (1.6%)        |                   |
|             |               | Missing                    | 1 (0.8%)      |                 | 1 (0.8%)          |
|             |               | 1n                         | 121           | 112             | 115               |
|             |               | Abnormal                   | 39 (32.2%)    | 49 (43.8%)      | 66 (57.4%)        |
|             |               | G1                         | 36 (29.8%)    | 45 (40.2%)      | 61 (53.0%)        |
| Hemoglobin  | Low           | G2                         | 2 (1.7%)      | 2 (1.8%)        | 4 (3.5%)          |
|             |               | G3                         |               | 2 (1.8%)        |                   |
|             |               | G4                         |               |                 |                   |
| Leukocytes  |               | Missing                    | 1 (0.8%)      |                 | 1 (0.9%) 128      |
| Leukocytes  |               | 11                         | 129           | 124             |                   |
| Leukocytes  |               | Abnormal                   | 16 (12.4%)    | 22 (17.7%)      | 30 (23.4%)        |
| Leukocytes  |               | G1                         | 14 (10.9%)    | 18 (14.5%)      | 26 (20.3%)        |
| Leukocytes  | Low           | G2                         | 1 (0.8%)      | 4 (3.2%)        | 3 (2.3%)          |
| Leukocytes  |               | G3                         |               |                 |                   |
| Leukocytes  |               | G4                         |               |                 | 1 (0.8%)          |
| Lymphocytes |               | Missing 1n                 | 1 (0.8%) 124  | 120             | 121               |
| Lymphocytes |               | Abnormal                   | 20 (16.1%)    | 39 (32.5%)      | 51 (42.1%)        |
| Lymphocytes |               | G1                         | 11 (8.9%)     | 27 (22.5%)      | 31 (25.6%)        |
| Lymphocytes | Low           | G2                         | 8 (6.5%)      | 12 (10.0%)      | 20 (16.5%)        |
| Lymphocytes |               | G3                         |               |                 |                   |
| Lymphocytes |               | G4                         |               |                 |                   |
|             |               | Missing 11                 | 1 (0.8%) 129  | 130             | 125               |
|             |               | Abnormal                   | 6 (4.7%)      | 10 (7.7%)       | 9 (7.2%)          |
|             |               | G1                         | 5 (3.9%)      | 10 (7.7%)       | 8 (6.4%)          |
| Platelets   | Low           | G2                         |               |                 |                   |
|             |               | G3 G4                      |               |                 |                   |
|             |               | Missing                    | 1 (0.8%)      |                 | 1 (0.8%)          |
| Hemoglobin  |               | N                          | 129           | 126             | 125               |
| Hemoglobin  |               | Abnormal                   | 39 (30.2%)    | 49 (38.9%)      | 66 (52.8%)        |
| Hemoglobin  |               | G1                         | 36 (27.9%)    | 45 (35.7%)      | 61 (48.8%)        |
| Hemoglobin  | High          | G2                         | 2 (1.6%)      | 2 (1.6%)        | 4 (3.2%)          |
| Hemoglobin  |               | G3                         |               | 2 (1.6%)        |                   |
|             |               | G4                         |               |                 |                   |
| Leukocytes  |               | Missing N                  | 1 (0.8%) 132  | 130             | 1 (0.8%) 129      |
| Leukocytes  |               | Abnormal                   | 16 (12.1%)    | 22 (16.9%)      | 30 (23.3%)        |
| Leukocytes  |               | G1                         | 14 (10.6%)    | 18 (13.8%)      | 26 (20.2%)        |
| Leukocytes  | High          | G2                         | 1 (0.8%)      | 4 (3.1%)        | 3 (2.3%)          |
| Leukocytes  |               | G3                         |               |                 |                   |
|             |               | G4                         |               |                 | 1 (0.8%)          |
|             |               | Missing                    | 1 (0.8%)      |                 |                   |
| Lymphocytes |               | N                          | 130           | 129             | 128               |
| Lymphocytes |               | Abnormal                   | 20 (15.4%)    | 40 (31.0%)      | 51 (39.8%)        |
| Lymphocytes | High          | G1                         | 11 (8.5%)     | 28 (21.7%)      | 31 (24.2%)        |
| Lymphocytes |               | G2                         | 8 (6.2%)      | 12 (9.3%)       | 20 (15.6%)        |
| Lymphocytes |               | G3                         |               |                 |                   |
| Lymphocytes |               | G4 Missing                 | 1 (0.8%)      |                 |                   |

<div style=\"page-break-after: always\"></div>

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Number of patients in the arm. n=Number of patients with a normal (i.e., not low if calculating low and not high if calculating high) baseline and at least one postbaseline measure.

## Biochemistry Parameters

## Study AB10015, during W0-W48

No  specific  safety  signal  was  identified  after  review  of  the  laboratory  data.  Most  of  the  laboratory abnormalities were of Grade 1 or 2. The risk of severe high alanine aminotransferase with Masitinib AB Science was observed at 1.1%.  The risk of severe low phosphate with Masitinib AB Science was observed at 2.5%.

<div style=\"page-break-after: always\"></div>

Table 90: Abnormal Biochemistry Values (Shift from Normal/High to Low) - in Study AB10015 (W0-W48, N=393)

| Parameter   | Abnormality Worst grade during study   | P+R (N=133)   | M3.0 +R (N=131)   | M4.5+R (N=129)   |
|-------------|----------------------------------------|---------------|-------------------|------------------|
| Albumin     | 1n                                     | 131           | 125               | 128              |
| Albumin     | Abnormal                               | 7 (5.3%)      | 2 (1.6%)          | 13 (10.2%)       |
| Albumin     | G1                                     | 4 (3.1%)      |                   | 8 (6.3%)         |
| Albumin     | Low G2                                 |               |                   | 1 (0.8%)         |
| Albumin     | G3                                     |               | 1 (0.8%)          | 1 (0.8%)         |
| Albumin     | G4                                     |               |                   |                  |
| Albumin     | Missing                                | 3 (2.3%)      | 1 (0.8%)          | 3 (2.3%)         |
| Glucose     | 11                                     | 128           | 127               | 125              |
| Glucose     | Abnormal                               | 12 (9.4%)     | 9 (7.1%)          | 8 (6.4%)         |
| Glucose     | G1                                     | 5 (3.9%)      | 5 (3.9%)          | 1 (0.8%)         |
| Glucose     | Low G2                                 |               |                   | 1 (0.8%)         |
| Glucose     | G3                                     |               |                   |                  |
| Glucose     | G4                                     |               |                   |                  |
| Glucose     | Missing                                | 7 (5.5%)      | 4 (3.1%)          | 6 (4.8%)         |
| Calcium     | 11                                     | 131           | 128               | 126              |
|             | Abnormal                               | 23 (17.6%)    | 13 (10.2%)        | 17 (13.5%)       |
|             | G1 Low                                 | 16 (12.2%)    | 8 (6.3%)          | 9 (7.1%)         |
|             | G2                                     |               | 1 (0.8%)          | 1 (0.8%)         |
|             | G3                                     |               | 1 (0.8%)          |                  |
|             | G4                                     |               |                   |                  |

| Parameter   | Abnormality   | Worst grade during study   | P+R (N=133)   | M3.0+R (N=131)   | M 4.5 + R (N=129)   |
|-------------|---------------|----------------------------|---------------|------------------|---------------------|
|             | Low           | Missing                    | 7 (5.5%)      | 3 (2.5%)         | 7 (5.8%)            |
|             |               | 1n                         | 127           | 125              | 120                 |
|             |               | Abnormal                   | 13 (10.2%)    | 20 (16.0%)       | 38 (31.7%)          |
|             |               | G1                         | 2 (1.6%)      | 9 (7.2%)         | 8 (6.7%)            |
| Phosphate   |               | G2                         | 4 (3.1%)      | 6 (4.8%)         | 21 (17.5%)          |
|             |               | G3                         |               |                  | 3 (2.5%)            |
|             |               | G4                         |               |                  |                     |
|             |               | Missing                    | 7 (5.5%)      | 5 (4.0%)         | 6 (5.0%)            |
| Potassium   |               | n                          | 131           | 130              | 129                 |
| Potassium   |               | Abnormal                   | 12 (9.2%)     | 4 (3.1%)         | 8 (6.2%)            |
| Potassium   |               | G1                         | 3 (2.3%)      | 1 (0.8%)         | 2 (1.6%)            |
| Potassium   | Low           | G2                         | 1 (0.8%)      |                  |                     |
| Potassium   |               | G3                         | 1 (0.8%)      | 1 (0.8%)         | 1 (0.8%)            |
| Potassium   |               | G4                         |               |                  |                     |
| Potassium   |               | Missing                    | 7 (5.3%)      | 2 (1.5%)         | 5 (3.9%)            |
|             |               | n                          | 130           | 130              | 126                 |
|             |               | Abnormal                   | 16 (12.3%)    | 12 (9.2%)        | 17 (13.5%)          |
|             | Low           | G1                         | 9 (6.9%)      | 7 (5.4%)         | 12 (9.5%)           |
| Sodium      |               | G2 G3                      |               | 1 (0.8%)         |                     |
|             |               | G4                         |               | 1 (0.8%)         |                     |
|             |               | Missing                    | 7 (5.4%)      | 3 (2.4%)         | 5 (4.0%)            |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Number of patients in the arm. n=Number of patients with a normal (i.e., not low if calculating low and not high if calculating high).

<div style=\"page-break-after: always\"></div>

Table 91: Abnormal Biochemistry Values (Shift from Normal/Low to High) - in Study AB10015 (W0W48, N=393)

<!-- image -->

| Parameter                  |      | AbnormalityWorst grade during study   | P+R (N=133)         | M3.0 + R (N=131)    | M4.5 + R (N=129)   |
|----------------------------|------|---------------------------------------|---------------------|---------------------|--------------------|
| Alanine aminotransferase   |      | n Abnormal                            | 92 22 (23.9%)       | 101 37 (36.6%)      | 86 45 (52.3%)      |
|                            |      | G1                                    | 21 (22.8%)          | 32 (31.7%)          | 41 (47.7%)         |
|                            | High | G2                                    |                     | 3 (3.0%)            |                    |
|                            |      | G3                                    |                     | 1 (1.0%)            | 1 (1.2%)           |
|                            |      | G4                                    |                     |                     |                    |
|                            |      | Missing                               | 1 (1.1%)            | 1 (1.0%)            | 3 (3.5%)           |
| Aspartate aminotransferase |      | n                                     | 104                 | 104                 | 103                |
| Aspartate aminotransferase |      | Abnormal                              | 22 (21.2%)          | 34 (32.7%)          | 58 (56.3%)         |
| Aspartate aminotransferase |      | G1                                    | 18 (17.3%)          | 31 (29.8%)          | 55 (53.4%)         |
| Aspartate aminotransferase | High | G2                                    |                     | 2 (1.9%)            |                    |
| Aspartate aminotransferase |      | G3                                    | 2 (1.9%)            |                     | 1 (1.0%)           |
| Aspartate aminotransferase |      | G4                                    |                     |                     |                    |
| Aspartate aminotransferase |      | Missing                               | 2 (1.9%)            | 1 (1.0%)            | 2 (1.9%)           |
| Alkaline phosphatase       |      | n                                     | 130                 | 124                 | 126                |
|                            |      | Abnomal                               | 6 (4.6%)            | 7 (5.6%)            | 15 (11.9%)         |
|                            |      | G1                                    | 4 (3.1%)            | 6 (4.8%)            | 10 (7.9%)          |
|                            | High | G2                                    |                     |                     | 1 (0.8%)           |
|                            |      | G3                                    |                     |                     |                    |
|                            |      | G4                                    |                     |                     |                    |
|                            |      | Missing                               | 2 (1.5%)            | 1 (0.8%)            | 4 (3.2%)           |
| Gamma glutamyl transferase | High | n                                     | 109                 | 98                  | 106                |
| Gamma glutamyl transferase |      | Abnormal                              | 14 (12.8%)          | 10 (10.2%)          | 18 (17.0%)         |
| Gamma glutamyl transferase |      | G1                                    | 10 (9.2%)           | 8 (8.2%)            | 13 (12.3%)         |
| Gamma glutamyl transferase |      | G2                                    | 1 (0.9%)            |                     | 2 (1.9%)           |
| Gamma glutamyl transferase |      | G3                                    |                     |                     |                    |
| Gamma glutamyl transferase |      | G4                                    |                     |                     |                    |
| Gamma glutamyl transferase |      | Missing                               | 3 (2.8%)            | 2 (2.0%)            | 3 (2.8%)           |
| Bilinmbin                  | High | n                                     | 114                 | 119                 | 115                |
| Bilinmbin                  |      | Abnormal                              | 20 (17.5%)          | 29 (24.4%)          | 40 (34.8%)         |
| Bilinmbin                  |      | G1                                    | 13 (11.4%) 4 (3.5%) | 20 (16.8%) 8 (6.7%) | 32 (27.8%)         |
| Bilinmbin                  |      | G2                                    |                     |                     | 4 (3.5%) 1 (0.9%)  |
| Bilinmbin                  |      | G3 G4                                 |                     |                     |                    |
| Bilinmbin                  |      | Missing                               | 3 (2.6%)            | 1 (0.8%)            | 3 (2.6%)           |
| Creatinine                 |      | n                                     | 128                 | 127                 | 129                |
| Creatinine                 |      | Abnoimal                              | 2 (1.6%)            | 2 (1.6%)            | 9 (7.0%)           |
| Creatinine                 |      | G1                                    | 1 (0.8%)            | 1 (0.8%)            | 6 (4.7%)           |
| Creatinine                 | High | G2                                    |                     |                     |                    |
| Creatinine                 |      | G3                                    |                     |                     |                    |
| Creatinine                 |      | G4                                    |                     |                     |                    |
|                            |      | Missing                               | 1 (0.8%)            | 1 (0.8%)            | 3 (2.3%)           |
| Cholesterol                |      | n                                     | 45                  | 65                  | 46                 |
|                            |      | Abnomal                               | 20 (44.4%)          | 14 (21.5%)          | 7 (15.2%)          |
|                            |      | G1                                    | 18 (40.0%)          | 12 (18.5%)          | 6 (13.0%)          |
|                            | High | G2                                    | 1 (2.2%)            |                     |                    |
|                            |      | G3 G4                                 |                     |                     |                    |
|                            |      | Missing                               |                     |                     |                    |
|                            |      |                                       | 1 (2.2%) 06         | 2 (3.1%) 87         | 1 (2.2%) 88        |
|                            |      | n Abnomal                             | 33 (36.7%)          | 17 (19.5%)          | 24 (27.3%)         |
| Triglycerides              | High | G1                                    | 24 (26.7%)          | 12 (13.8%)          | 18 (20.5%)         |
| Triglycerides              |      | G2 G3                                 | 2 (2.2%)            | 1 (1.1%)            | 1 (1.1%)           |
| Triglycerides              |      | G4                                    |                     |                     |                    |
| Triglycerides              |      | Missing                               | 7 (7.8%)            | 4 (4.6%)            | 5 (5.7%)           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | 113                 | 107                | 113                  |
|-------------|---------------------|--------------------|----------------------|
| Abnormal    | 40 (35.4%)          | 32 (29.9%)         | 48 (42.5%)           |
| G1          | 32 (28.3%)          | 27 (25.2%)         | 39 (34.5%)           |
| G2          | 1 (0.9%)            | 1 (1.0%)           | 3 (2.7%)             |
| G3          |                     |                    |                      |
| G4          |                     |                    |                      |
| Missing     | 7 (6.2%)            | 4 (3.7%)           | 6 (5.3%)             |
| n           | 120                 | 115                | 117                  |
| Abnomal     | 23 (19.2%)          | 13 (11.3%)         | 17 (14.5%)           |
| G1          | 16 (13.3%)          | 8 (7.0%)           | 9 (7.7%)             |
| G2          |                     | 1 (0.9%)           | 1 (0.9%)             |
| G3          |                     | 1 (0.9%)           |                      |
| G4          |                     |                    |                      |
| Missing     | 7 (5.8%)            | 3 (2.6%)           | 7 (6.0%) 129         |
| n           | 128                 | 127                |                      |
| Abnomal     | 11 (8.6%)           | 3 (2.4%)           | 8 (6.2%)             |
| G1          | 3 (2.3%)            | 1 (0.8%)           | 2 (1.6%)             |
| G2          | 1 (0.8%)            |                    |                      |
| G3          | 1 (0.8%)            |                    | 1 (0.8%)             |
| G4          |                     |                    |                      |
| Missing     | 6 (4.7%)            | 2 (1.6%)           | 5 (3.9%)             |
| n           | 133                 | 126                | 129                  |
| Abnormal G1 | 16 (12.0%) 9 (6.8%) | 12 (9.5%) 7 (5.6%) | 17 (13.2%) 12 (9.3%) |
| G2          |                     |                    |                      |
| G3          |                     | 1 (0.8%)           |                      |
| G4          |                     | 1 (0.8%)           |                      |
| Missing     | 7 (5.3%)            | 3 (2.4%)           | 5 (3.9%)             |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Number of patients in the arm. n=Number of patients with a normal (i.e., not low if calculating low and not high if calculating high).

## Study AB10015, during extension period

## Neutrophils Count

A low neutrophil count was reported for one patient in placebo arm, two patients in Masitinib AB Science 3 mg/kg/day arm and none in Masitinib AB Science 4.5 mg/kg/day arm. All the cases were of Grade 1 or 2.

## Haemoglobin

An increased haemoglobin (Grade 1) was observed for one patient in Masitinib AB Science 3 mg/kg/day arm, and none in placebo and Masitinib AB Science 4.5 mg/kg/day arm.

Number of patients with decreased haemoglobin was higher in the Masitinib AB Science arms during the protocol  extension  period:  19.0%  of  the  patients  in  placebo  arm,  35.8%  in  Masitinib  AB  Science  3 mg/kg/day arm and 28.1% in Masitinib AB Science 4.5 mg/kg/day arm. A severe decrease (G3) of haemoglobin was reported for one patient in Masitinib AB Science 3 mg/kg/day arm and none in other two arms. The risk of severe decrease of haemoglobin with Masitinib AB Science was observed at 0.9% during the protocol extension period of the study.

## Leukocytes

Decreased leukocytes count was higher in placebo arm: 7.4% in placebo arm, 1.6% in Masitinib AB Science 3 mg/kg/day arm and 3.1% in Masitinib AB Science 4.5 mg/kg/day arm. No case of severe decreased leukocyte count was reported.

<div style=\"page-break-after: always\"></div>

## Lymphocytes

Decreased lymphocytes count was higher in the Masitinib AB Science arms: 7.9% in placebo arm, 21.4% in Masitinib AB Science 3 mg/kg/day arm and 36.1% in Masitinib AB Science 4.5 mg/kg/day arm. No case of severe decreased lymphocytes count was reported.

## Platelets

Low platelet counts were reported in 2 patients (3.0%) in placebo arm, 2 patients (3.2%) in the Masitinib AB Science 3 mg/kg/day arm and one patient (1.6%) in the Masitinib AB Science 4.5 mg/kg/day arm during the protocol extension. All of them were of Grade 1.

Table 92: Frequency of Abnormal Biochemistry (Hepatobiliary Enzymes) Values (Shift from Normal/High to Low and from Normal/Low to High) - (Extended Period)

<!-- image -->

| Parameter                                                                                                                                                                 |                                                                                                                                                                           | Abnorimality Worst grade during study                                                                                                                                     | P+R                                                                                                                                                                       | M3.0 + R                                                                                                                                                                  | M4.5 +R                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                           |                                                                                                                                                                           | N                                                                                                                                                                         | 46                                                                                                                                                                        | 44                                                                                                                                                                        | 40                                                                                                                                                                        |
| Alanine                                                                                                                                                                   |                                                                                                                                                                           | Abnormal                                                                                                                                                                  | 8 (17.4%)                                                                                                                                                                 | 11 (25.0%)                                                                                                                                                                | 8 (20.0%)                                                                                                                                                                 |
| Alanine                                                                                                                                                                   |                                                                                                                                                                           | G1                                                                                                                                                                        | 8 (17.4%)                                                                                                                                                                 | 11 (25.0%)                                                                                                                                                                | 8 (20.0%)                                                                                                                                                                 |
| Alanine                                                                                                                                                                   |                                                                                                                                                                           | G2                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| aminotransferase                                                                                                                                                          | High                                                                                                                                                                      | G3                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Alanine                                                                                                                                                                   |                                                                                                                                                                           | G4                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Alanine                                                                                                                                                                   |                                                                                                                                                                           | Missing                                                                                                                                                                   |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Aspartate aminotransferase                                                                                                                                                | High                                                                                                                                                                      | N                                                                                                                                                                         | 51                                                                                                                                                                        | 46                                                                                                                                                                        | 54                                                                                                                                                                        |
| Aspartate aminotransferase                                                                                                                                                |                                                                                                                                                                           | Abnomal                                                                                                                                                                   | 5 (9.8%)                                                                                                                                                                  | 10 (21.7%)                                                                                                                                                                | 16 (29.6%)                                                                                                                                                                |
| Aspartate aminotransferase                                                                                                                                                |                                                                                                                                                                           | G1                                                                                                                                                                        | 5 (9.8%)                                                                                                                                                                  | 10 (21.7%)                                                                                                                                                                | 16 (29.6%)                                                                                                                                                                |
| Aspartate aminotransferase                                                                                                                                                |                                                                                                                                                                           | G2                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Aspartate aminotransferase                                                                                                                                                |                                                                                                                                                                           | G3                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Aspartate aminotransferase                                                                                                                                                |                                                                                                                                                                           | G4                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Aspartate aminotransferase                                                                                                                                                |                                                                                                                                                                           | Missing                                                                                                                                                                   |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
|                                                                                                                                                                           |                                                                                                                                                                           | N                                                                                                                                                                         | 61                                                                                                                                                                        | 59                                                                                                                                                                        | 62                                                                                                                                                                        |
| Alkaline phosphatase                                                                                                                                                      |                                                                                                                                                                           | Abnormal                                                                                                                                                                  | 2 (3.3%)                                                                                                                                                                  | 1 (1.7%)                                                                                                                                                                  |                                                                                                                                                                           |
| Alkaline phosphatase                                                                                                                                                      |                                                                                                                                                                           | G1                                                                                                                                                                        | 2 (3.3%)                                                                                                                                                                  | 1 (1.7%)                                                                                                                                                                  |                                                                                                                                                                           |
| Alkaline phosphatase                                                                                                                                                      |                                                                                                                                                                           | G2                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Alkaline phosphatase                                                                                                                                                      | High                                                                                                                                                                      | G3                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Alkaline phosphatase                                                                                                                                                      |                                                                                                                                                                           | G4                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Alkaline phosphatase                                                                                                                                                      |                                                                                                                                                                           | Missing                                                                                                                                                                   |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Gamma glutamyl transferase                                                                                                                                                | High                                                                                                                                                                      | N                                                                                                                                                                         | 54                                                                                                                                                                        | 44                                                                                                                                                                        | 56                                                                                                                                                                        |
| Gamma glutamyl transferase                                                                                                                                                |                                                                                                                                                                           | Abnormal                                                                                                                                                                  | 6 (11.1%)                                                                                                                                                                 | 6 (13.6%)                                                                                                                                                                 | 2 (3.6%)                                                                                                                                                                  |
| Gamma glutamyl transferase                                                                                                                                                |                                                                                                                                                                           | G1                                                                                                                                                                        | 6 (11.1%)                                                                                                                                                                 | 6 (13.6%)                                                                                                                                                                 | 1 (1.8%)                                                                                                                                                                  |
| Gamma glutamyl transferase                                                                                                                                                |                                                                                                                                                                           | G2                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           | 1 (1.8%)                                                                                                                                                                  |
| Gamma glutamyl transferase                                                                                                                                                |                                                                                                                                                                           | G3                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Gamma glutamyl transferase                                                                                                                                                |                                                                                                                                                                           | G4                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Gamma glutamyl transferase                                                                                                                                                |                                                                                                                                                                           | Missing                                                                                                                                                                   |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Albumin                                                                                                                                                                   | Low                                                                                                                                                                       | N                                                                                                                                                                         | 66                                                                                                                                                                        | 58                                                                                                                                                                        | 62                                                                                                                                                                        |
| Albumin                                                                                                                                                                   |                                                                                                                                                                           | Abnormal                                                                                                                                                                  | 1 (1.5%)                                                                                                                                                                  | 0                                                                                                                                                                         | 0                                                                                                                                                                         |
| Albumin                                                                                                                                                                   |                                                                                                                                                                           | G1                                                                                                                                                                        | 1 (1.5%)                                                                                                                                                                  |                                                                                                                                                                           |                                                                                                                                                                           |
| Albumin                                                                                                                                                                   |                                                                                                                                                                           | G2                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Albumin                                                                                                                                                                   |                                                                                                                                                                           | G3                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Albumin                                                                                                                                                                   |                                                                                                                                                                           | G4                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Albumin                                                                                                                                                                   |                                                                                                                                                                           | Missing                                                                                                                                                                   |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| Bilinubin                                                                                                                                                                 |                                                                                                                                                                           | N                                                                                                                                                                         | 60                                                                                                                                                                        | 57                                                                                                                                                                        | 56                                                                                                                                                                        |
| Parameter                                                                                                                                                                 | Abnormality                                                                                                                                                               | Worstgrade duringstudy                                                                                                                                                    | P+R                                                                                                                                                                       | M3.0 + R                                                                                                                                                                  | M4.5 +R                                                                                                                                                                   |
|                                                                                                                                                                           |                                                                                                                                                                           | Abnomal                                                                                                                                                                   | 4 (6.7%)                                                                                                                                                                  | 8 (14.0%)                                                                                                                                                                 | 12 (21.4%)                                                                                                                                                                |
|                                                                                                                                                                           |                                                                                                                                                                           | G1                                                                                                                                                                        | 3 (5.0%)                                                                                                                                                                  | 7 (12.3%)                                                                                                                                                                 | 11 (19.6%)                                                                                                                                                                |
|                                                                                                                                                                           |                                                                                                                                                                           | G2                                                                                                                                                                        | 1 (1.7%)                                                                                                                                                                  | 1 (1.8%)                                                                                                                                                                  | 1 (1.8%)                                                                                                                                                                  |
|                                                                                                                                                                           | High                                                                                                                                                                      | G3                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
|                                                                                                                                                                           |                                                                                                                                                                           | G4                                                                                                                                                                        |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
|                                                                                                                                                                           |                                                                                                                                                                           | Missing                                                                                                                                                                   |                                                                                                                                                                           |                                                                                                                                                                           |                                                                                                                                                                           |
| P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Source: Statistical Table 14.3.4.48 | P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Source: Statistical Table 14.3.4.48 | P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Source: Statistical Table 14.3.4.48 | P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Source: Statistical Table 14.3.4.48 | P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Source: Statistical Table 14.3.4.48 | P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Source: Statistical Table 14.3.4.48 |

<div style=\"page-break-after: always\"></div>

Table 93: Frequency of Abnormal Biochemistry (Renal Enzyme) Values (Shift from Normal/High to Low and from Normal/Low to High) - (Extended Period)

|            |      | Worstgradeduringstudy   | P +R     | M3.0+R   | M4.5+R   |
|------------|------|-------------------------|----------|----------|----------|
| Creatinine | High | N                       | 66       | 62       | 64       |
| Creatinine | High | Abnormal                | 1 (1.5%) | 0        | 1 (1.6%) |
| Creatinine | High | G1                      | 1 (1.5%) |          | 1 (1.6%) |
| Creatinine | High | G2                      |          |          |          |
| Creatinine | High | G3                      |          |          |          |
| Creatinine | High | G4                      |          |          |          |
| Creatinine | High | Missing                 |          |          |          |

<!-- image -->

Table 94: Frequency of Abnormal Biochemistry (Lipoproteins) Values (Shift from Normal/High to Low and from Normal/Low to High) - (Extended Period)

<!-- image -->

| Parameter                                                                                                                                                              | Abnormality                                                                                                                                                            | Worstgradeduringstudy                                                                                                                                                  | P+R                                                                                                                                                                    | M 3.0 + R                                                                                                                                                              | M 4.5 +R                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cholesterol                                                                                                                                                            |                                                                                                                                                                        | N                                                                                                                                                                      | 21                                                                                                                                                                     | 30                                                                                                                                                                     | 26                                                                                                                                                                     |
| Cholesterol                                                                                                                                                            |                                                                                                                                                                        | Abnormal                                                                                                                                                               | 6 (28.6%)                                                                                                                                                              | 4 (13.3%)                                                                                                                                                              | 1 (3.8%)                                                                                                                                                               |
| Cholesterol                                                                                                                                                            |                                                                                                                                                                        | G1                                                                                                                                                                     | 6 (28.6%)                                                                                                                                                              | 4 (13.3%)                                                                                                                                                              | 1 (3.8%)                                                                                                                                                               |
| Cholesterol                                                                                                                                                            | High                                                                                                                                                                   | G2                                                                                                                                                                     |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cholesterol                                                                                                                                                            |                                                                                                                                                                        | G3                                                                                                                                                                     |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cholesterol                                                                                                                                                            |                                                                                                                                                                        | Missing                                                                                                                                                                |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Tniglycenides                                                                                                                                                          |                                                                                                                                                                        | N                                                                                                                                                                      | 44                                                                                                                                                                     | 41                                                                                                                                                                     | 42                                                                                                                                                                     |
| Tniglycenides                                                                                                                                                          |                                                                                                                                                                        | Abnormal                                                                                                                                                               | 13 (29.5%)                                                                                                                                                             | 10 (24.4%)                                                                                                                                                             | 10 (23.8%)                                                                                                                                                             |
| Tniglycenides                                                                                                                                                          |                                                                                                                                                                        | G1                                                                                                                                                                     | 12 (27.3%)                                                                                                                                                             | 10 (24.4%)                                                                                                                                                             | 10 (23.8%)                                                                                                                                                             |
| Tniglycenides                                                                                                                                                          | High                                                                                                                                                                   | G2                                                                                                                                                                     | 1 (2.3%)                                                                                                                                                               |                                                                                                                                                                        |                                                                                                                                                                        |
| Tniglycenides                                                                                                                                                          |                                                                                                                                                                        | G3                                                                                                                                                                     |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Tniglycenides                                                                                                                                                          |                                                                                                                                                                        | Missing                                                                                                                                                                |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| P=placebo: R =riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Souuce: Statistical Table 14.3.4.48 | P=placebo: R =riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Souuce: Statistical Table 14.3.4.48 | P=placebo: R =riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Souuce: Statistical Table 14.3.4.48 | P=placebo: R =riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Souuce: Statistical Table 14.3.4.48 | P=placebo: R =riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Souuce: Statistical Table 14.3.4.48 | P=placebo: R =riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. N=Patients with available data at baseline Souuce: Statistical Table 14.3.4.48 |

The percentage of patients with high AST values during the protocol extension period was observed to be higher in the Masitinib AB Science arms; 9.8% in the active control arm, 22.2% in Masitinib AB Science 3 mg/kg/day arm and 29.6% in Masitinib AB Science 4.5 mg/kg/day arm. Only Grade 1 of high AST values were reported during the extension period. No risk of severe high AST with Masitinib AB Science was observed.

The percentage of patients with high bilirubin  values  during  the  extension  period  was  higher  in  the Masitinib AB Science arms; 6.7% in the active control arm, 14.0% in Masitinib AB Science 3 mg/kg/day arm and 21.4% in Masitinib AB Science 4.5 mg/kg/day arm. The majority of patients (%) experienced Grade 1 or 2 of high bilirubin values. No risk of severe high bilirubin with Masitinib AB Science was observed.

Other abnormal biochemistry values were in general similar in placebo and masitinib groups.

No important safety information was observed. Much less abnormal blood cell counts/biochemistry were reported during the extension period comparing with the main period (26 vs. 168 AEs). During the extension period, no action was taken with the study drug for them. No case of positive dechallenge or dechallenge  was  reported.  During  both  main  and  extension  period,  most  of  abnormal  blood  cell counts/biochemistry resolved without drug interruption/discontinuation and were in generally mild to moderate and transient.

<div style=\"page-break-after: always\"></div>

## 2.6.8.5. In vitro biomarker test for patient selection for safety

Not applicable.

## 2.6.8.6. Safety in special populations

## Elderly population

There were 73 elderly patients (18.6%) aged &gt;65 years and 320 non-elderly patients (81.4%) in the age group 18 to 65 years in ALS study. The safety profile of Masitinib AB Science seems to be better in the non-elderly patients as compared to the elderly patients at a dose of 3.0 mg/kg/day, and comparable at a dose of 4.5 mg/kg/day.

Table 95: Safety profile of masitinib in patients aged 18 to 65 year and &gt;65 years - in Study AB10015 (W0-W48, N=393)

|                                       | 18 to 65 years (N=320)   | 18 to 65 years (N=320)   | 18 to 65 years (N=320)   | >65 years (N=73)   | >65 years (N=73)   | >65 years (N=73)   |
|---------------------------------------|--------------------------|--------------------------|--------------------------|--------------------|--------------------|--------------------|
| Nunber (%) of patients withatleastone | P+R                      | M3.0+R                   | M4.5+R                   | P+R                | M3.0+R             | M4.5 + R           |
|                                       | (N=110)                  | (N=105)                  | (N=105)                  | (N=23)             | (N=26)             | (N=24)             |
| AE                                    | 86 (78.2%)               | 89 (84.8%)               | 92 (87.6%)               | 18 (78.3%)         | 22 (84.6%)         | 22 (91.7%)         |
| Death                                 | 8 (7.3%)                 | 9 (8.6%)                 | 8 (7.6%)                 | 4 (17.4%)          | 2 (7.7%)           | 2 (8.3%)           |
| Non-fatal SAE                         | 21 (19.1%)               | 21 (20.0%)               | 33 (31.4%)               | 3 (13.0%)          | 9 (34.6%)          | 7 (29.2%)          |
| Severe AE                             | 20 (18.2%)               | 20 (19.0%)               | 30 (28.6%)               | 6 (26.1%)          | 8 (30.8%)          | 9 (37.5%)          |
| Discontinuation (excluding deaths)    | 9 (8.2%)                 | 13 (12.4%)               | 14 (13.3%)               | 2 (8.7%)           | 7 (26.9%)          | 7 (29.2%)          |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day.

Table  96:  Summary of TEAEs by dose and Patients aged 18-65 year and above 65 years - in nononcology studies excluding AB10015

|                                                   | 18-65 year's         | 18-65 year's         | 18-65 year's   | 18-65 year's                    | 65 years   | 65 years             | 65 years    | 65 years    |
|---------------------------------------------------|----------------------|----------------------|----------------|---------------------------------|------------|----------------------|-------------|-------------|
|                                                   | M3.0                 | M4.5                 | M-AIl          | Placebo*                        | M3.0       | M4.5                 | M-AIl       | Placebo*    |
| No. of Subjects with at least one                 | (N= 93)              | (N= 298)             | (N=1398)       | (N= 707)                        | (N= 63)    | (N=163)              | (N=526)     | (N= 297)    |
| All AEs                                           | 80 (86.0%)           | 273 (91.6%)          | 1242 (88.8%)   | 584 (82.6%)56 (88.9%)           |            | 148 (90.8%)          | 460 (87.5%) | 250 (84.2%) |
| SAE (non-fatal) (all)                             |                      | 19 (20.4%)68 (22.8%) | 320 (22.9%)    | 101 (14.3%)13 (20.6%)30 (18.4%) |            |                      | 103 (19.6%) | 33 (11.1%)  |
| Death (all)                                       | 0                    | 0                    | 6 (0.4%)       | 5 (0.7%)                        | 0          | 5 (3.1%)             | 7 (1.3%)    | 6 (2.0%)    |
| Leading to permanent discontinuation (excl Death) | 30 (32.3%)72 (24.2%) |                      | 315 (22.5%)    | 43 (6.1%)                       |            | 19 (30.2%)38 (23.3%) | 152 (28.9%) | 23 (7.7%)   |
| Leading to dose reduction                         | 0                    | 13 (4.4%)            | 105 (7.5%)     | 9 (1.3%)                        | 1 (1.6%)   | 12 (7.4%)            | 38 (7.2%)   | 11 (3.7%)   |
| Severe(Grade3and above)                           | 20 (21.5%)91 (30.5%) |                      | 562 (40.2%)    | 211 (29.8%)17 (27.0%)54 (33.1%) |            |                      | 170 (32.3%) | 77 (25.9%)  |

There was no safety analysis performed in detailed elderly groups (refer to the table below)

<div style=\"page-break-after: always\"></div>

Table 97: Occurrence of Treatment-Emergent Adverse Events - Number and Percent of Subjects by age group Classic frequency: Number (%) of patients (Main Period) Safety Population

| MedDRA PTs                                                                                     | Age<65 (N=310) Age 65-74 (N=80) Age 75-84 (N=3) Age 85+ (N=0)   | Age<65 (N=310) Age 65-74 (N=80) Age 75-84 (N=3) Age 85+ (N=0)   | Age<65 (N=310) Age 65-74 (N=80) Age 75-84 (N=3) Age 85+ (N=0)   | Age<65 (N=310) Age 65-74 (N=80) Age 75-84 (N=3) Age 85+ (N=0)   |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Total AEs                                                                                      | 258 (83.2)                                                      | 68 (85.0)                                                       | 3 (100.0)                                                       | 0                                                               |
| Serious AEs - Total                                                                            | 90 (29.0)                                                       | 27 (33.8)                                                       | 1 (33.3)                                                        | 0                                                               |
| -Fatal                                                                                         | 24 (7.7)                                                        | 9 (11.3)                                                        | 0                                                               | 0                                                               |
| Hospitalization/prolong existing hospitalization                                               | 58 (18.7)                                                       | 15 (18.8)                                                       | 1 (33.3)                                                        | 0                                                               |
| -Life-threatening                                                                              | 4 (1.3)                                                         | 1 (1.3)                                                         | 0                                                               | 0                                                               |
| - Disability/incapacity                                                                        | 2 (0.6)                                                         | 1 (1.3)                                                         | 0                                                               | 0                                                               |
| -Other (medically significant)                                                                 | 14 (4.5)                                                        | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| AE leading to drop-out(excl. death)                                                            | 35 (11.3)                                                       | 17 (21.3)                                                       | 0                                                               | 0                                                               |
| Psychiatric disorders                                                                          | 47 (15.2)                                                       | 15 (18.8)                                                       | 0                                                               | 0                                                               |
| Nervous system disorders                                                                       | 43 (13.9)                                                       | 11 (13.8)                                                       | 1 (33.3)                                                        | 0                                                               |
| Accidents and injuries                                                                         | 41 (13.2)                                                       | 7 (8.8)                                                         | 1 (33.3)                                                        |                                                                 |
| Cardiac disorders                                                                              | 11 (3.5)                                                        | 7 (8.8)                                                         | 0                                                               | 0                                                               |
| Vascular disorders                                                                             | 19 (6.1)                                                        | 4 (5.0)                                                         | 0                                                               | 0                                                               |
| Cerebrovascular disorders                                                                      | 3 (1.0)                                                         | 2 (2.5)                                                         | 0                                                               |                                                                 |
| Infections and infestations                                                                    | 83 (26.8)                                                       | 23 (28.8)                                                       | 0                                                               | 0                                                               |
| Anticholinergic syndrome                                                                       | 49 (15.8)                                                       | 13 (16.3)                                                       | 0                                                               | 0                                                               |
| Quality of life decreased                                                                      | 0                                                               | 0                                                               | 0                                                               | 0                                                               |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures 30 (9.7) |                                                                 | 6 (7.5)                                                         | 0                                                               | 0                                                               |
| <other AE appearing more frequently in older patients>                                         |                                                                 |                                                                 |                                                                 |                                                                 |
| Abdominal Discomfort                                                                           | 1 (0.3)                                                         | 0                                                               | 1 (33.3)                                                        | 0                                                               |
| Abdominal Pain                                                                                 | 1 (0.3)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Abdominal Pain Upper                                                                           | 13 (4.2)                                                        | 3 (3.8)                                                         | 0                                                               | 0                                                               |
| Anaemia                                                                                        | 4 (1.3)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Anxiety                                                                                        | 12 (3.9)                                                        | 1 (1.3)                                                         | 0                                                               | 0                                                               |
| Aspartate Aminotransferase Increased                                                           | 5 (1.6)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Back Pain                                                                                      | 6 (1.9)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Blood Phosphorus Decreased                                                                     | 2 (0.6)                                                         | 3 (3.8)                                                         | 0                                                               | 0                                                               |
| Blood Urea Increased                                                                           | 1 (0.3)                                                         | 1 (1.3)                                                         | 1 (33.3)                                                        | 0                                                               |
| Bronchitis                                                                                     | 11 (3.5)                                                        | 4 (5.0)                                                         | 0                                                               | 0                                                               |
| Cardio-Respiratory Arrest                                                                      | 2 (0.6)                                                         | 4 (5.0)                                                         | 0                                                               | 0                                                               |
| MedDRA PTs                                                                                     | Age <65 (N=310) Age 65-74 (N=80)Age 75-84 (N=3) Age 85+ (N=0)   |                                                                 |                                                                 |                                                                 |
| Constipation                                                                                   | 7 (2.3)                                                         | 3 (3.8)                                                         | 0                                                               | 0                                                               |
| Cough                                                                                          | 8 (2.6)                                                         | 1 (1.3)                                                         | 0                                                               | 0                                                               |
| Cystitis Bacterial                                                                             | 7 (2.3)                                                         | 6 (7.5)                                                         | 0                                                               | 0                                                               |
| Decreased Appetite                                                                             | 4 (1.3)                                                         | 4 (5.0)                                                         | 0                                                               | 0                                                               |
| Depression                                                                                     | 22 (7.1)                                                        | 10 (12.5)                                                       | 0                                                               | 0                                                               |
| Diarrhoea                                                                                      | 21 (6.8)                                                        | 4 (5.0)                                                         | 1 (33.3)                                                        | 0                                                               |
| Dysarthria                                                                                     | 2 (0.6)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Dyspepsia                                                                                      | 12 (3.9)                                                        | 3 (3.8)                                                         | 0                                                               | 0                                                               |
| Dysphagia                                                                                      | 38 (12.3)                                                       | 11 (13.8)                                                       | 0                                                               | 0                                                               |
| Dyspnoea                                                                                       | (2.3)                                                           | 4 (5.0)                                                         | 1 (33.3)                                                        | 0                                                               |
| Dyspnoea Exertional                                                                            | 1 (0.3)                                                         | 0                                                               | 1 (33.3)                                                        | 0                                                               |
| Eosinophil Count Decreased                                                                     | 0                                                               | 0                                                               | 1 (33.3)                                                        | 0                                                               |
| Eosinophil Count Increased                                                                     | 6 (1.9)                                                         | 1 (1.3)                                                         | 1 (33.3)                                                        | 0                                                               |
| Erythema                                                                                       | 11 (3.5)                                                        | 3 (3.8)                                                         | 0                                                               | 0                                                               |
| Fall                                                                                           | 26 (8.4)                                                        | 5 (6.3)                                                         | 0                                                               | 0                                                               |
| Fatigue                                                                                        | 4 (1.3)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Foot Fracture                                                                                  | 0                                                               | 0                                                               | 1 (33.3)                                                        | 0                                                               |
| Gastrooesophageal Reflux Disease                                                               | 5 (1.6)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Haematocrit Decreased                                                                          | 2 (0.6)                                                         | 3 (3.8)                                                         | 0                                                               | 0                                                               |
| Haematuria                                                                                     | 0                                                               | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Haemoglobin Decreased                                                                          | 5 (1.6)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
|                                                                                                |                                                                 |                                                                 | 0                                                               |                                                                 |
| Headache                                                                                       | 18 (5.8)                                                        | 5 (6.3)                                                         |                                                                 | 0                                                               |
| Hypertension                                                                                   | 13 (4.2)                                                        | 4 (5.0)                                                         | 0                                                               | 0                                                               |
| Hypokalaemia                                                                                   | 0                                                               | 2 (2.5) 2 (2.5)                                                 | 0 0                                                             | 0 0                                                             |
| Influenza Insomnia                                                                             | 8 (2.6) 14 (4.5)                                                | 6 (7.5)                                                         | 0                                                               | 0                                                               |
| Iron Deficiency Anaemia                                                                        | 10 (3.2)                                                        | 1 (1.3)                                                         | 2 (66.7)                                                        | 0 0                                                             |
| Lymphocyte Count Decreased                                                                     | 4 (1.3)                                                         | 1 (1.3)                                                         | (33.3)                                                          |                                                                 |
| Lymphopenia                                                                                    | 1 (0.3)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |
| Muscle Spasms                                                                                  | 5 (1.6)                                                         | 2 (2.5)                                                         | 0                                                               | 0                                                               |

<div style=\"page-break-after: always\"></div>

| MedDRA PTs                              | Age <65 (N=310) Age 65-74 (N=80)Age 75-84 (N=3)Age 85+ (N=0)   |         |          |    |
|-----------------------------------------|----------------------------------------------------------------|---------|----------|----|
| Muscular Weakness                       | 7 (2.3)                                                        | (1.3)   | 0        |  0 |
| Nausea                                  | 27 (8.7)                                                       | (5.0)   | 0        |  0 |
| Neutropenia                             | 2 (0.6)                                                        | 2 (2.5) | 0        |  0 |
| Oedema Peripheral                       | 12 (3.9)                                                       | (6.3)   | 0        |  0 |
| Oral Fungal Infection                   | 0                                                              | 2 (2.5) | 0        |  0 |
| Pneumonia                               | 2 (0.6)                                                        | 3 (3.8) | 0        |  0 |
| Pruritus                                | 5 (1.6)                                                        | 3 (3.8) | 0        |  0 |
| Pruritus Generalised                    | 7 (2.3)                                                        | 0       | 0        |  0 |
| Rash                                    | 11 (3.5)                                                       | 5 (6.3) | 0        |  0 |
| Rash Maculo-Papular                     | 17 (5.5)                                                       | 1 (1.3) | 0        |  0 |
| Red Blood Cell Count Decreased          | 5 (1.6)                                                        | 3 (3.8) | 0        |  0 |
| Respiratory Failure                     | 22 (7.1)                                                       | 5 (6.3) | 0        |  0 |
| Salivary Hypersecretion                 | 2 (0.6)                                                        | 2 (2.5) | 0        |  0 |
| Sciatica                                | 2 (0.6)                                                        | 0       | 1 (33.3) |  0 |
| Upper Respiratory Tract Infection       | 7 (2.3)                                                        | 0       | 0        |  0 |
| Urinary Tract Infection                 | 9 (2.9)                                                        | 3 (3.8) | 0        |  0 |
| Vertigo                                 | 1 (0.3)                                                        | 2 (2.5) | 0        |  0 |
| Viral Upper Respiratory Tract Infection | 17 (5.5)                                                       | 5 (6.3) | 0        |  0 |
| Weight Decreased                        | 31 (10.0)                                                      | 7 (8.8) | 0        |  0 |
| White Blood Cell Count Increased        | 0                                                              | 2 (2.5) | 0        |  0 |
| White Blood Cells Urine Positive        | 2 (0.6)                                                        | 1 (1.3) | 1 (33.3) |  0 |

Abbreviations: N = number of patients in age group (Safety population).

Limited information is available on elderly patients due to very small number of patients from 75 years old (3 subjects in age group 75-84 and 0 subjects in age group 85 and more). In general, number of AEs in total and serious AEs was similar in both subjects up to 64 years old and for subjects from 65 to 74 years old, with slight increase in older group. Fatal AEs were more frequent in patients of 65 years old and more versus patients younger than 65 (7.7 vs. 11.3%) as well as AE leading to drop-out (excl. death) (11.3 vs. 21.3%). No new safety issues were identified in elderly population.

## Pregnant and breast-feeding women

All pregnant or breast-feeding women were excluded from participation in any of the Masitinib AB Science clinical trials. Additionally, pregnancy and breast-feeding were contraindicated being under Masitinib AB Science treatment, or within 1 month of their last intake.

One  female  patient  in  study  AB04010  (Mastocytosis,)  became  pregnant  in,  2006  despite  hormonal contraception. The patient underwent an abortion and study drug was maintained.

Two cases of pregnancies were reported in study AB14001, 117 and 174 days respectively after the first intake of Masitinib AB Science. Treatment with study drug was permanently discontinued for those two patients soon after the confirmation of pregnancies. In both cases patients gave birth to healthy babies and had a normal post-partum.

There were no reported cases of women breast-feeding in any of the Masitinib AB Science clinical trials.

## Patients with renal impairment

Patients with pre-existing severe renal impairment or with abnormal laboratory results at screening and baseline (CrCl &lt; 60 mL/min or proteinuria &gt; 30 mg/dL (1+) on dipstick; in case of the proteinuria ≥ 1+ on the dipstick, 24 hours proteinuria must be &gt; 1.5g/24 hours) were excluded in all Masitinib AB Science clinical trials.

## Patients with hepatic impairment

Patients  with  history  of  hepatic  disorders,  with  a  known  liver  disease,  recent  alcohol  abuse  or  with abnormal laboratory results at screening and/or baseline (hepatic transaminase levels &gt; 2 ULN, or total

<div style=\"page-break-after: always\"></div>

bilirubin level &gt; 1.5 ULN, or both hepatic transaminase levels and total bilirubin level outside of the normal ranges, or albuminaemia &lt; 1 x LLN) were excluded in all Masitinib AB Science clinical trials.

## Children

No patients aged less than 18 years old were included in any Masitinib AB Science study.

## 2.6.8.7. Safety related to drug-drug interactions and other interactions

No case of DDI was reported in the ALS study or the non-oncology studies.

The PK interactions with itraconazole were characterised in healthy volunteers in Study AB14004. This was a repeat dose study with administration of itraconazole 200 mg QD for 5 days, (from day 9 to 13) in 12 healthy volunteers. On the morning of Day 12, a single dose of Masitinib AB Science 3.0 mg/kg was administered 1 hour after the administration of 200 mg itraconazole. The results indicated a trend of increase in Cmax and AUC0-∞ of Masitinib AB Science when using concomitantly with itraconazole. The increase was of 27% for Cmax and 43% for AUC0-∞ , however the coefficients of variations were of 45% and 36% for Cmax and of 42% and 30% for AUC0-∞ ,  for  Masitinib AB Science alone and Masitinib AB Science with itraconazole respectively. It may suggest a DDI risk between Masitinib AB Science and concomitant treatments interacting with CYP3A4.

Depending on the interactions between Masitinib AB Science and a concomitant treatment, the plasma concentration of Masitinib AB Science or the concomitant treatment can either be increased or decreased. Thus,  may  result  in  either  increase  in  related  ADRs  or  decrease  in  the  efficacy  of  masitinib  or  the concomitant treatment.

Possible interactions between masitinib and concomitant treatments interacting with cytochromes P450:

- Masitinib may increase plasma concentration of certain medicinal products

There is a risk of DDI with medicinal products which are substrates for CYP3A4, P-gp and BCRP. The extent has not been elucidated in vivo . Concomitant administration of these substrates should be avoided for narrow therapeutic index drugs and carefully monitored for medicinal products with large therapeutic window. If monitoring is not possible in practice, then co-administration should be avoided especially in case of long-term prescribed medications. No data are available for the inhibitory potential of Masitinib AB Science on CYP2B6, so caution recommended when taken concomitantly.

- Masitinib may decrease plasma concentration of certain medicinal products

There is a risk of DDI with medicinal products for which the uptake depends on BCRP. Concomitant oral administration of substrates of BCRP (e.g. anthracyclines, topotecan) is not recommended unless the healthcare practitioner considers that the potential benefit justifies the risk.

Concomitant administration of Masitinib AB Science with medicinal products which are substrates of Pgp transporters or OCT2 transporters could decrease the plasma concentration to these substances. Caution should be taken when administering Masitinib AB Science with substrates of P-gp transporters with a narrow therapeutic window (e.g. digoxin, loperamide, berberine). It is recommended to take the concomitant treatment in between the two daily doses of Masitinib AB Science.

- Plasma concentration of masitinib may be decreased by certain medicinal products

Concomitant administration of Masitinib AB Science with inducers of CYP3A4 could decrease Masitinib AB Science  plasma  concentrations.  Administration  of  Masitinib  AB  Science  with  inducers  of  CYP3A4  is contraindicated. The selection of an alternative medication that has no, or minimal enzyme induction potential is recommended.

<div style=\"page-break-after: always\"></div>

- Plasma concentration of masitinib may be increased by certain medicinal products

Concomitant  administration  of  Masitinib  AB  Science  with  CYP3A4  inhibitors  or  P-gp  inhibitors  could increase masitinib plasma concentrations. There was an increase in exposure to Masitinib AB Science in healthy subjects when it was co-administered with itraconazole (a CYP3A4 inhibitor and P-gp inhibitor). The mean Cmax and AUC0-t of masitinib rose by 26% and 41.6%, respectively. Patients taking Masitinib AB Science with inhibitors of CYP3A4 (e.g. itraconazole, erythromycin, grapefruit juice) or inhibitors of P-gp (e.g. itraconazole, cyclosporine) should be monitored for adverse effects of masitinib. CYP2C8 is partially responsible for Masitinib AB Science in vitro biotransformation. Because of the lack of in vivo DDI  investigations,  the  coadministration  of  Masitinib  AB  Science  with  CYP2C8  inhibitors  should  be avoided.

## Medicinal product that moderate pH in the gut

Because of the lack of interaction studies with pH modifier drugs, H2 antagonist and PPI should be taken 2 hours after Masitinib AB Science, while antacid medicinal products should be administered 2 hours before  or  2  hours  after  masitinib.  If  this  particular  restriction  is  not  possible  to  respect,  the  coadministration with medicinal products that moderate pH should be avoided.

## Interactions with riluzole and masitinib

Riluzole is metabolised by CYP1A2. This P450 isoenzyme is not inhibited by Masitinib AB Science and Masitinib AB Science is not an inducer or substrate of CYP1A2. DDI with Masitinib AB Science due to the major metabolizing enzyme of riluzole are therefore unlikely. In addition, Masitinib AB Science is mainly metabolised by CYP3A4 to its demethylated metabolite AB3280. Riluzole is not a substrate/inhibitor or inducer of CYP3A4 and therefore, DDI due to the major metabolizing enzyme of Masitinib AB Science is not expected.

## 2.6.8.8. Discontinuation due to adverse events

Table 98 : AEs Leading Permanently to Discontinuation (Risk ≥1% in any PT) - Study AB10015

| SYSTEM ORGANCLASS PREFERREDTERM                 | P+R (N=133)   | M3.0+R (N=131)   | M4.5+R (N=129)   | P+R (N=133)   | M3.0+R (N=131)   | M4.5+R (N=129)   |
|-------------------------------------------------|---------------|------------------|------------------|---------------|------------------|------------------|
| SYSTEM ORGANCLASS PREFERREDTERM                 | All           | All              | All              | Related       | Related          | Related          |
| All                                             | 11 (8.3)      | 20 (15.3)        | 21 (16.3)        | 3 (2.3)       | 8 (6.1)          | 15 (11.6)        |
| GastrointestinalDisorder's                      | 6 (4.5)       | 7 (5.3)          | 5 (3.9)          | 0 (0.0)       | 3 (2.3)          | 1 (0.8)          |
| Dysphagia                                       | 6 (4.5)       | 3 (2.3)          | 4 (3.1)          | 0             | 0                | 0                |
| Respiratory, Thoracic and MediastinalDisorder's | 2 (1.5)       | 4 (3.1)          | 1 (0.8)          | 0             | 0                | 0                |
| Respiratory Failure                             | 1 (0.8)       | 3 (2.3)          | 1 (0.8)          | 0             | 0                | 0                |
| Investigations                                  | 1 (0.8)       | 4 (3.1)          | 3 (2.3)          | 1 (0.8)       | 0 (0.0)          | 3 (2.3)          |
| Weight Decreased                                | 0             | 4 (3.1)          | 0                | 0             | 0                | 0                |
| TransaminasesIncreased                          | 0             | 0                | 2 (1.6)          | 0             | 0                | 2 (1.6)          |
| NervousSystemDisorder's                         | 0             | 3 (2.3)          | 1 (0.8)          | 0             | 0                | 0                |
| Amyotrophic Lateral Sclerosis                   | 0             | 2 (1.5)          | 1 (0.8)          | 0             | 0                | 0                |
| SkinandSubcutaneousTissue Disorders             | 0             | 3 (2.3)          | 6 (4.7)          | 0             | 3 (2.3)          | 6 (4.7)          |
| RashMaculo-Papular                              | 0             | 2 (1.5)          | 1 (0.8)          | 0             | 2 (1.5)          | 1 (0.8)          |

P = placebo; R = riluzole; M3.0 = masitinib 3.0 mg/kg/day; M4.5 = masitinib 4.5 mg/kg/day. Related = suspected or not assessable.

Number of AEs leading to study treatment permanent discontinuation during extension period is provided above.

<div style=\"page-break-after: always\"></div>

Table 99 : AEs Leading Permanently to Discontinuation (Risk ≥1% in any PT) - in non-oncology studies excluding AB10015

|                                                                     | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   | Masitinib   |                 |                 |
|---------------------------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------------|-----------------|
|                                                                     | 3.0 N=156   | 3.0 N=156   | 4.5 N=461   | 4.5 N=461   | AIl N=1924  | AIl N=1924  | Placebo* N=1004 | Placebo* N=1004 |
| No. of Subjects with at least one                                   | (%)u        | events      | (%)u        | events      | n(%)        | events      | n(%)            | events          |
| All AEs                                                             | 49 (31.4%)  | 68          | 110 (23.9%) | 161         | 467 (24.3%) | 773         | 66 (6.6%)       | 103             |
| Blood and Lymphatic System Disorder's                               | 8 (5.1%)    | 8           | 13 (2.8%)   | 14          | 57 (3.0%)   | 64          | 4 (0.4%)        | 4               |
| Neutropenia                                                         | 8 (5.1%)    | 8           | 6 (1.3%)    | 6           | 37 (1.9%)   | 37          | 1 (0.1%)        | 1               |
| GastrointestinalDisorder's                                          | 10 (6.4%)   | 11          | 23 (5.0%)   | 32          | 104 (5.4%)  | 150         | 7 (0.7%)        | 12              |
| Diarrhoea                                                           | 5 (3.2%)    | 5           | 7 (1.5%)    | 8           | 36 (1.9%)   | 37          | 4 (0.4%)        | 4               |
| Nausea                                                              | 1 (0.6%)    | 1           | 6 (1.3%)    | 6           | 34 (1.8%)   | 34          | 0               | 0               |
| Vomiting                                                            | 1 (0.6%)    | 1           | 4 (0.9%)    | 4           | 19 (1.0%)   | 19          | 2 (0.2%)        | 2               |
| General Disorders and AdministrationSiteConditions                  | 3 (1.9%)    | 4           | 6 (1.3%)    | 6           | 42 (2.2%)   | 55          | 3 (0.3%)        | 3               |
| Oedema Peripheral                                                   | 2 (1.3%)    | 2           | 1 (0.2%)    | 1           | 8 (0.4%)    | 8           | 0               | 0               |
| Infections and Infestations                                         | 2 (1.3%)    | 2           | 4 (0.9%)    | 5           | 27 (1.4%)   | 31          | 2 (0.2%)        | 5               |
| Investigations                                                      | 4 (2.6%)    | 4           | 6 (1.3%)    | 6           | 33 (1.7%)   | 60          | 8 (0.8%)        | 14              |
| Weight Decreased                                                    | 2 (1.3%)    | 2           | 1 (0.2%)    | 1           | 5 (0.3%)    | 5           | 1 (0.1%)        | 1               |
| Metabolism and Nutrition Disorder's                                 | 1 (0.6%)    | 1           | 5 (1.1%)    | 5           | 27 (1.4%)   | 27          | 10 (1.0%)       | 10              |
| Musculoskeletal and ConnectiveTissueDisorder's                      | 6 (3.8%)    | 6           | 4 (0.9%)    | 4           | 22 (1.1%)   | 23          | 2 (0.2%)        | 2               |
| Rheumatoid Arthritis                                                | 4 (2.6%)    | 4           | 0           | 0           | 6 (0.3%)    | 6           | 1 (0.1%)        | 1               |
| Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) | 0           | 0           | 6 (1.3%)    | 6           | 11 (0.6%)   | 13          | 8 (0.8%)        | 10              |
| NervousSystemDisorder's                                             | 4 (2.6%)    | 5           | 10 (2.2%)   | 12          | 37 (1.9%)   | 49          | 12 (1.2%)       | 15              |
| Amnesia                                                             | 2 (1.3%)    | 2           | 0           | 0           | 2 (0.1%)    | 2           | 0               | 0               |
| Respiratory, Thoracic and MediastinalDisorders                      | 4 (2.6%)    | 4           | 8 (1.7%)    | 9           | 31 (1.6%)   | 35          | 5 (0.5%)        | 5               |
| Asthma                                                              | 3 (1.9%)    | 3           | 4 (0.9%)    | 4           | 11 (0.6%)   | 11          | 5 (0.5%)        | 5               |
| Disorders                                                           | 18 (11.5%)  | 19          | 37 (8.0%)   | 45          | 156 (8.1%)  | 182         | 1 (0.1%)        | 1               |
| Rash Maculo-Papular                                                 | 3 (1.9%)    | 3           | 9 (2.0%)    | 9           | 34 (1.8%)   | 34          | 0               | 0               |
| Rash                                                                | 4 (2.6%)    | 4           | 8 (1.7%)    | 8           | 28 (1.5%)   | 28          | 0               | 0               |
| Pruritus Generalised                                                | 2 (1.3%)    | 2           | 1 (0.2%)    | 1           | 5 (0.3%)    | 5           | 0               | 0               |

Discontinuation in healthy subjects

Seven subjects discontinued for safety reasons. Of those, 4 subjects withdrew because of moderate abdominal pain, diarrhoea, nausea and vomiting, and 3 subjects who withdrew due to moderate skinrelated adverse events, including macular papular rashes and urticaria.

## 2.6.8.9. Post marketing experience

Masitinib AB Science is not yet approved or marketed in any country.

<div style=\"page-break-after: always\"></div>

## 2.6.9. Discussion on clinical safety

Primary clinical safety data on Masitinib AB Science received from the Phase 2/3 study in patients with ALS.  Safety  analysis  from  nineteen  (19)  2  and  3  phase  studies  for  non-oncological  indications  and supportive safety information from 6 phase 1 studies in healthy subjects is available as well.

In study AB10015 during the main study protocol period (48 weeks), at least 1 AE was reported by 83.7% of patients.  Of  them,  78.2%  in  placebo,  84.7%  in  the  3.0  mg/kg,  88.4%  in  the  4.5  mg/kg Masitinib AB Science arm. More frequently reported AEs in one of the Masitinib AB Science versus placebo arm were maculo-papular rash, nausea, peripheral oedema, iron deficiency anaemia, respiratory failure, and dyspnoea. Majority of them were mild to moderate in intensity and their occurrence and severity appeared to be dose related. Severe AEs were more expressed in Masitinib AB Science 3.0 mg/kg/day and Masitinib AB Science 4.5 mg/kg/day groups comparing with placebo: 21.4%, and 30.2% respectively vs. 19.5%.

In regard to abnormal blood cell counts, percentage of such cases (both low and high) was higher in masitinib arms. Three cases of severe neutropenia were recorded on masitinib. Patients recovered after study treatment was temporally interrupted. Two cases of decreased haemoglobin grade 3 and one case of increased haemoglobin grade 3 were recorded on masitinib. Most of cases of abnormal blood cell counts were grade 1 or 2. In regard to increased biochemistry values, there were seven grade 3 values (ALT, AST, bilirubin, calcium, potassium, sodium) and one grade 4 value (sodium) recorded in masitinib arms  vs.  three  grade  3  values  (AST,  potassium)  in  placebo  arm.  Increase  in  AST,  ALT,  Alkaline phosphatase  values  was  highly  dependent  on  Masitinib  AB  Science  dose.  In  regard  to  decreased biochemistry values, there were ten grade 3 values (albumin, calcium, phosphate, potassium, sodium) and one grade 4 value (sodium) recorded in Masitinib AB Science arms vs. one grade 3 value (potassium) in placebo arm.

In regard to abnormal Biochemistry values during extension period, the percentage of patients with high AST values during the protocol extension period was observed to be higher in the Masitinib AB Science arms; 9.8% in the active control arm, 22.2% in Masitinib AB Science 3 mg/kg/day arm and 29.6% in Masitinib AB Science 4.5 mg/kg/day arm. Only Grade 1 of high AST values were reported during the extension period. No risk of severe high AST with Masitinib AB Science was observed.

The percentage of patients with high bilirubin  values  during  the  extension  period  was  higher  in  the Masitinib AB Science arms; 6.7% in the active control arm, 14.0% in Masitinib AB Science 3 mg/kg/day arm and 21.4% in Masitinib AB Science 4.5 mg/kg/day arm. The majority of patients (%) experienced Grade 1 or 2 of high bilirubin values. No risk of severe high bilirubin with Masitinib AB Science was observed.

Other abnormal biochemistry values were in general similar in placebo and Masitinib AB Science groups.

Much less abnormal blood cell counts/biochemistry were reported during the extension period comparing with the main period (26 vs. 168 AEs). During the extension period, no action was taken with the study drug for them. No case of positive dechallenge or dechallenge was reported. During both main and extension period, most of abnormal blood cell counts/biochemistry resolved without drug interruption/discontinuation and were in generally mild to moderate and transient.

Increase  in  the  frequency  of  non-fatal  SAEs  in  Masitinib  AB  Science  arms  was  dose  dependent.  94 patients experienced SAEs: 24 placebo patients (18.0%), 30 patients (22.9%) in the Masitinib AB Science 3  mg/kg/day,  and  40  patients  (31.1%)  in  the  Masitinib  AB  Science  4.5  mg/kg/day  arm.  The  most frequently  reported  non-fatal  SAEs  in  Masitinib  AB  Science  patients  under  MedDRA  SOC  were Gastrointestinal Disorders, then  Respiratory, Thoracic and  Mediastinal Disorders, Infection  and Infestations, Injury Poisoning and Procedural Complications, and Investigations. The most frequent PTs

<div style=\"page-break-after: always\"></div>

were  Dysphagia,  Respiratory  Failure,  Dyspnoea,  Lower  Respiratory  Tract  Infection,  Bronchitis,  Fall, Transaminases Increased, Weight Decreased, and Neutropenia. According to the applicant, Respiratory failure, Dysphagia, and Dyspnoea were associated with ALS disease progression and were not reported as  drug  related.  Above  mentioned  AEs,  except  for  Lower  Respiratory  Tract  Infection,  Bronchitis  and Weight Decreased were agreed to be added to SmPC section 4.8. by the applicant.

33 patients had a fatal SAEs. Of them, 12 patients (9.0%) in placebo arm, 11 patients (8.4%) in the 3.0 mg/kg/day Masitinib AB Science arm, and 10 patients (7.8%) in the 4.5 mg/kg/day Masitinib AB Science arm.

In study AB10015 during extension period, at least 1 AE was reported in 48.8% placebo, 56.3% of the Masitinib  AB  Science  3  mg/kg/day,  63.0% of the Masitinib AB Science 4.5 mg/kg/day arm. Most of mentioned AEs were mild to moderate in intensity, usually more frequent at the start of therapy and manageable with symptomatic treatments and dose reductions. In regard to abnormal blood cell counts, a severe decrease (G3) of haemoglobin was reported for one patient in Masitinib AB Science 3 mg/kg/day arm. None of severe abnormal blood cell counts were reported during extension period.

Overall, in non-oncological studies 89% of patients reported at least 1 AE. The most frequently reported SOC were Eye Disorders, GI Disorders, Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Disorders. The most frequently reported PTs in Masitinib AB Science patients were Nausea, Diarrhoea, Rash, Eyelid Oedema, Pruritus and Rash Maculo-Papular. Of most frequently reported AEs, such as Cutaneous adverse reaction, Gastrointestinal disorders, Superficial oedema are known  AEs  of  the  THIs.  Gastrointestinal  disorders  were  experienced  by  up  to  70%  of  patients, uncomplicated  cutaneous  reactions  -  up  to  60%,  constitutional  symptoms  (myalgia,  pain,  fatigue, dizziness) - up to 30%, oedema related events - up to 20% of patients.

In non-oncology studies the most frequently reported non-fatal SAEs under SOC in Masitinib AB Science versus placebo patients were Skin and Subcutaneous Tissue Disorders (4.0% versus 0.3%), Infections and Infestations (4.2%  versus 2.3%), Blood and Lymphatic Disorders (2.4%  versus 0.5%), Gastrointestinal Disorders (2.4% versus 0.7%) and Investigations (1.3% vs 0.2%).

In  study  with  healthy  subjects,  30%  of  population  reported  154  AEs.  The  most  common  ones  were nausea, vomiting, diarrhoea, abdominal pain, rash, dizziness, and episodes of headaches. The majority of AEs were assessed as related to Masitinib AB Science.

Number  of  deaths  increased  during  ALS  study  extension  period.  During  extension,  34  deaths  were recorded: 7 placebo patients (8.8%), 13 patients (16.3%) in the Masitinib AB Science 3 mg/kg/day and 14 patients (19.2%) in the Masitinib AB Science 4.5 mg/kg/day arm.

The applicant stated that this imbalance may be explained by:

- the longer duration of treatment in Masitinib AB Science groups as compared to placebo group.
- the  imbalance  in  terms  of  duration  of  disease  from  onset  to  randomization:  patients  from Masitinib AB Science groups had a longer duration of disease progression prior to randomization.
- the imbalance in terms of severity of clinical status at baseline: more very severe patients were enrolled in masitinib groups, which is likely to bias the interpretation of mortality rates.
- an increased rate of tracheostomy due to disadvantage at baseline/at start of extension period in masitinib patients (higher severity and longer duration of progression of the disease).
- a longer delay between disease onset and tracheostomy in Masitinib AB Science patients, despite disadvantage at baseline.
- an imbalance in severity of bulbar onset forms.

<div style=\"page-break-after: always\"></div>

All deaths in Masitinib AB Science patients were assessed as not related to study drug, but it has to be noted as well, that assessment was performed by investigators and not by independent committee. It is agreed by CHMP, that factors mentioned above could be a reasonable explanation for imbalance between two  study arms.  However,  long-term  safety should be further characterised using additional pharmacovigilance activities. Also, increased number of deaths on Masitinib AB Science raised concern regarding efficacy of the drug, it will not be discussed further during safety evaluation.

Limited information is available on elderly patients due to very small number of patients from 75 years old (3 subjects in age group 75-84 and 0 subjects in age group 85 and more). In general, number of AEs in total and serious AEs was similar in both subjects up to 64 years old and for subjects from 65 to 74 years old, with slight increase in older group. Fatal AEs were more frequent in patients of 65 years old and more versus patients younger than 65 (7.7 vs. 11.3%) as well as AE leading to drop-out (excl. death) (11.3 vs. 21.3%). No new safety issues were identified in elderly population.

By increasing the dose of Masitinib AB Science all kinds of AEs, except for fatal SAEs during main protocol period - AEs in total, fatal/non-fatal SAE, severe AE, AE leading to treatment discontinuation or dose reduction - have been increased. Especially it was noticeable during extension period. It can be stated, that from safety point of view 3.0 mg/kg dose is preferable to with 4.5 mg/kg.

Most of patients in the ALS study reported at least one AE. Higher dose dependent incidence of AEs was reported in the Masitinib AB Science + riluzole groups (84.7% in Masitinib AB Science 3 mg/kg/day and 88.4% in 4.5 mg/kg/day Masitinib AB Science + riluzole groups vs 78% in placebo + riluzole groups).

In  ALS  patients  the  most  common  AEs  in  all  study  groups  by  System  Organ  Class  (SOC)  were Gastrointestinal Disorders, Infection and Infestations and Investigations. The most frequently reported adverse  in  patients  receiving  masitinib  categorised  under  the  MedDRA  System  Organ  Class  were Gastrointestinal  Disorders,  Skin  and  Subcutaneous  Tissue  Disorders  and  Respiratory,  Thoracic  and Mediastinal Disorders.

The most common AEs with reported more than &gt; 5% higher incidence in the blood and lymphatic system disorders  (more  specifically  discussed  further  in  Section  4.5)  (8.4%  in  Masitinib  AB  Science 3mg/kg/day group and 14.7% in Masitinib AB Science 4.5 mg/kg/day group vs 1.5% in placebo group); nausea  (6.9%  in  Masitinib  AB  Science  3mg/kg/day  group  and  12.45  in  Masitinib  AB  Science  4.5 mg/kg/day group vs 4.5% in placebo group); diarrhoea (8.4% in Masitinib AB Science 3mg/kg/day group and 7.8% in Masitinib AB Science 4.5 mg/kg/day group vs 3.8% in placebo group); dyspepsia (7% in Masitinib AB Science 4.5 mg/kg/day group versus 2.3% in placebo group); peripheral oedema (5.3% in Masitinib AB Science 3mg/kg/day group and 7% in Masitinib AB Science 4.5 mg/kg/day group versus 0.8% in placebo group); nervous system disorders (18.6% in Masitinib AB Science 4.5 mg/kg/day group versus 9.8% in placebo group); respiratory and thoracic disorders (27.1% in Masitinib AB Science 4.5 mg/kg/day group versus 12% in placebo group including reported respiratory failure in 10.1% patients in Masitinib AB Science 4.5 mg/kg/day group vs 4.5 % in placebo group and dyspnoea 6.2% in Masitinib AB Science 4.5 mg/kg/day group versus 0.8% in placebo group); skin and subcutaneous tissue disorders (20.6% in Masitinib AB Science 3 mg/kg/day group and 30.2% in Masitinib AB Science 4.5 mg/kg/day group versus 12% in placebo group); infections and infestations (34.9% in Masitinib AB Science 4.5 mg/kg/day  group  versus  21.15  in  placebo  group).  Skin  and  subcutaneous  tissue  disorders  and gastrointestinal disorders were the most frequently reported AEs also for other non-oncology patients exposed to masitinib. These events are all representing well known safety profile of tyrosine kinase inhibitors. However, it seems that nausea, vomiting, rash, and peripheral oedema are more commonly associated with masitinib exposure across various indications. Reported higher proportion of Respiratory and thoracic disorders in Masitinib AB Science exposed ALS patients is of particular concern in the context of ALS as a fatal neurodegenerative disease with respiratory failure as one of primary reasons of death.

<div style=\"page-break-after: always\"></div>

Dose dependent respiratory and thoracic disorders were reported in Masitinib AB Science 4.5 mg/kg/day group with more than twice higher incidence compared to placebo group, including 10,1% severe AEs in Masitinib AB Science group compared to 6% in placebo group. The applicant discussed possible reasons leading to the reported dose dependent increase in incidence of AEs in the SOC of respiratory and thoracic disorders in masitinib exposed ALS patients. Indeed, number of very severe patients enrolled in Masitinib AB Science group was significantly higher (18 patients in placebo group vs 31 patient in Masitinib AB Science 3 mg/kg/day group and 33 patients in Masitinib AB Science 4.5 mg/kg/day group) most likely leading to the reported higher incidence of the AES typical for ALS progression.

Gastrointestinal disorders were most frequently reported disorders in ALS and non-ALS Masitinib AB Science exposed patients. Some aspects again were not specifically discussed in the context of ALS patients. Most frequently related AEs in the SOC of GI disorders were dysphagia, nausea, and diarrhoea. While  nausea  and  diarrhoea  were  among  frequently  reported  AEs  also  in  non-ALS  patients,  in  ALS patients dysphagia was reported with the higher incidence in Masitinib AB Science exposed patients (13.7% in Masitinib AB Science 3 mg/kg/day group and 13.2% in Masitinib AB Science 4.5 mg/kg/day group versus 10.5% in placebo group, including two-fold higher incidence of severe dysphagia reported in Masitinib AB Science 4.5 mg/kg group vs 2.3% in placebo group).  The applicant explains the reason for  dysphagia by justifying it with a higher number of very severe patients represented in masitinib groups  compared  to  placebo  group.  It  is  agreed  that  the  apparent  increased  incidence  of  severe dysphagia can be explained by higher number of very severe ALS patients enrolled in masitinib groups. Additionally, it seems that masitinib is intended for use as add-on therapy to riluzole. Gastrointestinal AEs including nausea, vomiting and diarrhoea are very common and common AEs reported for riluzole and the most common reason for discontinuation of riluzole treatment. The applicant has agreed that there is some cumulative effect of riluzole and Masitinib AB Science in terms of gastrointestinal adverse events. The applicant pointed that information to be included in the SmPC sufficiently reflects reported gastrointestinal disorders in Masitinib AB Science exposed patients. The cumulative effect of riluzole and Masitinib was agreed to be adequately addressed in the SmPC Section 4.4.

Markedly higher incidence of infections and infestations were reported in the higher Masitinib AB Science 4.5 mg/kg/day group (34.9%) compared to in placebo group (21.1%). It is generally agreed that the higher incidence of infections reported in Masitinib AB Science groups might be due to the higher number of very severe ALS patients enrolled in the masitinib groups.

## Additional safety data needed in the context of a conditional

The  CHMP  noted    that  data  from  clinical  study  AB10015  cannot  be  relied  upon,  increasing  the uncertainties and limitations also regarding safety data. However, data from other trials evaluating safety of Masitinib AB Science in non-oncological indications were assessed to further understand the safety profile  of  Masitinib  AB  Science.  Overall,  the  CHMP  considers  that  the  safety  profile  for  Masitinib  AB Science has been reasonably characterised for a CMA.  However, the safety profile is characterised based on non-comprehensive evidence.

Both Study AB19001 - initially presented as confirmatory study- and the newly presented confirmatory AB23005 study were proposed by the applicant as specific obligations. While these studies are primarily focused  on  efficacy,  they  include  safety  secondary  objectives  that  could  have  helped  to  further characteriseise the important identified risks as well as to the missing information about the long-term safety.

## 2.6.10. Conclusions on the clinical safety

The safety profile of mentioned medicinal product is considered acceptable for a CMA. The uncertainties and limitations regarding reliability of safety data of the pivotal clinical trial are alleviated by the safety

<div style=\"page-break-after: always\"></div>

data from the trials in non-oncological conditions. It is considered that the safety concerns could have been manageable with risk minimisation measures as highlighted in the RMP.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

Table SVIII.1: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                       |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                                                                                                             |
| Important potential risks    | Severe cutaneous adverse reactions Hepatotoxicity Infection due to Severe neutropenia Cardiotoxicity Acute Kidney Injury Carcinogenicity Risk of fractures Reproductive toxicity |
| Missing information          | Long-term safety                                                                                                                                                                 |

## 2.7.2. Pharmacovigilance plan

Table Part III.3: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                           | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                                                                                                                                      | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| none                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                                                                                      | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| AB19001                                                                                                                                                                                                                    | Study AB19001 is a multicenter, randomised, double-blind, placebo- controlled, phase 3 study to compare the efficacy and safety of two ascending dose titrations of masitinib (dose titration to 4.5 mg/kg/day; dose titration to 6.0 mg/kg/day) in combination with riluzole (50 mg b.i.d) versus matching placebo in combination with riluzole (50 mg b.i.d) in the treatment of patients diagnosed with ALS. | -Serious Cutaneous Adverse Reactions -Hepatotoxicity -Infections due to severe neutropenia -Cardiotoxicity -Risk of acute kidney injury -Carcinogenicity -Risk of fractures -Reproductive toxicity -Long-term safety       | Protocol submission Study initiation Study completion Clinical study report                                                                                                                                                | 22 May 2020 26 Jan 2021 31 Dec 2024 31 Dec 2025                                                                                                                                                                            |
| AB23005 planned                                                                                                                                                                                                            | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis                                                                                     | -Serious Cutaneous Adverse Reactions -Hepatotoxicity -Infections due to severe neutropenia -Cardiotoxicity -Risk of acute kidney injury -Carcinogenicity -Risk of fractures -Reproductive toxicity -Long-term safety       | Protocol submission Study initiation Study completion Clinical study report                                                                                                                                                | 31 May 2024 31 Dec 2024 31 Dec 2027 30 Jun 2028                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Category 3 - Required additional pharmacovigilance activities   | Category 3 - Required additional pharmacovigilance activities   | Category 3 - Required additional pharmacovigilance activities   | Category 3 - Required additional pharmacovigilance activities   |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| none                                                            |                                                                 |                                                                 |                                                                 |

## 2.7.3. Risk minimisation measures

Summary table of pharmacovigilance activities and risk minimization activities by safety concern.

<div style=\"page-break-after: always\"></div>

| Safety concern                       | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                | Pharmacovigilance activities                                                                                                                                            |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IMPORTANT POTENTIAL RISKS            | IMPORTANT POTENTIAL RISKS                                                                                                                                                                                                                                                                                                                                                                 | IMPORTANT POTENTIAL RISKS                                                                                                                                               |
| Severe cutaneous reactions           | Routine Risk Communication: SmPC Section 4.2 Posology and method of administration SmPC Section 4.8 Undesirable effects PL section 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4 Special warnings and precautions of use: fecommendations for monitoring                                                           | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| Hepatotoxicity                       | Routine Risk Communication: SmPC Section 4.2 Posology and method of administration SmPC Section 4.8 Undesirable effects PL section 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4 Special warnings and precautions of use: recommendations for monitoring and dose modifications                                    | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| Infections due to severe neutropenia | Routine Risk Communication: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects PL section 4 Routine risk minimisation activities fecommending specific clinical measures to address the risk: SmPC Section 4.4 Special warnings and precautions of use: recommendations for monitoring | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| Cardiotoxicity                       | Routine Risk Communication SmPC Section 4.2 Posology and method of administration PL section 4                                                                                                                                                                                                                                                                                            | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |

<div style=\"page-break-after: always\"></div>

|                                                                   | Routine risk minimisation activities fecommending specific clinical measuures to address the risk: SmPC Section 4.4 Special warnings and precautions of use: recommendations for monitoring                                                                                                                                |                                                                                                                                                                         |
|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Acute Kidney Injury                                               | Routine Risk Communication: SmPC Section 4.2 Posology and method of administration Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4 Special warnings and precautions of use: fecommendations for monitoring                                              | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| Carcinogenicity                                                   | Routine Risk Communication: PL section 4 Routine risk minimisation activities fecommending specific clinical measures to address the risk: Section 4.4 Special warnings and precautions of use: recommendations for monitoring                                                                                             | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| Risk of fractures                                                 | Routine Risk Communication: SmPC Section 4.2 Posology and method of administration SmPC Section 4.8 Undesirable effects PL section 4 Routine risk minimisation activities fecommending specific clinical measures to address the risk: Section 4.4 Special warnings and precautions of use: recommendations for monitoring | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| Reproductive toxicity including embryotoxicity and teratogenicity | Routine Risk Communication: Section 4.6 Fertility, pregnancy and lactation Routine risk minimisation activities fecommending specific clinical measures to address the risk: Section 4.4 Special warnings and precautions of use: recommendations for monitoring                                                           | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |
| MISSING INFORMATION                                               | MISSING INFORMATION                                                                                                                                                                                                                                                                                                        | MISSING INFORMATION                                                                                                                                                     |
| Long term safety                                                  | Routine risk minimisation activities: Not applicable                                                                                                                                                                                                                                                                       | AB19001 Clinical study (category 2 study) as additional pharmacovigilance activity. AB23005 Clinical study (category 2 study) as additional pharmacovigilance activity. |

## 2.7.4. Conclusion

The CHMP, having considered the data submitted in the application was of the opinion that due to the

<div style=\"page-break-after: always\"></div>

concerns identified with this application, the risk management plan cannot be agreed at this stage.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

Not applicable.

## 2.9. Product information

In light of the negative recommendation, a satisfactory summary of product characteristics, labelling and package leaflet cannot be agreed at this stage.

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

ALS is a neurodegenerative disorder affecting primarily the motor system, but in which extra -motor manifestations are increasingly recognised. The loss of UMN and LMN in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS  often  has  a  focal  onset  but  subsequently  spreads  to  different  body  regions,  where  failure  of respiratory muscles typically limits survival to 2-5 years after disease onset.

## 3.1.2. Available therapies and unmet medical need

Riluzole is currently the only medical product specifically authorised in the EU for ALS. Tofersen has recently been authorised for the treatment of SOD1-ALS, representing 2% of ALS. The cornerstone of disease  management  for  ALS  patients  remains  multidisciplinary  care  which  has  a  positive  effect  on patient  satisfaction  and  outcome.  Several  discomforting  symptoms  of  ALS  can  be  managed  by symptomatic treatment options, including pharmacological and non -pharmacological interventions. Non -invasive  ventilation  is  the  preferred  life -prolonging  treatment  for  respiratory  insufficiency.  Currently, there  is  no  cure  for  ALS,  and  it  is  agreed  that  the  unmet  medical  need  remains  substantial  for  the majority of the ALS patients.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The  main  efficacy  study  was  a  phase  2/3,  randomised,  double-blind,  placebo-controlled  study (AB10015). The study was initially planned as a phase 2 dose-finding study and only after an amendment it was upgraded to a phase 3 pivotal study for this application. The primary objective of study AB10015 was to evaluate the efficacy of Masitinib AB Science in combination with riluzole based on the change in the ALSFRS-R ( Δ ALSFRS-R) from baseline to week 48 in the full study population. Only while the study was ongoing, the applicant amended the protocol to redefine the primary efficacy population as the 'normal progressors' subpopulation. A total of 394 patients from 34 sites in 9 countries were available for the main study efficacy analysis (132, 131, and 128 patients in the placebo, Masitinib AB Science 3 mg/kg/day,  and  Masitinib  AB  Science  4.5  mg/kg/day  treatment-arms,  respectively).  A  total  of  267 patients completed the week 48 main protocol period at week 48. A long-term survival follow-up analysis of this study has been provided.

A phase 3 study (AB19001) is ongoing, but no data were provided.

## 3.2. Favourable effects

The analysis of the primary endpoint in the full study population comprising normal + fast progressors in  the  Masitinib  AB  Science  4.5  mg/kg/day  group  showed  a  difference  of  2.09  95%CI  (-0.55-4.73) pnominal=0.1202. In the amended primary analysis, a statistically significant difference in the 48-week change from baseline in the ALSFRS-R score was claimed between Masitinib AB Science 4.5 mg/kg/day and placebo (difference of least-square means=3.39;  p=0.0158)  in the 'normal progressor' subpopulation.

The difference in PFS in the full study population comprising normal + fast progressors was 3 months gain in favour of Masitinib AB Science 4.5 mg/kg/day group (pnominal 0.1389). In the 'Normal progressor' subpopulation, median PFS was increased by 4 months with Masitinib AB Science 4.5 mg/kg/day as compared with placebo arm (pnominal = 0.0159).

Analysis of ALSAQ-40 (mLOCF Rule 1) showed difference of means -6.59, pnominal 0.0148 in the full study population  including  normal  +  fast  progressors  and  difference  of  -7.76,  pnominal  0.0078  in  favour  of Masitinib AB Science 4.5 mg/kg/day group in normal progressor subpopulation.

In analysis of FVC in the full study population comprising normal + fast progressors difference of means was 5.63, pnominal 0.0914 and in normal progressor subpopulation difference of means was 7.55, pnominal 0.0296 in favour of Masitinib AB Science 4.5 mg/kg/day group.

A  summary  of  long-term  median  OS  results  (cut  off  June  2020)  for  various  patient  cohorts  of  the AB10015 study population has been submitted. In moderate ALS population, including ALS patients with ≥2 on each baseline ALSFRS -R item the between group difference in median OS was 25 if population was  further  restricted  to  pre-randomization Δ FS&lt;1.10  (moderate  ALS  enriched  cohort  of  restricted normal progressors  subpopulation)  or  15  months  if  regardless  of  baseline Δ FS  (restricted  full  study population comprising normal and fast progressors) corresponding to a 43-44% reduced risk of death.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

A triggered GCP inspection was requested by the CHMP on the conduct of the clinical study AB10015 in the previous MAA for the same medicinal product as a treatment for ALS. Major and critical findings were identified,  and  GCP  inspection  concluded  that  the data  obtained  at  the  sites  inspected  are  not trustworthy.    In  accordance  with  the  GCP  inspection  report  conclusion,  after  the  evaluation  of  the responses submitted by the applicant, the Inspection Team considered that in view of the observed departures  from  GCP,  it  cannot  be  ensured  that  the  data  inspected  are  trustworthy  and  the aforementioned deficiencies are likely to have an impact on the final results. Data integrity is high likely to be impaired as several protocol deviations at eligibility, conduct and in other aspects inspected.  The applicant claims that the GCP findings were addressed with implementation of preventive actions across study and functions within AB Science. The applicant also claims that for study AB10015, corrective actions were implemented wherever feasible. It is noted that the measures specified by the applicant have been assessed in the current marketing authorisation procedure and were not found sufficient to recommend the use of data.

Given the nature of the findings, the systematic deficiencies observed (i.e. massive number of protocol deviations) and the fact that some findings such as the deficiencies during inclusion/exclusion criteria verification  and  subjects'  follow  up  (Critical  finding  1  in  the  inspection  report)  cannot  be  corrected retrospectively, the corrective actions presented are not considered adequate to address all the concerns raised. Data from clinical study AB10015 cannot be relied upon.

The total  population  (normal  +  fast  progressors)  is  regarded  as  primary  population  and  statistically significant difference was not demonstrated for the primary endpoint in this population.

In a study amendment while the study was already ongoing, the applicant introduced division of enrolled participants in two subgroups: fast and normal progressors. Normal progressors were re-defined as the population for the primary analysis with aim to reduce heterogeneity in study population. This approach is not supported. First, the dichotomisation was implemented during the ongoing study as recognised by the applicant and it is not supported by the CHMP. Second, it leads to selective subgroup that is not representative of general ALS population. Additionally, the chosen cut-off point ( Δ FS 1.1) is of no clinical relevance and is not based on pathophysiology of ALS or mechanism of action of masitinib. Furthermore, Δ FS alone has relatively low predictive value of progression (Thakore et al, 2017) and is not stable throughout the course of disease (Requardt, 2021) thus, a linear assumption for the Δ FS decline (average rate of change from onset to randomization) might lead to misclassification of patients.

There was a substantial number of early dropouts across study arms. To account for missing data, the applicant used mLOCF method and provided various sensitivity analysis. The approach is not supported, because in the context of progressive ALS it overestimates effect. Considering the progressive nature of ALS and that the effect of treatment will not be maintained after discontinuation of medication, the J2R method is considered the most appropriate method. For this method, the applicant maintained that the defined intercurrent events are lack of efficacy or related toxicity. However, this definition is considered too narrow and is not supported.

As  per  the  data  on  survival  or  survival  equivalents  that  is  requested  as  per  the  EMA  guideline,  the applicant provided data on long-term overall survival. A limitation of this analysis is that no information on the post-study use of invasive ventilation was collected, nor was information regarding which drugs were taken following withdrawal from study AB10015 or its associated NPP. Also, more than 20% of participants have discontinued the treatment before the open-label extension phase due to the lack of efficacy. Therefore, due to this discontinuation, analysis of long-term overall survival could cause bias in favour to Masitinib AB Science treatment arms.

<div style=\"page-break-after: always\"></div>

The effect in the long-term survival claimed by the applicant is derived from a highly selected patients' population defined post hoc therefore can be considered only as descriptive not confirmatory of Masitinib AB Science efficacy in the proposed indication. When analysis was conducted in population that more closely corresponds to full study population of pivotal study and hence, the overall ALS population OS was not observed. The between mean difference for the moderate/severe/very severe ALS enriched cohort of restricted full study population comprising normal and fast progressors [i.e. regardless of (any) baseline ALSFRS-R item) regardless of Δ FS] was 1 month (median OS of 36 versus 37 months) for patients receiving Masitinib AB Science 4.5 mg/kg/day (n=130) versus placebo (n=133). Based on updated efficacy and safety analyses, the applicant presented a proposal for a modified indication to the ' treatment of ALS patients prior to any loss of function' (wherein loss of function is defined as a score of zero on any item of the ALSFRS-R) . However, the strategies to post hoc identify new target populations (M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1) are considered as data driven decisions and are, therefore, not acceptable.

## 3.4. Unfavourable effects

In study AB10015 during main study protocol period (48 weeks), at least 1 AE was reported by 83.7% of patients. Of them, 78.2% in placebo, 84.7% in the 3.0 mg/kg, 88.4% in the 4.5 mg/kg Masitinib AB Science arm.

More frequently reported AEs in one of the Masitinib AB Science versus placebo arm were maculo-papular rash, nausea, peripheral oedema, iron deficiency anaemia, respiratory failure, and dyspnoea.

The most frequently reported non-fatal SAEs in Masitinib AB Science patients under MedDRA SOC were Gastrointestinal Disorders, then  Respiratory, Thoracic and  Mediastinal Disorders, Infection  and Infestations, Injury Poisoning and Procedural Complications, and Investigations. The most frequent PTs were  Dysphagia,  Respiratory  Failure,  Dyspnoea,  Lower  Respiratory  Tract  Infection,  Bronchitis,  Fall, Transaminases Increased, Weight Decreased, and Neutropenia.

According  to  the  applicant,  Respiratory  failure,  Dysphagia,  and  Dyspnoea  were  associated  with  ALS disease progression and were not reported as drug related.

The most common AEs with reported more than &gt; 5% higher incidence in ALS patients were in the blood and lymphatic system disorders (8.4% in Masitinib AB Science 3mg/kg/day group and 14.7% in Masitinib AB Science 4.5 mg/kg/day group versus 1.5% in placebo group); nausea (6.9% in 3 mg/kg/day group and 12.45 in Masitinib AB Science 4.5 mg/kg/day group versus 4.5% in placebo group); diarrhoea (8.4% in  Masitinib  AB  Science 3 mg/kg/day group and 7.8% in Masitinib AB Science 4.5 mg/kg/day group versus 3.8% in placebo group); dyspepsia (7% in Masitinib AB Science 4.5 mg/kg/day group versus 2.3% in placebo group); peripheral oedema (5.3% in Masitinib AB Science 3 mg/kg/day group and 7% in Masitinib AB Science 4.5 mg/kg/day group versus 0.8% in placebo group); nervous system disorders (18.6% in Masitinib AB Science 4.5 mg/kg/day group versus 9.8% in placebo group); respiratory and thoracic disorders (27.1% in Masitinib AB Science 4.5 mg/kg/day group versus 12% in placebo group including reported respiratory failure in 10.1% patients in Masitinib AB Science 4.5 mg/kg/day group vs 4.5 % in placebo group and dyspnoea 6.2% in Masitinib AB Science 4.5 mg/kg/day group versus 0.8% in placebo group); skin and subcutaneous tissue disorders (20.6% in Masitinib AB Science 3 mg/kg/day group and 30.2% in Masitinib AB Science 4.5 mg/kg/day group versus 12% in placebo group); infections and infestations (34.9% in Masitinib AB Science 4.5 mg/kg/day group versus 21.15 in placebo group).

Cardiovascular  disorders  were  identified  as  an  important  potential  risk  and  patients  with  current  or history of severe cardiovascular disease were excluded from the study. Nonetheless, 3 severe cardiac events were reported in masitinib exposed patients including 2 death events. Although none of them

<div style=\"page-break-after: always\"></div>

was reported as study drug related, potential cardiotoxicity remains as a significant and not properly addressed safety risk.

ALS  is  a  disease,  which  leads  to  death  mainly  from  respiratory  complications;  however,  also  has underestimated cardiovascular effects, like increased heart rate variability, malignant arrhythmias, and sudden death (Orsini et al, 2021). Furthermore, cardiac symptoms in ALS patients may develop at any stage of the disease and initial cardiac symptoms if not closely monitored may go unnoticed in ALS patients.

## 3.5. Uncertainties and limitations about unfavourable effects

Important uncertainty of unfavourable effects is also related to the reliability of data. Many deviations from the protocol have been found during the inspections of the study centres. As part of this marketing authorization Applicant presented implemented preventive actions across study and functions within AB Science. Given the nature of the findings, the systematic deficiencies observed (i.e. massive number of protocol deviations) and the fact that some findings such as the deficiencies during inclusion/exclusion criteria verification and subjects' follow up (Critical finding 1 in the inspection report) cannot be corrected retrospectively, the corrective actions presented are not considered adequate to address all the concerns raised.  Data  from  clinical  study  AB10015  cannot  be  relied  upon,  increasing  the  uncertainties  and limitations also regarding unfavourable effects.

The  uncertainties  and  limitations  regarding  reliability  of  safety  data  of  the  pivotal  clinical  trial  are alleviated by the safety data from the trials in non-oncological conditions. It is considered that the safety concerns could have been manageable with risk minimization measures as outlighted in the RMP.

## 3.6. Effects Table

Table 100: Effects Table for Masitinib AB Science

| Effect                 | Short Description                      | Unit               | Masitini b 4.5 mg   | Placebo            | Uncertainties/ Strength of evidence                                                                                                                                             | Referen ces        |
|------------------------|----------------------------------------|--------------------|---------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects     | Favourable Effects                     | Favourable Effects | Favourable Effects  | Favourable Effects | Favourable Effects                                                                                                                                                              | Favourable Effects |
| Difference in ALSFRS-R | Normal progressors Between groups, LS  | score              |                     |                    | Difference 3.39 CI (0.65- 6.13), p-value 0.0157 Uncertainties for all estimates: multiple imputation suboptimal, reliability of data, high levels of treatment discontinuation. | (1)                |
|                        | Normal + Fast progressors              | score              | -10.89              | -12.97             | Difference 2.09 (-0.55-4.73) p=0.1202                                                                                                                                           |                    |
| Median PFS             | Normal progressors, Between groups, LS | months             | 20                  | 16                 | 4 months, p-value 0.0159.                                                                                                                                                       | (1)                |
|                        | Normal + Fast progressors              |                    | 17                  | 14                 | 3 months, p-value 0.1389                                                                                                                                                        |                    |

<div style=\"page-break-after: always\"></div>

| Effect                                          |                      | Short Description                               | Unit                 | Masitini b 4.5 mg                       | Placebo                          | Uncertainties/ Strength of evidence                                                           | Referen ces          |
|-------------------------------------------------|----------------------|-------------------------------------------------|----------------------|-----------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------|----------------------|
| Quality life                                    | of                   | Normal progressors Between groups, LS ALSAQ- 40 | score                | mLOCF Rule 1 19.42 mLOCF Rule 5 18.79   | mLOCF Rule 1 27.18 mLOCF Rule 5  | difference of means 7.76, p- value 0.0078 (mLOCF Rule 1). -6.72, p-value 0.0143               | (1)                  |
|                                                 |                      | Normal + Fast progressors                       |                      | 21.58                                   | 28.17                            | difference of means -6.59, p- value 0.0148                                                    |                      |
| FVC                                             |                      | Normal progressors Between groups, LS           | change from baseline | mLOCF Rule 1 -26.45 mLOCF Rule 5- 25.62 | mLOCF Rule 1 -33.99 mLOCF Rule 5 | difference of means 7.55, p- value 0.0296 (mLOCF Rule 1). 6.40, p-value 0.0511 (mLOCF Rule 5) | (1)                  |
|                                                 |                      | Normal + Fast progressors                       |                      | -30.81                                  | -36.45                           | difference of means 5.63, p- value 0.0914                                                     |                      |
| TFS                                             |                      | Normal progressors                              | months               | 30                                      | 32                               | p-value 0.7382                                                                                |                      |
|                                                 |                      | Normal + Fast progressors                       |                      | Not presented                           | Not presented                    |                                                                                               |                      |
| CAFS                                            |                      | Normal progressors                              | score                | 115.72                                  | 100.77                           | difference 14.95, p-value 0.0776.                                                             |                      |
|                                                 |                      | Normal + Fast progressors                       |                      | 135.83                                  | 121.40                           | Difference of means 14.43, p-value 0.1185                                                     |                      |
| Survival OS                                     |                      | Normal progressors Between groups, LS           | months               | Median OS not reached                   | Median OS not reached            | p-value 0.3727                                                                                | (1)                  |
|                                                 |                      | Normal + Fast progressors                       |                      | Median OS not reached                   | Median OS not reached            | p-value 0.4862                                                                                |                      |
| Unfavourable Effects                            | Unfavourable Effects | Unfavourable Effects                            | Unfavourable Effects | Unfavourable Effects                    | Unfavourable Effects             | Unfavourable Effects                                                                          | Unfavourable Effects |
| Deaths                                          |                      | Number (and Percent of Patients)                | Number               | 10 (7.8)                                | 12 (9.0)                         | Up to week 48 SoE: longer duration of treatment and more severe patients in masitinib arm     | (2)                  |
| Gastrointesti nal Disorders                     |                      | Number (and Percent of Patients)                | Number               | 14 (10.9)                               | 10 (7.5)                         | Up to week 48 Unc: cumulative effect of riluzole and masitinib in terms of GI events.         | (2)                  |
| Respiratory, Thoracic and Mediastinal Disorders |                      | Number (and Percent of Patients)                | Number               | 13 (10.1)                               | 4 (3.0)                          | Up to week 48 SoE: larger # of very severe patients in masitinib arm                          | (2)                  |

<div style=\"page-break-after: always\"></div>

| Effect                      | Short Description        | Short Description   | Unit   | Masitini b 4.5 mg   | Placebo   | Uncertainties/ Strength of evidence                                  | Referen ces   |
|-----------------------------|--------------------------|---------------------|--------|---------------------|-----------|----------------------------------------------------------------------|---------------|
| Infections and Infestations | Number Percent Patients) | (and of             | Number | 10 (7.8)            | 7 (5.3)   | Up to week 48 SoE: larger # of very severe patients in masitinib arm | (2)           |
| Transaminas es Increased    | Number Percent Patients) | (and of             | Number | 2 (1.6)             | 0         | Up to week 48                                                        | (2)           |

Abbreviations: ALSFRS-R - Amyotrophic lateral sclerosis functional rating scale-revised, ALSAQ-40 - Amyotrophic Lateral Sclerosis Assessment Questionnaire, long form, 40 questions, FP - Fast Progressors, FVC - Forced vital capacity, LS-Difference of least-square means, median PFS - median progression-free survival, TD - Treatment Difference M vs P, M = ALSITEK + Riluzole ; P = Placebo + Riluzole.

Notes: (1) Clinical Study Report Protocol No. AB10015, (2) 2.7.4 Summary of Clinical Safety

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

ALS is a neurodegenerative disease with limited treatment options with overall survival of 2-5 years after disease onset.

The  current  application  is  based  on  one  pivotal  study  (AB10015);  A  prospective,  multicentre, randomised, double-blind, placebo controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of two doses of Masitinib AB Science versus placebo in the treatment of patients suffering from ALS. The primary endpoint was originally the change from baseline to week 48 in the ALSFRS-R in the full study population.

A triggered GCP inspection was requested by the CHMP on the conduct of the clinical study AB10015 in the previous MAA for masitinib use in ALS. Major and critical findings were identified, and the GCP report concluded that the data obtained at the sites inspected are not trustworthy. As part of this submission the applicant claims that the GCP findings were addressed with implementation of preventive actions across  study  and  functions  within  AB  Science.  The  applicant  also  claims  that  for  study  AB10015, corrective actions were implemented wherever feasible. It is noted that the measures specified by the applicant in this application have been assessed and were not found sufficient to reassure the CHMP to recommend the use of data. Therefore, data from clinical study AB10015 cannot be relied upon.

In 2014, an amendment to the study protocol introduced a distinction between 'normal progressor' patients and 'fast progressor' subpopulations while the study was ongoing, and the primary efficacy analysis was to be done in the normal progressor subpopulation randomised to an initial Masitinib AB Science dose of 4.5mg/kg/day versus placebo patients at a 5% alpha-level. This categorization is not considered acceptable for the following reasons: the categorization was implemented while the study was ongoing, the use of ALSFRS-R score as the only variable to inform the progression of ALS, the linear assumption of ALSFRS-R decline being unreliable for long time periods, the use of arbitrary cut-offs for the categorization that are not based on clinical relevant thresholds, ALS pathology or mechanism of action  of  Masitinib  AB  Science.    The  full  study  population  comprising  normal  +  fast  progressors  is regarded as primary population.

Considering  that  there  were  approximately  30%  of  missing  data  in  each  Masitinib  AB  Science  arm, handling of missing data can have a significant impact on the results. In order to account for missing data after treatment discontinuation, the applicant used the mLOCF method for the first and secondary endpoints. A mLOCF approach assumes that the benefit experienced until the time of missing data is also retained thereafter. This is a strong assumption for imputing data after treatment discontinuation. This approach of handle missing data is prone to overestimate the effects of Masitinib AB Science. The applicant provided more conservative approaches such as J2R that assumes that the benefit experienced

<div style=\"page-break-after: always\"></div>

until the point of missing data is not retained and instead the outcome would correspond to the outcome in  the  reference  group.  However,  J2R  was  only  used  by  the  applicant  to  handle  missing  data  after discontinuations  that  were  attributed  to  lack  of  efficacy  or  toxicity,  whereas  missing  data  after discontinuations  for  other  reasons  were  presumably  handled  with  a  mLOCF  approach.  A  detailed description of the statistical methods is not available, which further increases the uncertainty about the appropriateness of this analysis approach. Additionally, as an underlying assumption, the applicant is assuming that it can ascertain which missing case are MAR (protocol deviation / non-compliance, etc.) and which cases are MNAR (efficacy/toxicity). The applicant does not provide convincing arguments that substantiate  this  categorisation,  hence  the  handling  of  missing  data  following  discontinuations  for different reasons with different methods is not considered adequate. The CHMP is of the opinion that as conservative methods such J2R are considered the preferred option in the view of the progressive nature of ALS.

The primary statistical analysis in the phase 2/3 main efficacy study revealed a statistically significant difference in the ALSFRS-R score between Masitinib AB Science 4.5 mg/kg/day and placebo (difference of  least-square  means=3.39;  p=0.0158)  in  'normal  progressor'  subpopulation.  However  significant difference  was  not  observed  in  the  full  study  population  comprising  normal  and  fast  progressors subpopulations,  which  is  considered  the  primary  population  of  this  trial.  With  respect  to  secondary endpoints, in the 'normal progressor' subpopulation, median PFS was increased by 4 months in the Masitinib AB Science 4.5 mg/kg/day group compared with placebo, (pnominal=0.016). However, these effects were not seen in the full study population comprising normal and fast progressors.

A summary of long-term median OS results for various patient cohorts of the AB10015 study population has been provided (cut-off date 14 June 2020). No long-term survival advantage was observed for the overall Masitinib AB Science 4.5 mg/kg/day cohort.  The results indicating prolonged survival in a post hoc selected,  enriched  population  (cohortLTM4.5  with  ≥2  on  each  baseline  ALSFRS -R  item,  and Δ FS&lt;1.1) is not considered robust and is not representative for the population intended to be treated. The new proposed indication ( ALS patients prior to any loss of function ) based on post hoc analyses is not acceptable as it is considered data driven.

Dose dependent respiratory and thoracic disorders were reported in 4.5 mg/kg/day Masitinib AB Science group with more than twice higher incidence compared to placebo group, including 10,1% severe AEs in Masitinib AB Science group compared to 6% in placebo group. Furthermore, it is a concern that data reliability issues identified in the triggered GCP inspection also affects proper reporting of safety data. Nevertheless, the safety profile was further characterised based on safety data of trials conducted in non-oncological conditions. It is considered that the safety profile is reasonably characterised for a CMA (i.e. based on non-comprehensive data) and that the proposed specific obligations could have provided comprehensive data during the post-authorisation phase.

## 3.7.2. Balance of benefits and risks

The provided analyses of the single pivotal study are not considered to establish efficacy in the target population of patients with ALS. In addition, a triggered GCP inspection has concluded that the data from clinical  study  AB10015.  Data  cannot  be  relied  upon  and  the  corrective  measures  presented  by  the applicant have not resolved this issue.

## 3.7.3. Additional considerations on the benefit-risk balance

## Conditional marketing authorisation

As comprehensive data on the product are not available, a conditional marketing authorisation (CMA) was  requested  by  the  applicant  in  the  initial  submission.  The  CHMP  agrees  that  the  data  is  not

<div style=\"page-break-after: always\"></div>

comprehensive. The application is based on a single pivotal trial, study AB10015, which was designed as a phase 2 dose-finding trial. Only upon a protocol amendment, it was upgraded to a phase 3 pivotal trial. The study population of AB10015 study is not considered fully representative of the overall ALS population and the efficacy endpoints did not include any measures of muscle strength. These features could have been acceptable for a phase 2 dose-finding trial but are considered serious limitations for a phase 3 pivotal study intended to provide comprehensive evidence of efficacy and safety. Moreover, a triggered GCP inspection has concluded that the data from clinical study AB10015 are not trustworthy Data cannot be relied upon, and the corrective measures presented by the applicant have not resolved this issue.

The CHMP considers that the product cannot be recommended for a CMA as the benefit-risk balance is negative  (as  discussed),  the  applicant  is  unlikely  to  be  able  to  provide  comprehensive  data  after authorisation, it has not been demonstrated that the product will address an unmet medical need, and the benefits to public health of the immediate availability do not outweigh the risks inherent in the fact that additional data are still required.

## 1. Positive benefit/risk balance:

The applicant argued that results from Study AB10015 are valid and demonstrate efficacy of Masitinib AB Science for patients with ALS with an adequate safety profile. The CHMP position is that a positive benefit/risk balance of Masitinib AB Science for the treatment of patients with ALS cannot be established because the data from the pivotal clinical study AB10015 cannot be relied upon. Despite the applicant's arguments and corrective measures, the current assessment concluded that the deficiencies identified during  previous  GCP  inspection  cannot  be  resolved  by  performing  re-monitoring  and  retrospective analyses at the study sites and cannot be corrected retrospectively. Beside the data not being reliable, the results from the pivotal study AB10015 do not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS, because a statistically significant difference compared to placebo was not demonstrated for the primary endpoint in the full study population; the approach to categorise the population into normal and fast progressors is not supported (the categorization was implemented while the study was ongoing, the use of ALSFRS-R score as the only variable to inform the progression of ALS, the linear assumption of ALSFRS-R decline being unreliable for long time periods, the use of arbitrary cut-offs  for  the  categorization  that  are  not  based  on  clinical  relevant  thresholds,  ALS  pathology  or mechanism of action of Masitinib AB Science); considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition of intercurrent events in J2R strategy are not considered acceptable and the strategies to post hoc identify new target populations (M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1' for analyses of survival and ALS patients prior to any loss of function as proposed in the latest version of 4.1 of the SmPC) are considered as data driven decisions and are, therefore, not acceptable.

## 2. It is likely that the applicant will be able to provide comprehensive data

As per the requested CMA, the applicant initially presented Study AB19001 as the one that would lead to  comprehensive  evidence  on  efficacy  and  safety  of  Masitinib  AB  Science.  Study  AB19001  is  a multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to evaluate the efficacy and safety of masitinib as add-on therapy in Amyotrophic Lateral Sclerosis (ALS) patients treated with Riluzole. Patients will be randomised (1:1:1) to receive Masitinib AB Science 6 mg/kg/day, Masitinib AB Science 4.5mg/kg/day or matching placebo. The primary endpoint is the absolute change in ALSFRS-R from baseline to week 48 week. In this study, the secondary endpoints include measures of  muscle strength and survival. Within this study, the applicant presented categorization of the full study population into three subpopulations of progressors based on the change in ALSFRS-R score from onset to screening and also from screening to baseline. More importantly, the applicant establishes the

<div style=\"page-break-after: always\"></div>

primary efficacy population as the one including moderate progressors, i.e. patients with an ALSFRS-R total score progression between onset of the disease and screening of &gt; 0.3 and &lt;1.1 point/month and an  ALSFRS-R  total  score  decrease  of ≥ 1  point  between  screening  and  baseline.  All  regulatory considerations aforementioned detailed are applicable here. It is considered that these study design features could lead to a study population that is not fully representative of the broad ALS population.

During the procedure, the applicant stated that the enrolment in study AB19001 has been slow due to the restrictive design features of that study (i.e. long 3 months run-in period, with no control of FVC at baseline / Moderate ALS only / Approved treatment in the USA - Edaravone, Relyvrio - not allowed / blinded  extension  at  week  48).  Consequently,  the  applicant  proposed  a  new  confirmatory  study  AB23005 study- and presented the previously proposed confirmatory AB19001 study as an exploratory one.

Study AB23005 is a multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to evaluate the efficacy and safety of masitinib as add-on therapy in ALS patients treated with standard of care. Patients will be randomised (1:1) to receive Masitinib AB Science 4.5 mg/kg/day or matching  placebo  and  Masitinib  AB  Science  6  mg/kg/day  will  not  be  pursued  further  in  the  study AB23005. The primary endpoint is the absolute change in ALSFRS-R from baseline to week 48. In this study, the secondary endpoints include measurements of muscle strength, progression free survival and overall  survival.  According  to  the  synopsis  of  the  study  provided  during  the  procedure,  the  primary efficacy population will be the ITT (all randomised full study population). The applicant specifies two measures of ALSFRS-R progression rate (point/month) will be evaluated at screening to categorise ALS patient as slow, moderate, or fast progressor. As per the inclusion criteria, only patients with a ALSFRSR progression rate between &gt; 0.3 and &lt;1.1 point/month as measured between onset of the disease and screening AND as measured by any available ALSFRS-R assessment during the period ranging from 7 months to 2 months prior to screening and screening, reassessed and documented by certified rater performing ALSFRS-R assessment from screening visit onward will be enrolled (synopsis of AB23005 protocol). Further restriction is included as per the baseline ALSFRS-R scores as a total score of at least 15 points of ALSFRS-R at baseline and screening [at least 3 in item3; at least 2 in item12; at least 1 in each of the other items] is also requested as inclusion criterion. All aforementioned considerations on using delta FS to select study population are also applicable here. While no further categorization is proposed to be done after enrolment (i.e. primary efficacy population is full study population), it is considered that the mentioned inclusion criteria could lead to the inclusion of a restricted ALS population. Moreover, it is considered that a duration of the study AB23005 (48 weeks) might not be long enough to generate sufficient data on survival events, which are necessary to support the primary endpoint and taking into account that the positive data on survival or survival equivalent are expected.

Besides to the above considerations on the study design features and the potential impact on the ability of Study AB23005 to provide comprehensive evidence, the CHMP was concerned about the feasibility to properly conduct that study if Masitinib AB Science is authorised in the EU. It needs to be bear in mind that ALS is a fatal condition for which the only therapeutic options in the EU are symptomatic treatment and riluzole for all ALS patients expect those with SOD1-ALS. Hence, the CHMP is concerned that the authorisation of Masitinib AB Science will impact the recruitment and the conduction of the AB23005 study in the EU sites as ALS patients will likely start (i.e., impact on recruitment) or shift (i.e. impact on conduction) to the commercial Masitinib AB Science when available. The new confirmatory AB23005 study is expected to enrol 408 patients. The applicant presented a feasibility analysis and concluded that a  total  of  855  patients  could  be  enrolled  over  a  12-month  period  including  583  patients  in  non-EU countries and US. The applicant claimed that Study AB23005 can be completed within 2.5 years with involvement of site from USA and other non-EU countries or within 3 years with involvement of site only from other non-EU countries. These figures assume the study starts in Q2 2024. Thus, the applicant position is that confirmatory study AB23005 is feasible outside of the EU and further facilitated since

<div style=\"page-break-after: always\"></div>

Relyvrio is withdrawn from market in USA and Canada. However, considering the numerous changes undertaken in the protocol of the pivotal study during its execution as well as the slow enrolment in the study AB19001, which became an exploratory study later on  the applicant capability of properly conduct this study is still unclear, despite the applicant's declared commitment.

In view of the above, high uncertainties remain with regard to the possibility to provide comprehensive clinical data, should a CMA have been granted.

## 3. Fulfilment of unmet medical need

The third criterion requires that unmet medical needs will be fulfilled. As other medicinal products for the treatment of ALS are authorised in EU, the applicant should justify that Masitinib AB Science provides a major therapeutic advantage (MTA) over each existing authorised medicinal products in an overlapping indication, in case a CMA would be granted. The currently authorised medicinal products for ALS are riluzole and tofersen (the latter, only for SOD1-ALS).

The pivotal study AB10015 of this CMA is a prospective, multicenter, randomised, double-blind, placebocontrolled, parallel groups, phase II/III study to compare the efficacy and safety of Masitinib AB Science versus placebo in ALS patients. The study objective was to evaluate efficacy and safety of Masitinib AB Science as add-on therapy to riluzole. Indeed, all patients included in this pivotal study received riluzole. Hence, this pivotal trial is designed to measure causal effects (efficacy) of Masitinib AB Science on top of Riluzole. If efficacy was demonstrated for Masitinib AB Science on top of riluzole in this pivotal trial, the differences in ALSFRS-R score and survival equivalent (PFS) estimates observed in the pivotal trial in  favour  of  Masitinib  AB  Science  arms  in  principle  could  have  been  considered  as  meaningful improvements of morbidity or mortality of the disease and thus supporting that Masitinib AB Science provides  MTA  versus  riluzole.  However,  as  efficacy  was  not  demonstrated,  it  cannot  be  concluded whether Masitinib AB Science provides a MTA versus riluzole.

On the other hand, the applicant provided a succinct justification of an MTA over tofersen during the oral explanation. The applicant claimed that Masitinib AB Science and tofersen have different mechanisms of action. This is agreed; however, a different mechanism of action does not automatically justify for MTA, it needs to be justified that the new mechanism of action provides a significant clinical advantage versus the existing therapies. In accordance with the Guideline on the scientific application and the practical arrangements  necessary  to  implement  Regulation  (EC)  No  507/2006  on  the  conditional  marketing authorisation  for  medicinal  products  for  human  use  falling  within  the  scope  of  Regulation  (EC)  No 726/2004 MTA would normally be based on meaningful improvement of efficacy or clinical safety or, in exceptional  cases,  on  major  improvements  to  patient  care .  Furthermore, the  applicant  claimed  that SOD1-ALS represents approximately 2% of people living with ALS. This is also correct, but the MTA needs to be justified in the overlapping indication. Hence, in view of the claimed indication for Masitinib AB Science, it is still the case that the applicant has to demonstrate that Masitinib AB Science provides MTA versus  tofersen  in  the  SOD1-ALS  subpopulation.  Finally,  the  applicant  claimed  during  the  oral explanation  that  Masitinib  AB  Science  makes  a  major  contribution  to  patient  care  with  a  benefit  on ALSFRS, QOL, and PFS, OS (+ 12 months).

Based on the above, it is understood  the applicant is claiming MTA based on  improved efficacy and major contribution to patient care. With regard to the first claim (i.e. improved efficacy), it needs to be considered that the pivotal trial did not enrol any patient treated with Qalsody. It is unclear whether SOD1-ALS patients were enrolled at all in the pivotal trial. The applicant has not sufficiently justified that the  claimed  benefits-  if  finally  accepted  by  the  CHMP-  could  be  extrapolable  to  the  SOD1-ALS subpopulation who could benefit from a more targeted therapy (Tofersen addressed overexpression of SOD1  as  a  key  pathological  mechanism  of  damage  in  SOD1-ALS)  and  thus,  provides  meaningful improvement of efficacy versus tofersen in this ALS sub-population. With regard to the third claim (i.e.

<div style=\"page-break-after: always\"></div>

major  contribution  to  patient  care),  the  applicant  has  not  sufficiently  justified  which  is  exactly  the contribution to the patient care.

## 4. The benefit of immediate availability outweighs the risks

The applicant position is that benefit associated with the immediate availability of Masitinib AB Science based on number of deaths avoided and total gain in life-years as estimated based on study AB10015 (pivotal study for this CMA) outweighs the risk of adverse events.

However, taking all above into account, especially since the benefit risk balance has not been determined as positive, the benefits to public health of the immediate availability of Masitinib AB Science do not outweigh the risks inherent in the fact that additional data are still required.

## Third Party Interventions

The CHMP received correspondences from two patient organisations (hereinafter referred to as 'third parties') which expressed their position on the unmet medical need for ALS and on their understanding of the efficacy and safety profile of Masitinib AB Science.

The CHMP considered the intervention and concluded that the arguments put forward by the third-party did not impact the CHMP conclusions.

## 3.8. Conclusions

The overall benefit/risk balance of Masitinib AB Science is negative.

## 4. Recommendations

Based  on  the  CHMP  review  of  data  on  quality,  safety  and  efficacy  for  Masitinib  AB  Science  in  the treatment  of  adult  patients  with  amyotrophic  lateral  sclerosis  (ALS)  prior  to  any  loss  of  function  in combination with riluzole, the CHMP considers by consensus that the quality and efficacy of the abovementioned medicinal product is not sufficiently demonstrated, and therefore recommends the refusal of the granting of the conditional marketing authorisation for the above-mentioned medicinal product. The CHMP considers that:

- The suitability of the proposed dissolution method to ensure proper control of the medicinal products during the lifecycle of the medicinal product, especially for the 200 mg strength, and therefore to ensure batch to batch consistency has not been sufficiently demonstrated. Several deficiencies and the lack of an acceptable explanation for the significant differences of dissolution data between the 100 mg strength and the 200 mg strength, as well as differences in dissolution profiles between different  batches  of  the  200  mg  strength  remain  at  the  time  of  opinion.  The  applicant  has  not convincingly demonstrated that tablet hardness and film-coating are the main issues for differences in dissolution results between 100 mg and 200 mg tablets as dissolution results do not correlate with these parameters. Moreover, the potential reasons of different dissolution results between 200 mg batches (intra-batch and inter-batches) were not discussed in order to ensure that, e.g., the manufacturing process is adequate to obtain a product with the intended high quality.
- A positive benefit/risk balance of Masitinib AB Science for the treatment of patients with ALS cannot be established based on the following:
1. The data from the pivotal clinical study AB10015 cannot be relied upon. Despite the applicant's arguments and the implementation of corrective measures, the deficiencies identified during

<div style=\"page-break-after: always\"></div>

previous  GCP  inspection  cannot  be  resolved  by  performing  re-monitoring  and  retrospective analyses at the study sites and cannot be corrected retrospectively.

2. Beside  the  data  not  being  reliable,  the  results  from  the  pivotal  study  AB10015  do  not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS, because:
- A  statistically  significant  difference  compared  to  placebo  was  not  demonstrated  for  the primary endpoint in the full study population.
- The  approach  to  categorise  the  population  into  normal  and  fast  progressors  is  not supported.
- Considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition of intercurrent events in J2R strategy are not considered acceptable.
- The strategies to post hoc identify new target populations ('M4.5 with ≥2 on each baseline ALSFRS-R item and Δ FS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1) are considered as data driven decisions and are, therefore, not acceptable.
- A CMA requires that all requirements as described in Article 4 of Commission Regulation (EC) No. 507/2006 are met. In addition to not fulfilling the first criterion, which relates to the positive benefit / risk balance, also other CMA criteria are not considered fulfilled: it is considered unlikely that the applicant  will  be  in  a  position  to  provide  comprehensive  clinical  data  post-authorisation,  the applicant has not sufficiently justified that Masitinib AB Science would provide a major therapeutic advantage versus tofersen and, taking all the above into account, it is considered that the benefits to public health of the immediate availability of Masitinib AB Science do not outweigh the risks inherent in the fact that additional data are still required.

Due  to  the  aforementioned  concerns  a  satisfactory  summary  of  product  characteristics,  labelling, package leaflet, pharmacovigilance system, risk management plan and post-authorisation measures to address other concerns as outlined in the list of outstanding issues cannot be agreed at this stage.

Furthermore, following review of the available data in the context of the applicant's claim of new active substance status, the CHMP position at the time of this report is reflected in Appendix 5.2.

## 5. Re-examination of the CHMP opinion of 27 June 2024

Following the CHMP conclusion that Masitinib AB Science was not approvable, the Applicant submitted detailed grounds for the re-examination of the grounds for refusal.

## 5.1. Detailed grounds for re-examination submitted by the Applicant

## 5.1.1. Ground #1

The suitability of the proposed dissolution method to ensure proper control of the medicinal products during the lifecycle of the medicinal product, especially for the 200 mg strength, and therefore to ensure batch to batch consistency has not been sufficiently demonstrated. Several deficiencies and the lack of an acceptable explanation for the significant differences of dissolution data between the 100 mg strength and the 200 mg strength, as well as differences in dissolution profiles between different batches of the

<div style=\"page-break-after: always\"></div>

200 mg strength remain at the time of opinion. The applicant has not convincingly demonstrated that tablet hardness and film-coating are the main issues for differences in dissolution results between 100 mg and 200 mg tablets as dissolution results do not correlate with these parameters. Moreover, the potential reasons of different dissolution results between 200 mg batches (intra-batch and inter-batches) were not discussed in order to ensure that, e.g., the manufacturing process is adequate to obtain a product with the intended high quality.

## Applicant´s position on the Ground for re-examination

The Applicant presented first their interpretation of the CHMP position

The Applicant confirmed that batches No 2006325, 2211821 (100 mg) and 2103375, 2211820 (200 mg) were manufactured in a site between April 2020-September 2022 with the proposed formulation and manufacturing process. Therefore, they could be considered as representative.

The Applicant repeated the conclusion that both 100 rpm and 75 rpm gave similar in vitro dissolution profiles supporting the selection of 75 rpm for the conditions of the dissolution method which is aimed to be discriminatory.

Slight differences in disintegration time between 100 mg and 200 mg, as well as differences in tablet mass and tablet hardness and tablet coating where provided as possible root causes for the variability observed regarding the dissolution data of 100 mg and 200 mg at 100 rpm and 75 rpm. However, these explanations deserve further reflection and altogether do not adequately justify the variability of the dissolution data provided for the additional 200 mg batches submitted with the responses of the previous round.

The Applicant has not performed comparative dissolution testing between two 100 mg tablets and one 200 mg tablet, as suggested, in order to obtain data that could potentially reveal the causes of the different and variable dissolution results. The Applicant indicated that it is not relevant as sink conditions are achieved. Although it is stated in the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98) that above mentioned test could be necessary when not all strengths can reach sink condition, it should be noted that in connection with this application, the aim of this experiment is to reveal the causes of the significant differences in the dissolution profile between both strengths, e.g., due to hydrodynamic processes.

During the development, the tablet hardness acceptance criteria were adjusted several times and the following process parameters are set for the industrial batches (Module 3.2.P.3.3):

For three 100 mg strength batches and seven 200 mg strength batches, comparative hardness and sequential dissolution data can be found in Module 3.2.P.2, however, not all batches were tested for dissolution at 5- and 15-minutes time points. See industrial batch data extracted by assessor below:

The Applicant has concluded (section 3.2.P.2, p.91-92/102) that the hardness of the tablet at the highest limit affects dissolution in the first 5 minutes, but at the specification time point (20 minutes) the results are acceptable.

However, at the same time the Applicant has performed tableting tooling study (section 3.2.P.2, p.9092/102) in order to investigate the influence of the tablet hardness on drug product characteristics. The influence of tablets hardness to dissolution rate also was investigated.

According to dissolution data obtained during tableting tooling study, only extreme tablets' hardness has influence on dissolution results in first 5 minutes. The established in-process specification for hardness for 100 mg tablets is 70-110N and for 200 mg tablets - 130-170N.

Taking into account the above mentioned, no obvious conclusion can be made that tablet hardness is the main issue for differences in dissolution results between 100 mg and 200 mg tablets.

<div style=\"page-break-after: always\"></div>

Moreover, dissolution data of batch No 1409991 have been used in the development of the dissolution method (RSD % exceeds the fluctuations determined in the Reflection paper at 15 min at both rotation speeds). For other batches used to justify the suitability of the dissolution method (e.g., 200 mg batches No 1600847, 2103375, 2211820), no hardness versus dissolution data is available. The argument about the effect of the tablet coating is not clear because, as the Applicant already pointed out, the coating has no functional purpose, which is also demonstrated by the dissolution data of the 200 mg strength batch No 0911434. Additionally, the Applicant stated that Opadry® from Colorcon was selected as film agent as it is used as a suspension in water, it disintegrates quickly and it does not change significantly dissolution (section 3.2.P.2, p.7/102).

For finished product batches of 200 mg strength where results of dissolution do not exceed 85% in 15 minutes and high RSD% values have been observed, it was requested to confirm the similarity with 100 mg strength by statistical  methods  other  than  F2  calculation  (e.g.,  bootstrap  method  etc).  No  such statistical data has been submitted by the Applicant. The quality control method to be used during the life  cycle  of  the  drug  product  should  be  suitable  for  all  strengths,  regardless  of,  e.g.,  tablet  mass, hardness etc. properties. In the case of larger fluctuations in dissolution results (see EMA/CHMP/CVMP/QWP/336031/2017), it should be demonstrated by statistical methods that the results obtained with the specific test method are comparable. If this cannot be demonstrated, then the question of  the  suitability  of  the  method  remains open, because there are doubts about the suitability of the method for proper routine quality control of the drug product (an issue not related with bioavailability).

The Applicant stated that the variability of the in vitro dissolution results between batches are at 5 min and 10 minutes time points and it correlates with the disintegration times. However, also at 15 min there is still differences between dissolution data gathered at 75 rpm and 100 rpm and between batches for the 200 mg strength. Potential reasons of different dissolution results between 200 mg batches (intrabatch and inter-batches) are not discussed at all which may raise also the concern on whether not only on the suitability of the selected dissolution method as quality control method for both strengths but whether the manufacturing process is adequate to obtain the 200 mg strength with consistent quality. For this reason, this part of the major objection is not considered resolved.

## AB Science Response

Note: During the two previous registration procedures (EMEA/H/C/004398: resolved at D150 (appendix 1a and appendix 1b); EMEA/H/C/004159/0000: resolved at D195 (appendix 2a and appendix 2b)), i)  the  selected parameters of the in vitro dissolution method, ii) the discriminance of the dissolution method at 100 rpm and iii) the specification limits were considered acceptable. Indeed, during the two procedures, the assessment of the Applicants responses were considered as 'Solved' at the end of these procedures.

## 1- About the in vitro dissolution testing method

During the current procedure, the Applicant provided additional information (refers section 3.2.P.2 and response to D180 1st and 2nd LoI answers) to demonstrate the accuracy of the dissolution method.

Based on the results collected on the proposed formulation with the proposed manufacturing process, we demonstrated that the proposed dissolution method at 100 rpm provided the closest results to the EMA guidelines recommendations. In addition, this 100 rpm method was able to exclude batches which would not be compliant with the proposed specifications (Figure 8).

However, following the clarification meeting held on 7 February 2024 and submitted data for 2nd D180 LoI, AB Science subsequently proposed a dissolution method at 75 rpm since this speed is more in line with in vitro dissolution testing rules and generate comparable dissolution results with 100 rpm.

<div style=\"page-break-after: always\"></div>

Considering that during the previous two procedures, the 100 rpm dissolution method was considered acceptable by the CHMP, the Applicant proposes to keep this dissolution method at 100 rpm instead of the 75 rpm.

Figure 8: In vitro dissolution tests profiles - granulation parameters investigations

<!-- image -->

## 2- About intra/inter batch variability investigations

The issue of intra-batch and inter-batches variability occurs at the 5 and 10 minutes time points, not at the proposed specification time point at 20 minutes.

A comparative dissolution testing between two 100 mg tablets and one 200 mg tablet has been initiated. Results are expected by end of September 2024 and will be communicated to the Rapporteurs. However, as the sink conditions are largely fulfilled, difference between two 100mg tablets and 200mg tablet are not expected.

Still, potential reasons of different dissolution results between 200 mg batches (intra-batch and interbatches) have been investigated (32P2 section) and the following causes could be ruled out

- a. API particle size distribution: Not the root cause
- b. Excipients functional characteristics: Their key physico-chemical properties are tested and no potential impact are expected

The following causes were also investigated and had a slight impact, but only at the 5 and 10 min time points, without impacting the 20 min time point (the proposed specification time point)

- c. Tablet harness (uncoated tablet): The selected hardness range would only have a slight impact at the highest hardness values (ref the tooling study -3.2.P.2.3.2.3 B).i) and therefore is not the main reason for the variability.
- d. Coating agent: Very slight impact on the profile.

The intra difference (or inter-difference) on a granulated batch might be a potential explanation. Indeed, it was demonstrated during the product development that the granulation might have an impact on the in vitro dissolution profiles (see fig 1). However, testing this hypothesis would require to manufacture industrial/semi industrial batches using the same equipment and formulation, which is not feasible within the timeline of the procedure.

<div style=\"page-break-after: always\"></div>

To complete these arguments and referring back to the point 1- , the over-discriminance of the method, especially at 75 rpm, could not be excluded.

## 3- Potential impact and risks

The issue of intra-batch and inter-batches variability does not impact the patient safety and treatment efficacy because it has not impact on the bioavailability of the treatment.

This is supported by a bioequivalence study which demonstrate equivalence between a fast dissolving form (capsule - batch 03206/0001) and the proposed formulation (coated tablet with the proposed formulation and manufacturing process - batch 04JM100).

By examining the in vitro dissolution profiles of the clinical phase III batches used for the purpose of the clinical study AB10015, it is clearly proved that any batch is in the range of the bioequivalence (see here after).

Figure 9: Phase 3 batches - in vitro dissolution profiles comparison

<!-- image -->

Please note that batches 1110245, 1110278 and 1211430 were not analyzed at 5 min time point. The values at 10 min time point are respectively 100%, 100% and 101%. The argument remains valid.

In summary, both the 75 rpm and the 100 rpm dissolution methods comply with EMA guidance at the proposed specification 20 minutes time point. Potential reasons for intra difference or inter-difference at 5 min and 10 minutes time points were investigated whenever feasible. No root cause is well identified at  that  time  but  the  bioequivalence  of  the  batches  is  not  affected  by  the  intra  difference  or  interdifference at 5 min and 10 minutes. This method is discriminant, could exclude non-compliant batches with the proposed specification and could then be used as a quality control tool.

## CHMP position on the Ground for re-examination

The Applicant's conclusions are unconvincing, as no sound justifications to the specific ground of refusal (GfR) raised by the CHMP has been provided, but rather hypothesis that needs to be confirmed.

## 1- About the in vitro dissolution testing method

The  studies  conducted  are  insufficient  to  draw  robust  conclusions  on  the  appropriateness  of  the dissolution method and, consequently, its reliability to detect product quality attributes, that, if altered,

<div style=\"page-break-after: always\"></div>

could affect in vivo performance.

It is worth noting that in addressing the grounds for refusal, the Applicant referred to the dissolution behaviour of the medicinal product by presenting dissolution profiles (graphs), without providing clear information regarding the nature of the batches reported or the conditions under which the dissolution methods were conducted.

The  Applicant's  response  on  the  adequacy  of  the  speed  selected  for  the  dissolution  method  is  not discussed  in  light  of  findings  obtained  by  a  study  of  the  discriminatory  power  but  only  mentioning previous masitinib applications, where the same speed of the dissolution method was accepted by the CHMP. This approach is not endorsed, as each marketing authorisation procedure and dossier is unique, and assessed on its own merit based on the data presented in the application. Furthermore, additional data compared to the previous applications was presented by the Applicant, and this additional data was also taken into account during assessment and in reaching the conclusions.

According to the relevant EMA guidelines, the discussion on the dissolution method development should be performed in a sequential manner. For example, when discussing the stirring speed for paddle the starting  point  should  be  50  rpm.  If  deemed  inappropriate,  the  subsequent  stirring  speed  should  be discussed. In this case, the 50 rpm was not evaluated, and the exclusion of the 75 rpm stirring speed was not substantiated by a sound justification. In fact, in the Applicant's response to GfR it is stated that, although the speed at 75 rpm is more in line with in vitro dissolution testing rules and produces comparable dissolution results with 100 rpm, the Applicant preferred to keep the dissolution method at 100 rpm, considering the previous experience with the two earlier procedures where the 100 rpm was accepted.

However, the higher stirring speed of 100 rpm is expected to lead to a reduced discriminatory power, by decreasing variability  of  the  results  and  obtaining  a  more  rapid  complete  dissolution.  This  approach should be avoided, since the stirring speed should not be selected at the expense of the discriminatory power.

## 2- About intra/inter batch variability investigations

The deficiencies and the lack of a satisfactory explanation for the significant differences of dissolution data between the 100 mg and the 200 mg strengths, as well as differences in dissolution profiles between different  batches  of  the  200  mg  strength,  remain  unsolved  since  the  Applicant  has  not  clarified  the reasons of intra-batch (or inter-batches) difference. Indeed, in the re-examination dossier the Applicant declared that tablet hardness and film-coating were no more identified as the main causes of dissolution variability, as they were found to have only a minor impact at the 5 and 10 min time points, without impacting the 20 min time point. Thus, excluding these causes, the Applicant suggested that granulation might be a potential explanation of the intra-batch (or inter-batches) difference. However, this aspect has  not  been  substantiated,  as  according  to  the  Applicant,  generating  new  data  on  industrial/semiindustrial batches using the same equipment and formulation intended for the market is not feasible within the re-examination procedure.

The identification of the granulation step as a possible cause of variability in dissolution results raises concerns on the adequacy of the drug product development and, consequently on the know-how of the production process.

The Applicant stated that a comparative dissolution testing between two 100 mg tablets and one 200 mg  tablet  has  been  initiated  and  results  are  expected  by  end  of  September  2024.  While  this  is acknowledged, it is reminded that the re-examination procedure can be based only on the scientific data available at the time of initial opinion and cannot take into account new data, and above all the issue on the  intra-batch  differences  would  remain  unsolved,  since  only  results  on  the  comparison  of  the  two strengths would be available.

<div style=\"page-break-after: always\"></div>

## 3- Potential impact and risks

The Applicant reiterated that the issue of intra-batch and inter-batches variability does not impact patient safety and treatment efficacy, as it does not affect the bioavailability of the treatment. This claim is supported by the bioequivalence study, which demonstrates equivalence between a fast dissolving form (2x50 mg capsule - batch 03206/0001) and the proposed formulation (1x100 mg coated tablet with the proposed manufacturing process - batch 04JM100).

However, the in vivo results cannot overcome the need to establish the suitability of the dissolution method for proper routine quality control of the drug product. Thus, concerns regarding batch to batch consistency remain, since the discriminatory power of the dissolution method was not demonstrated. Moreover, according to the Applicant's hypothesis on the impact of the granulation step on the variability observed in the dissolution profiles, the manufacturing process has not been demonstrated adequate to obtain a product with the intended quality.

Unless it is not unequivocally demonstrated that the manufacturing process is robust and adequate to produce uniform and consistent batches, doubts persist about the reliability of the bioavailability results.

## Overall Conclusion

The GfR related to the quality of masitinib remain unsolved. The Applicant has not presented compelling arguments to resolve the quality issues.

## Point not resolved

## 5.1.2. Ground #2.1

The  data  from  the  pivotal  clinical  study  AB10015  cannot  be  relied  upon.  Despite  the  Applicant's arguments and the implementation of corrective measures, the deficiencies identified during previous GCP inspection cannot be resolved by performing re-monitoring and retrospective analyses at the study sites and cannot be corrected retrospectively.

## Applicant´s position on the Ground for re-examination

The Applicant presented first some statements already detailed in section 2.6.6 - Discussion on clinical efficacy of this CHMP AR:

A triggered GCP inspection (GCP/2017/001) was requested by the CHMP on the conduct of the clinical study AB10015 in the context of a previous marketing authorisation application for ALS. The triggered GCP inspection reported critical and major inspection findings affecting different aspects of the study, which  impact  on  the  reliability  of  the  study  data.  Major  findings  were  observed  at  qualification  and training, trial master file, clinical conduct of the trial, safety reporting, investigational medicinal product, source data verification and clinical study report. The GCP inspection concluded that the data obtained at the sites inspected are not trustworthy.

It is noted that at the time of the GCP inspection, the Applicant presented a series of corrective and preventive  actions  which  have  been  assessed  by  the  inspectors  and  were  not  found  sufficient  to recommend the use of data. In accordance with the GCP inspection report conclusion, after the evaluation of the responses submitted by the Applicant, the Inspection Team considered that due to the departures from GCP observed, it cannot be ensured that the data inspected are trustworthy and are likely to have an impact on the final results. Data integrity is high likely to be impaired as several protocol deviations at eligibility, conduct and in other aspects inspected.

Given the nature of the findings, the systematic deficiencies observed (i.e. massive number of protocol deviations) and the fact that some findings such as the deficiencies during inclusion/exclusion criteria

<div style=\"page-break-after: always\"></div>

verification  and  subjects'  follow  up  (critical  finding  1  in  the  inspection  report)  cannot  be  corrected retrospectively,  the  proposed  corrective  actions  presented  by  the  Applicant  were  not  considered adequate to address all the concerns raised.

As part of this current application, the Applicant claimed that the GCP findings were addressed with implementation of preventive actions across study and functions within AB Science. The Applicant also claimed that for study AB10015, corrective actions were implemented wherever feasible. The measures which the Applicant claims to have implemented after the inspection, have been assessed as part of the current marketing authorisation procedure and were found insufficient to address the issues raised and re-assure CHMP on the trustworthiness of the data.

During the procedure, the Applicant argued that GCP findings related to ALSFRS-R were not systematic and  the  ALSFRS-R  scores  data  are  reliable,  it  is  feasible  to  perform  re-monitoring  and  manage retrospective/impact analysis and refers to the EMA guidelines EMA/868942/2011. In addition, during the procedure the Applicant performed an impact analysis of protocol deviations and concluded that GCP inspection findings which are likely to influence the evaluation of the primary efficacy endpoint, whether correctable or not, had no significant impact on the study's outcomes. The Applicant's conclusions that the primary endpoint is not affected are not agreed by the CHMP. In addition, it should be noted that even the execution of the different analysis excluding just one or two inspected sites are often not meaningful since these do not address the uncertainty regarding the non-inspected sites (EMA/8689942/2011).

The Applicant has provided justifications for the GCP aspects during the procedure including expanded written  discussions  after  the  oral  explanation.  The  Applicant  provided  numerous  arguments  on  the extensive corrective actions implemented after the inspection conducted in the context of the previous marketing authorisation application and other regulatory authorities, including an impact analysis of identified protocol deviations. The Applicant upholds the position that the corrective actions implemented after the GCP inspection and the Applicant interpretation of the guidelines on benefit/risk evaluation demonstrates an absence of impact on the results of the AB10015 study. Following the review of the information submitted in support of this application, including the implemented corrective measures, it is considered that the issues identified cannot be resolved by performing re-monitoring and retrospective analyses  at  the  study  sites.  The  numerous  retrospectives  analyses  applied  by  the  Applicant  do  not compensate for the deficiencies in the conduct of the study and thus the data are not considered reliable. The Applicant has reiterated the relevance of the impact analysis of identified deviations during GCP inspections, however the Applicant ' s claim that the primary endpoint is not affected is not agreed by the CHMP. From this point of view, the primary and secondary endpoint results (i.e. ALSFRS-R) of the single pivotal study are based on dataset of compromised quality and reliability. The statement of the Applicant that ' the CHMP ' s decision to base its findings solely on the inspectors ' position from 2017, fails to take into  consideration  the  entire  sum  of  evidence  now  available  and  is  not  therefore  consistent  with guidelines on benefit- risk assessment ' is not agreed with.

Therefore, despite the fact, that the Applicant has provided impact analysis and arguments, the existing evidence  of  data  quality  does  not  assure  CHMP  that  the  AB10015  trial  data  is  trustworthy..  The Applicant ' s provided impact analysis and arguments are not sufficient to assure CHMP that the AB10015 trial data is trustworthy considering the conclusions of GCP inspection and the presented implemented corrective actions. The data from clinical study AB10015 cannot be relied upon. The CHMP is of the opinion that this conclusion is in line with EMA/8689942/2011 document ' Points to consider on GCP inspection findings and the benefit-risk balance '.

## AB Science Response

<div style=\"page-break-after: always\"></div>

## Argument 1.1: AB Science has a legitimate doubt regarding the potential bias of the ALS inspection  and  urge  the  Rapporteurs  to  take  into  account  all  available  information,  in particular actions implemented by AB Science after the inspection

CHMP  currently  adheres  strictly  to  the  conclusions  of  the  inspection  report,  without  evaluating  the additional analyses provided by AB Science.

We faced two negative concomitant trial inspections, one in mastocytosis and one in ALS. The inspection in mastocytosis was led by an inspector who later wrote to the Autorité des Marchés Financiers , that triggered an investigation for insider trading. This investigation, which is now closed, concluded that there was no insider trading and demonstrated the profound bias of the said inspector.

AB Science has a legitimate doubt regarding the potential bias of the ALS inspection by the Mastocytosis inspection.

For these reasons, we urge the Rapporteurs to:

- -assess all correspondence between the Mastocytosis and the ALS inspectorates and share them in transparency with AB Science,
- -take the conclusion of the inspection with extreme caution
- -take into consideration the actions implemented by AB Science and the impact analysis on the benefit -risk assessment, which shows there is no impact. There were several measures taken by AB science post- inspection to overcome the drawbacks of the clinical study conduct. One of them being an impact analysis, which was performed in a GCP-compliant system, was not reviewed or assessed by the EMA inspectors.

## Argument  1.2:  According  to  guidance  EMA/8689942/2011  evaluators  must  go  beyond inspection report

Guidance EMA/8689942/2011 clearly states that ' GCP inspectors and clinical assessors have different roles in the overall regulatory process of evaluating new medicines. Hence, it should be acknowledged that  the  focus  of  the  GCP  inspectors  and  clinical  assessors  is  different  and  as  a  consequence  the evaluation of the significance of the findings may also differ. For the assessors, the focus is on the particular  medicine  under  assessment  to  ensure  that  the  benefit-risk  balance  is  favourable  before licensing and that the overall ethical conduct is acceptable '.

There have been instances where similar conclusions from the Inspectors have not led the CHMP to inevitably  dismiss  that  data,  including  for  example  EPAR  EMA/174182/2014,  wherein  the  inspection report concluded that ' Inspectors cannot recommend that the presented data and CSR is accepted by the CHMP or used for further assessment' and where no major objection was raised as the CHMP noted that ' The Applicant, in response to the inspector's findings, provided a follow-up of the post inspection corrective  action  plan.  The  Applicant  has  responded  to  the  numerous  GCP  inspection  findings  with corrective measures whenever possible '.

Four examples of negative GCP findings and positive Benefit- Risk assessments are provided in Appendix 1.

## Argument 1.3: The other inspections reports available, as well as audit reports; are consistent and they do not conclude that data are not trustworthy or should be disregarded. Therefore, they have to be considered as well

The conclusions of the EMA Inspection were divergent from: i) inspections conducted by other health regulatory authorities and ii) the audits conducted at the request of AB Science, although findings were comparable.

<div style=\"page-break-after: always\"></div>

A  total  of  four  GCP  inspections  of  study  AB10015  were  conducted:  EMA,  Health  Canada,  ANMAT (Argentina), and Infarmed (Portugal) andthe second largest recruiting site, was inspected by both EMA and Argentina

While EMA found the data unreliable, other authorities such as Health Canada and Infarmed did not find critical issues affecting data integrity.

- Conclusion from site inspection in Argentina by ANMAT

The Argentina health agency inspected  the second largest recruiting site, before inspection of the same site by EMA.

ANMAT did not conclude to the rejection of the data at the site . The translation of the conclusion, from the inspection report is provided below.

'In conformity with the verified findings, the result of the inspection is the following:

- -Official Action Indicated point 12.2, Section D, ANMAT Disposition 6677/10 for the PI to carry out the following actions: Sign a commitment letter with the Administration for the future clinical trials to be conducted.
- -Official Action Indicated for the Sponsor LAT Research to carry out the following actions: Sign a commitment letter with the Administration for the future clinical trials to be conducted'.
-  Conclusion from site inspection in Canada by Health Canada

## The  outcome  of  inspection  by  Canadian  Health  Regulatory  Authority  showed  no  critical findings to AB Science and the authority rated the study as 'Compliant'.

The translation of the conclusion, from the inspection report is provided below.

'As a result of this inspection, the above noted clinical trial has been assigned a Compliant (C) rating, meaning that at the time of the inspection, the regulated party has demonstrated that the activities it conducts are in compliance with the Food and Drugs Act and its associated Regulations. A Compliant rating does not mean that there are no observations or corrective actions required'.

-  Conclusion from site inspection in Portugal by Infarmed

## The  inspection  carried  out  by  Infarmed  did  not  conclude  that  the  study  data  were  not trustworthy. Five Major and Four minor findings were identified. No critical noncompliance was identified.

The translation of the conclusion, from the inspection report is provided below.

'During this inspection it has been confirmed that the monitoring by the Sponsor of centre has not been sufficiently robust and this has caused the occurrence of several non-compliances described above. The selection of participants was made by fulfilling the inclusion criteria (although with certain shortcomings in  the  documentation  process).  There  were  no  indications  of  a  possible  relationship  between  the publication of results of the interim analysis that might have put into question the concealment of the trial in this centre.

Critical non-compliances were not identified.

Five (5) major non-compliances were identified related to: conformity of the eCRF to the protocol in force; monitoring process; deviations from the protocol, recording of data, verification of compliance of EM.

<div style=\"page-break-after: always\"></div>

Four (4) minor non-compliances were detected relating to: training in the field of GCP; calibration of measuring  instruments,  management  of  secure  data  and  temperature  monitoring  records  during transportation of the EM.'

- Conclusion

Among the four inspections carried-out, only EMA inspectors conclude that data are not trustworthy.

The EMA has a framework that allows it to rely on inspection reports from other competent authorities under mutual recognition agreements (MRAs). These agreements are in place with several countries, including the United States, Canada, Japan, and others, to facilitate regulatory processes and reduce duplication of inspections. The mutual recognition agreements ensure that inspections carried out by regulatory  authorities  in  these  countries  are  recognized  as  meeting  the  necessary  standards  for compliance with good manufacturing practices (GMP).

Additionally,  the  EMA  collaborates  with  the  World  Health  Organization  (WHO)  through  the  WHO collaborative  registration  procedure,  which  involves  sharing  detailed  assessment  reports,  including inspection  reports,  to  facilitate  faster  regulatory  approvals  in  participating  countries.  This  procedure emphasizes reliance on inspections and assessments carried out by recognized regulatory authorities like the EMA, thus streamlining the approval process and reducing the administrative burden.

Therefore, the CHMP  should take into account conclusion from other inspections regarding trustworthiness of the data for benefit-risk assessment.

In addition, the Applicant conducted extensive audits by external, independent professionals to ensure full compliance and integrity of the study data. A total of 16 audits were performed at the request of AB Science between 18 May 2017 and 28 December 2017, across six countries. The audited patients in those sites accounted for than 30% of the total randomized patients at those sites. The findings and conclusions of these 16 audits were in line with the inspections conducted by ANMAT, Health Canada and Infarmed, and similarly to these inspections, did not conclude that the data were not trustworthy. One critical finding was identified related to the fact that 'changes to a protocol, particularly those related to safety reporting/monitoring or to interpretation of the protocol should be setup through an amendment and submitted as substantial  amendment' . Several major findings were reported, including inconsistencies  in  AE/SAE  reporting,  delayed  reporting,  documentation  errors,  and  administrative oversights.  For  instance,  incorrect  start/end  dates  for  SAEs,  missing  documentation,  and  the  use  of correction  fluid  on  SAE  documentation  were  noted.  Additionally,  there  were  instances  of  unreported concomitant medications and unsigned SUSAR reports. These audits were not reviewed during the EMA GCP inspection as the EMA inspection was only a site inspection, not a Sponsor inspection.

Despite these audits being conducted in accordance with industry standards and providing comprehensive insights into the study's conduct, it appears that the rapporteurs did not fully account for these independent audits in their assessment.

## Argument 1.4: The conclusion of the EMA GCP inspection diverges from the conclusions of all audits and other inspections

Before  the  EMA  GCP  inspection  of  two  sites  in  late  2017  and  early  2018,  we  conducted  16  audits. Additionally, as mentioned in previous section, three sites were inspected before the EMA GCP inspection. These audits and inspections did not identify the critical non-compliances level, later highlighted by EMA inspectors, suggesting that the EMA findings may not reflect a systematic issue across all sites.

<div style=\"page-break-after: always\"></div>

To demonstrate this, we can categorize the site quality as follows:

| Excellent Quality Sites :           | 0 Critical Findings / 0 Major Findings                         |
|-------------------------------------|----------------------------------------------------------------|
| Good Quality Sites :                | 0 Critical Findings / 1-2 Major Findings                       |
| Moderate Quality Sites : 0 Critical | Findings / 3-5 Major Findings                                  |
| At Risk Sites :                     | 1 critical finding and/or 6-10 Major findings                  |
| Critical Risk Quality Sites         | More than 1 Critical Finding an/or more than 10 major findings |

The results of this categorization are detailed in the table below and can be summarized as follows:

## · Excellent and Good Quality Sites : 48%

- 6 sites had 0 critical and 0 major findings, and 4 sites had 0 critical and 1 or 2 major finding.
- This indicates that a considerable percentage of sites - approximately 48% - were managed with excellent or good quality.
- Moderate Quality Sites: 19% (4 sites)
- 5 sites showed more findings, categorized as moderate risk,
- At risk and High-Risk Sites: 33%
- 5 sites showed more serious findings, categorized as ' at risk '.
- But these sites present still a less critical level of quality than those identified at sites inspected by the EMA and categorized as high-risk in the table below:

| START AUDIT DATE   | CRITICAL FINDINGS   | MAJOR FINDINGS   | Site category   | Patients Randomized   |
|--------------------|---------------------|------------------|-----------------|-----------------------|
| 10-juil-17         | 0                   | 0                | Excellent       | 9                     |
| 05-juil-17         | 0                   | 0                | Excellent       | 30                    |
| 18-oct-17          | 0                   | 0                | Excellent       | 7                     |
| 24/Aug/2017        | 0                   | 0                | Excellent       | 16                    |
| 06-juil-17         | 0                   | 0                | Excellent       | 18                    |
| 04-juil-17         | 0                   | 0                | Excellent       | 16                    |
| 10-juil-17         | 0                   | 1                | Good            | 25                    |
| 06-juil-17         | 0                   | 1                | Good            | 5                     |
| 28/Dec/2017        | 0                   | 2                | Good            | 4                     |
| 04-juil-17         | 0                   | 2                | Good            | 4                     |
| 18/Dec/2017        | 0                   | 3                | Moderate        | 6                     |
| 04-juil-17         | 0                   | 4                | Moderate        | 106 (2)               |
| 05-juil-17         | 0                   | 4                | Moderate        | 10                    |
| 24-oct-16          | 0                   | 5                | Moderate        | 3                     |
| 27-sept-17         | 0                   | 6                | at-risk         | 9                     |
| 01/Apr/2016        | 0                   | 6                | at-risk         | 2                     |
| 27/Dec/2017        | 0                   | 8                | at-risk         | 22                    |
| 29/May/2017        | 0                   | 9 observations   | at-risk         | 53 (2)                |
| 18/May/2017        | 1 (2)               | 7                | at-risk         | 14                    |

Note: Total Number of patients randomized in the trial = 391

(1) Not the same system of findings evaluation

(2) The patients of these sites were categorized as 'a critical risk' by EMA inspection

The last audit was conducted on 28 December 2017, just before the EMA inspections in late 2017 and early 2018. These audits did not highlight the level of critical non-compliances later highlighted by EMA inspectors, suggesting that the EMA findings may not reflect a systematic issue across all sites. Moreover,

<div style=\"page-break-after: always\"></div>

inspections by ANMAT, Canada, INFARMED and the audits, while identifying similar problems, do not conclude that these issues are systemic or that the data are not trustworthy. We can highlight that it concerns sites which enrolled 92 % of all the randomized patients. For accuracy, please find enclosed the wording of the unique critical finding identified during an audit:

- (3) The CRITICAL finding identified in one Italian site is: 'Changes to a protocol, particularly those related  to  safety  reporting/monitoring  or  to  interpretation  of  the  protocol  should  be  setup through an amendment and submitted as substantial amendment'

The  auditor concludes  that 'Because  the  critical finding is from  2013,  …,  the  global recommendations are:

- -The guidelines/documentation/training aimed at improving performance and monitoring of a study are to be improved (refer to CAPAs).
- -AB Science can go on with this site, in performing a monitoring closer to GCP and stricter.

This finding does not impact the efficacy nor the safety data.

At the end of the trial, a total of 134 patients randomized were followed by sites with excellent and good level of quality (6 sites with 0 critical and 0 major finding and 4 sites with 0 critical and 1/2 major finding) which represents 34% of all patients randomized.

- -40% of all patients randomized were followed during the trial by sites inspected by EMA
1. 30% - 122 - at randomized at the time of the inspection
2. 10 % - followed up after the inspection with better level of follow-up as impact of the inspection
- -34% (134) of all patients randomized were followed by sites with excellent and good quality level
- -5% of all patients randomized were followed by sites with moderate quality level
- -12% of all patients randomized were followed by sites at risk
- -Only 32 patients were followed by a site non audited and non-inspected: 9%

Is  it  justified  to  claim  that  all  the  study  data  are  misleading,  given  the  lack  of  uniformity  in  site management quality and considering that only 8% of patients were followed by sites that were neither inspected nor audited, which means we have a fairly good understanding of the site typologies in the study?

The results of the audits and other inspections, clearly differ from the highly negative outcomes of the EMA inspections. A significant proportion of the sites (29%) exhibited excellent or good quality, which is substantial. Less than 6 % of sites are at critical-risk and this distribution supports the assertion that the critical issues identified at the two EMA-inspected sites are not systematic across all study sites.

Consequently, there is a real divergence in conclusions between EMA inspection and all other audits and inspections:

- The heterogeneity in site management quality further suggests that the data integrity concerns raised by the EMA are not representative of the entire study. It cannot be concluded that the issues identified by the EMA are systemic.

No audit or inspection, other than the EMA inspection, has concluded that the data from the entire study are not trustworthy. Given that only 32 patients, representing 9%, were followed by a site that was neither audited nor inspected, this is an important consideration.

<div style=\"page-break-after: always\"></div>

## Argument  1.5:  Inspectors  and  the  Rapporteurs  did  not  account  for  analyses  done  after inspection

Rapporteurs stated that ' It is noted that at the time of the GCP inspection, the Applicant presented a series of corrective and preventive actions which have been assessed by the inspectors and were not found sufficient to recommend the use of data. In accordance with the GCP inspection report conclusion, after the evaluation of the responses submitted by the Applicant, the Inspection Team considered that due to the departures from GCP observed, it cannot be ensured that the data inspected are trustworthy and are likely to have an impact on the final results '.

However, numerous actions were taken after the EMA GCP inspection report, rendering, to a certain extent, the inspection report obsolete.

As a reminder, the following actions were implemented for the quality system and the reliability of the data.

- Post-Inspection Corrective Actions: We have undertaken significant corrective actions (and preventive actions) to address the quality system deficiencies when possible and it included remonitoring of adverse events, vital signs, and lab values at 31 out of 34  study sites.  This extensive re- monitoring ensured that all source data were accurately reflected in the updated clinical study report (CSR v3.0), which has not been reviewed by the inspectors.
- Reinforced Data Integrity and historical  Data  Validation: Critical  data  from  the  trial, particularly the primary endpoint (ALSFRS-R) and safety data, were re-evaluated and validated through multiple layers of independent audits and verifications, ensuring their reliability. These validations  demonstrated that, despite the quality system issues, the data integrity for the primary endpoint was maintained
- Safety data and continuous improvement after inspection but before CSR v3.0: The corrective actions implemented after the EMA GCP inspection confirmed that the safety data, derived  from  the  same  continuously  improved  quality  framework,  are  reliable  for  risk assessment. Detailed impact analyses of protocol deviations (on all sites, all patients, eligibility protocol deviations, all other kind of protocol deviations), demonstrating that these deviations did not significantly affect the primary efficacy or safety outcomes .

The inspectors did not have the opportunity to review our post-inspection corrective measures, including the updated CSR and additional impact analyses.

- -EMA GCP inspection report was completed in February 2018, based on the CSR V1.0.
- -The re-monitoring occurred during the period between the data extraction of the CSRV1.0 date and the data extraction of the CSR v3.0 and included an additional 97 monitoring in 31 sites (91% of the 34 sites).
- -The detailed impact analysis was communicated for the first time at D180.

As a reminder also, two CGP inspections report were provided, ANSM inspection report (GCP-181801FR)  and  MHRA  inspection  report  (INSP  GCP  21687/22860-0003),  indicating  that  the  CSR  v3.0  was released within a GCP compliant environment, as demonstrated by.

## i. ANSM Inspection

The ANSM inspection primarily concerned the vigilance system and the integrity of masitinib safety data. Review of CAPA required for deficiencies related to PV, which were identified during previous inspections. Post Inspection Report Follow-up until resolution of last Major Corrective Actions. Reassessment of the

<div style=\"page-break-after: always\"></div>

safety profile of masitinib with impact analysis of the corrective actions and release of a new investigator brochure [Edition 2018-1] was performed by AB Science.

The conclusion of the final inspection report, dated 27 March 2019, considered ' that the evolution of AB Science's  vigilance  system  and  the  recovery  of  all  the  vigilance  data  carried  out  to  date  provide  a sufficient response to points a, b and of the last recital of the decision of 11 May 2017 suspending the clinical trials promoted by the company AB Science '.

## ii. MHRA Inspection

The  MHRA  inspection  covered  various  activities  (Quality  management,  pharmacovigilance,  project management, monitoring, data-management, and biometry). Review of CAPA required for deficiencies which  were  identified  during  previous  inspections.  Post  Inspection  Report  Follow-up  occurred  until resolution of findings according to MHRA.

The conclusion of the final inspection report, dated 11 November 2021, considered that ' The organisation has provided corrective and preventative actions in response to the inspection report. These have been reviewed by the GCP Inspectorate and are considered acceptable. This inspection can be considered closed '.

A summary of the main improvements and a summary of the impact analysis is available (please refer to the hyperlink in the table below).

A summary and analysis ANSM and MHRA inspection reports is available. ANSM and MHRA inspection reports are available (please refer to the hyperlink in the table below).

Finally, to reiterate our position, provided below is the timeline of events which demonstrate that the inspectors did not have access to the new documents/findings and therefore, the conclusions of the EMA inspection were

## Chronology of the actions taken with respect to the GCP inspection of study AB10015

| Period              | Date                          | Action                                                                                                       | Document                                               |
|---------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Pre EMA Inspection  | 11 AUG 2017                   | Clinical study report provided for initial MA application and inspected                                      | AB10015_CSR v1.0_11aug2017_Final                       |
| Inspection          | 18 DEC 2017 until 12 JAN 2018 | Investigator site GCP inspection Conducted at two sites (one in Spain and one in Argentina). on 07 FEB 2018. |                                                        |
| Post-EMA Inspection | 07 FEB 2018                   | Integrated inspection report GCP/2017/001                                                                    | EMA Masitinib_FINAL Integrated Inspection Report (IIR) |

## Actions Initiated Before, But finalized AFTER or impacting AFTER, the GCP Inspection

| Date                | Action                                                                                                                                                                                                                                        | Document                                                                                                              |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| MAY 2017- DEC 2017  | Audit plan A campaign of 16 audits was performed by external auditors                                                                                                                                                                         | List of audits                                                                                                        |
| JULY 2017-SEPT 2018 | Re-monitoring Conducted between the data extraction dates of CSR V1.0 and CSR V3.0, involving an additional 97 monitoring visits at 31 sites (91% of the 34 sites). Only 3 sites were not re-monitored (two in Canada, and one in Argentina). | List of monitoring visits performed between CSR v1.0 and V3.0 (provided in Response D180 1 st LoI_Seq0008_Appendix 1) |

<div style=\"page-break-after: always\"></div>

| 19 FEB 2010        | Addendum to CSR This addendum addresses one of the issues highlighted in the inspection report regarding certain discrepancies between the eCRF data and the CSR v1.0 At the time of DB lock for the efficacy analysis, many patients were still in the extension phase, and data in safety-related CRF pages of both the main protocol period and the extension protocol period continued to be added, cleaned and modified. In order to respond to the EMA's questions at D121 of initial MAA procedure (h0004398), a second DB extraction on 12 July 2017 was done to analyse the safety of the main protocol period. At the time of this second extraction, a total of 75 patients were still followed up in the extension phase and safety data continued to be recorded on the safety CRF pages. AB Science electronic data capture system is not setup to allow page lock at page or visit level. CRF lock is done at patient level. CRF pages dedicated to the main protocol period remained unlocked until completion of the extension period of each patient. Consequently, the DB continued to be updated, including data changes to the main protocol period. Our electronic data capture system has an audit trial and any changes made to the DB were recorded. Although data cleaning of the extension period had not been completed, safety data of the main protocol period had been completed. The DB was locked on 03 February 2018. A third extraction of the safety data was performed in order to repeat all safety analyses pertaining to the main protocol period (i.e. Week 48). The updated safety tables integrating the changes between the 12 July 2017 and 03 February 2018 are displayed in the present addendum to the CSR v1.0.   | AB10015_CSR v1.0_Addendum_19feb2018                                                                          |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| 27 MAR 2019        | The ANSM inspection primarily concerned the vigilance system and the integrity of masitinib safety data. Review of CAPA required for deficiencies related to PV, which were identified during previous inspections. Post Inspection Report Follow-up until resolution of last Major Corrective Actions. Reassessment of the safety profile of masitinib with impact analysis of the corrective actions and release of a new investigator brochure [Edition 2018-1] was performed by AB Science.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | ANSM Inspection report (provided in Response D180 1 st LoI_Seq0008_Appendix 6)                               |
| 19 to 21 SEPT 2018 | ANSM GCP Inspection of the Sponsor The ANSM inspection primarily concerned the vigilance system and the integrity of masitinib safety data. Review of CAPA required for deficiencies related to PV, which were identified during previous inspections. Post Inspection Report Follow-up until resolution of last Major Corrective Actions. Reassessment of the safety profile of masitinib with impact analysis of the corrective actions and release of a new investigator brochure [Edition 2018-1] was performed by AB Science. The final report was released the 27 Mar 2019 (after ANSM's review of the two impact analyses presented in the 2 lines below of the same table).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | GCP-181801-FR - ANSM Final report_ CONCUSION _VEnglish                                                       |
| 26 NOV 2018        | Analysis of the masitinib safety profile following legacy PV case reevaluation and integration into the new validated PV database. Since October 2018, AB Science has implemented a new validated pharmacovigilance (PV) database system. All legacy safety reports received prior to the launch of this new system have been fully reassessed and re-entered into the new system. A comparison between this new PV database and the safety data recorded in the clinical trial database was conducted to ensure the adequacy and accuracy of the safety profile of masitinib, as described in the approved Investigator's Brochure (Edition 2018-1). Differences were analyzed in terms of their potential impact on the product's safety profile, and no impact was identified. During the previous ANSM inspection, it was acknowledged                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | ABS Impact Analysis Safety Profile masitinib_Nov 2018(provided in Response D180 1st LoI_Seq0008_Appendix 4b) |
| 15 JAN 2019        | the hold. MEDDRA coding reconciliation and analysis of impact As part of the Data Quality Control Plan supporting the implementation of the new AB Science Pharmacovigilance System, a comparison between MedDRA coded AEs stored in PV247 and those available in the clinical database was performed to ensure the adequacy and accuracy of the safety data. During the previous ANSM inspection, it was acknowledged that this impact report would be submitted to ANSM for review by their internal evaluators. This report played a major role in the decision to lift the hold.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ABS Impact Analysis MedDRA Coding masitinib_Jan2019 (provided in Response D180 1st LoI_Seq0008_Appendix 4c)  |

<div style=\"page-break-after: always\"></div>

| 16 SEP 2021   | 2021 CSR for AB10015 Clinical study report, based on safety dataset extraction December 2018 provided for current CMA application                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | CSR_AB10015_v3.0 September 2021                                                                                                |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| 11 NOV 2021   | MHRA GCP inspection The MHRA inspection covered various activities (Quality management, pharmacovigilance, project management, monitoring, data- management, and biometry). Review of CAPA required for deficiencies which were identified during previous inspection (2017). Post Inspection Report Follow-up occurred until resolution of findings according to MHRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | MHRA GCP Inspection Statement Science 11 November 2021 (provided in Response D180 1st LoI_Seq0008_Appendix 6)                  |
| 30 APR 2024   | Impact analysis of eligibility protocol deviations on efficacy and safety data, for all sites and all patients: A thorough, broad detection, systematic review of the final locked database (Cut-off date: 03 December 2018) was performed to identify eligibility criteria queries. These were then assessed to establish deviation status, deviation impact on safety, and separately deviation impact on efficacy. In this manner, all eligibility criteria queries were assessed on a case- by- case basis and subsequently categorized according to seriousness (i.e., negligible query, minor deviation, and major deviation) and potential impact (i.e., no impact, possible impact). The methodology was reviewed and validated by an independent expert a , coordinator of the French rare diseases network on ALS and motor neurone disease (FILSLAN). A matrix of deviations analysis is shown in table below | Responses to D180 2nd list of outstanding issues - Clinical Efficacy_V1.0_April- 2024: Page 10 + Appendix 1, 2 and 3 (Seq0010) |
| 30 APR 2024   | Impact analysis of all protocol deviations (except eligibility criteria managed previously) on efficacy and safety data, for all sites and all patients: As some deviation could not be resolved by corrective actions, we have performed an impact analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Responses to D180 2nd list of outstanding issues - Clinical Efficacy_V1.0_April- 2024: Page 12 (Seq0010)                       |
| 30 APR 2024   | Potential underdosing of riluzole was investigated and an impact analysis was performed A total of 7 patients (1.8%) received sub-dosing of riluzole, including 6 patients in either M4.5 arm (n=3) or placebo arm (n=3). Sensitivity analysis excluding these 6 patients does not modify the study results.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Responses to D180 2nd list of outstanding issues - Clinical Efficacy_V1.0_April- 2024: Page 12 (Seq0010)                       |
| 30 APR 2024   | Masitinib dosing deviations impact analysis Identified deviations that were related to masitinib underdosing could only minimize masitinib efficacy and have no impact.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Responses to D180 2nd list of outstanding issues - Clinical Efficacy_V1.0_April- 2024 Page 13 _(Seq0010)                       |
| 30 APR 2024   | Visit Windows deviation impact analysis DSMB decided (25 Feb 2016) that no impact on efficacy data is expected if non-respect of visit windows is not higher than 28 days and not repeated at 2 consecutive visits. No visit window deviations to this rule occurred in the Masitinib 4.5 mg/kg/day treatment arm or placebo arm, thereby having no impact on the primary analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Responses to D180 2nd list of outstanding issues - Clinical Efficacy_V1.0_April- 2024 Page 13 (Seq0010)                        |

## Argument 1.6:  The  Rapporteurs  provided  no  review  of  AB  Science  corrective  actions  and impact analyses justifying why the data remain not trustworthy

From  the  very  beginning  of  the  procedure,  the  Rapporteurs  adhered  to  the  conclusions  from  the Inspectors and made not no attempt to evaluate the consequences of inspection findings in relation to the benefit-risk balance. This is not in line with the guidance recommendation.

In particular, the rapporteurs stated that ' the Applicant's provided impact analysis and arguments are not sufficient to assure CHMP that the AB10015 trial data is trustworthy considering the conclusions of GCP inspection and the presented implemented corrective actions ', however, these impacted analyses were communicated for the first time at D180, yet the Rapporteurs

- -Maintained without altering them their conclusion that the data were not trustworthy before and after communication of these analyses at D180
- -Did not share any information suggesting these analyses were assessed and how they were assessed

<div style=\"page-break-after: always\"></div>

## Argument 1.7: A complete reassessment of safety has been done and a new CSR has been released that the inspectors could not assess

The safety data are reliable for risk assessment, following the corrective actions that were implemented after EMA GCP inspection

EMA GCP inspection report was completed in February 2018, based on CSR v1.0. The following dates apply to the data reported in CSR v1.0.

- -Cut-off date: 5 December 2016
- -Efficacy dataset extraction date: 16 March 2017
- -Safety dataset extraction date: 25 July 2017

The following dates apply to the data reported in CSR v3.0 submitted as part of the current application.

- -Cut-off date: 5 December 2016
- -Efficacy dataset extraction date: 16 March 2017
- -Safety dataset extraction date: 03 December 2018

## a) Re-monitoring was performed between the CSR V1.0 and the CSR V3.0 to support the integrity of the safety data

The re-monitoring occurred during the period between the data extraction of the CSRV1.0 date and the data extraction of the CSRV3.0 and included an additional 97 monitoring in 31 sites (91% of the 34 sites). Only 3 sites were not re-monitored, one site in Canada (2 patients randomized, Inspected by  Health  Canada),  another  site  in  Canada  (1  patient  randomized),  and  one  site  in  Argentina  (9 patients randomized).

The list of these re-monitoring visits are available as an appendix (provided in Response D180 1st LoI\\_Seq0008\\_Appendix 1)

## b) Updated safety data between CSRV1.0 and CSRV3.0

An overview of the updates in safety data as a result of the re-monitoring activities is provided below. The updates in the number of patients with at least one event was the following:

Adverse event: 1 patient previously identified was deleted in the control group. As compared with placebo, very slightly increase.

## AE  leading  to  death:  No  change

Non-fatal serious AE: No change

Severe AE Update for 6 patients

- 5 patients identified with serious adverse events, 1 in the masitinib 4.5 group and 4 with control group
- 1 patient previously identified was deleted with masitinib 3.0 group

Table 101 provides the summary of safety between v1.0 and v3.0 are a result of this re-monitoring activity.

<div style=\"page-break-after: always\"></div>

Table 101: Summary of safety profile between CSR v1.0 and CSR v3.0

|                                           | W0 TO W48 - DATA IN CSR V1.0   | W0 TO W48 - DATA IN CSR V1.0   | W0 TO W48 - DATA IN CSR V1.0   | W0 TO W48 - DATA IN CSR V1.0   | W0 TO W48 - DATA IN CSR V1.0   |
|-------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Number (%) of patients with at least one: | P (1) (N=133)                  | M4.5 (2) (N=129)               | (M4.5 - P)                     | M3 (3) (N=131)                 | (M3 - P)                       |
| AE                                        | 105 (78.9%)                    | 114 (88.4%)                    | 9.4                            | 111 (84.7%)                    | 5.8                            |
| Leading to Death (4)                      | 12 (9.0%)                      | 10 (7.8%)                      | -1.2                           | 11 (8.4%)                      | -0.6                           |
| Non-fatal SAE                             | 24 (18.0%)                     | 40 (31.0%)                     | 13.0                           | 30 (22.9%)                     | 4.9                            |
| Severe AE                                 | 22 (16.5%)                     | 38 (29.5%)                     | 12.9                           | 29 (22.1%)                     | 5.6                            |

|                                           | W0 TO W48 - DATA IN CSR V3.0   | W0 TO W48 - DATA IN CSR V3.0   | W0 TO W48 - DATA IN CSR V3.0   | W0 TO W48 - DATA IN CSR V3.0   | W0 TO W48 - DATA IN CSR V3.0   |
|-------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Number (%) of patients with at least one: | P (1) (N=133)                  | M4.5 (2) (N=129)               | (M4.5 - P)                     | M3 (3) (N=131)                 | (M3 - P)                       |
| AE                                        | 104 (78.2%)                    | 114 (88.4%)                    | 10.2                           | 111 (84.7%)                    | 6.5                            |
| Leading to Death (4)                      | 12 (9.0%)                      | 10 (7.8%)                      | -1.2                           | 11 (8.4%)                      | -0.6                           |
| Non-fatal SAE                             | 24 (18.0%)                     | 40 (31.0%)                     | 13.0                           | 30 (22.9%)                     | 4.9                            |
| Severe AE                                 | 26 (19.5%)                     | 39 (30.2%)                     | 10.7                           | 28 (21.4%)                     | 1.9                            |

P  (1) : Placebo + Riluzole - M4.5  (2) : 4.5 mg/kg/day Masitinib + Riluzole - M3  (3) : 3 mg/kg/day Masitinib + Riluzole.

Leading to Death  (4) : Adverse events were recorded until 28 days after treatment interruption, and adverse events not resolved at the death of the patients were recorded as adverse events leading to death. Given the severity of the condition, several AEs in each treatment-arm were therefore recorded as adverse events leading to death. However, none of these adverse events were considered to be related to either masitinib or Riluzole.

Regarding the detail of severe AEs, the updates in the number of events were the following:

3  cases  previously  reported  were  deleted  (1  case  of  blood  triglycerides  increased  with  masitinib  3 mg/kg/day, 1 case of Muscular Weakness and 1 case of Muscle atrophy with masitinib 4.5 mg/kg/day).

6 cases were added:

- Control group: + 2 events (1 case of cardiac arrest and 1 of blood pressure systolic increase).
- Masitinib 3 mg/kg/day group: + 2 events (1 chronic respiratory failure, 1 hypercapnia and 1 hypoxia).
- Masitinib 4.5 mg/kg/day group: + 1 event (1 peritoneal haemorrhage) All frequency of severe AE by SOC/PT changes available.

## Argument 1.8: Safety profile being acceptable, what matters is ALSFRS-R data

The CHMP considered that ' the safety profile of mentioned medicinal product is considered acceptable for a CMA '. The guidance EMA EMA/868942/2011 states that:

-  ' in  superiority  studies,  once  the  study  has  been  completed,  and  superiority  has  been  established, inspection  findings  merely  indicating  increased  variability  and  not  introducing  bias  favouring  one treatment over the other are relatively unproblematic in the interpretation of the study results '.

And

-' Further, it is important to assess whether the findings affect the interpretation of the primary efficacy endpoint or important safety endpoints. Needless to state, the findings have less significance for the benefit-risk assessment if they only have consequences for secondary or exploratory endpoints ' .

Therefore, as per guideline, the main consideration for benefit -risk assessment is the ALSFRS-R data.

<div style=\"page-break-after: always\"></div>

## Argument 1.9: ALSFRS-R had no systemic errors according to the inspection

-  Raters were experienced in ALSFRS-R scale according to inspectors.

Although inspection pointed out that the sites, particularly at one Spanish  site, had experience with the scale used, there was a lack of documented formal training at the beginning of the trial. On September 2014, AB Science released ALSFRS-R guidelines/instruction which were drafted and validated by the PI of this site who became the international coordinating investigator of the study. 263 patients (66.8%) were randomized after September 08, 2014. A statement letter from each rater was collected by AB Science to document that the raters were experienced and trained before the study began. AB10015 raters certified that they strictly followed AB Science guidelines for the administration of ALSFRS-R when conducting ALSFRS-R assessment in AB10015 trials. The list of raters is available.

-  Findings regarding the primary endpoint ALSFRS-R were not systematic.

In one of the two inspected sites (Argentina, n=53 randomized patients), for 3 subjects (4, 26, 55) the score recorded on the eCRF was different from the source data.

No  discrepancy  between  source  data  and  eCRF  was  found  for  ALSFRS-R  data  at  other  site  (n=109 randomized patients).

Likewise, Infarmed inspection for one site (n=3 patients) and Health Canada inspection for  other site (n=2 patients) did not identify such discrepancy between source data and eCRF for the ALSFR.

## Argument 1.10: A complete reassessment of ALSFRS-R data by certified raters has been done that showed no impact

A  retrospective  analysis  of  ALSFRS-R  source  data  was  performed  based  on  validated  published methodology by Lechtzin showing that accurate ALSFRS-R scores can be generated from retrospective review of clinic notes.

Only 13 ALSFRS-R discrepancies (0.5% total) were observed in 9 patients (2.3%). In protocol period we have observed only 8 ALSFRS-R discrepancies (0.3% total) were observed in 7 patients (1.8%)

| Patient number                             | Arm                                        | Visit                                      | Previous score                             | Updated score                              | Treatment arm   | Treatment arm   | Treatment arm   |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------|-----------------|-----------------|
| Patient number                             | Arm                                        | Visit                                      | Previous score                             | Updated score                              | M4.5            | M3              | P               |
| Change on ALSFRS-R Score - Protocol period | Change on ALSFRS-R Score - Protocol period | Change on ALSFRS-R Score - Protocol period | Change on ALSFRS-R Score - Protocol period | Change on ALSFRS-R Score - Protocol period | -8              | -7              | -12             |
|                                            | Masitinib 4.5                              | W24                                        | 19                                         | 18                                         | -1              |                 |                 |
|                                            | Masitinib 4.5                              | W36                                        | 30                                         | 29                                         | -1              |                 |                 |
|                                            | Placebo                                    | W24                                        | 26                                         | 20                                         |                 |                 | -6              |
|                                            | Placebo                                    | W36                                        | 32                                         | 26                                         |                 |                 |                 |
|                                            | Placebo                                    | W48                                        | 27                                         | 22                                         |                 |                 | -2              |
|                                            | Placebo                                    | W36                                        | 13                                         | 9                                          |                 |                 | -4              |
|                                            | Masitinib 3                                | W24                                        | 37                                         | 30                                         |                 | -7              |                 |
|                                            | Masitinib 4.5                              | W48                                        | 31                                         | 25                                         | -6              |                 |                 |
| No change on ALSFRS-R Score                | No change on ALSFRS-R Score                | No change on ALSFRS-R Score                | No change on ALSFRS-R Score                | No change on ALSFRS-R Score                |                 |                 |                 |
|                                            | Masitinib 4.5                              | W24                                        | 21                                         | 21                                         |                 |                 |                 |

There  was  no  impact  on  the  primary  endpoint  analysis  as  a  result  of  this  reassessment,  using  J2R analysis.

<div style=\"page-break-after: always\"></div>

| J2R (Jump to Reference)   | J2R (Jump to Reference)   | With ALSFRS-R score based on investigator assessment   | With ALSFRS-R score based on investigator assessment   | With ALSFRS-R score based on investigator assessment   | With ALSFRS-R score based on retrospective reassessment   | With ALSFRS-R score based on retrospective reassessment   | With ALSFRS-R score based on retrospective reassessment   |
|---------------------------|---------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Treatment group           | N                         | LS Mean                                                | Diff. of means [95% CI]                                | p-value                                                | LS Mean                                                   | Diff. of means [95% CI]                                   | p-value                                                   |
| Control                   | 113                       | -13.23                                                 | 2.80 [0.14;5.46]                                       | 0.0387                                                 | -13.23                                                    | 2.74 [0.09;5.40]                                          | 0.0428                                                    |
| Masitinib 4.5 mg          | 105                       | -10.43                                                 | 2.80 [0.14;5.46]                                       | 0.0387                                                 | -10.49                                                    | 2.74 [0.09;5.40]                                          | 0.0428                                                    |

Model based on post baseline data as per SAP

In conclusion, the deviations on ALSFRS-R score are limited and not systemic in nature.

- Out of 4 sites inspected, only one showed a discrepancy in the ALSFRS-R score between the source file and the eCRF for only 3 patients (1.8%) of the 168 patients inspected (43% of the study).
- All ALSFRS-R scores have been reevaluated by an independent certified rater and the 13/2758 data points (0.5%) inconsistencies identified in 9/394 patients do not impact the outcome.

In conclusion, ALSFRS was not affected in a systemic manner and the discrepancies were identified and have no impact.

## Argument 1.11: The Applicant did not limit its effort on sites inspected but did an impact analysis of all sites

The following statement from the Rapporteurs, ' The Applicant's conclusions that the primary endpoint is not affected are not agreed by the CHMP. In addition, it should be noted that even the execution of the different analysis excluding just one or two inspected sites are often not meaningful since these do not address the uncertainty regarding the non-inspected sites (EMA/8689942/2011). ', does not reflect the actions carried out by the Applicant.

The Applicant conducted a holistic assessment that included sensitivity analyses, involving not just the inspected sites but all sites to ensure the robustness of the findings. When corrective actions could not be implemented, impact analyses were performed. These impact analyses concerned all study data, not just the data from the inspected sites.

- The re-monitoring implemented during the period between the data extraction of the CSRV1.0 date and the data extraction of the CSRV3.0 included an additional 97 monitoring in 31 sites (91% of the 34 sites). Only 3 sites were not re-monitored, one in Canada (2 patients randomized, Inspected by Health Canada), other site in Canada (1 patient randomized), and one site  in Argentina (9 patients randomized).
- The reassessment of ALSFRS-R scores based on Lechtzin methodology, which is a validated methodology
- Exhaustive review of all eligibility criteria deviations was performed for all patients, using SAS programs  and  cut-off  values  for  inclusion  criteria,  and  using  SMQs  and  medical  history  for exclusion criteria.
- Potential underdosing of riluzole, of masitinib, as well as visit windows, were investigated for all patients

These analyses consistently demonstrated that the primary endpoint results were stable and reliable.

<div style=\"page-break-after: always\"></div>

## Argument 1.12: Inspectors concluded that the protocol deviations were likely to negatively impact  data  reliability,  but  sponsor  conducted  an  impact  analysis  and  with  certainty demonstrated that there was no impact

An impact analysis was performed. A detailed report is available.

-  Analysis of  deviations  that  could  not  be  corrected  and  that  could  impact  safety  showed  no impact on the safety profile of masitinib

On safety data, deviations of eligibility criteria that could not be corrected retrospectively have been analysed for their impact using a robust methodology, and there is no impact.

Impact of eligibility criteria deviations on safety was performed as recommended in EMA guideline (EMA/868942/2011)

- Exhaustive review of all eligibility criteria deviation
- For inclusion criteria, using SAS programs and cut-off values
- For exclusion criteria, using SMQs and medical history
- Categorization was done based on the nature and potential impact of deviations
- The methodology was reviewed and validated by an independent expert coordinator of the French rare diseases network on ALS and motor neurone disease (FILSLAN).

| Nature deviation   | Negligible query                              | Minor Deviation                                                                                                                        | Minor Deviation                                                                                                                        | Major Deviation                                                                                                                        | Major Deviation                                                                                                                        |
|--------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Nature deviation   | A technical infringement, that can be ignored | A case-by-case assessment for causality and seriousness based on the deviation's nature, magnitude, and medical history of the patient | A case-by-case assessment for causality and seriousness based on the deviation's nature, magnitude, and medical history of the patient | A case-by-case assessment for causality and seriousness based on the deviation's nature, magnitude, and medical history of the patient | A case-by-case assessment for causality and seriousness based on the deviation's nature, magnitude, and medical history of the patient |
| Potential Impact   | No Impact                                     | No Impact                                                                                                                              | Possible impact                                                                                                                        | No Impact                                                                                                                              | Possible impact                                                                                                                        |

389 eligibility criteria queries were generated, among which only 9 deviations in 5 patients (1.3%) having possible impact on safety.

| Negligi ble Eligibil ity Query   | Minor Deviation (non- important)   | Minor Deviation (non- important)   | Minor Deviation (non- important)   | Major Deviation (Important)   | Major Deviation (Important)   | Major Deviation (Important)   | Tota l   |
|----------------------------------|------------------------------------|------------------------------------|------------------------------------|-------------------------------|-------------------------------|-------------------------------|----------|
| Negligi ble Eligibil ity Query   | No Impact                          | Possi ble Impa ct                  | Total                              | No Impact                     | Possi ble Impa ct             | Total                         |          |
| 98                               | 258                                | 6                                  | 264                                | 24                            | 3                             | 27                            | 389      |

These eligibility criteria queries/deviations were well balanced across treatment arms

|                                | PBO       | M3.0      | M4.5      |   Total |
|--------------------------------|-----------|-----------|-----------|---------|
| Total number (%) of deviations | 135 (35%) | 129 (33%) | 125 (32%) |     389 |

The 5 patients had the following deviations and subsequent AEs:

- 2 patients randomized in the placebo arm, with infectious screening tests missing (HIV and hepatitis testing) and infections TEAE: one presented diarrhoea related to Clostridium difficile infection at D67, of mild severity and non-serious, at D95, of moderate severity and serious;

<div style=\"page-break-after: always\"></div>

Both episodes resolved without sequalae and were assessed as not related to study drug by investigators.

- 1 patient randomized in a Masitinib AB Science arm, with creatinine clearance low and medical history of lung fibrosis and creatinine increase TEAE. This moderate patient was randomized in the  4.5  mg/kg/day  Masitinib  AB  Science  arm  with  a  creatinin  clearance  at  58.6  mL/min  at screening.  The  clearance  continued  to  decrease  during  study  varying  between  40  and  57 mL/min  dropping  to  40  mL/min  at  the  end  of  study.  The    medical  history    included hypercholesterolemia,  hypertension,  treated  with  hydrochlothiazide,  enalapril,  atorvastatin. Creatinin increase at W36 was reported as TEAE. Considering creatinin clearance value closed to 60, this deviation is considered as minor but could have had an impact on safety. This patient had also a medical history of pulmonary fibrosis (fibrosis scar on right lung). This is considered as a minor deviation since FVC was in the range accepted by the protocol. No respiratory TEAEs were reported. This deviation had no impact on safety but could have had an impact on efficacy.
- 1  patient  randomized  in  the  placebo  arm,  with  morbid  obesity  (screening  &amp;  baseline): radiculalgia TEAE. This moderately severe patient with bulbar presentation was randomized in the placebo arm with a BMI above 40 kg/m². The morbid obesity might explain radicular pain L5 reported as TEAE. Possibly, an osteoporosis even not reported in medical history of this postmenopausal female patient might also have contributed to this TEAE. This is a major deviation with a possible impact on safety.
- 1 patient randomized in a masitinib arm, with medical history of toxic oil syndrome with no related TEAE. This severe, bulbar, middle aged patient was randomized in the 4.5 mg/kg/day Masitinib AB Science arm. A toxic oil syndrome is reported in his medical history. Toxic oil syndrome  may  have  induced  a  chronic  disease  with  neuromuscular  symptoms,  pulmonary infiltrates and liver impairment. ALT was high at screening 1.3xULN and raised at 1.7xULN with bilirubin at 1.9xULN at W4. ALT raised up to 2.5xULN at W48. This deviation could have had an impact on eligibility, therefore on efficacy and on safety because a participation of the toxic oil syndrome in his ALS symptomatology cannot be ruled out.

The impact of these 5 patients do not change the safety profile of Masitinib AB Science 4.5 mg/kg/day in ALS.

-  Exclusion of patients with possible impact on efficacy from deviations to eligibility criteria does not modify efficacy outcome, even with J2R approach
- First, all patients had ALS diagnosis confirmed (no deviation)
- Data Review Committee before unblinding previously identified 5 patients with possible impact

| Arm                   | W48                   | Deviation Description                       | Deviation Status      | Deviation Impact      |
|-----------------------|-----------------------|---------------------------------------------|-----------------------|-----------------------|
| Data Review Committee | Data Review Committee | Data Review Committee                       | Data Review Committee | Data Review Committee |
| PBO                   | No                    | Hb<10g/dL                                   | Major                 | Possible impact       |
| PBO                   | No                    | Bilirubin > 1.5 ULN                         | Major                 | Possible impact       |
| M3.0                  | No                    | Suspicion of HBV infection                  | Major                 | Possible impact       |
| M3.0                  | No                    | Creatinine Clearance < 60 mL/min            | Minor                 | Possible impact       |
| M4.5                  | No                    | Treatment with phenytoin (high risk of SJS) | Minor                 | Possible impact       |

· Exhaustive new eligibility criteria deviation analysis identified 7 additional patients with possible impact

<div style=\"page-break-after: always\"></div>

| Exhaustive Impact Analysis   | Exhaustive Impact Analysis   | Exhaustive Impact Analysis                     | Exhaustive Impact Analysis   | Exhaustive Impact Analysis   |
|------------------------------|------------------------------|------------------------------------------------|------------------------------|------------------------------|
| M4.5                         | Yes                          | Forbidden medical history (toxic oil syndrome) | Major                        | Possible impact              |
| PBO                          | Yes                          | BMI > 35 kg/m² (morbid obesity)                | Major                        | Possible impact              |
| M4.5                         | No                           | Forbidden medical history (pulmonary fibrosis) | Major                        | Possible impact              |
| M3.0                         | Yes                          | BMI > 35 kg/m² (exceeded threshold by 5%)      | Minor                        | Possible impact              |
| M4.5                         | Yes                          | BMI > 35 kg/m² (exceeded threshold by 2%)      | Minor                        | Possible impact              |
| M4.5                         | No                           | Age > 75 years (exceeded threshold by 5%)      | Minor                        | Possible impact              |
| M4.5                         | Yes                          | Age > 75 years (exceeded threshold by 4%)      | Minor                        | Possible impact              |

- Therefore, there were a total of 9 patients (3.4%) in the masitinib 4.5 mg/kg/day or placebo arms with deviation on eligibility criteria having a possible impact on efficacy
- The impact analysis excluding these 9 patients did not modify the study outcome, using J2R analysis.

|                       | PBO (n=133)   | M4.5 (n=130)   | M3.0 (n=131)   | TOTAL (n=394)   |
|-----------------------|---------------|----------------|----------------|-----------------|
| DRC - Major deviation | 2 (1.5%)      | 1 (0.8%)       | 2 (1.5%)       | 5 (1.3%)        |
| Impact Analysis       | 1 (0.8%)      | 5 (3.8%)       | 1 (0.8%)       | 7 (1.8%)        |
| Total                 | 9 (3.4%)      | 9 (3.4%)       | 3 (2.3%)       | 12 (3.0%)       |

| Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                               | Arm                                                           | N                                                             | LS Mean                                                       | Diff. of means [95% CI]                                       | p-value                                                       |
| Normal Progressor                                             | PBO                                                           | 113                                                           | -13.23                                                        | 2.80 [0.14;5.46]                                              | 0.0387                                                        |
| Normal Progressor                                             | M4.5                                                          | 105                                                           | -10.43                                                        | 2.80 [0.14;5.46]                                              | 0.0387                                                        |
| Normal + Fast Progressor                                      | PBO                                                           | 132                                                           | -13.51                                                        | 1.81 [- 0.75;4.37]                                            | 0.1664                                                        |
| Normal + Fast Progressor                                      | M4.5                                                          | 128                                                           | -11.70                                                        | 1.81 [- 0.75;4.37]                                            | 0.1664                                                        |

model based on post baseline data as per SAP

| Sensitivity analysis - Rule MI J2R with 9 patients with eligibility deviation having a possible impact excluded   | Sensitivity analysis - Rule MI J2R with 9 patients with eligibility deviation having a possible impact excluded   | Sensitivity analysis - Rule MI J2R with 9 patients with eligibility deviation having a possible impact excluded   | Sensitivity analysis - Rule MI J2R with 9 patients with eligibility deviation having a possible impact excluded   | Sensitivity analysis - Rule MI J2R with 9 patients with eligibility deviation having a possible impact excluded   | Sensitivity analysis - Rule MI J2R with 9 patients with eligibility deviation having a possible impact excluded   |
|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
|                                                                                                                   | Arm                                                                                                               | N                                                                                                                 | LS Mean                                                                                                           | Diff. of means [95% CI]                                                                                           | p-value                                                                                                           |
| Normal Progressor                                                                                                 | PBO                                                                                                               | 111                                                                                                               | -13.3414                                                                                                          | 2.87 [0.15;5.59]                                                                                                  | 0.0390                                                                                                            |
| Normal Progressor                                                                                                 | M4.5                                                                                                              | 99                                                                                                                | -10.4738                                                                                                          | 2.87 [0.15;5.59]                                                                                                  | 0.0390                                                                                                            |
| Normal + Fast Progressor                                                                                          | PBO                                                                                                               | 130                                                                                                               | -13.7293                                                                                                          | 1.83 [-0.79;4.45]                                                                                                 | 0.1720                                                                                                            |
| Normal + Fast Progressor                                                                                          | M4.5                                                                                                              | 122                                                                                                               | -11.9034                                                                                                          | 1.83 [-0.79;4.45]                                                                                                 | 0.1720                                                                                                            |

model based on post baseline data as per SAP

-  Potential underdosing of riluzole was investigated and sensitivity analysis showed no impact

A total of 7 patients (1.8%) received sub-dosing of riluzole, including 6 patients in either M4.5 arm (n=3) or placebo arm (n=3).

| Subject Number   | Treatment   |   Compliance (%) |   Planned Exposed Days |   Cumulative Planned dose |   Actual Exposed Day |   Cumulative Actual dose |
|------------------|-------------|------------------|------------------------|---------------------------|----------------------|--------------------------|
|                  | M3          |             64.6 |                     99 |                      9900 |                   99 |                     6400 |
|                  | M4.5        |             53   |                    166 |                     16600 |                   88 |                     8800 |
|                  | M4.5        |             50   |                     50 |                      5000 |                   50 |                     2500 |
|                  | M4.5        |             30.3 |                     66 |                      6600 |                   83 |                     2000 |
|                  | PBO         |              8.8 |                    329 |                     32900 |                   58 |                     2900 |
|                  | PBO         |             50   |                    337 |                     33700 |                  337 |                    16850 |

<div style=\"page-break-after: always\"></div>

| PBO   | 52.9   | 87   | 8700   | 58   | 4600   |
|-------|--------|------|--------|------|--------|

Sensitivity analysis excluding these 6 patients does not modify the study results.

| Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   | Primary efficacy population - Rule MI J2R with all patients   |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                               | Arm                                                           | N                                                             | LS Mean                                                       | Diff. of means [95% CI]                                       | p-value                                                       |
| Normal Progressor                                             | PBO                                                           | 113                                                           | -13.23                                                        | 2.80 [0.14;5.46]                                              | 0.0387                                                        |
| Normal Progressor                                             | M4.5                                                          | 105                                                           | -10.43                                                        | 2.80 [0.14;5.46]                                              | 0.0387                                                        |
| Normal + Fast Progressor                                      | PBO                                                           | 132                                                           | -13.51                                                        | 1.81 [- 0.75;4.37]                                            | 0.1664                                                        |
| Normal + Fast Progressor                                      | M4.5                                                          | 128                                                           | -11.70                                                        | 1.81 [- 0.75;4.37]                                            | 0.1664                                                        |

model based on post baseline data as per SAP

| Sensitivity analysis - Rule MI J2R with 6 patients with riluzole sub-dosing   | Sensitivity analysis - Rule MI J2R with 6 patients with riluzole sub-dosing   | Sensitivity analysis - Rule MI J2R with 6 patients with riluzole sub-dosing   | Sensitivity analysis - Rule MI J2R with 6 patients with riluzole sub-dosing   | Sensitivity analysis - Rule MI J2R with 6 patients with riluzole sub-dosing   | Sensitivity analysis - Rule MI J2R with 6 patients with riluzole sub-dosing   |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
|                                                                               | Arm                                                                           | N                                                                             | LS Mean                                                                       | Diff. of means [95% CI]                                                       | p-value                                                                       |
| Normal Progressor                                                             | PBO                                                                           | 110                                                                           | -13.34                                                                        | 2.91 [0.23;5.59]                                                              | 0.0331                                                                        |
| Normal Progressor                                                             | M4.5                                                                          | 105                                                                           | -10.43                                                                        | 2.91 [0.23;5.59]                                                              | 0.0331                                                                        |
| Normal + Fast Progressor                                                      | PBO                                                                           | 129                                                                           | -13.53                                                                        | 1.77 [-0.80;4.35]                                                             | 0.1774                                                                        |
| Normal + Fast Progressor                                                      | M4.5                                                                          | 125                                                                           | -11.75                                                                        | 1.77 [-0.80;4.35]                                                             | 0.1774                                                                        |

model based on post baseline data as per SAP

-  Masitinib dosing deviations were evaluated and showed no impact

Identified deviations that were related to masitinib underdosing could only minimize masitinib efficacy and have no impact

| Subject Number   | Arm   | Category           | Description                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------|-------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | M 3   | IMP Compliance     | Patient was 22 days without take medication because he/she could not attend to visit week 72 due to hospitalization. Remote visit week 72 was performed and medication was sent and first intake two days after kits reception.                                                                                                                                                                                                        |
|                  | M 3   | Efficacy or Safety | visit 36 was delayed, study drug was not taken during four months                                                                                                                                                                                                                                                                                                                                                                      |
|                  | M 3   | IMP Allocation     | Patient was randomized at 4.5 mg/kg/day 300mg. At week 12 visit sub investigator performed IMP assignation but by mistake she indicated that a dose reduction was needed, so the system assigned to patient only 100 mg kits, total daily dose 200 mg. So patient is taking the reduced dose of 200 mg instead of 300 mg.                                                                                                              |
|                  | M 4.5 | IMP Compliance     | Patient experienced persistent diarrhea (severe) in 2016. According to the protocol in case of severe diarrhea the study treatment should be interrupted until return to baseline or mild intensity, then resume with a close exclusion 6 days after (SAE stop date), the patient was instructed to resume the medication with a dose reduction, however patient interrupted the medication until her next visit around 2 months later |
|                  | M 4.5 | IMP Compliance     | In masitinib dispensation for week 8 to week 12: subject was not dispensed with masitinib-placebo for 13 days .. IP compliance was 50 %                                                                                                                                                                                                                                                                                                |
|                  | PBO   | IMP Compliance     | Patient during the week 24 visit, returned all the previous IMP bottles that he had received at week 12 visit, except of this with number of Masitinib/placebo 100mg. The patient had discarded the respective bottle. IP compliance could not be calculated regarding the 100mg.                                                                                                                                                      |
|                  | PBO   | Efficacy or Safety | Patient CME to w48 3 weeks later than scheduled. Patient was 21 days without medication                                                                                                                                                                                                                                                                                                                                                |
|                  | PBO   | IMP Allocation     | Patient was dispensed with not enough IMP till next planned visit                                                                                                                                                                                                                                                                                                                                                                      |
|                  | PBO   | IMP Allocation     | IWRS dispensation was done before the patient arrives at hospital, the same day the visit took place. The weight used for eCRF was an estimated weight given by caregiver by phone to investigators. This                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| patient during a 12 weeks period, the dose administrated was less than should be given.   |
|-------------------------------------------------------------------------------------------|

-  Visit window deviations were evaluated and showed no impact

DSMB decided (25 Feb 2016) that no impact on efficacy data is expected if non-respect of visit windows is not higher than 28 days and not repeated at 2 consecutive visits.

According to this rule, no visit window deviations occurred in the Masitinib 4.5 mg/kg/day treatment arm or placebo arm, thereby having no impact on the primary analysis.

| Subject Identifier the Study   | for Treatment   |   Visit Week |   ALSFRS- R score | Planned Date   | Actual date   |   Visit Window Deviation From Plan Visit (in days) More 28 twice row | Visit Window Deviation From Plan Visit (in days) More 28 twice row   | than days in a from Planned Visit(Y/N) Window Deviation From Previous Visit (in days) More 28 twice row   | Previous Visit(Y/N)   | than days in a from   |
|--------------------------------|-----------------|--------------|-------------------|----------------|---------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------|-----------------------|
|                                | Masitinib 3     |           36 |                28 | 03/02/2015     | 13/03/2015    |                                                                   38 | Y                                                                    |                                                                                                           | Y                     |                       |
|                                | Masitinib 3     |           48 |                29 | 28/04/2015     | 11/06/2015    |                                                                   44 | Y                                                                    |                                                                                                           | Y                     |                       |
|                                | Masitinib 3     |           36 |                36 | 09/07/2015     | 18/08/2015    |                                                                   40 | Y                                                                    |                                                                                                           | N                     |                       |
|                                | Masitinib 3     |           48 |                35 | 01/10/2015     | 23/11/2015    |                                                                   53 | Y                                                                    |                                                                                                           | N                     |                       |
|                                | Placebo         |           36 |                31 | 08/08/2016     | 08/09/2016    |                                                                   31 | Y                                                                    |                                                                                                           | N                     |                       |
|                                | Placebo         |           48 |                35 | 31/10/2016     | 02/12/2016    |                                                                   32 | Y                                                                    |                                                                                                           | N                     |                       |

## Argument 1.13: An  impact  analysis  on  all  items  that  could  have  impacted  benefit  risk  assessment beyond primary efficacy and safety, as per guideline, and it showed no impact. This analysis has been rejected without any query from the Rapporteurs to the Applicant

The extensive impact analysis conducted by the Applicant covered all critical aspects that could influence the benefit-risk assessment. This includes detailed evaluations of protocol deviations, missing data, and their potential impact on primary efficacy and safety endpoints. This included sensitivity analyses, remonitoring  data,  and  reassessment  of  safety  and  efficacy  endpoints.  The  results  of  these  extended analyses  support  the  conclusion  that  the  overall  data  integrity  and  the  primary  endpoint  are  not compromised.  By  aligning  the  impact  analysis  with  EMA  guidelines,  the  Applicant  demonstrated adherence to regulatory standards and best practices. This alignment should be a significant factor in the regulatory decision-making process, reinforcing the credibility of the presented data.

On the other hand, the CHMP based its decision on the EMA inspection of 2 sites and finally does not address the uncertainty regarding the non-inspected sites.

It is crucial to assess whether the quality system deficiencies significantly affected critical data, such as primary efficacy and safety endpoints. Since impact analyses show that the essential data remain robust and reliable. The inspectors did not review the presented impact analysis supporting that the critical data are still adequate for the benefit-risk assessment as per guideline EMA/8689942/2011.

## Argument 1.14: Guideline states that if safety is acceptable and the primary variable is robust, then benefit risks is valid. Guideline should apply

Guidances (EMA/868942/2011; Good Clinical Practice Inspectors Working Group (GCP IWG). Chapter 2.  General Notes on Findings) recommendations are fulfilled.

- In superiority studies, […], inspection findings merely indicating increased variability and not introducing  bias  favouring  one  treatment  over  the  other  are  relatively  unproblematic  in  the interpretation of the study results
- It is important to assess whether the findings affect the interpretation of the primary efficacy

<div style=\"page-break-after: always\"></div>

## endpoint or important safety endpoints

The Applicant's actions and analyses are in strict adherence to the EMA/8689942/2011 guidelines.

The comprehensive impact analysis, corrective actions, and validation efforts align with the 'Points to consider on GCP inspection findings and the benefit-risk balance' guidelines, ensuring that the data are reliable.

The Applicant addressed the Rapporteurs concerns through:

- i. Performing comprehensive data reviews to ensure the reliability of the primary endpoint and safety data.
- ii. Conducting a thorough impact analysis of protocol deviations, demonstrating that there is no impact on efficacy and safety data.
- iii. Including data from non-inspected sites in broader analyses.
- iv. Ensuring all actions align with regulatory guidelines and standards.

These  comprehensive  measures  and  analyses  demonstrated  that  the  primary  endpoint  remained unaffected, and the data from clinical study AB10015 are reliable.

## Argument 1.15: There is a contradiction with the initial position of the reviewers at the start of the procedure since the  inspection  reports  conclusion  was  known.  If  nothing  could  be done, then why the Rapporteur asked to explain how the GCP issues were resolved

Stating that the numerous retrospectives analyses applied by the Applicant do not compensate for the deficiencies in the conduct of the study is contradictory with the position from the Rapporteurs during the during the pre-submission meeting held on 24 May 2022.

During the pre-submission meeting held on 24 May 2022, the Applicant stated very clearly that ' AB Science is willing to submit an application for CMA in ALS only if this is supported by the Rapporteur and the  Co-rapporteur.  AB  Science  would  not  file  if  there  were  no  support  Rapporteur  and  the  CoRapporteur '. The Applicant further indicated that ' A new version of the CSR has been released after full reassessment of the safety data in a validated pharmacovigilance system '.

In response, the Rapporteur stated that ' The Rapporteur indicated AB Science should go back to the major points for refusal of the previous EPAR and explain how these issues were addressed, in particular GCP issues '.

If  the  conclusion expressed by the Rapporteurs was valid, it would/should have been notified to the Applicant at the time of the pre-submission meeting. Otherwise, it means that corrective actions and impact analyses perfomred can compensate for the deficiencies in the conduct of the study.

## Argument 1.16: The argument of poor global quality is debatable since the same guideline indicates that if deviations show no impact on the primary efficacy variable nor safety then the benefit risk balance remains evaluable

The guidance EMA EMA/868942/2011 states that 'it is important to assess whether the findings affect the interpretation of the primary efficacy endpoint or important safety endpoints. Needless to state, the findings  have  less  significance  for  the  benefit-risk  assessment  if  they  only  have  consequences  for secondary or exploratory endpoints'.

The corrective actions and the impact analyses performed are methodologically adequate to provide assurance that the study data reliable

<div style=\"page-break-after: always\"></div>

-  Re-Monitoring in regulatory guidance and industry experience versus in AB15001 trial

Re-monitoring is recognized as a viable approach under certain circumstances, as highlighted during the COVID-19 pandemic, where traditional on-site monitoring was often not feasible. The MHRA has shared insights  from  their  experience  during  the  pandemic,  emphasizing  that  many  trials  had  to  adapt processes, leading to a significant increase in protocol:

- -The  MHRA  advised  a  risk-based  approach  to  documenting  these  deviations,  emphasizing  that deviations impacting participant safety and the reliability of results should be clearly identified and considered during data analysis. AB Science performed a risk-based analysis approach presented in the CAPA report proposed in answer to the EMA GCP inspection report and in this document.
- -The MHRA also suggested that re-monitoring might be necessary in cases where there are concerns about data quality or when data are critical to the reliability of the trial results : 'Following questions arising on the quality of the data after carrying out remote monitoring, we have advised sponsors who have suggested to do re-monitoring once it is safe to be back on site that it needs to be done on a risk-based approach. Therefore, if there are concerns about data quality, or there are data that are critical to the reliability of the results of the trial, such that you would only have  confidence  in  the  data  if  on-site  monitoring  took  place,  sponsors  may  want  to consider re-monitoring. '

These regulatory  perspectives  reinforce  that  re-monitoring  can  be  a  valuable  tool  for  ensuring  data integrity, if applied with clear understanding of its scope and limitations: it depends on the nature of the data, the clarity of the source documentation, and the ability to unambiguously verify the accuracy and completeness of the data entries.

## The re-monitoring in the AB10015 trial is particularly defendable and effective because:

- -Source Data are available and clearly documented: AB10015 inspection outcomes did not identify questionable quality nor availability of source data.
- -The Type of Data Concerned are adapted for an efficient re-monitoring:
- o Documented Events as Adverse Events: The  occurrence,  severity,  and  timing  of  adverse events can be re-verified through medical records, subject diaries, or investigator notes.
- o Clear &amp; Unambiguous data as some Eligibility Criteria: Re-monitoring is efficient for criteria that are based on objective measures (e.g. lab values, age, specific medical history elements …)
- o Efficacy  Endpoint: for  quantifiable  endpoints  re-verification  can  be  done  against  medical records. It is the case for the ALS Functional Rating Scale-Revised (ALSFRS-R) because:
-  Objective &amp; quantifiable:

1. The  ALSFRS-R  provides  a  quantifiable  measure  of  a  patient's  functional  status,  with scores assigned to specific functional tasks. This quantification allows for objective re-assessment and comparison of data over time.

-  Standardized Assessment:

2. The ALSFRS-R is a standardized tool used globally in ALS clinical trials and care settings. Its  widespread  use  and  standardization  mean  that  re-monitoring  can  be  reliably  performed, provided  the  assessors  are  trained  and  the  assessment  conditions  are  consistent  as  in  the AB15001 trial.

-  Source Data Verification:

<div style=\"page-break-after: always\"></div>

3. If  ALSFRS-R  assessments  are  documented  thoroughly,  including  notes  on  patient responses and any relevant observations during the assessment, these source documents can serve as a basis for re-monitoring. The EMA GCP did identify very limited discrepancies between source data and eCRF especially for the ALSFRS-R scale.

##  Retrospective/Impact Analysis in AB10015 trial

## · Why ALSFRS-R retrospective analysis is reliable?

As patient medical files are maintained by neurologists experienced in treating ALS, the potential for accurately  regenerating  ALSFRS-R  data  is  high.  Neurologists'  records  are  likely  to  contain  detailed observations on motor functions and other relevant clinical aspects pertinent to ALSFRS-R domains. These details can provide indirect insights into the patient's functional status over time.

The article by Lechtzin et al. demonstrates that accurate ALSFRS-R scores can be generated from a retrospective review of clinic notes [Lechtzin 2009]. The study's findings are significant because they suggest  that  even  in  the  absence  of  prospectively  collected  ALSFRS-R  scores,  valuable  disease progression data can still be obtained from patients' medical records.

Attempting  to  rectify  deficiencies  retrospectively  could  introduce  bias  into  the  trial,  so  AB  Science approached the matter cautiously. The process employed by AB Science to validate the integrity of ALSFRS-S data does not involve retrospective corrections of the scores.  Trained  raters  conducted  a second assessment based on accurate source data (re-monitoring). Subsequently, the results obtained were analyzed using a sensitivity analysis approach, yet the clinical database remained unaltered by the new scores obtained.

## · Why protocol deviations impact analysis is reliable?

In the AB10015 trial, some GCP issues cannot be resolved nor corrected after they occur, like protocol deviations but their impact on efficacy and safety data can be evaluated retrospectively (EMA/868942/2011 guidance) as inspections/audits  and  corrective  actions  have  made  it  possible  to ensure that:

- -Source  data  are  available  and  clearly  documented  (no  issue  identified  during  the  EMA  GCP inspection).
- -Discrepancies between source data and clinical database are limited after re-monitoring for those critical data we are focusing on.

## Argument 1.17:  The position adopted by the CHMP for Qalsody and Albrioza in ALS shows that numerous protocol deviations are not an obstacle to registration if these deviations have no impact

EPAR (EMA/CHMP/487533/2023) of Albrioza indicates that the study supporting CMA application had 417 deviations for 137 patients (i.e., an average of 3 deviations per patient), with 91% of patients affected, therefore, clearly a systemic finding. This was not considered as a major objection, and the CHMP  concluded  with  no  inspection  that  it  had  no  impact  on  benefit/risk,  precising,  in  line  with EMA/868942/2011  guidance  that  ' The  percentage  of  subjects  with  protocol  deviations  was  similar between treatment group '.

Similarly, in the pivotal study supporting the approval of Qalsody, 89% of patients have major protocol deviation and 63%  of  deviations affected efficacy. The deviations appeared to be systemic (EMA/276404/2024). Yet this drug was approved by the EMA.

The Applicant does not understand why the application of EMA guidelines appear to have been interpreted differently for similar past examples of studies with deviations.

<div style=\"page-break-after: always\"></div>

The inconsistency in the application of EMA guidelines for different drug approvals raises questions about the  uniformity  of  the  regulatory  process.  If  Albrioza  and  Qalsody,  with  significantly  higher  protocol deviations, were approved, it sets a precedent that similar studies, such as the one for Masitinib, should be evaluated with the same standard.

## Argument 1.18:  There is a perception that masitinib dossier is treated more severely than the other sponsors dossier

With  all  due  respect,  there  is  a  perception  that  study  AB10015  has  been  evaluated  with  excessive severity. We have noted EMA's position that deviations from eligibility criteria and subject follow-up procedures are likely to impact data integrity

- -Balanced  Impact:  The  Applicant's  detailed  analysis  showed  that  eligibility  deviations  were balanced across treatment arms and did not impact safety or efficacy outcomes. The impact of these deviations has been assessed thoroughly, and it has been demonstrated that there is no significant impact on the overall study outcomes.
- -Post  Hoc Analysis:  The  inspectors  did  not  have  the  benefit  of  reviewing  our  post-inspection corrective  measures,  including  the  updated  CSR  and  additional  impact  analyses.  These documents provide substantial evidence that the data from AB10015 are reliable.
- -Protocol  deviations  need  to  be  assessed  based  on  their  significance  and  impact  on  critical endpoints: The Applicant conducted a comprehensive impact analysis, showing that the identified deviations  did  not  significantly  affect  the  primary  efficacy  or  safety  outcomes.  A  risk-based approach focuses on deviations that have a material impact on study results rather than treating all deviations as equally critical.
- -No Systematic Errors: Inspectors did not find systemic errors in ALSFRS-R but a minor number of errors, and a reassessment by certified raters proved there is no impact.
- -In addition, ethical conduct is paramount in clinical trials and the Applicant has demonstrated that the rights, safety, and well-being of trial subjects were protected throughout the study. The corrective measures taken post-inspection, further ensure that all ethical standards were met.

Conclusion : The Applicant respectfully asserts that CHMP's decision to base its findings solely on the inspectors' position from 2017, fails to take into consideration the entire sum of evidence now available and  is  not  therefore  consistent  with  the  guideline  on  benefit-risk  assessment.  The  Applicant  has demonstrated an absence of impact from any findings. The argument of overall poor quality overlooks the  corrective  actions  implemented  post-inspection  and  our  interpretation  of  the  guidelines  on benefit/risk evaluation. Safety is deemed acceptable by EMA, and the primary variable (ALSFRS-R) does not suffer from systemic issues.

## CHMP position on the Ground for re-examination

A triggered GCP inspection (GCP/2017/001) was requested by the CHMP on the conduct of the clinical study  AB10015  in  the  context  of  a  previous  MAA  of  masitinib  for  the  treatment  of  ALS  (Alsitek, EMEA/H/C/004398/0000). In total, 8 critical and 12 major findings were identified during this inspection at the two inspected sites affecting different aspects of the study. Critical findings were related to the clinical conduct of the trial, management of the trial by the sponsor/CRO, safety reporting, source data review/verification  and  clinical  trial  monitoring.  Major  findings  were  observed  at  qualifications  and training, trial master file, clinical conduct of the trial, safety reporting, investigational medicinal product, clinical data management, source data review/verification and clinical study report. Inspectors concluded that given the nature and relevance of the findings and also the systemic deficiencies observed i.e. massive number of protocol deviations meaning a general lack of adherence to the protocol, in addition to the suboptimal quality applied by the sponsor and CROs involved, are likely to have a negative impact on data reliability. The data obtained at the sites inspected were judged to be not trustworthy.

<div style=\"page-break-after: always\"></div>

The current application (Masitinib AB Science, EMEA/H/C/005897/0000) is based on the same study AB10015 as submitted for the previous procedure, with the only difference being the addition of the OLE part of the study.

As part of the current application, the Applicant claimed that the GCP findings were addressed with implementation of preventive actions across study and functions within AB Science. The Applicant also claimed that for study AB10015, corrective actions were implemented wherever feasible. Moreover, the Applicant performed an impact analysis of protocol deviations and concluded that GCP inspection findings which are likely to influence the evaluation of the primary efficacy endpoint, whether correctable or not, had no significant impact on the study's outcomes.

However, despite the fact, that the Applicant has provided impact analysis and arguments, the existing evidence of data quality did not assure CHMP that the AB10015 trial data is trustworthy

In terms of GCP, the Applicants grounds for re-examination are based on the following main aspects:

[Argument 1.2-1.4] Highlighting that the other available inspection reports (Health Canada, ANMATArgentina, Infarmed - Portugal) and audit reports do not conclude that data are not trustworthy and that those reports should be considered in the assessment.

[Argument 1.1, 1.5-1.6] Claiming that Inspectors and the CHMP did not account for analyses done after inspection (specifically focussing on the detailed impact analysis that was communicated for the first time at D180). It is the Applicant's position that from the very beginning of the procedure, the CHMP adhered to the conclusions from the Inspectors and made no attempt to evaluate the consequences of inspection findings in relation to the benefit-risk balance.

[Argument 1.7-1.8] Focusing on re-assessment of safety, highlighting the updated CSR V3.0.

[Argument 1.9-1.10] Focussing on re-assessment of the primary endpoint ALSFRS-R score, highlighting the retrospective analysis of ALSFRS-R source data.

[Argument 1.11 - 1.13] Highlighting and discussing results of the performed deviation impact analysis (Detailed Report Deviation Impact Analysis).

[Argument 1.14, 1.16] Referring to certain parts of the guideline on Points to consider on GCP inspection findings  and  the  benefit-risk  balance  (EMA/868942/2011),  underlining  their  claim  that  the  B/R  is evaluable and that the corrective actions e.g. re-monitoring and retrospective/impact analyses are valid.

[Argument 1.15] Claiming that a contradiction between feedback on the pre-submission meeting held on 24 May 2022 and the assessment of the current application.

[Argument 1.17-1.18] Referring to other products in ALS with similar amount of protocol deviations and claiming that the masitinib dossier is treated more strictly than other sponsor's dossiers.

The main aspects are discussed in more detail below:

## [Argument 1.2 - 1.4]

The Applicant is referring to marketing authorisation procedures where CHMP reached a positive benefitrisk conclusion despite negative GCP findings (Appendix 1 of the clinical grounds for re-examination). The precedents of marketing authorisations (MA) discussed by the Applicant are acknowledged, however it should be noted that every MA application is assessed on its own merit, based on the totality of the data presented in the application, in support of the claimed indication. There are multiple factors affecting the benefit-risk evaluation for each application. It is the totality of data which is taken into account in every individual dossier. Overarching comparisons are not possible.

Moreover, the Applicant argues that besides the EMA inspection three additional GCP inspections (Health

<div style=\"page-break-after: always\"></div>

Canada, ANMAT Argentina, Infarmed Portugal) were performed, that did not conclude that data are not trustworthy. While it is agreed with the Applicant that other GCP inspections did not reject the data, several major findings were reported. The only overlapping site to be inspected was the second largest recruiting  site  in  Argentina.  The  Applicant  claims  Argentinian  regulatory  authority  inspected  the  site before EMA and did not conclude the data is untrustworthy. However, the ANMAT inspection outcome for the inspected site was Indication of Official Action (IAO), subpoint (i) Administrative and/or legal penalty  against  the  investigator,  Sponsor  or  CRO,  after  development  of  the  pertaining  disciplinary proceedings. In other words, the inspection identified significant deficiencies and GCP non-compliances that  required  formal  penalties  against  the  investigator/CRO/Sponsor  preceded  by  formal  disciplinary proceedings. This process includes further review, evaluation and the opportunity of the involved parties to respond to the issues. The formal penalties are defined after the disciplinary procedures have been completed. It is further stated that the result of the inspection was that the principal investigator and the Sponsor had to sign a commitment letter with ANMAT for the future trials to be conducted. The contents of this commitment letter are not known. Overall, stating that the ANMAT inspection did not conclude  the  data  is  untrustworthy  is  factually  correct,  but  fails  to  convey  the  information  that deficiencies identified during the inspection warranted administrative and/or legal penalties against the PI  and  the  Sponsor.  Further,  one  site  was  inspected  by  Infarmed  Portugal  and  five  major  noncompliances  were  identified  related  to  conformity  of  the  eCRF  to  the  protocol  in  force,  monitoring process, deviations from the protocol, recording of data, and verification of compliance of EM, which are largely  in  line  with  findings  identified  during  the  triggered  GCP  inspection  requested  by  CHMP  and coordinated by EMA. Importantly, sites inspected during the GCP inspection coordinated by EMA were the two largest recruiting sites, with 53 and 106 patients enrolled, accounting for &gt;40% of the full study population, while sites inspected by Canada and Portugal only enrolled 2 and 3 patients respectively.

Besides the 4 GCP inspections, 16 audits were performed by an external professional on request of the Applicant. Audits are quality assurance activities performed by third parties on behalf of the Applicant, while inspections are quality assurance activities performed by the regulatory authority. Audits occur during the course of the trial and can point to activities to be improved during study conduct, while a triggered inspection is performed after the study has finished with the aim of determining if the data are trustworthy and can be used for regulatory purposes. Therefore, audits and inspections do not carry the same weight in the context of regulatory activities. Within the 16 audits, 19 sites were audited, including both sites inspected later on during the GCP inspection coordinated by EMA. In total, one critical finding and 58 major findings were reported, identifying similar problems as identified during the inspections. Even though the conducted audits did not conclude on unreliability of the data, it needs to be clarified that such conclusions are not in the scope of audits. Against the Applicant´s argumentation that audit outcomes did not conclude that data are not trustworthy, similar findings as during the GCP inspections were identified and hence the audit results are in line with the inspection findings.

The categorization of sites by quality level performed by the Applicant based on the audit outcomes is not standardized, therefore, considered informative but less relevant for the assessment. Indeed, as outlined by the Applicant, of all patients randomized, 40% were inspected during the GCP inspection coordinated by EMA, 51% were audited and 9% were neither inspected, nor audited, however, given the weighting of inspections and audits (see above), this information has to be looked at critically. Further, the scope of inspections by different regulatory authorities were not the same. Additionally, the scope of inspections  might  differ  between  routine  and  triggered  inspections.  The  triggered  GCP  inspection, GCP/2017/001 is regarded as crucial one, and during the assessment the provisions of the EMA guideline EMA/868942/2011 were taken into account.

## [Argument 1.1, 1.5-1.6]

The Applicant claims that there were several measures taken by AB Science post the GCP inspection coordinated by EMA to overcome the drawbacks of the clinical study conduct, that were not reviewed or

<div style=\"page-break-after: always\"></div>

assessed  by  the  inspectors  or  taken  into  account  by  CHMP.  These  measures  include  corrective  and preventive actions e.g. re-monitoring of adverse events, vital signs, and lab values at 31 out of 34 study sites to ensure that all source data were accurately reflected in the updated clinical study report (CSR V3.0), re-evaluation of critical data from the trial, particularly the primary endpoint (ALSFRS-R) and safety data, detailed impact analyses of protocol deviations (on all sites, all patients, eligibility protocol deviations, potential underdosing of riluzole, masitinib dosing deviations and visit window deviations).

The Applicant's statement is not supported. First, it is noted that at the time of the GCP inspection, the Applicant  presented  a  series  of  corrective  and  preventive  actions  in  response  to  the  GCP  inspection findings (see EMA Inspection report, Addendum 1: Response form the sponsor or inspectee for both sites; dated 30 Jan 2018 site 1, and 01 Feb 2018 site 2) which have been assessed by the inspectors and were not found sufficient to recommend the use of data. Moreover, as outlined by the Applicant in the chronological listing of actions taken after the GCP inspection coordinated by EMA, it is indeed agreed that the majority of corrective measures were performed after the said GCP inspection. However, all information and documents (i.e. Addendum to CSR V1.0. CSR V3.0, ANSM GCP Inspection report GCP181801-FR,  MHRA  GCP  inspection  report  INSP  GCP  21687/22860-0003  and  the  Impact  analysis  of protocol deviations on efficacy and safety data) that resulted from the Applicant's corrective actions were provided during the initial assessment procedure (although some of them late during the procedure e.g. with D180 responses) and were assessed by the CHMP, as stated in the CHMP report.

Moreover,  as  correctly  cited  by  the  Applicant,  Guidance  EMA/8689942/2011  clearly  states  that  GCP inspectors and clinical assessors have different roles in the overall regulatory process of evaluating new medicines. Hence, it should be acknowledged that the focus of the GCP inspectors and clinical assessors is different and as a consequence the evaluation of the significance of the findings may also differ. For the assessors, the focus is on the particular medicine under assessment to ensure that the benefit-risk balance is favourable before licensing and that the overall ethical conduct is acceptable. It is reiterated, that the GCP inspectors' role is different from the clinical assessors' role in the evaluation process of the new medicine. The GCP inspection is aimed to verify whether the Applicant has a robust quality system in place to guarantee the quality of the data of the trial(s) inspected. While it is the assessors' task to evaluate whether corrective measures and re-assessments can outweigh findings identified during the GCP inspection and whether the B/R balance is favourable or not.

A more detailed assessment of corrective measures and impact analysis is given in the following sections.

## [Argument 1.7-1.8]

The Applicant refers to re-monitoring actions (97 monitorings in 31 out of 34 sites) that occurred during the period between the data extraction of the CSR V1.0 (available at the time of inspection) and the data extraction of the CSR V3.0. After the inspections, adverse events, vital signs, and lab values were remonitored to ensure that all source data were accurately reflected in the updated clinical study report CSR V3.0 (September 2021). The updated safety data between CSR V1.0 and CSRV 3.0 refer to the number of patients with at least one AE (1 patient deleted in control group) and severe AE data that was updated for 6 patients (5 patients additionally identified with severe AEs: 1 in the M4.5 group and 4 in the control group; 1 patient previously identified with a severe AE was deleted in the M3.0 group).

The CSR V3.0 was already provided during the initial assessment procedure, and it was concluded that the safety profile of mentioned medicinal product is considered acceptable for a CMA. As indicated in the initial opinion, the uncertainties and limitations regarding reliability of safety data of the pivotal clinical trial are alleviated by the safety data from the trials in non-oncological conditions.

Hence, it is agreed that the main considerations for the assessment on the impact of the inspection findings on the B/R are related to efficacy data. However, it still needs to be taken into account that the safety profile was characterized based on non-comprehensive evidence as corresponds to the requested

<div style=\"page-break-after: always\"></div>

## CMA.

## [Argument 1.9-1.10]

During the GCP inspection coordinated by EMA, major issues were identified regarding proper training of the principal investigators on the ALSFRS-R. For both sites, lack of documented formal training on the ALSFRS-R at the beginning of the trial was identified. The main impact of not performing these meetings is related with several revisions of the ALSFRS-R scale (primary efficacy endpoint) due to mistakes and inconsistencies. Although it can be agreed with the Applicant that raters were likely familiar with ALSFRSR evaluation based on their experience in treating ALS patients and based on the statement letters provided by each PI confirming that they were trained before the study began, and strictly followed AB Science  ALSFRS-R  guidelines/instruction,  it  is  noted  that    the  study  was  initiated  in  April  2013  and guidelines were available from September 2014, when appr. 33.2% of the study population were already randomized. Most critically, several discrepancies were identified in the ALSFRS-R score between source data and eCRF. In the Argentinian site, the inspection team reviewed all ALSFRS-R scales for the 53 randomized subjects. Corrections of the ALSFRS-R scales were identified and several of them were due to mistakes summing the single item points. For three subjects the score recorded on the eCRF was different from the source data.  Furthermore, the Applicant did not mention that there were changes identified on the score of some scale points not contemporaneous and made months or one year later, that the score of W24 was not recorded on eCRF for subject 04, and that for subject 55 (W24, W36, W48) the score after reassessment was not recorded on eCRF. The list of differences and changes were identified during scale verification on the site, and are available in the IR. At the other inspected site , indeed, no discrepancies between source and eCRF were identified, however, the inspection report states that minor retrospective changes were done and the scale eCRF page was revised four times due to typos, mistakes and misinformation. Of note, one site randomised 69 out of 88 screened instead of 109 participants as erroneously stated in argument 1.9. Considering that the ALSFRS-R score is the primary outcome of the study, reliability of the ALSFRS-R score data is vital.

As a corrective measure, all ALSFRS-R scores have been re-evaluated by an independent certified rater based on clinical notes. Of the total 2758 data points, 13 discrepancies (in 9 patients) were identified between the initial PI assessment of the ALSFRS-R score and the retrospective re-assessment of the ALSFRS-R score by the independent rater. When excluding these 9 patients from the primary endpoint analysis, no relevant change in the outcome was observed. With this analysis, the Applicant intends to demonstrate that composing ALSFRS-R scores retrospectively from review of clinical notes is possible, and ALSFRS-R was not affected in a systemic manner. This is not fully agreed. The article referenced by the Applicant (Lechtzin et al.) indeed states that ALSFRS-R scores can be obtained from review of clinical notes and can be a useful research tool. However, it is further stated that ALSFRS-R scores should be completed in person or via telephone interview for clinical prognostication in individual patients. From the CSR V3.0, and Protocol Version 5.0, it is not evident how exactly ALSFRS-R was recorded for each patient - was a narrative of patient's functional abilities provided alongside the number per item on the ALSFRS-R questionnaire or not. If a narrative was provided, was it available for each of the 12 subscores and for 100% of patients. In the absence of a narrative/clinical notes, it is unclear how a retrospective calculation can be done and how it could differ from the initial score (apart from simple mathematical miscalculations). During the oral explanation on 16 October 2024 the Applicant explained that the reevaluation of the ALSFRS-R scores was based on clinical notes, not solely based on re-calculating the scores. Data collected by the phone call visits not envisaged in the clinical study protocol are possible source of erroneous ALSFRS-R score data, some of which were not even documented. Moreover, results from the retrospective analysis provided within the table in Argument 1.10 are not fully understood. It is assumed that the discrepancy score for the placebo group should be -21, and not -12 as stated in the table (both discrepancy scores for that patient appear to be faulty). In any case, a retrospective analysis relies on the quality and accuracy of the initial data. As already stated, the deficiencies identified during

<div style=\"page-break-after: always\"></div>

the inspection render data (inclusive of primary efficacy data) untrustworthy. This is not changed with a reanalysis.

Noticeably, 6 of the 9 identified patients with discrepancies in the ALSFRS-R score (PI assessment vs. retrospective assessment by external rater) came from one site (25 patients randomized, site was not inspected) pointing at possible issues in ALSFRS-R score assessment also at this site.

## [Argument 1.11 - 1.13]

Inspectors  concluded  that  data  consistency  is  compromised,  and  its  integrity  is  highly  likely  to  be impaired  as  several  protocol  deviations  at  eligibility,  conduct  and  in  other  aspects  inspected  were confirmed. Given the massive number of protocol deviations observed at the sites inspected and the relevant number of GCP departures, the inspection team could not confirm that the management of the trial has been adhering to all principles as laid down in ICH GCP.

Based on this critical finding, the Applicant performed an impact analysis where all eligibility criteria deviations  were  reviewed  for  all  patients  from  all  sites.  Moreover,  potential  underdosing  of  riluzole, Masitinib AB Science dosing deviations and visit window deviations were investigated. A report of the impact analysis was provided. It is the Applicant's position, that the impact analysis demonstrated that those deviations had no impact on the assessment of the B/R. To begin with, the largest drawback of this analysis is that it was performed after the data base lock when data was already unblinded.

A systemic review of the final locked database (cut-off date: 03 December 2018) was performed to identify all deviations from in-exclusion criteria. Eligibility criteria queries were generated by considering 8 inclusion criteria and 8 exclusion criteria that are of relevance to safety and/or efficacy. Selection of these 8 in- and exclusion criteria was performed as recommended in EMA guideline EMA/868942/2011 (point 3. Categorization of findings). For the inclusion criteria, a SAS program was developed by the company's  Biostatistics  Department  to  perform  queries  based  on  deviation  definitions  using  cut-off values  defined  in  the  study  protocol.  For  exclusion  criteria,  different  SMQs  (Standardised  MedDRA Queries) or specific Preferred Terms were used and evaluated by the Medical Review Department to identify eligibility criteria deviations from the medical history of patients. A total of 389 eligibility criteria deviations were identified (35% in the control group, 33% in the M3.0 group and 32% in the M4.5 group). The qualitative analysis, including categorization of deviations and whether those deviations have  an  impact  on  efficacy  and/or  safety  was  performed  by  the  European  qualified  person  for pharmacovigilance (EUQPPV), i.e., the Global Patient Safety Director &amp; Head of Pharmacovigilance at AB Science. The 389 identified eligibility criteria deviations were categorized based on the nature (negligible, minor, major) and potential impact (no impact, possible impact) of the deviations. Regarding safety, 9 deviations in 5 patients were identified having possible impact on safety. When assessing case-by-case, it was concluded that the impact of these 9 deviations in 5 patients do not change the safety profile of masitinib 4.5 mg/kg/day in ALS.

Regarding efficacy, 7 deviations in 7 patients were identified, having possible impact on efficacy. In addition, the Data Review Committee previously (before the final database lock), identified 5 patients with possible impact on efficacy before unblinding. Hence, in total 12 patients with possible impact on efficacy were identified. Three out of these 12 patients participated in the M3.0 arm and were therefore not considered in the subsequent sensitivity analyses. The 9 identified patients (M4.5 arm n=6; control arm n=3) were excluded from the primary endpoint analysis, using MI J2R imputation method. The sensitivity  analysis  showed that there is minimal impact on efficacy due to the exclusion of these 9 protocol deviators (slightly larger confidence intervals and higher p-values).

In addition to eligibility criteria deviations, potential underdosing of riluzole, Masitinib AB Science dosing deviations and visit window deviations were investigated. A total of 7 patients received sub dosing of riluzole, including 3 patients in the M4.5 arm and 3 patients in the placebo arm. A sensitivity analysis

<div style=\"page-break-after: always\"></div>

excluding these 6 patients did not modify the primary efficacy analysis. 9 deviations related to masitinib underdosing were identified. Since those were considered to only minimize Masitinib AB Science efficacy they were concluded to have no impact on the study result. While it is agreed that these dosing deviations do not positively impact Masitinib AB Science efficacy, underdosing might indeed have an impact on safety in favour of Masitinib AB Science. Six visit window deviations were identified. However, those were assessed to have no impact on the primary efficacy analysis since none of those deviations fulfilled a rule established by the DSMB (25 Feb 2016) i.e. no impact on efficacy data is expected if non respect of visit windows is not higher than 28 days and not repeated at 2 consecutive visits.

In principle, the impact analysis performed by the Applicant is acknowledged and considered informative. However, as stated above, the largest drawback of this analysis is that it was performed after the data base  lock  when  data  was  already  unblinded.  Hence,  although  the  approach  can  be  followed,  the autonomy of this analysis is not given. Moreover, the identification of eligibility deviations was performed by the company's own departments, and the identification and categorization of eligibility deviations was performed  by  the  company's  Global  Patient  Safety  Director  &amp;  Head  of  Pharmacovigilance.  Hence, although  the  methodology  was  validated  by  an  independent  expert,  objectivity  of  this  analysis  is questionable.  No  information  regarding  the  identification  of  potential  underdosing  of  riluzole  events, Masitinib AB Science dosing deviations and visit window deviations were given.

Importantly, the Applicant performed an impact analysis for protocol deviations. However, during the inspection, data was deemed untrustworthy not solely due to protocol deviations. The problem was much deeper and much broader - it encompasses the lack of training, lack of monitoring, lack of proper record keeping, suboptimal trial management, data entry changes and other deviations.

Hence, it is agreed with the previous CHMP conclusion that the post hoc performed impact analysis cannot compensate for deficiencies identified during the conduct of the study and that the integrity of the primary endpoint is not given.

## [Argument 1.14, 1.16]

The Applicant refers to guideline EMA/868942/2011 which states that if safety is acceptable and the primary variable is robust, then benefit risks is valid. It is the Applicant's opinion, that this criterion is fulfilled. While it is agreed, that in superiority trials indeed, poor quality of data may merely introduce variability and not introduce bias favouring one treatment over the other, the guideline also clearly states that this assumption can only be made once the study has been completed, and superiority has been established, which is not the case for Masitinib AB Science (please refer to GfR#2.2).

Moreover,  the  Applicant  repeatedly  refers  to  the  paragraph  in  the  EMA/868942/2011  guideline  that states that it is important to assess whether the findings affect the interpretation of the primary efficacy endpoint or important safety endpoints. Needless to state, the findings have less significance for the benefit-risk assessment if they only have consequences for secondary or exploratory endpoints. This is acknowledged; however, it is not agreed that findings have no impact on the primary efficacy endpoint (see above). This aspect is particularly relevant since the clinical development programme is based on a single pivotal trial. The same guideline states that it should be born in mind that secondary endpoints may serve important purposes of ensuring internal consistency, in particular in applications with a single pivotal trial. Since the impact of inspection findings on secondary efficacy data was not considered/addressed, internal consistency is unclear.

Moreover,  and  most  important,  the  guideline  also  states  that  even  if  individual  findings  in  the intermediate  and  low-impact  category  may  not  affect  the  benefit-risk  assessment  looked  upon  in isolation, the combination of several of these findings is an indicator of overall poor data quality and therefore likely to become significant. This is considered to apply here.

It  is  agreed  with  the  Applicant,  that  re-monitoring  is  recognized  as  a  viable  approach  under  certain

<div style=\"page-break-after: always\"></div>

circumstances, as highlighted during the COVID-19 pandemic, where traditional on-site monitoring was often not feasible. However, in the case of the COVID-19 pandemic, re-monitoring was performed (onsite) if there were concerns about data quality/reliability following remote monitoring. This is different from the situation of Masitinib AB Science, where re-monitoring was intended to be used as corrective action following a negative GCP inspection.

The  Applicant's  justification  that  re-monitoring  in  the  AB10015  trial  is  particularly  defendable  and effective because source data are available and clearly documented and the type of data concerned (AEs, ALSFRS-R) are adapted for an efficient re-monitoring is not supported. Although no critical findings were reported as regards the integrity of the source data, several issues regarding this aspect were seen and described throughout the inspection report. As an example, a common deficiency was detected at the site  in  Spain  and  Argentina  regarding  the  report  of  PDs  not  documented  on  medical  records/eCRF. Regarding the retrospective re-assessment of the ALSFRS-R score please refer to section above.

## [Argument 1.15]

The Applicant claimed that as response to whether the Applicant should file a CMA for Masitinib AB Science, the CHMP Rapporteur of the initial application stated during the pre-submission meeting (24 May 2022) that ' The Rapporteur indicated AB Science should go back to the major points for refusal of the previous EPAR and explain how these issues were addressed, in particular GCP issues '. In the final minutes, it is reflected that the question on whether the CHMP Rapporteur of the initial application could support and encourage the filing of an application for CMA based on currently available data, and what would be the major considerations to be addressed was discussed. However, the minutes reflected that the CHMP Rapporteur of the initial application stated that no pre-assessment can be made until the application has been filed and that the CHMP Rapporteur will liaise with the initial CHMP Co-Rapporteur to provide further feedback to AB Science. It has been confirmed that no further feedback was provided. In the minutes, it is indeed reflected that the CHMP Rapporteur stated that ' The Rapporteur indicated AB Science should go back to the major points for refusal of the previous EPAR and explain how these issues were addressed, in particular GCP issues ' but this was a comment in relation to the discussion about issues raised in the previous EPAR. Whether to apply for a marketing authorisation or not is solely the decision and the responsibility of the Applicant.

## [Argument 1.17-1.18]

The  Applicant  refers  to  other  marketing  authorisation  procedures  (Albrioza  and  Qalsody)  where  a similar/higher number of protocol deviations did not lead to major objections or refusal of MA. While it is noted that the marketing authorization for Albrioza was not granted, it is reiterated that every MA application is assessed on its own merit, based on the totality of the data presented. There are multiple factors affecting the benefit-risk evaluation for each application besides the number of protocol deviation. It is the totality of data which is taken into account in every individual dossier.

The Applicant's position that the Masitinib AB Science dossier is treated more strictly than dossiers by other sponsors is strongly disagreed on. As for every other dossier, B/R evaluation is based on the totality of provided evidence.

## Overall conclusion

Although  the  Applicant's  corrective  measures  and  actions  including  re-monitoring  and  a  detailed deviation  impact  analysis  are  acknowledged,  they  can  only  be  considered  as  supportive  but  cannot compensate for the identified deficiencies during the conduct of the study. The previous CHMP opinion is upheld.

The note including clarifications on the GCP aspects provided by the Applicant during the evaluation time of the re-examination phase was assessed but the clarifications did not change the CHMP conclusions on

<div style=\"page-break-after: always\"></div>

this ground.

## Point not resolved

## 5.1.3. Ground #2.2

Beside  the  data  not  being  reliable,  the  results  from  the  pivotal  study  AB10015  do  not  demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS, because:

1. A  statistically  significant  difference  compared  to  placebo  was  not  demonstrated  for  the  primary endpoint in the full study population.
2. The approach to categorize the population into normal and fast progressors is not supported.
3. Considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition of intercurrent events in J2R strategy are not considered acceptable.
4. The strategies to post hoc identify new target populations ('M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1) are considered as data driven decisions and are, therefore, not acceptable.

## Applicant´s position on the Ground for re-examination

The Applicant presented first some statements already detailed in sections 3.3 - Uncertainties and limitations about favourable effects and 2.6.6 - Discussion on clinical efficacy of this CHMP AR.

## 1. A statistically significant difference compared to placebo was not demonstrated for the primary endpoint in the full study population.

The total  population  (normal  +  fast  progressors)  is  regarded  as  primary  population  and  statistically significant difference was not demonstrated for the primary endpoint in this population. The second key amendment is post hoc division of enrolled participants in two subgroups: fast and normal progressors. The division into two subpopulations was made based on the mITT population. Normal progressors were defined as the primary analysis population while the study was already ongoing. During the assessment, the Applicant was requested to justify this approach. The Applicant claimed that such approach reduces heterogeneity  in  trial  population.  The  reasoning  for  reducing  heterogeneity  is  understood  but  the approach  with post  hoc dichotomization  while  the  study  is  ongoing  is  not  supported.  The  Applicant appealed to the guideline EMA/CHMP/539146/2013 (section 5.4. Assessment scenario 3) to justify the validity of the division into groups. Indeed, the section 5.4. Assessment scenario 3 presents the situation in  which  the  clinical  data  presented  fail  to  establish  statistically  persuasive  evidence  in  the  primary analysis population but there is interest in identifying a subgroup where a relevant treatment effect and compelling evidence of a favourable risk-benefit profile can be assessed (guideline EMA/CHMP/539146/2013). It should be noted that no further confirmatory conclusions are possible in a clinical trial where the primary null hypothesis cannot be rejected in the total ITT population. To remind: ' a statistically significant difference compared to placebo was not demonstrated for the primary endpoint in the full study population '. The introduction of the subpopulations as an attempt to rescue the study is  acceptable  by  the  guideline  only  in  certain  situations.  The  guideline  states  that  interpretation  of subgroup findings should be done with caution. Credibility of the subgroup findings, in other words, the extent to which subgroup findings can be concluded as being well substantiated and hence, relied on for decision making depends on the degree of well-founded, a priori definition, the biological plausibility for a particular finding and replication. Indeed, the guideline EMA/CHMP/539146/2013 in section 6.1 states the assessors should have ' expected to find discussion in the trial protocol of the expected degree of

<div style=\"page-break-after: always\"></div>

heterogeneity  of  the  patient  population '.  However,  the  ' restrictions  of  a  trial  population  to  a  subpopulation of the target population should be justified, detailing whether restrictions are made due to safety concerns, anticipated lack of efficacy, or other operational considerations ' at the planning stage of the study (EMA/CHMP/539146/2013). Indeed, if the study results indicate that the treatment effect may vary according to the levels of a particular factor, subsequent investigations might need to be based on a categorisation (for a continuous factor) or collapsing categories (for an ordered categorical variable with a higher number of levels). This is because these categories should relate to criteria that might ultimately be used in product labelling or clinical decision-making ((EMA/CHMP/539146/2013). However, this possibility should be carefully considered at the planning stage, pre-specifying categories that might ultimately  serve  this  purpose.  Analyses  investigating  the  choice  of  cut-off  on  the  robustness  of conclusions should also be planned as well (EMA/CHMP/539146/2013). The Applicant claims that the normal progressors' subpopulation is the pre-planned primary analysis population of study AB10015. However,  the  Applicant  recognized  that  the  dichotomisation  of  patients  into  'fast'  and  'normal' progressors was implemented after the study start, which is not agreed. This approach can generate the questionable results, as ' post-baseline covariates may be affected by treatment received and will not usually be appropriate to define subgroups for the investigation of a treatment effect ' (EMA/CHMP/539146/2013). Moreover, if a particular factor is considered prognostic for outcome or at least  some  biological  plausibility  or  external  evidence  such  that  an  inconsistent  response  might  be observed, the CHMP expected to find a discussion of subgroup of investigations conducted and their consideration.

In the opinion of the CHMP, the aforementioned criteria for subgroup analyses (guideline EMA/CHMP/539146/2013) were not met nor for the normal progressor was subpopulation selected by the Applicant after an amendment of the protocol while the study ongoing.

## AB Science Response

## Argument 2.1: The  Rapporteurs'  position  that  the  Applicant  justified  the  analysis  in Normal progressors based on scenario 3 of guidance EMA/CHMP/539146/2013 is inaccurate. Such justification was never formulated by the Applicant as the analysis  in  the  Normal  progressors  was  prespecified  in  an  amendment submitted prior to the availability of any study data and the study is positive on its  planned  amended  protocol  transitioning  from  phase  2  to  phase  3,  as validated by competent authorities

The main amendment introducing the distinction between 'Normal' progressors and 'Fast' progressors, was the amendment #3. This amendment was implemented in October 2014, approximately 2.5 years prior to trial completion (March 2017 for unblinding).

From this protocol version onward, a fixed sequence methodology was used to control the global familywise error rate at the 0.05 significance level.

- -Sequence 1 'Normal Progressor' population - Masitinib 4.5 mg/kg/day
- -Sequence 2 'Normal Progressor' population - Masitinib 3 mg/kg/day
- -Sequence 3 'Normal +Fast Progressor' population - Masitinib 4.5 mg/kg/day
- -Sequence 4 'Normal +Fast Progressor' population - Masitinib 3 mg/kg/day

The amendment was submitted based on the justification provided below, which had nothing to do with the reasoning set in guidance EMA/CHMP/539146/2013.

<div style=\"page-break-after: always\"></div>

## Argument .2.2: The  main  amendment  excluding  Fast  progressors  from  the  primary analysis was recommended by principal investigator

Because of transition from phase 2 to phase 3, it was necessary to minimize expected high missing data due to discontinuations from Fast progressors in a study with a long time-point of 48-weeks and with a tablet formulation.

The  distinction  between  normal  and  fast  progressors  with  motivated  by  the  need  to  have  a  more homogeneous population.

The distinction between normal and fast progressors with a cut-off of 1.1 points was recommended by the new coordinating investigator, who was appointed in July 2014.

## Argument 2.3: The  distinction  between  Normal  and  Fast  progressors  was  widely endorsed by all Investigators and by ALS experts

This proposal was then validated by the steering members of the trial, as well as all investigators and other independent experts in ALS from the below countries

Table 102: List of investigators and external experts in ALS agreeing with the distinction between Normal and Fast progressors (redacted)

| Status       | Country     |
|--------------|-------------|
| Investigator | Spain       |
| Investigator | Spain       |
| Investigator | Netherlands |
| Investigator | Portugal    |
| Investigator | Italy       |
| Investigator | Italy       |
| Investigator | Italy       |
| Investigator | Italy       |
| Investigator | Italy       |
| Investigator | Hungary     |
| Investigator | Hungary     |
| Investigator | Mexico      |
| Investigator | Serbia      |
| ALS Experts  | Ireland     |
| ALS Experts  | Germany     |
| ALS Experts  | Germany     |
| ALS Experts  | USA         |
| ALS Experts  | Belgium     |
| ALS Experts  | Switzerland |

## Argument 2.4: The amendment was fully justified in the context of a phase 3 study in ALS with 48 week time point, as around 55% of fast progressors discontinued before week 48

AB Science provided new data showing discontinuation rate above 50% in Fast progressors at week 48, validating the necessity to exclude Fast progressors from the primary analysis.

<div style=\"page-break-after: always\"></div>

Table 103: Rate of discontinuation at week 48

| Patient Status   | Placebo   | M4.5   |
|------------------|-----------|--------|
| Normal           | 26.5%     | 30.5%  |
| Fast             | 52.6%     | 56.5%  |

## Argument 2.5: Retaining fast progressors in the primary analysis and accounting for the expected standard deviation would have required 800 patients for a phase 2b/3 which is contrary to the objective in an orphan drug development

Exclusion of fast progressors from the primary analysis was necessary, in particular for a week 48 study in ALS

At the time of transitioning from a phase 2 to a 48-week duration phase 3 clinical trial, patient selection criteria  for  study  AB10015  were  amended in order to better minimize data variability. This included mitigation of premature patient withdrawal by pre-empting and excluding those cohorts that represented a higher risk. Exclusion of fast progressors is therefore a strategy aimed at limiting the amount of missing data and data variance.

This design consideration is directly related to the EMA guidance EMA/CPMP/EWP/1776/99 Rev. 1 (2 July 2010) on Missing Data in Confirmatory Clinical Trials, which states that '… by careful  planning  it  is possible to reduce the amount of data that are missing. This is important because missing data are a potential source of bias when analysing data from clinical trials. Interpretation of the results of a trial is always problematic when the proportion of missing values is substantial.' The guideline further insists that the study should be designed to minimize missing data 'it is extremely important to avoid the presence of unobserved measurements as much as possible, by favouring designs that minimise this problem, … '.

If Normal and Fast progressors were to be kept for the primary analysis population, the sample size should have been around 1000 patients across three arms, as calculated below.

Because efficacy of masitinib was not yet established, it was considered more ethical to limit the sample size by performing the sequential analysis in Normal then in Normal + Fast progressors, rather that inflating the sample size.

To  estimate  the  necessary  sample  size  a  study  designed  for  normal  +  fast  progressors, hypotheses would have been to detect a difference of 3.3 points in the mean change of ALSFRSR  score  between  the  two  masitinib  arms  (3.0  mg/kg/day  and  4.5  mg/kg/day)  and  the corresponding placebo arm after 48 weeks of treatment.

But the major difference would have been to integrate in the sample size a Standard deviation of the change from baseline to week 48 in ALSFRS-R score estimated at 15 points

Alpha set to 2.5% for one -sided test

Global Power set to 80%

Randomization ratio 1:1:1 between masitinib 3mg/kg and masitinib 4.5mg/kg and placebo

With these assumptions, approximately 331 patients would have been necessary in each arm to detect  a  3.3  point  difference  in  ALSFRS-R  score  between  the  masitinib  group  and  the corresponding placebo group, in order to achieve a global power above 80% with a significance level for a one-sided t-test of 0.025%.

In total the sample size would have been around 1,000 patients just because of the increase in standard deviation.

The sample-size calculations were performed by AB-Science using PASS.

Please note that the difference of 3.3 points in change in alsfrs for Normal+fast is what was observed when the bias of the subset of patients with at least one complete loss of function is removed.

<div style=\"page-break-after: always\"></div>

## Argument 2.6: The main amendment excluding Fast progressors from primary analysis was validated by all competent authorities

The amended protocol proposing the split into Fast and Normal Progressor subgroups was subsequently approved by the following national competent authorities, at a time when the study was already amended into a phase 3:

Table 104:  Approval of amendment #3 by all countries

| National Competent Authority   | Protocol version   | Approval date   |
|--------------------------------|--------------------|-----------------|
| Argentina                      | v3 ROW             | 30-Nov-14       |
| Canada                         | v4 CAN             | 05-Aug-15       |
| Greece                         | v3 ROW             | 06-Mar-15       |
| Italy                          | v3 ROW             | 05-May-15       |
| Mexico                         | v4 ROW             | 09-Mar-17       |
| Netherlands                    | v4 EU              | 21-Sep-15       |
| Portugal                       | v4 EU              | 19-Apr-17       |
| Slovakia                       | v3 ROW             | 03-Feb-15       |
| Spain                          | v4 Spain           | 01-Dec-14       |

## Argument 2.7: Substantial protocol amendments during the enrolment period are not uncommon, especially for rare diseases

There are numerous examples of clinical studies transitioning phase status while the trial is on-going. Examples include studies NCT03149003, NCT02631876, NCT03941444 and NCT01224106).

Furthermore, a survey by Tufts Center for the Study of Drug Development revealed that occurrence of multiple  substantial  protocol  changes  during  phase  3  studies  is  not  uncommon,  especially  for  rare diseases [Getz 2022; Getz 2024]. Analysis from the 2022 follow-up study, based on data provided by 19 major and mid-sized pharmaceutical companies and CROs, showed that overall, more than three quarters  of  protocols  required  at  least  one  amendment,  with  a  mean  average  of  3.3  amendments implemented per protocol when required. Considering breakdown by protocol phase, 88.2% of phase 2 protocols and 82.2% of phase 3 protocols had at least one substantial protocol amendment with an average of 3.3 and 3.5 amendments per protocol, respectively. More complex protocol designs were associated with a higher average number of substantial amendments, with an average of 3.7 being associated with rare disease protocols. Changes in clinical trial strategy and regulatory agency requests were  consistently  among  the  most  common  primary  causes  of  amendments.  Considering  timing  of amendment implementation, approximately 60% of phase 3 studies had amendments occurring during the enrolment period.

In study AB10015, three amendments were done, which is in line with Tufts publication.

## Argument 2.8: Precedents exist for such substantial amendments to the pivotal studies of drugs granted marketing authorisation

In  May  2023,  the  EMA  granted  Columvi  (glofitamab)  a  conditional  marketing  authorzation  for  the treatment of relapsed or refractory diffuse large B-cell lymphoma. This was despite the study being initiated as a Phase 1 study that was upgraded to a Phase 1/2 study following a late protocol amendment (the ninth of ten), and that definition of the primary analysis cohort was made only after all data had been accrued.

While EMA decision is pending, the FDA approved, in July 2024, Kisunla (donanemab) injection for the treatment  of  Alzheimer's  disease.  Eli  Lilly's  TRAILBLAZER-ALZ  2  pivotal  trial  of  donanemab  in  early symptomatic Alzheimer's disease, closely mirrors the two-tiered design of study AB10015. That is to say,

<div style=\"page-break-after: always\"></div>

the main primary analysis population is a subgroup of the overall population, the latter of which was tested as a subordinate part of a hierarchical test procedure (see table below for comparison of the TRAILBLAZER-ALZ 2 design and amendments). Furthermore, both of these studies showed no treatment effect (post hoc analyses) in the smaller complement subgroup (i.e., the cohort added to the primary analysis  subgroup  to  make  the  overall  population),  which  had  the  result  of  diluting  (lessening)  the between  group  difference  of  the  overall  population  analysis  in  both  cases.  Based  on  the  striking similarities between the substantial amendments of studies AB10015 and TRAILBLAZER-ALZ 2 (in terms of nature and timing) and their amended statistical designs, it would seem logical that both studies will be held to the same regulatory standards regarding impact of said amendments and whether or not these allow for interpretation of the benefit-risk balance.

Table 105: Comparison of amendments for studies AB10015 and TRAILBLAZER-ALZ 2

|                                 | TRAILBLAZER-ALZ 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | AB10015                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Substantial protocol amendments | The trial was originally designed as a phase 2 trial with a plan to enrol 500 participants but was subsequently amended to a phase 3 trial (n=1736) assessing a different primary outcome in a subgroup of the overall study population. Amendment (17-Feb-2021) included: - Transition from phase 2 to phase 3. - Increase in the sample size. - Changed the primary analysis from 'CDR- SB in the low-medium (intermediate) tau pathology population' to 'iADRS in the low-medium (intermediate) tau pathology population and the overall population (low- medium and high tau pathology).' Amendment (Sep 2021) included: - Increased sample size by 300 participants. | The trial was originally designed as a phase 2 trial with a plan to enrol 45 participants but was subsequently amended to a phase 2/3 trial (n=394) assessing a subgroup of the overall study population. Amendment (July 2013) included: - Transition from phase 2 to phase 2/3. - Increase in the sample size. Amendment (Oct-2014) included: - Changed the primary analysis population to 'Normal Progressor' ( Δ FS < 1.1 points/mo) while concurrently permitting assessment of the overall 'Normal and Fast Progressor' population. - Increase in the sample size. |
| Timing of amendments            | Enrolment began June 2020, and ended November 2021, indicating that these amendments occurred after a substantial number of patients had been recruited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Amendments occurred early during the study, at a time when 9% (July 2013) and 36% (October 2014) of patients had been enrolled, corresponding to 0% and 12% patients having reached the primary outcome week-48 timepoint.                                                                                                                                                                                                                                                                                                                                               |
| Trial blinding at amendments    | No unblinded data analysis of TRAILBLAZER-ALZ 2 was performed or used to inform design or analyses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | No unblinded data analysis of AB10015 was performed or used to inform design or analyses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Amended primary objective       | To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic AD, according to iADRS change from baseline through Week 76 in at least one of: - the low-medium (intermediate) tau pathology population or - the overall population (low-medium and high tau pathology)                                                                                                                                                                                                                                                                                                                                                  | To assess the effect of masitinib versus placebo on clinical progression in participants with ALS according to decline in ALSFRS-R from baseline to week 48 in: - the 'Normal Progressor' population - the overall population ('Normal and Fast Progressor')                                                                                                                                                                                                                                                                                                             |
| Hypothesis testing scheme       | Gating scheme. Statistical testing allocated α of .04 to testing low/medium tau population outcomes, with the remainder (.01) for combined population (low/medium and high tau) outcomes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Stepwise manner (fixed sequence method), with the hierarchy of: 1. 'Normal Progressor' masitinib 4.5 mg/kg/day cohort 2. 'Normal and Fast Progressor' masitinib 4.5 mg/kg/day cohort                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                   | TRAILBLAZER-ALZ 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | AB10015                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Post Hoc Outcomes | Analysis of the smaller (n=552) high tau population alone (i.e., not combined with the low/medium tau population) was completed post hoc and showed that high tau participants demonstrated no differences on the primary outcome or on most secondary clinical outcomes in donanemab-treated compared with placebo- treated participants. Absence of treatment-effect reduced magnitude of difference in the overall population, but not to such an extent that it lost statistical significance (because of large treatment-effect driven by the low/medium tau population). | Analysis of the smaller (n=42) Fast Progressor population alone (i.e., not combined with the Normal Progressor population) was completed post hoc and showed that Fast Progressor participants demonstrated no differences on the primary outcome or on secondary clinical outcomes in masitinib-treated compared with placebo. Absence of treatment-effect reduced magnitude of difference in the overall population to such an extent that statistical significance was lost. |

## Argument 2.9: The  integrity  of  the  study  was  preserved,  the  amendment  was  done blinded

The  amendments  were  implemented  while  the  study  remained  blinded,  thereby,  preserving  data integrity.

The GCP inspection did not report any finding related to potential unblinding of the study.

## Argument 2.10: The amendment was implemented 2.5 years prior to study completion with only 12% of data acquired and excluding these data does not modify the study outcome

The  amendment  was  implemented  early  (October  2014),  approximately  2.5  years  prior  to  trial completion (March 2017 for unblinding), with only 8 Fast Progressor patients across 3 arms who could have reach week 48.

Table 106: Number of patients by treatment group and ΔFS subgroup at time of amendment introducing the distinction between Normal and Fast Progressor (Protocol version v3.0, submitted 08 October 2014)

| Number of patients n (%)   | Placebo N = 133   | Masitinib 3.0 N = 131   | Masitinib 4.5 N = 130   | Total 394   |
|----------------------------|-------------------|-------------------------|-------------------------|-------------|
| Normal Progressor          | 15 (11.3)         | 13 (9.9)                | 10 (7.7)                | 38 (9.6)    |
| Fast Progressor            | 3 (2.3)           | 2 (1.5)                 | 3 (2.3)                 | 8 (2.0)     |
| All                        | 18 (13.5)         | 15 (11.5)               | 13 (10.0)               | 46 (11.7)   |

## Argument 2.11: Removing those 12% data would not have changed the outcome of the primary analysis

The sensitivity analysis excluding 40 Normal Progressors who could have reached the 48-week time point shows no impact (diff of 3.20, p=0.0384)

Table 107: Post hoc analysis of the AB10015 primary endpoint, excluding those patients who had reached week 48 by the time of submission of protocol introducing this distinction between Normal and Fast Progressor (Analysis Rule 1 - mLOCF, Normal Progressor)

| Treatment group   |   N |   LS Mean ALSFRS-R | Difference of means [95% confidence interval]   |   p-value (no re- randomization test) |
|-------------------|-----|--------------------|-------------------------------------------------|---------------------------------------|
| Placebo           |  87 |             -12.31 | 3.20                                            |                                0.0384 |
| Masitinib 4.5     |  89 |              -9.11 | [0.17;6.23]                                     |                                0.0384 |

<div style=\"page-break-after: always\"></div>

## Argument 2.12: The interim analysis was positive in the overall study population and there was no amendment after the interim analysis

The  preplanned  interim  analysis  (March  2016)  with  Normal  +  Fast  Progressor  patients  was  positive (p=0.0213).

Table 108: Interim Analysis - Normal + Fast Progressor

| Treatment group   |   N |   LS Mean ALSFRS-R | Difference of means [95% confidence interval]   |   p-value (no re- randomization test) |
|-------------------|-----|--------------------|-------------------------------------------------|---------------------------------------|
| Placebo           |  57 |             -14.5  | 4.29                                            |                                0.0213 |
| Masitinib 4.5     |  62 |             -10.21 | [0.14;8.43]                                     |                                0.0213 |

The CHMP recommended to continue the study and there was no amendment after the interim analysis.

## 2. The approach to categorize the population into normal and fast progressors is not supported.

The Applicant presented first some statements included in section 2.6.6 of this CHMP AR

During the assessment, the Applicant was arguing that categorization of patients in Normal and Fast progressors was endorsed by the CHMP scientific advice (SA). This is not agreed as the SA addressed the use of Δ FS as a potential inclusion criterion for the Phase 3 AB10019 study. The Applicant insisted on that this categorization of the population is supported in terms of clinical relevance, statistical design, and pathophysiology of ALS. Although changes in the ALSFRS-R could be considered a useful measure of disease progression in some studies. However, its use as a single indicator for convincing prediction of the progression of ALS is not acceptable, because Δ FS alone has relatively low predictive value of progression (Thakore et al, 2017) and is not stable throughout the course of disease (Requardt, 2021). For  this  reason,  a  linear  assumption  for  the Δ FS  decline  (average  rate  of  change  from  onset  to randomization) might lead to misclassification of patients. Additionally, despite the fact that delta FS from the first symptom to time of diagnosis or during the whole disease could be reliable predictor of survival,  it  possesses  uncertainties  related  to  the  patient's  knowledge  of  the  exact  time  of  the  first symptoms as well as the investigator knowledge of the exact time of the first symptoms' set up. The justifications  for  the  cut-off  ( Δ FS  1.1)  provided  by  the  Applicant  during  the  assessment  were  not convincing and the Applicant was repeatedly informed during the application assessment that the delta FS cut-off 1.1 points/months for the categorization of patients into normal and fast progressors is not acceptable as a single indicator of the progression.

During the extended discussion after the OE, the Applicant insisted on that the cut-off 1.1 of delta FS is based on the best evidence found in the literature at the moment of study development. According to the Applicant, the calculation of the cut off level 1.1 of delta FS is based on the study of Kollewe et al J. (2008). Referring to Kollewe et al (2008) the Applicant has explained the calculation of cut-off of delta FS: ' the median delta FS calculated between onset and first examination was 1.0 points/month and the median delta FS calculated over the whole course of disease was 1.185 points/month, a range therefore of approximately 1.0 - 1.2 points/month. The choice of 1.1 points/month is situated at the midpoint of this range '. However, the authors highlighted in the referred publication that if the investigators fail to note exact time there will be no correct calculation for ALSFRS-R score ratio between first symptom and first examination. Additionally, the authors noted that the change of ALSFRS-R score over the whole course of disease is not useful to establish, because only the endpoint defined as death or tracheotomy allows assuming it. They concluded that ALSFRS-R score ratio within a defined period (i.e. 100 days) could solve the problem. They proposed to compute this parameter as ' difference of ALSFRS-R score between two visits divided by days between two visits '. Notably, the conclusion of the authors was that the ratio of ALSFRS-R score within 100 days is a useful parameter for clinical trials and they proposed

<div style=\"page-break-after: always\"></div>

&lt;0.25; 0.25-0.65 and &gt;0.65 cut-off levels of delta FS. Based on all above, it could be concluded that the applied cut-off level by the Applicant seems to be chosen arbitrarily and, therefore, the quantitative choice  of  delta  FS  cut-off  at  1,1  is  not  supported  for  the  distinction  patients  into  Normal  and  Fast progressors. The CHMP stressed again that the distinction into normal and Fast progresses are unlikely to happen in the clinical practice by simply applying a cut-off level 1.1.

The Applicant states that showed benefit in ALSFRS-R and PFS and a trend towards benefit on OS and CAFS is in alignment with EMA guidance (ref.: EMA/531686/215, Corr. 1.1.). According to the Applicant, many ALS studies, including pivotal studies of registered products such and Tofersen (EMA approval), have used delta FS as a patients' selection criterion without providing justification that defined cut-off is stable over time. Based on this, the Applicant believes that there is no precedent to reject a study based on the categorization of its population via delta FS. In response to the Applicant's argument about the delta FS use in other trials, it is acknowledged that the calculation of delta FS has been used in clinical studies, however the exact cut-off of delta FS to distinct fast or normal progressors is questionable. Indeed, the numerous clinical studies operate with a variety of slope of ALSFRS-R, which could be defined as early, late, pre-randomized or run-in slope, and they range from 0.25 to 1.7. However, no exact cutoff  level  can  be  defined  for  the  categorization  of  disease  progression,  as  the  higher  delta  FS  simply indicates the higher chance or probability of the survival event (death or tracheotomy) compared with lower one. The CHMP considers that the distinction into normal and fast progresses are unlikely to happen in the clinical practice taking into account the variety of ALS phenotypes or predominated type of onset of disease and severity of disease at the baseline. As per reference to Tofersen, the Applicant categorized the population using two factors the delta ALSFRS-R and type of SOD1-ALS. Results from the Tofersen clinical data suggested that two factors did not adequately discriminate the probability progression of ALSFRS-R. The data suggested that the baseline level of neurofilaments was a better prognostic factor (Tofersen EPAR). It is believed that, yet no new convincing data or arguments were presented that would alter  previous  assessment  and  CHMP  conclusions  about  efficacy  demonstration  in  the  full  study population, thus issue is not resolved.

## AB Science Response

## Argument 3.1: The definition of fast progressors measured from onset of symptoms is the most classic way to define fast progressor and is widely used by sponsor

Δ FS  can  provide  patient  enrichment  by  selecting  a  more  homogeneous  population,  and  it  has  now become common practice for ALS clinical studies to use Δ FS related inclusion criterion for selecting a more homogenous population.

Examples  include  trials  of  edaravone,  FNP122  (oral  edaravone),  tofersen,  Nurown,  rasagiline, ravulizumab, lenzumestrocel, bosutinib, nitrazine, beta hydroxybutyrate ester and high-caloric fatty diet (see table below).

Table 109 : ALS clinical studies with patient selection based on ΔFS

| Drug                       | Study                 | ∆ FS patient selection criterion                                                                                         | Ref                 |
|----------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------|
| Masitinib                  | AB10015, NCT02588677  | Predefined primary analysis population: 'Normal Progressor' Δ FS <1.1 per month)                                         | Mora 2020 Mora 2021 |
| Beta Hydroxybutyrate Ester | KETO-ALS, NCT04820478 | Inclusion criterion: ΔFS ≥0.33 per month since onset (first paresis), in the period between first symptoms and screening | clinicaltrials.gov  |

<div style=\"page-break-after: always\"></div>

| Drug                                                                                        | Study                                                                                       | ∆ FS patient selection criterion                                                                                               | Ref                                                                                         |
|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Bosutinib                                                                                   | NCT04744532                                                                                 | Inclusion criterion: Decrease of 1-3 points during 12-week observation period (equivalent to Δ FS 0.36-1.09 per month)         | Imamura 2019                                                                                |
| Edaravone                                                                                   | MCI186-19, NCT01492686                                                                      | Inclusion criterion: Decrease of 1-4 points during 12-week observation period (equivalent to Δ FS 0.36-1.45 per month)         | The Writing Group 2017                                                                      |
| FNP122 (oral edaravone)                                                                     | ADORE, NCT05178810                                                                          | Inclusion criterion: Δ FS between 0.35 and 1.5 per month in the period between first symptoms and the screening visit          | van Eijk 2022                                                                               |
| High-caloric fatty diet                                                                     | NCT02306590                                                                                 | Fast progression rate: Δ FS >0.65 per month (defined post hoc )                                                                | Ludolph 2020                                                                                |
| Lenzumestrocel                                                                              | NCT04745299                                                                                 | Inclusion criterion: intermediate rate of disease progression; Δ FS of 1.03±0.5 per month during a 17-week period              | Nam 2022                                                                                    |
| Methylcobalamin                                                                             | NCT03548311                                                                                 | Inclusion criterion: Decrease of 1-2 points during 12-week observation period (equivalent to Δ FS 0.36-0.72 per month)         | Oki 2022                                                                                    |
| Nitrazine                                                                                   | NCT04950647                                                                                 | Inclusion criterion: Decrease of 1-4 points during 12-week observation period (equivalent to Δ FS 0.36-1.45 per month)         | clinicaltrials.gov                                                                          |
| NurOwn                                                                                      | NCT03280056                                                                                 | Inclusion criteria: ≥3 ALSFRS -R points decline during 12-weeks (equivalent to ΔFS ≥ 1.09 per month; i.e., 'Rapid Progressor') | Cudkowicz 2022                                                                              |
| Rasagiline                                                                                  | NCT01879241                                                                                 | Normal to fast progression rate: Δ FS >0.5 per month (defined post hoc )                                                       | Ludolph 2018                                                                                |
| Ravulizumab                                                                                 | NCT04248465                                                                                 | Inclusion criterion: Δ FS >0.3 per month                                                                                       | Genge 2023                                                                                  |
| Tofersen                                                                                    | NCT02623699                                                                                 | Primary population: Faster Progressor subgroup defined as ΔFS ≥0.9 per month                                                   | Miller 2022                                                                                 |
| * For conversion between weeks and months, it is assumed that 1 month equals 4.348125 weeks | * For conversion between weeks and months, it is assumed that 1 month equals 4.348125 weeks | * For conversion between weeks and months, it is assumed that 1 month equals 4.348125 weeks                                    | * For conversion between weeks and months, it is assumed that 1 month equals 4.348125 weeks |

## Argument 3.2: The definition of fast progressors measured from onset of symptoms is a highly robust, independent prognostic predictor of survival. ALSFRS-R is a surrogate of survival

Δ FS  from  onset  of  symptoms  has  been  identified  as  being  a  highly  robust  independent  prognostic predictor of survival. Research by Requardt and colleagues has shown that the clinical determinant of greatest  prognostic  importance  for  survival  is  the  early  ALSFRS-R  slope  (i.e., Δ FS  from  onset  of symptoms), with a statistically significant hazard ratio (HR) of 1.50, p &lt; 0.0001, according to univariable Cox regression for continuous measures, and an HR of 1.33 (95% confidence interval, 1.19-1.5, p &lt; 0.0001),  according  to  multivariable  Cox  regression  model  [Requardt  2021].  On  the  contrary,  late ALSFRS-R slope (e.g., Δ FS calculated over a relatively short observation or lead-in period) showed no prognostic  value  under  this  clinical  setting.  Hence, Δ FS  from  onset  of  symptoms  is  an  entirely independent clinical determinant of survival prognosis from that of run-in Δ FS, and therefore robust irrespective of any Δ FS instability over the duration of disease.

The importance of this latter point cannot be overstated; Δ FS is  a  timeframe  dependent  parameter meaning that different methods of calculating the ratio's denominator may have significant impact on the resulting value. Consequently, there are in fact different 'noncomparable' Δ FS measurements. It is

<div style=\"page-break-after: always\"></div>

well-established  that  ALSFRS-R  progression  of  ALS  is  curvilinear  over  the  course  of  the  disease, therefore, it is important to distinguish which part of the overall ALSFRS-R trajectory is being considered when defining or comparing Δ FS values. Hence, Δ FS is  typically  defined  using  one  of  the  following, noncomparable, calculations:

- o Post-onset  (early  slope) Δ FS  =  [(48  minus  total  ALSFRS-R  score  at  diagnosis  or  initial assessment) divided by (symptom duration from onset in months)].
- o Interval (late slope) Δ FS = [(total ALSFRS-R score at first assessment minus total ALSFRSR score at follow-up assessment) divided by (follow-up time in months)].

Indeed, this timeframe dependence is well-illustrated by Kollewe and colleagues who defined Δ FS over three  different  timeframes;  namely, Δ FS  calculated  from  first  symptom  to  time  of  diagnosis, Δ FS calculated over the whole course of disease (i.e., from first assessment until last assessment prior to death or tracheotomy), and Δ FS calculated within a defined period of 100 days [Kollewe 2008]. According to their study population, the median Δ FS calculated for each of these timeframes was 1.0, 1.185 and 0.65 points/month, respectively.

Another finding of the Requardt research was that patients frequently switched between Δ FS categories over  time,  i.e.,  there  were  significant  differences  between  early  and  late Δ FS  group  distributions [Requardt 2021]. However, as explained above, this is entirely to be expected because the comparison being made is confounded by differences in the Δ FS methodology applied. To assess instability in Δ FS categorization it would be necessary to fix the timeframe's starting point, i.e., from first symptom, first assessment or a given baseline assessment. Hence, the Δ FS categorical instability observed by Requardt does not preclude stability in post-onset (early slope) Δ FS over time.

Moreover, in the context of excluding fast progressors as a strategy to limit the amount of missing data, a certain amount of misclassification around the chosen Δ FS cut-off is of little consequence because this approach will still achieve its aim of reducing data variance by excluding those patients with persistently fast progression. Indeed, it has been shown that study AB10015 was successful across a range of possible Δ FS cut offs, from 0.8 to 1.4 points/month.

## Argument 3.3: The Δ FS  eligibility  criterion  cut-off  of  1.1  points/month  was  not arbitrary but based on available literature

The Rapporteurs has repeatedly concluded that the Δ FS eligibility criterion cut-off of 1.1 points/month applied in study AB10015, has been arbitrarily chosen and does not therefore support the categorization of patients into 'normal' and 'fast' progressors. The Applicant respectfully challenges this opinion and contends that the Δ FS eligibility criterion cut-off of 1.1 points/month was not chosen in an arbitrary manner but was based on the most credible evidence found in the literature at that time.

As a reminder, Kollewe and colleagues showed that Δ FS, whether calculated from first symptom to time of diagnosis, during the whole disease, or within an interval of 100 days, correlates with survival time and is a reliable, independent predictor of survival [Kollewe 2008]. The authors even concluded that 'Predictors of survival are not only an instrument for better management in individual ALS-patients but could also be helpful for the design of new trials, randomization of patients and studying different types of disease progression correctly.' This is exactly what the design of study AB10015 has endeavored to achieve, and now it would seem is being penalized for.

As mentioned above, Kollewe and colleagues defined Δ FS over three different timeframes; namely, Δ FS calculated from first symptom to time of diagnosis, Δ FS calculated over the whole course of disease (i.e., from first assessment until last assessment prior to death or tracheotomy), and Δ FS calculated within a defined period of 100 days. According to their study population, the median Δ FS calculated for each of these timeframes was 1.0, 1.185 and 0.65 points/month, respectively. The difference between these values highlights an important aspect of this measurement, in so far as Δ FS is a timeframe dependent parameter, meaning that different methods of calculating the ratio's denominator may have significant impact  on  the  resulting  value.  Consequently,  these  are  in  fact  different  'noncomparable' Δ FS

<div style=\"page-break-after: always\"></div>

measurements. It was therefore necessary for the Applicant to choose one of these techniques (i.e., timeframes)  as  a  basis  for  the  study's Δ FS  eligibility  criterion.  Each  has  its  advantages  and disadvantages, as discussed further below.

-  The gold standard Δ FS for survival predication is logically that which is calculated over the whole course  of  disease;  however,  as  pointed  out  by  the  authors,  ' this  is  not  useful  to  establish, because only the endpoint defined as death or tracheotomy allows to assume it '. Nevertheless, the findings from Kollewe established its strong correlation with survival time and the benchmark of 1.185 points/month as a rational criterion for categorization of patients into rapid (i.e., faster) and non-rapid (i.e., normal) progressors.
-  Δ FS calculated from first symptom to time of diagnosis (i.e., post-onset Δ FS) has the advantage of being calculated over a relatively long timeframe, given that time to diagnosis is typically between 12 to 18 months, meaning that it better approximates the 'averaged' measurement of Δ FS during the whole disease and is less sensitive to short-term fluctuations (signal noise). This assumption is supported by the similar median Δ FS values of 1.0 and 1.185 points/month for these two calculations, indicating that a range of approximately 1.0 - 1.2 points/month is a rational criterion for categorization of patients into rapid (or faster) and non-rapid (i.e., normal) progressors. However, it was also stated by the authors that patient recall error regarding the date of first symptom onset could hinder this approach. Although recall error may introduce some uncertainty (for example, the month of onset can be recalled but not the exact day), this position  is  countered  in  a  recent  article  by  Ludolph  and  colleagues.  In  that  article,  it  was concluded that because the clinical relevance of Δ FS is now so well-established and post-onset Δ FS  is  derived  from  information  routinely  collected  as  part  of  standard  patient  care  and monitoring, it provides a suitable patient selection tool for treating physicians, with no obvious barriers regarding its application in clinical practice [Ludolph 2024].
-  Finally, Kollewe and colleagues calculated Δ FS within a defined period of 100 days as a way to avoid the abovementioned problems. The Applicant rejected this approach, however, in part because the median Δ FS value of 0.65 points/month was very dissimilar to that of Δ FS during the whole disease (cf. 1.185 points/month), and more importantly because use of an untreated lead-in period was considered unethical in terms of the delay in starting the intervention and a probable hinderance in timely achievement of recruitment targets. In contrast, Δ FS calculated from first symptom to time of diagnosis shortens the interval from disease onset to therapy, potentially  being  favorable  to  detect  a  drug's  efficacy  because  of  less  advanced  motoneuron degeneration  (which  is  a  very  important  consideration  for  a  neuroprotective  drug  such  as masitinib).

For these reasons, the cut-off of 1.1 points/month, situated at the midpoint of the 1.0-1.2 points/month range  and  calculated  from  first  symptom  to  time  of  diagnosis,  provides  a  rational  criterion  for categorization of patients into fast and normal progressors.

## Argument 3.4: The  risk of misclassification is minimized  by  the  fact that fast progressors is defined from onset of symptoms

Because progression in ALS is non-linear, it is important to distinguish which part of the overall ALSFRSR trajectory is being considered when defining or comparing Δ FS values. Hence, Δ FS (points per unit time) is typically defined using one of the following, noncomparable, calculations:

- -Post-onset (early) Δ FS = [(48 minus total ALSFRS-R score at diagnosis or initial assessment) divided by (symptom duration from onset in months)]
- -Interval (late) Δ FS = [(total ALSFRS-R score at first assessment minus total ALSFRS-R score at follow-up assessment) divided by (follow-up time in months)]

Another distinguishing feature between these measures of Δ FS is the timeframe over which they are calculated. Meta-analysis (n=3367) from Thakore and colleagues estimated the median time from onset to  first  ALSFRS-R  measurement  was  16.9  months  (IQR  [11.3-23.7])  [Thakore  2018],  while  smaller cohorts have estimated mean diagnostic latency to be between 13.4 to 16.6 months [Kjældgaard 2021;

<div style=\"page-break-after: always\"></div>

Requardt 2021]. Hence, post-onset Δ FS will typically be measured during the initial 12 to 24 months of the  symptomatic  disease  phase.  In  contrast,  interval Δ FS  is  more  often  measured  over  a  shorter timeframe; for  example,  a  3-month  lead-in  (pretreatment)  period.  Post-onset Δ FS therefore  has  an advantage of being relatively insensitive to short-term intraindividual variations, whereas the 'snap-shot' interval Δ FS may be misrepresentative of the general disease progression trend.

Importantly,  it  has  been  shown  that  the  clinical  determinant  of  greatest  prognostic  importance  for survival is post-onset Δ FS (i.e., the early ALSFRS-R slope), with a statistically significant hazard ratio (HR) of 1.50, p &lt; 0.0001, according to univariable Cox regression for continuous measures, and an HR of  1.33  (95%CI  [1.19-1.5]),  p&lt;0.0001,  according  to  multivariable  Cox  regression  model  [Requardt 2021]. This finding is in marked contrast to other calculations of Δ FS (e.g., interval Δ FS), which showed no prognostic value.

Hence, according to Requardt and colleagues, the early ALSFRS-R slope (i.e., post-onset Δ FS) and late ALSFRS-R slope (i.e., interval Δ FS exemplified by lead-in period Δ FS or post-randomization Δ FS) are distinct  clinical  features  in  terms  of  prognostic  value.  By  consequence,  post-onset Δ FS  is  the  most relevant and robust measure of Δ FS for patient selection. Moreover, there is no contradiction or negative impact  to  the  validity  of  post-onset Δ FS  categorization  should  an  individual  switch Δ FS  categories between early and later stages of the disease course.

## Argument 3.5: The study outcome is positive with a cut from 0.8 to 1.5 points decline

Verification  that Δ FS represents an appropriate and robust tool for selection of the primary efficacy population  in  study  AB10015,  is  provided  by  sensitivity  analyses  to  determine  the  margin  of  error associated with the Δ FS cut-off and potential impact of misclassification from the requisite estimation of time to first symptom. As described in further detail below, results showed that the Δ FS cut-off value was well-judged  and  associated  with  a  sizeable  margin  of  error,  while  the  possibility  and  impact  of misclassification  is  small.  This  indicates  that  the Δ FS  cut-off  of  1.1  is  not  an  absolute  requirement because  the  primary  analysis  remains  positive  based  on  ∆FS  cut -offs  ranging  from  0.8  to  1.5,  as presented in the table below.

To test the robustness of this cut-off threshold, sensitivity analyses were performed based on the primary endpoint (rule 1 for handling of missing data) and using a ∆FS cut -off ranging from 0.8 (corresponding to a predefined sensitivity analysis cut-off from the Statistical Analysis Plan of study AB10015) until the cut-off at which treatment-effect became non-significant.

It is seen that treatmenteffect remains in favour of masitinib until a ∆FS threshold of 1.4 (inclusive), accounting for 90% of patients. From this we can conclude that the positive treatment-effect seen for masitinib in study AB10015 cannot be dismissed as being a statistical anomaly of the dataset and its interaction with the ∆FS=1.1 cut -off, nor that this threshold makes for a highly volatile, changeable outcome. On the contrary, this analysis shows the categorization of patients based on our estimate of ∆FS=1.1  to  be  robust  with  a  demonstrable  'buffer  zone'  (i.e.,  ∆FS  cut -offs  from  0.8  to  1.3  or  1.4 points/month, ∆FS = 1.1 ± 0.3) for maintained positive treatment -effect.

<div style=\"page-break-after: always\"></div>

Table 110: Difference (masitinib 4.5 mg/kg/d versus placebo) in ALSFRS-R score among Normal Progressor with ∆FS ranging from 0.8 to 1.5 for selection of the Normal Progressor population

| ∆ FS cut-off   |   ∆ LSM (ALSFRS-R) | 95%[CI]      |   P-value | Proportion of randomized patients n, (%)   |
|----------------|--------------------|--------------|-----------|--------------------------------------------|
| 0.8            |             3.4951 | [0.62;6.37]  |    0.0174 | 191 (73.5%)                                |
| 0.9            |             3.3355 | [0.56;6.11]  |    0.0188 | 204 (78.5%)                                |
| 1.0            |             3.1453 | [0.40;5.89]  |    0.0251 | 210 (80.8%)                                |
| 1.1 *          |             3.3878 | [0.65;6.13]  |    0.0157 | 218 (83.9%)                                |
| 1.2            |             3.2707 | [0.55;5.99]  |    0.0186 | 223 (85.8%)                                |
| 1.3            |             3.2972 | [0.60;5.99]  |    0.0168 | 226 (86.6%)                                |
| 1.4            |             2.6897 | [0.01;5.37]  |    0.0495 | 233 (89.9%)                                |
| 1.5            |             2.562  | [-0.08;5.21] |    0.0576 | 241 (92.7%)                                |

Primary efficacy population prospectively defined as 'Normal Progressor' patients receiving masitinib at 4.5 mg/kg/day versus placebo. 'Normal Progressor' dataset defined as patients with a post-onset Δ FS of less than 1.1 points/month. Δ FS  =  ALSFRS-R  progression  rate  from  disease-onset  to  baseline.  ALSFRS-R  =  Amyotrophic  Lateral  Sclerosis Functional Rating Scale-Revised. LSM = Leastsquares means difference from baseline. ∆LSM = Between treatment -arm difference of LSM. 95% two-sided confidence intervals [95%CI].

## Argument 3.6: The risk of inaccuracy due to the dependence of the recollection of date of onset is mitigated by the fact that patients would not change class if they remind month of symptoms

The range of days in time to first symptom (TTFS) whereby a patient with Δ FS of 1.1 would remain within the 'buffer zone' of Δ FS from 0.8 to 1.3, ranges from [-113; +277] days for a patient with a baseline score of 21, and from [-4; +11] days for a patient with a baseline score of 47.

Therefore, patients with baseline ALSFRS-R score ranging from 41 to 47 presents a greater of risk of misclassification due to error in TTFS, because a deviation by less than 30 days affects the classification Normal versus Fast progressor.

Table 111: Margin of Error on Time to First Symptoms (TTFS)

| Days                                           | Baseline score   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |     |
|------------------------------------------------|------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----|-----|
| between onset date and baseline for ( Δ FS) of | 21               | 23   | 25   | 27   | 29   | 31   | 33   | 34   | 35   | 36   | 37   | 38   | 39   | 40   | 41   | 42   | 43   | 44   | 45   | 4 6 | 4 7 |
| 1.1                                            | 736              | 68 2 | 62 7 | 57 3 | 51 8 | 46 4 | 40 9 | 38 2 | 35 5 | 32 7 | 30 0 | 27 3 | 24 5 | 21 8 | 19 1 | 16 4 | 13 6 | 10 9 | 82   | 55  | 27  |
| 1.3                                            | 623              | 57 7 | 53 1 | 48 5 | 43 8 | 39 2 | 34 6 | 32 3 | 30 0 | 27 7 | 25 4 | 23 1 | 20 8 | 18 5 | 16 2 | 13 8 | 11 5 | 92   | 69   | 46  | 23  |
| 0.8                                            | 101 3            | 93 8 | 86 3 | 78 8 | 71 3 | 63 8 | 56 3 | 52 5 | 48 8 | 45 0 | 41 3 | 37 5 | 33 8 | 30 0 | 26 3 | 22 5 | 18 8 | 15 0 | 11 3 | 75  | 38  |
| Range to 1.3                                   | 1.1 11 3         | 10 5 | 96   | 88   | 80   | 72   | 63   | 59   | 55   | 50   | 46   | 42   | 37   | 33   | 29   | 26   | 21   | 17   | 13   | 9   | 4   |
| Range 0.8 to 1.1                               | 27 7             | 25 6 | 23 6 | 21 5 | 19 5 | 17 4 | 15 4 | 14 3 | 13 3 | 12 3 | 11 3 | 10 2 | 93   | 82   | 72   | 61   | 52   | 41   | 31   | 2 0 | 1 1 |
| Overall range (buffer zone)                    | 36 1             | 39 0 | 33 2 | 30 3 | 27 5 | 24 6 | 21 7 | 20 2 | 18 8 | 17 3 | 15 9 | 14 4 | 13 0 | 11 5 | 10 1 | 87   | 73   | 58   | 44   | 2 9 | 1 5 |

However, based on AB10015data, patients with baseline ALSFRS-R [41-47] have a low rate of disease progression with mean Δ FS (±SD) of 0.34 (±0.22) and median Δ FS of 0.27.

<div style=\"page-break-after: always\"></div>

There are only 5 patients (1.25% of the ITT population) in the vicinity of the 1.1 cut-off (e.g. 1.1±0.2); specifically, 2 patients with baseline Δ FS &gt;1.1 (none exceeded a Δ FS of 1.3) and 3 patients with baseline Δ FS between 0.9 to 1.1.

Figure 10: Distribution of Δ FS for patients with baseline ALSFRS [41-47]

<!-- image -->

The percentage of patient in AB10015 that could shift from category due to the amplitude in the time to first symptoms is provided below. We considered the following scenarios:

- -Normal Progressors ( Δ FS&lt;1.1) that shift to Fast Progressors ( Δ FS&gt;1.4 (upper limit of efficacy)) due to inaccuracy and would therefore be excluded from treatment whereas they should actually receive treatment (i.e. false negative). In this scenario (i.e. classification shifts from Normal to Fast Progressor) only a shortening of the time to first symptom should generate misclassification.
- -The complement scenario is when inaccuracy leads patients with baseline Δ FS of 1.4 to shift to Δ FS&lt;1.1, therefore receiving treatment whereas they should be excluded (i.e. false positive). In this scenario (i.e. classification shifts from Fast to Normal Progressor) only a lengthening of the time to first symptom should generate misclassification.

Table 112: Shift in classification depending on error in time to first symptoms

| Shift                                                         |                                                               | -30 days                                                      | +30 days                                                      | -45 days                                                      | +45 days                                                      | -60 days                                                      | +60 days                                                      | -75 days                                                      | +75 days                                                      | -90 days                                                      | +90 days                                                      |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) | Upper cut-off for Δ FS>1.4 (i.e. recall error in Δ FS of 0.3) |
| From Normal                                                   | n                                                             | 0                                                             | -                                                             | 1                                                             | -                                                             | 3                                                             | -                                                             | 6                                                             | -                                                             | 9                                                             | -                                                             |
| (<1.1) to Fast (>1.4)                                         | %                                                             | 0.0%                                                          | -                                                             | 0.3%                                                          | -                                                             | 0.8%                                                          | -                                                             | 1.5%                                                          | -                                                             | 2.3%                                                          | -                                                             |
| From Fast (>1.4)                                              | n                                                             | -                                                             | 0                                                             | -                                                             | 0                                                             | -                                                             | 1                                                             | -                                                             | 2                                                             | -                                                             | 8                                                             |
| to Normal (<1.1)                                              | %                                                             | -                                                             | 0.0%                                                          | -                                                             | 0.0%                                                          | -                                                             | 0.3%                                                          | -                                                             | 0.5%                                                          | -                                                             | 2.0%                                                          |

Taken together, these analyses on margin of error associated with accuracy on the date of first symptoms show that the possibility of misclassification are marginal.

## Argument 3.7: Post-onset Δ FS is derived from information routinely collected as part of standard patient care and monitoring, with no obvious barriers regarding its application in clinical practice

The CHMP has previously stated that it is questionable to assume that ALSFRS-R is documented in routine care of ALS patients as this is a scale used only in clinical trials.

This  position  is  however  countered  by  a  recent  article  published  in  the  journal Muscle  &amp;  Nerve by

<div style=\"page-break-after: always\"></div>

Professor Albert Ludolph and colleagues (including Professors Philippe Couratier, Philippe Corcia, Claude Desnuelle, Terry Heiman-Patterson, and Jesus Mora) [Ludolph 2024]. This article discusses the merits of using Δ FS as a relevant tool for innovative ALS study design. It concludes that post-onset Δ FS serves not only as a critical stratification factor and basis for patient enrichment, but also as a tool to explore differences in treatment response across the overall population for identification of preferential responder subgroups, and as such is recommended for inclusion in the design of clinical trials.

Importantly, the authors concluded that because post-onset Δ FS is derived from information routinely collected as part of standard patient care and monitoring, it provides a suitable patient selection tool for treating physicians, with no obvious barriers regarding its application in clinical practice [Ludolph 2024].

## Argument 3.8: Qalsody defined fast progressors from onset of symptoms and a cut of 0.9 based on literature and EMA did not conclude this cut was arbitrary. Later sponsor amended Qalsody protocol to include fast progressors in the primary analysis population which improved P value

The  EMA  registered  Qalsody  based  on  a  pivotal  study  with  the  primary  population  defined  as  fast progressors, with fast progressors also defined from onset of symptoms, and with a chosen 0.9 point cut-off for decline of the ALSFRS-R score also based on literature. The sponsor then amended the protocol to  change  the  primary  population  to  include  non-fast  progressors.  The  CHMP  concluded  this  was acceptable.

In the Scientific advice procedure regarding the design of AB23005 phase 3 masitinib confirmatory study (EMADOC-360526170-1973369), the scientific advice working party (SAWP) confirmed that: ' Qalsody (tofersen) has been authorized for treating adults with a type of amyotrophic lateral sclerosis (ALS) caused  by  a  mutation  (defect)  in  the  gene  responsible  for  producing  an  enzyme  called  superoxide dismutase 1 (SOD1) (EMA/93332/2024) and, therefore, constitutes a regulatory precedence for ALS prespecified subgroups defined as Faster-Progressing Subgroup and Slower-Progressing Subgroup by Mutation type, pre-randomisation ALS Functional Rating Scale-Revised (ALSFRS-R slope), and Slow vital capacity (SVC) cutoff (EMA/276404/2024) '.

3. Considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition of intercurrent events in J2R strategy are not considered acceptable.

The Applicant presented first some statements included in section 2.6.2 of this CHMP AR.

The study had approximately 30% of missing data in each Masitinib AB Science arm despite highly selective patient population. In the clinical trial, high rates of treatment discontinuation were showed, the regulatory interest is to handle this intercurrent event with a treatment policy strategy. In particular, mainly after treatment discontinuation, high proportions of missing data were observed in each Masitinib AB Science arm despite highly selective patient population. Therefore, an adequate choice of statistical methods for handling missing data which are appropriately conservative and not biased in favour of the investigational treatment under realistic data generating mechanisms is critical for the trustworthiness of the study results.

The methods for handling missing data applied by the Applicant and requested by CHMP included:

- -a mLOCF approach that assumes that the benefit experienced until the time of missing data is also retained thereafter.
- -a  Copy  increments  from  reference  (CIR)  method  was  used  that  assumes  that  the  outcome develops similarly from that point onward to the placebo group.
- -a J2R method was used that assumes that the benefit experienced until the point of missing data is not retained and instead the outcome would correspond to the outcome in the reference group.

<div style=\"page-break-after: always\"></div>

In the situation of ALS, only the J2R method is considered to not potentially overestimate the missing outcome and hence lead to a biased treatment effect estimate in favour of the investigational treatment. Therefore, only the J2R approach is considered to be appropriately conservative. In order to account for missing data after treatment discontinuation, the Applicant used the mLOCF method for the first and secondary endpoints. More conservative approaches were also provided such as the J2R, but only to handle missing data after discontinuations that were attributed to lack of efficacy or toxicity, whereas missing data after discontinuations for other reasons were presumably handled with a mLOCF approach. A detailed description of the statistical methods is not available, which further increases the uncertainty about the appropriateness of this analysis approach.

Additionally, as an underlying assumption, the Applicant is assuming that it can ascertain which missing case are MAR (protocol deviation / non-compliance, etc.) and which cases are MNAR (efficacy/toxicity). The Applicant does not provide convincing arguments that substantiate this categorisation, hence the handling of missing data following discontinuations for different reasons with different methods is not considered adequate.

Further, the Applicant has presented a tipping point analysis based on the mLOCF approach, where the assumed retained effect as compared to baseline is reduced by increasingly larger percentages

In the clarification after the OE  the  Applicant maintains that CHMP  is  inconsistent with its recommendations on acceptability of tipping point analysis above 75% and CIR with p value below 5%. The methods for handling missing data applied by the Applicant and requested by CHMP include mLOCF, CIR and J2R methods. The statistical analyses applied by the Applicant were assessed respectively. Moreover, the Applicant is acknowledged for the providing the multiple statistical analyses requested by CHMP. Indeed, the Applicant has presented a tipping point analysis based on the mLOCF approach, where the assumed retained effect as compared to baseline is reduced by increasingly larger percentages

The Applicant shows that retaining 24% of the difference to baseline still leads to p-value smaller than 5% in the corresponding analysis and argues that this should be sufficient proof of efficacy since the same threshold had been accepted in a different regulatory procedures. However, this argument does not hold since the suitable statistical method for analysis (including an assumption about a realistic and acceptable loss  in  efficacy  in  the  imputation  model)  depends  on  the  specific  clinical  context.  In  this situation, the analysis assuming the retainment of some effect is still considered not as adequate as the J2R approach, which assumes that patients discontinuing treatment have outcomes similar to the control group.

Overall,  the  Applicant's  position  that  the  mLOCF  and  the  cluster  method  are  the  most  appropriate methods to address missing data in the AB10015 trial is not acceptable Considering the progressive nature of ALS and that, the effect of treatment will not be maintained after discontinuation of medication, the J2R method is considered the most appropriately conservative method in this setting. This analysis does not show a convincing result in favour of Masitinib AB Science.

## AB Science Response

## Argument 4.1: The quantity of missing data at 30% at week 48 is in line with other studies

Missingness  in  clinical  trials  of  ALS  is  inherent  to  the  disease  and  mostly  results  from  premature discontinuations.

<div style=\"page-break-after: always\"></div>

As displayedbelow , the amount of discontinuation is in line or even lower than what is observed in other clinical studies on ALS patients, with a rate of around 30% at week 48, similar to what was observed in studies of AMX0035, Edaravone, Levosimendam, Tirasemtiv and Ozanesumab.

Table 113: Comparison of discontinuation rates at week 48 timepoint

| Study discontinuation rate                 | Investigation Arm   | Control Arm    |
|--------------------------------------------|---------------------|----------------|
| Masitinib AB10015 (DB 48-week) a           | 31.1% (33/106)      | 27.7% (31/114) |
| AMX0035 NCT05021536 (DB 48-week)           | 42% (167/397)       | 43% (115/267)  |
| Edaravone NCT01492686 (Overall, 48-week) b | 20.9% (14/67)       | 39.4% (26/66)  |
| Levosimendan NCT03505021 (DB 48-week)      | 34.0% (112/329)     | 32.9% (55/167) |
| Tirasemtiv NCT02496767 (DB 48-week)        |                     |                |
| Tirasemtiv 250 mg                          | 36.5% (46/126)      | 29.8% (56/188) |
| Tirasemtiv 375 mg                          | 48.4% (61/126)      | 29.8% (56/188) |
| Tirasemtiv 500 mg                          | 52.8% (66/125)      | 29.8% (56/188) |
| Tirasemtiv (All)                           | 45.9% (173/377)     | 29.8% (56/188) |
| Ozanezumab NCT01753076 (DB 48-week)        | 30.3% (46/152)      | 27.1% (41/151) |

DB = Double blind protocol period. OLE = Open label extension. (a) Normal Progressors (primary efficacy population).  (b) Of patients completing the DB period, 2 patients in the edaravone group and 2 patients in the placebo group did not participate in the OLE.

## Argument 4.2: mLOCF treatment of missing data for change of ALSFRS was the primary analysis but Applicant always recognized that this is the sensitivity analysis non LOCF that are supportive for registration

The Applicant did not argue that the mLOCF method was the most appropriate method to address missing data.

mLOCF method was the preplanned method for primary analysis and it the study was positive based on this method.

Various sensitivity analyses were implemented using methodologies recommended by the Rapporteurs.

What  makes  the  results  robust  is  that  these  analyses  were  convergent,  both  in  term  of  statistical significance and treatment effect.

## Argument 4.3: Among sensitivity  analysis,  cluster  imputation,  pre  planned,  and  JTR based on discontinuation due to lack of efficacy and toxicity are demonstrative

-  Preplanned cluster-based imputation analysis was positive

Cluster based imputation method imputed score at Week 48 based on last non-missing ALSFRS-R, plus average increments from Week 4 to Week 48 for all patients in that cluster with non-missing data from Week 4 to Week 48.

- Preplanned clusters

Two clusters were formed based on Site of Onset at baseline: Bulbar and Spinal.

Region was split between Western European and Canada (Italy, Netherlands, Portugal, Spain, Canada) and Rest of the World (Greece, Slovakia, Argentina, Mexico). Treatments groups also formed another level of clustering. The flow-chart given below details the formation of clusters.

Progression at baseline was taken into account in the protocol by splitting the normal progressors from Faster Progressors and therefore not further used for clustering.

<div style=\"page-break-after: always\"></div>

- Justification for clustering

Patients with site of onset Bulbar at baseline are known to progress faster than spinal [Moura 2015]. Therefore,  these  patients  belong  to  same  cluster  of  faster  progressing  patients.  All  Spinal  patients belonged to the cluster of slower progressors. Progression at baseline was considered in the protocol by splitting the normal progressors from Faster Progressors.

Rule 6 cluster imputation method was based on EMA guidance (EMA/CPMP/EWP/1776/99 Rev. 1): Other simple approaches for single imputation of missing data are to replace the unobserved measurements by  values  derived  from  other  sources.  Possible  sources  include  information  from  the  same  subject collected before withdrawal, from other subjects with similar baseline characteristics, a predicted value from an empirically developed model or historical data.

- Results of analysis

The results for sensitivity analysis by Cluster based imputation is mean LS= 3.01; p-value = 0.0176, consistent with the primary analysis.

Table 114: Primary analysis population (M4.5 mg/kg/day vs placebo) - Rule 6 cluster-based imputation

| Treatment group   |   N |   LS Mean | Difference of means [95% confidence interval] p-value (no re- randomisation test)   |
|-------------------|-----|-----------|-------------------------------------------------------------------------------------|
| Placebo           | 113 |  -13.9611 | 3.01 0.0176                                                                         |
| Masitinib 4.5     | 105 |  -10.9487 | [0.5306;5.4942]                                                                     |

model based on post baseline data as per sap

-  JTR analysis requested by EMA was positive

We used Multiple Imputation with Jump to Reference for MNAR data. Expert working group of statisticians from London School of Hygiene and Tropical Medicine developed set of macros for this approach.

Referenced-Based Multiple imputation (RBMI) using JTR for reasons of discontinuation due to lack of efficacy or any adverse event (related or not) showed a significant (p=0.0387) advantage of Masitinib 4.5 of 2.80 ALSFRS-R points.

Table 115: AB10015 - NP - Masitinib 4.5 mg/kg/day - Primary endpoint Multiple Imputation Jump to Reference

| JTR MI (Normal)               | JTR MI (Normal)   | JTR MI (Normal)   | JTR MI (Normal)    |
|-------------------------------|-------------------|-------------------|--------------------|
| JTR analysis                  | Estimate          | 95% interval      | confidence p-value |
| Lack of efficacy and Toxicity | 2.80              | [0.14; 5.46]      | 0.0387             |

## Argument 4.4: In the JTR analysis, imputation of missing data after discontinuations for  other  reasons  than  lack  of  efficacy  or  toxicity  did  not  rely  on  mLOCF approach

In the JTR analysis, imputation of missing data after discontinuations for other reasons than lack of efficacy  or  toxicity  relied  on  copying  increment  from  'similar'  patients,  also  named  cluster  based imputation.

A detailed description of the statistical methods used for this cluster based imputation is described in SAP version 1.0 dated 16 March 2017, pages 11 to13.

The Imputed score at week 48 missing data after discontinuations for other reasons than lack of efficacy or toxicity is equal to: Last non-missing ALSFRS score + average increment, from week 4 to week 48, of all the patients in the cluster with non-missing compliant data from week 4 to week 48.

<div style=\"page-break-after: always\"></div>

## Argument 4.5: Reasons of discontinuation has been recorded in the eCRF by investigators. In case of multiple reasons recorded a central algorithm defined in the sap was used to define main reason

Reasons for discontinuation  were  documented  in  the  eCRF  and  classification  MNAR  versus  MAR  was prespecified in the SAP before unblinding.

All reasons of discontinuation were assessed by investigator in the eCRF prior to unblinding.

Additionally, investigators made comments in the eCRF that were used to precise the main reason of discontinuation.

An algorithm encompassing data available in the eCRF was programmed to derive a single main reason for discontinuation.

This was done before database lock. This algorithm is available.

The reasons of discontinuations were classified between MNAR and MAR in the SAP prior to unblinding.

This  classification  was  conventional  with  reasons  MNAR  being  discontinuation  for  lack  of  efficacy  or toxicity related or not and others being considered at random.

As stated by Kenward (Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation, Clinical Trial Methodology), considering all missing data as MNAR is extreme and may be seen as a worst-case scenario that in practice may be more relevant for treatments with only short-term effect.

Table 116: AB10015 - NP - Reasons of premature discontinuation

| Type   | Cause of discontinuation            | Placebo N=113 n (%)   | Masitinib N=105 n (%)   |
|--------|-------------------------------------|-----------------------|-------------------------|
| MNAR   | ALL                                 | 10 (8.8)              | 24 (22.9)               |
| MNAR   | AE Related                          | 1 (0.9)               | 11 (10.5)               |
| MNAR   | Lack of Efficacy                    | 9 (8.0)               | 13 (12.4)               |
| Travel | ALL                                 | 6 (5.3)               | 3 (2.9)                 |
| MAR    | ALL                                 | 14 (12.4)             | 5 (4.8)                 |
| MAR    | Cancer not related                  | 2 (1.8)               | 1 (1.0)                 |
| MAR    | Death                               | 7 (6.2)               | 2 (1.9)                 |
| MAR    | Non compliance (1)                  | 0                     | 2 (1.9)                 |
| MAR    | Procedure (2)                       | 2 (1.8)               | 0                       |
| MAR    | Prohibited Concomitant treatment (3 | 1 (0.9)               | 0                       |
| MAR    | Protocol Deviation (4)              | 2 (1.8)               | 0                       |

(1) Non-compliance means not compliant to the treatment

(2) Procedure means fed up with procedures of the protocol.

(3) Prohibited concomitant treatment means use of prohibited concomitant treatment not related to ALS

(4) Protocol Deviations means deviations to the eligibility criteria

As described in the table above, there was 22.9% of patients with discontinuations classified as MNAR in the masitinib group and 7.6% of patients with discontinuation classified as MAR (including 2.9% for travel), meaning that the majority of discontinuations were considered MNAR.

For placebo, this was the opposite, the discontinuation not missing at random represents 8.8% of the patients in the placebo group while the discontinuations considered missing at random represents 17.7% of the patients in the placebo group.

<div style=\"page-break-after: always\"></div>

The difference in percentage of discontinuation at random comes from death because there were more deaths in the placebo group, which was classified as not related to treatment by the investigator.

Reviewers challenged one reason, which is travel.

Discontinuation due to travel encompassed patients who moved to another city but also patients who cannot travel to the hospital anymore, which could be confounded with lack of efficacy.

The sensitivity analysis presented in the next section shows that classifying travels as MNAR has no impact on the analysis of the primary endpoint.

## Argument 4.6: EMA  argument  that  only  JTR  with  penalty  on  all  discontinuation  is demonstrative is 'extreme' and not realistic

'Full penalty of all discontinuation' analysis used Jump to Reference (JTR) for the imputation of all missing data whatever the reason for discontinuation. This approach represents the worst-case scenario. Indeed, the  seminal  paper  in  which  Carpenter  and  colleagues  introduced  referenced-based  imputation approaches,  described  the  JTR  approach  as  follows:  ' Such a change may be seen as extreme, and choosing the reference group to be the control group might be used as a worst-case scenario in terms of reducing any treatment effect since withdrawn patients on active will lose the effect of their period on treatment' [Carpenter 2013].

Besides, the Jump to Reference imputation method assumes that as soon as a patient from the active arm discontinues the treatment, the mean distribution of his responses becomes identical to that of the reference arm. This assumption is adequately suited in the case of a purely symptomatic treatment, which effect disappears shortly following discontinuation.

## Argument 4.7: The Applicant showed that best fit model validates the covariates lack of efficacy and toxicity among all reasons of discontinuations

CHMP says that no covariate analysis has been shown supporting the choice of discontinuation. An expost analysis shows that the best fit is obtained with MNAR being lack of efficacy or toxicity.

The selection of MNAR and MAR is based on clinical judgment and has been validated by predictive and covariate modeling. Additionally, classification was performed before unblinding and documented in the SAP. Our clinical approach is based on the nature of the dropout reasons and the observed data patterns.

Our model data used logistic regression analysis comparing different reasons for discontinuation in a stepwise manner with covariates. The inclusion of covariates significantly improved model fit, particularly in cases where dropout reasons are linked to treatment efficacy or toxicity (All adverse events). the Below tables compare the AIC, SC, and -2 Log L values for the various combinations of reasons for discontinuation.

Table 117 : Model with intercept and covariates

| Reason for discontinuation                                       | Reason for discontinuation                                 | Reason for discontinuation                                 |     AIC |      SC |   -2 Log L |
|------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|---------|---------|------------|
| Lack of Efficacy/Toxicity                                        | Lack of Efficacy/Toxicity                                  | Lack of Efficacy/Toxicity                                  | 361.573 | 385.385 |    349.573 |
| Lack of Efficacy/Toxicity/Lost to Follow-up                      | Lack of Efficacy/Toxicity/Lost to Follow-up                | Lack of Efficacy/Toxicity/Lost to Follow-up                | 364.578 | 388.39  |    352.578 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non compliance       | Lack of Efficacy/Toxicity/Lost to Follow-up/Non compliance | Lack of Efficacy/Toxicity/Lost to Follow-up/Non compliance | 376.694 | 400.506 |    364.694 |
| Lack of Efficacy/Toxicity/Lost compliance/Travel                 | to                                                         | Follow-up/Non-                                             | 401.053 | 424.865 |    389.053 |
| Lack of Efficacy/Toxicity/Lost compliance/Travel/Procedure       | to                                                         | Follow-up/Non-                                             | 406.06  | 429.873 |    394.06  |
| Lack of Efficacy/Toxicity/Lost compliance/Travel/Procedure/Death | to                                                         | Follow-up/Non-                                             | 443.974 | 467.786 |    431.974 |

<div style=\"page-break-after: always\"></div>

| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death/Protocol Deviation                                                     |   448.052 |   471.865 |   436.052 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------|-----------|
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death/Protocol Deviation/Cancer not related                                  |   455.723 |   479.536 |   443.723 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death/Protocol Deviation/Cancer not related/Prohibited Concomitant treatment |   458.597 |   482.409 |   446.597 |

Table 118: Model with intercept only

| Reason for discontinuation                                                                                                                                |     AIC |      SC |   -2 Log L |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------|------------|
| Lack of Efficacy/Toxicity                                                                                                                                 | 375.497 | 379.466 |    373.497 |
| Lack of Efficacy/Toxicity/Lost to Follow-up                                                                                                               | 378.458 | 382.426 |    376.458 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non compliance                                                                                                | 392.76  | 396.728 |    390.76  |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel                                                                                        | 423.883 | 427.852 |    421.883 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure                                                                              | 430.998 | 434.967 |    428.998 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death                                                                        | 479.186 | 483.155 |    477.186 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death/Protocol Deviation                                                     | 485.8   | 489.769 |    483.8   |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death/Protocol Deviation/Cancer not related                                  | 490.509 | 494.477 |    488.509 |
| Lack of Efficacy/Toxicity/Lost to Follow-up/Non- compliance/Travel/Procedure/Death/Protocol Deviation/Cancer not related/Prohibited Concomitant treatment | 495.005 | 498.973 |    493.005 |

## Argument 4.8: Full JTR has P value of 0.07 which exhibits a trend towards benefit

Still under this extreme scenario, this analysis shows a 2.31 benefit favouring Masitinib 4.5 over active control, that shortly fails to reach the conventional statistical significance threshold of 0.05 (p=0.0678). Note that the study was not powered for such a 'worst-case' analysis, yielding still a clinically relevant treatment effect of 2.31, but smaller than the 3.3 effect the study was powered to detect.

The observed p=0.0678 in such a penalised analysis should be considered as indicative of an effect.

Table 119: AB10015 - NP - Masitinib 4.5 mg/kg/day - Primary endpoint Multiple Imputation Jump to Reference

| JTR MI (Normal)         | JTR MI (Normal)   | JTR MI (Normal)   | JTR MI (Normal)    |
|-------------------------|-------------------|-------------------|--------------------|
| JTR analysis            | Estimate          | 95% interval      | confidence p-value |
| Full placebo imputation | 2.31              | [-0.17;4.80]      | 0.0678             |

## Argument 4.9: CHMP noted that travel as not at random is debatable. Integrating travel in the reasons not at random does not change outcome that remains significant

Travel could be challenged as lack of efficacy.

As requested by the Rapporteurs, AB Science added travel as MNAR (i.e. interpreted as lack of efficacy).

This analysis showed a significant (p=0.0372) advantage of Masitinib 4.5 of 2.84 ALSFRS-R points.

<div style=\"page-break-after: always\"></div>

Table 120: AB10015 - NP - Masitinib 4.5 mg/kg/day - Primary endpoint Multiple Imputation Jump to Reference

| JTR MI (Normal)                          | JTR MI (Normal)   | JTR MI (Normal)   | JTR MI (Normal)    |
|------------------------------------------|-------------------|-------------------|--------------------|
| JTR analysis                             | Estimate          | 95% interval      | confidence p-value |
| Lack of efficacy and Toxicity and Travel | 2.84              | [0.17;5.51]       | 0.0372             |

## Argument 4.10:  Other MAR data not at random reasons are cancer not related to treatment, violation of eligibility criteria and non-compliance to treatment other than for lack of efficacy reason or toxicity

MAR data are Cancer not related (n=3), Non-compliance (meaning not compliant to the treatment, n=2), Procedure (meaning fed up with procedures of the protocol, n=2), Prohibited Concomitant treatment (meaning use of prohibited concomitant treatment not related to ALS, n=1), and Protocol Deviations (meaning deviations to the eligibility criteria, n=2).

These reasons for discontinuation were documented in the eCRF and MAR classification was prespecified in the SAP before unblinding.

These reasons for discontinuation can reasonably be considered at random events.

## Argument 4.11:  CHMP  recommended  in  previous  application  of  masitinib  for  conditional approval two methods, Tipping on full JTR which if above 75% was assessed as demonstrative and CIR which assumes progressive return to reference. Both analysis show benefit in favor of masitinib

-  Tipping point analysis

As per recommendation of EMA Scientific Advice Working Party (SAWP) on 4 September 2018, as part of the protocol assistance procedure for the design of the new phase 3 study, the SAWP indicated ' a tipping point analysis is a valid approach to handle missing data '.

The tipping point analysis applies a penalty on all reasons of discontinuation.

Its results show the robustness of the findings with the tipping point corresponding to a 76% penalty on Masitinib effect.

Table 121: Tipping point 76% penalty all reasons

| Treatment group   |   N | LS Mean   | Difference of means [95% confidence interval]   |   p-value |
|-------------------|-----|-----------|-------------------------------------------------|-----------|
| Placebo           | 113 | - 14.0597 | 2.48 [0.0024;4.959]                             |    0.0498 |
| Masitinib 4.5     | 105 | - 11.5790 | 2.48 [0.0024;4.959]                             |    0.0498 |

Model based on post baseline data as per sap

This 76% penalty corresponds to the assumption that patients discontinuing from masitinib would have experienced on average only 24% of the mean masitinib treatment-effect, while patients discontinued from the reference arm would have experienced the same deterioration as those completing the study in the reference arm.

This  level  of  penalty  was  considered  adequate  by  the  CHMP  in  the  former  assessment  of  masitinib application (EMEA/H/C/4398, D180 JAR). Indeed, the following question was stated ' Rule #7 covers the lack of efficacy variability but not toxicity. Setting 76% penalty for lack of efficacy is within what would be empirically expected, but is a fair approach to the primary endpoint. It should also be applied to all

<div style=\"page-break-after: always\"></div>

## key endpoints. '

As a matter of fact, AB Science presented tipping point analysis for ALSAQ40 and FVC endpoints. On ALSAQ40, even with a penalty of 100%, Masitinib treatment effect was significantly better than placebo (Diff of means = -5.26 [-10.36; -0.15], p=0.0437). On FVC, with a penalty of 93%, Masitinib treatment effect was significantly better than placebo (Diff of means = 6.10 [0.01; 12.20], p=0.0497).

-  Copy Increment in Reference

In  the  case  of  ALS,  a  progressively  deteriorating  disease,  and  taking  into  account  the  expected mechanism of action of Masitinib that is to slow down the deteriorative process, it is unlikely that a patient discontinuing Masitinib will abruptly 'jump' back to the mean effect of the reference arm.

It is much more likely that the deterioration speed after discontinuation would become similar to that of the reference arm, while the patient would still benefit from the initial slower deterioration. The 'Copy Increments in Reference' (CIR) imputation method from Carpenter would be more suitable in such a case [Carpenter 2013].

Figure 11: Schematic representation of J2R and CIR

<!-- image -->

CHMP recommended CIR in previous assessment (EMEA/H/C/4398, D150 JAR)

Therefore, we performed a new post hoc analysis using CIR imputation for all missing data whatever the reason for dropout. The results are presented in the table below:

Table 122: Normal Progressor Masitinib 4.5 mg/kg/day - CIR imputation, 100% penalty for all reasons

| Treatment group   |   N |   Estimate | [95% confidence interval]   |   p-value |
|-------------------|-----|------------|-----------------------------|-----------|
| Placebo           | 113 |       2.67 | [0.03;5.32]                 |    0.0477 |
| Masitinib 4.5     | 105 |       2.67 | [0.03;5.32]                 |    0.0477 |

Model based on post baseline data as per sap

This 'Full penalty on all discontinuations' using 'Copy Increments in Reference' (CIR) imputation shows a statistically significant (p=0.0477) 2.67 benefit favouring Masitinib 4.5 over active control.

## Argument 4.12:  CHMP rejected the two previous recommendations justifying this was not done in the same context, whereas it is exactly in the same context

The recommendations expressed by the CHMP, regarding tipping (SAWP dated 4 September 2018 and EMEA/H/C/4398, D150 JAR) and CIR(EMEA/H/C/4398, D150 JAR) concerned the analysis of AB10015 study and the protocol for the phase 3 confirmatory study.

AB Science respectfully disagree with the position that these recommendations applied to a different

<div style=\"page-break-after: always\"></div>

context.

As a matter of fact, in a different context, namely the assessment of Albrioza CMA (EMA/CHMP/487533/2023),  the  CHMP  reiterated  the  same  recommendations,  stating  that  ' several approaches would be possible (i.e. jump to reference, copy reference, copy increments in reference…) '.

## Argument 4.13:  CAFS show a trend toward benefit of p=0.07

Study AB10015 was not designed to show any significant effect on CAFS, which was pre-planned as a secondary endpoint.

Still, there was a near significant effect (p = 0.0776; difference = 14.95) observed between masitinib (4.5 mg/kg/day) and active control for CAFS score in the Normal Progressor population, supporting the primary analysis.  This  endpoint  is  also  consistent  with  the  PFS  data  and  supports  the  benefit  when factoring survival.

Table 123: AB10015 - Normal Progressor - CAFS score - Masitinib 4.5 mg/kg/day

| Treatment group   |   N |   Mean Score |   Difference of means |   p-value |
|-------------------|-----|--------------|-----------------------|-----------|
| Active control    | 111 |       100.77 |                 14.95 |    0.0776 |
| Masitinib 4.5 + R | 104 |       115.72 |                 14.95 |    0.0776 |

A  p-value  of  0.078,  approaching  the  conventionally  statistically  significant  outcome  of  5%,  could represent an acceptable level, considering comments made by an ALS advocacy group.

The benefit/risk trade-offs in light of the severity and rapid progression of ALS coupled with the lack of effective  treatments  has  been  addressed  in  draft  Guidance  for  Industry  Drug  Development  for Amyotrophic Lateral Sclerosis [FDA/ALSA Guidance 2016] [FDA Guidance 2017]. This guidance highlights that there is a demonstrated appetite for risk of the patient population and the fact that roughly half of all patients will die within 2 years of diagnosis without the discovery of a new treatment justifies an appropriate choice of statistical standard [FDA/ALSA Guidance 2016]. ALS patients are reported to be more willing to take risks than some other populations with serious illnesses. Of the oncology patients surveyed, 83% would participate in a clinical study compared with 96% of patients with ALS. ALS patients are also reported to be less concerned regarding the possibility of adverse effects than surveyed oncology patients (22% versus 45%) [FDA Guidance 2017].

Of note, this guidance indicates that given their prognosis in the absence of treatment, some people with ALS may be willing to accept somewhat more uncertainty than 5% regarding whether the observations from a trial of a particular intervention are likely entirely due to chance, especially if there are no serious safety concerns associated with the intervention under study [FDA/ALSA Guidance 2016].

## Argument 4.14:  Secondary  variables  calculated  with  non  LOCF  methods  show  benefit  on ALSAQ or trend towards benefit on FVC

-  Significant ALSAQ40 benefit based on conservative imputation methods

The improvement in decline in ALSFRS-R did not come at the expense of quality of life.

Indeed, there was a statistically significant benefit on quality of life (measured by ALSAQ40), calculated based on non LOCF method.

Table 124: Normal Progressor Masitinib 4.5 mg/kg/day -ALSAQ-40 analysis

| Analysis Method          | Difference, [95% CI]   |   p-Value |
|--------------------------|------------------------|-----------|
| Primary analysis - mLOCF | -7.76 [-13.45;-2.06]   |    0.0078 |

<div style=\"page-break-after: always\"></div>

| MI     | -7.27 [-13.18; -1.37]   |   0.0161 |
|--------|-------------------------|----------|
| MI+JTR | -5.99 [-11.55;-0.44]    |   0.0343 |
| CIR    | -6.04 [-11.51;-0.57]    |   0.0305 |

-  Trend towards benefit for FVC based on conservative imputation methods

The clinical functional benefit was supported by a trend towards benefit on respiratory function (measure by FVC), calculated based on non LOCF method recommended for primary endpoint.

Table 125: Normal Progressor Masitinib 4.5 mg/kg/day -FVC analysis

| Analysis Method          | Difference, [95% CI]   |   p-Value |
|--------------------------|------------------------|-----------|
| Primary analysis-- mLOCF | 7.54 [0.76;14.32]      |    0.0296 |
| MI                       | 6.43 [-0.71; 13.57]    |    0.0772 |
| MI+JTR                   | 5.85 [-1.11;12.81]     |    0.0993 |
| CIR                      | 5.85 [-0.98;12.67]     |    0.0931 |

## Argument 4.15:  Secondary analysis were not controlled for alpha but all variables except TFS showed benefit of trends towards benefit, supporting evidence of efficacy

Table 126: Normal Progressor Masitinib 4.5 mg/kg/day -Overview of main efficacy endpoints

| Differential treatment effect (M4.5 vs placebo)                             | Differential treatment effect (M4.5 vs placebo)   | Primary analysis population (Normal Progressors)   |
|-----------------------------------------------------------------------------|---------------------------------------------------|----------------------------------------------------|
| ∆ ALSFRS-R (CIR)                                                            | Diff. of mean                                     | 2.68                                               |
| ∆ ALSFRS-R (CIR)                                                            | p-value                                           | 0.0462                                             |
| CAFS                                                                        | Relative benefit                                  | 14.8%                                              |
| CAFS                                                                        | P-value                                           | 0.0776                                             |
| ALSAQ-40 (CIR)                                                              | Diff. of mean                                     | -6.04                                              |
| ALSAQ-40 (CIR)                                                              | p-value                                           | 0.0305                                             |
| FVC (CIR)                                                                   | Diff. of mean                                     | 5.85                                               |
| FVC (CIR)                                                                   | p-value                                           | 0.0931                                             |
| Median PFS                                                                  | Gain                                              | + 4 months                                         |
| Median PFS                                                                  | Median [95% CI]                                   | 20 [14; 30] vs 16 [11; 19]                         |
| Median PFS                                                                  | p-value log rank                                  | 0.0159                                             |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | Gain                                              | + 6 months                                         |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | Median [95% CI]                                   | 46 [33; 69] vs 40 [30; 49]                         |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | p-value log rank                                  | 0.0761                                             |

## Argument 4.16:  Time to event PFS, pre planned in SAP, showed benefit

EMA guidance on ALS requires for registration that in addition to a significant effect on ALSFRS, there is at least a trend on a time to event endpoint.

Choice of a 9-point cut-off for progression was based on information from the scientific literature [Gordon 2007]. This research suggests that a 9-point decline in ALSFRS-R represents a clinically meaningful change in functionality. Hence, the 9-point threshold is appropriate for two reasons:

- -Provides a well-matched and sensitive endpoint for detecting treatment-effect over a 48-week period  (with  an  anticipated  active  control  decline  of  around  1  point/month).  For  example,

<div style=\"page-break-after: always\"></div>

thresholds of 6 or 12 points are likely to be insensitive because the survival-to-event condition is, respectively, reached too soon with loss of sensitivity or is not reached by a sufficient number of patients in the treatment-arm.

- -Represents a clinically meaningful change in functionality reported to be discernible by patients [Gordon, 2007].

Study AB10015 showed a significant improvement in PFS (+4 months, P=0.0159) defined as the earliest of a decline of 9 points in ALSFRS-R or death.

Table 127: Normal Progressor Masitinib 4.5 mg/kg/day - PFS

| Treatment group   |   Total | Median months [95% CI]   |   Wilcoxon p-value |
|-------------------|---------|--------------------------|--------------------|
| Placebo           |     113 | 16 [ 11; 19]             |             0.0159 |
| Masitinib 4.5     |     105 | 20 [ 14; 30]             |             0.0159 |

model based on post baseline data as per sap

Figure 12: Normal Progressors - KM analysis of PFS - Masitinib 4.5 mg vs Placebo

Argument 4.17:  Tracheotomy, ventilation and gastrostomy occurred mainly after progression, making PFS robust

<!-- image -->

To make sure that PFS was not potentially biased by ventilation and gastrostomy and tracheostomy, we looked at the occurrence of those events as compared to progression.

Table 128: Summary of Interventions with respect to time of progression

| Event Type   | Treatment             |   Total(n) | (n%)< Progression (n%) >= Progression   | (n%)< Progression (n%) >= Progression   |
|--------------|-----------------------|------------|-----------------------------------------|-----------------------------------------|
| Tracheostomy | Placebo (N=114)       |          5 | 0                                       | 5(100.0)                                |
| Tracheostomy | Masitinib 4.5 (N=106) |         11 | 0                                       | 11(100.0)                               |
| Ventilator   | Placebo (N=114)       |         21 | 0                                       | 21(100.0)                               |
| Ventilator   | Masitinib 4.5 (N=106) |         24 | 2(8.3)                                  | 22(91.7)                                |
| Gastrostomy  | Placebo (N=114)       |         20 | 3(15.0)                                 | 17(85.0)                                |
| Gastrostomy  | Masitinib 4.5 (N=106) |         22 | 6(27.3)                                 | 16(72.7)                                |

As seen in table above, all tracheotomy and most of the ventilation or gastrostomy events occurred after progression which is an earlier event.

Argument 4.18:  When accounting for progression, tracheotomy, ventilation and gastrostomy or death in EFS, EFS showed benefit

<div style=\"page-break-after: always\"></div>

Even when integrating those events, in an Event Free Survival (EFS), with Event being the earlier event between  progression,  tracheotomy,  ventilation  or  gastrostomy,  the  EFS  test  remains  statistically significant (p=0.01) showing a benefit of 3 months in median for masitinib as presented below.

Table 129: Analysis of PTVGFS - Masitinib 4.5 mg/kg/day -Normal Progressor

| Treatment group   |   Total |   No. of Events | Median [95% CI]   | Wilcoxon value   | p-   |
|-------------------|---------|-----------------|-------------------|------------------|------|
| Placebo           |     113 |              76 | 11 [ 10; 17]      |                  |      |
| Masitinib 4.5     |     105 |              66 | 14 [ 12; 20]      | 0.0162           |      |

PTVGFS: Progressor, Tracheostomy, Ventilator, Gastrostomy free survival

Table 130: Analysis of PTVGFS - Masitinib 4.5 mg/kg/day - mITT Population (Normal Progressor prior to any loss of function)

| Treatment group   |   Total |   No. of Events | Median [95% CI]   |   Wilcoxon p-value |
|-------------------|---------|-----------------|-------------------|--------------------|
| Placebo           |     104 |              69 | 11 [ 10; 19]      |             0.0106 |
| Masitinib 4.5     |      84 |              47 | 17 [ 14; 25]      |             0.0106 |

PTVGFS: Progressor, Tracheostomy, Ventilator, Gastrostomy free survival

EFS in the subgroup described in the next section, normal progressors prior to any loss of function showed an even larger benefit of 6 months in median (p=0.0106)

## Argument 4.19:  Survival  of  placebo  who  switched  to  masitinib  in  Open  Label  Extension showed benefit versus the ones who did not switch

As requested by the Rapporteur, new long-term OS analysis was performed, censoring placebo patients at the time they switched to masitinib treatment in the NPP program.

This retreatment is essential because OS was significantly improved for placebo patients who switched to masitinib 4.5 mg/kg/day as compared with placebo patients who did not switch.

Table 131: Normal Progressor- Analysis of overall survival in the NPP program (placebo switch vs no switch to masitinib)

| Treatment group   |   Total |   No. of Events | Median [95% CI]   |   Log Rank |
|-------------------|---------|-----------------|-------------------|------------|
| Placebo           |      48 |              20 | 62 [49; NE]       |     0.0367 |
| Masitinib 4.5     |      23 |              10 | 69 [44; NE]       |     0.0367 |

## Argument 4.20:  Censoring  placebo  who  switched  to  masitinib  at  the  time  of  the  switch showed trend towards benefit of OS from randomization

OS showed a trend in the population normal progressor with the censoring of placebo when they switched to masitinib in the open label extension, since this switch provided a significant benefit.

Table 132: Normal Progressor- Masitinib 4.5 mg/kg/day - OS (censoring of placebo patients at time of switch to masitinib)

| Treatment group   |   Total |   No. of Events | Median [95% CI]   |   Log Rank |
|-------------------|---------|-----------------|-------------------|------------|
| Placebo           |     114 |              63 | 40 [ 30; 49]      |     0.0761 |
| Masitinib 4.5     |     106 |              60 | 46 [ 33; 69]      |     0.0761 |

## Argument 4.21:  Strength was not measured but according to guideline this is a necessity only for  treatment which are purely symptomatic, whereas masitinib targeting mast cells and microglia acts as a disease modifying

As per EMA Guidance on ALS, muscle strength is a required efficacy endpoint for symptomatic treatment,

<div style=\"page-break-after: always\"></div>

for disease modifying treatment like masitinib.

For disease modifying treatment, EMA Guidance required either time to death including other end of life measures that prolong life or function, or both, or alternatively, time-to-event endpoint with the event defined as death or a predefined deterioration on the ALSFRS-R scale, or CAFS.

In addition, the EMA guidance became effective after the initiation of AB10015 study.

EMA  Scientific  advice  for  phase  3  confirmatory  study  (EMA/CHMP/SAWP/596883/2018)  was  first provided in 2018. AB Science diligently implemented the recommendation from the CHMP regarding measuring muscle strength.

However, this advice was provided after the completion of AB10015 study.

## Argument 4.22:  TFS showed no benefit because Tracheostomy was not measured systematically after discontinuation and because there were several biased against masitinib

CHMP has a concern that TFS shows no benefit. However, the following considerations need to be taken into account:

- -The number of tracheostomies are limited and tracheostomy is known to be biased due to personal decision or cultural factors.
- -Tracheotomy has been followed until discontinuation. Long-term follow-up of tracheostomy was not planned and has not therefore been monitored in the same manner as OS was, the latter of which was followed for 75.6 months.
- -The rate of tracheostomy has been impacted by multiple disbalances against masitinib, in particular by a greater proportion of patients with a loss of function at baseline (i.e., very severe ALS), a cohort with longer duration of disease at baseline, and also a cohort that had a longer treatment duration in the extension period.
- -All  tracheotomy  occurred  after  the  protocol  defined  progression  of  ALSFRS-R  and  PFS  was statistically significant when integrating any earlier event than tracheotomy.
- -Potential confounding factors such as ventilation, gastrostomy and tracheostomy events, have been assessed and had no impact on PFS.
- -Ventilation and gastrostomy occurred mostly after ALSFRS-R progression and even when taken into account  via  an  event  free  survival  (EFS)  analysis,  with  progression,  tracheostomy,  ventilation gastrostomy or death, the EFS showed a statistically significant benefit in favor of masitinib.
- -No drug registered for treatment of ALS or investigational drugs for ALS have demonstrated survival benefit with the exception of riluzole, which is used in combination with masitinib.
-  Tracheostomies are limited up to week 48 and tracheostomy events in extension are impacted by several  imbalances  in  disfavor  of  masitinib,  more  very  severe  patients,  longer  duration  in extension, longer time from disease or time from onset to randomization

There was no statistically significant difference (p=0.7382) observed between masitinib (4.5 mg/kg/day) and placebo for time to tracheostomy free survival (TFS) in the Normal Progressor population.

<div style=\"page-break-after: always\"></div>

Table 133: Analysis of TFS-- Masitinib 4.5 mg/kg/day - Normal Progressor

| Treatment group   |   Total |   No. Events |   of Percentage censored | Median [95% CI]   |   p-value Wilcoxon test | using   |
|-------------------|---------|--------------|--------------------------|-------------------|-------------------------|---------|
| Placebo           |     113 |           34 |                     69.9 | 32 [ 23; . ]      |                  0.7382 |         |
| Masitinib 4.5 + R |     105 |           35 |                     66.7 | 30 [ 22; . ]      |                  0.7382 |         |

During  the  main  study  period,  in  there  were  few  (4)  tracheostomy  events  the  primary  analysis population, 3 events in the masitinib 4.5 mg/kg/arm versus 1 in the placebo arm.

During the extension period, there were 12 tracheostomy events the primary analysis population, 8 events in the masitinib 4.5 mg/kg/arm versus 4 in the placebo arm.

Table 134: Summary of Tracheotomy patients in Normal progressor

|                   | Masitinib 4.5 mg/kg   | Masitinib 4.5 mg/kg   | Masitinib 4.5 mg/kg   | Masitinib 4.5 mg/kg   | Placebo   | Placebo         | Placebo    | Placebo       |
|-------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------|-----------------|------------|---------------|
| Cumulative Events | All                   | Very severe ALS       | Severe ALS            | Moderate ALS          | All       | Very severe ALS | Severe ALS | Moderat e ALS |
| Week 48           | 3                     | 0                     | 2                     | 1                     | 1         | 0               | 0          | 1             |
| Extension         | 8                     | 3                     | 3                     | 2                     | 4         | 1               | 2          | 1             |
| Total             | 11                    | 3                     | 5                     | 3                     | 5         | 1               | 2          | 2             |

This disbalance was essentially visible in the extension phase between the two treatment arms

There were multiple reasons to explain the disbalance in tracheotomy:

- -Time under treatment in extension which we know is not the same for masitinib 4.5mg/kg, 25 weeks in median, versus 15 weeks for placebo.
- -Severity of patients at baseline.
- o there is a disbalance of number of very severe patients (20% of very severe patients with masitinib 4.5mg/kg versus 9% with placebo),
- o but also, a disbalance against masitinib in number of functions lost within the very severe patients
- o and also, a disbalance against masitinib in time from diagnostic to baseline or time from onset of symptoms to baseline
- o and also a disbalance against masitinib in median duration of treatment in the extension phase
- o despite these disbalances, tracheotomy occurred later and death after tracheotomy also

In addition, the study was not designed to record the tracheostomy as a long term efficacy endpoint.

By contrast, survival has been followed as a key secondary endpoint after discontinuation and very long term and all data have been monitored. As such, when it comes to analyzing the long-term time to event time point that includes a large part of the data post discontinuation, survival is a more robust measure, based on the design of the protocol.

-  Imbalance at baseline that impacted tracheotomy

<div style=\"page-break-after: always\"></div>

TFS has been impacted by multiple imbalances that could affect the masitinib arms, in particular the masitinib 4.5 mg/kg/day treatment arm.

## i. Greater  severity  at  baseline  in  patients  under  masitinib  group  4.5  mg/kg/day  as compared to patients in placebo group

Table 135: Disposition of patients by ALS severity status at baseline

|                 | Placebo   | Placebo   | Masitinib 4.5   | Masitinib 4.5   |
|-----------------|-----------|-----------|-----------------|-----------------|
| Severity Status | N         | %         | N               | %               |
| Moderate ALS    | 62        | 54.4%     | 45              | 42.4%           |
| Severe ALS      | 42        | 36.8%     | 40              | 37.7%           |
| Very Severe ALS | 10        | 8.8%      | 21              | 19.8%           |
| Total           | 114       | 100%      | 106             | 100%            |

- -more very severe  patients  (score  of  zero  on  any  ALSFSR-R  score)  being  randomized  in  the masitinib arm (19.8%) than in the control arm (8.8%).
- -The  severity  in  this  subset  of  very  severe  patients  was  higher  in  the  masitinib  arm,  with  a disbalance in favour of placebo in terms of number of items with ALSFSR-R score=zero (see response to MO2B).

## ii. Longer median duration of treatment in the extension phase

The number of tracheotomy events that occurred in the extension phase were also impacted by a longer duration of treatment in the masitinib arm relative to the placebo arm, with a median of 25 versus 15 weeks, respectively.

Table 136: Summary of time on treatment (extension period) according to treatment arm

|                           | Placebo   | Masitinib 4.5   |
|---------------------------|-----------|-----------------|
| Time on treatment (weeks) |           |                 |
| n                         | 80        | 73              |
| Median                    | 15.4      | 25.0            |

## iii. Median time to tracheostomy free was extended in patients from the masitinib 4.5 mg/kg/day arm as compared with the placebo arm, despite the fact that patients from the masitinib 4.5 mg/kg/day arm had a longer disease duration. Death occurred also later post tracheotomy with masitinib.

It is important to note that patients treated by masitinib 4.5 mg/kg/day underwent tracheostomy later than patients treated by placebo. The overall mean time to tracheostomy from symptoms onset was 28.5 versus 39.4 months for placebo and masitinib arms, respectively. This delay in tracheostomy was also seen in terms of overall mean time to tracheostomy from baseline; i.e., 24.7 versus 38.5 months, respectively.  Furthermore,  this  masitinib  related  delay  in  tracheostomy  was  independent  of  baseline disease severity, as evidenced by it being seen across moderate, severe and very severe subgroups. Indeed,  the  largest  difference  was  associated  with  the  very  severe  subgroup,  with  a  delay  of approximately  10  months,  despite  the  fact  that  their  disease  was  already  at  an  advanced  stage  at baseline and that there were more very severe patients in the masitinib arm than the placebo arm.

After tracheostomy, patients treated with masitinib 4.5 mg/kg/day survived longer than those treated with placebo, as evidenced by an overall mean time to death from tracheostomy of 24.7 versus 38.5 months for placebo and masitinib arms, respectively.

<div style=\"page-break-after: always\"></div>

Table  137:  Time  to  tracheostomy  from  onset  and  from  baseline,  time  to  death/last  follow-up  from tracheostomy (in months, population Normal Progressors)

| Patients with tracheostomy                              | Placebo (n=5)   | Masitinib 4.5 (n=11)   |
|---------------------------------------------------------|-----------------|------------------------|
| Mean time to tracheostomy from symptoms onset (months)  |                 |                        |
| Moderate                                                | 27.38 (±2.21)   | 30.37 (±9.69)          |
| Severe                                                  | 25.74 (±3.74)   | 37.20 (±13.17)         |
| Very Severe                                             | 36.47 (± n/a)   | 46.06 (±21.95)         |
| Mean time to tracheostomy from baseline (months)        |                 |                        |
| Moderate                                                | 15.44 (±10.27)  | 21.34 (±16.73)         |
| Severe                                                  | 12.07 (±0.67)   | 14.99 (±8.14)          |
| Very Severe                                             | 12.91 (± n/a)   | 20.10 (±7.27)          |
| Mean time to death/last follow-up tracheostomy (months) |                 |                        |
| Moderate                                                | 18.91 (±3.46)   | 44.46 (±13.69)         |
| Severe                                                  | 22.09 (±28.23)  | 38.23 (±26.05)         |
| Very Severe                                             | 41.56 (±n/a)    | 32.88 (±29.74)         |
| Total mean time to tracheostomy from symptoms onset     | 28.54 (±5.0)    | 39.39 (±14.25)         |
| Total mean time to tracheostomy from baseline           | 13.59 (±5.43)   | 18.11 (±10.11)         |
| Total mean time to death from tracheostomy              | 24.71 (±17.13)  | 38.47 (±22.50)         |

n= number of tracheostomy. Values shown a Mean (± standard deviation)

-  Other potential bias affecting TFS

In addition to the above factors, the TFS analysis may have been confounded by the fact that:

- -Criteria for tracheostomy and continuous assisted ventilation dependence were not pre-specified or standardized in the protocol and furthermore, the study enrolled patients from multiple countries where the standard of care for end-of-life situations may vary.
- -Tracheostomy is invasive is highly subject to patient personal choice.
- -The use of tracheostomy in ALS patients is therefore controversial and varies from one country to another. In Switzerland, for example, it remains used only exceptionally.

## Argument 4.23:  Objection regarding TFS was considered resolved by the CHMP

During the procedure, that Rapporteurs had the following question (D120 - Q119)

SAP  includes  secondary  endpoint  'Survival  defined  as  the  time  from  randomization  to  the  date  of documented death or first tracheotomy' which is not presented elsewhere. The Applicant is asked to clarify this and present results for this endpoint.

Data as reported in Section 4.22 above were presented to the Rapporteurs.

In the Rapporteurs Day 150 Joint Assessment Report, the CHMP concluded that the issued is resolved

## Argument 4.24:  OS was followed for the very long term and is a robust long term time to event measure

Because median OS analysis remains the gold standard for demonstration of a drug's therapeutic benefit in ALS, long-term OS assessment represents a valuable complement to the study's primary analysis.

<div style=\"page-break-after: always\"></div>

All  investigational  sites  from  study  AB10015  were  contacted  with  a  request  for  an  update  on  each patient's vital (survival) status. Overall survival was defined as the time elapsed between randomization and death from any cause. Overall survival P values were calculated via the multivariate log-rank test using the covariates of age and ALSFRS-R score at randomization, site of onset (spinal versus bulbar), geographical region, and post-onset ALSFRS-R progression rate ( Δ FS). All covariates were prespecified in the AB10015 protocol as randomization stratification factors [Mora 2020]. Hazard ratios (HR) and 95%  confidence  intervals  (CI)  were  calculated  via  the  Cox  proportional-hazards  model  using  the abovementioned covariates.

Vital  status  (i.e.,  survival  status  of  alive  or  dead,  including  date  of  death)  of  all  patients  originally randomized to study AB10015 was collected from each participating investigational site. As such, three patient groups were defined long-term high-dose (4.5 mg/kg/day) masitinib, long-term low-dose (3.0 mg/kg/day) masitinib, and long-term placebo. Long-term assessment for study AB10015 encompassed the prospectively declared 48-week treatment period with associated double-blind extension (commencing in April 2013 until data readout), and a post study (unblinded) follow-up period (from November 2017 until June 2020). Patients still alive at the time of analysis were censored at the date of last contact. 95% of patients had status verified &lt;7 months prior to cut-off.

These entirely new long-term OS data is based on average follow-up of 75.6 months since diagnosis and 66.1 months since randomization and included cross-over from placebo to masitinib treatment.

| Period (Start-End)   | Week 48 LPLV Period (Apr 2013-Dec 2016)   | Extension Period (Dec 2016-Nov 2017)            | Cross-over Period (Nov 2017-June 2020)         |
|----------------------|-------------------------------------------|-------------------------------------------------|------------------------------------------------|
| Blinding status      | Blinded                                   | Blinded up to Apr 2017 Open label from Apr 2017 | Open-label                                     |
| M3.0                 | 131*                                      |                                                 | Enter NPP 30* No NPP (discontinue) 37*         |
| M4.5                 | 130*                                      |                                                 | Enter NPP 29* No NPP (discontinue) 41*         |
| Control              | 133*                                      |                                                 | Cross-over to NPP 25* No NPP (discontinue) 53* |

## Argument 4.25:  OS remains the gold standard and cannot be biased

In  accordance  with  'Guideline  on  clinical  investigation  of  medicinal  products  for  the  treatment  of amyotrophic  lateral  sclerosis  (ALS)'  (EMA/531686/2015,  Corr.1) criteria  for  tracheostomy  and continuous assisted ventilation dependence as a study endpoint event should be carefully pre-specified and standardised since patient management varies considerably between countries and regions. Where these endpoints are used, an additional analysis using only time to death as the endpoint should also be provided to allow evaluation of the consistency of the results .

OS remains the gold standard variable in ALS. In study AB10015, OS was followed long term for 83.5 month from diagnosis.

Survival has been the only event that was followed post discontinuation and very long term.

Therefore, when it comes to a long-term analysis only OS can be used

<div style=\"page-break-after: always\"></div>

## Argument 4.26:  Consistency between ALSFRS, PFS, and OS

Study AB10015 showed a robust consistency between the significant benefit on ALSFRS-R calculated with a non LOCF conservative methodology, the significant benefit in PFS which is unbiased and the trend towards  benefit  in  OS  which  is  the  gold  standard,  in  the  primary  population  of  the  study,  normal progressors.

These benefits did not come at the expense of toxicity since there was also a significant benefit in quality of life on ALSAQ using non LOCF methodology.

The consistency of the benefit on key variables is a justification in favor of the demonstration of efficacy.

## Argument 4.27:  There  is  no  treatment  that  can  extend  life,  investigational  or  registered, except riluzole which was given add on

Failure of numerous phase 2 or 3 programs in ALS have recently been reported, including confirmatory phase 3 studies of registered drugs such as Albrioza (Amylyx) and oral edaravone (Ferrer), as well as studies from investigational drugs such as TUDCA  (the  TUDCA-ALS  consortium), reldesemtiv (Cytokinetics) and the RIPK1 inhibitor SAR443820 (Sanofi).

Tofersen is registered for use in SOD1 familial forms, which represent approximately 2% of patients.

For sporadic ALS, riluzole therefore remains the only reference treatment with a proven modest effect on survival and no effect on motor function, which is a key dysfunctional impairment in ALS.

## Argument 4.28:  The lag time of efficacy is compatible with masitinib MoA being a disease modifying

Published non-clinical data indicate that the reduction of CNS and PNS neuroinflammation of masitinib in ALS animal models is observed in few days or weeks after treatment onset [Trias 2020; Trias 2016]. However, one must consider that the final therapeutic effect of masitinib on ALS patients' neurological deficits is not only dependent on neuroinflammation, but rather on the preservation or repair of the anatomy and functionality of central and peripheral motor pathways.

Most motor neurons bear long myelinated axons that establish neuromuscular junctions (NMJ) to control skeletal muscle. In ALS, motor axons develop axonopathy in the CNS and PNS, followed by demyelination and accumulation of myelin debris. Any therapeutic agent that stops or reduces the inflammatory cellular microenvironment  around  the  damaged  motor  neurons,  is  expected  to  take  time  to  normalize  the function of motor neuron cell bodies and subsequently improve the structure and physiology of motor axons. The length of time this takes can be significant.

Because masitinib ameliorates the neurodegenerative cellular microenvironment that surrounds motor neuron cell bodies and the peripheral projections, it is expected that the therapeutic effect on motor symptoms is observed after a period of several weeks or months.

Examples of similar delayed response to therapeutic agents, also referred to as 'therapeutic lag', is seen in the treatment of multiple sclerosis and depression.

- -Roos and colleagues calculated the duration of therapeutic lag for numerous immunomodulatory therapies used in the treatment of multiple sclerosis (for example, alemtuzumab, natalizumab, mitoxantrone, rituximab, fingolimod, dimethyl fumarate, teriflunomide, and glatiramer acetate) [Roos  2020].  Results  showed  that  the  duration  of  therapeutic  lag  for  relapses  (defined  as occurrence of new symptoms or the exacerbation of existing symptoms) ranged between 12 and 30 weeks, whereas the duration of therapeutic lag for disability progression (defined as 6-month confirmed EDSS progression) ranged between 30 and 70 weeks.

<div style=\"page-break-after: always\"></div>

- -In order to eliminate the effects of therapeutic lag, Kalincik and colleagues disregarded EDSS events within 6 months from treatment start for their study on MS prediction modelling [Kalincik 2022].
- -Giovannoni and colleagues discuss the concept of a therapeutic lag in progressive MS being supported by the observation of randomised placebo-controlled study of interferon-beta-1b in primary progressive MS [Giovannoni 2017]. The authors state that 'therapeutic lag may manifest as  a  delay  for  a  specific  treatment  in  the  slowing  down,  or  a  plateauing  out,  in  the  rate  of progression in a particular pathway.

## Argument 4.29:  A lag time to detect a treatment effect in ALS is expected since ALSFRS is not a responsive endpoint to give a reliable result before week 24

A trend towards separation of the treatment-arms is evident as early as week-12, especially for the secondary endpoints, and becomes more apparent by week-24. The separation between treatment-arms is  then  maintained  or  continues  to  increase  (as  is  the  case  for  ALSFRS-R)  through  to  the  week-48 timepoint for all endpoints.

Gordon and colleagues have previous stipulated that '6 months are needed to detect changes in the ALSFRS-R  because  of  variability,  due  principally  to  differing  rates  of  progression  among  patients' [Gordon 2006].

This is therefore perfectly consistent with the treatment-effect of masitinib only clearly manifesting itself at week-24 of study AB10015.

Figure 13: Time series plots of least-squares mean difference in ALSFRS-R from baseline in Normal Progressor  patients  receiving  Masitinib  AB  Science  4.5  mg/kg/day  versus  placebo  (primary  efficacy population)

<!-- image -->

Reference

## Argument 4.30:  Qalsody exhibited similar lag time, if effective

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: EMA/276404/2024

Argument 4.31:  The position adopted by the CHMP for Qalsody shows that full JTR is not the single and absolute requirement to be fulfilled since it failed for Qalsody

The position adopted by the CHMP for Qalsody shows that JTR is not the single and absolute requirement to be fulfilled.

Indeed, the EMA registered Qalsody with the EPAR showing that the JTR for the preplanned analysis had a p-value of 0.5, and a p-value of 0,2 when introducing post hoc the NfL biomarker covariate.

Qalsody showed no benefit in any efficacy variables at week 28.

Nevertheless, and despite these statistical results, the CHMP concluded that there was a benefit because NfL reduction has been considered predictive of a clinical benefit.

## Argument 4.32:  Other supportive evidences show a perceived strong efficacy of masitinib from practitioners having relevant clinical experience with masitinib in ALS patients

Two testimonies, based on real life evidence over a long period of time and numerous patients treated, show a perceived strong efficacy of masitinib on control of functional score and survival.

## Argument 4.33:  Support from patient associations

We wish to inform the Rapporteurs that EUpALS has close ties (including financial) with TRICALS, which is committed to other projects than masitinib clinical development. As such, we consider that there might be a potential conflict of interest and we recommend the Rapporteurs/ SAG to consult with (or to add in their consultation) other ALS patients associations or representatives, such as:

- -ARSLAN (France)
- -APELA (Portugal)
- -ConALSncio (Italy)
- -Post Fata Resurgo (Italy)
- -ZsALSa (Czech Republic)

<div style=\"page-break-after: always\"></div>

- EUpALS patients and carers expert board (PCEB).

4. The strategies to post hoc identify new target populations ('M4.5 with ≥2 on each baseline ALSFRS -R item and ΔFS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1) are considered as data driven decisions and are, therefore, not acceptable.

The Applicant presented first some statements included in section 2.6.6 of this CHMP AR.

The CHMP considers that the compelling evidence of efficacy on all clinically relevant endpoints including PFS and OS was not demonstrated. The long-term assessment of the available data encompassed five distinct periods. Notably, the categorization of patients into normal and fast progressions were conducted with third amendment, while the open label post study follow-up period from November 2017 until June 2020 was added as the fifth the amendment. During the open label period patients were followed for overall survival, however, the PFS and OS results generated in the open label conditions inherit potential biased  information  on  survival  events,  because  of  impact  of  various  factors,  which  occurred  under unrandomized conditions (i.e. used medicines in the post pivotal study period, tracheostomy events, needs for the non-/invasive ventilation etc.). Therefore, the long-term survival data presented by the Applicant  is  derived  from  a  highly  selected  patients'  population  defined post  hoc therefore,  can  be considered  only  as  descriptive  not  confirmatory  of  Masitinib  AB  Science  efficacy  in  the  proposed indication.  Further, in order to address the concern of CHMP regarding an indication for ALS treatment that excludes fast progressors, the Applicant has presented a modified indication, based on up-dated efficacy and safety analyses, to the 'treatment of ALS patients prior to any loss of function' (wherein loss of function is defined as a score of zero on any item of the ALSFRS-R). However, the strategies to post hoc identify new target populations ('M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of section 4.1 of the SmPC) are considered as data driven decisions and are, therefore, not acceptable. In the response, the Applicant has reiterated previously assessed data and justifications. The post hoc subgroup  analysis  may  be  performed  at  the  initiative  of  the  Applicant  according  to  the  guidelines EMA/CHMP/539146/2013. However, the guideline Scenario 2 criteria ' Replication of subgroup findings from other relevant trials or if not available the biological plausibility and the clinical trial data from the subgroup would have to be exceptionally strong ' is considered not fulfilled, as the effect observed in the subgroup is not replicated across trials by the time of opinion.

## AB Science Response

## Argument 5.1: CHMP  stated  there  is  no  new  data  but  Applicant  showed  a  major disbalance against masitinib with the subset of patients with at least one loss of function (20% vs 8% ) and more functions lost in masitinib subset. This has not been taken into consideration so far, including in the CHMP final opinion

-  The preplanned primary analysis population of Normal progressors was disbalanced in favour of the control arm

Indeed, upon further analysis, it appears that the preplanned primary analysis population of Normal progressors was disbalanced in favour of the control arm in a subset of patients with 'very severe' ALS (i.e. patients having at least a zero on any the 12 ALSFRS-R item).

- -more  very  severe  patients  (score  of  zero  on  any  ALSFSR-R  score)  being  randomized  in  the masitinib arm (20%) than in the control arm (8%).
- -The  severity  in  this  subset  of  very  severe  patients  was  higher  in  the  masitinib  arm,  with  a disbalance in favour of placebo in terms of number of items with ALSFSR-R score=zero
- -This disbalance could occur because ALSFRS-R score was minimized but not stratified by category of severity

<div style=\"page-break-after: always\"></div>

Table 138: Distribution of subset of very severe patients in primary analysis population

| Population                                       | Statistic   | Placebo N=113 n (%)   | Masitinib 3 mg N=110 n (%)   | Masitinib 4.5 mg N=105 n (%)   |
|--------------------------------------------------|-------------|-----------------------|------------------------------|--------------------------------|
| Normal Progressor all patients                   | n (%)       | 113 (100)             | 110 (100)                    | 105 (100)                      |
| Normal Progressor (Moderate/Severe ALS) patients | n (%)       | 104 (92)              | 94 (85.5)                    | 84 (80)                        |
| Excluded patients (Very severe ALS) patients     | n (%)       | 9 (8)                 | 16 (15.5)                    | 21 (20)                        |
| 1 Question (item) with score 0                   | n [Q]       | 8 [8]                 | 10 [10]                      | 10 [10]                        |
| Within Bulbar subdimension                       | n [Q]       | 2 [1]                 | 1 [1]                        | 1 [1]                          |
| Within Fine motor subdimension                   | n [Q]       | 0                     | 0                            | 1 [1]                          |
| Within Gross motor subdimension                  | n [Q]       | 6 [1]                 | 8 [1]                        | 7 [1]                          |
| Within Respiratory subdimension                  | n [Q]       | 0                     | 1 [1]                        | 1 [1]                          |
| 2 Questions (item) with score 0                  | n [Q]       | 0                     | 3 [6]                        | 7 [10]                         |
| Within Bulbar subdimension                       | n [Q]       | 0                     | 0                            | 1 [2]                          |
| Within Fine motor subdimension                   | n [Q]       | 0                     | 3 [4]                        | 2 [3]                          |
| Within Gross motor subdimension                  | n [Q]       | 0                     | 2 [2]                        | 3 [5]                          |
| Within Respiratory subdimension                  | n [Q]       | 0                     | 0                            |                                |
| 3 Questions (item) with score 0                  | n [Q]       | 0                     | 3 [9]                        | 3 [9]                          |
| Within Bulbar subdimension                       | n [Q]       | 0                     | 1 [2]                        | 0                              |
| Within Fine motor subdimension                   | n [Q]       | 0                     | 3 [5]                        | 3 [8]                          |
| Within Gross motor subdimension                  | n [Q]       | 0                     | 1 [2]                        | 1 [1]                          |
| Within Respiratory subdimension                  | n [Q]       | 0                     | 0                            | 0                              |
| 4 Questions (item) with score 0                  | n [Q]       | 1 [4]                 | 0                            | 1 [4]                          |
| Within Bulbar subdimension                       | n [Q]       | 0                     | 0                            | 0                              |
| Within Fine motor subdimension                   | n [Q]       | 1 [2]                 | 0                            | 1 [2]                          |
| Within Gross motor subdimension                  | n [Q]       | 1 [2]                 | 0                            | 1 [2]                          |
| Within Respiratory subdimension                  | n [Q]       | 0                     | 0                            | 0                              |

The efficacy profile of masitinib, as well as the safety profile of masitinib, are improved when analysed without this disbalanced subset of patients, as justified in the section below.

-  When excluding this subset of very severe patients (i.e. score of 0 on at least one ALSFRS-R item), the baseline characteristics in the subgroup are balanced and unlikely to create a bias in favour of masitinib

Baseline characteristics in the subgroup were balanced between treatment-arms.

Table 139: Baseline characteristics - Subjects prior to any loss of function

|                            |                 | Placebo (N=104)           | Masitinib 3.0 (N=94)      | Masitinib 4.5 (N=84)      |
|----------------------------|-----------------|---------------------------|---------------------------|---------------------------|
| Sex; n (%)                 | Male            | 64 (61.5%)                | 62 (66.0%)                | 57 (67.9%)                |
| Average Δ FS (pts/month)   | Mean ± SD Range | 0.49 +/- 0.25 0.05 ; 1.07 | 0.45 +/- 0.24 0.09 ; 1.04 | 0.45 +/- 0.25 0.03 ; 1.08 |
| ALSFRS-R score at baseline | Mean ± SD       | 39.8 +/- 4.3              | 39.8 +/- 3.9              | 39.9 +/- 4.2              |

<div style=\"page-break-after: always\"></div>

|                                                   |                              | Placebo (N=104)   | Masitinib 3.0 (N=94)   | Masitinib 4.5 (N=84)   |
|---------------------------------------------------|------------------------------|-------------------|------------------------|------------------------|
|                                                   | Range                        | 29.0 ;            | 28.0 ;                 |                        |
|                                                   |                              | 47.0              | 46.0                   | 30.0 ; 47.0            |
| Age (years)                                       | Mean ± SD                    | 55.4 +/- 10.8     | 54.4 +/- 10.7          | 54.3 +/- 10.7          |
|                                                   | Range                        | 27.0 ; 75.0       | 33.0 ; 75.0            | 24.0 ; 78.0            |
| Time from first symptom to randomization (months) | Mean ± SD                    | 18.9 +/- 8.3      | 19.6 +/- 7.6           | 20.4 +/- 8.7           |
| Time from first symptom to randomization (months) | Range                        | 3.0 ; 36.0        | 7.0 ; 35.0             | 4.0 ; 36.0             |
| Time from diagnosis to randomization (months)     | Mean ± SD                    | 9.4 +/- 7.1       | 10.1 +/- 7.4           | 9.9 +/- 7.8            |
| Time from diagnosis to randomization (months)     | Range                        | 1.1 ; 31.3        | 1.3 ; 30.1             | 1.0 ; 33.9             |
| FVC (% predicted)                                 | Mean ± SD                    | 90.9 +/- 18.4     | 89.2 +/- 18.4          | 91.8 +/- 16.0          |
| FVC (% predicted)                                 | Range                        | 37.0 ; 131.0      | 51.0 ; 149.0           | 60.0 ; 131.0           |
| Site of onset; n (%)                              | Spinal                       | 81 (77.9%)        | 80 (85.1%)             | 68 (81.0%)             |
| Site of onset; n (%)                              | Bulbar                       | 23 (22.1%)        | 14 (14.9%)             | 16 (19.0%)             |
| Region; n (%)                                     | North America & West. Europe | 66 (63.5%)        | 59 (62.8%)             | 49 (58.3%)             |
| Region; n (%)                                     | Eastern Europe               | 7 (6.7%)          | 3 (3.2%)               | 7 (8.3%)               |
| Region; n (%)                                     | Other Countries              | 31 (29.8%)        | 32 (34.0%)             | 28 (33.3%)             |

Figure  14:  ALSFRS-R  Score  (Descriptive  statistics  and  per  dimension  -  patients  prior  to  any  loss  of function - Normal Progressor)

<!-- image -->

Descriptive statistics showed balanced baseline ALSFRS-R score across each of the four dimensions.

Table 140: Baseline ALSFRS-R score per dimension - Subgroup of patients prior to any loss of function

|                   |             | Placebo N=104   | Masitinib 3 mg/kg/d N=94   | Masitinib 4.5 mg/kg/d N=84   |
|-------------------|-------------|-----------------|----------------------------|------------------------------|
| Bulbar (Q1 to Q3) | Mean +/- SD | 10.68 +/- 1.75  | 10.73 +/- 1.81             | 10.96 +/- 1.54               |
| Bulbar (Q1 to Q3) | Median      | 12              | 12                         | 12                           |
| Bulbar (Q1 to Q3) | Min, Max    | 5 , 12          | 5 , 12                     | 5 , 12                       |
| Bulbar (Q1 to Q3) | Q1 , Q3     | 9 , 12          | 10 , 12                    | 10 , 12                      |
| Fine moror        | Mean +/- SD | 8.48 +/- 2.41   | 8.54 +/- 2.68              | 8.44 +/- 2.31                |

<div style=\"page-break-after: always\"></div>

| (Q4 to Q6)               | Median      | 9              | 9              | 9              |
|--------------------------|-------------|----------------|----------------|----------------|
| (Q4 to Q6)               | Min, Max    | 3 , 12         | 3 , 12         | 3 , 12         |
| (Q4 to Q6)               | Q1 , Q3     | 7 , 10         | 7 , 11         | 7 , 10         |
| Gross motor (Q7 to Q9)   | Mean +/- SD | 8.96 +/- 2.29  | 8.99 +/- 2.12  | 8.92 +/- 2.33  |
| Gross motor (Q7 to Q9)   | Median      | 9              | 9              | 9              |
| Gross motor (Q7 to Q9)   | Min, Max    | 4 , 12         | 5 , 12         | 3 , 12         |
| Gross motor (Q7 to Q9)   | Q1 , Q3     | 7 , 11         | 7 , 11         | 7 , 11         |
| Respiratory (Q10 to Q12) | Mean +/- SD | 11.65 +/- 0.76 | 11.51 +/- 1.03 | 11.56 +/- 0.92 |
| Respiratory (Q10 to Q12) | Median      | 12             | 12             | 12             |
| Respiratory (Q10 to Q12) | Min, Max    | 8 , 12         | 7 , 12         | 7 , 12         |
| Respiratory (Q10 to Q12) | Q1 , Q3     | 12 , 12        | 12 , 12        | 11 , 12        |

After removing the patients with prior loss of function, the distribution of the ALSFRS-R items in the remaining population of patients without prior loss of function is well balanced between groups as visible in the figure below:

<div style=\"page-break-after: always\"></div>

<!-- image -->

The  use  of  'ALS  patients  prior  to  any  loss  of  functions'  allows  to  have  a  more  balanced  population excluding more extreme cases hence a lower variability and does not favour the active group.

<div style=\"page-break-after: always\"></div>

Figure  15:  ALSFRS-R  Score  (Descriptive  statistics  -  very  severe  ALS  patients  (prior  to  any  loss  of function) from Normal Progressor)

<!-- image -->

In very Severe ALS patients those with any loss of function only, when considering from the Normal Progressor population, descriptive statistics (mean, median, Q1, and Q3) with box plots across all subdimensions clearly demonstrate that both treatment groups are disbalance.

## Argument 5.2: EMA guidance EMA/CHMP/539146/2013 states that there is an interest to apply the guideline on subgroup when there is a disbalance

Scenario 2 of the guidance refers to a situation where the clinical data are statistically persuasive in the primary analysis population, but where it might be of interest to identify a subgroup that has not been pre-specified  as  part  of  the  confirmatory  testing  strategy,  where  efficacy  and  risk-benefit  would  be convincing.

However, as stated under option 3 of this scenario 2, there are ' risks and uncertainties are present in a subset of the population to the extent that a positive risk-benefit cannot be concluded in that subset '.

In the case of AB10015, the third option listed is applicable because, although statistically and clinically persuasive data is presented in the primary analysis population, there are risks and uncertainties present in a subset of the population to the extent that a positive risk-benefit cannot be concluded in that subset.

## Argument 5.3: EMA guidance applies to post hoc analyses initiated by the Applicant

This EMA guidance makes clear reference to situation where '[…] it is of interest to identify post hoc a subgroup, where efficacy and risk-benefit is convincing' .

<div style=\"page-break-after: always\"></div>

Such post hoc subgroup analysis may be performed at the initiative of the Applicant, as the guidance states  that  the  applicable  principles  on  which  to  build  a  credible  subgroup  analysis  applies  '  […] irrespective of whether it is the company or the regulator that is specifying additional investigations of interest '.

## Argument 5.4: EMA guidance on subgroup is applicable to single pivotal study where confirmatory evidence is not yet available

This EMA guidance is applicable to trials that are presented in a Marketing Authorisation Application, in particular  in  phase  III  confirmatory  clinical  trials,  but  not  exclusively.  This  guidance  makes  specific reference to applications based on a single pivotal study and quotes the EMA guidance on this matter (CPMP/EWP/2330/9).

The EMA guidance further states that ' A particular challenge exists in applications based on a single pivotal study since replication is a key component of credibility. In this instance the biological plausibility and the clinical trial data from the subgroup would have to be exceptionally stro ng'.

It therefore applies to AB10015, which is a phase 3 study presented for marketing authorization as a single pivotal study.

## Argument 5.5: Masitinib  study  fits  scenario  2  of  the  guidance,  where  the  study  is  a success on its predefined primary analysis but the outcome is not compelling enough

Scenario 2 of the guidance refers to a situation where the clinical data are statistically persuasive in the primary analysis population, but where it might be of interest to identify a subgroup that has not been pre-specified  as  part  of  the  confirmatory  testing  strategy,  where  efficacy  and  risk-benefit  would  be convincing.

In the case of AB10015, the third option listed is applicable because, although statistically and clinically persuasive data is presented in the primary analysis population, there are risks and uncertainties present in a subset of the population to the extent that a positive risk-benefit cannot be concluded in that subset.

##  Statistically persuasive efficacy in the primary analysis population

According to AB Science, assessment scenario 2 of the guidance is applicable because the condition ' The clinical data presented are statistically persuasive in the primary analysis population' is met.

Indeed, as presented is response to Q.8.2.iii, there are sufficient statistically persuasive evidences to consider that masitinib generated efficacy in the primary analysis population.

-  The quantity of missing data is in line with other ALS studies of 48-week duration.
-  The study results are based on a large number of patients above 100 per arm, providing more accurate estimation of treatment effect.
-  The primary analysis based on ANCOVA test and LOCF was positive.
-  The sensitivity analyses based on conservative non LOCF methods show a positive and treatment effect, in particular preplanned cluster imputation, multiple imputation, jump to reference for prespecified discontinuation MNAR.
-  The jump to reference methodology for any discontinuation is extreme, because not all reasons of discontinuation are because patients who withdraw may retain some of the benefit accrued during the treatment period. But even in this extreme case, the tipping point is 76% meaning

<div style=\"page-break-after: always\"></div>

24% remaining  efficacy  from  treatment  is  enough  for  the  study  to  be  successful,  meaning treatment effect remain relevant

-  The methodology Copy Increment, less brutal that JTR and recommended by EMA is positive
-  The primary endpoint analysis is supported by multiple key secondary endpoints.
-  The primary endpoint analysis is supported by a trend towards overall survival (OS) benefit (+6 months) based on the sensitivity  analysis  recommended  by  the  Rapporteurs,  i.e.,  censoring placebo patients at the time they switched to masitinib treatment.
-  Clinically persuasive efficacy in the primary analysis population
-  The magnitude of the functional benefit ranges from 2.8 to 3.4 depending on the sensitivity analysis applies and always remains above the threshold of 2 considered are clinically relevant by the majority of EMA experts.
-  The functional benefit was associated with a gain of +4 months of median PFS.
-  There was trend in survival benefit of + 6 months in median overall survival.
-  The improvement in decline in ALSFRS-R was not at the expense of quality of life, as there was a significant benefit on quality of life.
-  Risks and uncertainties have been identified in a subset of the population

As presented in section 5.1 above, there are ' risks  and uncertainties are present in a subset of the population to the extent that a positive risk-benefit cannot be concluded in that subset '.

## Argument 5.6: The 5 additional conditions to apply guideline are fulfilled

Irrespective of whether it is the company or the regulator that is specifying additional investigations of interest, the guidance lists five criteria that would usually apply for a subgroup to be considered credible.

- 1) External  evidence  should  exist  that  the  subgroup  of  interest  is  a  well-defined  and  clinically relevant entity.
- 2) A pharmacological rationale or a mechanistically plausible explanation.
- 3) The treatment effect observed in the subgroup would usually be larger.
- 4) Replication  of  subgroup  findings  from  other  relevant  trials  or  if  not  available  the  biological plausibility and the clinical trial data from the subgroup would have to be exceptionally strong.
- 5) Whenever a treatment recommendation is to be based on a subgroup, it is mandated that riskbenefit should be carefully inspected.

According to AB Science, the criteria are fulfilled in the context of AB10015 trial.

## 1. Subgroup of interest is a well-defined and clinically relevant

-  The subgroup is well defined and clinically relevant

The subgroup is well-defined and clinically relevant, based on the following considerations.

<div style=\"page-break-after: always\"></div>

- -Loss of function is well-characterized and fits guidance definition (§4.1).

Loss of function is based on ALSFRS-R score, which is a validated and widely used scale in ALS. ALSFRS-R score at baseline was a stratification factor. Furthermore, Loss of function is stable once reached.

- -The analysis to identify the subgroup is based on a credible number of patients ((104+84)/(113+105))≈86% of primary analysis population).

##  External evidence is available to support the subgroup

Severity is defined in terms of remaining functionality on items of the ALSFRS-R score, as opposed to the  total  ALSFRS-R  score.  A  drawback  of  this  latter  global  approach,  is  that  it  assumes  a  uniform deterioration across all items, and does not therefore adequately take into consideration that a complete loss of functionality may have occurred in one item, even though the global functionality may remain relatively high (i.e., a consequence of the scale's multidimensionality).

Hence,  the  following  categories  have  been  defined  (note  that  various  documents  may  use  different wording to describe these subgroup thresholds, however, the cohorts defined are identical):

- -Very severe ALS: Patient has a score of zero (i.e., loss of function) on at least one individual item of the ALSFRS-R.
- -Severe ALS: Patient has a score of 1 (i.e., severe impairment of function) on at least one of the individual ALSFRS-R items and a score of greater than zero on all individual ALSFRS-R items.
- -Moderate (or non-severe) ALS: Patient has a score of 2 (i.e., moderate impairment of function) on at least one of the individual ALSFRS-R items and a score of greater than 1 on all individual ALSFRS-R items.
- -Mild ALS: Patient has a score of 3 (i.e., mild impairment of function) on at least one of the individual ALSFRS-R items and a score of greater than 2 on all individual ALSFRS-R items.

The origin of this patient enrichment categorization is found in the edaravone MCI 186-16 trial post hoc analysis 'p atients with 2 points or better, on each of the individual items of the ALSFRS-R ' [Takahashi 2017], which was later incorporated as an inclusion criterion of the pivotal MCI 186-19 trial ' eligible patients had scores of at least 2 on all 12 items of ALSFRS-R ' [Writing Group 2017].

Given the structure of the ALSFRS-R scoring system, i.e., 12 items scored from 4 to 0 with higher scores indicating less severity, it is a logical progression of thought to also categorize patients with 3 points or better, 1 point or better, etc.

To facilitate the description and clinical interpretation of such severity categories it is common practice to adopt terminology such as 'mild', 'moderate' and 'severe', and this was also the case for the edaravone study populations mentioned above. An example of this is found in press releases issued by the study sponsor, Mitsubishi Tanabe Pharma Corporation, dated May 8th, 2017 [mitsubishimay82017] and also May  5th,  2023  [https://www.mt-pharma-de.com/aktuelles/pressemitteilungen.html],  in  which  the population of study MCI 186-19 is described as 'patients with comparatively moderate ALS'.

Hence, it logically follows from this 'moderate ALS' anchor point descriptor, that patients with scores of at least 3 on all 12 items of ALSFRS-R would be designated as 'mild ALS', whereas patients with scores of at least 1 on all 12 items of ALSFRS-R (but who do not meet the criteria for mild or moderate ALS) would be designated as 'severe ALS'. To this we can also add the category of 'very severe ALS' for any patient with any complete loss of function (score of zero) on at least one individual item of the ALSFRSR.

Beyond  the  terminology  introduced  by  the  Mitsubishi  Tanabe  Pharma  Corporation  for  describing  its

<div style=\"page-break-after: always\"></div>

edaravone study population, i.e., moderate ALS, Maier and colleagues have more recently developed a new revision of the ALSFRS-R, which they described as a 'disease-specific severity score that reflects motor impairment and functional deterioration in people with ALS' [Maier 2022]. They go on to highlight the following aspects of this scale:

- -The ALSFRS-R is a functional scale that measures deviations from unrestricted or \"normal\" motor functioning as caused by ALS.
- -To ordinally scale the loss of functionality, anchor points grade functionality from 0 to 4 for each item. To determine an ordinal score, the scale considers whether there is an increased need for assistance or assistive devices.
- o Scores of 4 designate unrestricted functionality.
- o Scores of 3 designate mild impairment, reflecting a condition that does not yet require compensatory help.
- o Scores of 2 are characterized by intermittent use of compensatory measures
- o Scores of 1 are given if assistive procedures or devices are needed in all instances and independence is severely reduced but not entirely lost
- o Scores of 0 designate a complete loss of functionality

Hence, it is further established in this article that a score of 3 on an individual component of the ALSFRSR is associated with mild impairment of function , that a score of 1 on an individual component of the ALSFRS-R is associated with severely reduced function, and that a score of 0 on an individual component of the ALSFRS-R is associated with complete loss of functionality. Although the anchor-point descriptors of 'moderate' and 'very severe' are not explicitly used by Maier, it is obvious that the pattern of 'mild', 'moderate'; 'severe' and 'complete loss of function (very severe)' are associated with the above scores of 3, 2, 1, and 0, respectively.

Hence, there are precedence in the literature for the ALSFRS-R severity-based patient categorization and terminology  used  for  AB10015  subgroup  analyses  (i.e.,  the  edaravone  trials  and  related  Mitsubishi Tanabe Pharma communications), and also evidence that the terminology and concepts used for this categorization are known and acceptable for clinical use in practice (i.e., as evidenced by the MND-NET consensus group).

## 2) Pharmacological rationale and mechanistically plausible explanation exist for differential efficacy

The subgroup 'prior to any loss of function' fits masitinib's mechanism of action because masitinib does not regenerate motor-neurons but slows down disease progression through modulation of mast cell and microglia activity.

Masitinib  acts  by  slowing  the  progression  of  the  disease  by  acting  on  the  innate  immune  systems, reducing macrophage infiltration, preventing terminal Schwann cells loss, and improving reinnervation in partially denervated plantaris muscles [Harrison 2020]. These results suggested that pharmacological interventions maintaining terminal Schwann cells at denervated endplates is a viable treatment strategy to attenuate the loss of motor function in ALS.

It is therefore expected that masitinib would provide better outcomes if administered when the larger motoneurons innervating type IIb fibers are still functioning and capable of sprouting terminal branches to reinnervate previously denervated endplates.

Hence, preserved or improved sprouting capacity would maintain motor function longer and slow the ALSFRS-R  decline  This  is  entirely  consistent  with  masitinib's  clinical  findings,  which  showed  that treatment-effect  was  greatest  when  masitinib  treatment  was  initiated  at  a  less  severe  stage  of  the disease, i.e., prior to any loss of function.

## 3) The treatment effect is larger in the subgroup

<div style=\"page-break-after: always\"></div>

There is clear increased benefit in the subgroup across all clinical endpoints at week 48, as presented in the table below.

The exclusion of the most severe patients, more frequent in the Masitinib 4.5 mg group led to significant improvement in survival. This shows that severe patients have major contribution to OS analysis.

Table 141: Differential treatment effect in the subgroup

|                                                                             |                  | Subgroup                       | Primary analysis Population (Normal Progressors)   |
|-----------------------------------------------------------------------------|------------------|--------------------------------|----------------------------------------------------|
| ∆ ALSFRS-R (CIR)                                                            | Diff. of mean    | 3.13                           | 2.68                                               |
| ∆ ALSFRS-R (CIR)                                                            | p-value          | 0.0308                         | 0.0462                                             |
| CAFS                                                                        | Relative benefit | 20.2%                          | 14.8%                                              |
| CAFS                                                                        | P-value          | 0.0290                         | 0.0776                                             |
| ALSAQ-40 (CIR)                                                              | Diff. of mean    | -6.22 [-12.27;-0.17]           | -6.04 [-11.51;-0.57]                               |
| ALSAQ-40 (CIR)                                                              | p-value          | 0.044                          | 0.0305                                             |
|                                                                             | Diff. of mean    | 7.59 [0.41;14.77]              | 5.85 [-0.98;12.67]                                 |
|                                                                             | p-value          | 0.0384                         | 0.0931                                             |
| Median                                                                      | Gain             | + 9 months                     | + 4 months                                         |
| Median                                                                      | Median [95% CI]  | 25 [17, NE] vs 16 [11, 19]     | 20 [14; 30] vs 16 [ 11; 19]                        |
| Median                                                                      | p-value log rank | 0.0057                         | 0.0159                                             |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | Gain             | + 12 months                    | + 6 months                                         |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | Median [95% CI]  | 53 [ 36; NE ] vs 41 [ 30; 54 ] | 46 [ 33; 69 ] vs 40 [ 30; 49 ]                     |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | p-value log rank | 0.0192                         | 0.0761                                             |

Figure 16: Normal Progressors- prior to any loss of function - KM analysis of PFS - Masitinib 4.5 mg vs Placebo

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 17: Normal Progressors- prior to any loss of function - KM analysis of OS - Masitinib 4.5 mg vs Placebo

<!-- image -->

Time since randomization (Months)

4) Replication of subgroup findings from other relevant trials or if not available the biological plausibility and the clinical trial data from the subgroup would have to be exceptionally strong

- a) The effect observed in the subgroup is not replicated by any masitinib trial at the time of conditional approval.  However,  the  biological  plausibility  and  the  clinical  trial  data  from  the  subgroup  are exceptionally strong.
2. -CHMP previously concluded (EMA/CHMP/171026/2019) that the mechanism of action and biological plausibility of using masitinib for treatment of ALS could be considered as demonstrated in preclinical animal  models.  The  assumption  that  a  similar  effect  could  be  translated  into  human  disease  is feasible. Masitinib's mechanism of action in ALS has been well-demonstrated in the preclinical setting using a relevant model that recapitulates the complexity of a multicomponent immune response with concomitant evidence of neurodegeneration [Kovacs 2021; Trias 2020; Harrison 2020; Trias 2018; Trias 2017; Trias 2016].

The clinical trial data from the subgroup are exceptionally strong, for example:

-  Benefit on CAFS

There is a significant effect on CAFS. There is a relative benefit of +20.2% (p=0.0290) in the subgroup. CAFS is a robust statistical measure to assess the superiority of the active treatment arm versus the control.

-  Benefit on PFS

There  is  a  statistically  significant  and  clinically  relevant  improvement  in  PFS  with  masitinib  in  the subgroup, with median increase in PFS of + 9 months (p=0.0057). It is also clinically relevant endpoints and an endpoint in line with EMA guidance on ALS that requires a time to event endpoint.

-  Benefit on overall survival

This survival benefit reported in AB10015 study is obtained in add-on to riluzole, which has been reported to provide a survival benefit of (~3-6 months).

Although  the  study  was  not  powered  for  survival,  with  a  follow-up  of  75  months,  there  was  in  the subgroup  further  enlarged  (+12  months,  p=0.0192)  when  censoring  as  recommended  by  the Rapporteurs the 25 placebo patients who switched to masitinib in open label extension.

<div style=\"page-break-after: always\"></div>

A survival benefit of greater than 4-5 months is considered in principle as clinically significant by the CHMP (EMA/CHMP/487533/2023).

The exclusion of the most severe patients, more frequent in the Masitinib 4.5 mg group led to significant improvement in survival. This shows that severe patients have major contribution to OS analysis.

- b) The replication of subgroup findings has been observed for other relevant clinical trials that have used similar patient enrichment strategies.

Edaravone is approved outside of the EU for the treatment of ALS and has been shown to slow the rate of  functional  decline.  Edaravone  was  not  approved  by  the  EMA,  but,  as  indicated  in  the  EMA documentation (EMA/293450/2019 https://www.ema.europa.eu/en/documents/medicine-qa/questionsand-answers-withdrawal-marketing-authorisation-application-radicava-edaravone\\_en.pdf)

- -Reasons from not approving edaravone were not related to the choice of the study population, in particular the exclusion of patients prior to loss of any function
- -Given the clear need for further evidence of edaravone's effectiveness, the CHMP considered the possibility of a conditional approval. However, there was not agreement between CHMP and the Applicant regarding confirmatory evidence to be provided

The FDA approval of edaravone was based on the outcomes from Study 19 (MCI186-19; clinicaltrials.org, NCT01492686), which was a 24-week, randomized, double-blind, placebo-controlled study.

Conversely, the initial randomized trials of edaravone in ALS (studies MCI-186-16, MCI-186-17, and MCI186-18) all failed to demonstrate a significant difference between treatment arms.

A key difference between the success and failure of these trials was that Study 19 introduced an inclusion criterion stipulating that patients must have a score above 1 on each item of the ALSFRS-R scale. This population has close similarities to that which has been defined for masitinib subgroup analysis, i.e., 'ALS patients prior to any loss of function'. On the contrary, patient cohorts for the failed edaravone studies did not include any eligibility criteria based on disease severity according to remaining functionality on each ALSFRS-R item (see table below).

Study 16 showed a decreased rate of decline in ALSFRS-R score in the edaravone group versus the placebo group, but the difference was not statistically significant. The statistically significant findings in Study 19, which had a more homogeneous population with less severe disease at baseline, indicates that heterogeneity in patients' baseline characteristics were major factors for the initial study failures. Put another way, the lack of significance treatment effect in Study 16 appears to have been due to the broader range in disease characteristics in that study cohort, and particularly the inclusion of patients with more severe disease (i.e., ALSFRSR item scores ≤1).

Hence, the exclusion of patients with more severe disease, for example, patients with complete loss of function on at least one item of ALSFRS-R, has been a critical factor for successful demonstration of edaravone  treatment  effect.  Subgroup  analysis  from  masitinib  study  AB10015  has  shown  the  same pattern, highlighting the importance of such patient enrichment strategies for neuroprotective therapies in ALS.

Table 142: Details of edaravone studies eligibility criteria [CADTH 2019]

|                | Study 16 (MCI186-16)               | Study 17 (MCI186-17)                                    | Study 18 (MCI186-18)               | Study 19 (MCI186-19)              |
|----------------|------------------------------------|---------------------------------------------------------|------------------------------------|-----------------------------------|
| Study Design   | Phase III, DB, parallel- group RCT | Extension phase III study, two arms DB, one arm OL, RCT | Phase III, DB, parallel- group RCT | Phase III, DB, parallel-group RCT |
| Locations      | Japan                              | Japan                                                   | Japan                              | Japan                             |
| Randomized (N) | 206 (one excluded from FAS)        | 206 randomized, 181 participated                        | 25                                 | 137                               |

<div style=\"page-break-after: always\"></div>

|                    | Study 16 (MCI186-16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Study 17 (MCI186-17)                                                    | Study 18 (MCI186-18)                                                                                                                                                                                                                                                                                                                                                                                                  | Study 19                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Inclusion Criteria | At enrolment: • definite ALS, probably ALS, or 'probable ALS - laboratory supported' according to the El Escorial revised Airlie House diagnostic criteria • grade 1 or 2 ALS according to the Japanese ALS severity classification • FVC of ≥ 70% • ≤ 3 years since onset of ALS • age of 20 to 75 years At randomization:                                                                                                                                                            | Completion of Study 16 • • At •                                         | At enrolment: • definite ALS, probably ALS, or 'probable ALS - laboratory supported' according to the El Escorial revised Airlie House diagnostic criteria • grade 3 ALS according to the Japanese ALS severity classification • FVC of ≥ 60% ≤ 3 years since onset of ALS age of 20 to 75 years randomization: a change in ALSFRS-R                                                                                  | (MCI186-19) At enrolment: • definite ALS or probable ALS according to the El Escorial revised Airlie House diagnostic criteria • grade 1 or 2 ALS according to the Japanese ALS severity classification • score of ≥ 2 points on each item of the ALSFRS- R (on each side for 'handwriting' and 'eating motion') • FVC of ≥ 80% (using actual values) • ≤ 2 years since onset of ALS • age of 20 to 75 years At randomization: • a change in ALSFRS-R score    |
| Exclusion Criteria | • Comorbidities that could affect evaluation (e.g., Parkinson's schizophrenia, or dementia) • Renal impairment in the 28 days to the start of treatment • Judged by the investigator to ineligible due to general deterioration due to requiring hospitalization concomitant infections antibiotic treatment • History of hypersensitivity to edaravone • Participation in another clinical study within 12 weeks of enrolment • Otherwise judged by the investigator to be ineligible | efficacy disease, prior be condition complications or requiring • • • • | Decreased respiratory function and a complaint of dyspnea (≤ 3 points on any of the following ALSFRS -R items under 'respiration': dyspnea, orthopnea, or respiratory insufficiency Comorbidities that could affect efficacy evaluation (e.g., Parkinson's disease, schizophrenia, or dementia) Renal impairment in the 28 days prior to the start of treatment Otherwise judged by the investigator to be ineligible | Decreased respiratory function and a complaint of dyspnea (≤ 3 points on any of the following ALSFRS -R items under 'respiration': dyspnea, orthopnea, or respiratory insufficiency Comorbidities that could affect efficacy evaluation (e.g., Parkinson's disease, schizophrenia, or dementia) Renal impairment in the 28 days prior to the start of treatment Otherwise judged by the investigator to be ineligible                                          |
| Exclusion Criteria | • Decreased respiratory function and a complaint of dyspnea (≤ 3 points on any of the following ALSFRS-R items under 'respiration': dyspnea, orthopnea, or respiratory insufficiency • History of treatment for malignancy                                                                                                                                                                                                                                                             | • Undergoing treatment for a concomitant malignancy                     | • Judged by the investigator to be ineligible due to general condition deterioration due to complications requiring hospitalization or concomitant infections requiring antibiotic treatment • History of treatment for malignancy • History of hypersensitivity to edaravone                                                                                                                                         | • History of spinal surgery after ALS onset or plans for spinal surgery during the study period • Current symptoms may be of a disease requiring differential diagnosis (e.g., cervical spondylosis, multifocal motor neuropathy) • Treatment for concomitant malignancy • Previously administered edaravone • Significant complication (grade 3 adverse drug reaction used as reference) • Administered an investigative product within 12 weeks of enrolment |

<div style=\"page-break-after: always\"></div>

## 5) Safety data in the population in the subgroup is improved

The safety of masitinib in ALS is deemed acceptable by the CHMP.

The safety of masitinib is further improved in the claim, as presented in the table below.

- o Reduction of serious AEs from 27.6% to 22.6% vs 16.3% with control arm
- o Reduction of AEs leading to death from 2.9% to 1.2% vs 6.7% with control arm
- o Reduction of severe AEs from 24.8% to 22.6% vs 17.3% with control arm

Table 143: Differential safety overview - Subgroup versus primary analysis population

| [W0 - W48]                          | Subgroup        | Subgroup         | Primary analysis Population (Normal Progressors   | Primary analysis Population (Normal Progressors   |
|-------------------------------------|-----------------|------------------|---------------------------------------------------|---------------------------------------------------|
|                                     | Placebo (N=104) | Masitinib (N=84) | 4.5 Placebo (N=114)                               | Masitinib 4.5 (N=105)                             |
| At least one AE                     | 80 (76.9%)      | 72 (85.7%)       | 88 (77.2%)                                        | 92 (87.6%)                                        |
| At least one serious AE (non fatal) | 17 (16.3%)      | 19 (22.6%)       | 19 (16.7%)                                        | 29 (27.6%)                                        |
| Death                               | 7 (6.7%)        | 1 (1.2%)         | 8 (7.0%) 3                                        | (2.9%)                                            |
| At least one severe AE              | 18 (17.3%)      | 19 (22.6%)       | 20 (17.5%)                                        | 26 (24.8%)                                        |

## Argument 5.7: In  particular  the  data  in  the  subgroup  prior  to  any  complete  loss  of function are extremely compelling including a +12 months benefit

In particular, there is a clear benefit increase in the subgroup, in particular on JTR analysis and OS

- o Primary endpoint: Difference of means =3.13 (p=0.0308)
- o Survival: +12 months median long-term OS (p=0.0192) when censoring placebo patients at the time they switch to masitinib as recommended by the Rapporteurs.

## Argument 5.8: Even  when  accounting  for  fast  progressors,  in  patients  prior  to  any complete loss of function, data remain very compelling

The efficacy in the subgroup remains persuasive when adding fast progressors.

The proportion of fast Progressor was higher in the Masitinib 4.5 group (13/97 = 13.4%) than in the placebo group (11/115 = 9.6%). Other baseline characteristics were balanced between treatment-arms.

A positive differential treatment effect was still observed in this patient population.

In particular, when adding fast progressors, the ALSFRS-R calculated with CAFS, the ALSAQ, the FVC and the PFS showed a statistically significant benefit. The OS benefit remained substantial (+7 to 8 months), and close to significance (p=0.0684) in line with requirements stated on ALS in terms of OS benefit.

Table 144: Differential treatment effect in patients prior to any loss of function (Normal + Fast Progressors

|                  |               |   Patients prior to any loss of function (Normal + Fast) |   Primary Population Progressors) | analysis (Normal   |
|------------------|---------------|----------------------------------------------------------|-----------------------------------|--------------------|
| ∆ ALSFRS-R (CIR) | Diff. of mean |                                                   2.76   |                            2.68   |                    |
| ∆ ALSFRS-R (CIR) | p-value       |                                                   0.0538 |                            0.0462 |                    |

<div style=\"page-break-after: always\"></div>

| CAFS                                                                        | Relative benefit   | 18.4%                          | 14.8%                          |
|-----------------------------------------------------------------------------|--------------------|--------------------------------|--------------------------------|
| CAFS                                                                        | P-value            | 0.0346                         | 0.0776                         |
| ALSAQ-40 (CIR)                                                              | Diff. of mean      | -6.74 [-12.57;-0.91]           | -6.04 [-11.51; -0.57]          |
| ALSAQ-40 (CIR)                                                              | p-value            | 0.0235                         | 0.0305                         |
| FVC (CIR)                                                                   | Diff. of mean      | 7.79 [0.47;15.11]              | 5.85 [-0.98;12.67]             |
| FVC (CIR)                                                                   | p-value            | 0.0369                         | 0.0931                         |
| Median                                                                      | Gain               | + 5 months                     | + 4 months                     |
| Median                                                                      | Median [95% CI]    | 20 [ 14; 30 ] vs 15 [ 11; 19 ] | 20 [14; 30] vs 16 [ 11; 19]    |
| Median                                                                      | p-value log rank   | 0.0183                         | 0.0159                         |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | Gain               | + 8 months                     | + 6 months                     |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | Median [95% CI]    | 46 [ 30; 69 ] vs 38 [ 29; 49 ] | 46 [ 33; 69 ] vs 40 [ 30; 49 ] |
| Median OS (Long-term) (censoring of placebo at time of switch to masitinib) | p-value log rank   | 0.0684                         | 0.0761                         |

The safety of masitinib was also improved in this population of patients prior to any loss of function including fast progressors.

- o Reduction of serious AEs from 31.0% to 26.0% vs 17.4% with control arm
- o Reduction of AEs leading to death from 7.8% to 5.2% vs 7.0% with control arm
- o Reduction of severe AEs from 30.2% to 26.0% vs 17.4% with control arm

Table 145: Differential safety overview - Subgroup versus primary analysis population

| [W0 - W48]                          | Patients prior to any loss function (Normal + Fast)   | Patients prior to any loss function (Normal + Fast)   | of Primary analysis Population (Normal Progressors   | of Primary analysis Population (Normal Progressors   |
|-------------------------------------|-------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                     | Placebo (N=115)                                       | Masitinib 4.5 (N=96)                                  | Placebo (N=133)                                      | Masitinib 4.5 (N=129)                                |
| At least one AE                     | 91 (79.1%)                                            | 83 (86.5%)                                            | 104 (78.2%)                                          | 114 (88.4%)                                          |
| At least one serious AE (non fatal) | 20 (17.4%)                                            | 25 (26.0%)                                            | 24 (18.0%)                                           | 40 (31.0%)                                           |
| Death                               | 8 (7.0%)                                              | 5 (5.2%)                                              | 12 (9.0%)                                            | 10 (7.8%)                                            |
| At least one severe AE              | 20 (17.4%)                                            | 25 (26.0%)                                            | 26 (19.5%)                                           | 39 (30.2%)                                           |

## Argument 5.9:

The Applicant proposes to use label that maximized benefit/risk: in patients prior to any complete loss of function, which might provide a solution not to exclude fast progressors from the label

##  Normal progressors

The Normal progressor population is the primary analysis population.

A claim based on Normal progressors only is acceptable because the study was positive in the preplanned primary analysis population and because:

-  Δ FS is a clinically relevant, independent predictor of survival, capable of distinguishing patient subgroups that have a different course of disease progression.
-  The Δ FS cut-off has a large margin of error of ±20% compatible with clinical practice.
-  Δ FS is a simple-to-use instrument for patient selection, the components of which are measured as part of routine clinical practice.

<div style=\"page-break-after: always\"></div>

##  Patients prior to any loss of function

The distribution of the ALSFRS-R score were unbalanced at baseline on normal progressor, with more severe cases in the active groups, particularly in the Masitinib 4.5 mg group (20%) than in the placebo group (8%).

The exclusion of the most severe patients, more frequent in the Masitinib 4.5 mg group, led to significant improvement across all efficacy endpoints, including survival. Importantly, the safety profile was also improved in these patients. As a result, the benefit -risk balance is improved in this claim.

In addition, treating patients with masitinib prior to any loss of function is more in line with masitinib mechanism of action.

The claim prior to any loss of function is easy to use in clinical practice based on ALSFRS-R assessment and is stable over time

Finally, initiating results in patients prior to any loss of function does not alter generalizability of the trial results, and a claim is this patient population is not expected to restrict access to the treatment.  Indeed, once the drug is commercially available, it is expected that patients will receive treatment shortly after diagnosis. The median time from first symptom to diagnosis being around 12 months [Mitchell 2010; Paganoni 2014], it can be expected that, at the time of treatment start, patients would have 24 months or less of disease duration. In addition, as previously discussed, it is also reasonable to expect at the time of treatment start, most patients would have a score of at least 1 on each of the 12 ALSFRS-R individual component items.

- -The average deterioration on ALSFRS-R score is around 1 point per month [Atassi 2014]
- -The deterioration in ALSFRS-R is approximately linear for each domain over the timeframe of interest, especially for the spinal cohort [Rooney 2017].

Results in patients prior to any loss of functions accounted for 81% of the study population and Fast progressors accounted for 11% of the patients prior to any loss of function, which is in line with the general ALS population.

This claim has therefore greater generalizability than a claim in Normal progressors only and provided greater clinical efficacy together with improved safety.

Figure 18: Disposition of patients in the claim and outside of the claim (M4.5 and placebo)

<!-- image -->

##  Conclusion

AB Science would like to discuss the most appropriate claim with the agency.

<div style=\"page-break-after: always\"></div>

AB Science considers that a claim prior to any loss of function should be favoured because it is more in line with masitinib mechanism of action and because there is an improved benefit/risk in these patients.

In the Scientific advice procedure regarding the design of AB23005 phase 3 masitinib confirmatory study (EMADOC-360526170-1973369),  the  scientific  advice  working  party  (SAWP)  confirmed  that:  ' The Applicant intends to include patients with definite or probable diagnosis of ALS (defined by the revised El Escorial criteria), prior to complete loss of function in any individual component of the ALSFRS-R at baseline in study AB23005 […]. Such population restriction is in principle acceptable '.

## Argument 5.11:  Qalsody introduced post hoc covariates to optimize statistical data and CHMP registered Qalsody

The position adopted by the CHMP for Qalsody shows that post hoc analysis can be acceptable.

EMA registered  Qalsody  with  the  EPAR  showing  that  the  sponsor  amended  its  SAP  once  data  were unblinded  and  introduced  new  covariates,  NfL  and  riluzole/edaravone  interactions,  leading  to  an improvement in statistics data on which EMA relied to conclude that NfL predicts some clinical benefit.

## CHMP position on the Ground for re-examination

Overall, the Applicant's responses to the grounds for refusal are excessive and unfocused , presented results lack methodological description and respective data sources are unclear. Several arguments are not deemed relevant for addressing the respective ground for refusal. Arguments relevant to the grounds for  refusal  are  discussed  in  more  detail,  whereas  arguments  not  deemed  relevant  are  listed  for completeness.

The following assessment concerns Ground #2.2: […] the results from the pivotal study AB10015 do not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS.

## 1.  A  statistically  significant  difference  compared  to  placebo  was  not  demonstrated  for  the  primary endpoint in the full study population.

The third amendment of study AB10015 dating from 8 October 2014 introduced a hierarchical testing scheme  with  change  in  ALSFRS-R  in  the  subset  of  'normal  progressors'  as  primary  analysis.  It  is understood that the main concern of this part of the ground for refusal is the post hoc nature of the subgroup analysis of normal progressors, which confers exploratory character to the analysis termed as primary by the Applicant.

An analysis is pre-specified if it is described before any data is seen and preferably (at least in its crucial aspects such as the definition of the primary endpoint and/or the primary population) before the first patient is enrolled. The change of primary analysis population was made after the study was already ongoing (1.5 years after study commencement) when 46 patients including 8 fast progressors could have reached study week 48 (Argument 2.10). According to the GCP Inspection Report, there was a lack of monitoring plan from the beginning of study until 2016, and the amendment in question was done in 2014.Therefore it can be said that the validity (including blinding) and timing of this amendment is questioned, as it was done during an essentially unmonitored part of the study. Functional unblinding cannot  be  excluded  if  changes  are  done  after  the  study  is  already  ongoing.  In  this  particular  case, functional  unblinding  cannot  be  ruled  out  in  the  view  of  the  different  safety  profiles  of  Masitinib  AB Science  and  placebo  arms. The  considerable  impact  of  the  change  in  study  population  on  the  study outcomes (i.e. on the formal 'success' of the study) raises further concerns. It should be noted that, when a submission is based on only one pivotal (ie. confirmatory) study, this has to be particularly compelling with respect to internal and external validity, clinical relevance, statistical significance, data quality and internal consistency (CPMP/EWP/2330/99).

Reducing heterogeneity of the study population was given as a justification for this approach in the initial

<div style=\"page-break-after: always\"></div>

assessment. Indeed, the guideline on the investigation of subgroups in confirmatory trials, EMA/CHMP/539146/2013,  clearly  outlines  that  consideration  on  the  heterogeneity  within  a  target population should be done but also outlines that this should be done during the planning of a clinical trial. Thus, it is expected that the choice of the study population for a confirmatory trial is made before study begin based on data from prior studies.

Consequently, the change in primary analysis population is deemed post hoc , and the ITT population (normal + fast progressors) is viewed as a primary efficacy analysis population.

For the question of prespecification, discussion of

· the approval of the investigators and ALS experts on the change of primary endpoint (Arguments 2.2 and 2.3),

- the expected amount of missing values in the excluded patients (Argument 2.4),
- the feasibility of the initially defined analysis in terms of statistical power (Argument 2.5),
- the validation of the third amendment by the competent authorities (Argument 2.6),
- the commonness of protocol amendments during the enrolment period (Arguments 2.7, 2.8),
- whether  excluding  the  patients  who  had  reached  study  week  48  at  the  time  of  the  third amendment changed the results for the population of normal progressors (Argument 2.11) and
- whether  the  interim  analysis  was  positive  in  the  total  study  population  (normal  +  fast progressors) (Argument 2.12)

is considered irrelevant for the acceptability of the change in the primary efficacy population. Whether the change was recommended / endorsed by investigators, ALS experts or competent authorities does not affect acceptability of the change in the primary efficacy population (Arguments 2.2, 2.3 and 2.6). The expected amount of missing values in the excluded patients and the un feasibility  of  the  initially defined analysis in terms of statistical power and sample size (Arguments 2.4 and 2.5) do not imply that this  change in the primary efficacy population is acceptable (although it may trigger a more careful definition of target population in a future trial). The commonness of protocol amendments during the enrolment period as illustrated by examples of other drug development programs (Arguments 2.7 and 2.8) does also not justify the acceptability of the amendment. Furthermore, it is reiterated that each MAA is evaluated on its own merits. Results from subgroup analysis (Argument 2.11) or interim results (Argument 2.12) cannot justify the acceptability of a change in the primary efficacy population.

Study AB10015 used a group-sequential design with one interim analysis to be performed at significance level 0.0311 (Pocock spending function) when about 50% of patients were randomized. Results from the interim  analysis  had  been  submitted  for  the  preceding  MAA  (EMEA/H/C/004398/0000).  The  current submission focuses on the results from the last planned analysis. The Applicant reports that as the interim analysis was successful in their opinion, the updated analysis was performed at 5% level of significance.  This  approach  is  not  agreed  to.  Effect  estimates  from  the  updated  analysis  should  be accompanied by repeated confidence intervals, assuring that the simultaneous coverage probability is maintained at 95%. These repeated confidence intervals would be wider than the currently provided naïve 95% confidence intervals. Moreover, it remains unclear from the submitted data, whether the interim analysis can be confirmed to have been successful.

To conclude, the post hoc change in the primary efficacy population from full study population to normal progressors only is not acceptable. The ITT full study population (normal + fast progressors) is viewed as a primary efficacy analysis population.

2. The approach to categorize the population into normal and fast progressors is not supported.

<div style=\"page-break-after: always\"></div>

Reference to other clinical trials (Argument 3.1) in ALS is not considered supportive of the use of ∆FS to define  normal  and  fast  progressors,  as  they  either  do  not  constitute  regulatory  precedence  in  the treatment of ALS (beta hydroxybutyrate ester, bosutinib, edaravone, high-caloric fatty diet, lenzumestrocel, methylcobalamin, nitrazine, NurOwn, rasagiline, ravulizumab) or in the case of Qalsody (tofersen)  (also  Argument  3.8)  use  different  parameters  for  the  categorization  of  patients  (different cutoff: Δ FS of 0.9 per month, plus mutation type and SVC cutoff) as compared to study AB10015. In general, reference to the assessment of study conduct in other procedures is inappropriate, as each product's  benefit-risk  needs  to  be  assessed  individually  and  comparative  assessment  of  different applications cannot be done as there are multiple factors affecting the benefit-risk evaluation for each application. In any case, the table provided by the Applicant for Argument 3.1 illustrates that the criteria for categorization of progressors in clinical trials vary widely across the trials in terms of cut-offs, periods of observation (n-weeks period, from onset) and definition of categories (normal, intermediate, fast). The selected cut-off of 1.1 points/month appears arbitrary and has not even been used in any other study presented by the Applicant.

The Applicant presented studies evaluating the utility of the Δ FS as a prognostic factor, mainly referring to Requardt et al 2021 and Kollewe et al 2008 (Argument 3.2). Both have limitations in terms of defining cut-off  values  and  time  measurements.  It  cannot  be  agreed  that  the  definition  of  fast  progressors measured from onset of symptoms is a highly robust, independent prognostic predictor of survival. More importantly, as shown by Requardt et al 2021, (Arguments 3.2+3.4) Δ FS is not stable throughout the course of disease. This was also not disputed by the Applicant, stating that Δ FS is a timeframe dependent parameter and patients frequently switch between Δ FS categories over time, hence the use of post-onset (early  slope) Δ FS  (as  opposed  to  interval/late  slope Δ FS).  However,  CHMP's  concerns  of  previous assessments are upheld due uncertainties regarding the retrospective determination of exact timing of symptom onset, despite a new publication by Ludolph et al 2024, claiming that post-onset Δ FS is derived from information routinely collected as part of standard patient care and monitoring (Argument 3.7). It can still not be excluded that items on the ALSFRS-R may not be recorded at all, and/or that the exact timing of symptom onset cannot be reliably determined retrospectively at some centers. The timeframe dependency of Δ FS is also highlighted by Kollewe et al 2008, as varying median Δ FS are calculated, depending on the timeframe considered: 1.0, 1.185 and 0.65 for Δ FS calculated from first symptom to time of diagnosis, Δ FS calculated over the whole course of disease (i.e., from first assessment until last assessment prior to death or tracheotomy), and Δ FS calculated within a defined period of 100 days, respectively. While the ethical concerns of an untreated lead-in period to assess the Δ FS within a defined period of 100 days are understood, rejecting this option due to 0.65 being very dissimilar to 1.185 (Argument 3.3) is considered arbitrary.

Sensitivity analyses showed that the difference in ALSFRSR (∆LSM) between Masitinib AB Science 4.5 mg/kg/d  vs  placebo  was  statistically  significant  (p&lt;0.05)  up  to  a  ∆FS  cut -off  of  1.4,  and  that  the difference  tends  to  increase  by  lowering  the  ∆FS  cut -off  (Argument  3.5).  The  relevance  of  this observation for applying the proposed 1.1 cutoff remains unclear. In fact, this observation may rather suggest there is no scientifically sound rationale for the selected 1.1 cutoff. Based on further analyses investigating the margin of error associated with accuracy on the date of first symptoms the Applicant concludes that the possibility of misclassification is marginal (Argument 3.6). Again, the relevance of these exploratory analyses, which use arbitrary cut-offs throughout, is unclear.

Taken together, none of the Applicant's arguments can alleviate the concern to categorize the population into normal and fast progressors. The previous CHMP opinion is upheld.

3. Considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition of intercurrent events in J2R strategy are not considered acceptable.

<div style=\"page-break-after: always\"></div>

The SAP dating from 16 March 2017 was finalized after performing the interim analysis on 10 March 2016 and after submitting this interim analysis in the course of the MAA for Alsitek (EMEA/H/C/004398/0000). In particular, only the methods listed in the protocol can be considered to have been prespecified.

When thinking about how to handle  missing  values  due  to  treatment  discontinuation  there  are  two aspects which need to be discussed. First, the estimand of primary interest needs to be defined, including the strategy for handling the intercurrent event of treatment discontinuation. Subsequently, it needs to be decided which analysis methods best approximate this estimand.

It is agreed with the previous view of the CHMP that for study AB10015 an estimand using a treatment policy strategy for treatment discontinuation is of primary interest from the regulatory perspective as it represents the treatment difference observed in practice. In contrast, applying a hypothetical strategy would result in an estimand not reflecting clinical practice, assuming that patients do not discontinue treatment  (see  the  ICH  E9  R1  addendum,  EMA/CHMP/ICH/436221/2017).  Ideally,  all  patients discontinuing treatment would have stayed in the study and data would have been collected also after treatment discontinuation, allowing to target the estimand of primary interest by an analysis using all observed data. It is agreed with the CHMP that the jump-to-reference (JTR) approach is suitable for approximating the values after treatment discontinuation if they had not been observed. As cited by the Applicant, JTR might be seen as extreme in some situations (Argument 4.6), but is considered plausible in  the  present  context.  Moreover,  all  other  employed  methods  are  considered  to  be  potentially anticonservative.

The mLOCF approach defined as primary analysis by the Applicant (Argument 4.2) imputes missing values due to discontinuation for toxicity or lack of efficacy as the last observed change from baseline. Given the progressive nature of ALS, this strategy is suspected to strongly overestimate the unobserved outcome of patients and consequently gives an overly optimistic estimate for the treatment effect as there were substantially more discontinuations due to toxicity or lack of efficacy in the masitinib arms compared to the placebo arm. The Applicant acknowledged that the mLOCF approach is not the most appropriate method to address missing data (Argument 4.2).

The  cluster-based  imputation  relying  on  copy-increment  from  'similar'  patients  does  not  target  the estimand of primary interest but might approximate a hypothetical strategy for the intercurrent event discontinuation (Argument 4.3), which is of minor relevance as pointed out above.

It  is  understood from the SAP that the tipping point analysis applies a similar type of penalty to all discontinued patients, independent of the treatment arm. Thus, it does not even seem to be clear that a larger penalty necessarily leads to a smaller estimated treatment effect, as would generally be expected from  a  tipping  point  analysis.  Consequently,  the  tipping  point  analysis  provided  by  the  Applicant (Argument 4.11) is considered of little value. The Applicant cited the SAWP to have stated that 'a tipping point analysis is a valid approach to handle missing data'. While this statement can be agreed to in general, it could not be found in the final letter of the cited procedure.

The copy-increment in reference approach (Argument 4.11) would approximate the estimand based on the treatment policy strategy if it could be assumed that after discontinuation the deterioration speed will become similar to that of the reference arm but that the patient will still benefit from the initial slower deterioration and that loss of that treatment effect after discontinuation is unlikely. However, the action of Masitinib as disease modifying agent is not considered sufficiently substantiated. The argument that the observed lag time of efficacy is compatible with Masitinib AB Science being a disease modifying medicinal product (Arguments 4.28 and 4.30) is not considered convincing.

In addition to the listed shortcomings, the mLOCF approach, the cluster-based imputation and the tipping point  analysis  are  implemented  as  single  imputation  methods,  which  might  bias  the  standard  error

<div style=\"page-break-after: always\"></div>

downwards by ignoring the uncertainty of imputed values. As explained in the Guideline on Missing Data in Confirmatory Clinical Trials (EMA/CPMP/EWP/1776/99 Rev. 1) confidence intervals for the treatment effect calculated using single imputation methods may be too narrow and give an artificial impression of precision that does not really exist. There is not enough information on the copy-increment in reference approach to know whether it was implemented as single or multiple imputation approach. Generally, the documentation lacks details on the multiple imputation methods.

The Applicant's reasoning that the tipping point analysis and the copy-increment in reference approach were recommended in this form by the CHMP cannot be followed (Argument 4.12). The final letter for the protocol assistance procedure from September 2018 does neither discuss the tipping point analysis nor the copy-increment approach. Furthermore, the applicant refers to the D150 JAR of the preceding MAA ('Alsitek'), but D150 JAR are not consolidated by the CHMP and there was no recommendation with regard to tipping point analysis or copy-increment in reference approach in the respective consolidated D180 LoOI.

The Applicant suggests that missing values associated with discontinuation due to travel, cancer, death, non-compliance, being fed up with study procedures and protocol deviations should be assumed to be missing at random (Argument 4.5, Argument 4.10), which can be understood to reflect a hypothetical strategy assuming that these events had not occurred. However, an estimand based on the treatment policy strategy for discontinuation due to any reason is considered to better reflect what to expect in clinical practice and is thus of primary interest from a regulatory perspective. Moreover, it is considered infeasible to reliably decide whether a patient's discontinuation was related to the study drug or not. A statistical approach based on model fit is not an appropriate method for deciding on the missing data mechanism or selecting strategies to address intercurrent events (Argument 4.7). Further, the details and purpose of the model-fit analysis are unclear. Typically, the AIC is used to compare models with different covariate sets. In the analysis presented by the Applicant the models seem to differ in the definition of the dependent variable. It is unclear how the AIC can be used for a comparison of models with different dependent variables.

Besides, death should have been handled as a separate intercurrent or rather terminal event. Neither the treatment policy strategy nor the hypothetical strategy can be reasonably applied to death. One option might be to use a composite strategy, for instance setting the ALSFRS-R values at study week 48 for deceased patients to zero as implemented for the mLOCF approach. However, as there is no single adequate approach for the handling of the terminal event death, it is difficult to decide post hoc which method to apply. The number of deaths was similar between the treatment arms in the main study period.

Consequently, applying the JTR approach to all values which were missing due to discontinuation of treatment independent of the underlying reason is considered the most relevant analysis. The Applicant argues that this 'full JTR' approach in the normal progressors exhibits a trend towards benefit (Argument 4.8) but fact is that this approach did not demonstrate superiority of Masitinib AB Science against placebo with a point estimate of 2.31 and 95% confidence interval of (-0.17; 4.80). Of note, repeated confidence intervals should have been provided which would be even wider. Further, when a submission is based on only one pivotal (ie. confirmatory) study, this has to be particularly compelling with respect to internal and external validity,  clinical  relevance,  statistical  significance,  data  quality  and  internal  consistency (CPMP/EWP/2330/99).

As discussed above, applying the JTR approach only to a subset of discontinued patients (Argument 4.9) is not considered to provide relevant information.

The Applicant clarified that in the JTR analysis provided with the last responses, imputation of missing data after discontinuation for reasons other than lack of efficacy or toxicity did not rely on the mLOCF approach but on copy increment from 'similar' patients (cluster-based imputation) (Arguments 4.3, 4.4).

<div style=\"page-break-after: always\"></div>

However, cluster-based imputation is not considered to give a realistic estimate for the disease course after discontinuation, i.e. is not considered suitable for targeting the treatment policy strategy.

The Applicant also provided additional analyses using different imputation strategies for the secondary variables  ALSAQ-40  and  FVC  (Argument  4.14).  Again,  using  JTR  for  all  missing  values  caused  by discontinuation ('full JTR' termed by the Applicant) is considered the most appropriate strategy. It is unclear whether this method is among the provided analyses, as 'MI+JTR' might as well refer to applying JTR to all missing observations or only to the missing values considered to be MNAR. Regardless, both secondary endpoints are of supportive nature and cannot compensate for a failed primary endpoint.

The precedent of the marketing authorisation for Qalsody discussed by the Applicant (Argument 4.31) is acknowledged however it should be noted that every MAA is assessed on its own merit, based on the totality of the data presented in the application, in support of the claimed indication.

The focus of this ground for reexamination was the handling of missing values. Thus, a discussion of

- whether the quantity of missingness is in line with other studies (Argument 4.1),
- the relevance of a p-value of 0.07 observed for CAFS (Argument 4.13),
- the results of secondary endpoints independent of imputation strategies (Arguments 4.15, 4.16, 4.18, 4.19, 4.20),
- the robustness of progression-free survival (Argument 4.17),
- the reasons for unavailability of measurements of muscle strength within trial AB10015 and the level of importance of this parameter (Argument 4.21),
- why there was no effect observed for tracheostomy-free-survival (Argument 4.22),
- the resolution of the issue of unavailability of results for tracheostomy-free-survival at D120 (Argument 4.23),
- the robustness, relevance and unbiasedness of overall survival (Arguments 4.24 and 4.25),
- the consistency between ALSFRS, PFS and OS (Argument 4.26),
- the lack of treatment alternatives for ALS (Argument 4.27),
- the plausibility of the delayed treatment effect (Argument 4.29),
- the general experience of practitioners with masitinib (Argument 4.32) and
- the general opinions of patient associations with regard to masitinib (Argument 4.33)

is considered to be out of the scope of this ground because none of the above arguments discuss the Applicant's  strategy  for  handling  the  intercurrent  event  of  treatment  discontinuation  including  the approach(es)  to  handle  missing  data  and  the  appropriateness  of  the  underlying  assumptions  on missingness patterns inherent to the chosen methods.

Regarding Argument 4.1, whether the quantity of missingness is in line with other studies is not relevant for the discussion on the strategies for handling the intercurrent event of treatment discontinuation and methods to handle missing data. However, the high discontinuation rates and large amount of missing data makes inference very sensitive to imputation assumptions and techniques used. In other words, the impact of an inappropriate selection of methods on handling missing data on the validity of the results is higher due to the large amount of missing data.

The discussions on the results of secondary endpoints independent of imputation strategies (Arguments 4.13, 4.15, 4.16, 4.17, 4.18, 4.19, 4.20, 4.22, 4.26), overall survival (Arguments 4.24, 4.25, 4.26) are

<div style=\"page-break-after: always\"></div>

not discussing the Applicant's strategy for handling the intercurrent event of treatment discontinuation including  the  approach(es)  to  handle  missing  data  and  the  appropriateness  of  the  underlying assumptions on missingness patterns inherent to the chosen methods. Thus, are not relevant for the assessment on whether this ground for refusal is solved or not.

Same applies to the other arguments potentially relevant for the efficacy in the context of this MAA (Arguments 4.21, 4.23, 4.29) or completely out of the scope of a discussion of a B/R balance (Arguments 4.27, 4.32, 4.33).

In  summary,  the  estimand  based  on  the  treatment  policy  strategy  for  missing  values  caused  by discontinuation due to any reason is the preferred one from a regulatory perspective. Furthermore, it is agreed with the previous assessment that this estimand is best implemented using the jump-to-reference approach. Based on this approach already the provided naive 95% confidence interval included zero for the analysis population of 'normal progressors'. As discussed above, repeated confidence intervals should have been provided, maintaining the simultaneous coverage probability taking into account the interim and  the  final  analysis.  The  repeated  confidence  interval  would  be  even  wider  than  the  provided confidence interval. The previous CHMP opinion is upheld.

## 4 . The strategies to post hoc identify new target populations ('M4.5 with ≥2 on each baseline ALSFRS -R item and ΔFS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1) are considered as data driven decisions and are, therefore, not acceptable.

The Applicant showed an imbalance of distribution and baseline data in the subset of patients of normal progressors (for a discussion on the subgroup of normal progressors see Ground #2.2. above) with at least one loss of function ('very severe' ALS, i.e. score of 0 on at least one ALSFRS-R item), and presented modified  baseline  data  excluding  this  subset  as  'new  data'  (Argument  5.1).  However,  the  observed imbalance is not surprising, as no stratification was implemented to account for this post hoc identified predictive  factor,  which  was  also  pointed  out  by  the  Applicant,  and  does  not  justify  the post  hoc modification of the analysis population. In principle, since these results are post hoc analyses and derived from a highly selected patient population, they have a high probability of being chance findings and not deemed confirmatory. Nevertheless, even if the definition of the new target population was deemed appropriate (which it is not), the efficacy in the proposed severity subgroup (prior to any loss of function) is only improved for OS (Argument 5.7), but not for the primary endpoint, for which the efficacy is similar to  the  normal  progressors  analysis  population,  questioning  the  biological  plausibility.  The  Applicant provided further post hoc analyses compiling yet another subgroup, claiming that with fast progressors included, the proposed severity subgroup still shows a treatment effect and improved safety (Argument 5.8). Only the post hoc exclusion of 'very severe' ALS patients allows - in the view of the Applicant - an extrapolation  from  normal  to  fast  progressors  (Argument  5.9).  These  analyses  suffer  from  similar shortcomings  as  the  subgroup  analysis  of  patients  prior  to  any  loss  of  function  and  are  thus  not considered relevant for the overall conclusion.

Even if the proposed population restriction may be acceptable to enrich a population in a future clinical trial, the post hoc analyses in study AB10015 are at best exploratory and would need confirmation in another RCT. Moreover, the proposed indication to only include ALS patients prior to any loss of function may not be practicable in clinical routine, as treatment with Masitinib AB Science would have to be stopped in a patient with any loss of function while on treatment. However, no stopping rules are foreseen in the proposed SmPC for Masitinib AB Science.

For a subgroup to be considered credible within the scope of Section 5.3. Assessment scenario 2 of EMA/CHMP/539146/2013 (Arguments 5.2-5.6), several criteria need to be fulfilled (see below). However, there  is  no  convincing  external  evidence  that  the  subgroup  of  interest  is  well-defined  and  clinically relevant, and there is no replication of subgroup findings from other relevant trials. Furthermore, the biological plausibility is not considered exceptionally strong. The fact that there is only one pivotal trial,

<div style=\"page-break-after: always\"></div>

which is not considered to yield compelling results, only adds to the uncertainties related to efficacy results, hampering a conclusion of true benefit.

The Applicant provided detailed explanations (Argument 5.6) why the five criteria apply for the subgroup to  be  considered  credible,  which  is  not  agreed  by  CHMP,  since  not  all  criteria  are  fulfilled:  (1)  The subgroup definition of very severe ALS is of debatable clinical relevance, as the external evidence is based on post hoc analyses of the edaravone MCI 186-16 trial, incorporated as inclusion criteria in the MCI  186-19  trial.  Both  trials  used  LOCF  as  imputation  method,  which  may  be  considered  overly optimistic. Furthermore, the analysis population differed in other aspects from study AB10015 (%FVC, disease duration). The main focus of Meier et al 2022 was to facilitate assessment of the ALSFRS-R, rather  than  demonstrating  clinical  relevance  or  predictive  value  of  individual  scores.  (2)  The pharmacological rationale for differential efficacy in less severely affected patients appears plausible. Masitinib acts on the innate immune system and not on neuronal function per se. Therefore, neuronal loss cannot be reversed by treatment with masitinib. (3) The larger treatment effect in the subgroup cannot be confirmed from the provided tables and figures with certainty as the details of the underlying analyses  are  insufficiently  described.  However,  the  previous  opinion  that  the post  hoc enrichment strategy based on survival data is deemed inappropriate, is upheld. (4) Replication of subgroup findings from other relevant trials (i.e. trials investigating the efficacy of masitinib) is currently not available. The biological plausibility is not exceptionally strong as it is only established in preclinical studies. Therefore, clinical  trial  data  from  AB10015  suggesting  improved  efficacy  in  some  endpoints  in  the  subgroup  is considered a circular argument. (5) Whether the safety data in the subgroup is improved cannot be concluded with certainty, as the safety data may not be of sufficient quality due to reporting issues (see Ground #2.1).

It is reiterated that reference to other procedures (Argument 5.11) is inappropriate, as each product's benefit-risk  needs  to  be  assessed  individually  and  comparative  assessment  of  different  applications cannot be done as there are multiple factors affecting the benefit-risk evaluation for each application.

Taken together, the post hoc identification of the target population 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1 of the SmPC, is considered data driven and exploratory. Moreover, the proposed indication to only include ALS patients prior to any loss of function may not be practicable in clinical routine, as treatment with masitinib would have to be stopped in a patient with any loss of function while on treatment. The previous CHMP opinion is upheld and no amendments to the B/R are necessary.

In  the  latest  stage  of  the  assessment,  the  Applicant  proposed  a  new  claimed  indication  as  follows: ' Masitinib, in combination with riluzole, is indicated for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) '. Therefore, in light of the latest claimed indication, this subitem of the ground 2.2 becomes obsolete and is not further pursued.

## Overall conclusion of Ground 2.2

The overarching ground for refusal (#2.2) was that the results from the pivotal study AB10015 do not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS. It is not agreed that normal progressors constitute the primary analysis population, the ITT full study population (normal + fast  progressors) is considered the primary efficacy population. The categorization of the population between normal and fast progressors is not agreed. The approach to handle missing data due to the intercurrent event treatment discontinuation is not agreed as it does not address the estimand of primary interest from regulatory perspective. The post hoc identification of the target population initially proposed for  section 4.1 of the SmPC is considered data driven and not acceptable. However, in light of the latest claimed indication, this last point is not further pursued.

Given that all the other points of ground 2.2 remain unsolved, the overarching ground 2.2 remains

<div style=\"page-break-after: always\"></div>

unsolved.

## Point not resolved

## 5.1.4. Ground #3

A  CMA  requires  that  all  requirements  as  described  in  Article  4  of  Commission  Regulation  (EC)  No. 507/2006 are met. In addition to not fulfilling the first criterion, which relates to the positive benefit / risk  balance,  also  other  CMA  criteria  are  not  considered  fulfilled:  it  is  considered  unlikely  that  the Applicant will be in a position to provide comprehensive clinical data post-authorisation, the Applicant has not sufficiently  justified  that  Masitinib  AB  Science  would  provide  a  major  therapeutic  advantage versus tofersen and, taking all the above into account, it is considered that the benefits to public health of the immediate availability of Masitinib AB Science do not outweigh the risks inherent in the fact that additional data are still required.

## Applicant´s position on the for re-examination

The Applicant presented first some statements included in section 2.6.6 of the CHMP AR.

## 1. It is considered unlikely that the Applicant will be in a position to provide comprehensive clinical data post-authorisation

As per the requested CMA, the Applicant initially presented study AB19001 as proposed specific obligation that would provide comprehensive evidence on efficacy and safety of Masitinib AB Science post approval. […].

During the procedure, the Applicant stated that the enrolment in study AB19001 has been slow due to the restrictive design features of that study (i.e. long 3 months run-in period, with no control of FVC at baseline / Moderate ALS only / approved treatment in the USA - Edaravone, Relyvrio - not allowed / blinded extension at week 48). Consequently, the Applicant proposed to conduct a new confirmatory study post approval - AB23005 study- and presented the AB19001 study as an exploratory study.

Study AB23005 is a multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to evaluate the efficacy and safety of masitinib as add-on therapy in ALS patients treated with standard of care. Patients will be randomized (1:1) to receive Masitinib AB Science 4.5 mg/kg/day or matching  placebo  and  Masitinib  AB  Science  6  mg/kg/day  will  not  be  pursued  further  in  the  study AB23005. The primary endpoint is the absolute change in ALSFRS-R from baseline to week 48. In this study, the secondary endpoints include measurements of muscle strength, progression free survival and overall  survival.  According  to  the  synopsis  of  the  study  provided  during  the  procedure,  the  primary efficacy population will be the ITT (all randomized full study population). The Applicant specifies two measures of ALSFRS-R progression rate (point/month) will be evaluated at screening to categorize ALS patient as slow, moderate, or fast progressor. As per the inclusion criteria, only patients with a ALSFRSR progression rate between &gt; 0.3 and &lt;1.1 point/month as measured between onset of the disease and screening AND as measured by any available ALSFRS-R assessment during the period ranging from 7 months to 2 months prior to screening and screening, reassessed and documented by certified rater performing ALSFRS-R assessment from screening visit onward will be enrolled (synopsis of AB23005 protocol). Further restriction is included as per the baseline ALSFRS-R scores as a total score of at least 15 points of ALSFRS-R at baseline and screening [at least 3 in item3; at least 2 in item12; at least 1 in each of the other items] is also requested as inclusion criterion. All aforementioned considerations on using delta FS to select study population are also applicable here. While no further categorization is proposed to be done after enrolment (i.e. primary efficacy population is full study population), it is considered that the mentioned inclusion criteria could lead to the inclusion of a restricted ALS population. Moreover, it is considered that a duration of the study AB23005 (48 weeks) might not be long enough

<div style=\"page-break-after: always\"></div>

to generate sufficient data on survival events, which are necessary to support the primary endpoint and considering that the positive data on survival or survival equivalent are expected.

Besides to the above considerations on the study design features and the potential impact on the ability of Study AB23005 to provide comprehensive evidence, the CHMP was concerned about the feasibility to properly conduct that study if Masitinib AB Science is authorised in the EU. It needs to be bear in mind that ALS is a fatal condition for which the only therapeutic options in the EU are symptomatic treatment and riluzole for all ALS patients except those with SOD1-ALS. Hence, the CHMP is concerned that the authorisation of Masitinib AB Science will impact the recruitment and the conduction of the AB23005 study in the EU sites as ALS patients will likely start (i.e. impact on recruitment) or shift (i.e. impact on conduction) to the commercial Masitinib AB Science when available. The new confirmatory AB23005 study is expected to enrol 408 patients. The Applicant presented a feasibility analysis and concluded that a  total  of  855  patients  could  be  enrolled  over  a  12-month  period  including  583  patients  in  non-EU countries and US. The Applicant claimed that Study AB23005 can be completed within 2.5 years with involvement of site from USA and other non-EU countries or within 3 years with involvement of site only from other non-EU countries. These figures assume the study starts in Q2 2024. Thus, the Applicant position is that confirmatory study AB23005 is feasible outside of the EU and further facilitated since Relyvrio is withdrawn from market in USA and Canada. However, considering the numerous changes undertaken in the protocol of the pivotal study during its execution as well as the slow enrolment in the study AB19001, which became an exploratory study later on, the Applicant capability of properly conduct this study is still unclear, despite the Applicant's declared commitment.

In view of the above, high uncertainties remain with regard to the possibility to provide comprehensive clinical data, should a CMA have been granted.

## AB Science Response

## Argument 6.1:  Confirmatory  study  will  enroll  408  patients  and  feasibility  shows  enrolment  of  583 patients from 62 sites per 12 month period outside of EU countries

Table 146: AB23005 feasibility study for non-EU sites

| Country                |   Sites |   Planned enrolment per month period |
|------------------------|---------|--------------------------------------|
| USA                    |      36 |                                  262 |
| Other non-EU countries |      26 |                                  321 |
| Argentina              |       5 |                                   47 |
| Australia              |       4 |                                   24 |
| Brazil                 |       1 |                                   48 |
| China                  |       3 |                                   75 |
| Israel                 |       2 |                                   20 |
| Japan                  |       2 |                                   11 |
| Russia                 |       1 |                                   24 |
| Saudi Arabia           |       1 |                                   12 |
| Serbia                 |       1 |                                   10 |
| South Korea            |       5 |                                   43 |

<div style=\"page-break-after: always\"></div>

Argument 6.2:  Study AB23005 can be completed within 2.5 years with involvement of site from USA and other non-EU countries or within 3 years with involvement of site only from other non-EU countries

| Ukraine                |   1 |   7 |
|------------------------|-----|-----|
| Total Non-EU countries |  62 | 583 |

Figure 19: AB23005 planned enrolment based on feasibility study

Argument 6.3:  Albrioza is not marketed anymore and other obstacles to enrolment in study AB19001 are removed with AB23005 study design

<!-- image -->

AB Science identified several delaying factors in the study AB19001 that are responsible for this the slow enrolment, and are circumvented with AB23003 study design, namely

- -Absence of 12-week run-in period
- -Enrolment  of  moderate  and  severe  (ALSFRS≥1)  ALS  patients,  as  opposed  to  moderate (ALSFRS≥2) ALS only
- -Albrioza  is  no  longer  marketed,  whereas  AB19001  study  did  not  authorized  concomitant treatment with Albrioza
- -Edaravone will be eligible in the country where it is registered, whereas AB19001 study did not authorized concomitant treatment with Edaravone
- -Authorization of an Open Label Extension beyond week 48, whereas its absence in AB19001 study led certain advocacy groups and patients to boycott study AB19001
- -Absence of investigation of Masitinib 6.0 mg/kg/day group treatment group

## Argument 6.4: The design of the confirmatory study AB23005 has been endorsed by the SAWP

In the Scientific advice procedure regarding the design of AB23005 phase 3 masitinib confirmatory study (EMADOC-360526170-1973369), the scientific advice working party (SAWP) indicated, overall that the

<div style=\"page-break-after: always\"></div>

study design was acceptable from the high-level point of view.

The endorsement of the study design by the SAWP will facilitate the rapid initiation of study AB23005

## 2.The Applicant has not sufficiently justified that Masitinib AB Science would provide a major therapeutic advantage versus tofersen.

The Applicant presented first some statements included in section 3.7.3 of the CHMP AR.

The third criterion requires that unmet medical needs will be fulfilled. As other medicinal products for the treatment of ALS are authorised in EU, the Applicant should justify that Masitinib AB Science provides a major therapeutic advantage (MTA) over each existing authorised medicinal products in an overlapping indication, in case a CMA would be granted. The currently authorised medicinal products for ALS are riluzole and tofersen (the latter, only for SOD1-ALS).

The pivotal study AB10015 of this CMA is a prospective, multicenter, randomised, double-blind, placebocontrolled, parallel groups, phase II/III study to compare the efficacy and safety of Masitinib AB Science versus placebo in ALS patients. The study objective was to evaluate efficacy and safety of Masitinib AB Science as add-on therapy to riluzole. Indeed, all patients included in this pivotal study received riluzole. Hence, this pivotal trial is designed to measure causal effects (efficacy) of Masitinib AB Science on top of Riluzole. If efficacy was demonstrated for Masitinib AB Science on top of riluzole in this pivotal trial, the differences in ALSFRS-R score and survival equivalent (PFS) estimates observed in the pivotal trial in  favor  of  Masitinib  AB  Science  arms  in  principle  could  have  been  considered  as  meaningful improvements of morbidity or mortality of the disease and thus supporting that Masitinib AB Science provides  MTA  versus  riluzole.  However,  as  efficacy  was  not  demonstrated,  it  cannot  be  concluded whether Masitinib AB Science provides a MTA versus riluzole.

On the other hand, the Applicant provided a succinct justification of an MTA over tofersen during the oral explanation. The Applicant claimed that Masitinib AB Science and tofersen have different mechanisms of action. This is agreed; however, a different mechanism of action does not automatically justify for MTA, it needs to be justified that the new mechanism of action provides a significant clinical advantage versus the existing therapies. In accordance with the Guideline on the scientific application and the practical arrangements  necessary  to  implement  Regulation  (EC)  No  507/2006  on  the  conditional  marketing authorisation  for  medicinal  products  for  human  use  falling  within  the  scope  of  Regulation  (EC)  No 726/2004 MTA would normally be based on meaningful improvement of efficacy or clinical safety or, in exceptional  cases,  on  major  improvements  to  patient  care.  Furthermore,  the  Applicant  claimed  that SOD1-ALS represents approximately 2% of people living with ALS. This is also correct, but the MTA needs to be justified in the overlapping indication. Hence, in view of the claimed indication for Masitinib AB Science, it is still the case that the Applicant has to demonstrate that Masitinib AB Science provides MTA versus  tofersen  in  the  SOD1-ALS  subpopulation.  Finally,  the  Applicant  claimed  during  the  oral explanation  that  Masitinib  AB  Science  makes  a  major  contribution  to  patient  care  with  a  benefit  on ALSFRS, QOL, and PFS, OS (+ 12 months).

Based on the above, it is understood the Applicant is claiming MTA based on improved efficacy and major contribution  to  patient  care.  With  regard  to  the  first  claim  (i.e.  improved  efficacy),  it  needs  to  be considered that the pivotal trial did not enroll any patient treated with Qalsody. It is unclear whether SOD1-ALS patients were enrolled at all in the pivotal trial. The Applicant has not sufficiently justified that the  claimed  benefits-  if  finally  accepted  by  the  CHMP-  could  be  extrapolable  to  the  SOD1-ALS subpopulation who could benefit from a more targeted therapy (Tofersen addressed overexpression of SOD1  as  a  key  pathological  mechanism  of  damage  in  SOD1-ALS)  and  thus,  provides  meaningful improvement of efficacy versus tofersen in this ALS sub-population. With regard to the third claim (i.e. major  contribution  to  patient  care),  the  Applicant  has  not  sufficiently  justified  which  is  exactly  the contribution to the patient care.

<div style=\"page-break-after: always\"></div>

## AB Science Response

## Argument  7.1:  Alsitek  (masitinib)  would  provide  a  major  therapeutic  advantage  versus  Qalsody (tofersen) in terms of improvements to patient care

Following the recent approval of Qalsody (tofersen), there is an overlap between Qalsody and masitinib indications,  namely,  the  SOD1-ALS  subpopulation,  which  comprises  just  2%  of  the  overall  ALS population. Because there is no data available for direct, or indirect, comparison of efficacy between masitinib  and  Qalsody,  we  must  instead  consider  other  relevant  aspects,  such  as  patient  burden associated with route of administration, procedural complications and safety concerns.

-  Tofersen is administered directly into the cerebrospinal fluid through intrathecal lumbar puncture and is absorbed by the central nervous system.

A lumbar puncture involves using a long, thin needle to puncture the skin and its underlying structures in the lower back, allowing access to the space surrounding the spinal cord for drug delivery. Antisense oligonucleotide  drugs  do  not  readily  pass  through  the  blood-brain  barrier  and,  as  a  result,  must  be administered directly into the central nervous system (CNS). Before administering a dose of tofersen, it is  recommended to extract 10 mL of cerebrospinal fluid (CSF) from the patient [Cerillo  2023]. This procedure prevents fluid overload and reduces the potential risk of increased intracranial pressure. To administer tofersen in patients, it is recommended to inject the medication slowly for 1 to 3 minutes using the same lumbar needle previously employed for the removal of the CSF.

The  recommended  dosage  of  tofersen  for  adults  is  100  mg  (per  15  mL)  per  administration.  The administration of tofersen begins with 3 loading doses, followed by a monthly maintenance dose. The first 3 doses of 100 mg are administered to patients at 14-day intervals, with subsequent doses provided at 28-day intervals after that [Qalsody SmPC].

Patients may be given a sedative if tofersen administration causes them severe distress [Cerillo 2023]. Lumbar punctures can be uncomfortable procedures and often lead to lower back discomfort, headaches, and dizziness. Imaging techniques, such as computed tomography and ultrasound guidance, may also be used to ensure accurate needle placement and depth during the tofersen administration; however, both measures add further complexity and expense to the procedure or will simply not be available options for all physicians.

The most common adverse effects of tofersen are headache, injection-site pain, fatigue, arthralgia (joint pain), pleocytosis (increase in CSF white blood cells), and myalgia (muscle pain) [Miller 2020; Miller 2022]. Tofersen may also cause more serious adverse events, including:

- -inflammation and damage of the spinal cord and nerve roots (i.e., myelitis and radiculitis)
- -swelling and increased pressure in the optic nerve and brain (i.e., papilledema and elevated intracranial pressure)
- -inflammation of the membranes covering the brain and spinal cord (i.e., aseptic meningitis, also called chemical meningitis or drug-induced aseptic meningitis).

These adverse effects may arise due to direct drug effects or complications related to administering the drug through a lumbar puncture, which introduces foreign materials into the sterile CNS cavity [Cerillo 2023].

The aforementioned clinical trial safety concerns have been reproduced in the real-world setting, with pleocytosis, elevated protein levels and intrathecal immunoglobulin synthesis being common findings in the CSF [Wiesenfarth 2024]. In a cohort of 24 patients with SOD1-ALS from ten German ALS reference centers, pleocytosis was observed in 73% of patients (11 of 15) and an intrathecal immunoglobulin synthesis (IgG, IgM, or IgA) was seen in 9 out of 10 patients. Pleocytosis and Ig synthesis in CSF with

<div style=\"page-break-after: always\"></div>

clinical symptoms related to myeloradiculitis in two patients, indicates the potential of an autoimmune reaction.  The  authors  concluded  that  such  alterations  in  the  CSF  are  suggestive  of  an  autoimmune inflammation of the CNS, which necessitates special attention when treating patients with tofersen.

In conclusion, tofersen treatment comes with considerable patient burden that is primarily related to the monthly intrathecal administration of the drug. This is turn raises questions of patient compliance over the longer-term. Furthermore, adverse effects related to this route of administration can be severe and potentially life-threatening, necessitating an immediate diagnostic workup and prompt medical treatment (if applicable) to aide recovery, with cessation of tofersen dosing thereafter.

For those SOD1-ALS patients that experience serious complications related to administration of the drug, or who find the burden/risk of regular intrathecal lumbar puncture procedures unacceptable, or who are unresponsive to tofersen, there remains an urgent unmet medical need.

-  Masitinib is an orally administered, CNS-penetrative drug, with minimal patient burden or risks associated with its route of administration

Masitinib  is  an  orally  administered,  film  coated  tablet  formulation,  which  can  penetrate  the  CNS  at therapeutically  relevant  concentrations.  In  contrast  to  tofersen,  masitinib  carries  none  of  the  safety complications or patient burden associated with invasive intrathecal lumbar puncture administration. Moreover, masitinib is comparatively simple to take, allowing for convenient, safe and inexpensive selfadministration, outside of the hospital setting, all of which are beneficial for improved patient compliance. Indeed, in the primary efficacy population of study AB10015, mean treatment compliance was 97.9% for masitinib 4.5 mg/kg/day versus 95.6% for active control. This excellent rate of compliance was also seen in the study's overall population, with a mean treatment compliance of 96.8% for masitinib-treated patients versus 95.5% for active control.

Masitinib therefore provides a major therapeutic advantage for all those patients unable or unwilling to take tofersen, for whom, riluzole remains the only available treatment option.

## Argument 7.2: Safety Profile and Autoimmune Reactions

Autoimmune reactions were a significant safety concern in the VALOR study, with approximately 6% of patients experiencing these events. These reactions included:

1. Pleocytosis (10-12%): An increase in white blood cells in the cerebrospinal fluid, sometimes asymptomatic but indicative of central nervous system inflammation.
2. Skin Rashes (4-5%): Mild to moderate erythematous or urticarial lesions.
3. Autoantibody Elevations (3%): Indicative of generalized immune activation, potentially leading to autoimmune conditions.
4. Systemic  Inflammatory  Syndromes  (&lt;2%):  Symptoms  like  fever,  fatigue,  and  joint  pain, requiring immunosuppressive treatment.

During post-marketing surveillance under conditional approval, the frequency of autoimmune reactions remained consistent with VALOR study findings, indicating a persistent risk.

- -Autoimmune reactions are a significant safety concern for several reasons:
- -Chronicity: Autoimmune reactions can be persistent and difficult to manage, potentially leading to chronic conditions that could outweigh the benefits of ALS treatment.
- -Severity: In some cases, autoimmune responses can lead to severe, life-threatening conditions, particularly if they involve the CNS or other vital organs.

Impact on ALS Patients: ALS patients are already in a fragile health state, and the added burden of an autoimmune condition could accelerate disease progression or reduce the quality of life.

In  conclusion,  while  tofersen  shows  potential  benefits  for  SOD1-related  ALS,  the  occurrence  of autoimmune reactions, such as pleocytosis and systemic inflammatory syndromes, raises significant safety concerns while no significant effect on disease progression has been provided so far.

<div style=\"page-break-after: always\"></div>

## Argument  7.3:  Masitinib  has  shown  clinical  and  survival  benefits  that  have  not  been demonstrated for Qalsody

Despite there being no head-to-head trial of masitinib against Qalsody, masitinib has demonstrated both clinical benefit (e.g., Δ ALSFRS-R, Δ FVC and Δ QoL) and survival benefit (e.g., OS, CAFS and PFS) to an extent that has not been demonstrated to date with Qalsody (see table below).

The efficacy of Qalsody has been predominately established on a significant reduction of SOD1 protein in cerebral spinal fluid, a marker of target engagement, and significant reduction of neurofilament light chain  (NfL)  in  plasma,  a  potential  marker  of  disease-modifying  effect.  However,  clinical  progression parameters  such  as  ALSFRS-R,  respiratory  function,  and  quality  of  life  did  not  reach  statistical significance after 6 months. No survival benefit over placebo has been demonstrated for Qalsody.

|                                                | Masitinib (AB1010)                                                                                                                                                                                                          | Qalsody (tofersen)                                                                                                                                                       |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Code                                     | AB10015 (NCT02588677)                                                                                                                                                                                                       | VALOR (NCT02623699)                                                                                                                                                      |
| Number of patients                             | N = 394 (ITT) Placebo = 132 masitinib 3.0 mg/kg/day = 131 masitinib 4.5 mg/kg/day = 128 Patients assessable for the primary endpoint Placebo = 102 masitinib 4.5 mg/kg/day = 99                                             | N = 108 (ITT) Tofersen = 72 Placebo = 36 Patients included in primary efficacy population (mITT) Tofersen = 39 Placebo = 21                                              |
| ALSFRS-R (Primary endpoint)                    | Between group difference at W48 = 3.39 points/mo 95%CI(0.65-6.13); P = 0.016 (masitinib 4.5 mg/kg/d vs placebo)                                                                                                             | - mITT Adjusted mean difference at W24 = 1.2 points/mo (95%CI[-3.2,5.5]); P = 0.9689 - ITT Adjusted mean difference at W24 = 2.1 points/mo (95%CI[-0.3,4.5]); P = 0.5015 |
| CAFS (Secondary endpoint)                      | Between group difference = 14.95; P = 0.0776 (masitinib 4.5 mg/kg/d vs placebo)                                                                                                                                             | Not done                                                                                                                                                                 |
| ALSAQ (Secondary endpoint)                     | ALSAQ-40 LMS Difference = -7.8 [-13.5 ; -2.1], p=0.008 (masitinib 4.5 mg/kg/d vs placebo)                                                                                                                                   | ALSAQ-5 - mITT Adjusted mean difference at W24 = -5.6 95%CI[-15.6,4.4]); P = 0.2715 - ITT Adjusted mean difference at W24 = -5.7 (95%CI[-11.8,0.4]); P = 0.0668          |
| FVC (Secondary endpoint)                       | FVC LMS Difference = 7.5 [0.8 ; 14.3]; p=0.03 (masitinib 4.5 mg/kg/d vs placebo)                                                                                                                                            | SVC - mITT Adjusted mean difference at W24 = 7.9 95%CI[-3.5,19.3]); P = 0.3233 - ITT Adjusted mean difference at W24 = 8.5 (95%CI[1.8,15.2]); P = 0.0689                 |
| HHD Megascore (Secondary endpoint)             | Not done                                                                                                                                                                                                                    | - mITT Adjusted mean difference at W24 = 7.9 95%CI[-0.21,0.26]); P = 0.8390 - ITT Adjusted mean difference at W24 = 0.1                                                  |
| TIME-TO-EVENT (Secondary endpoint)             | PFS Median[95%CI] PBO = 16 months [11;19] M4.5 = 20 months [14;30] Difference = 4 months; p = 0.016 (masitinib 4.5 mg/kg/d vs placebo)                                                                                      | (95%CI[-0.04,0.23]); P = 0.1547 Time to Death or PV Not estimable due to limited number of events                                                                        |
| Overall survival (months) (Secondary endpoint) | OS (Long-term analysis) LT- M4.5 (≥2 each baseline ALSFRS -R item, any Δ FS) - Masitinib median OS = 69 [44;NE] - Placebo median OS = 44 [31;62] - Survival benefit = 25 months; p = 0.037 - HR = 0.56 (95%CI [0.33-0.97]); | OS Not estimable due to limited number of events                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Masitinib (AB1010)                                                                                                                                                                                                                                                                                        | Qalsody (tofersen)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| P=0.037 - 44% reduced risk of death LT- M4.5 (≥2 each baseline ALSFRS -R item, Δ FS<1.1) - Masitinib median OS = 69 [47;NE] - Placebo median OS = 44 [31;62] - Survival benefit = 25 months; p = 0.037 - HR = 0.53 (95%CI[31-92]); P=0.025 - 47% reduced risk of death (masitinib 4.5 mg/kg/d vs placebo) |                      |

## Argument 7.4: Preclinical evidence based on the SOD1 G93A  model has strongly established masitinib's biological plausibility in ALS, with its clinical benefits therefore extrapolatable to SOD1-ALS patients

The  Applicant  confirms  that  no  head-to-head  data  exist  that  would  permit  a  direct  comparison  of masitinib versus Qalsody efficacy in the SOD1-ALS subpopulation. Indeed, no clinical data is available for  masitinib  in  the  SOD1-ALS  subpopulation  as  ALS  genotypes  were  not  assessed  as  part  of  study AB10015. There is, however, a wealth of preclinical evidence based on the SOD1 G93A  model, which has strongly established masitinib's biological plausibility in ALS.

The SOD1 model recapitulates the complexity of a multicomponent immune response with concomitant evidence of neurodegeneration [Kovacs 2021; Trias 2020; Harrison 2020; Trias 2018; Trias 2017; Trias 2016]. Of significance, these data also provide a direct link between SOD1 model-derived evidence and human ALS pathology (with data being derived from ALS patient autopsied quadriceps femoris muscles) [Kovacs 2021; Trias 2018]. This clearly implies that cell targets identified in masitinib preclinical studies are also implicated in ALS human pathology and supports the relevance of masitinib SOD1 model data to human pathology.

Recently generated preclinical evidence further support the mechanism of action of masitinib in ALS. masitinib has been shown to limit neuronal damage in a model of neuroimmune-driven neurodegenerative disease [Hermine 2024], the results of which can be extrapolated to ALS. Neuronal damage, or prevention thereof, can be rapidly assessed by measuring serum neurofilament light chain (NfL) concentration in EAE-induced mice. Results showed that masitinib can significantly lower serum NfL  levels  in  this  neurodegenerative  disease  model,  with  concomitant  reduction  in  pro-inflammatory cytokines and slowing of clinical (EAE) symptoms. The observed NfL treatment response indicates that masitinib  has  a  neuroprotective  effect  under  conditions  of  chronic  neuroinflammation  and  therefore plausible disease-modifying activity in ALS.

Taken together these preclinical findings establish the biological plausibility for using masitinib in ALS and support the hypothesis that masitinib may provide a neuroprotective effect in the clinical setting for both SOD1-ALS and sporadic ALS patients. Likewise, the clinical benefits observed in study AB10015, which was undoubtedly performed in a predominantly sporadic ALS population, are extrapolatable to SOD1-ALS patients.

- -Based  on  the  results  from  study  AB10015,  there  is  evidence  of  clinical  effectiveness  in  the treatment  of  ALS  patients,  with  Masitinib  AB  Science  4.5  mg/kg/day  providing  a  significant increase in efficacy in terms of slowing disease progression such that the overall benefit profile is improved over marketed ALS therapies in Europe. Data also presented an acceptable clinical safety profile in these patients who require effective new therapies for this progressive, lifethreatening medical condition.
- -Based on the long-term survival results from study AB10015, there is promising evidence of clinical effectiveness in the treatment of ALS patients (prior to any complete loss of functionality), with masitinib 4.5 mg/kg/day providing a significant increase in efficacy in terms of reduced mortality when compared to riluzole alone.

Key findings from the rodent SOD1 model studies are briefly described below.

- -Masitinib treatment in post-paralytic SOD1G93A rats [Trias 2016] was shown to modulate the functionality  of  microglia  cells  in  terms  of:  preventing  microglia  proliferation,  migration,  and

<div style=\"page-break-after: always\"></div>

transformation into neurotoxic aberrant glial cells; reducing the number of aberrant glial cells in the  degenerating  spinal  cord;  inhibiting  microgliosis  along  the  degenerating  spinal  cord; inhibiting microglia proinflammatory phenotype; and improving motor neuron pathology.

- -This  modulation  of  microglia  activity  was  also  shown  to  translate  into  a  significant  survival advantage [Trias 2016]. Masitinib treatment initiated at the time of paralysis onset or 7 days after  paralysis  onset  prolonged  post-paralysis  survival  by  35%  and  50%,  respectively,  with respect to the control group.
- -There is massive infiltration and accumulation of mast cells around degenerating motor axons and neuromuscular junctions in SOD1G93A rats with degranulation of mast cells correlating with paralysis progression. This indicates that mast cells may be deleterious for the maintenance of functional  neuromuscular  junctions.  Because  neuromuscular  junctions  serve  as  a  critical  link between skeletal muscles and the nervous system, this finding represents a novel pathogenic mechanism in ALS that can be therapeutically targeted by masitinib [Trias 2017].
- -Masitinib-induced mast cell inhibition significantly reduced the rate of neuromuscular junction denervation and motor deficits in SOD1G93A rats [Trias 2017].
- -Post-paralysis administration of masitinib to SOD1G93A rats, reduced the loss of 2B myofibers isotype in the EDL muscle [Trias 2018], slowing motor function decline [Trias 2017].
- -Masitinib preserved muscle strength as evidenced by a significantly improved latency-to-fall time (inverted screen test) from 5-15 days after onset [Trias 2017].
- -Massive mast cell infiltration was observed in sciatic nerve and ventral roots of SOD1G93A rats during paralysis progression [Trias 2018].
- -Mast cells infiltrate into the degenerating spinal cord of both murine models of ALS and ALS patients [Kovacs 2021]. This phenomenon is accompanied by marked blood spinal cord barrier pathology,  characterized  by  frequent  morphological  abnormalities  such  as  basal  membrane interruptions, strings, and sprouts, allowing the extravasation of cells from blood, including cKit+  mast  cell  precursors.  Post-paralysis  treatment  with  masitinib  for  10  days  significantly reduced the number of c-Kit+ and chymase+ mast cells in the lumbar motor neuron-vascular niche, with respect to the vehicle-treated mice. Also, masitinib-treated animals showed a 3040%  reduction  in  microvascular  abnormalities  relative  to  vehicle-  treated  mice  and  a  50% reduction in the number of c-Kit+ mast cell precursors infiltrating the spinal cord parenchyma. These results are consistent with a masitinib protective effect via c-Kit inhibition, preventing the trafficking of mast cell precursors and mast cell local differentiation in the motor neuron-vascular niche.
- -Neutrophil infiltration and neutrophil extracellular traps (NET) formation was observed in the extensor digitorum longus (EDL) muscle of SOD1G93A rats during paralysis progression [Trias 2018]. Post-paralysis masitinib administration to SOD1G93A rats significantly reduced both mast cell and neutrophil accumulation, as well as motor pathway degeneration [Trias 2018].
- -Schwann cell proinflammatory phenotype is present in both sporadic human ALS subjects and an animal model of ALS. Masitinib treatment in post-paralytic SOD1G93A rats sharply decreased Schwann cell reactivity,  immune  cell  infiltration  and  proliferation  along  the  peripheral  motor pathways [Trias 2020].
- -Masitinib also prevented morphological changes (degeneration) in Schwann cells and capillary networks that are typically observed in advanced paralysis [Trias 2017].
- -Treating SOD1G93A mice with masitinib significantly reduced macrophage infiltration, prevented terminal  Schwann  cells  loss,  and  improved  reinnervation  in  partially  denervated  plantaris muscles  [Harrison  2020].  Results  suggested  that  pharmacological  interventions  maintaining terminal Schwann cells at denervated endplates is a viable treatment strategy to attenuate the loss of motor function in ALS.

## Argument  7.5:  Significant  differences  exist  between  masitinib  and  Qalsody  in  terms  of mechanism of action and principal molecular structure, therefore, masitinib is not a similar medicinal product to Qalsody

As  demonstrated  in  the  Alsitek  (masitinib  mesilate)  Assessment  Report  on  Similarity,  significant differences exist between masitinib and Qalsody in terms of mechanism of action and principal molecular structure, therefore, in accordance with Article 3 of Commission Regulation (EC) No 847/2000, masitinib is  not  a  similar  medicinal product to Qalsody, even though there is overlap between the therapeutic

<div style=\"page-break-after: always\"></div>

indications.  Accordingly,  the  existence  of  any  market  exclusivity  for  Qalsody  in  the  treatment  of amyotrophic lateral sclerosis should not prevent the granting of the marketing authorisation of masitinib. Briefly,

- -The active substance of Qalsody is tofersen, another nervous system drug (ATC code: N07XX22). Qalsody is an antisense oligonucleotide that binds to the mRNA of the superoxide dismutase 1 (SOD1) gene to reduce the production of SOD1 protein. By reducing the amount of defective SOD1 protein,  this  medicine  is  expected  to  improve  the  symptoms  of  ALS.  Qalsody  will  be available as a 100 mg solution for injection and will be given intrathecally by lumbar puncture. Regarding molecular structure, Tofersen, an antisense oligonucleotide, is a 20-base residue (20mer)  5-10-5  MOE  gapmer  mixed  backbone  oligonucleotide.  Of  the  nineteen  internucleotide linkages, fifteen are 3′ -O to 5′ -O phosphorothioate diesters, and four are 3′ -O to 5′ -O phosphate diesters. Ten of the twenty sugar residues are 2-deoxy-Dribose and the remainder are 2′ -O-(2methoxyethyl)-D-ribose (MOE). The residues are arranged so that there are five MOE nucleosides at the 5′ and 3′ -ends of the molecule flanking a gap of ten 2′ -deoxynucleosides. The cytosine and uridine bases are methylated at the 5-position. The molecular formula is C230 H317 N72 O123 P19 S15 and the molecular weight is 7127.86 atomic mass units (amu).
- -The active substance of Alsitek is masitinib mesilate, an antineoplastic or immunomodulating agent, other protein kinase inhibitor drug (ATC code: L01EX06). Masitinib inhibits the activity of specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR- beta), in the sub-micromolar range. Masitinib can also inhibit cellular events mediated by activation of these receptor kinases. It is suggested that masitinib is capable of exerting neuroprotection via selective kinase inhibition that modulates the functionality of different cells implicated in ALS pathogenesis including microglia and mast cells. Masitinib Alsitek is proposed to act by slowing microglial-related  disease  progression,  reducing  neuro-inflammation,  and  modulating  the degenerative  neuronal  microenvironment  in  both  central  and  peripheral  nervous  systems. Regarding molecular structure, masitinib is a small molecule drug, selectively inhibiting specific tyrosine kinases. Masitinib is a 2-aminoarylthiazole derivative, which is a  compound characterized by the presence of a thiazolyl group substituted on position 2 (i.e., between the heterocyclic nitrogen and sulphur atoms) by a secondary or tertiary amine, wherein the nitrogen atom of the amine is substituted by at least one aryl group. The chemical name for masitinib is 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]benzamide,  methane  sulfonic  acid  salt.  The  molecular  formula  is  C28  H30  N6  OS  and  the molecular weight (free base of masitinib) is 498.66 g/mol.

## Argument  7.6:  Concluding  statements  on  major  therapeutic  advantage  over  existing treatments

The efficacy of Alsitek (masitinib) has been demonstrated as an add-on to riluzole, therefore establishing that masitinib provides a major therapeutic advantage over riluzole.

Qalsody  treatment  comes  with  considerable  patient  burden  that  is  primarily  related  to  the  monthly intrathecal administration of the drug. Adverse effects related to this route of administration can be severe  and  potentially  life-threatening,  with  myelitis,  radiculitis,  papilledema,  elevated  intracranial pressure and aseptic meningitis being established risks for Qalsody treated ALS patients.

Pleocytosis and Ig synthesis in CSF are suggestive of an autoimmune inflammation of the CNS, which necessitates special attention when treating patients with tofersen.

For those SOD1-ALS patients that experience serious complications related to administration of Qalsody (tofersen), or who find the burden/risk of regular intrathecal lumbar puncture procedures unacceptable, or who are unresponsive to tofersen, there remains an urgent unmet medical need.

Masitinib would provide a major therapeutic advantage versus Qalsody in terms of improvements to patient  care.  In  particular,  masitinib  addresses  serious  existing  issues  with  Qalsody  treatment

<div style=\"page-break-after: always\"></div>

compliance,  allowing  ambulatory  treatment  instead  of  hospital  treatment,  and  removes  the  safety complications  and  patient  burden  associated  with  monthly  intrathecal  administration  of  that  drug. Furthermore, masitinib has shown no signs of causing autoimmune-related complications.

Despite there being no head-to-head trial against all marketed ALS therapies, masitinib has shown both clinical benefit (e.g., Δ ALSFRS-R, Δ FVC and Δ QoL), and survival benefit (e.g., OS, CAFS and PFS) to an extent that has not been demonstrated to date with other marketed ALS therapies. Moreover, preclinical findings support the hypothesis that masitinib may provide a neuroprotective effect for both SOD1-ALS and sporadic ALS patients. It follows therefore, that the aforementioned clinical benefits observed in study AB10015 should be extrapolatable to SOD1-ALS patients.

Finally, it is also pertinent to emphasis that approximately 98% of the overall ALS population are not eligible for Qalsody.

## CHMP position on the Ground for re-examination

## 1. It is considered unlikely that the Applicant will be in a position to provide comprehensive clinical data post-authorisation.

The Applicant is proposing confirmatory study AB23005 where 408 patients are expected to be enrolled and provided a feasibility analysis which shows potential enrolment of 583 patients from 62 sites over a 12-month period outside of EU countries (USA and non-EU countries) [Argument 6.1]. It is noted that feasibility assessment for some sites appears overambitious having in mind actual enrolment numbers of sites from study AB10015 where most of the 34 sites recruited less than 20 patients. Moreover, the Applicant claimed that study AB23005 can be completed within 2.5 years with involvement of sites from the USA and other non-EU countries or within 3 years with involvement of sites only from other non-EU countries [Argument 6.2]. Obviously, completion of the study depends on recruitment speed, hence, given the ambitious recruitment numbers, this timeline might be challenging. Nevertheless, it is the Applicant's position that recruitment for study AB23005 is facilitated compared to previously planned confirmatory study AB19001, which has been declared supportive due to recruitment issues [Argument 6.3]. Modifications from study AB19001 to AB23005 based on their potential responsibility for the slow enrolment in study AB19001 (i.e. absence of 12-week run-in period, enrolment of moderate and severe (ALSFRS≥1) ALS patients, Albrioza/Relyvrio is no longer marketed but was back then not allowed as ConMed in study AB19001, Edaravone was also not permitted as ConMed ins study AB19001 but will be allowed in study AB23005, authorization of an open label extension beyond week 48 and omission of Masitinib 6.0 mg/kg/day treatment group) appear principally plausible to facilitate recruitment. However, as  already  outlined  in  the  previous  CHMP  AR,  considering  the  numerous  changes  undertaken  in  the protocol of the pivotal study during its execution as well as the slow enrolment in study AB19001, the Applicant's  capability  to  properly  conduct  study  AB23005  is  still  questionable.  Hence,  despite  the Applicant's declared commitment, high uncertainties remain with regard to the possibility to provide comprehensive clinical data.

Furthermore, the Applicant's claim that the design of study AB23005 has been endorsed by the SAWP [Argument  6.4]  cannot  be  confirmed.  There  have  been  two  scientific  advice  procedures  and  one clarification on the design of AB23005, EMA/SA/0000156604 from December 2023, EMA/SA/0000164743 from April 2024 and EMA/SA/0000182621. There, it was repeatedly discouraged, for several reasons, to only enroll patients with an initial disease progression rate of &gt;0.3&lt;1.1 ALSFRSR points per month (i.e. normal progressors).

Moreover, the study duration of study AB23005 of 48 weeks was not considered long enough to provide meaningful  information  on  overall  survival.  In  addition,  the  advice  to  avoid  using  a  minimisation algorithm for randomization was not adhered to. Imputation strategies were only discussed at high level, but are expected to be of particular importance at the time of assessment.

<div style=\"page-break-after: always\"></div>

## 2. The Applicant has not sufficiently justified that Masitinib AB Science would provide a major therapeutic advantage versus tofersen.

The Applicant's argument [Argument 7.1] that Masitinib AB Science would provide a MTA versus Qalsody (tofersen) in terms of improvements to patient care is agreed to. This is mainly based on the route of administration  which,  in  case  of  a  positive  B/R  balance,  would  be  expected  to  provide  major improvements to patient care. While tofersen treatment comes with considerable patient burden that is primarily related to the monthly invasive intrathecal lumbar puncture administration and bears risks of severe and potentially life-threatening adverse effects, Masitinib AB Science is an orally administered, CNS-penetrative drug, with minimal patient burden or risks associated with its route of administration. It is further agreed with the Applicant that Masitinib AB Science is comparatively simple to take, allowing for convenient, safe and inexpensive self-administration, outside of the hospital setting, all of which are beneficial for improved patient compliance. This is reflected in the high compliance rate in the primary efficacy population and the overall study population of study AB10015.

As further outlined by the Applicant, autoimmune reactions were detected in about 6% of patients treated with tofersen [Argument 7.2]. While this is acknowledged and it is agreed that autoimmune reactions bear additional patient burden, this argument is considered less relevant in terms of the MTA discussion, as the majority of these events are linked to the invasive administration route. Indeed, concerning the overall safety profile, AEs related to the administration of tofersen via intrathecal lumbar puncture can be prevented/diminished through oral administration of Masitinib AB Science, which is considered an improvement of patient care (see above).

Since the clinical benefit and survival benefit have not been demonstrated for Masitinib AB Science in the  intended  target  population  (see  GfR#2.2),  the  Applicant's  argumentation  [Argument  7.3],  that Masitinib AB Science has demonstrated both clinical benefit and survival benefit to an extent that has not been demonstrated to date with tofersen is obsolete. Even if deemed positive, there was no headto-head trial of Masitinib AB Science against tofersen and results are not comparable across trials (e.g. PEP/benefit  assessed  at  W48  with  Masitinib  AB  Science  vs.  W24  with  tofersen;  no  data  on  OS  for tofersen).

The Applicant argues [Argument 7.4] that pre-clinical data from SOD1G93A and EAE models support the hypothesis that Masitinib AB Science may provide a neuroprotective effect in the clinical setting for both SOD1-ALS and sporadic ALS patients. However, this argument is deemed irrelevant for the question of whether efficacy results in all ALS patients are extrapolatable to ALS patients with SOD1 mutations. In fact,  no  clinical  data  are  available  for  Masitinib  AB  Science  in  the  SOD1-ALS  subpopulation,  as  ALS genotypes were not assessed as part of study AB10015. Thus, no confirmation that Masitinib AB Science provides improved efficacy versus tofersen in the SOD1-ALS subpopulation is available.

The Applicant's claim [Argument 7.5] that Masitinib AB Science and tofersen have a different mechanism of action and different principal molecular structure is agreed to and justify the non-similarity overall conclusion in the similarity assessment versus Qalsody that has been already agreed by the CHMP. The concept of MTA in the CMA differs from the requirements to assess similarity with authorised orphan medicinal products. Indeed, difference in the mechanism of action and principal molecular structure are relevant  arguments  for  the  assessment  of  similarity  versus  Qalsody,  However,  as  already  stated,  a different mechanism of action does not automatically justify for MTA, it needs to be substantiated that the new mechanism of action provides a significant clinical advantage versus the existing therapies. Indeed, as stated above, an MTA of Masitinib AB Science over tofersen is considered justified solely based on its route of administration which would be expected to provide major improvements to patient care.

The final  argument [Argument 7.6] reiterates  previous arguments, claiming an MTA of Masitinib AB Science over tofersen, based on the route of administration, patient burden, safety profile and efficacy

<div style=\"page-break-after: always\"></div>

profile.  Please  see  assessments  above.  The  claim,  that  efficacy  of  Masitinib  AB  Science  has  been demonstrated as an add-on to riluzole, therefore masitinib's MTA over riluzole is established, is not agreed to. The study design of AB10015 does not allow a conclusion on MTA of Masitinib AB Science over riluzole, as patients in both study arms received riluzole. MTA as add-on to riluzole over riluzole alone would only apply, if GfR #2.2 was resolved and efficacy of Masitinib was established (please refer to GfR #2.2).

## Overall conclusion

In conclusion, it can be agreed that Masitinib AB Science could have provided a MTA versus tofersen, based on the route of administration which would be expected to provide major improvements to patient care, but only if an overall positive benefit/risk had been concluded. Furthermore, it is considered unlikely that the Applicant will be in a position to provide comprehensive clinical data post-authorisation (see also below 'Report from the SAG' and the question on feasibility of proposed study), and, taking all the above into account, it is considered that the benefits to public health of the immediate availability of Masitinib AB Science do not outweigh the risks inherent in the fact that additional data are still required. Thus, the overall conclusion is that none of the other (i.e. second, third and fourth) criteria for a CMA as described in Article 4 of Commission Regulation (EC) No. 507/2006 are met.

## 5.2. Report from the SAG

Following a request from the Applicant at the time of the re-examination, the CHMP convened a Scientific Advisory Group (SAG) inviting the experts to provide their views on the specific clinical questions in relation with the grounds of refusal.

1. The  Applicant  has  proposed  the  following  indication:  'Masitinib  AB  Science  in combination  with  riluzole  is  indicated  for  the  treatment  of  adult  patients  with amyotrophic lateral sclerosis (ALS) prior to any loss of function', i.e. excluding very severe ALS patients (that have a score of zero on at least one individual item of the ALSFRS-R).
- Is this subgroup easily identifiable in clinical practice and are the criteria to obtain the ALSFRS-R score well-documented in clinical practice?

The SAG-N experts considered that the ALSFRS-R scale is widely used in the clinical practice and criteria for  administration  are  available  for  health  care  professionals.  Hence,  this  subgroup  can  be  easily identifiable in the clinical practice.

From a patient's representative's perspective, the above statement is fully agreed.

The experts noted that the definition should be 'prior to any TOTAL loss of function' as 0 subscore represents a total loss function while the other subscores (1-3) represents partial loss of function

As a side note, the SAG-N experts questioned that severity phenotyping (as proposed in the indication) could be done using solely a single scale.

- Do you consider that the presented data can support a treatment effect in the proposed target population?

The SAG-N experts did not consider that the data can support a treatment effect in the proposed target population. The target population in the proposed indication is not aligned with the claimed primary efficacy analysis population (i.e. normal progressors/full study population regardless of the total ALSFRSR).  The  presented  data  is post  hoc derived  and  hence,  cannot  render  confirmatory  evidence  of  a treatment effect.

From a patient's representative's perspective, the above statement is fully agreed.

<div style=\"page-break-after: always\"></div>

2. The Applicant has proposed to categorize the study population into normal and fast progressors using an average rate of change in ALSFRS-R from onset to randomization lower than 1.1 points per month as cut-off for normal progressors.

## Is this categorization clinically relevant?

The SAG-N experts agreed that categorization of study population in a trial could reduce heterogeneity of study population. However, few SAG-N experts questioned the utility of ALFRS-R scale as a single instrument to predict the progression of the condition. Further, the chosen single cut-off of 1.1 per month was also questioned based on the non-linearity of the decline (i.e. the cut-off may be different across the different stages of the condition). It was also questioned that as currently proposed the observation period (denominator) over which the average decline in ALFRS-R scale is calculated, is different across the participants in the trial. Finally, the SAG-N experts noted that the categorization was done while the study  was  ongoing.  Nevertheless,  while  the  majority  of  SAG-N  experts  acknowledged  the  above limitations, they still agreed with the proposed categorization approach and the meaningfulness of the cutoff for a trial. Therefore, the SAG-N experts views were split on this aspect with a majority of views supporting the categorization proposal (use of ALSFRS-R, the period of observation from onset and the 1.1  points  per  month  as  cut-off)  if  properly  pre-specified  which  is  agreed  by  consensus  that  is  not applicable to this particular trial.

From a patient's representative's perspective, stratification is considered to be clinically relevant and the cut-off  point  of  1.1  month  is  reasonable  and  in  line  with  expected  evolution  of  the  condition.  So,  if properly planned (which is not the case for this trial), it would have been acceptable.

Considering the non-linear pattern in the ALSFRS-R decline, is the approach to use change from onset and the proposed cutoff meaningful?

The experts referred to the prior subquestion where the non-linearity and cutoff have been discussed.

3. As part of a conditional marketing authorisation commitment, the Applicant proposes to conduct study AB23005. The Applicant has presented a plan to enrol 583 patients from 62 sites per 12-month period outside of EU countries. The experts are invited to comment on the feasibility of this proposal?

The SAG-N experts including the patient's representatives agreed by consensus that the feasibility of the proposal is highly questionable based on the prior experience on recruitment in other trials conducted by the Applicant, the inclusion of certain countries (Russia, Ukraine) and the possibility to access the medicinal product (even if not authorised in their jurisdictions) by patients in the proposed countries which could limit the willingness to participate (limitation for recruitment) or to continue (limitation for conduction) in a trial.

## 5.3. Oral Explanation

The Applicant was invited to present its position during an oral explanation. On 16 October 2024, a presentation to address the grounds for refusal as made in front of the CHMP plenary meeting.

However, after this OE, the Committee concluded that the grounds for refusal, with the uncertainties and  concerns  regarding  the  quality  and  efficacy  of  Masitinib  AB  Science  as  expressed  above,  still remained.

## 5.4. Overall conclusion on grounds for re-examination

The CHMP assessed all the detailed grounds for re-examination and argumentations presented by the Applicant and considered the views of the Scientific Advisory Group.

<div style=\"page-break-after: always\"></div>

In  the  latest  stage  of  the  assessment,  the  Applicant  proposed  a  new  claimed  indication  as  follows: ' Masitinib, in combination with riluzole, is indicated for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) '.

The CHMP concluded that none of the grounds for refusal have been solved by the Applicant. However, the subitem number four of the ground 2.2 for refusal (i.e. The strategies to post hoc identify new target populations ('M4.5 with ≥2 on each baseline ALSFRS -R item and ΔFS&lt;1.1' for analyses of survival and 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1) are considered as data driven decisions and are, therefore, not acceptable ) becomes obsolete in light of the latest claimed indication and is not further pursued as ground for refusal notwithstanding the other points of ground 2.2 ( Beside the data not being reliable, the results from the pivotal study AB10015 do not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS ) remain unsolved and therefore, ground 2.2 remains unsolved.

After the oral explanation, the Applicant submitted a clarification note claiming that the following points were  adequately  addressed  by  the  Applicant  (1)  ALSFRS-R  could  not  be  relied  upon  according  to inspection; (2) dichotomization between normal and fast progressors is not supported and (3) the only statistical analysis retained for missing data is full JTR with a penalty on all discontinuations. The action of  Masitinib  as  disease  modifying  agent  is  not  considered  sufficiently  substantiated.  The  arguments included in the note were assessed and it is concluded that no new information was provided that impacts the assessment of the grounds for refusal. Therefore, the grounds for refusal remain unsolved.

Immediately prior to the Oral Explanation the Applicant submitted a clarification note on quality aspects. The arguments included in the note were assessed and it is concluded that no new information was provided that impacts the assessment of the ground for refusal. Therefore, the quality ground for refusal remains unsolved.

## 6. Benefit-risk balance following re-examination

## 6.1. Therapeutic Context

## 6.1.1. Disease or condition

ALS is a neurodegenerative disorder affecting primarily the motor system, but in which extra -motor manifestations are increasingly recognized. The loss of UMN and LMN in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS  often  has  a  focal  onset  but  subsequently  spreads  to  different  body  regions,  where  failure  of respiratory muscles typically limits survival to 2-5 years after disease onset.

## 6.1.2. Available therapies and unmet medical need

Riluzole is currently the only medical product specifically authorised in the EU for ALS. Tofersen has recently been authorised for the treatment of SOD1-ALS, representing 2% of ALS. The cornerstone of disease  management  for  ALS  patients  remains  multidisciplinary  care  which  has  a  positive  effect  on patient  satisfaction  and  outcome.  Several  discomforting  symptoms  of  ALS  can  be  managed  by symptomatic treatment options, including pharmacological and non -pharmacological interventions. Non -invasive  ventilation  is  the  preferred  life -prolonging  treatment  for  respiratory  insufficiency.  Currently, there  is  no  cure  for  ALS,  and  it  is  agreed  that  the  unmet  medical  need  remains  substantial  for  the majority of the ALS patients.

<div style=\"page-break-after: always\"></div>

## 6.1.3. Main clinical studies

The  main  efficacy  study  was  a  phase  IIb/III,  randomised,  double-blind,  placebo-controlled  study (AB10015). The study was initially planned as a phase 2 dose-finding study and only after an amendment it was upgraded to a phase 3 pivotal study for this application. The primary objective of study AB10015 was to evaluate the efficacy of Masitinib AB Science in combination with riluzole based on the change in the ALSFRS-R ( Δ ALSFRS-R) from baseline to week 48 in adult patients with ALS. While the study was ongoing, the applicant amended the protocol to redefine the primary efficacy population as the 'normal progressors'  subpopulation,  i.e.  patients  with Δ FS&lt;1.1.  A  total  of  394  patients  from  34  sites  in  9 countries were randomised (133, 131, and 130 patients in the placebo, Masitinib AB Science 3 mg/kg/day [M3.0], and Masitinib AB Science 4.5 mg/kg/day [M4.5] treatment-arms, respectively). A total of 267 patients completed the week 48 main protocol period at week 48. A long-term survival follow-up analysis of this study has been provided.

## 6.2. Favourable effects

The analysis of the primary endpoint in the full study population comprising normal + fast progressors in  the  Masitinib  AB  Science  4.5  mg/kg/day  group  showed  a  difference  of  2.09  95%CI  (-0.55-4.73) pnominal=0.1202.

The difference in PFS in the full study population comprising normal + fast progressors was 3 months gain in favour of Masitinib AB Science 4.5 mg/kg/day group (pnominal 0.1389).

Analysis of ALSAQ-40 (mLOCF Rule 1) showed difference of means -6.59, pnominal 0.0148 in the full study population including normal + fast progressors.

In analysis of FVC in the full study population comprising normal + fast progressors difference of means was 5.63, (pnominal 0.0914).

In  the  latest  stage  of  the  assessment,  the  applicant  proposed  a  new  claimed  indication  as  follows: ' Masitinib, in combination with riluzole, is indicated for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) '. The above estimates are derived from analyses including the full study population regardless of any ALSFRS-R. Thus, they are applicable for the new claimed indication.

A  summary  of  long-term  median  OS  results  (cut  off  June  2020)  for  various  patient  cohorts  of  the AB10015 study population has been submitted. No estimates for the OS were provided for the full study population comprising normal + fast progressors during the re-examination. During the procedure, the applicant claimed that the median OS was 36 months (95% CI 28, 48)  for patients receiving Masitinib AB Science 4.5 mg/kg/day (n=130) versus 37 months (95% CI 28,44) for patients receiving placebo (n=133).

## 6.3. Uncertainties and limitations about favourable effects

A triggered GCP inspection (GCP/2017/001) was requested by the CHMP on the conduct of the clinical study AB10015 in the previous MAA for the same medicinal product as a treatment for ALS. Major and critical  findings  were  identified,  and  GCP  inspection  concluded  that  the  data  obtained  at  the  sites inspected  are  not  trustworthy.  In  accordance  with  the  GCP  inspection  report  conclusion,  after  the evaluation of the responses submitted by the applicant in response to the GCP inspection findings (EMA Inspection report, Addendum 1: Response form the sponsor or inspectee for both sites; dated 30 Jan 2018 site 1, and 01 Feb 2018 site 2), the Inspection Team considered that in view of the observed departures  from  GCP,  it  cannot  be  ensured  that  the  data  inspected  are  trustworthy  and  the aforementioned deficiencies are likely to have an impact on the final results. Data integrity is highly likely

<div style=\"page-break-after: always\"></div>

to be impaired as several protocol deviations were identified at eligibility, conduct and in other aspects inspected. The applicant claims that the GCP findings were addressed with implementation of preventive actions across study and functions within AB Science. The applicant also claims that for study AB10015, corrective actions were implemented wherever feasible. It is noted that the measures specified by the applicant  have been assessed in the current marketing authorisation procedure and were not found sufficient  to  recommend  the  use  of  data.  These  measures  were  also  re-assessed  as  part  of  the  reexamination. (See also section 5.1.2 of this report).

Given the nature of the findings, the systematic deficiencies observed (i.e. massive number of protocol deviations) and the fact that some findings such as the deficiencies during inclusion/exclusion criteria verification  and  subjects'  follow  up  (Critical  finding  1  in  the  inspection  report)  cannot  be  corrected retrospectively, the corrective actions presented are not considered adequate to address all the concerns raised.

The deviation impact analysis, conducted by the applicant as corrective measure, was performed after the data base lock when data was already unblinded. Moreover, it was implemented by the applicant and therefore, objectivity of this analysis is questionable. Additionally, during the inspection, data was deemed untrustworthy not solely due to protocol deviations but also due to broader concerns such as lack of training, lack of monitoring, lack of proper record keeping, suboptimal trial management, data entry changes and other deviations.

Data from clinical study AB10015 cannot be relied upon. Thus, the CHMP maintains the position that the internal validity of the clinical study AB10015 is highly compromised in light of the outcome of the CHMP triggered GCP inspection, GCP/2017/001 and that the clinical study data are not deemed trustworthy.

In a study amendment while the study was already ongoing, the applicant introduced division of enrolled participants in two subgroups: fast and normal progressors. Normal progressors were re-defined as the population for the primary analysis with aim to reduce heterogeneity in study population. This approach is not supported as the categorization was not pre-specified but performed once the study was already ongoing.  Functional  unblinding  could  not  be  ruled  out  in  this  context.  The  full  study  population  is considered  the  primary  efficacy  population.  Furthermore,  the  dichotomisation  leads  to  a  selective subgroup that is not representative of general ALS population. Additionally, the chosen cut-off point ( Δ FS 1.1) is of questionable clinical relevance and is not based on pathophysiology of ALS or mechanism of action of Masitinib AB Science. Furthermore, Δ FS alone has relatively low predictive value of progression (Thakore et al, 2017) and is not stable throughout the course of disease (Requardt, 2021) thus, a linear assumption for the Δ FS decline (average rate of change from onset to randomization) might lead to misclassification of patients.  Moreover, randomization was unsuccessful, which undermines the quality of the results of this pivotal study.

It  is  unclear  whether formal success of the trial could indeed already be concluded from the interim analysis as claimed by the applicant. During the re-examination, the applicant presented results from the interim analysis but only for the normal progressors subpopulation. In any case, performing the updated analysis at significance level of 5% is considered overly optimistic. Repeated confidence intervals should have been provided, maintaining the simultaneous coverage probability taking into account the interim and the final analysis. The repeated confidence interval would be even wider than the provided confidence interval.

There was a substantial number of early dropouts across study arms. Due to the high proportion of missing data, handling of missing data has a significant impact on the study results. To account for missing data, the applicant used mLOCF method and provided various sensitivity analysis. The approach is  not  supported, because in the context of progressive ALS it overestimates effect. Considering the progressive nature of ALS and that the effect of treatment will not be maintained after discontinuation of medication, applying the J2R method to all missing values independent of whether considered related

<div style=\"page-break-after: always\"></div>

or  unrelated to treatment is considered the most appropriate approach. Based on the J2R approach already the provided naive 95% confidence interval included zero for the treatment effect in the analysis population of 'normal progressors'. The repeated confidence interval would be even wider. Hence, the results of the primary efficacy analysis when using appropriate methods for accounting for missing data did not render statistically significant results for the primary endpoint, even if the normal progressor would have been considered as prespecified (which is not supported by the CHMP). For the full study population already the 95% confidence interval based on mLOCF included zero and it is assumed that the J2R approach would result in an even smaller estimated treatment effect. Thus, there is insufficient evidence to support efficacy in this single pivotal trial.

As per the data on survival or survival equivalents that is requested as per the EMA guideline for ALS, the  applicant  provided  data  on  long-term  overall  survival.  A  limitation  of  this  analysis  is  that  no information on the post-study use of invasive ventilation was collected, nor was information regarding which  drugs  were  taken  following  withdrawal  from  study  AB10015  or  its  associated  named  patient programme. Also, more than 20% of participants have discontinued the treatment before the open-label extension phase due to the lack of efficacy. Therefore, due to this discontinuation, analysis of long-term overall survival could cause bias in favour to Masitinib AB Science treatment arms. Further, the effect in the long-term survival claimed by the applicant is derived from a highly selected patients' population defined post hoc therefore can be considered only as descriptive not confirmatory of Masitinib AB Science efficacy  in  the  proposed  indication.  The  OS  analysis  was  largely  underpowered  and  inadequate.  In addition, inconsistency in the reporting of OS analysis was noted, increasing uncertainty and concern about how this study was conducted and analysed. When the analysis was conducted in a population that corresponds to the primary analysis population of pivotal study and hence, full study population regardless of (any) baseline ALSFRS-R item, significant benefit in OS was not observed.

Based  on  up-dated  efficacy  and  safety  analyses,  the  applicant  presented  a  proposal  for  a  modified indication to the 'treatment of ALS patients prior to any loss of function' (wherein loss of function is defined as a score of zero on any item of the ALSFRS-R). However, the strategies to post hoc identify new target populations (M4.5 with ≥2 on each baseline ALSFRS -R item and Δ FS&lt;1.1 for analyses of survival and subsequently only including 'ALS patients prior to any loss of function) are considered as data driven decisions and are, therefore, not acceptable. The study has no basis to define the target population post hoc . This trial does not fall under the exception rule for the post hoc definition of a target subgroup because the study did not show an effect in the overall population and does not fulfil the credibility criteria as outlined in the guideline EMA/CHMP/539146/2013 for scenario 2. In the latest stage of the assessment, the applicant proposed a new claimed indication as follows: ' Masitinib, in combination with riluzole, is indicated for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) '. In light of the latest claimed indication, this concern is not further pursued.

## 6.4. Unfavourable effects

In study AB10015 during main study protocol period (48 weeks), at least 1 AE was reported by 83.7% of patients in the full study population. Of them, 78.2% in placebo, 84.7% in the 3.0 mg/kg, 88.4% in the 4.5 mg/kg Masitinib AB Science arm.

More frequently reported AEs in one of the Masitinib AB Science versus placebo arms were maculopapular rash, nausea, peripheral oedema, iron deficiency anaemia, respiratory failure, and dyspnoea.

The most frequently reported non-fatal SAEs in Masitinib AB Science patients under MedDRA SOC were Gastrointestinal Disorders, then  Respiratory, Thoracic and  Mediastinal Disorders, Infection  and Infestations, Injury Poisoning and Procedural Complications, and Investigations. The most frequent PTs

<div style=\"page-break-after: always\"></div>

were  Dysphagia,  Respiratory  Failure,  Dyspnoea,  Lower  Respiratory  Tract  Infection,  Bronchitis,  Fall, Transaminases Increased, Weight Decreased, and Neutropenia.

According  to  the  applicant,  respiratory  failure,  dysphagia,  and  dyspnoea  were  associated  with  ALS disease progression and were not reported as drug related.

The most common AEs with reported more than &gt; 5% higher incidence in ALS patients were in the blood and lymphatic system disorders (8.4% in Masitinib AB Science 3mg/kg/day group and 14.7% in Masitinib AB Science 4.5 mg/kg/day group versus 1.5% in placebo group); nausea (6.9% in 3 mg/kg/day group and 12.45 in Masitinib AB Science 4.5 mg/kg/day group versus 4.5% in placebo group); diarrhoea (8.4% in  Masitinib  AB  Science 3 mg/kg/day group and 7.8% in Masitinib AB Science 4.5 mg/kg/day group versus 3.8% in placebo group); dyspepsia (7% in Masitinib AB Science 4.5 mg/kg/day group versus 2.3% in placebo group); peripheral oedema (5.3% in Masitinib AB Science 3 mg/kg/day group and 7% in Masitinib AB Science 4.5 mg/kg/day group versus 0.8% in placebo group); nervous system disorders (18.6% in Masitinib AB Science 4.5 mg/kg/day group versus 9.8% in placebo group); respiratory and thoracic disorders (27.1% in Masitinib AB Science 4.5 mg/kg/day group versus 12% in placebo group including reported respiratory failure in 10.1% patients in Masitinib AB Science 4.5 mg/kg/day group vs 4.5 % in placebo group and dyspnoea 6.2% in Masitinib AB Science 4.5 mg/kg/day group versus 0.8% in placebo group); skin and subcutaneous tissue disorders (20.6% in Masitinib AB Science 3 mg/kg/day group and 30.2% in Masitinib AB Science 4.5 mg/kg/day group versus 12% in placebo group); infections and infestations (34.9% in Masitinib AB Science 4.5 mg/kg/day group versus 21.15 in placebo group).

Cardiovascular  disorders  were  identified  as  an  important  potential  risk  and  patients  with  current  or history of severe cardiovascular disease were excluded from the study. Nonetheless, 3 severe cardiac events were reported in masitinib exposed patients including 2 death events. Although none of them was reported as study drug related, potential cardiotoxicity remains as a significant and not properly addressed safety risk.

ALS  is  a  disease,  which  leads  to  death  mainly  from  respiratory  complications;  however,  also  has underestimated cardiovascular effects, like increased heart rate variability, malignant arrhythmias, and sudden death (Orsini et al, 2021). Furthermore, cardiac symptoms in ALS patients may develop at any stage of the disease and initial cardiac symptoms if not closely monitored may go unnoticed in ALS patients.

## 6.5. Uncertainties and limitations about unfavourable effects

Important uncertainty of unfavourable effects is also related to the reliability of data. Many deviations from the protocol have been found during the inspections of the study centres. As part of this marketing authorization Applicant presented implemented preventive actions across study and functions within AB Science. Given the nature of the findings, the systematic deficiencies observed (i.e. massive number of protocol deviations) and the fact that some findings such as the deficiencies during inclusion/exclusion criteria verification and subjects' follow up (Critical finding 1 in the inspection report) cannot be corrected retrospectively, the corrective actions presented are not considered adequate to address all the concerns raised.  Data  from  clinical  study  AB10015  cannot  be  relied  upon,  increasing  the  uncertainties  and limitations also regarding unfavourable effects.

The  uncertainties  and  limitations  regarding  reliability  of  safety  data  of  the  pivotal  clinical  trial  are alleviated by the safety data from the trials in non-oncological conditions. It is considered that the safety concerns could have been manageable with risk minimization measures as outlined in the RMP.

<div style=\"page-break-after: always\"></div>

## 6.6. Effects Table

Table 147: Effects table for Masitinib AB Science

| Effect                                          | Short Description                | Unit                 | Masitinib 4.5 mg     | Placebo              | Uncertainties/ Strength of evidence                                                       | Referen ces          |
|-------------------------------------------------|----------------------------------|----------------------|----------------------|----------------------|-------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects                              | Favourable Effects               | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                        | Favourable Effects   |
| Difference in ALSFRS-R                          | Normal + Fast progressors        | score                | -10.89               | -12.97               | Difference 2.09 (-0.55-4.73) p=0.1202                                                     | (1)                  |
| Median PFS                                      | Normal + Fast progressors        |                      | 17                   | 14                   | 3 months, p-value 0.1389                                                                  | (1)                  |
| Quality of Life (ALSAQ- 40)                     | Normal + Fast progressors        |                      | 21.58                | 28.17                | difference of means -6.59, p- value 0.0148                                                | (1)                  |
| FVC                                             | Normal + Fast progressors        |                      | -30.81               | -36.45               | difference of means 5.63, p- value 0.0914                                                 | (1)                  |
| Survival OS                                     | Normal + Fast progressors        |                      | 36                   | 37                   | p-value 0.1778                                                                            | (2)                  |
| Unfavourable Effects                            | Unfavourable Effects             | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                      | Unfavourable Effects |
| Deaths                                          | Number (and Percent of Patients) | Number               | 10 (7.8)             | 12 (9.0)             | Up to week 48 SoE: longer duration of treatment and more severe patients in masitinib arm | (3)                  |
| Gastrointesti nal Disorders                     | Number (and Percent of Patients) | Number               | 14 (10.9)            | 10 (7.5)             | Up to week 48 Unc: cumulative effect of riluzole and masitinib in terms of GI events.     | (3)                  |
| Respiratory, Thoracic and Mediastinal Disorders | Number (and Percent of Patients) | Number               | 13 (10.1)            | 4 (3.0)              | Up to week 48 SoE: larger # of very severe patients in masitinib arm                      | (3)                  |
| Infections and Infestations                     | Number (and Percent of Patients) | Number               | 10 (7.8)             | 7 (5.3)              | Up to week 48 SoE: larger # of very severe patients in masitinib arm                      | (3)                  |
| Transaminas es Increased                        | Number (and Percent of Patients) | Number               | 2 (1.6)              | 0                    | Up to week 48                                                                             | (3)                  |

Abbreviations: ALSFRS-R - Amyotrophic lateral sclerosis functional rating scale-revised, ALSAQ-

40 - Amyotrophic Lateral Sclerosis Assessment Questionnaire, long form, 40 questions, FP - Fast Progressors, FVC - Forced vital capacity, LS-Difference of least-square means, median PFS - median progression-free survival, TD - Treatment Difference M vs P, M = ALSITEK + Riluzole; P = Placebo + Riluzole.

Notes:  (1)  Clinical  Study  Report  Protocol  No.  AB10015,  (2)  Supplemental  Clinical  Study  Report  (Long-term  Survival  Analysis  of Masitinib in Amyotrophic Lateral Sclerosis (ALS) from Study AB10015) (3) 2.7.4 Summary of Clinical Safety

## 6.7. Benefit-risk assessment and discussion

## 6.7.1. Importance of favourable and unfavourable effects

ALS is a neurodegenerative disease with limited treatment options with overall survival of 2-5 years after disease onset.

The current application is based on one pivotal study (AB10015); prospective, multicentre, randomised, double-blind, placebo controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of

<div style=\"page-break-after: always\"></div>

two doses of Masitinib AB Science versus placebo in the treatment of patients suffering from ALS. The primary endpoint was originally the change from baseline to week 48 in the ALSFRS-R in patients with ALS. The clinical study protocol had multiple amendments including change from Phase 2 to Phase 2/3 and change of the primary efficacy analysis population (see below).

A triggered GCP inspection was requested by the CHMP on the conduct of the clinical study AB10015 in the  previous  MAA  for  masitinib  use  in  ALS.  Major  and  critical  findings  were  identified  during  the inspection. The critical and major issues are overarching and impact all study-related activities, from staff training to trial monitoring, data collection process, data entry and, finally, data interpretation. The GCP report concluded that the data obtained at the sites inspected are not trustworthy. As part of this submission the applicant claims that the GCP findings were addressed with implementation of preventive actions across study and functions within AB Science. The applicant also claims that for study AB10015, corrective actions were implemented wherever feasible. It is noted that the measures specified by the applicant in this application have been thoroughly re-assessed and were not found sufficient to reassure the CHMP to recommend the use of data. Therefore, data from clinical study AB10015 cannot be relied upon. See also section 5.1.2 of this report.

In 2014, an amendment to the study protocol introduced a distinction between 'normal progressor' patients and 'fast progressor' subpopulations while the study was ongoing, and the primary efficacy analysis was to be done in the normal progressor subpopulation randomised to an initial Masitinib AB Science dose of 4.5mg/kg/day versus placebo patients at a 5% alpha-level.  This is not agreed by the CHMP. The change was done 1.5 years after study commenced while considerations about heterogeneity and the decision of the study population should be done before starting a confirmatory study. The validity (including blinding) and timing of this amendment is questioned, as it was done during an essentially unmonitored  part  of  the  study  as  indicated  by  the  GCP  reports,  which  suggest  that  there  was  no monitoring plan from the start of the study until 2016

The functional unblinding cannot be ruled out in this context since safety profiles of placebo and Masitinib AB Science obviously differed. Finally, this change is not accepted because of its considerable impact on the study outcomes (ie. on the formal 'success' of the study).

Furthermore,  the categorization itself is not considered acceptable for the following reasons: the use of ALSFRS-R score as the only variable to inform the progression of ALS, the linear assumption of ALSFRSR decline being unreliable for long time periods (i.e. change from disease onset), the use of arbitrary cut-offs  for  the  categorization  that  are  not  based  on  clinically  relevant  thresholds,  ALS  pathology  or mechanism of action of Masitinib AB Science. Nevertheless, it should be highlighted that the majority of the SAG-N experts could have considered the categorization approach (i.e. use of a single scale, the time from onset and the cutoff point) as acceptable had it been prespecified in the study protocol. Considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results.

In  order  to  account  for  missing  data  after  treatment  discontinuation,  the  applicant  used  the  mLOCF method for the first and secondary endpoints. A mLOCF approach assumes that the benefit experienced until the time of missing data is also retained thereafter. This is a strong assumption for imputing data after treatment discontinuation. This approach of handle missing data is prone to overestimate the effects of Masitinib AB Science. The applicant provided more conservative approaches such as J2R that assumes that the benefit experienced until the point of missing data is not retained and instead the outcome would correspond to the outcome in the reference group. The CHMP is of the opinion that J2R is the preferred option in the view of the progressive nature of ALS.

The primary statistical analysis in the phase 2/3 main efficacy study revealed an estimated difference in the change in ALSFRS-R score between Masitinib AB Science 4.5 mg/kg/day and placebo of 2.09 (95% CI -0.55, 4.73; p=0.1202) in 'normal + fast progressor' population. These results are based on the mLOCF method and it is expected that the preferred J2R approach would result in an even smaller

<div style=\"page-break-after: always\"></div>

treatment difference as discussed above. Moreover, repeated confidence intervals should have been provided, maintaining the simultaneous coverage probability taking into account the interim and the final analysis. The repeated confidence interval would be even wider than the provided confidence interval.

A summary of long-term median OS results for various patient cohorts of the AB10015 study population has been provided (cut-off date 14 June 2020). No statistically significant long-term survival advantage was observed for the full study population for Masitinib AB Science 4.5 mg/kg/day cohort. The results indicating prolonged survival in a post hoc selected, enriched population (cohortLTM4.5 with ≥2 on each baseline  ALSFRS-R  item,  and Δ FS&lt;1.1)  is  not  considered  robust  and  is  not  representative  for  the population intended to be treated.

The proposed indication ( ALS patients prior to any loss of function [i.e. cohortLT-M4.5 with &gt;0 on each baseline ALSFRS-R item, and Δ FS&lt;1.1]) based on post hoc analyses is not acceptable as it is considered data  driven.  This  is  also  the  position  from  the  SAG-N  experts.  As  described  in  the  document EMA/CHMP/539146/2013 and in line with the ICH principles, the definition of a new target population should be done in a separate study. The exception to the rule of defining a new target population in a separate study cannot be not applied to AB10015 as the study results were not statistically persuasive. However, in light  of  the  latest  claimed  indication,  this  concern  becomes  obsolete  and  is  not  further pursued.

Dose dependent respiratory and thoracic disorders were reported in 4.5 mg/kg/day Masitinib AB Science group with more than twice higher incidence compared to placebo group, including 10.1% severe AEs in Masitinib AB Science group compared to 6% in placebo group. Furthermore, it is a concern that data reliability issues identified in the triggered GCP inspection also affects proper reporting of safety data. Nevertheless, the safety profile was further characterised based on safety data of trials conducted in non-oncological conditions. It is considered that the safety profile is reasonably characterised for a CMA (i.e. based on non-comprehensive data).

## 6.7.2. Balance of benefits and risks

The provided analyses of the single pivotal study are not considered to establish efficacy in the target population of patients with ALS. In addition, a triggered GCP inspection has concluded that the data from clinical study AB10015 are not trustworthy. Data cannot be relied upon, and the corrective measures and actions presented by the applicant (including re-monitoring and impact analysis) have not resolved this issue. Hence, efficacy of Masitinib AB Science in the treatment of ALS is not established and there is therefore nothing to outweigh any unfavourable effects.

## 6.7.3. Additional considerations on the benefit-risk balance

## Quality

Based on an unresolved Ground for refusal, several deficiencies and the lack of an acceptable explanation for the observed significant intra-batch and inter-batch variability of the dissolution results still remain. The root cause of this variability has not been convincingly identified by the applicant.

Furthermore,  the  observed  significant  inter-batch  and  intra-batch  variability  in  dissolution  profiles between the tested drug product batches may indicate that the manufacturing process is not under sufficient  control.  Namely,  based  on  the  presented  dissolution  profile  data,  it  is  concluded  that  the dissolution profiles of the drug product batches manufactured according to the proposed manufacturing process are not similar, i.e. the presented dissolution profiles do not demonstrate reproducibility of the proposed manufacturing process. The differences in dissolution behaviour between the two strengths further  underline  the  lack  of  understanding  of  the  potential  causes  related  to  high  variability  of  the

<div style=\"page-break-after: always\"></div>

dissolution results.

In conclusion, the suitability of the proposed dissolution method to ensure adequate control of the drug product during the drug product lifecycle has not been sufficiently demonstrated. Furthermore, it has not been demonstrated that the proposed manufacturing process is robust and reproducible and that it ensures adequate batch to batch consistency in order to obtain a medicinal product with the intended high quality.

## Conditional marketing authorisation

As comprehensive data on the product are not available, a conditional marketing authorisation (CMA) was requested by the applicant in the initial submission and maintained during the re-examination phase. The CHMP agrees that the data is not comprehensive. The application is based on a single pivotal trial, study AB10015, which was designed as a phase 2 dose-finding trial. Only upon a protocol amendment, it was upgraded to a phase 3 pivotal trial. The study population of AB10015 study is not considered fully representative of the overall ALS population and the efficacy endpoints did not include any measures of muscle strength. These features could have been acceptable for a phase 2 dose-finding trial but are considered serious limitations for a phase 3 pivotal study intended to provide comprehensive evidence of efficacy and safety. Moreover, a triggered GCP inspection has concluded that the data from clinical study AB10015 are not trustworthy. Data cannot be relied upon, and the corrective measures presented by the applicant have not resolved this issue.

The CHMP considers that the product cannot be recommended for a CMA as the benefit-risk balance is negative  (as  discussed),  the  applicant  is  unlikely  to  be  able  to  provide  comprehensive  data  after authorisation, it has not been demonstrated that the product will address an unmet medical need, and the benefits to public health of the immediate availability do not outweigh the risks inherent in the fact that additional data are still required.

## 1. Positive benefit/risk balance:

The applicant argued that results from Study AB10015 are valid and demonstrate efficacy of Masitinib AB Science for patients with ALS with an adequate safety profile. The CHMP position is that a positive benefit/risk balance of Masitinib AB Science for the treatment of patients with ALS cannot be established because the data from the pivotal clinical study AB10015 cannot be relied upon. Despite the applicant's arguments and corrective measures, the re-assessment concluded that the deficiencies identified during previous GCP inspection cannot be resolved by performing re-monitoring and retrospective analyses at the study sites and cannot be corrected retrospectively. Beside the data not being reliable, the results from the pivotal study AB10015 do not demonstrate efficacy of Masitinib AB Science in the treatment of patients  with  ALS,  because  a  statistically  significant  difference  compared  to  placebo  was  not demonstrated for the primary efficacy population (i.e. full study population encompassing normal and fast progressors); the approach to categorise the population into normal and fast progressors is not supported (the use of ALSFRS-R score as the only variable to inform the progression of ALS, the linear assumption of ALSFRS-R decline being unreliable for long time periods, the use of arbitrary cut-offs for the categorization that are not based on clinical relevant thresholds, ALS pathology or mechanism of action of Masitinib AB Science); considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data in the primary analysis is not considered acceptable. In light of the latest claimed indication, the concern about the post hoc identification of new target population ('M4.5 with ≥2 on each baseline ALSFRS -R item and ΔFS&lt;1.1' for analyses of survival and subsequently only including 'ALS patients prior to any loss of function' as proposed in the latest version of 4.1 of the SmPC ) is not further pursued.

## 2. It is likely that the applicant will be able to provide comprehensive data

<div style=\"page-break-after: always\"></div>

As per the requested CMA, the applicant initially presented Study AB19001 as the one that would lead to  comprehensive  evidence  on  efficacy  and  safety  of  Masitinib  AB  Science.  Study  AB19001  is  a multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 3 study to evaluate the efficacy and safety of masitinib as add-on therapy in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole (further details can be found in section 3.7.3).

During the procedure, the applicant stated that the enrolment in study AB19001 has been slow due to the restrictive design features of that study (i.e. long 3 months run-in period, with no control of FVC at baseline / Moderate ALS only / by that time approved treatment in the USA - Edaravone, Relyvrio (no longer marketed) - not allowed / blinded extension at week 48). Consequently, the applicant proposed a  new  confirmatory  study  -  AB23005  study-  and  presented  the  previously  proposed  confirmatory AB19001 study as an exploratory one.

Study AB23005 is a multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 3 Trial to evaluate the efficacy and safety of masitinib as add-on therapy in ALS patients treated with standard of care. Patients will be randomised (1:1) to receive Masitinib AB Science 4.5 mg/kg/day or matching placebo.

Besides some considerations on the study design features and the potential impact on the ability of Study AB23005 to provide comprehensive evidence, as already discussed in section 3.7.3 and grounds for re-examination (n.3), the CHMP was concerned about the feasibility to properly conduct that study if Masitinib AB Science is authorised in the EU. It needs to be bear in mind that ALS is a fatal condition for which the only therapeutic options in the EU are symptomatic treatment and riluzole for all ALS patients expect  those  with  SOD1-ALS.  Hence,  the  CHMP  is  concerned  that  the  authorisation  of  Masitinib  AB Science will impact the recruitment and the conduction of the AB23005 study in EU sites as ALS patients will  likely  start  (i.e.  impact  on  recruitment)  or  shift  (i.e.  impact  on  conduction)  to  the  commercial Masitinib AB Science when available. In response to this concern, the applicant presented a feasibility analysis and concluded that 583 patients in non-EU countries and US could be enrolled over a 12-month period. The applicant claimed that Study AB23005 can be completed within 2.5 years with involvement of site from USA and other non-EU countries or within 3 years with involvement of site only from other non-EU countries. Thus, the applicant position is that confirmatory study AB23005 is feasible outside of the EU and further facilitated since Relyvrio is withdrawn from market in USA and Canada. However, considering the numerous changes undertaken in the protocol of the pivotal study during its execution as well as the slow enrolment in the study AB19001, which became an exploratory study later on  the applicant's  capability  to  properly  conduct  this  study  is  still  unclear,  despite  the  applicant's  declared commitment.

The SAG-N experts considered that the feasibility of the proposal is highly questionable based on the aforementioned reasons (see SAG-N minutes above). In the late phase of the procedure, the applicant presented a new feasibility analysis including some modifications (e.g. no sites proposed to be  included in  Ukraine,  Russia,  Japan,  Saudi  Arabia,  and  Israel  and  fewer  patients  as  initially  proposed  will  be recruited in Brazil and China) and concluded that 466 patients in non-EU countries and US could be enrolled  over  a  12-month  period.  Then,  the  applicant  proposed  to  enrol  408  patients  in  1.5  years. However, it  is  still  considered  unlikely  that  the  applicant  provides  comprehensive  clinical  data  postauthorisation based on the prior experience and the concerns about the possibility to access the medicinal product (even if not authorised in their jurisdictions) by patients in the proposed countries which could limit the willingness to participate (limitation for recruitment) or to continue (limitation for conduction) in a trial.

In  view  of  the  above,  it  is  considered  unlikely  that  the  applicant  will  be  in  a  position  to  provide comprehensive clinical data post-authorisation.

## 3. Fulfilment of unmet medical need

<div style=\"page-break-after: always\"></div>

The third criterion requires that unmet medical needs will be fulfilled. As other medicinal products for the treatment of ALS are authorised in EU, the applicant should justify that Masitinib AB Science provides a MTA over each existing authorised medicinal products in an overlapping indication, in case a CMA would be granted. The currently authorised medicinal products for ALS are riluzole and tofersen (the latter, only for SOD1-ALS).

The pivotal study AB10015 of this CMA is a prospective, multicenter, randomised, double-blind, placebocontrolled, parallel groups, phase II/III study to compare the efficacy and safety of Masitinib AB Science versus placebo in ALS patients. The study objective was to evaluate efficacy and safety of Masitinib AB Science as add-on therapy to riluzole. Indeed, all patients included in this pivotal study received riluzole. Hence, this pivotal trial is designed to measure causal effects (efficacy) of Masitinib AB Science on top of riluzole. If efficacy was demonstrated for Masitinib AB Science on top of riluzole in this pivotal trial, the differences in ALSFRS-R score and survival equivalent (PFS) estimates observed in the pivotal trial in  favour  of  Masitinib  AB  Science  arms  in  principle  could  have  been  considered  as  meaningful improvements of morbidity or mortality of the disease and thus, supporting that Masitinib AB Science provides  MTA  versus  riluzole.  However,  as  efficacy  was  not  demonstrated,  it  cannot  be  concluded whether Masitinib AB Science provides an MTA versus riluzole.

Regarding the MTA over tofersen, the applicant claimed that Masitinib AB Science and tofersen have different  mechanisms  of  action.  This  is  agreed;  however,  a  different  mechanism  of  action  does  not automatically  justify  for  MTA,  it  needs  to  be  justified  that  the  new  mechanism  of  action  provides  a significant  clinical  advantage  versus  the  existing  therapies.  In  accordance  with  the  Guideline  on  the scientific  application  and  the  practical  arrangements  necessary  to  implement  Regulation  (EC)  No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 MTA would normally be based on meaningful improvement of efficacy or clinical safety or, in exceptional cases, on major improvements to patient care . The applicant's claim that Masitinib AB Science would provide a MTA over tofersen in terms of improvements to patient care based on the route of administration is agreed to. While tofersen treatment comes with considerable patient burden  that  is primarily related  to  the  monthly  invasive  intrathecal  lumbar  puncture administration and bears risks of severe and potentially life-threatening adverse effects, Masitinib AB Science is an orally administered, CNS-penetrative drug, with minimal patient burden or risks associated with  its  route  of  administration.  It  is  further  agreed  with  the  applicant  that  Masitinib  AB  Science  is comparatively simple to take, allowing for convenient, safe and inexpensive self-administration, outside of the hospital setting, all of which are beneficial for improved patient compliance. Concerning the overall safety  profile,  AEs  related  to  the  administration  of  tofersen  via  intrathecal  lumbar  puncture  can  be prevented/diminished  through  oral  administration  of  Masitinib  AB  Science,  which  is  considered  an improvement of patient care, as stated above.

The applicant´s argumentations on superior efficacy are not relevant because the CHMP considers that efficacy of Masitinib AB Science in ALS has not been demonstrated.

In conclusion, it could have been agreed that Masitinib AB Science could have provided a MTA versus tofersen, in terms of improvements to patient care based on the route of administration. However, as an overall positive benefit/risk is not established, it cannot be concluded whether Masitinib AB Science provides an MTA versus tofersen.

## 4. The benefit of immediate availability outweighs the risks

The applicant position is that benefit associated with the immediate availability of Masitinib AB Science based on number of deaths avoided and total gain in life-years as estimated based on study AB10015 (pivotal study for this CMA) outweighs the risk of adverse events.

However, taking all above into account, especially since the benefit risk balance has not been determined

<div style=\"page-break-after: always\"></div>

as positive, the benefits to public health of the immediate availability of Masitinib AB Science do not outweigh the risks inherent in the fact that additional data are still required

## Third Party Intervention

The CHMP received, during the assessment of the re-examination of this application, one correspondence from ALS patients organisations (hereinafter referred to as 'third parties') expressing the third parties' views about the efficacy and safety profile of Masitinib AB Science and the unmet medical need of ALS patients. The permission to share was granted for all.

The CHMP considered the intervention and concluded that the arguments put forward by the third-party did not impact the CHMP conclusions.

## 6.8. Conclusions

The overall benefit/risk balance of Masitinib AB Science is negative.

## 7. Recommendations following re-examination

Based on the arguments of the applicant and all the supporting data on quality, safety and efficacy, the CHMP re-examined its initial opinion and in its final opinion concluded by consensus that the quality and efficacy  of  the  above-mentioned  medicinal  product  is  not  sufficiently  demonstrated  and  therefore recommends  the  refusal  of  the  granting  of  the  conditional  marketing  authorisation  for  the  abovementioned medicinal product. The CHMP considers that:

- The suitability of the proposed dissolution method to ensure proper control of the medicinal products during the lifecycle of the medicinal product, especially for the 200 mg strength, and therefore to ensure batch to batch consistency has not been sufficiently demonstrated. Several deficiencies and the lack of an acceptable explanation for the significant differences of dissolution data between the 100 mg strength and the 200 mg strength, as well as differences in dissolution profiles between different  batches  of  the  200  mg  strength  remain  at  the  time  of  opinion.  The  applicant  has  not convincingly demonstrated that tablet hardness and film-coating are the main issues for differences in dissolution results between 100 mg and 200 mg tablets as dissolution results do not correlate with these parameters. Moreover, the potential reasons of different dissolution results between 200 mg batches (intra-batch and inter-batches) were not discussed in order to ensure that, e.g., the manufacturing process is adequate to obtain a product with the intended high quality.
- A positive benefit/risk balance of Masitinib AB Science for the treatment of patients with ALS cannot be established based on the following:
- The data from the pivotal clinical study AB10015 cannot be relied upon. Despite the applicant's arguments and the implementation of corrective measures, the deficiencies identified during previous  GCP  inspection  cannot  be  resolved  by  performing  re-monitoring  and  retrospective analyses at the study sites and cannot be corrected retrospectively.
- Beside  the  data  not  being  reliable,  the  results  from  the  pivotal  study  AB10015  do  not demonstrate efficacy of Masitinib AB Science in the treatment of patients with ALS, because:
- A  statistically  significant  difference  compared  to  placebo  was  not  demonstrated  for  the primary endpoint in the full study population.
- The  approach  to  categorise  the  population  into  normal  and  fast  progressors  is  not supported.

<div style=\"page-break-after: always\"></div>

- Considering that there were approximately 30% of missing data in each Masitinib AB Science arm, handling of missing data can have a significant impact on the results. The approach to handle missing data including statistical assumptions on missingness and the definition of intercurrent events in J2R strategy are not considered acceptable.
- A CMA requires that all requirements as described in Article 4 of Commission Regulation (EC) No. 507/2006 are met. In addition to not fulfilling the first criterion, which relates to the positive benefit / risk balance, also the other CMA criteria are not considered fulfilled. It is considered unlikely that the applicant will be in a position to provide comprehensive clinical data post-authorisation. Further in the view of the negative benefit / risk balance, it cannot be agreed that Masitinib AB Science provides a major therapeutic advantage versus the already authorised medicinal products and  that the benefits to public health of the immediate availability of Masitinib AB Science outweighs the risks inherent in the fact that additional data are still required.

Due  to  the  aforementioned  concerns  a  satisfactory  summary  of  product  characteristics,  labelling, package leaflet, pharmacovigilance system, risk management plan and post-authorisation measures to address other concerns as discussed during the procedure cannot be agreed at this stage.

Furthermore, following review of the available data in the context of the applicant's claim of new active substance status, the CHMP position at the time of this report is reflected in Appendix 8.2.